Unnamed: 0,datetime,title,source,link
0.0,9/6/2005 1:07:00 PM,"Burden of ADHD Greater than Asthma, According to New Study",PR Newswire,/news/stocks/burden-of-adhd-greater-than-asthma-according-to-new-study-588983
1.0,1/20/2006 1:37:00 PM,Lilly ICOS LLC Reports First Full-Year Profit in its History,PR Newswire,/news/stocks/lilly-icos-llc-reports-first-full-year-profit-in-its-history-1004417673
2.0,2/7/2006 2:22:00 PM,Lilly Launches Humalog(R) Mix50/50(TM) Insulin in United States,PR Newswire,/news/stocks/lilly-launches-humalogr-mix50-50tm-insulin-in-united-states-405092
3.0,3/14/2006 8:02:00 PM,Study Shows More Potent and More Reliable Platelet Inhibition with Prasugrel Compared to Clopidogrel Even in Patients With More Reactive Platelets,PR Newswire,/news/stocks/study-shows-more-potent-and-more-reliable-platelet-inhibition-with-prasugrel-compared-to-clopidogrel-even-in-patients-with-more-reactive-platelets-1005660628
4.0,11/15/2007 12:30:00 PM,Eli Lilly and Company to Receive Honor from National Urban League,PR Newswire,/news/stocks/eli-lilly-and-company-to-receive-honor-from-national-urban-league-1024085798
5.0,5/9/2008 2:42:00 PM,"Seven Summits Research Releases Comments on XOM, NVDA, ICE, LLY, and ATVI",PR Newswire,/news/stocks/seven-summits-research-releases-comments-on-xom-nvda-ice-lly-and-atvi-1027513098
6.0,5/9/2014 8:50:07 PM,Eli Lilly and Italian firm fined $450 million for poisoning in Brazil,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/jyvEcP3twVI/story01.htm
7.0,9/26/2016 6:10:23 PM,BRIEF-Cerecor announces acquisition of TARP-8-AMPA receptor antagonist (CERC-611) from Lilly (LLY),Reuters,/news/stocks/brief-cerecor-announces-acquisition-of-tarp-8-ampa-receptor-antagonist-cerc-611-from-lilly-lly-1001418592
8.0,10/3/2016 12:10:22 PM,"Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001431817
9.0,10/3/2016 2:20:21 PM,"RPT-Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/rpt-big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001432682
10.0,10/5/2016 2:40:20 PM,"BRIEF-Elanco Animal Health enters agreement to acquire Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccines portfolio (LLY)",Reuters,/news/stocks/brief-elanco-animal-health-enters-agreement-to-acquire-boehringer-ingelheim-vetmedicas-u-s-feline-canine-and-rabies-vaccines-portfolio-lly-1001437877
11.0,10/5/2016 2:50:23 PM,Eli Lilly to buy Boehringer Ingelheim's U.S. pet vaccines unit (LLY),Reuters,/news/stocks/eli-lilly-to-buy-boehringer-ingelheims-u-s-pet-vaccines-unit-lly-1001437874
12.0,10/5/2016 3:30:21 PM,"UPDATE 1-Lilly to buy Boehringer's U.S. pet vaccines unit (SAN, LLY)",Reuters,/news/stocks/update-1-lilly-to-buy-boehringers-u-s-pet-vaccines-unit-san-lly-1001438067
13.0,10/5/2016 4:40:27 PM,BRIEF-Lilly highlights advancements in its oncology portfolio (LLY),Reuters,/news/stocks/brief-lilly-highlights-advancements-in-its-oncology-portfolio-lly-1001438169
14.0,10/10/2016 7:10:21 AM,"Novartis challenges Pfizer with strong breast cancer drug data (LLY, PFE)",Reuters,/news/stocks/novartis-challenges-pfizer-with-strong-breast-cancer-drug-data-lly-pfe-1001444918
15.0,10/10/2016 8:00:22 AM,"UPDATE 1-Novartis challenges Pfizer with strong breast cancer drug data (LLY, PFE)",Reuters,/news/stocks/update-1-novartis-challenges-pfizer-with-strong-breast-cancer-drug-data-lly-pfe-1001445007
16.0,10/19/2016 10:40:20 PM,Lilly's soft tissue sarcoma treatment gets U.S. approval (LLY),Reuters,http://www.businessinsider.com/r-lillys-soft-tissue-sarcoma-treatment-gets-us-approval-2016-10
17.0,10/19/2016 10:40:20 PM,BRIEF-U.S. FDA grants approval to Lilly's treatment for advanced soft tissue sarcoma (LLY),Reuters,http://www.businessinsider.com/r-brief-us-fda-grants-approval-to-lillys-treatment-for-advanced-soft-tissue-sarcoma-2016-10
18.0,10/19/2016 11:00:36 PM,UPDATE 1-FDA grants accelerated approval to Lilly's soft tissue sarcoma drug (LLY),Reuters,http://www.businessinsider.com/r-update-1-fda-grants-accelerated-approval-to-lillys-soft-tissue-sarcoma-drug-2016-10
19.0,10/25/2016 12:40:18 PM,Lilly third-quarter revenue rises 4.7 percent (LLY),Reuters,http://www.businessinsider.com/r-lilly-third-quarter-revenue-rises-47-percent-2016-10
20.0,10/25/2016 12:40:19 PM,BRIEF-Lilly reports third-quarter 2016 results (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-third-quarter-2016-results-2016-10
21.0,10/25/2016 1:02:21 PM,UPDATE 1-Lilly third-quarter results miss estimates (LLY),Reuters,http://www.businessinsider.com/r-update-1-lilly-third-quarter-results-miss-estimates-2016-10
22.0,10/25/2016 4:50:19 PM,BRIEF-Lilly says likely to boost funding of other Alzheimer's drugs if solanezumab succeeds (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-likely-to-boost-funding-of-other-alzheimers-drugs-if-solanezumab-succeeds-2016-10
23.0,10/25/2016 9:10:19 PM,U.S. FDA adds abuse warning to prescription testosterone (LLY),Reuters,http://www.businessinsider.com/r-us-fda-adds-abuse-warning-to-prescription-testosterone-2016-10
24.0,10/27/2016 10:20:20 PM,BRIEF-Bank of America declares quarterly dividend of $0.075/share (BAC),Reuters,http://www.businessinsider.com/r-brief-bank-of-america-declares-quarterly-dividend-of-0075/share-2016-10
25.0,10/27/2016 11:06:30 PM,"Biotech's election-year political cloud threatens to linger (VRX, LLY, BMY, ARIA, VRX)",Reuters,http://www.businessinsider.com/r-biotechs-election-year-political-cloud-threatens-to-linger-2016-10
26.0,11/2/2016 5:48:50 AM,"Bernie Sanders is going after insulin makers over price hikes (LLY, NVO, SNY)",Business Insider,http://www.businessinsider.com/bernie-sanders-criticizes-insulin-price-hikes-2016-11
27.0,11/4/2016 5:52:18 AM,"U.S. lawmakers call for probe of possible insulin price collusion (SAN, LLY, MRK, NOVO )",Reuters,http://www.businessinsider.com/r-us-lawmakers-call-for-probe-of-possible-insulin-price-collusion-2016-11
28.0,11/8/2016 2:46:21 PM,"BRIEF-Becton Dickinson launches syringe for use with Humulin R U-500 insulin (BDX, LLY)",Reuters,http://www.businessinsider.com/r-brief-becton-dickinson-launches-syringe-for-use-with-humulin-r-u-500-insulin-2016-11
29.0,11/14/2016 1:04:20 PM,"Richter's generic osteoporosis drug gets EU recommendation (RICHTER, LLY)",Reuters,http://www.businessinsider.com/r-richters-generic-osteoporosis-drug-gets-eu-recommendation-2016-11
30.0,11/14/2016 6:56:18 PM,"BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-incyte-says-baricitinib-treatment-show-improvements-in-rheumatoid-arthritis-symptoms-in-phase-3-2016-11
31.0,11/14/2016 7:00:18 PM,"BRIEF-Baricitinib demonstrates early response compared to placebo (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-baricitinib-demonstrates-early-response-compared-to-placebo-2016-11
32.0,11/14/2016 10:14:20 PM,BRIEF-U.S. FDA approves Itrafungol for treating ringworm in cats (LLY),Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-itrafungol-for-treating-ringworm-in-cats-2016-11
33.0,11/15/2016 2:36:18 AM,"BRIEF-Paulson & Co cuts share stake in Pfizer, raises share stake in Facebook (PFE, LLY)",Reuters,http://www.businessinsider.com/r-brief-paulson--co-cuts-share-stake-in-pfizer-raises-share-stake-in-facebook-2016-11
34.0,11/17/2016 1:04:18 PM,"UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data (AGN, LLY, TEVA, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-amgen-novartis-aim-for-big-crowded-migraine-market-after-new-drug-data-2016-11
35.0,11/18/2016 4:54:18 PM,BRIEF-Athenex and Lilly enter clinical collaboration agreement (LLY),Reuters,http://www.businessinsider.com/r-brief-athenex-and-lilly-enter-clinical-collaboration-agreement-2016-11
36.0,11/21/2016 3:22:18 PM,"BRIEF-Intelgenx secures a license for tadalafil erectile dysfunction dosing patent (IGX, LLY)",Reuters,http://www.businessinsider.com/r-brief-intelgenx-secures-a-license-for-tadalafil-erectile-dysfunction-dosing-patent-2016-11
37.0,11/23/2016 2:44:20 PM,"Lilly Alzheimer's drug fails to slow memory loss in big study (LLY, BIIB)",Reuters,http://www.businessinsider.com/r-lilly-alzheimers-drug-fails-to-slow-memory-loss-in-big-study-2016-11
38.0,11/23/2016 2:46:20 PM,BRIEF-Lilly to abandon Alzheimer's drug after late-stage failure (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-to-abandon-alzheimers-drug-after-late-stage-failure-2016-11
39.0,11/23/2016 2:58:20 PM,BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-incoming-ceo-david-ricks-on-cnbc---amyloid-hypothesis-should-be-continued-to-be-studied-in-reference-to-its-alzheimers-drug-2016-11
40.0,11/23/2016 3:50:06 PM,A major Alzheimer's drug just failed a key trial (LLY),Business Insider,http://www.businessinsider.com/solanezumab-alzheimers-disease-drug-fails-phase-3-trial-2016-11
41.0,11/23/2016 6:42:20 PM,"Lilly failure a blow for Alzheimer's research, not end of road (LLY, BIIB, AZN)",Reuters,http://www.businessinsider.com/r-lilly-failure-a-blow-for-alzheimers-research-not-end-of-road-2016-11
42.0,11/23/2016 11:28:18 PM,"Roche confident in Alzheimer's programmes, despite Lilly flop (LLY)",Reuters,http://www.businessinsider.com/r-roche-confident-in-alzheimers-programmes-despite-lilly-flop-2016-11
43.0,12/1/2016 12:04:06 PM,"BRIEF-Lupin Ltd and Eli Lilly expand partnership in India (LUPIN, LLY)",Reuters,http://www.businessinsider.com/r-brief-lupin-ltd-and-eli-lilly-expand-partnership-in-india-2016-12
44.0,12/2/2016 10:30:03 PM,BRIEF-FDA approves jardiance to reduce cardiovascular death in adults with Type 2 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-approves-jardiance-to-reduce-cardiovascular-death-in-adults-with-type-2-diabetes-2016-12
45.0,12/2/2016 10:42:03 PM,Lilly's diabetes drug Jardiance cuts risk of cardiovascular death: FDA,Reuters,http://www.businessinsider.com/r-lillys-diabetes-drug-jardiance-cuts-risk-of-cardiovascular-death-fda-2016-12
46.0,12/2/2016 11:20:03 PM,UPDATE 1-FDA allows use of diabetes drug Jardiance to reduce heart risk (LLY),Reuters,http://www.businessinsider.com/r-update-1-fda-allows-use-of-diabetes-drug-jardiance-to-reduce-heart-risk-2016-12
47.0,12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12
48.0,12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12
49.0,12/8/2016 4:16:09 PM,BRIEF-Lilly says neoMONARCH phase 2 trial met primary endpoint of reducing expression of KI67 (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-neomonarch-phase-2-trial-met-primary-endpoint-of-reducing-expression-of-ki67-2016-12
50.0,12/9/2016 2:46:03 PM,BRIEF-Eli lilly says Solanezumab did not meet primary endpoint in expedition3 clinical trial (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-solanezumab-did-not-meet-primary-endpoint-in-expedition3-clinical-trial-2016-12
51.0,12/9/2016 3:14:03 PM,"BRIEF-Lilly, Astrazeneca to develop potentially disease-modifying Alzheimer's treatment (LLY, AZN)",Reuters,http://www.businessinsider.com/r-brief-lilly-astrazeneca-to-develop-potentially-disease-modifying-alzheimers-treatment-2016-12
52.0,12/9/2016 3:55:11 PM,"We just got some of the most promising Alzheimer's drug data of the year (BIIB, LLY)",Reuters,http://www.businessinsider.com/r-update-1-further-promising-data-seen-with-biogen-alzheimers-drug-study-2016-12
53.0,12/9/2016 4:00:08 PM,"Astra, Lilly stick with Alzheimer's approach despite setback (BIIB, LLY, AZN)",Reuters,http://www.businessinsider.com/r-astra-lilly-stick-with-alzheimers-approach-despite-setback-2016-12
54.0,12/9/2016 11:36:03 PM,"New diabetes guidelines imminent, Jardiance sales may surge",Reuters,http://www.businessinsider.com/r-new-diabetes-guidelines-imminent-jardiance-sales-may-surge-2016-12
55.0,12/12/2016 11:14:05 PM,BRIEF-FDA approves Synjardy XR tablets for adults with type 2 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-approves-synjardy-xr-tablets-for-adults-with-type-2-diabetes-2016-12
56.0,12/13/2016 7:06:05 AM,BRIEF-Lilly reports dividend increase (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-dividend-increase-2016-12
57.0,12/13/2016 2:16:04 PM,"BRIEF-Eli Lilly announces program to provide Insulin at discounted prices (ESRX, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-program-to-provide-insulin-at-discounted-prices-2016-12
58.0,12/13/2016 2:54:09 PM,Lilly to offer insulin at discounted prices,Reuters,http://www.businessinsider.com/r-lilly-to-offer-insulin-at-discounted-prices-2016-12
59.0,12/13/2016 4:15:23 PM,"Some people spend as much on insulin as their mortgage - and drugmakers are taking note (NVO, LLY)",Business Insider,http://www.businessinsider.com/lilly-express-scripts-blink-health-insulin-discounts-2016-12
60.0,12/13/2016 4:40:06 PM,"UPDATE 1-Lilly to offer insulin at discounted prices to certain patients (LLY, CVS, TGT, ESRX)",Reuters,http://www.businessinsider.com/r-update-1-lilly-to-offer-insulin-at-discounted-prices-to-certain-patients-2016-12
61.0,12/15/2016 12:50:03 PM,BRIEF-Eli Lilly provides 2017 financial forecast and 2016 update (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-provides-2017-financial-forecast-and-2016-update-2016-12
62.0,12/15/2016 1:06:03 PM,"Lilly forecasts 2017 revenue, profit above estimates (LLY)",Reuters,http://www.businessinsider.com/r-lilly-forecasts-2017-revenue-profit-above-estimates-2016-12
63.0,12/15/2016 1:46:03 PM,"UPDATE 1-Lilly forecasts 2017 revenue, profit above estimates (LLY)",Reuters,http://www.businessinsider.com/r-update-1-lilly-forecasts-2017-revenue-profit-above-estimates-2016-12
64.0,12/15/2016 4:59:53 PM,"A cheaper version of the lifesaving diabetes medication just launched in the US (NVO, LLY, SNY)",Business Insider,http://www.businessinsider.com/insulin-cheaper-generic-2016-12
65.0,12/15/2016 5:20:05 PM,BRIEF-Eli Lilly sees potential launch of 20 new drugs through 2023 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-sees-potential-launch-of-20-new-drugs-through-2023-2016-12
66.0,12/16/2016 2:00:07 PM,BRIEF-EMA recommends approving new Eli Lilly rheumatoid arthritis drug (LLY),Reuters,http://www.businessinsider.com/r-brief-ema-recommends-approving-new-eli-lilly-rheumatoid-arthritis-drug-2016-12
67.0,12/16/2016 7:06:03 PM,BRIEF-Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with type 1 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-adocia-and-lilly-announce-successful-completion-of-an-insulin-pump-study-with-biochaperone-lispro-in-people-with-type-1-diabetes-2016-12
68.0,12/16/2016 10:44:02 PM,"BRIEF-Incyte Corp , Eli Lilly amended license, development and commercialization agreement, entered into as of December 18, 2009 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-corp--eli-lilly-amended-license-development-and-commercialization-agreement-entered-into-as-of-december-18-2009-2016-12
69.0,12/23/2016 8:42:05 PM,Migraine drugs may repeat rheumatoid arthritis success,Reuters,http://www.businessinsider.com/r-migraine-drugs-may-repeat-rheumatoid-arthritis-success-2016-12
70.0,12/27/2016 6:26:03 PM,Sanofi sues Novo Nordisk over diabetes drugs in the U.S.,Reuters,http://www.businessinsider.com/r-sanofi-sues-novo-nordisk-over-diabetes-drugs-in-the-us-2016-12
71.0,12/28/2016 11:24:03 PM,"UPDATE 1-U.S. FTC requires divestitures in $13.53 bln Boehringer-Sanofi deal (SAN, BAYN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-ftc-requires-divestitures-in-1353-bln-boehringer-sanofi-deal-2016-12
72.0,1/23/2017 2:08:04 PM,BRIEF-Inovalon announces agreement with Boehringer Ingelheim to support outcome-based contracting (LLY),Reuters,http://www.businessinsider.com/r-brief-inovalon-announces-agreement-with-boehringer-ingelheim-to-support-outcome-based-contracting-2017-1
73.0,1/24/2017 10:50:06 PM,BRIEF-Galliprant now available for canine osteoarthritis (LLY),Reuters,http://www.businessinsider.com/r-brief-galliprant-now-available-for-canine-osteoarthritis-2017-1
74.0,1/25/2017 8:52:06 AM,"UPDATE 2-Novartis considers Alcon spin-off, launches share buyback (LLY)",Reuters,http://www.businessinsider.com/r-update-2-novartis-considers-alcon-spin-off-launches-share-buyback-2017-1
75.0,1/27/2017 8:16:10 AM,BRIEF-Adocia says Eli Lilly terminates collaboration biochaperone Lispro (LLY),Reuters,http://www.businessinsider.com/r-brief-adocia-says-eli-lilly-terminates-collaboration-biochaperone-lispro-2017-1
76.0,1/27/2017 2:04:05 PM,"BRIEF-EMA recommends approval of two biosimilars from Amgen (AMGN, LLY, GSK)",Reuters,http://www.businessinsider.com/r-brief-ema-recommends-approval-of-two-biosimilars-from-amgen-2017-1
77.0,1/30/2017 9:46:06 PM,"Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit",Reuters,http://www.businessinsider.com/r-sanofi-novo-nordisk-and-lilly-named-in-patients-price-fixing-suit-2017-1
78.0,1/30/2017 10:06:06 PM,"UPDATE 1-Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit (SAN, NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-novo-nordisk-and-lilly-named-in-patients-price-fixing-suit-2017-1
79.0,1/31/2017 7:34:07 AM,"PRESS DIGEST- New York Times business news - Jan 31 (AMZN, EXPE, DBK, SAN, NOVO , LLY)",Reuters,http://www.businessinsider.com/r-press-digest--new-york-times-business-news---jan-31-2017-1
80.0,1/31/2017 12:56:06 PM,Lilly revenue rises 7.2 pct on higher demand for new drugs (LLY),Reuters,http://www.businessinsider.com/r-lilly-revenue-rises-72-pct-on-higher-demand-for-new-drugs-2017-1
81.0,1/31/2017 1:00:52 PM,10 things you need to know today,Business Insider,http://www.businessinsider.com/opening-bell-january-31-2017-2017-1
82.0,1/31/2017 1:02:07 PM,BRIEF-Lilly reports Q4 EPS $0.73 (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-q4-eps-073-2017-1
83.0,1/31/2017 2:30:32 PM,"10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, DB, LLY)",Business Insider,http://markets.businessinsider.com/news/stocks/opening-bell-january-31-2017-2017-1-1001708230
84.0,1/31/2017 4:10:07 PM,"Trump meets with drugmakers, seeks lower prices, U.S. production (MRK, JNJ, CELG, LLY, AMGN)",Reuters,http://www.businessinsider.com/r-trump-meets-with-drugmakers-seeks-lower-prices-us-production-2017-1
85.0,1/31/2017 7:06:07 PM,"UPDATE 3-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-3-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1
86.0,1/31/2017 7:44:07 PM,BRIEF-Lilly CEO says prepared for all scenarios in case of ACA repeal (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-ceo-says-prepared-for-all-scenarios-in-case-of-aca-repeal-2017-1
87.0,1/31/2017 7:51:41 PM,Trump Calls For Increased Competition To Reduce Drug Prices ,RTTNews,/news/stocks/trump-calls-for-increased-competition-to-reduce-drug-prices-1001710287
88.0,1/31/2017 9:30:07 PM,"UPDATE 4-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-4-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1
89.0,2/2/2017 3:34:08 PM,BRIEF-Japan high court rules in Lilly's favor on Alimta patents (LLY),Reuters,http://www.businessinsider.com/r-brief-japan-high-court-rules-in-lillys-favor-on-alimta-patents-2017-2
90.0,2/2/2017 11:16:08 PM,"GE, Boeing, Oracle form coalition to support Republican border tax",Reuters,http://www.businessinsider.com/r-ge-boeing-oracle-form-coalition-to-support-republican-border-tax-2017-2
91.0,2/8/2017 12:55:01 PM,Lilly's Trulicity Label Updated On Basal Insulin ,RTTNews,/news/stocks/lilly-s-trulicity-label-updated-on-basal-insulin-1001732734
92.0,2/8/2017 1:10:09 PM,BRIEF-Lilly announces label update for its diabetes drug Trulicity (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-label-update-for-its-diabetes-drug-trulicity-2017-2
93.0,2/9/2017 1:30:06 PM,BRIEF-Carolyn Bertozzi elected to Lilly board of directors (LLY),Reuters,http://www.businessinsider.com/r-brief-carolyn-bertozzi-elected-to-lilly-board-of-directors-2017-2
94.0,2/13/2017 10:56:10 PM,"BRIEF-European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-once-daily-olumiant-tablets-for-treatment-of-rheumatoid-arthritis-2017-2
95.0,2/14/2017 6:46:10 PM,BRIEF-Adocia 2016 revenue down at 22.4 million euros (LLY),Reuters,http://www.businessinsider.com/r-brief-adocia-2016-revenue-down-at-224-million-euros-2017-2
96.0,2/15/2017 12:22:10 AM,Merck to halt study of mild to moderate Alzheimer's drug,Reuters,http://www.businessinsider.com/r-merck-to-halt-study-of-mild-to-moderate-alzheimers-drug-2017-2
97.0,2/15/2017 1:08:10 AM,"UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails (MRK, LLY)",Reuters,http://www.businessinsider.com/r-update-1-merck-stopping-late-stage-study-as-another-alzheimers-drug-fails-2017-2
98.0,2/16/2017 12:12:11 AM,"BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-additional-results-from-pivotal-ra-beam-study-published-in-new-england-journal-of-medicine-2017-2
99.0,2/21/2017 1:50:12 PM,"Export companies tell U.S. Congress to push tax code rewrite (BA, CAT, GE, DOW, CE, CELG, LLY, RTN, MRK, UTX, PFE, VAR)",Reuters,http://www.businessinsider.com/r-export-companies-tell-us-congress-to-push-tax-code-rewrite-2017-2
100.0,2/21/2017 5:56:12 PM,"UPDATE 1-CEOs of 16 U.S. companies urge Congress to pass border tax (BA, CAT, GE, AAPL, IBM, INTC, DOW, CE, CELG, LLY, RTN, MRK, UTX, PFE, VAR)",Reuters,http://www.businessinsider.com/r-update-1-ceos-of-16-us-companies-urge-congress-to-pass-border-tax-2017-2
101.0,2/21/2017 10:16:12 PM,BRIEF-Lilly says provisions included in legislation to repeal Affordable Care Act could adversely affect results (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-provisions-included-in-legislation-to-repeal-affordable-care-act-could-adversely-affect-results-2017-2
102.0,2/24/2017 8:22:12 PM,"BRIEF-FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi (SAN, BAYN, LLY)",Reuters,http://www.businessinsider.com/r-brief-ftc-approves-final-order-settling-charges-for-boehringer-ingelheims-asset-swap-with-sanofi-2017-2
103.0,2/28/2017 3:00:00 PM,Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting,PR Newswire,/news/stocks/lilly-to-present-new-data-for-taltz-ixekizumab-in-psoriasis-and-psoriatic-arthritis-at-the-american-academy-of-dermatology-aad-annual-meeting-1001790430
104.0,2/28/2017 3:20:41 PM,"The quest to find new drugs to treat Alzheimer's just suffered another blow (MRK, LLY, BIIB, AMGN)",Reuters,http://www.businessinsider.com/r-acceras-alzheimers-trial-fails-in-yet-another-setback-for-disease-2017-2
105.0,3/1/2017 2:45:00 PM,Lilly Completes Acquisition of CoLucid Pharmaceuticals,PR Newswire,/news/stocks/lilly-completes-acquisition-of-colucid-pharmaceuticals-1001794873
106.0,3/1/2017 3:10:19 PM,BRIEF-Perrigo announces FDA final approval for the generic version of Axiron topical solution (LLY),Reuters,http://www.businessinsider.com/r-brief-perrigo-announces-fda-final-approval-for-the-generic-version-of-axiron-topical-solution-2017-3
107.0,3/2/2017 12:45:00 PM,Lilly Announces Changes in Senior Management,PR Newswire,/news/stocks/lilly-announces-changes-in-senior-management-1001798603
108.0,3/3/2017 8:45:00 PM,Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®',PR Newswire,/news/stocks/lilly-diabetes-becomes-official-diabetes-health-partner-of-nascar-1001804016
109.0,3/4/2017 3:20:00 PM,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis,PR Newswire,/news/stocks/new-head-to-head-data-shows-significantly-higher-response-rates-for-lilly-s-taltz-ixekizumab-compared-to-stelara-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-1001804620
110.0,3/5/2017 5:55:17 AM,Lilly: Taltz Shows Superior Efficacy Compared To Stelara In Plaque Psoriasis ,RTTNews,/news/stocks/lilly-taltz-shows-superior-efficacy-compared-to-stelara-in-plaque-psoriasis-1001804733
111.0,3/8/2017 5:42:22 PM,"INSIGHT-'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks (JNJ, MRK, LLY, CELG, AMGN, GM, F, CPB, TGT, LUV, UAL, DAL)",Reuters,http://www.businessinsider.com/r-insight-its-like-kumbaya-trumps-genial-private-meetings-with-ceos-jar-with-public-attacks-2017-3
112.0,3/13/2017 1:00:00 PM,OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon,PR Newswire,/news/stocks/oilprice-com-the-next-big-biotech-breakthrough-could-just-be-on-the-horizon-1001828875
113.0,3/17/2017 12:10:00 PM,"Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/technical-reports-on-drug-makers-stocks-bristol-myers-squibb-astrazeneca-eli-lilly-and-immune-pharma-1001845502
114.0,3/17/2017 1:00:00 PM,First dedicated outcome trials of empagliflozin in chronic heart failure initiated,PR Newswire,/news/stocks/first-dedicated-outcome-trials-of-empagliflozin-in-chronic-heart-failure-initiated-1001845706
115.0,3/17/2017 2:04:43 PM,BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated (LLY),Reuters,http://www.businessinsider.com/r-brief-first-dedicated-outcome-trials-of-empagliflozin-in-chronic-heart-failure-initiated-2017-3
116.0,3/19/2017 9:12:46 PM,Newer type 2 diabetes drugs show heart protective quality in study,Reuters,http://www.businessinsider.com/r-newer-type-2-diabetes-drugs-show-heart-protective-quality-in-study-2017-3
117.0,3/20/2017 11:45:00 AM,Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival,PR Newswire,/news/stocks/lilly-announces-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint-of-progression-free-survival-1001849408
118.0,3/20/2017 12:10:07 PM,Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint ,RTTNews,/news/stocks/lilly-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint-1001849493
119.0,3/20/2017 12:24:44 PM,"UPDATE 1-Lilly's breast cancer drug combination succeeds key study (LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-lillys-breast-cancer-drug-combination-succeeds-key-study-2017-3
120.0,3/20/2017 3:34:46 PM,BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-says-ceo-john-lechleiters-2016-total-compensation-was-184-mln-2017-3
121.0,3/23/2017 5:00:00 PM,Lilly and the William Sansum Diabetes Center announce a five-year research collaboration,PR Newswire,/news/stocks/lilly-and-the-william-sansum-diabetes-center-announce-a-five-year-research-collaboration-1001863095
122.0,3/23/2017 9:50:47 PM,BRIEF-Ignyta to explore strategic options for Taladegib through amendment of Taladegib license agreement with Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-ignyta-to-explore-strategic-options-for-taladegib-through-amendment-of-taladegib-license-agreement-with-lilly-2017-3
123.0,3/24/2017 11:33:55 AM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1001865270
124.0,3/24/2017 1:00:00 PM,Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017,PR Newswire,/news/stocks/lilly-announces-850-million-investment-in-u-s-capital-projects-in-2017-1001865606
125.0,3/24/2017 1:12:49 PM,Eli Lilly Plans $850 Mln Investments In U.S. Operations In FY17 - Quick Facts ,RTTNews,/news/stocks/eli-lilly-plans-850-mln-investments-in-u-s-operations-in-fy17-quick-facts-1001865658
126.0,3/24/2017 1:30:48 PM,BRIEF-Eli Lilly announces $850 mln investment in U.S. capital projects in 2017 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-850-mln-investment-in-us-capital-projects-in-2017-2017-3
127.0,3/24/2017 1:30:48 PM,Drugmaker Lilly to invest $850 mln in U.S. operations in 2017 (LLY),Reuters,http://www.businessinsider.com/r-drugmaker-lilly-to-invest-850-mln-in-us-operations-in-2017-2017-3
128.0,3/24/2017 2:14:46 PM,UPDATE 1-Drugmaker Lilly to invest $850 mln in U.S. operations in 2017 (LLY),Reuters,http://www.businessinsider.com/r-update-1-drugmaker-lilly-to-invest-850-mln-in-us-operations-in-2017-2017-3
129.0,3/24/2017 4:42:45 PM,"LPC: Top US firms raise loans on tax reform hopes (LLY, BMY, CSCO)",Reuters,http://www.businessinsider.com/r-lpc-top-us-firms-raise-loans-on-tax-reform-hopes-2017-3
130.0,3/28/2017 2:28:49 PM,"BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent (IGX, LLY)",Reuters,http://www.businessinsider.com/r-brief-intelgenx-technologies-says-eli-lilly-granted-versafilm-exclusive-license-for-tadalafil-film-product-under-erectile-dysfunction-dosing-patent-2017-3
131.0,3/31/2017 6:24:48 PM,"BRIEF-Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-lilly-endowment-inc-reports-open-market-sale-of-210000-of-stock-2017-3
132.0,4/4/2017 7:00:00 PM,Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students,PR Newswire,/news/stocks/lilly-and-ohio-university-heritage-college-of-osteopathic-medicine-partner-on-rotation-program-for-medical-students-1001895732
133.0,4/5/2017 11:00:52 AM,"Boehringer eyes marked sales gain, boosted by animal health (SAN, LLY)",Reuters,http://www.businessinsider.com/r-boehringer-eyes-marked-sales-gain-boosted-by-animal-health-2017-4
134.0,4/7/2017 4:00:00 PM,"Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences",PR Newswire,/news/stocks/life-with-type-1-diabetes-made-a-little-easier-through-lilly-diabetes-scholarship-donations-for-camps-college-and-conferences-1001907024
135.0,4/11/2017 8:13:02 AM,"PRESS DIGEST - Wall Street Journal - April 11 (WFM, WFC, BARC, UAL, TSLA, LLY, 2354, 6502)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---april-11-2017-4
136.0,4/11/2017 5:00:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2017-financial-results-announcement-1001914519
137.0,4/14/2017 3:00:00 PM,U.S. FDA Issues Complete Response Letter for Baricitinib,PR Newswire,/news/stocks/u-s-fda-issues-complete-response-letter-for-baricitinib-1001922584
138.0,4/14/2017 3:10:34 PM,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib ,RTTNews,/news/stocks/eli-lilly-and-incyte-say-fda-issues-crl-for-baricitinib-1001922595
139.0,4/14/2017 3:59:02 PM,"BRIEF-U.S. FDA issues CRL for baricitinib (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-us-fda-issues-crl-for-baricitinib-2017-4
140.0,4/14/2017 6:05:04 PM,"U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant (LLY, INCY, PFE)",Reuters,http://www.businessinsider.com/r-us-fda-declines-to-approve-eli-lilly-and-incyte-arthritis-drug-olumiant-2017-4
141.0,4/17/2017 6:24:50 AM,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move ",RTTNews,/news/stocks/fda-says-no-to-incy-zts-snaps-up-nvet-mdxg-on-the-move-1001923443
142.0,4/17/2017 1:59:03 PM,"US STOCKS-Futures dip on soft U.S. data, geopolitical risks (NFLX, UAL, INCY, LLY, PFE)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-dip-on-soft-us-data-geopolitical-risks-2017-4
143.0,4/17/2017 2:50:35 PM,"The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling (INCY, LLY)",Business Insider,http://www.businessinsider.com/fda-rejects-lilly-and-incytes-baricitinib-2017-4
144.0,4/17/2017 3:13:03 PM,"US STOCKS-Wall Street looks set to open slightly higher (NFLX, UAL, INCY, LLY, PFE, ALR, ABT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-looks-set-to-open-slightly-higher-2017-4
145.0,4/17/2017 4:55:07 PM,"US STOCKS-Wall St edges higher as tech, financials gain (NFLX, UAL, INCY, LLY, ALR, ABT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-higher-as-tech-financials-gain-2017-4
146.0,4/17/2017 10:45:05 PM,"US STOCKS-Wall St rallies in low volume led by banks, tech (NFLX, AMZN, BA, INCY, LLY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-rallies-in-low-volume-led-by-banks-tech-2017-4
147.0,4/19/2017 5:41:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-eli-lilly-and-company-lly-1001931509
148.0,4/20/2017 5:35:00 PM,Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting,PR Newswire,/news/stocks/lilly-to-present-data-for-galcanezumab-for-the-prevention-of-migraine-at-the-american-academy-of-neurology-aan-annual-meeting-1001935489
149.0,4/21/2017 3:15:05 PM,"UPDATE 1-Valeant prices psoriasis treatment at $3,500 per month (VRX, LLY, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-valeant-prices-psoriasis-treatment-at-3500-per-month-2017-4
150.0,4/21/2017 9:51:09 PM,"EMA panel recommends nod for Sanofi, Regeneron's arthritis drug (SAN, REGN, JNJ, LLY, INCY)",Reuters,http://www.businessinsider.com/r-ema-panel-recommends-nod-for-sanofi-regenerons-arthritis-drug-2017-4
151.0,4/24/2017 12:25:00 PM,"Drug Makers Stocks Under Scanner -- Bristol-Myers, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-bristol-myers-astrazeneca-eli-lilly-and-immune-pharma-1001941450
152.0,4/24/2017 12:45:00 PM,Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis,PR Newswire,/news/stocks/lilly-announces-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-demonstrated-superior-progression-free-survival-at-interim-analysis-1001941508
153.0,4/24/2017 12:53:03 PM,Lilly :Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Shows Superior PFS ,RTTNews,/news/stocks/lilly-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-shows-superior-pfs-1001941530
154.0,4/24/2017 1:25:10 PM,BRIEF-Lilly says phase 3 MONARCH 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-demonstrated-superior-progression-free-survival-at-interim-analysis-2017-4
155.0,4/24/2017 7:01:12 PM,"Lilly reports positive interim data on breast cancer combo drug (LLY, PFE)",Reuters,http://www.businessinsider.com/r-lilly-reports-positive-interim-data-on-breast-cancer-combo-drug-2017-4
156.0,4/25/2017 8:33:08 AM,"BRIEF-Novartis CEO says takeover prices have risen, focusing on early-stage targets (LLY)",Reuters,http://www.businessinsider.com/r-brief-novartis-ceo-says-takeover-prices-have-risen-focusing-on-early-stage-targets-2017-4
157.0,4/25/2017 12:05:10 PM,"UPDATE 2-Novartis sets sights on return to growth in 2018 (GSK, LLY)",Reuters,http://www.businessinsider.com/r-update-2-novartis-sets-sights-on-return-to-growth-in-2018-2017-4
158.0,4/25/2017 12:25:00 PM,Lilly Reports First-Quarter 2017 Results,PR Newswire,/news/stocks/lilly-reports-first-quarter-2017-results-1001945666
159.0,4/25/2017 12:32:28 PM,Eli Lilly And Co. Announces 18% Increase In Q1 Profit,RTTNews,/news/stocks/eli-lilly-and-co-announces-18-increase-in-q1-profit-1001945700
160.0,4/25/2017 12:49:08 PM,BRIEF-Lilly Q1 non-GAAP earnings per share $0.98 (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-q1-non-gaap-earnings-per-share-098-2017-4
161.0,4/25/2017 12:58:20 PM,Lilly Q1 Results Top Estimates; Cuts 2017 EPS View ,RTTNews,/news/stocks/lilly-q1-results-top-estimates-cuts-2017-eps-view-1001945794
162.0,4/25/2017 1:11:08 PM,"UPDATE 1-Eli Lilly's profit beats on demand for newer drugs (LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-eli-lillys-profit-beats-on-demand-for-newer-drugs-2017-4
163.0,4/25/2017 2:25:00 PM,Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders,PR Newswire,/news/stocks/autism-awareness-puts-spotlight-on-development-of-innovative-therapies-and-treatments-for-youth-mental-disorders-1001946378
164.0,4/25/2017 2:25:00 PM,Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders,PR Newswire,/news/stocks/autism-awareness-puts-spotlight-on-development-of-innovative-therapies-and-treatments-for-youth-mental-disorders-1001946377
165.0,4/26/2017 4:00:00 PM,The global car rental industry is expected to reach $99.6 billion by 2022,PR Newswire,/news/stocks/the-global-car-rental-industry-is-expected-to-reach-$99-6-billion-by-2022-1001611911
166.0,4/28/2017 12:49:07 PM,"CORRECTED-UPDATE 2-Valeant prices psoriasis treatment at $3,500 per month (April 21) (VRX, LLY, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-corrected-update-2-valeant-prices-psoriasis-treatment-at-3500-per-month-april-21-2017-4
167.0,5/1/2017 6:58:05 PM,BRIEF-Eli Lilly says got civil investigative demand from Washington AG's office about pricing of insulin products (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-got-civil-investigative-demand-from-washington-ags-office-about-pricing-of-insulin-products-2017-5
168.0,5/1/2017 8:45:00 PM,Lilly Declares Second-Quarter 2017 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2017-dividend-1001966540
169.0,5/1/2017 9:32:02 PM,BRIEF-Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-sets-q2-2017-dividend-of-052-per-share-2017-5
170.0,5/2/2017 9:30:00 PM,Lilly Announces Webcast to Discuss Oncology Pipeline,PR Newswire,/news/stocks/lilly-announces-webcast-to-discuss-oncology-pipeline-1001639351
171.0,5/3/2017 11:24:05 AM,"UPDATE 1-Drugmaker Novo Nordisk nudges up full-year profit outlook after Q1 beat (NOVO , SAN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-novo-nordisk-nudges-up-full-year-profit-outlook-after-q1-beat-2017-5
172.0,5/3/2017 7:00:00 PM,Lilly to Participate in UBS Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-global-healthcare-conference-1001975846
173.0,5/4/2017 1:44:02 PM,"BRIEF-Incyte Q1 loss per share $0.96 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-q1-loss-per-share-096-2017-5
174.0,5/4/2017 2:50:03 PM,BRIEF-Eli Lilly and Co files for potential three-part notes offering (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-files-for-potential-three-part-notes-offering-2017-5
175.0,5/10/2017 2:00:00 PM,Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications,PR Newswire,/news/stocks/leigh-ann-pusey-joins-lilly-as-senior-vice-president-of-corporate-affairs-and-communications-1001998994
176.0,5/10/2017 7:00:00 PM,Lilly to Participate in Bernstein Strategic Decisions Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bernstein-strategic-decisions-conference-1002000451
177.0,5/11/2017 12:00:05 AM,"UPDATE 1-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer (MRK, LLY, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-2017-5
178.0,5/12/2017 12:45:00 PM,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,PR Newswire,/news/stocks/lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-for-the-prevention-of-episodic-and-chronic-migraine-1002007829
179.0,5/12/2017 12:57:09 PM,Lilly: Galcanezumab For Migraine Met Primary Endpoint In Three Phase 3 Trials ,RTTNews,/news/stocks/lilly-galcanezumab-for-migraine-met-primary-endpoint-in-three-phase-3-trials-1002007862
180.0,5/12/2017 1:02:03 PM,BRIEF-Lilly announces positive results for three phase 3 studies of galcanezumab (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-2017-5
181.0,5/12/2017 1:12:02 PM,Lilly migraine treatment meets main goal in late-stage studies (LLY),Reuters,http://www.businessinsider.com/r-lilly-migraine-treatment-meets-main-goal-in-late-stage-studies-2017-5
182.0,5/12/2017 4:29:13 PM,An experimental treatment for migraines just passed a critical study (LLY),Reuters,http://www.businessinsider.com/r-update-1-lilly-migraine-treatment-meets-main-goal-in-late-stage-studies-2017-5
183.0,5/16/2017 12:00:04 AM,"BRIEF-Soros Fund Management dissolves share stake in Ebay Inc (EBAY, LLY)",Reuters,http://www.businessinsider.com/r-brief-soros-fund-management-dissolves-share-stake-in-ebay-inc-2017-5
184.0,5/16/2017 12:44:03 PM,"BRIEF-Lupin and Lilly expand partnership in India (LUPIN, LLY)",Reuters,http://www.businessinsider.com/r-brief-lupin-and-lilly-expand-partnership-in-india-2017-5
185.0,5/16/2017 1:30:00 PM,Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom,PR Newswire,/news/stocks/actress-angela-bassett-joins-for-your-sweetheart-to-urge-people-with-diabetes-to-know-their-heart-disease-risk-in-honor-of-her-mom-1002016569
186.0,5/16/2017 2:08:04 PM,BRIEF-3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-3sbio-inc-enters-distribution-and-promotion-agreement-with-two-subsidiaries-of-eli-lilly-2017-5
187.0,5/17/2017 1:26:03 AM,"U.S. FDA warns of foot, leg amputations with J&J diabetes drug (JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-us-fda-warns-of-foot-leg-amputations-with-jj-diabetes-drug-2017-5
188.0,5/18/2017 12:26:05 PM,"BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company (UTHR, LLY)",Reuters,http://www.businessinsider.com/r-brief-united-therapeutics-says-it-entered-into-first-amendment-to-license-agreement-with-eli-lilly-and-company-2017-5
189.0,5/20/2017 9:22:05 AM,"U.S., China accelerate beef talks; deal possible by early June (TSN, JBSS3, LLY)",Reuters,http://www.businessinsider.com/r-us-china-accelerate-beef-talks-deal-possible-by-early-june-2017-5
190.0,5/22/2017 12:38:07 PM,"RPT-U.S., China accelerate beef talks; deal possible by early June (TSN, JBSS3, LLY)",Reuters,http://www.businessinsider.com/r-rpt-us-china-accelerate-beef-talks-deal-possible-by-early-june-2017-5
191.0,5/30/2017 7:26:03 PM,"U.S. top court restricts patent owners' right to block resale of goods (002180, PFE, LLY, INTC)",Reuters,http://www.businessinsider.com/r-us-top-court-restricts-patent-owners-right-to-block-resale-of-goods-2017-5
192.0,5/30/2017 8:46:04 PM,"UPDATE 1-U.S. top court restricts patent owners' right to block resale of goods (002180, PFE, LLY, INTC)",Reuters,http://www.businessinsider.com/r-update-1-us-top-court-restricts-patent-owners-right-to-block-resale-of-goods-2017-5
193.0,5/30/2017 10:54:03 PM,BRIEF-Canadian pork processor Olymel says shipped tainted pork to China (LLY),Reuters,http://www.businessinsider.com/r-brief-canadian-pork-processor-olymel-says-shipped-tainted-pork-to-china-2017-5
194.0,5/31/2017 7:24:05 AM,"Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study (SHP, LLY)",Reuters,http://www.businessinsider.com/r-swiss-biotech-nls-pharmas-adhd-drug-succeeds-in-mid-stage-study-2017-5
195.0,5/31/2017 8:14:00 AM,"ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD ",RTTNews,/news/stocks/albo-spikes-glyc-abuzz-fda-approves-1st-generic-strattera-for-adhd-1002052929
196.0,5/31/2017 12:45:00 PM,"Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival",PR Newswire,/news/stocks/lilly-announces-phase-3-range-urothelial-cancer-trial-of-cyramza-ramucirumab-met-primary-endpoint-improving-progression-free-survival-1002053990
197.0,5/31/2017 12:59:34 PM,Lilly Says Phase 3 RANGE Urothelial Cancer Trial Of CYRAMZA Met Primary Endpoint ,RTTNews,/news/stocks/lilly-says-phase-3-range-urothelial-cancer-trial-of-cyramza-met-primary-endpoint-1002054014
198.0,5/31/2017 1:04:03 PM,BRIEF-Eli Lilly announces phase 3 RANGE Urothelial cancer trial of CYRAMZA met primary endpoint (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-phase-3-range-urothelial-cancer-trial-of-cyramza-met-primary-endpoint-2017-5
199.0,5/31/2017 8:30:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1002056191
200.0,6/1/2017 12:20:00 PM,"Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi",PR Newswire,/news/stocks/drug-makers-stocks-on-investors-radar-astrazeneca-bristol-myers-squibb-eli-lilly-and-sanofi-1002058233
201.0,6/1/2017 12:45:00 PM,Derica Rice to Retire as Lilly Chief Financial Officer,PR Newswire,/news/stocks/derica-rice-to-retire-as-lilly-chief-financial-officer-1002058356
202.0,6/1/2017 1:00:09 PM,BRIEF-Eli Lilly says Derica Rice to retire as CFO (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-derica-rice-to-retire-as-cfo-2017-6
203.0,6/1/2017 1:03:27 PM,Eli Lilly CFO Derica Rice To Retire By End Of 2017  - Quick Facts ,RTTNews,/news/stocks/eli-lilly-cfo-derica-rice-to-retire-by-end-of-2017-quick-facts-1002058456
204.0,6/1/2017 1:04:03 PM,Lilly CFO to retire by the end of this year (LLY),Reuters,http://www.businessinsider.com/r-lilly-cfo-to-retire-by-the-end-of-this-year-2017-6
205.0,6/1/2017 2:30:00 PM,Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®,PR Newswire,/news/stocks/boehringer-ingelheim-and-lilly-diabetes-alliance-to-present-33-abstracts-at-the-american-diabetes-association-s-77th-scientific-sessions-1002059036
206.0,6/2/2017 5:18:08 PM,"Novo Nordisk looks to shore up European market share (NOVO , SAN, LLY)",Reuters,http://www.businessinsider.com/r-novo-nordisk-looks-to-shore-up-european-market-share-2017-6
207.0,6/3/2017 8:15:00 PM,Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer,PR Newswire,/news/stocks/lilly-builds-upon-body-of-data-for-abemaciclib-with-phase-3-monarch-2-data-demonstrating-superior-progression-free-survival-in-advanced-breast-cancer-1002065390
208.0,6/5/2017 7:26:03 AM,"RPT-INSIGHT-Canada beats US in pork sales to China - feet, elbows and all (SEB, LLY, TSN, HRL, 288)",Reuters,http://www.businessinsider.com/r-rpt-insight-canada-beats-us-in-pork-sales-to-china---feet-elbows-and-all-2017-6
209.0,6/5/2017 7:26:04 AM,"INSIGHT-Canada beats US in pork sales to China - feet, elbows and all (SEB, LLY, TSN, HRL, 288)",Reuters,http://www.businessinsider.com/r-insight-canada-beats-us-in-pork-sales-to-china---feet-elbows-and-all-2017-6
210.0,6/7/2017 2:00:00 PM,Blink Health Commits To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment,PR Newswire,/news/stocks/blink-health-commits-to-give-away-10-million-worth-of-free-diabetes-medications-to-help-people-afford-treatment-1002074089
211.0,6/7/2017 2:52:06 PM,"UPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage trial (AMGN, PFE, LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-abbvies-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-2017-6
212.0,6/7/2017 6:23:00 PM,News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment,PR Newswire,/news/stocks/news-alert-blink-health-to-give-away-10-million-worth-of-free-diabetes-medications-to-help-people-afford-treatment-1002075532
213.0,6/8/2017 12:30:00 PM,Lilly Announces Strategic Collaboration with KeyBioscience AG,PR Newswire,/news/stocks/lilly-announces-strategic-collaboration-with-keybioscience-ag-1002077714
214.0,6/8/2017 12:46:04 PM,BRIEF-Lilly announces strategic collaboration with Keybioscience (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-strategic-collaboration-with-keybioscience-2017-6
215.0,6/8/2017 9:00:00 PM,Lilly Announces Webcast to Discuss Pain Management Portfolio,PR Newswire,/news/stocks/lilly-announces-webcast-to-discuss-pain-management-portfolio-1002079693
216.0,6/8/2017 9:25:00 PM,Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting,PR Newswire,/news/stocks/lilly-to-present-late-breaking-data-for-galcanezumab-and-lasmiditan-at-the-american-headache-society-annual-scientific-meeting-1002079732
217.0,6/9/2017 12:30:00 PM,"IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention",PR Newswire,/news/stocks/idf-in-partnership-with-lilly-announces-second-phase-of-bridges-programme-funding-for-translational-research-in-diabetes-with-focus-on-secondary-prevention-1002081464
218.0,6/9/2017 12:50:05 PM,"BRIEF-IDF, Eli Lilly announce second phase of BRIDGES programme funding (LLY)",Reuters,http://www.businessinsider.com/r-brief-idf-eli-lilly-announce-second-phase-of-bridges-programme-funding-2017-6
219.0,6/10/2017 4:00:00 PM,Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS,PR Newswire,/news/stocks/lilly-s-galcanezumab-significantly-reduces-number-of-migraine-headache-days-for-patients-with-migraine-new-results-presented-at-ahs-1002083346
220.0,6/12/2017 9:54:03 AM,"Chi-Med steps closer to Chinese pharma first with drug filing (HCM, 1, LLY)",Reuters,http://www.businessinsider.com/r-chi-med-steps-closer-to-chinese-pharma-first-with-drug-filing-2017-6
221.0,6/12/2017 1:28:08 PM,"BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development (LLY)",Reuters,http://www.businessinsider.com/r-brief-zymeworks-two-bispecific-immuno-oncology-drug-candidates-have-been-nominated-by-eli-lilly-for-late-stage-preclinical-development-2017-6
222.0,6/12/2017 1:28:08 PM,"BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development (LLY)",Reuters,http://www.businessinsider.com/r-brief-zymeworks-two-bispecific-immuno-oncology-drug-candidates-have-been-nominated-by-eli-lilly-for-late-stage-preclinical-development-2017-6
223.0,6/12/2017 2:00:00 PM,Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease,PR Newswire,/news/stocks/jardiance-empagliflozin-tablets-to-be-studied-in-chronic-kidney-disease-1002085320
224.0,6/12/2017 2:12:08 PM,BRIEF-Lilly says Jardiance tablets to be studied in chronic kidney disease (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-jardiance-tablets-to-be-studied-in-chronic-kidney-disease-2017-6
225.0,6/12/2017 2:12:54 PM,"Boehringer, Eli Lilly To Conduct New Trial Investigating Jardiance Tablets ",RTTNews,/news/stocks/boehringer-eli-lilly-to-conduct-new-trial-investigating-jardiance-tablets-1002085383
226.0,6/12/2017 9:00:00 PM,Elanco Releases First-Ever Corporate Social Responsibility Impact Report,PR Newswire,/news/stocks/elanco-releases-first-ever-corporate-social-responsibility-impact-report-1002086742
227.0,6/12/2017 10:30:06 PM,"There’s a race to treat a condition that affects 38 million Americans — here’s what you need to know (AMGN, TEVA, LLY, ALDR)",Business Insider,http://www.businessinsider.com/new-migraine-prevention-treatments-2017-6
228.0,6/12/2017 11:22:08 PM,U.S. finalizes talks to resume beef exports to China after ban (LLY),Reuters,http://www.businessinsider.com/r-us-finalizes-talks-to-resume-beef-exports-to-china-after-ban-2017-6
229.0,6/13/2017 12:30:07 AM,"J&J diabetes drug shows heart benefit in large safety study (JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-jj-diabetes-drug-shows-heart-benefit-in-large-safety-study-2017-6
230.0,6/13/2017 2:34:06 PM,"BRIEF-Pfizer and Lilly receive FDA fast track designation for Tanezumab (PFE, LLY)",Reuters,http://www.businessinsider.com/r-brief-pfizer-and-lilly-receive-fda-fast-track-designation-for-tanezumab-2017-6
231.0,6/13/2017 8:00:00 PM,Jardiance® (empagliflozin) analysis reinforces established safety profile,PR Newswire,/news/stocks/jardiance-empagliflozin-analysis-reinforces-established-safety-profile-1002090306
232.0,6/13/2017 8:18:05 PM,BRIEF-Eli Lilly updates on study data on Jardiance (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-updates-on-study-data-on-jardiance-2017-6
233.0,6/14/2017 12:01:00 AM,Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017),PR Newswire,/news/stocks/lilly-to-present-new-data-on-olumiant-baricitinib-in-rheumatoid-arthritis-and-taltz-ixekizumab-in-psoriatic-arthritis-at-the-annual-european-congress-of-rheumatology-eular-2017-1002090752
234.0,6/14/2017 7:18:05 AM,"PRESS DIGEST - Wall Street Journal - June 14 (IBM, VOW3, LLY, VZ, YHOO)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---june-14-2017-6
235.0,6/14/2017 2:45:00 PM,Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments,PR Newswire,/news/stocks/patented-biotechnology-formulations-resulting-in-new-generation-of-animal-healthcare-medications-and-treatments-1002092780
236.0,6/14/2017 2:45:00 PM,Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments,PR Newswire,/news/stocks/patented-biotechnology-formulations-resulting-in-new-generation-of-animal-healthcare-medications-and-treatments-1002092769
237.0,6/15/2017 4:35:00 PM,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate...,PR Newswire,/news/stocks/eular-2017-lilly-s-taltz-ixekizumab-demonstrated-significant-improvements-in-disease-signs-and-symptoms-at-24-weeks-among-patients-with-active-psoriatic-arthritis-who-had-prior-inadequate-1002096764
238.0,6/15/2017 5:09:55 PM,Lilly's Taltz Shows Improvements In Disease Signs And Symptoms In PsA ,RTTNews,/news/stocks/lilly-s-taltz-shows-improvements-in-disease-signs-and-symptoms-in-psa-1002096914
239.0,6/15/2017 6:22:05 PM,BRIEF-Eli Lilly files supplemental biologics license application with FDA for Taltz (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-files-supplemental-biologics-license-application-with-fda-for-taltz-2017-6
240.0,6/16/2017 4:23:42 AM,"ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits ",RTTNews,/news/stocks/admp-soars-on-fda-nod-it-is-advantage-oxfd-lly-in-good-spirits-1002098096
241.0,6/16/2017 7:00:00 AM,"Eli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis",PR Newswire,/news/stocks/eli-lilly-and-company-ra-matters-survey-uncovers-what-matters-most-to-over-5-000-people-living-with-rheumatoid-arthritis-1002098212
242.0,6/16/2017 10:15:00 AM,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,PR Newswire,/news/stocks/new-safety-and-long-term-efficacy-data-from-baricitinib-clinical-trials-in-patients-with-moderate-to-severe-rheumatoid-arthritis-presented-at-eular-2017-1002098713
243.0,6/16/2017 11:10:00 AM,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks,PR Newswire,/news/stocks/eular-2017-lilly-s-taltz-ixekizumab-demonstrated-no-progression-or-minimal-progression-of-radiographic-disease-in-patients-with-psoriatic-arthritis-through-52-weeks-1002098847
244.0,6/16/2017 11:51:38 AM,Eli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial ,RTTNews,/news/stocks/eli-lilly-reports-results-from-extension-period-of-spirit-p1-trial-1002098956
245.0,6/16/2017 11:51:57 AM,"Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib ",RTTNews,/news/stocks/eli-lilly-incyte-announce-positive-results-from-pooled-analysis-of-baricitinib-1002098955
246.0,6/19/2017 2:11:00 PM,Lilly and NRAS Launch New Film for RA Awareness Week to Reveal the True Impact of RA,PR Newswire,/news/stocks/lilly-and-nras-launch-new-film-for-ra-awareness-week-to-reveal-the-true-impact-of-ra-1002103419
247.0,6/19/2017 7:05:00 PM,Lilly Declares Third-Quarter 2017 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2017-dividend-1002104701
248.0,6/19/2017 7:12:03 PM,BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-sets-quarterly-dividend-of-052-per-share-2017-6
249.0,6/21/2017 5:00:00 PM,Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego,PR Newswire,/news/stocks/eli-lilly-and-company-unveils-expanded-biotechnology-center-in-san-diego-1002112722
250.0,6/21/2017 5:38:05 PM,BRIEF-Eli Lilly unveils expanded biotech center in San Diego (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-unveils-expanded-biotech-center-in-san-diego-2017-6
251.0,6/27/2017 2:00:00 PM,Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour,PR Newswire,/news/stocks/lilly-diabetes-brings-an-extra-splash-of-summertime-fun-and-inspiration-to-diabetes-camps-with-launch-of-annual-camp-care-package-speaker-tour-1002127158
252.0,6/27/2017 3:12:00 PM,Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications,PR Newswire,/news/stocks/blink-health-giving-away-10-million-worth-of-free-diabetes-medications-1002127694
253.0,6/28/2017 3:12:00 PM,Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications,PR Newswire,/news/stocks/blink-health-giving-away-10-million-worth-of-free-diabetes-medications-1002131451
254.0,7/3/2017 2:00:00 PM,"Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis",PR Newswire,/news/stocks/japan-ministry-of-health-labor-and-welfare-mhlw-grants-marketing-approval-for-olumiant-baricitinib-for-the-treatment-of-rheumatoid-arthritis-1002143353
255.0,7/3/2017 2:06:59 PM,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-japan-marketing-approval-for-olumiant-quick-facts-1002143389
256.0,7/3/2017 2:16:04 PM,"BRIEF-Incyte says Japan Ministry of Health, Labor And Welfare grants marketing approval for Olumiant (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-says-japan-ministry-of-health-labor-and-welfare-grants-marketing-approval-for-olumiant-2017-7
257.0,7/5/2017 7:02:05 PM,"New cancer treatments that are programmed to treat a person's specific tumor just passed 2 early tests (MRK, BMY, SAN, LLY)",Reuters,http://www.businessinsider.com/r-personalised-vaccines-hold-cancer-at-bay-in-two-early-trials-2017-7
258.0,7/6/2017 2:11:39 PM,"Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts ",RTTNews,/news/stocks/lilly-purdue-university-announce-strategic-research-collaboration-quick-facts-1002152422
259.0,7/6/2017 2:32:03 PM,BRIEF-Lilly and Purdue University announce strategic research collaboration (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-and-purdue-university-announce-strategic-research-collaboration-2017-7
260.0,7/6/2017 6:22:09 PM,"UPDATE 1-Celgene signs deal with BeiGene for tumor cancer treatment (CELG, AZN, HCM, LLY)",Reuters,http://www.businessinsider.com/r-update-1-celgene-signs-deal-with-beigene-for-tumor-cancer-treatment-2017-7
261.0,7/7/2017 1:59:10 PM,UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents ,RTTNews,/news/stocks/uk-supreme-court-rules-in-favor-of-lilly-on-alimta-vitamin-regimen-patents-1002155906
262.0,7/7/2017 2:00:10 PM,BRIEF-UK Supreme Court rules in Lilly's favor on Alimta vitamin regimen patents (LLY),Reuters,http://www.businessinsider.com/r-brief-uk-supreme-court-rules-in-lillys-favor-on-alimta-vitamin-regimen-patents-2017-7
263.0,7/7/2017 2:52:08 PM,"UK Supreme Court rules in favor of Lilly's Alimta patents (LLY, AGN)",Reuters,http://www.businessinsider.com/r-uk-supreme-court-rules-in-favor-of-lillys-alimta-patents-2017-7
264.0,7/7/2017 3:52:03 PM,"UPDATE 1-UK Supreme Court rules in favor of Lilly's Alimta patents (LLY, TEVA, AGN)",Reuters,http://www.businessinsider.com/r-update-1-uk-supreme-court-rules-in-favor-of-lillys-alimta-patents-2017-7
265.0,7/10/2017 1:06:11 PM,Lilly: FDA Files NDA For Abemaciclib For Treatment Of Advanced Breast Cancer ,RTTNews,/news/stocks/lilly-fda-files-nda-for-abemaciclib-for-treatment-of-advanced-breast-cancer-1002159665
266.0,7/10/2017 1:38:06 PM,BRIEF-FDA grants priority review for Lilly's abemaciclib (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-for-lillys-abemaciclib-2017-7
267.0,7/12/2017 4:08:03 PM,BRIEF-Eli lilly reaches settlement agreement in U.S. Cialis patent litigation (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-reaches-settlement-agreement-in-us-cialis-patent-litigation-2017-7
268.0,7/12/2017 4:16:25 PM,Lilly Reaches Settlement Deal In US Cialis Patent Litigation ,RTTNews,/news/stocks/lilly-reaches-settlement-deal-in-us-cialis-patent-litigation-1002167646
269.0,7/14/2017 1:48:03 PM,"Novartis stocks drug cabinet with ""Big-3"" arthritis blockbusters (AMGN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-novartis-stocks-drug-cabinet-with-big-3-arthritis-blockbusters-2017-7
270.0,7/18/2017 3:20:08 PM,BRIEF-Adimab says entered into agreement to transfer adimab platform to Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-adimab-says-entered-into-agreement-to-transfer-adimab-platform-to-lilly-2017-7
271.0,7/20/2017 6:58:08 PM,"FDA tentatively approves Merck's copycat of Sanofi's Lantus (MRK, SAN, LLY, CVS)",Reuters,http://www.businessinsider.com/r-fda-tentatively-approves-mercks-copycat-of-sanofis-lantus-2017-7
272.0,7/24/2017 1:30:00 PM,"Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy",PR Newswire,/news/stocks/lilly-and-nektar-therapeutics-announce-alliance-to-develop-and-commercialize-nktr-358-a-novel-autoimmune-therapy-1002198244
273.0,7/24/2017 1:48:34 PM,Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358 ,RTTNews,/news/stocks/eli-lilly-agrees-with-nektar-to-co-develop-nktr-358-1002198315
274.0,7/24/2017 3:02:06 PM,"BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358 (LLY, NKTR)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-nektar-therapeutics-to-develop-commercialize-nktr-358-2017-7
275.0,7/25/2017 12:15:00 PM,Lilly and Incyte Provide Update on Baricitinib,PR Newswire,/news/stocks/lilly-and-incyte-provide-update-on-baricitinib-1002201262
276.0,7/25/2017 12:25:00 PM,Lilly Reports Second-Quarter Results,PR Newswire,/news/stocks/lilly-reports-second-quarter-results-1002201298
277.0,7/25/2017 12:28:12 PM,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib ,RTTNews,/news/stocks/eli-lilly-incyte-issue-update-on-resubmission-of-nda-for-baricitinib-1002201296
278.0,7/25/2017 12:28:25 PM,Eli Lilly And Co. Reports 30% Advance In Q2 Profit,RTTNews,/news/stocks/eli-lilly-and-co-reports-30-advance-in-q2-profit-1002201295
279.0,7/25/2017 12:36:07 PM,"BRIEF-Lilly and Incyte provide update on baricitinib (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-and-incyte-provide-update-on-baricitinib-2017-7
280.0,7/25/2017 12:39:28 PM,Eli Lilly Raises 2017 Non-GAAP EPS Guidance - Quick Facts ,RTTNews,/news/stocks/eli-lilly-raises-2017-non-gaap-eps-guidance-quick-facts-1002201353
281.0,7/25/2017 12:50:05 PM,BRIEF-Lilly reports second-quarter results (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-second-quarter-results-2017-7
282.0,7/25/2017 12:50:06 PM,Drugmaker Lilly's profit jumps 35 percent (LLY),Reuters,http://www.businessinsider.com/r-drugmaker-lillys-profit-jumps-35-percent-2017-7
283.0,7/25/2017 2:58:03 PM,"US STOCKS-Caterpillar, McDonald's to lift S&P, Dow at open (CAT, MCD, AMZN, AAPL, T, CMG, CB, BIIB, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-caterpillar-mcdonalds-to-lift-sp-dow-at-open-2017-7
284.0,7/25/2017 3:58:03 PM,"US STOCKS-McDonald's, Caterpillar power S&P to record (MCD, CAT, AMZN, AAPL, T, CMG, CB, DD, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-mcdonalds-caterpillar-power-sp-to-record-2017-7
285.0,7/25/2017 4:52:06 PM,BRIEF-Eli lilly says seeks external early cancer assets (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-seeks-external-early-cancer-assets-2017-7
286.0,7/25/2017 5:22:05 PM,"US STOCKS-Strong earnings boost S&P, Dow; Alphabet drags Nasdaq (MCD, CAT, AMZN, AAPL, DD, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-strong-earnings-boost-sp-dow-alphabet-drags-nasdaq-2017-7
287.0,7/25/2017 6:58:05 PM,"US STOCKS-S&P hits record on strong earnings; Alphabet drags Nasdaq (MCD, CAT, AMZN, AAPL, DD, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-hits-record-on-strong-earnings-alphabet-drags-nasdaq-2017-7
288.0,7/25/2017 8:58:05 PM,"US STOCKS-S&P 500 jumps to record high on busy earnings day (MCD, CAT, C, MMM, LLY, FCX)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-500-jumps-to-record-high-on-busy-earnings-day-2017-7
289.0,7/25/2017 10:32:06 PM,"US STOCKS-Earnings, bank shares propel S&P 500 to record high (MCD, CAT, C, MMM, LLY, FCX)",Reuters,http://www.businessinsider.com/r-us-stocks-earnings-bank-shares-propel-sp-500-to-record-high-2017-7
290.0,7/26/2017 8:55:22 AM,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX ",RTTNews,/news/stocks/positive-data-ignites-ttph-mdco-makes-a-good-tango-wait-continues-for-egrx-1002204619
291.0,7/28/2017 6:08:11 PM,"BRIEF-Lilly gets civil investigative demand from Minnesota AG for insulin product pricing‍​ (LLY, 8086)",Reuters,http://www.businessinsider.com/r-brief-lilly-gets-civil-investigative-demand-from-minnesota-ag-for-insulin-product-pricing-2017-7
292.0,8/2/2017 10:52:04 AM,"Two biggest U.S. drug purchasers keep key Novo Nordisk drugs on 2018 list (CVS, NOVO , LLY)",Reuters,http://www.businessinsider.com/r-two-biggest-us-drug-purchasers-keep-key-novo-nordisk-drugs-on-2018-list-2017-8
293.0,8/4/2017 12:45:00 PM,Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine,PR Newswire,/news/stocks/lilly-announces-positive-results-for-second-phase-3-study-of-lasmiditan-for-the-acute-treatment-of-migraine-1002233546
294.0,8/4/2017 12:52:03 PM,BRIEF-Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-positive-results-for-second-phase-3-study-of-lasmiditan-for-treatment-of-migraine-2017-8
295.0,8/4/2017 12:52:03 PM,Lilly's acute migraine drug succeeds in late-stage study (LLY),Reuters,http://www.businessinsider.com/r-lillys-acute-migraine-drug-succeeds-in-late-stage-study-2017-8
296.0,8/4/2017 12:59:00 PM,Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study ,RTTNews,/news/stocks/eli-lilly-lasmiditan-meets-primary-endpoint-in-second-phase-3-study-1002233573
297.0,8/4/2017 1:27:07 PM,"UPDATE 1-Lilly's acute migraine drug succeeds in late-stage study (LLY, AMGN, TEVA)",Reuters,http://www.businessinsider.com/r-update-1-lillys-acute-migraine-drug-succeeds-in-late-stage-study-2017-8
298.0,8/9/2017 7:07:03 PM,"UPDATE 1-Mexico watchdog finds big pharma faces no competition on some drugs (GSK, PFE, MRK, ABT, LLY, SAN, AZN)",Reuters,http://www.businessinsider.com/r-update-1-mexico-watchdog-finds-big-pharma-faces-no-competition-on-some-drugs-2017-8
299.0,8/16/2017 11:37:17 PM,"Novo Nordisk's diabetes drug succeeds in key trial (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-novo-nordisks-diabetes-drug-succeeds-in-key-trial-2017-8
300.0,8/17/2017 12:42:07 AM,"UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-novo-nordisks-diabetes-drug-succeeds-in-key-trial-2017-8
301.0,8/17/2017 7:02:03 AM,"RPT-UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-rpt-update-1-novo-nordisks-diabetes-drug-succeeds-in-key-trial-2017-8
302.0,8/17/2017 12:15:00 PM,"Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi",PR Newswire,/news/stocks/technical-snapshots-for-these-drug-makers-stocks-pfizer-eli-lilly-merck-and-sanofi-1002264947
303.0,8/18/2017 7:52:14 PM,"BRIEF-Teva announces exclusive launch of generic Axiron® in United States (TEVA, LLY)",Reuters,http://www.businessinsider.com/r-brief-teva-announces-exclusive-launch-of-generic-axiron-in-united-states-2017-8
304.0,8/25/2017 11:37:18 PM,"BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement (NKTR, LLY)",Reuters,http://www.businessinsider.com/r-brief-nektar-therapeutics-and-eli-lilly-got-notice-of-early-termination-of-waiting-period-related-to-license-agreement-2017-8
305.0,8/28/2017 8:00:00 PM,Lilly to Participate in Morgan Stanley Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-1002289223
306.0,8/29/2017 9:07:04 AM,"Merck cholesterol drug cuts heart risk by 9 pct in study (MRK, PFE, LLY)",Reuters,http://www.businessinsider.com/r-merck-cholesterol-drug-cuts-heart-risk-by-9-pct-in-study-2017-8
307.0,8/29/2017 12:45:00 PM,New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress,PR Newswire,/news/stocks/new-phase-3-data-for-abemaciclib-and-ramucirumab-presented-at-esmo-2017-congress-1002290925
308.0,8/29/2017 1:14:50 PM,"Eli Lilly To Present Data From Phase 3 Studies Of Abemaciclib, Ramucirumab ",RTTNews,/news/stocks/eli-lilly-to-present-data-from-phase-3-studies-of-abemaciclib-ramucirumab-1002291015
309.0,8/30/2017 12:45:00 PM,Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018,PR Newswire,/news/stocks/lilly-to-file-baricitinib-resubmission-to-u-s-fda-before-end-of-january-2018-1002294227
310.0,8/30/2017 12:57:05 PM,"BRIEF-Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-to-file-baricitinib-resubmission-to-us-fda-before-end-of-january-2018-2017-8
311.0,8/30/2017 1:02:01 PM,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018 ,RTTNews,/news/stocks/lilly-to-resubmit-nda-for-baricitinib-to-fda-before-end-of-january-2018-1002294296
312.0,8/31/2017 2:52:03 PM,"AstraZeneca aims to offset drug setback at big cancer congress (AZN, LLY, PFE, BMY, MRK, INCY)",Reuters,http://www.businessinsider.com/r-astrazeneca-aims-to-offset-drug-setback-at-big-cancer-congress-2017-8
313.0,9/6/2017 3:17:04 AM,"BRIEF-Acrux says co and Eli Lilly and Co agreed to terminate licensing agreement for Axiron (ACR, LLY)",Reuters,http://www.businessinsider.com/r-brief-acrux-says-co-and-eli-lilly-and-co-agreed-to-terminate-licensing-agreement-for-axiron-2017-9
314.0,9/6/2017 12:45:00 PM,Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC),PR Newswire,/news/stocks/lilly-to-present-new-data-for-galcanezumab-and-lasmiditan-at-the-18th-congress-of-the-international-headache-society-ihc-1002344737
315.0,9/6/2017 2:30:00 PM,Landmark M&A Deals Continue to Shape Big Pharma,PR Newswire,/news/stocks/landmark-m-a-deals-continue-to-shape-big-pharma-1002345383
316.0,9/6/2017 2:30:00 PM,Landmark M&A Deals Continue to Shape Big Pharma,PR Newswire,/news/stocks/landmark-m-a-deals-continue-to-shape-big-pharma-1002345356
317.0,9/7/2017 3:15:00 PM,"Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth",PR Newswire,/news/stocks/lilly-takes-steps-to-streamline-business-invest-in-new-medicines-and-drive-growth-1002350156
318.0,9/7/2017 3:32:03 PM,"Lilly to cut 8 pct jobs, focus on developing new medicines (LLY)",Reuters,http://www.businessinsider.com/r-lilly-to-cut-8-pct-jobs-focus-on-developing-new-medicines-2017-9
319.0,9/7/2017 3:37:03 PM,"BRIEF-Eli Lilly to cuts jobs, focus on developing new medicines (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-to-cuts-jobs-focus-on-developing-new-medicines-2017-9
320.0,9/7/2017 3:51:44 PM,"Lilly Plans To Cut About 3,500 Jobs Globally ",RTTNews,/news/stocks/lilly-plans-to-cut-about-3-500-jobs-globally-1002350308
321.0,9/7/2017 3:57:06 PM,UPDATE 1-Lilly to cut 8 pct jobs as it works to reduce costs (LLY),Reuters,http://www.businessinsider.com/r-update-1-lilly-to-cut-8-pct-jobs-as-it-works-to-reduce-costs-2017-9
322.0,9/7/2017 9:12:18 PM,"US STOCKS-Wall St slips as media stocks, Hurricane Irma weigh (MSFT, AMZN, GILD, CMCSA, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slips-as-media-stocks-hurricane-irma-weigh-2017-9
323.0,9/7/2017 10:32:09 PM,"US STOCKS-Wall St ends flat as media stocks slump, healthcare gains (CMCSA, BMY, MSFT, AMZN, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ends-flat-as-media-stocks-slump-healthcare-gains-2017-9
324.0,9/8/2017 7:02:05 AM,"PRESS DIGEST - Wall Street Journal - Sept 8 (AMZN, EFX, PFE, LLY)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---sept-8-2017-9
325.0,9/8/2017 12:45:00 PM,IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine,PR Newswire,/news/stocks/ihc-2017-lilly-s-galcanezumab-demonstrates-positive-long-term-safety-results-for-up-to-12-months-in-patients-with-migraine-1002353219
326.0,9/8/2017 12:56:40 PM,Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study ,RTTNews,/news/stocks/eli-lilly-galcanezumab-shows-positive-safety-results-in-12-month-phase-3-study-1002353243
327.0,9/8/2017 1:22:05 PM,BRIEF-Eli Lilly says galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-galcanezumab-demonstrates-positive-long-term-safety-results-for-up-to-12-months-in-patients-with-migraine-2017-9
328.0,9/9/2017 2:00:00 PM,IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine,PR Newswire,/news/stocks/ihc-2017-lilly-s-lasmiditan-significantly-reduces-pain-in-patients-with-migraine-1002355527
329.0,9/10/2017 12:12:11 AM,"Lilly drug cuts risk of advanced breast cancer progression -study (LLY, PFE)",Reuters,http://www.businessinsider.com/r-lilly-drug-cuts-risk-of-advanced-breast-cancer-progression--study-2017-9
330.0,9/10/2017 8:26:00 AM,Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer,PR Newswire,/news/stocks/lilly-builds-upon-body-of-clinical-evidence-for-cyramza-ramucirumab-with-phase-3-range-data-demonstrating-superior-progression-free-survival-in-advanced-or-metastatic-urothelial-cancer-1001656476
331.0,9/10/2017 11:12:03 AM,"UPDATE 1-Lilly takes on Pfizer, Novartis with new breast cancer drug data (LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-lilly-takes-on-pfizer-novartis-with-new-breast-cancer-drug-data-2017-9
332.0,9/11/2017 3:00:00 PM,Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress,PR Newswire,/news/stocks/lilly-to-present-new-data-for-olumiant-baricitinib-and-taltz-ixekizumab-at-the-european-academy-of-dermatology-and-venereology-eadv-annual-congress-1002358235
333.0,9/12/2017 12:59:00 PM,Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control,PR Newswire,/news/stocks/jardiance-empagliflozin-tablets-reduced-risk-of-cardiovascular-death-in-people-with-type-2-diabetes-and-established-cardiovascular-disease-independent-of-background-blood-sugar-control-1002361308
334.0,9/12/2017 1:31:40 PM,Lilly: Jardiance Tablets Reduces Cardiovascular Death Risks In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-jardiance-tablets-reduces-cardiovascular-death-risks-in-type-2-diabetes-1002361542
335.0,9/13/2017 2:30:00 PM,Biosynthesis Technology Could Transform Cannabinoid Production,PR Newswire,/news/stocks/biosynthesis-technology-could-transform-cannabinoid-production-1002365968
336.0,9/13/2017 2:30:00 PM,Biosynthesis Technology Could Transform Cannabinoid Production,PR Newswire,/news/stocks/biosynthesis-technology-could-transform-cannabinoid-production-1002365995
337.0,9/14/2017 10:02:03 AM,"Astra's Farxiga results may open up type 1 diabetes opportunity (AZN, LLY, JNJ)",Reuters,http://www.businessinsider.com/r-astras-farxiga-results-may-open-up-type-1-diabetes-opportunity-2017-9
338.0,9/14/2017 3:00:00 PM,Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,PR Newswire,/news/stocks/baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-1002370452
339.0,9/14/2017 3:02:03 PM,"Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9
340.0,9/14/2017 3:12:05 PM,"BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incytes-baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-2017-9
341.0,9/14/2017 3:13:25 PM,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib ,RTTNews,/news/stocks/lilly-announces-new-safety-and-efficacy-data-from-phase-2-study-of-baricitinib-1002370600
342.0,9/14/2017 8:52:15 PM,"UPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9
343.0,9/22/2017 11:02:07 PM,"UPDATE 1-U.S. FDA declines to approve J&J arthritis drug (JNJ, SAN, REGN, LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-declines-to-approve-jj-arthritis-drug-2017-9
344.0,9/25/2017 2:30:00 PM,"Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications,...",PR Newswire,/news/stocks/geisinger-and-boehringer-ingelheim-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-at-greatest-risk-of-serious-long-term-complications-1002519082
345.0,9/25/2017 2:43:15 PM,"Geisinger, Boehringer Ingelheim Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/geisinger-boehringer-ingelheim-announce-collaboration-quick-facts-1002519436
346.0,9/25/2017 3:17:03 PM,BRIEF-Boehringer Ingelheim and Eli Lilly collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-boehringer-ingelheim-and-eli-lilly-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-2017-9
347.0,9/28/2017 2:05:00 PM,Elanco Celebrates 10 Years of Volunteerism During Global Day of Service,PR Newswire,/news/stocks/elanco-celebrates-10-years-of-volunteerism-during-global-day-of-service-1002732913
348.0,9/28/2017 8:17:07 PM,"Eli Lilly wins U.S. approval for breast cancer drug (LLY, PFE)",Reuters,http://www.businessinsider.com/r-eli-lilly-wins-us-approval-for-breast-cancer-drug-2017-9
349.0,9/28/2017 8:42:12 PM,"UPDATE 1-Eli Lilly wins U.S. approval for breast cancer drug (LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-eli-lilly-wins-us-approval-for-breast-cancer-drug-2017-9
350.0,9/28/2017 10:27:16 PM,"BRIEF-Eli Lilly sets list price of new breast cancer drug at $10,948/month (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-sets-list-price-of-new-breast-cancer-drug-at-10948-month-2017-9
351.0,9/29/2017 3:26:19 AM,FDA Okays Lilly's Breast Cancer Drug Verzenio ,RTTNews,/news/stocks/fda-okays-lilly-s-breast-cancer-drug-verzenio-1002795433
352.0,9/29/2017 12:45:00 PM,"Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing",PR Newswire,/news/stocks/lilly-announces-senior-leadership-appointments-for-finance-research-development-and-manufacturing-1002840402
353.0,9/29/2017 12:59:22 PM,Lilly Promotes Josh Smiley To SVP And CFO ,RTTNews,/news/stocks/lilly-promotes-josh-smiley-to-svp-and-cfo-1002840425
354.0,9/29/2017 4:32:03 PM,"Lilly names new CFO, replaces head of R&D in management shakeup (LLY)",Reuters,http://www.businessinsider.com/r-lilly-names-new-cfo-replaces-head-of-rd-in-management-shakeup-2017-9
355.0,9/29/2017 5:22:03 PM,"U.S. FDA approves Novo Nordisk fast-acting insulin Fiasp (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-novo-nordisk-fast-acting-insulin-fiasp-2017-9
356.0,9/29/2017 5:27:05 PM,"Puerto Rico power outage set to hurt global reinsurers (MAP, QBE, AIG, BMY, LLY, PFE, AMGN, AZN, MMC)",Reuters,http://www.businessinsider.com/r-puerto-rico-power-outage-set-to-hurt-global-reinsurers-2017-9
357.0,10/2/2017 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2017-financial-results-announcement-1002916339
358.0,10/2/2017 5:08:00 PM,"NAFTA, retail innovation, brand resilience and entrepreneurial retailer leadership examined on Oct 12 at Retail West 2017",PR Newswire,/news/stocks/nafta-retail-innovation-brand-resilience-and-entrepreneurial-retailer-leadership-examined-on-oct-12-at-retail-west-2017-1001597388
359.0,10/4/2017 3:00:00 PM,Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes,PR Newswire,/news/stocks/humalog-junior-kwikpen-now-available-in-the-u-s-for-people-with-diabetes-1002996757
360.0,10/5/2017 2:54:00 PM,"MDA Completes Acquisition of DigitalGlobe, Creates Industry Leader in Satellite Systems, Earth Imagery, Geospatial Solutions and Analytics",PR Newswire,/news/stocks/mda-completes-acquisition-of-digitalglobe-creates-industry-leader-in-satellite-systems-earth-imagery-geospatial-solutions-and-analytics-1001610444
361.0,10/5/2017 9:12:19 PM,"BRIEF-Eli lilly says Lilly Endowment Inc reports open market sale of 205,000 shares of co's common stock on Oct. 4 (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-lilly-endowment-inc-reports-open-market-sale-of-205000-shares-of-cos-common-stock-on-oct-4-2017-10
362.0,10/5/2017 9:48:00 PM,Additional Delivery of Insulin Ready for Distribution in Puerto Rico,PR Newswire,/news/stocks/additional-delivery-of-insulin-ready-for-distribution-in-puerto-rico-1003104398
363.0,10/5/2017 10:13:00 PM,U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent,PR Newswire,/news/stocks/u-s-patent-and-trademark-office-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patent-1003106521
364.0,10/5/2017 10:32:54 PM,BRIEF-U.S. PTO rules in Eli Lilly's favor on Alimta (LLY),Reuters,http://www.businessinsider.com/r-brief-us-pto-rules-in-eli-lillys-favor-on-alimta-2017-10
365.0,10/5/2017 10:42:16 PM,Eli Lilly defeats challenge to Alimta cancer drug patent (LLY),Reuters,http://www.businessinsider.com/r-eli-lilly-defeats-challenge-to-alimta-cancer-drug-patent-2017-10
366.0,10/5/2017 10:47:14 PM,Lilly wins Alimta patent dispute in US (LLY),Reuters,http://www.businessinsider.com/r-lilly-wins-alimta-patent-dispute-in-us-2017-10
367.0,10/6/2017 6:56:00 AM,SK Planet Japan to Launch Geo-Targeted Crypto-Currencies to Attract Booming Chinese Tourists,PR Newswire,/news/stocks/sk-planet-japan-to-launch-geo-targeted-crypto-currencies-to-attract-booming-chinese-tourists-452684
368.0,10/6/2017 7:00:00 PM,Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer,PR Newswire,/news/stocks/lilly-monarch-3-study-published-in-journal-of-clinical-oncology-demonstrates-benefit-of-verzenio-abemaciclib-plus-nsai-in-advanced-breast-cancer-1003196213
369.0,10/8/2017 3:03:03 PM,"It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)",Business Insider,http://www.businessinsider.com/what-alzheimers-disease-drugs-are-in-development-next-trial-2017-10
370.0,10/9/2017 11:48:57 AM,New Drugs Approved In September ,RTTNews,/news/stocks/new-drugs-approved-in-september-1003503219
371.0,10/10/2017 12:00:00 PM,InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board,PR Newswire,/news/stocks/inmed-appoints-dr-mauro-maccarrone-to-its-scientific-advisory-board-479404
372.0,10/10/2017 12:45:00 PM,"Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer",PR Newswire,/news/stocks/lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verzenio-abemaciclib-in-kras-mutated-advanced-non-small-cell-lung-cancer-1003649489
373.0,10/10/2017 12:57:05 PM,BRIEF-Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verzenio-2017-10
374.0,10/10/2017 1:02:03 PM,Lilly's lung cancer drug fails late-stage study (LLY),Reuters,http://www.businessinsider.com/r-lillys-lung-cancer-drug-fails-late-stage-study-2017-10
375.0,10/10/2017 1:27:03 PM,"US STOCKS-Futures higher as earnings take focus (BLK, DAL, JPM, C, GE, AIG, PG, LLY, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-higher-as-earnings-take-focus-2017-10
376.0,10/10/2017 3:02:03 PM,"US STOCKS-Wall St set to open higher as earnings take focus (BLK, DAL, JPM, C, GE, WMT, PFE, LLY, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-as-earnings-take-focus-2017-10
377.0,10/10/2017 4:07:03 PM,"US STOCKS-Wall St scales new records on gains in Wal-Mart, energy stocks (WMT, BLK, DAL, JPM, C, NVDA, LLY, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-scales-new-records-on-gains-in-wal-mart-energy-stocks-2017-10
378.0,10/10/2017 5:27:05 PM,"US STOCKS-Wall St scales new records, helped by Wal-Mart, energy stocks (WMT, PG, AMZN, NVDA, LLY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-scales-new-records-helped-by-wal-mart-energy-stocks-2017-10
379.0,10/11/2017 7:42:28 AM,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4 ",RTTNews,/news/stocks/cry-opens-wallet-lly-s-juniper-flops-mdxg-catches-eyes-rnn-awaits-data-in-q4-1003777417
380.0,10/11/2017 5:47:03 PM,"BRIEF-‍BIOLOGICS SAYS SELECTED BY ELI LILLY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​ (LLY, MCK)",Reuters,http://www.businessinsider.com/r-brief-biologics-says-selected-by-eli-lilly-to-be-in-limited-distribution-network-for-verzenio-2017-10
381.0,10/11/2017 11:17:08 PM,"Merck says will not seek approval of cholesterol treatment (MRK, PFE, LLY)",Reuters,http://www.businessinsider.com/r-merck-says-will-not-seek-approval-of-cholesterol-treatment-2017-10
382.0,10/12/2017 12:45:00 PM,FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer,PR Newswire,/news/stocks/fda-grants-priority-review-for-potential-new-indication-for-lilly-s-verzenio-abemaciclib-as-initial-treatment-of-advanced-breast-cancer-1003968302
383.0,10/12/2017 12:56:50 PM,Lilly's Verzenio Gets FDA Priority Review Designation For Advanced Breast Cancer ,RTTNews,/news/stocks/lilly-s-verzenio-gets-fda-priority-review-designation-for-advanced-breast-cancer-1003968320
384.0,10/12/2017 1:07:04 PM,BRIEF-FDA grants priority review for Lilly's verzenio (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-for-lillys-verzenio-2017-10
385.0,10/14/2017 3:00:00 AM,"Indigenous groups, science community, marine industry, and government partners make progress in protecting endangered killer whale population",PR Newswire,/news/stocks/indigenous-groups-science-community-marine-industry-and-government-partners-make-progress-in-protecting-endangered-killer-whale-population-487896
386.0,10/16/2017 12:45:00 PM,Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis,PR Newswire,/news/stocks/rapidly-progressing-advanced-non-small-cell-lung-cancer-patients-shown-to-benefit-in-new-cyramza-ramucirumab-phase-3-subgroup-analysis-1004476575
387.0,10/16/2017 1:04:21 PM,Eli Lilly: REVEL Data Show Efficacy Of Ramucirumab Plus Docetaxel - Quick Factsz ,RTTNews,/news/stocks/eli-lilly-revel-data-show-efficacy-of-ramucirumab-plus-docetaxel-quick-factsz-1004477469
388.0,10/16/2017 2:42:11 PM,"UPDATE 1-Novo Nordisk diabetes drug effective, preliminary FDA review finds (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-novo-nordisk-diabetes-drug-effective-preliminary-fda-review-finds-2017-10
389.0,10/16/2017 8:45:00 PM,Lilly Declares Fourth-Quarter 2017 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2017-dividend-1004519947
390.0,10/16/2017 9:02:14 PM,BRIEF-Eli Lilly sets quarterly dividend of $0.52 per share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-sets-quarterly-dividend-of-052-per-share-2017-10
391.0,10/16/2017 9:37:50 PM,BRIEF-Eli Lilly ‍declares Q4 dividend of $0.52/share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-declares-q4-dividend-of-052-share-2017-10
392.0,10/17/2017 9:32:03 PM,Trump favors ex-pharma executive Azar for health secretary -Politico (LLY),Reuters,http://www.businessinsider.com/r-trump-favors-ex-pharma-executive-azar-for-health-secretary--politico-2017-10
393.0,10/18/2017 12:32:03 AM,UPDATE 1-Trump favors ex-pharma executive Azar for health secretary -Politico (LLY),Reuters,http://www.businessinsider.com/r-update-1-trump-favors-ex-pharma-executive-azar-for-health-secretary--politico-2017-10
394.0,10/18/2017 12:45:00 PM,Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines,PR Newswire,/news/stocks/lilly-and-curevac-announce-global-collaboration-to-develop-mrna-cancer-vaccines-1004756424
395.0,10/18/2017 10:42:09 PM,"UPDATE 1-U.S. FDA panel backs approval of Novo Nordisk diabetes drug (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-panel-backs-approval-of-novo-nordisk-diabetes-drug-2017-10
396.0,10/19/2017 8:27:14 AM,"INSIGHT-China biotech's 'coming out party' masks long road ahead (HCM, AZN, PFE, LLY, CELG, GSK, SAN)",Reuters,http://www.businessinsider.com/r-insight-china-biotechs-coming-out-party-masks-long-road-ahead-2017-10
397.0,10/20/2017 6:12:03 PM,"Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care (MRK, LLY)",Reuters,http://www.businessinsider.com/r-merck-to-cut-1800-us-sales-jobs-add-960-jobs-in-chronic-care-2017-10
398.0,10/20/2017 6:42:11 PM,"UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care (MRK, LLY)",Reuters,http://www.businessinsider.com/r-update-1-merck-to-cut-1800-us-sales-jobs-add-960-in-chronic-care-2017-10
399.0,10/23/2017 12:45:00 PM,Lilly announces $72 million investment in diabetes manufacturing in Indianapolis,PR Newswire,/news/stocks/lilly-announces-72-million-investment-in-diabetes-manufacturing-in-indianapolis-1005324110
400.0,10/23/2017 1:02:06 PM,BRIEF-Lilly announces $72 million investment in diabetes manufacturing in Indianapolis (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-72-million-investment-in-diabetes-manufacturing-in-indianapolis-2017-10
401.0,10/23/2017 1:21:22 PM,Eli Lilly Plans To Invest $72 Mln In Insulin Manufacturing Project - Quick Facts ,RTTNews,/news/stocks/eli-lilly-plans-to-invest-72-mln-in-insulin-manufacturing-project-quick-facts-1005326357
402.0,10/24/2017 12:25:00 PM,"Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health",PR Newswire,/news/stocks/lilly-reports-third-quarter-results-announces-strategic-review-of-elanco-animal-health-1005434556
403.0,10/24/2017 12:30:51 PM,Eli Lilly And Co. Q3 Earnings Rise 19%,RTTNews,/news/stocks/eli-lilly-and-co-q3-earnings-rise-19-1005433730
404.0,10/24/2017 12:52:12 PM,BRIEF-Eli Lilly reports Q3 EPS $0.53 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-reports-q3-eps-053-2017-10
405.0,10/24/2017 1:02:14 PM,"UPDATE 1-Lilly beats profit estimates, mulls sale of animal health business (LLY, MON)",Reuters,http://www.businessinsider.com/r-update-1-lilly-beats-profit-estimates-mulls-sale-of-animal-health-business-2017-10
406.0,10/24/2017 1:18:31 PM,Lilly Lifts FY17 View As Q3 Results Top Estimates; Mulls IPO Or Sale Of Elanco ,RTTNews,/news/stocks/lilly-lifts-fy17-view-as-q3-results-top-estimates-mulls-ipo-or-sale-of-elanco-1005438151
407.0,10/24/2017 4:37:03 PM,"BRIEF-Lilly ""very optimistic"" on U.S. prospect for arthritis drug (LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-very-optimistic-on-us-prospect-for-arthritis-drug-2017-10
408.0,10/24/2017 9:57:00 PM,Eli Lilly and Company -- Moody's: Lilly's animal health separation would reduce diversity and earnings,Moodys,/news/bonds/eli-lilly-and-company-moody-s-lilly-s-animal-health-separation-would-reduce-diversity-and-earnings-1005486217
409.0,10/25/2017 2:37:12 PM,"UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (BAX, MRK, JNJ, PFE, GSK, MDT, DEPO, AMGN, BMY, LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-baxter-expects-70-mln-hit-to-4th-qtr-sales-from-hurricane-maria-2017-10
410.0,10/25/2017 4:00:00 PM,Lilly To Participate In Credit Suisse 26th Annual Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-credit-suisse-26th-annual-healthcare-conference-1005581041
411.0,10/25/2017 4:29:00 PM,5 Tenets for Successful Robotic Process Automation Deployment,PR Newswire,/news/stocks/5-tenets-for-successful-robotic-process-automation-deployment-641645
412.0,10/25/2017 7:12:15 PM,"Teva accuses Lilly in U.S. court of infringing migraine drug patents (TEVA, LLY)",Reuters,http://www.businessinsider.com/r-teva-accuses-lilly-in-us-court-of-infringing-migraine-drug-patents-2017-10
413.0,10/27/2017 9:17:03 PM,FDA tentatively approves Eagle Pharma's cancer drug (LLY),Reuters,http://www.businessinsider.com/r-fda-tentatively-approves-eagle-pharmas-cancer-drug-2017-10
414.0,10/27/2017 10:47:21 PM,UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version (LLY),Reuters,http://www.businessinsider.com/r-update-1-eagle-pharma-gets-tentative-fda-approval-for-lillys-alimta-version-2017-10
415.0,10/30/2017 12:22:25 PM,"BRIEF-‍Kymera Therapeutics announces $30 mln series A financing round​ (AMGN, LLY)",Reuters,http://www.businessinsider.com/r-brief-kymera-therapeutics-announces-30-mln-series-a-financing-round-2017-10
416.0,10/30/2017 2:00:00 PM,Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting,PR Newswire,/news/stocks/lilly-to-present-new-data-on-immunology-portfolio-at-acr-arhp-annual-meeting-1006175661
417.0,10/30/2017 2:00:00 PM,"BMO Blue Book: Provinces in Central Canada See Strengthening Growth, Led by Ontario",PR Newswire,/news/stocks/bmo-blue-book-provinces-in-central-canada-see-strengthening-growth-led-by-ontario-491818
418.0,11/1/2017 11:07:12 AM,"UPDATE 2-Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018 (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-2-drugmaker-novo-nordisk-warns-of-us-legislation-cautious-on-2018-2017-11
419.0,11/2/2017 9:07:04 AM,"UPDATE 1-Sanofi refines expectations on drop in sales at diabetes arm (SAN, CVS, UNH, LLY)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-refines-expectations-on-drop-in-sales-at-diabetes-arm-2017-11
420.0,11/3/2017 12:00:00 PM,Boyd Group Income Fund Announces Completion of Redemption of Convertible Debentures,PR Newswire,/news/stocks/boyd-group-income-fund-announces-completion-of-redemption-of-convertible-debentures-492517
421.0,11/5/2017 3:00:00 PM,ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo,PR Newswire,/news/stocks/acr-arhp-2017-new-analysis-shows-rheumatoid-arthritis-patients-treated-with-baricitinib-reported-greater-improvements-in-pain-compared-to-adalimumab-or-placebo-1006960473
422.0,11/6/2017 5:38:55 AM,"Lilly, Incyte: Baricitinib Shows Greater Improvements In Pain Control In RA ",RTTNews,/news/stocks/lilly-incyte-baricitinib-shows-greater-improvements-in-pain-control-in-ra-1007018255
423.0,11/8/2017 11:02:05 AM,"UPDATE 1-Novartis takes fight to Pfizer's Ibrance with new Kisqali data (PFE, LLY)",Reuters,http://www.businessinsider.com/r-update-1-novartis-takes-fight-to-pfizers-ibrance-with-new-kisqali-data-2017-11
424.0,11/8/2017 1:22:20 PM,BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98 (LLY),Reuters,http://www.businessinsider.com/r-brief-eagle-pharmaceuticals-q3-earnings-per-share-098-2017-11
425.0,11/8/2017 3:00:00 PM,ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors,PR Newswire,/news/stocks/acr-arhp-2017-long-term-use-of-lilly-s-taltz-ixekizumab-shows-efficacy-improvements-in-psoriatic-arthritis-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors-1007295077
426.0,11/8/2017 8:07:03 PM,Ex-pharma exec Azar is top choice to run U.S. health agency -sources (LLY),Reuters,http://www.businessinsider.com/r-ex-pharma-exec-azar-is-top-choice-to-run-us-health-agency--sources-2017-11
427.0,11/10/2017 12:30:00 AM,New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis,PR Newswire,/news/stocks/new-data-on-forteo-teriparatide-rdna-origin-injection-showed-reduced-risk-for-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-severe-osteoporosis-1007481715
428.0,11/10/2017 2:17:04 AM,BRIEF-New data on Forteo showed reduced risk for new vertebral and clinical fractures in postmenopausal women with severe osteoporosis (LLY),Reuters,http://www.businessinsider.com/r-brief-new-data-on-forteo-showed-reduced-risk-for-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-severe-osteoporosis-2017-11
429.0,11/10/2017 5:31:00 PM,"Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe",PR Newswire,/news/stocks/elanco-aratana-announce-positive-opinion-on-galliprant-grapiprant-tablets-in-europe-1007570282
430.0,11/10/2017 5:42:17 PM,"BRIEF-ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE (LLY)",Reuters,http://www.businessinsider.com/r-brief-elanco-aratana-announce-positive-opinion-on-galliprant-in-europe-2017-11
431.0,11/13/2017 5:07:03 PM,UPDATE 1-Trump to tap ex-pharma executive Azar as U.S. health secretary (LLY),Reuters,http://www.businessinsider.com/r-update-1-trump-to-tap-ex-pharma-executive-azar-as-us-health-secretary-2017-11
432.0,11/13/2017 8:00:00 PM,Lilly Appoints Philip Johnson to Senior Vice President and Treasurer,PR Newswire,/news/stocks/lilly-appoints-philip-johnson-to-senior-vice-president-and-treasurer-1007901662
433.0,11/14/2017 12:02:03 AM,"Cost of diabetes epidemic reaches $850 billion a year (NOVO , SAN, LLY)",Reuters,http://www.businessinsider.com/r-cost-of-diabetes-epidemic-reaches-850-billion-a-year-2017-11
434.0,11/14/2017 12:45:00 AM,Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease,PR Newswire,/news/stocks/jardiance-reduced-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-peripheral-artery-disease-1007925692
435.0,11/14/2017 2:46:23 AM,Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD ,RTTNews,/news/stocks/lilly-jardiance-reduces-risk-of-cardiovascular-death-in-type-2-diabetes-and-pad-1007934701
436.0,11/14/2017 7:02:03 AM,"PRESS DIGEST-New York Times business news - Nov 14 (GE, LLY)",Reuters,http://www.businessinsider.com/r-press-digest-new-york-times-business-news---nov-14-2017-11
437.0,11/14/2017 8:34:47 AM,"FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz ",RTTNews,/news/stocks/fda-nod-for-agn-zyme-strikes-a-deal-with-janssen-biotech-tcon-abuzz-1007962961
438.0,11/15/2017 1:22:04 PM,BRIEF-Leap Therapeutics announces $18 million private placement offering (LLY),Reuters,http://www.businessinsider.com/r-brief-leap-therapeutics-announces-18-million-private-placement-offering-2017-11
439.0,11/17/2017 9:45:00 PM,Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference,PR Newswire,/news/stocks/lilly-to-participate-in-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-1008473720
440.0,11/20/2017 4:30:00 PM,Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-2018-financial-guidance-announcement-1008808514
441.0,11/21/2017 12:32:03 PM,"UPDATE 1-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs (NOVO , 4523, OREX, LLY, VVUS)",Reuters,http://www.businessinsider.com/r-update-1-under-pressure-in-diabetes-novo-nordisk-steps-up-focus-on-obesity-drugs-2017-11
442.0,11/21/2017 3:30:00 PM,Ontario Nurses' Association Welcomes New Members,PR Newswire,/news/stocks/ontario-nurses-association-welcomes-new-members-633054
443.0,11/21/2017 4:42:06 PM,"BRIEF-Dexcom announces development agreement with Lilly (DXCM, LLY)",Reuters,http://www.businessinsider.com/r-brief-dexcom-announces-development-agreement-with-lilly-2017-11
444.0,11/22/2017 10:32:03 PM,BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-reports-175-pct-passive-stake-in-leap-therapeutics-as-of-nov-14-2017-11
445.0,11/29/2017 4:27:08 PM,HHS nominee Azar says drug pricing a top priority (LLY),Reuters,http://www.businessinsider.com/r-hhs-nominee-azar-says-drug-pricing-a-top-priority-2017-11
446.0,11/29/2017 5:12:04 PM,"UPDATE 1-Health secretary nominee Azar says drug pricing a top priority (LLY, SAN, MRK, NOVO )",Reuters,http://www.businessinsider.com/r-update-1-health-secretary-nominee-azar-says-drug-pricing-a-top-priority-2017-11
447.0,11/29/2017 6:54:03 PM,One topic dominated a Senate hearing for Trump's top healthcare pick (LLY),Business Insider,http://www.businessinsider.com/hhs-alex-azar-hearing-drug-pricing-comments-2017-11
448.0,12/1/2017 11:01:00 PM,Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis,PR Newswire,/news/stocks/lilly-s-taltz-ixekizumab-receives-u-s-fda-approval-for-the-treatment-of-active-psoriatic-arthritis-1010234717
449.0,12/1/2017 11:17:04 PM,BRIEF-Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Active Psoriatic Arthritis (LLY),Reuters,http://www.businessinsider.com/r-brief-lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-active-psoriatic-arthritis-2017-12
450.0,12/5/2017 3:00:00 PM,Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System,PR Newswire,/news/stocks/lilly-initiates-clinical-trial-to-evaluate-the-functionality-and-safety-of-its-automated-insulin-delivery-system-1010351813
451.0,12/5/2017 3:17:03 PM,BRIEF-Eli Lilly initiates clinical trial to evaluate its automated insulin delivery system (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-initiates-clinical-trial-to-evaluate-its-automated-insulin-delivery-system-2017-12
452.0,12/5/2017 7:07:03 PM,"U.S. FDA approves Novo Nordisk diabetes drug Ozempic (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-novo-nordisk-diabetes-drug-ozempic-2017-12
453.0,12/5/2017 7:22:04 PM,"UPDATE 1-U.S. FDA approves Novo Nordisk diabetes drug Ozempic (NOVO , LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-novo-nordisk-diabetes-drug-ozempic-2017-12
454.0,12/6/2017 12:42:03 PM,"BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018 (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-brief-novo-nordisk-expects-to-launch-new-diabetes-drug-in-japan-during-h1-2018-2017-12
455.0,12/6/2017 3:17:04 PM,"BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center (LLY)",Reuters,http://www.businessinsider.com/r-brief-juno-therapeutics-signs-licensing-agreements-with-lilly-oncotracker-and-fred-hutchinson-cancer-research-center-2017-12
456.0,12/8/2017 11:00:00 PM,Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer,PR Newswire,/news/stocks/lilly-reports-top-line-results-from-cyramza-ramucirumab-phase-3-study-in-first-line-advanced-gastric-cancer-1010637173
457.0,12/8/2017 11:37:04 PM,Lilly's Cyramza meets main goal in gastric cancer study (LLY),Reuters,http://www.businessinsider.com/r-lillys-cyramza-meets-main-goal-in-gastric-cancer-study-2017-12
458.0,12/8/2017 11:42:03 PM,BRIEF-Lilly's Cyramza meets Primary Endpoint in gastric cancer study (LLY),Reuters,http://www.businessinsider.com/r-brief-lillys-cyramza-meets-primary-endpoint-in-gastric-cancer-study-2017-12
459.0,12/9/2017 12:32:03 AM,"UPDATE 1-Lilly's stomach cancer drug meets main goal, but fails to improve survival rate (LLY, BMY)",Reuters,http://www.businessinsider.com/r-update-1-lillys-stomach-cancer-drug-meets-main-goal-but-fails-to-improve-survival-rate-2017-12
460.0,12/11/2017 12:30:00 PM,"Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology",PR Newswire,/news/stocks/kimberly-blackwell-m-d-to-become-vice-president-of-early-phase-development-and-immuno-oncology-at-lilly-oncology-1010931086
461.0,12/11/2017 12:45:00 PM,FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults,PR Newswire,/news/stocks/fda-accepts-biologics-license-application-bla-to-review-galcanezumab-for-the-prevention-of-migraine-in-adults-1010932888
462.0,12/11/2017 12:57:04 PM,BRIEF-Kimberly Blackwell To Become Vice President Of Early Phase Development And Immuno-Oncology At Lilly Oncology (LLY),Reuters,http://www.businessinsider.com/r-brief-kimberly-blackwell-to-become-vice-president-of-early-phase-development-and-immuno-oncology-at-lilly-oncology-2017-12
463.0,12/11/2017 1:00:03 PM,Eli Lily: FDA Accepts BLA To Review Galcanezumab For Prevention Of Migraine ,RTTNews,/news/stocks/eli-lily-fda-accepts-bla-to-review-galcanezumab-for-prevention-of-migraine-1010932913
464.0,12/11/2017 1:07:04 PM,BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-biologics-license-application-bla-to-review-galcanezumab-for-the-prevention-of-migraine-in-adults-2017-12
465.0,12/11/2017 7:17:03 PM,"FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog (SAN, LLY)",Reuters,http://www.businessinsider.com/r-fda-clears-sanofis-follow-on-diabetes-biologic-of-lillys-humalog-2017-12
466.0,12/11/2017 8:07:03 PM,"UPDATE 1-FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog (SAN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-fda-oks-sanofis-follow-on-biologic-of-lillys-diabetes-drug-humalog-2017-12
467.0,12/11/2017 9:30:00 PM,Lilly Announces 8 Percent Dividend Increase,PR Newswire,/news/stocks/lilly-announces-8-percent-dividend-increase-1010982620
468.0,12/11/2017 9:42:07 PM,BRIEF-Lilly Announces 8 Percent Dividend Increase (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-8-percent-dividend-increase-2017-12
469.0,12/13/2017 12:45:00 PM,Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020,PR Newswire,/news/stocks/lilly-announces-2018-financial-guidance-and-enhances-outlook-through-2020-1011229095
470.0,12/13/2017 1:08:03 PM,Lilly Cuts 2017 EPS View; Announces Outlook Through 2020 ,RTTNews,/news/stocks/lilly-cuts-2017-eps-view-announces-outlook-through-2020-1011230227
471.0,12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12
472.0,12/14/2017 5:57:08 PM,BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-nsav-subsidiary-signs-agreement-with-eli-lilly-2017-12
473.0,12/14/2017 6:30:00 PM,Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin,PR Newswire,/news/stocks/rimidi-and-lilly-collaborate-to-personalize-solutions-for-people-using-insulin-1011419613
474.0,12/15/2017 11:37:04 AM,"UPDATE 1-Boehringer CFO Menne quits in differences over strategy (LHA, SAN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-boehringer-cfo-menne-quits-in-differences-over-strategy-2017-12
475.0,12/15/2017 1:17:04 PM,"Novo Nordisk wins EU panel's backing for key diabetes drug (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-novo-nordisk-wins-eu-panels-backing-for-key-diabetes-drug-2017-12
476.0,12/15/2017 1:47:03 PM,"UPDATE 1-Novo Nordisk wins EU panel's backing for key diabetes drug (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-novo-nordisk-wins-eu-panels-backing-for-key-diabetes-drug-2017-12
477.0,12/18/2017 3:30:00 PM,Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-healthcare-ceos-unscripted-conference-1011618202
478.0,12/19/2017 9:07:04 AM,"BRIEF-Puretech Says Lilly To Invest $5M In PureTech's Entrega (PDC, LLY)",Reuters,http://www.businessinsider.com/r-brief-puretech-says-lilly-to-invest-5m-in-puretechs-entrega-2017-12
479.0,12/20/2017 10:17:04 PM,"BRIEF-U.S. Fda Approves New Diabetes Drug From Merck And Pfizer (MRK, PFE, JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12
480.0,12/20/2017 10:27:06 PM,"U.S. FDA approves new diabetes drug from Merck and Pfizer (MRK, PFE, AZN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12
481.0,12/20/2017 10:42:03 PM,"UPDATE 1-U.S. FDA approves new diabetes drug from Merck and Pfizer (MRK, PFE, AZN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12
482.0,12/22/2017 11:17:03 PM,"UPDATE 2-U.S. judge tosses verdict against AbbVie in AndroGel case (LLY, ENDP)",Reuters,http://www.businessinsider.com/r-update-2-us-judge-tosses-verdict-against-abbvie-in-androgel-case-2017-12
483.0,1/2/2018 6:00:00 PM,Vancouver Island 2018 Property Assessment Notices in the Mail,PR Newswire,/news/stocks/vancouver-island-2018-property-assessment-notices-in-the-mail-1001658057
484.0,1/5/2018 3:00:00 PM,Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-fourth-quarter-2017-financial-results-announcement-1012522652
485.0,1/8/2018 3:00:00 PM,Livongo and Lilly Collaborate on Real-World Diabetes Research,PR Newswire,/news/stocks/livongo-and-lilly-collaborate-on-real-world-diabetes-research-1012665767
486.0,1/9/2018 3:11:00 PM,Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law,Moodys,/news/bonds/moody-s-us-pharmaceutical-companies-cash-holdings-set-to-decline-under-new-tax-law-1012731176
487.0,1/11/2018 2:20:00 PM,"Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe",PR Newswire,/news/stocks/elanco-aratana-announce-marketing-authorization-of-galliprant-grapiprant-tablets-in-europe-1001662149
488.0,1/11/2018 10:30:00 PM,Elanco Announces Addition of New North America and Global Strategy Senior Executive,PR Newswire,/news/stocks/elanco-announces-addition-of-new-north-america-and-global-strategy-senior-executive-1012956084
489.0,1/15/2018 9:00:00 PM,Federal-Mogul Motorparts' Abex® Brand Introduces New Brake Rotors for Commercial Vehicle Market,PR Newswire,/news/stocks/federal-mogul-motorparts-abex-brand-introduces-new-brake-rotors-for-commercial-vehicle-market-668085
490.0,1/18/2018 2:00:00 PM,GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017,PR Newswire,/news/stocks/galliprant-grapiprant-tablets-named-best-companion-animal-product-for-2017-677514
491.0,1/18/2018 6:02:00 PM,Elanco Innovations Named Best Products for 2017,PR Newswire,/news/stocks/elanco-innovations-named-best-products-for-2017-1013235455
492.0,1/22/2018 8:58:59 AM,Some Branded Drugs Going Generic In 2018 ,RTTNews,/news/stocks/some-branded-drugs-going-generic-in-2018-1013567302
493.0,1/22/2018 2:00:00 PM,Elanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio® (lotilaner) to Treat and Protect Against Ticks and Fleas,PR Newswire,/news/stocks/elanco-animal-health-announces-u-s-food-and-drug-administration-fda-approval-of-credelio-lotilaner-to-treat-and-protect-against-ticks-and-fleas-1013590548
494.0,1/22/2018 2:18:20 PM,Eli Lilly Animal Health Unit Announces FDA Approval Of Credelio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-animal-health-unit-announces-fda-approval-of-credelio-quick-facts-1013591458
495.0,1/26/2018 12:27:00 AM,Elanco Announces Global Agreement with Ab E Discovery for New Technology,PR Newswire,/news/stocks/elanco-announces-global-agreement-with-ab-e-discovery-for-new-technology-1014052394
496.0,1/26/2018 2:45:00 PM,Lilly To Present At Leerink Partners Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-present-at-leerink-partners-global-healthcare-conference-1014129587
497.0,1/31/2018 12:25:00 PM,"Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance",PR Newswire,/news/stocks/lilly-reports-strong-fourth-quarter-and-full-year-2017-revenue-growth-increases-2018-eps-guidance-1014670122
498.0,1/31/2018 12:28:50 PM,Eli Lilly And Co. Profit Rises In Q4,RTTNews,/news/stocks/eli-lilly-and-co-profit-rises-in-q4-1014669352
499.0,1/31/2018 12:48:41 PM,Lilly Lifts 2018 Profit View; Backs Revenue Outlook ,RTTNews,/news/stocks/lilly-lifts-2018-profit-view-backs-revenue-outlook-1014670972
500.0,2/13/2018 12:45:00 PM,Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis),PR Newswire,/news/stocks/lilly-announces-positive-top-line-phase-3-results-for-taltz-ixekizumab-in-ankylosing-spondylitis-radiographic-axial-spondyloarthritis-1015625005
501.0,2/13/2018 1:02:17 PM,Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis ,RTTNews,/news/stocks/eli-lilly-taltz-phase-3-study-meets-endpoints-to-treat-ankylosing-spondylitis-1015625982
502.0,2/14/2018 7:17:00 PM,Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting,PR Newswire,/news/stocks/lilly-to-showcase-new-data-for-taltz-ixekizumab-and-other-products-across-immunology-pipeline-at-aad-annual-meeting-1015793140
503.0,2/19/2018 12:45:00 PM,AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity,PR Newswire,/news/stocks/aad-2018-treatment-with-lilly-s-taltz-ixekizumab-resulted-in-improvement-in-impact-of-genital-psoriasis-on-sexual-activity-1016320495
504.0,2/19/2018 1:18:26 PM,Eli Lilly: Taltz Improves Sexual Health Of Genital Psoriasis Patients ,RTTNews,/news/stocks/eli-lilly-taltz-improves-sexual-health-of-genital-psoriasis-patients-1016321992
505.0,2/20/2018 1:00:00 PM,Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month,PR Newswire,/news/stocks/survey-reveals-many-people-with-migraine-live-with-pain-nearly-half-of-every-month-1016433555
506.0,2/20/2018 9:30:00 PM,Lilly to Participate in Cowen Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-cowen-health-care-conference-1016483072
507.0,2/21/2018 6:30:00 PM,Lilly to Participate in Barclays Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-barclays-global-healthcare-conference-1016600550
508.0,2/26/2018 12:45:00 PM,New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes,PR Newswire,/news/stocks/new-data-show-lilly-s-trulicity-dulaglutide-in-combination-with-an-sglt-2-inhibitor-improves-blood-sugar-control-in-people-with-type-2-diabetes-1017168573
509.0,2/26/2018 1:03:27 PM,Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-new-data-from-trulicity-phase-3b-study-quick-facts-1017169447
510.0,2/26/2018 10:16:00 PM,"Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer",PR Newswire,/news/stocks/lilly-receives-additional-fda-approval-for-verzeniotm-abemaciclib-as-initial-treatment-for-advanced-breast-cancer-1017216252
511.0,2/26/2018 10:25:48 PM,Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-additional-fda-approval-for-verzenio-quick-facts-1017216273
512.0,3/6/2018 2:00:00 PM,Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials,PR Newswire,/news/stocks/boehringer-ingelheim-and-lilly-expand-heart-failure-program-for-jardiance-with-new-exercise-capacity-trials-1018128182
513.0,3/8/2018 12:30:00 PM,"EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research",PR Newswire,/news/stocks/efsd-jdrf-and-lilly-extend-collaboration-supporting-type-1-diabetes-research-1018393644
514.0,3/8/2018 12:39:58 PM,"EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research ",RTTNews,/news/stocks/efsd-jdrf-lilly-extend-collaboration-supporting-type-1-diabetes-research-1018393686
515.0,3/9/2018 2:59:00 PM,"Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology",PR Newswire,/news/stocks/maura-dickler-m-d-to-become-vice-president-of-late-phase-development-at-lilly-oncology-1018548952
516.0,3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162
517.0,4/3/2018 1:54:24 PM,Will These Drugs Reach Blockbuster Status? ,RTTNews,/news/stocks/will-these-drugs-reach-blockbuster-status-1020339832
518.0,4/3/2018 4:05:00 PM,Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes,PR Newswire,/news/stocks/improving-cardiology-care-biotronik-us-to-distribute-aziyo-ecm-envelopes-541488
519.0,4/4/2018 12:45:00 PM,Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint,PR Newswire,/news/stocks/lilly-announces-cyramza-ramucirumab-phase-3-reach-2-study-in-second-line-hepatocellular-carcinoma-patients-met-overall-survival-endpoint-1020452409
520.0,4/4/2018 12:53:36 PM,Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-cyramza-phase-3-reach-2-study-meets-primary-endpoint-quick-facts-1020452419
521.0,4/4/2018 1:00:00 PM,Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes,PR Newswire,/news/stocks/lilly-and-sigilon-therapeutics-announce-strategic-collaboration-to-develop-encapsulated-cell-therapies-for-the-treatment-of-type-1-diabetes-541863
522.0,4/4/2018 1:15:11 PM,"Eli Lilly, Sigilon Announce Global Collaboration - Quick Facts ",RTTNews,/news/stocks/eli-lilly-sigilon-announce-global-collaboration-quick-facts-1020454022
523.0,4/4/2018 10:49:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2018-financial-results-announcement-1020501857
524.0,4/5/2018 6:33:03 AM,"CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct. ",RTTNews,/news/stocks/cnat-disappoints-ebio-to-report-vista-data-in-may-prtk-to-face-fda-in-oct-1020539894
525.0,4/15/2018 2:30:00 PM,St. Baldrick's Foundation Commits $8 million to Support Pediatric Cancer Dream Team with Stand Up To Cancer,PR Newswire,/news/stocks/st-baldrick-s-foundation-commits-8-million-to-support-pediatric-cancer-dream-team-with-stand-up-to-cancer-1001935114
526.0,4/16/2018 2:00:00 PM,Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease,PR Newswire,/news/stocks/boehringer-ingelheim-and-lilly-announce-an-academic-collaboration-with-university-of-oxford-to-investigate-the-effects-of-jardiance-in-adults-with-chronic-kidney-disease-1021397180
527.0,4/19/2018 10:26:00 AM,"Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising",Moodys,/news/bonds/moody-s-stable-outlook-for-global-pharmaceuticals-m-a-event-risk-is-rising-1021562771
528.0,4/20/2018 4:14:00 PM,"Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine",PR Newswire,/news/stocks/lilly-to-present-phase-3-data-at-aan-2018-reinforcing-commitment-to-new-innovative-therapies-in-migraine-1021688075
529.0,4/20/2018 8:50:00 PM,Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer,PR Newswire,/news/stocks/lilly-reports-additional-top-line-results-from-cyramza-ramucirumab-phase-3-range-study-in-advanced-or-metastatic-urothelial-cancer-1021708657
530.0,4/21/2018 3:23:59 AM,"An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-10-stocks-to-watch-bhvn-lly-toca-aldr-1021738099
531.0,4/23/2018 1:30:00 PM,Elanco Announces Addition of Chief Financial Officer,PR Newswire,/news/stocks/elanco-announces-addition-of-chief-financial-officer-1021990678
532.0,4/24/2018 2:11:00 AM,"FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis",PR Newswire,/news/stocks/fda-advisory-committee-recommends-the-approval-of-baricitinib-2mg-but-not-4mg-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-1022051417
533.0,4/24/2018 2:58:55 AM,"FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose ",RTTNews,/news/stocks/fda-panel-backs-lower-dose-of-lilly-incyte-arthritis-drug-but-not-higher-dose-1022054657
534.0,4/24/2018 8:46:50 AM,"PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA ",RTTNews,/news/stocks/prta-jolted-fda-strikes-down-pfe-s-herceptin-biosimilar-no-relief-yet-for-kmda-1022084035
535.0,4/24/2018 12:00:00 PM,AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies,PR Newswire,/news/stocks/aan-2018-lillys-galcanezumab-significantly-reduced-monthly-migraine-headache-days-in-patients-with-migraine-who-previously-failed-to-respond-to-multiple-preventive-therapies-611371
536.0,4/24/2018 12:25:00 PM,"Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance",PR Newswire,/news/stocks/lilly-reports-strong-first-quarter-2018-results-raises-eps-guidance-1001618899
537.0,4/24/2018 12:29:36 PM,Eli Lilly And Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-beat-estimates-1022103401
538.0,4/24/2018 1:24:18 PM,Lilly Q1 Results Beat Estimates; Raises 2018 Outlook ,RTTNews,/news/stocks/lilly-q1-results-beat-estimates-raises-2018-outlook-1022108942
539.0,4/25/2018 12:45:00 PM,Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease,PR Newswire,/news/stocks/lilly-and-china-s-nccd-announce-collaboration-to-advance-scientific-understanding-and-care-for-people-living-with-diabetes-and-cardiovascular-disease-1022247073
540.0,4/27/2018 9:53:00 PM,Lilly to Participate in Bank of America Merrill Lynch Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-1022585365
541.0,4/30/2018 12:45:00 PM,"Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development",PR Newswire,/news/stocks/leena-gandhi-m-d-ph-d-to-lead-lilly-oncology-immuno-oncology-medical-development-1022880135
542.0,5/1/2018 3:52:00 PM,Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis,PR Newswire,/news/stocks/lilly-and-local-partners-launch-diabetes-prevention-and-management-pilot-in-three-underserved-neighborhoods-in-indianapolis-1023017542
543.0,5/7/2018 9:15:00 PM,Lilly Declares Second-Quarter 2018 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2018-dividend-1023678242
544.0,5/10/2018 1:30:00 PM,Lilly Announces Agreement To Acquire ARMO BioSciences,PR Newswire,/news/stocks/lilly-announces-agreement-to-acquire-armo-biosciences-1023991146
545.0,5/10/2018 1:30:00 PM,Elanco Animal Health Announces Addition of General Counsel,PR Newswire,/news/stocks/elanco-animal-health-announces-addition-of-general-counsel-1023991147
546.0,5/10/2018 1:41:44 PM,Eli Lilly To Acquire ARMO BioSciences For Approx. $1.6 Bln - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-acquire-armo-biosciences-for-approx-1-6-bln-quick-facts-1023992084
547.0,5/11/2018 7:00:00 PM,Lilly to Participate in UBS Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-global-healthcare-conference-1024148444
548.0,5/12/2018 5:44:25 AM,"An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYAD…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-8-stocks-to-watch-vygr-bold-rxii-cyad-1024202578
549.0,5/14/2018 1:44:00 PM,Lilly to Acquire AurKa Pharma,PR Newswire,/news/stocks/lilly-to-acquire-aurka-pharma-1024436961
550.0,5/14/2018 1:55:23 PM,Lilly To Buy AurKa Pharma ,RTTNews,/news/stocks/lilly-to-buy-aurka-pharma-1024436976
551.0,5/14/2018 5:38:00 PM,WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders,PR Newswire,/news/stocks/weisslaw-llp-armo-biosciences-inc-acquisition-may-not-be-in-the-best-interests-of-armo-shareholders-1024456187
552.0,5/15/2018 12:45:00 PM,Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache,PR Newswire,/news/stocks/lilly-s-galcanezumab-meets-primary-endpoint-in-phase-3-study-evaluating-galcanezumab-for-the-prevention-of-episodic-cluster-headache-1024553454
553.0,5/15/2018 12:56:11 PM,Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-galcanezumab-meets-primary-endpoint-in-phase-3-study-quick-facts-1024553486
554.0,5/16/2018 8:48:18 AM,"LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim ",RTTNews,/news/stocks/lly-gets-headache-relief-xene-abuzz-3rd-time-s-a-charm-for-pfe-s-epogen-biosim-1024665378
555.0,5/16/2018 11:00:00 PM,Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care,PR Newswire,/news/stocks/lilly-data-at-asco-illustrate-patient-driven-advances-in-cancer-care-1024752450
556.0,5/18/2018 3:13:00 PM,AAM to Present at the 2018 Barclays High Yield Bond and Syndicated Loan Conference on May 22,PR Newswire,/news/stocks/aam-to-present-at-the-2018-barclays-high-yield-bond-and-syndicated-loan-conference-on-may-22-1001708162
557.0,5/22/2018 2:30:00 PM,Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area,PR Newswire,/news/stocks/lilly-s-taltz-ixekizumab-receives-the-first-u-s-fda-approval-for-label-update-to-include-data-for-psoriasis-involving-the-genital-area-1025087539
558.0,5/22/2018 2:39:30 PM,Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fda-approves-label-update-for-taltz-quick-facts-1025087624
559.0,5/23/2018 4:02:00 PM,"Elanco, Heifer International 10-Year Effort Breaks the Cycle of Hunger for 160,000 Families",PR Newswire,/news/stocks/elanco-heifer-international-10-year-effort-breaks-the-cycle-of-hunger-for-160-000-families-1025140337
560.0,5/23/2018 8:00:00 PM,Sue Mahony to Retire as President of Lilly Oncology,PR Newswire,/news/stocks/sue-mahony-to-retire-as-president-of-lilly-oncology-1025150757
561.0,5/30/2018 11:21:00 PM,Lilly to Participate in Jefferies Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-jefferies-global-healthcare-conference-1025896236
562.0,5/31/2018 11:00:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1026027094
563.0,6/1/2018 12:45:00 PM,Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis,PR Newswire,/news/stocks/lilly-to-showcase-new-data-at-digestive-disease-week-2018-for-mirikizumab-in-moderate-to-severe-ulcerative-colitis-1026103392
564.0,6/1/2018 6:04:00 PM,FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis,PR Newswire,/news/stocks/fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-to-severely-active-rheumatoid-arthritis-1026133279
565.0,6/4/2018 6:46:25 AM,"FDA Nod For LLY/INCY RA Drug, JAZZ Hits Right Tones, SLS' Study Stopped Early ",RTTNews,/news/stocks/fda-nod-for-lly-incy-ra-drug-jazz-hits-right-tones-sls-study-stopped-early-1026406603
566.0,6/5/2018 12:45:00 PM,"FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer,...",PR Newswire,/news/stocks/fda-expands-lilly-s-alimta-pemetrexed-label-to-include-combination-with-keytruda-pembrolizumab-and-carboplatin-as-first-line-treatment-for-metastatic-nonsquamous-non-small-cell-lung-cancer-1026553603
567.0,6/5/2018 12:51:56 PM,Eli Lilly: FDA Expands ALIMTA Label To Include Combination With KEYTRUD ,RTTNews,/news/stocks/eli-lilly-fda-expands-alimta-label-to-include-combination-with-keytrud-1026553625
568.0,6/5/2018 4:15:00 PM,DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial,PR Newswire,/news/stocks/ddw-2018-patients-with-moderate-to-severe-ulcerative-colitis-achieved-clinical-and-endoscopic-remission-with-mirikizumab-in-phase-2-trial-1026573276
569.0,6/5/2018 8:53:00 PM,Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.,PR Newswire,/news/stocks/lilly-recommends-shareholders-reject-below-market-mini-tender-offer-by-trc-capital-corp-1026600910
570.0,6/11/2018 12:45:00 PM,"Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology",PR Newswire,/news/stocks/lilly-to-unveil-new-data-at-the-annual-european-congress-of-rheumatology-furthering-commitment-to-scientific-discovery-in-immunology-1026834212
571.0,6/11/2018 12:53:06 PM,Eli Lilly To Present New Data From Its Immunology Portfolio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-present-new-data-from-its-immunology-portfolio-quick-facts-1026834226
572.0,6/11/2018 1:00:00 PM,Elanco Animal Health Introduces New Respiratory PRRS Vaccine,PR Newswire,/news/stocks/elanco-animal-health-introduces-new-respiratory-prrs-vaccine-1026834355
573.0,6/12/2018 8:00:00 AM,Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease,PR Newswire,/news/stocks/update-on-phase-3-clinical-trials-of-lanabecestat-for-alzheimer-s-disease-1026857734
574.0,6/12/2018 8:16:31 AM,"AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's ",RTTNews,/news/stocks/astrazeneca-eli-lilly-to-discontinue-lanabecestat-trials-in-alzheimer-s-1026858002
575.0,6/13/2018 7:45:47 AM,"CAH Closer To FDA Approval, Another Alzheimer's Disease Drug Fails, VTVT Tanks ",RTTNews,/news/stocks/cah-closer-to-fda-approval-another-alzheimer-s-disease-drug-fails-vtvt-tanks-1026908489
576.0,6/18/2018 10:27:00 PM,Lilly Declares Third-Quarter 2018 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2018-dividend-1027177119
577.0,6/23/2018 3:58:14 PM,Eli Lilly: Trulicity Phase 2 Data Shows Efficacy In People With Type 2 Diabetes ,RTTNews,/news/stocks/eli-lilly-trulicity-phase-2-data-shows-efficacy-in-people-with-type-2-diabetes-1027312332
578.0,6/23/2018 8:20:16 PM,Eli Lilly: Lispro Shows Improved Blood Sugar Control In Phase 1b Studies ,RTTNews,/news/stocks/eli-lilly-lispro-shows-improved-blood-sugar-control-in-phase-1b-studies-1027312415
579.0,6/23/2018 9:19:19 PM,Eli Lilly: Jardiance Reduces Risk Of Kidney Disease Progression In Diabetes ,RTTNews,/news/stocks/eli-lilly-jardiance-reduces-risk-of-kidney-disease-progression-in-diabetes-1027312421
580.0,6/25/2018 5:21:12 AM,"LLY Scores Win In Alimta Patent Suit, LXRX For The Long Haul, MNKD Breathes Easy ",RTTNews,/news/stocks/lly-scores-win-in-alimta-patent-suit-lxrx-for-the-long-haul-mnkd-breathes-easy-1027312812
581.0,6/25/2018 12:59:54 PM,"Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts ",RTTNews,/news/stocks/eli-lilly-to-present-phase-3-data-for-galcanezumab-lasmiditan-quick-facts-1027314032
582.0,6/25/2018 2:19:15 PM,Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint ,RTTNews,/news/stocks/boehringer-ingelheim-eli-lilly-empagliflozin-trials-meet-primary-endpoint-1027314563
583.0,6/25/2018 2:51:33 PM,Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C ,RTTNews,/news/stocks/eli-lilly-humulin-r-u-500-administered-in-insulin-pump-shows-improved-a1c-1027314738
584.0,6/28/2018 8:03:05 AM,"ACRX Gets EC Nod, AQXP Tanks As LEADERSHIP 301 Fails, ZSAN Catches Eye ",RTTNews,/news/stocks/acrx-gets-ec-nod-aqxp-tanks-as-leadership-301-fails-zsan-catches-eye-1027324885
585.0,7/18/2018 12:55:49 PM,Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab ,RTTNews,/news/stocks/pfizer-and-lilly-announce-positive-results-from-phase-3-trial-of-tanezumab-1027377487
586.0,7/19/2018 2:14:55 PM,Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint ,RTTNews,/news/stocks/lilly-tradjenta-s-carmelina-cardiovascular-outcome-trial-meets-primary-endpoint-1027382111
587.0,7/23/2018 3:01:43 PM,Eli Lilly and is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q2-quarterly-earnings-preview-1027389862
588.0,7/24/2018 12:31:50 PM,Eli Lilly And Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-beat-estimates-1027393216
589.0,7/24/2018 12:47:34 PM,Eli Lilly Revises Guidance; To Pursue IPO Of Elanco - Quick Facts ,RTTNews,/news/stocks/eli-lilly-revises-guidance-to-pursue-ipo-of-elanco-quick-facts-1027393284
590.0,7/24/2018 4:52:00 PM,Eli Lilly and Company -- Moody's: Lilly's planned separation of Elanco is credit negative,Moodys,/news/bonds/eli-lilly-and-company-moody-s-lilly-s-planned-separation-of-elanco-is-credit-negative-1027395121
591.0,8/2/2018 11:54:40 PM,Elanco Animal Health Files Registration Statement For IPO - Quick Facts ,RTTNews,/news/stocks/elanco-animal-health-files-registration-statement-for-ipo-quick-facts-1027428046
592.0,8/31/2018 12:05:59 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1027499929
593.0,9/20/2018 3:00:11 AM,Lilly's Elanco Animal Health Prices IPO Of 62.9 Mln Shares At $24.00/shr ,RTTNews,/news/stocks/lilly-s-elanco-animal-health-prices-ipo-of-62-9-mln-shares-at-24-00-shr-1027549293
594.0,9/21/2018 1:59:57 PM,Lilly' Emgality Gets Positive CHMP Opinion For Prophylaxis Of Migraine In Adults ,RTTNews,/news/stocks/lilly-emgality-gets-positive-chmp-opinion-for-prophylaxis-of-migraine-in-adults-1027554576
595.0,9/28/2018 2:52:53 AM,FDA Approves Lilly's Emgality For Preventive Treatment Of Migraine In Adults ,RTTNews,/news/stocks/fda-approves-lilly-s-emgality-for-preventive-treatment-of-migraine-in-adults-1027572913
596.0,9/28/2018 3:45:03 AM,A new medication that's changing the way we treat a condition that affects 38 million Americans just got approved (LLY),Business Insider,https://www.businessinsider.com/eli-lilly-migraine-drug-emgality-approved-by-fda-2018-9
597.0,10/2/2018 12:58:43 PM,Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint ,RTTNews,/news/stocks/eli-lilly-phase-3-studies-show-urli-meets-primary-efficacy-endpoint-1027582521
598.0,10/4/2018 12:51:16 PM,Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint ,RTTNews,/news/stocks/boehringer-ingelheim-eli-lilly-empagliflozin-meets-primary-efficacy-endpoint-1027589821
599.0,10/4/2018 8:00:05 PM,Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial show positive results (LLY),Business Insider,https://www.businessinsider.com/eli-lilly-stock-gets-bump-after-drug-trial-positive-results-2018-10
600.0,10/22/2018 4:25:03 AM,Lilly And Incyte Update Safety Analysis Of OLUMIANT ,RTTNews,/news/stocks/lilly-and-incyte-update-safety-analysis-of-olumiant-1027636343
601.0,10/24/2018 7:39:15 AM,"CMTA Fast Tracks NDA Filing, USNA In Good Health, DERM To Report Data In Apr. ",RTTNews,/news/stocks/cmta-fast-tracks-nda-filing-usna-in-good-health-derm-to-report-data-in-apr-1027647548
602.0,10/29/2018 1:11:21 PM,Dicerna Stock Surges On RNAi Deal With Lilly ,RTTNews,/news/stocks/dicerna-stock-surges-on-rnai-deal-with-lilly-1027665366
603.0,10/31/2018 9:23:57 AM,"Dr. Reddy's Launches Atomoxetine Capsules, Generic Version Of Strattera, In U.S. ",RTTNews,/news/stocks/dr-reddy-s-launches-atomoxetine-capsules-generic-version-of-strattera-in-u-s-1027674796
604.0,11/5/2018 1:09:27 PM,Eli Lilly: REWIND Trial Demonstrates MACE Reduction By Trulicity - Quick Facts ,RTTNews,/news/stocks/eli-lilly-rewind-trial-demonstrates-mace-reduction-by-trulicity-quick-facts-1027690457
605.0,11/5/2018 3:02:36 PM,Eli Lilly and earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q3-quarterly-earnings-preview-1027691145
606.0,11/6/2018 1:04:14 PM,Eli Lilly Q3 Results Beat View; Lifts FY18 Outlook ,RTTNews,/news/stocks/eli-lilly-q3-results-beat-view-lifts-fy18-outlook-1027695886
607.0,12/12/2018 12:13:14 PM,Lilly And AC Immune Enter Into License And Collaboration Agreement ,RTTNews,/news/stocks/lilly-and-ac-immune-enter-into-license-and-collaboration-agreement-1027801850
608.0,12/13/2018 12:58:22 PM,Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program ,RTTNews,/news/stocks/eli-lilly-fda-grants-fast-track-designation-to-baricitinib-development-program-1027806092
609.0,12/17/2018 1:00:38 PM,Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study ,RTTNews,/news/stocks/eli-lilly-taltz-meets-primary-and-secondary-endpoints-in-spirit-h2h-study-1027813489
610.0,12/19/2018 1:02:49 PM,Lilly Sees FY19 Results Above View; Hikes Dividend ,RTTNews,/news/stocks/lilly-sees-fy19-results-above-view-hikes-dividend-1027821066
611.0,12/19/2018 6:48:58 PM,Eli Lilly Pulls Back Off Best Levels But Remains Firmly Positive ,RTTNews,/news/stocks/eli-lilly-pulls-back-off-best-levels-but-remains-firmly-positive-1027822751
612.0,12/27/2018 8:47:47 AM,"Innovent, Lilly Co-developed Tyvyt Gets China's NMPA Approval For CHL ",RTTNews,/news/stocks/innovent-lilly-co-developed-tyvyt-gets-china-s-nmpa-approval-for-chl-1027833166
613.0,1/7/2019 12:52:33 PM,Lilly To Buy Loxo Oncology In $8.0 Bln Deal ,RTTNews,/news/stocks/lilly-to-buy-loxo-oncology-in-8-0-bln-deal-1027847015
614.0,1/7/2019 7:53:00 PM,Eli Lilly and Company -- Moody's affirms Eli Lilly's A2/P-1 ratings; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-affirms-eli-lilly-s-a2-p-1-ratings-stable-outlook-1027848947
615.0,1/18/2019 5:15:09 AM,"FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz ",RTTNews,/news/stocks/fda-turns-down-immu-s-breast-cancer-drug-mgnx-lly-deal-progresses-zfgn-abuzz-1027878304
616.0,1/18/2019 1:27:40 PM,Lilly : Phase 3 Soft Tissue Sarcoma Study Fails Not Meet Primary Endpoints ,RTTNews,/news/stocks/lilly-phase-3-soft-tissue-sarcoma-study-fails-not-meet-primary-endpoints-1027879277
617.0,1/29/2019 12:39:19 PM,"Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain ",RTTNews,/news/stocks/pfizer-lilly-announce-results-from-phase-3-study-of-tanezumab-in-oa-pain-1027904214
618.0,2/1/2019 1:00:44 PM,"Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period ",RTTNews,/news/stocks/eli-lilly-loxo-oncology-report-expiration-of-hsr-act-waiting-period-1027916192
619.0,2/4/2019 12:52:11 PM,Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2 ,RTTNews,/news/stocks/lilly-baricitinib-meets-primary-endpoint-in-breeze-ad1-and-breeze-ad2-1027920368
620.0,2/4/2019 3:02:00 PM,What Wall Street expects from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-q4-quarterly-earnings-preview-1027920992
621.0,2/6/2019 12:28:49 PM,Eli Lilly And Co. Q4 adjusted earnings Miss Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q4-adjusted-earnings-miss-estimates-1027928952
622.0,2/6/2019 12:48:46 PM,Eli Lilly Lowers FY19 Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-lowers-fy19-outlook-quick-facts-1027929033
623.0,2/8/2019 1:17:44 PM,Eli Lilly To Divest Remaining Stake In Elanco Animal Health Via Exchange Offer ,RTTNews,/news/stocks/eli-lilly-to-divest-remaining-stake-in-elanco-animal-health-via-exchange-offer-1027936747
624.0,2/8/2019 2:00:22 PM,Elanco Animal Health To File Registration Statement On Lilly Divestiture ,RTTNews,/news/stocks/elanco-animal-health-to-file-registration-statement-on-lilly-divestiture-1027936863
625.0,2/8/2019 7:28:00 PM,Eli Lilly and Company -- Moody's: Lilly's animal health divestiture will reduce scale and diversity,Moodys,/news/bonds/eli-lilly-and-company-moody-s-lilly-s-animal-health-divestiture-will-reduce-scale-and-diversity-1027937747
626.0,2/15/2019 10:09:00 PM,Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company,Moodys,/news/bonds/eli-lilly-and-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-eli-lilly-and-company-1027957884
627.0,2/15/2019 10:20:00 PM,Elanco Animal Health Incorporated -- Moody's announces completion of a periodic review of ratings of Elanco Animal Health Incorporated,Moodys,/news/bonds/elanco-animal-health-incorporated-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-elanco-animal-health-incorporated-1027957917
628.0,2/19/2019 12:55:51 PM,Eli Lilly: Tanezumab 10 Mg Meets Primary Endpoint In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-tanezumab-10-mg-meets-primary-endpoint-in-phase-3-study-quick-facts-1027963149
629.0,2/20/2019 4:12:00 PM,Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-assigns-a2-rating-to-eli-lilly-s-notes-stable-outlook-1027968672
630.0,3/1/2019 1:07:07 PM,"Lilly To Present Data For Taltz, Mirikizumab At AAD Annual Meeting ",RTTNews,/news/stocks/lilly-to-present-data-for-taltz-mirikizumab-at-aad-annual-meeting-1027996687
631.0,3/4/2019 12:41:36 PM,Eli Lilly To Introduce Lower-priced Version Of Insulin Humalog - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-introduce-lower-priced-version-of-insulin-humalog-quick-facts-1028000383
632.0,3/4/2019 4:21:03 PM,A drugmaker just released a half-price version of a life-saving diabetes medication in a bet that a lower price tag will help it escape the political crosshairs (LLY),Business Insider,https://www.businessinsider.com/eli-lilly-cuts-price-of-humalog-insulin-by-50-through-authorized-generic-2019-3
633.0,3/4/2019 11:12:06 PM,"A drugmaker just slashed the price of its life-saving medication by 50%, but people are worried the $137 price tag is still unaffordable (LLY)",Business Insider,https://www.businessinsider.com/lillys-50-price-cut-to-insulin-humalog-is-still-unaffordable-2019-3
634.0,3/5/2019 1:00:51 PM,Lilly Gets FDA Priority Review Designation For Emgality Injection - Quick Facts ,RTTNews,/news/stocks/lilly-gets-fda-priority-review-designation-for-emgality-injection-quick-facts-1028004391
635.0,3/11/2019 12:10:20 PM,Eli Lilly: Elanco Exchange Offer Oversubscribed - Quick Facts ,RTTNews,/news/stocks/eli-lilly-elanco-exchange-offer-oversubscribed-quick-facts-1028018614
636.0,3/12/2019 12:05:54 PM,Eli Lilly: Phase 3 RELAY Study With CYRAMZA Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-phase-3-relay-study-with-cyramza-meets-primary-endpoint-quick-facts-1028022486
637.0,3/13/2019 11:56:12 AM,Elanco Appoints Four Members To Board ,RTTNews,/news/stocks/elanco-appoints-four-members-to-board-1028026375
638.0,3/26/2019 10:30:16 PM,"Lilly, ImmuNext Sign Licensing And Research Agreement ",RTTNews,/news/stocks/lilly-immunext-sign-licensing-and-research-agreement-1028060919
639.0,3/27/2019 9:59:02 AM,"Dr. Reddy's Labs Launches Tadalafil Tablets, Generic Version Of Cialis, In U.S. ",RTTNews,/news/stocks/dr-reddy-s-labs-launches-tadalafil-tablets-generic-version-of-cialis-in-u-s-1028061852
640.0,4/1/2019 11:35:32 AM,Royalty Pharma Buys Royalty Of Eli Lilly's Emgality From Arteaus For $260 Mln ,RTTNews,/news/stocks/royalty-pharma-buys-royalty-of-eli-lilly-s-emgality-from-arteaus-for-260-mln-1028073761
641.0,4/1/2019 2:58:21 PM,Merck Announces Post-hoc Analysis From KEYNOTE-189 Trial - Quick Facts ,RTTNews,/news/stocks/merck-announces-post-hoc-analysis-from-keynote-189-trial-quick-facts-1028074699
642.0,4/22/2019 1:00:29 PM,"Eli Lilly, Avidity Collaborate To Develop New Medicines In Immunology ",RTTNews,/news/stocks/eli-lilly-avidity-collaborate-to-develop-new-medicines-in-immunology-1028125831
643.0,4/22/2019 1:46:54 PM,Eli Lilly Reports Positive Top-line Results From Phase 3 Study Of Taltz ,RTTNews,/news/stocks/eli-lilly-reports-positive-top-line-results-from-phase-3-study-of-taltz-1028125955
644.0,4/29/2019 3:02:37 PM,Eli Lilly and earnings preview: what to expect,Markets Insider Automation,/news/stocks/eli_lilly-stock-q1-earnings-preview-1028148484
645.0,4/30/2019 12:29:04 PM,Eli Lilly And Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-beat-estimates-1028152591
646.0,4/30/2019 12:51:54 PM,Eli Lilly Updates 2019 Guidance To Reflect Elanco Disposition - Quick Facts ,RTTNews,/news/stocks/eli-lilly-updates-2019-guidance-to-reflect-elanco-disposition-quick-facts-1028152679
647.0,4/30/2019 2:07:16 PM,Incyte To No Longer Participate In Co-funding Of Development Of Baricitinib ,RTTNews,/news/stocks/incyte-to-no-longer-participate-in-co-funding-of-development-of-baricitinib-1028153188
648.0,5/13/2019 1:10:07 PM,Eli Lilly Announces FDA Approval Of CYRAMZA For New Indication - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-fda-approval-of-cyramza-for-new-indication-quick-facts-1028194198
649.0,5/28/2019 2:11:11 PM,Eli Lilly To Acquire Global Rights For Non-Opioid Pain Asset From Centrexion ,RTTNews,/news/stocks/eli-lilly-to-acquire-global-rights-for-non-opioid-pain-asset-from-centrexion-1028235024
650.0,5/28/2019 2:18:35 PM,Eli Lilly Licenses Early-phase Molecule From Centrexion To Treat Chronic Pain ,RTTNews,/news/stocks/eli-lilly-licenses-early-phase-molecule-from-centrexion-to-treat-chronic-pain-1028235053
651.0,6/4/2019 1:41:24 PM,FDA Accepts NDA For Triple Combination Tablet For Adults With Type 2 Diabetes ,RTTNews,/news/stocks/fda-accepts-nda-for-triple-combination-tablet-for-adults-with-type-2-diabetes-1028252127
652.0,6/5/2019 3:25:07 AM,Lilly : FDA Approves Emgality To Treat Episodic Cluster Headache In Adults ,RTTNews,/news/stocks/lilly-fda-approves-emgality-to-treat-episodic-cluster-headache-in-adults-1028254538
653.0,6/11/2019 9:18:35 AM,Lilly Reports Positive Results From Taltz 5-yr Study - Quick Facts ,RTTNews,/news/stocks/lilly-reports-positive-results-from-taltz-5-yr-study-quick-facts-1028268598
654.0,6/14/2019 1:17:22 PM,Eli Lilly Reports Positive Results From Phase 3b/4 Study Of Taltz - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-positive-results-from-phase-3b-4-study-of-taltz-quick-facts-1028280046
655.0,6/26/2019 12:20:00 PM,Eli Lilly: FDA Grants Fast Track Designation To Empagliflozin - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fda-grants-fast-track-designation-to-empagliflozin-quick-facts-1028308830
656.0,6/26/2019 1:09:19 PM,Eli Lilly: Trulicity AWARD-11 Trial Meets Endpoints - Quick Facts ,RTTNews,/news/stocks/eli-lilly-trulicity-award-11-trial-meets-endpoints-quick-facts-1028309097
657.0,6/27/2019 12:34:54 PM,"3 Big Stock Charts for Thursday: H & R Block, Boeing and Eli Lilly",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-lly-ba-hrb-1028315917
658.0,7/9/2019 1:05:35 PM,"3 Big Stock Charts for Tuesday: Eli Lilly, SYSCO and Interpublic Group",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-eli-lilly-sysco-and-interpublic-group-1028340756
659.0,7/11/2019 7:00:51 PM,4 Drug Stocks Getting Smashed,InvestorPlace,/news/stocks/4-drug-stocks-getting-smashed-1028347976
660.0,7/12/2019 1:33:44 PM,Eli Lilly To Present Post-hoc Analyses On Emgality Compared To Placebo ,RTTNews,/news/stocks/eli-lilly-to-present-post-hoc-analyses-on-emgality-compared-to-placebo-1028348887
661.0,7/25/2019 9:27:18 AM,First Needle-free Treatment For Severe Hypoglycemia Gets FDA Nod ,RTTNews,/news/stocks/first-needle-free-treatment-for-severe-hypoglycemia-gets-fda-nod-1028383560
662.0,7/25/2019 12:10:53 PM,"GEMP Gets Facelift, Castle Bio To Debut Today, What's The Buzz About Baqsimi? ",RTTNews,/news/stocks/gemp-gets-facelift-castle-bio-to-debut-today-what-s-the-buzz-about-baqsimi-1028384130
663.0,7/26/2019 3:53:32 PM,"Notable Earnings To Watch Next Week - LLY, AAPL, PG, MRK, PFE, CVX ",RTTNews,/news/stocks/notable-earnings-to-watch-next-week-lly-aapl-pg-mrk-pfe-cvx-1028388673
664.0,7/29/2019 3:02:47 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-q2-quarterly-earnings-preview-1028393689
665.0,7/30/2019 12:30:29 PM,Eli Lilly And Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-beat-estimates-1028397681
666.0,7/30/2019 12:39:19 PM,Eli Lilly Raises FY19 Earnings Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-raises-fy19-earnings-outlook-quick-facts-1028397734
667.0,8/5/2019 1:03:12 PM,Eli Lilly: Emgality Meets Endpoints In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-emgality-meets-endpoints-in-phase-3-study-quick-facts-1028416801
668.0,8/7/2019 1:03:07 PM,Eli Lilly Announces Several Leadership Changes - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-several-leadership-changes-quick-facts-1028425928
669.0,8/8/2019 3:17:33 PM,Lilly Says Emgality Meets Primary And Secondary Outcomes In CONQUER Study ,RTTNews,/news/stocks/lilly-says-emgality-meets-primary-and-secondary-outcomes-in-conquer-study-1028431201
670.0,8/13/2019 1:17:45 PM,Eli Lilly: Taltz Shows Efficacy In Phase 4 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-taltz-shows-efficacy-in-phase-4-study-quick-facts-1028441379
671.0,8/23/2019 6:37:40 PM,Will Lawsuits Sink Johnson & Johnson Stock?,InvestorPlace,/news/stocks/lawsuits-jnj-stock-probably-not-1028470702
672.0,8/26/2019 12:55:02 PM,Lilly : FDA Approves Taltz To Treat Active Ankylosing Spondylitis ,RTTNews,/news/stocks/lilly-fda-approves-taltz-to-treat-active-ankylosing-spondylitis-1028472709
673.0,9/9/2019 9:43:20 AM,Eli Lilly Reports Positive Results From Selpercatinib Trial - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-positive-results-from-selpercatinib-trial-quick-facts-1028507827
674.0,9/10/2019 2:55:17 PM,10 Healthcare Stocks to Buy Despite the Headlines,InvestorPlace,/news/stocks/10-healthcare-stocks-to-buy-despite-the-headlines-1028514931
675.0,9/20/2019 1:26:11 PM,Lilly : CHMP Issues Positive Opinion To Expand Trulicity Label ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-to-expand-trulicity-label-1028540642
676.0,9/23/2019 1:12:08 PM,Lilly To Present Data Across Its Oncology Product Portfolio ,RTTNews,/news/stocks/lilly-to-present-data-across-its-oncology-product-portfolio-1028544292
677.0,10/3/2019 1:05:34 PM,Eli Lilly: Taltz Shows Superiority At Week 12 Of Phase 4 IXORA-R Study ,RTTNews,/news/stocks/eli-lilly-taltz-shows-superiority-at-week-12-of-phase-4-ixora-r-study-1028573567
678.0,10/3/2019 3:41:34 PM,Eli Lilly Shares To Be Delisted From Euronext Paris On Oct. 31 - Quick Facts ,RTTNews,/news/stocks/eli-lilly-shares-to-be-delisted-from-euronext-paris-on-oct-31-quick-facts-1028574388
679.0,10/7/2019 6:51:22 PM,Why Johnson & Johnson Stock Is Not a Screaming Buy,InvestorPlace,/news/stocks/johnson-johnson-jnj-stock-not-screaming-buy-1028581887
680.0,10/9/2019 11:15:46 AM,"3 Big Stock Charts for Wednesday: General Mills, Eli Lilly and Hartford Financial Services",InvestorPlace,/news/stocks/3-big-stock-charts-for-wednesday-general-mills-eli-lilly-and-hartford-financial-services-1028588734
681.0,10/14/2019 3:13:21 PM,FDA Approves Reyvow Tablets To Treat Migraine ,RTTNews,/news/stocks/fda-approves-reyvow-tablets-to-treat-migraine-1028596616
682.0,10/16/2019 1:11:06 PM,Lilly Says Phase 3 SEQUOIA Study Did Not Meet Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/lilly-says-phase-3-sequoia-study-did-not-meet-primary-endpoint-quick-facts-1028603135
683.0,10/22/2019 3:01:31 PM,Eli Lilly and is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q3-earnings-preview-stock-1028618955
684.0,10/22/2019 5:23:57 PM,5 Healthcare Stocks to Buy,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-2-1028620498
685.0,10/23/2019 12:31:10 PM,Eli Lilly And Co. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q3-adjusted-earnings-beat-estimates-1028622377
686.0,10/23/2019 12:32:14 PM,Eli Lilly Boosts FY19 Earnings Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-boosts-fy19-earnings-outlook-quick-facts-1028622376
687.0,10/24/2019 10:36:53 AM,"3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-cisco-systems-eli-lilly-colgate-palmolive-1028627304
688.0,10/29/2019 10:48:00 AM,Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's euro notes; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-assigns-a2-rating-to-eli-lilly-s-euro-notes-stable-outlook-1028638218
689.0,10/31/2019 11:27:44 AM,"3 Big Stock Charts for Thursday: Merck, Anheuser-Busch InBev, and PPG Industries",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-merck-anheuser-busch-inbev-ppg-industries-1028648405
690.0,11/1/2019 6:16:10 PM,"The Good, Bad, and Ugly for Biogen Stock",InvestorPlace,/news/stocks/the-good-bad-and-ugly-for-biogen-stock-1028652569
691.0,11/1/2019 8:24:18 PM,WeWork IPO was a Failure – These 2 IPO Stocks are Surging,InvestorPlace,/news/stocks/wework-ipo-was-a-failure-these-2-ipo-stocks-are-surging-1028652783
692.0,11/4/2019 3:23:09 PM,Boehringer Ingelheim - Lilly Alliance To Focus Full Expertise On Jardiance ,RTTNews,/news/stocks/boehringer-ingelheim-lilly-alliance-to-focus-full-expertise-on-jardiance-1028655365
693.0,11/12/2019 12:56:11 PM,Lilly Says Phase 3 Study Of Taltz Meets Primary & All Major Secondary Endpoints ,RTTNews,/news/stocks/lilly-says-phase-3-study-of-taltz-meets-primary-all-major-secondary-endpoints-1028680102
694.0,11/17/2019 7:27:06 PM,Lilly Announces Interim Analysis From EMPRISE Real-world Study ,RTTNews,/news/stocks/lilly-announces-interim-analysis-from-emprise-real-world-study-1028694769
695.0,11/20/2019 12:40:13 PM,Lilly Plans To Invest $400 Mln In Manufacturing Facilities In Indianapolis ,RTTNews,/news/stocks/lilly-plans-to-invest-400-mln-in-manufacturing-facilities-in-indianapolis-1028703519
696.0,11/25/2019 11:37:00 AM,Moody's  - Novo Nordisk cements its position in the big league after FDA approves new diabetes drug,Moodys,/news/bonds/moody-s-novo-nordisk-cements-its-position-in-the-big-league-after-fda-approves-new-diabetes-drug-1028714115
697.0,12/5/2019 12:42:19 PM,Lilly Announces New Leadership In Oncology R&D ,RTTNews,/news/stocks/lilly-announces-new-leadership-in-oncology-r-d-1028740135
698.0,12/9/2019 3:39:38 AM,Lilly Presents Interim Data From Trial In B-Cell Leukemias And Lymphomas ,RTTNews,/news/stocks/lilly-presents-interim-data-from-trial-in-b-cell-leukemias-and-lymphomas-1028745937
699.0,12/13/2019 12:56:48 PM,What to Do with Karuna Stock After It Soared and Then Plunged,InvestorPlace,/news/stocks/karuna-stock-soared-and-plunged-1028762057
700.0,12/13/2019 1:04:57 PM,Lilly : CHMP Issues Positive Opinion To Expand Cyramza Label ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-to-expand-cyramza-label-1028761852
701.0,12/13/2019 2:22:39 PM,Lilly Updates On Jardiance Exercise Ability Studies In Chronic Heart Failure ,RTTNews,/news/stocks/lilly-updates-on-jardiance-exercise-ability-studies-in-chronic-heart-failure-1028762101
702.0,12/16/2019 1:00:57 PM,Lilly To Include Dexcom's Technology Into Its Diabetes Management System ,RTTNews,/news/stocks/lilly-to-include-dexcom-s-technology-into-its-diabetes-management-system-1028765048
703.0,12/17/2019 12:34:22 PM,Drugs That Missed Key Goals In Phase III Trials ,RTTNews,/news/stocks/drugs-that-missed-key-goals-in-phase-iii-trials-1028768208
704.0,12/17/2019 12:49:13 PM,"Eli Lilly Reaffirms FY19 Adj. EPS, Revenue Outlook - Quick Facts ",RTTNews,/news/stocks/eli-lilly-reaffirms-fy19-adj-eps-revenue-outlook-quick-facts-1028768250
705.0,12/17/2019 2:27:25 PM,Collect on the Pharmaceutical Boom With Eli Lilly,InvestorPlace,/news/stocks/collect-pharmaceutical-boom-eli-lilly-lly-1028769423
706.0,12/17/2019 9:25:49 PM,Stock Market Today: Roku’s CFO Stepping Down; Buy Microsoft?,InvestorPlace,/news/stocks/stock-market-today-roku-cfo-buy-microsoft-stock-1028770587
707.0,12/18/2019 1:00:02 PM,Lilly Launches Real-World Evidence Study Of Emgality On Migraine ,RTTNews,/news/stocks/lilly-launches-real-world-evidence-study-of-emgality-on-migraine-1028771779
708.0,1/10/2020 12:45:03 PM,Lilly To Acquire Dermira In $1.1 Bln Deal - Quick Facts ,RTTNews,/news/stocks/lilly-to-acquire-dermira-in-1-1-bln-deal-quick-facts-1028808907
709.0,1/14/2020 7:03:00 PM,Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company,Moodys,/news/bonds/eli-lilly-and-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-eli-lilly-and-company-1028817192
710.0,1/15/2020 4:37:07 PM,Pfizer Stock Offers Good Value to Patient Investors,InvestorPlace,/news/stocks/pfizer-stock-offers-good-value-investors-1028820483
711.0,1/16/2020 1:27:17 PM,"Beyond the Growing Dividend, Abbvie Stock Is a Good Buy Here",InvestorPlace,/news/stocks/growing-dividend-abbvie-stock-good-buy-1028823662
712.0,1/27/2020 12:57:19 PM,Lilly : Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation ,RTTNews,/news/stocks/lilly-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-1028846153
713.0,1/28/2020 2:12:13 AM,FDA Oks Triple-combination Tablet With Jardiance For Adults With Type 2 Diabetes ,RTTNews,/news/stocks/fda-oks-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes-1028848360
714.0,1/28/2020 3:41:09 AM,"XLRN Soars, FDA Approves Triple Combo Pill For Type 2 Diabetes, MGEN On Watch ",RTTNews,/news/stocks/xlrn-soars-fda-approves-triple-combo-pill-for-type-2-diabetes-mgen-on-watch-1028848386
715.0,1/29/2020 11:00:56 AM,Why Teva Stock Could Be the Next General Electric Stock,InvestorPlace,/news/stocks/teva-stock-next-general-electric-1028854259
716.0,1/29/2020 3:02:11 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-q4-earnings-preview-stock-1028855403
717.0,1/30/2020 3:44:30 AM,"CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST ",RTTNews,/news/stocks/caba-hits-new-high-immp-on-watch-sbph-drops-catalyst-1028857403
718.0,1/30/2020 12:32:02 PM,Eli Lilly And Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q4-adjusted-earnings-beat-estimates-1028858989
719.0,1/30/2020 12:41:58 PM,Eli Lilly FY20 Non-GAAP Earnings Outlook Unchanged - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fy20-non-gaap-earnings-outlook-unchanged-quick-facts-1028859032
720.0,1/30/2020 12:47:34 PM,"Eli Lilly, Incyte: Baricitinib Meets Primary Endpoint In BREEZE-AD5 Study ",RTTNews,/news/stocks/eli-lilly-incyte-baricitinib-meets-primary-endpoint-in-breeze-ad5-study-1028859050
721.0,1/31/2020 12:27:53 PM,Lilly Receives Positive CHMP Opinion For New Mealtime Insulin ,RTTNews,/news/stocks/lilly-receives-positive-chmp-opinion-for-new-mealtime-insulin-1028862918
722.0,2/3/2020 2:15:36 PM,There Are Better Pharmaceutical Names Than Teva Stock,InvestorPlace,/news/stocks/teva-stock-has-rebounded-off-its-lows-but-its-not-a-buy-right-now-1028868411
723.0,2/4/2020 4:40:51 PM,Teva Pharmaceutical Just Got a Little Migraine Relief ,InvestorPlace,/news/stocks/teva-stock-just-got-a-little-migraine-relief-1028873202
724.0,2/10/2020 7:20:36 AM,Eli Lilly: DIAN-TU Study With Solanezumab Fails To Meet Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-dian-tu-study-with-solanezumab-fails-to-meet-endpoint-quick-facts-1028887627
725.0,2/10/2020 3:36:10 PM,Eagle Pharma nabs final FDA nod for Pemfexy,Seeking Alpha,https://seekingalpha.com/news/3540074-eagle-pharma-nabs-final-fda-nod-for-pemfexy?utm_source=markets.businessinsider.com&utm_medium=referral
726.0,2/10/2020 3:54:36 PM,Stock Alert: Eli Lilly Drops As Alzheimer's Drug Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/stock-alert-eli-lilly-drops-as-alzheimer-s-drug-fails-to-meet-primary-endpoint-1028889581
727.0,2/11/2020 12:19:34 PM,Lilly's Taltz OK'd in Canada for arthritis of the spine,Seeking Alpha,https://seekingalpha.com/news/3540423-lillys-taltz-okd-in-canada-for-arthritis-of-spine?utm_source=markets.businessinsider.com&utm_medium=referral
728.0,2/12/2020 3:42:23 AM,Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation ,RTTNews,/news/stocks/lilly-s-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-1028895966
729.0,2/19/2020 2:28:44 PM,FDA Ad Com in April for Lilly imaging agent,Seeking Alpha,https://seekingalpha.com/news/3543254-fda-ad-com-in-april-for-lilly-imaging-agent?utm_source=markets.businessinsider.com&utm_medium=referral
730.0,2/20/2020 3:58:47 PM,FDA implements new rule aimed at boosting competition in insulin,Seeking Alpha,https://seekingalpha.com/news/3544009-fda-implements-new-rule-aimed-boosting-competition-in-insulin?utm_source=markets.businessinsider.com&utm_medium=referral
731.0,2/21/2020 12:30:11 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3544390-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral
732.0,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
733.0,2/24/2020 12:14:25 PM,Eli Lilly's Trulicity approved for new indication,Seeking Alpha,https://seekingalpha.com/news/3544724-eli-lillys-trulicity-approved-for-new-indication?utm_source=markets.businessinsider.com&utm_medium=referral
734.0,2/27/2020 2:20:58 AM,FDA Panels Backs Lilly's Cyramza As Treatment For Metastatic EGFR-Mutated NSCLC ,RTTNews,/news/stocks/fda-panels-backs-lilly-s-cyramza-as-treatment-for-metastatic-egfr-mutated-nsclc-1028943503
735.0,3/2/2020 1:03:08 PM,Pfizer & Eli Lilly: FDA To Review BLA For Tanezumab - Quick Facts ,RTTNews,/news/stocks/pfizer-eli-lilly-fda-to-review-bla-for-tanezumab-quick-facts-1028954544
736.0,3/2/2020 2:56:53 PM,FDA accepts Pfizer application for novel pain med,Seeking Alpha,https://seekingalpha.com/news/3547448-fda-accepts-pfizer-application-for-novel-pain-med?utm_source=markets.businessinsider.com&utm_medium=referral
737.0,3/3/2020 12:22:57 PM,Coronavirus outbreak to not affect supply of medicines - Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3547921-coronavirus-outbreak-to-not-affect-supply-of-medicines-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral
738.0,3/3/2020 1:15:05 PM,Eli Lilly Anticipates No Shortages Of Products Due To Coronavirus Impact ,RTTNews,/news/stocks/eli-lilly-anticipates-no-shortages-of-products-due-to-coronavirus-impact-1028958877
739.0,3/11/2020 4:59:50 PM,Lilly to participate in new Medicare model lowering out-of-pocket insulin costs,Seeking Alpha,https://seekingalpha.com/news/3550626-lilly-to-participate-in-new-medicare-model-lowering-out-of-pocket-insulin-costs?utm_source=markets.businessinsider.com&utm_medium=referral
740.0,3/12/2020 1:19:54 PM,Boehringer Ingelheim & Eli Lilly: Jardiance Granted FDA Fast Track Designation ,RTTNews,/news/stocks/boehringer-ingelheim-eli-lilly-jardiance-granted-fda-fast-track-designation-1028989427
741.0,3/13/2020 10:39:42 AM,Lilly in the mix of coronavirus therapy developers,Seeking Alpha,https://seekingalpha.com/news/3551442-lilly-in-mix-of-coronavirus-therapy-developers?utm_source=markets.businessinsider.com&utm_medium=referral
742.0,3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral
743.0,3/16/2020 11:10:24 AM,FDA grants BTD tag to baricitinib for alopecia areata,Seeking Alpha,https://seekingalpha.com/news/3551919-fda-grants-btd-tag-to-baricitinib-for-alopecia-areata?utm_source=markets.businessinsider.com&utm_medium=referral
744.0,3/16/2020 11:14:02 AM,U.S. stocks set to gap down at open,Seeking Alpha,https://seekingalpha.com/news/3551922-u-s-stocks-set-to-gap-down-open?utm_source=markets.businessinsider.com&utm_medium=referral
745.0,3/20/2020 8:46:00 PM,FDA rejects Lilly's Jardiance for type 1 diabetes,Seeking Alpha,https://seekingalpha.com/news/3553964-fda-rejects-lillys-jardiance-for-type-1-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
746.0,3/23/2020 4:00:40 AM,Lilly Offers Free Coronavirus Tests To Indianapolis Health Care Workers ,RTTNews,/news/stocks/lilly-offers-free-coronavirus-tests-to-indianapolis-health-care-workers-1029020877
747.0,3/23/2020 10:21:55 AM,Companies continue to step up during Covid-19 outbreak,Seeking Alpha,https://seekingalpha.com/news/3554085-companies-continue-to-step-up-during-covidminus-19-outbreak?utm_source=markets.businessinsider.com&utm_medium=referral
748.0,3/23/2020 10:40:29 AM,Lilly pauses enrollment in clinical trials amid coronavirus outbreak,Seeking Alpha,https://seekingalpha.com/news/3554088-lilly-pauses-enrollment-in-clinical-trials-amid-coronavirus-outbreak?utm_source=markets.businessinsider.com&utm_medium=referral
749.0,3/23/2020 11:41:26 AM,Eli Lilly To Delay Most New Study Starts - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-delay-most-new-study-starts-quick-facts-1029021992
750.0,3/23/2020 6:12:19 PM,FDA enacts abbreviated approval pathway for insulin biosimilars,Seeking Alpha,https://seekingalpha.com/news/3554323-fda-enacts-abbreviated-approval-pathway-for-insulin-biosimilars?utm_source=markets.businessinsider.com&utm_medium=referral
751.0,3/24/2020 1:25:21 PM,Eli Lilly Issues Updates On Insulin Supply - Quick Facts ,RTTNews,/news/stocks/eli-lilly-issues-updates-on-insulin-supply-quick-facts-1029026506
752.0,3/30/2020 12:54:16 PM,Eli Lilly: Taltz Receives FDA Approval For Treatment Of Pediatric Patients ,RTTNews,/news/stocks/eli-lilly-taltz-receives-fda-approval-for-treatment-of-pediatric-patients-1029043917
753.0,3/30/2020 8:16:47 PM,Stock Market Today: Healthcare Stocks Leads the Way; Buy Zoom?,InvestorPlace,/news/stocks/stock-market-today-healthcare-stocks-leads-the-way-buy-zoom-1029046564
754.0,3/31/2020 12:50:18 PM,"Eli Lilly, Sitryx Announce Global Licensing & Research Collaboration ",RTTNews,/news/stocks/eli-lilly-sitryx-announce-global-licensing-research-collaboration-1029048200
755.0,3/31/2020 3:18:40 PM,Teva prevails in migraine patent dispute; shares up 9%,Seeking Alpha,https://seekingalpha.com/news/3556858-teva-prevails-in-migraine-patent-dispute-shares-up-9?utm_source=markets.businessinsider.com&utm_medium=referral
756.0,3/31/2020 4:19:54 PM,Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?,InvestorPlace,/news/stocks/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-1029050739
757.0,4/5/2020 6:55:44 PM,Incyte details late-stage data on ruxolitinib cream for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3558456-incyte-details-late-stage-data-on-ruxolitinib-cream-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
758.0,4/7/2020 1:23:31 PM,Lilly Says New $35 Co-Pay Available Through Lilly Insulin Value Program ,RTTNews,/news/stocks/lilly-says-new-35-co-pay-available-through-lilly-insulin-value-program-1029071176
759.0,4/8/2020 10:47:18 PM,FDA OKs Pfizer's Braftovi combo for certain type of colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3559539-fda-oks-pfizers-braftovi-combo-for-certain-type-of-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
760.0,4/9/2020 11:32:59 AM,Evercore bearish on medical device makers in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3559606-evercore-bearish-on-medical-device-makers-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
761.0,4/11/2020 1:35:01 AM,Eli Lilly launches clinical testing of potential coronavirus treatment,Seeking Alpha,https://seekingalpha.com/news/3559950-eli-lilly-launches-clinical-testing-of-potential-coronavirus-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
762.0,4/15/2020 9:37:44 AM,Stock Alert: Eli Lilly Continues Its Uptrend ,RTTNews,/news/stocks/stock-alert-eli-lilly-continues-its-uptrend-1029092856
763.0,4/15/2020 3:13:45 PM,RemeGen candidate Fast Track'd for lupus,Seeking Alpha,https://seekingalpha.com/news/3560931-remegen-candidate-fast-trackd-for-lupus?utm_source=markets.businessinsider.com&utm_medium=referral
764.0,4/20/2020 1:46:26 PM,"Trading at 52-Week Highs, LLY Stock Is Already Priced to Perfection",InvestorPlace,/news/stocks/hold-off-overvalued-lly-stock-1029107790
765.0,4/21/2020 4:33:49 PM,10 S&P 500 Stocks That Are Still Overvalued By Discounted Cash Flow,InvestorPlace,/news/stocks/10-sp-500-stocks-that-are-still-overvalued-by-discounted-cash-flow-1029113970
766.0,4/22/2020 3:01:37 PM,Here's what to expect from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-q1-earnings-preview-1029117737
767.0,4/23/2020 12:29:47 PM,Eli Lilly And Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-beat-estimates-1029121783
768.0,4/23/2020 1:22:56 PM,Eli Lilly Q1 Results Top Estimates; Lifts 2020 Profit View ,RTTNews,/news/stocks/eli-lilly-q1-results-top-estimates-lifts-2020-profit-view-1029122063
769.0,4/23/2020 6:51:18 PM,Eli Lilly Earnings: LLY Stock Leaps 2% on Q1 Beat,InvestorPlace,/news/stocks/eli-lilly-earnings-boost-lly-stock-up-1029124611
770.0,4/23/2020 9:05:42 PM,"5 Top Stock Trades for Friday: GILD, INO, LVS, DPZ, LLY",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-gild-ino-lvs-dpz-lly-1029124957
771.0,4/24/2020 4:02:00 PM,Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-rates-eli-lilly-s-notes-a2-stable-outlook-1029127334
772.0,4/30/2020 3:20:25 PM,Why Investors Should Avoid Inovio Pharmaceuticals,InvestorPlace,/news/stocks/why-investors-should-avoid-inovio-pharmaceuticals-1029151438
773.0,5/1/2020 2:48:55 PM,3 Bullish Coronavirus Stocks to Trade Into Weakness,InvestorPlace,/news/stocks/3-bullish-coronavirus-stocks-to-trade-into-weakness-1029155697
774.0,5/4/2020 2:38:58 PM,"Junshi, Eli Lilly Agree To Co-develop JS016 Antibodies Against COVID-19 ",RTTNews,/news/stocks/junshi-eli-lilly-agree-to-co-develop-js016-antibodies-against-covid-19-1029160111
775.0,5/5/2020 6:18:48 PM,3 Healthcare Stocks Popping Off Support,InvestorPlace,/news/stocks/3-healthcare-stocks-popping-off-support-1029167820
776.0,5/7/2020 4:55:34 AM,Innovent:phase 3 Study On Advanced Lung Cancer Meets Predefined Primary Endpoint ,RTTNews,/news/stocks/innovent-phase-3-study-on-advanced-lung-cancer-meets-predefined-primary-endpoint-1029173381
777.0,5/8/2020 12:25:16 PM,"3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-bristol-myers-squibb-eli-lilly-and-glaxosmithkline-1029182410
778.0,5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral
779.0,5/8/2020 10:57:18 PM,FDA approves Eli Lilly drug to treat three types of tumors,Seeking Alpha,https://seekingalpha.com/news/3572368-fda-approves-eli-lilly-drug-to-treat-three-types-of-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
780.0,5/19/2020 3:24:21 PM,Eli Lilly Reports Results Of GERAS-US Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-results-of-geras-us-study-quick-facts-1029215497
781.0,5/26/2020 1:36:09 PM,Lilly and BI team up with Duke in study of Jardiance following heart attack,Seeking Alpha,https://seekingalpha.com/news/3577514-lilly-and-bi-team-up-duke-in-study-of-jardiance-following-heart-attack?utm_source=markets.businessinsider.com&utm_medium=referral
782.0,5/26/2020 3:45:27 PM,Lilly partner Junshi Biosciences advances COVID-19 antibody candidate,Seeking Alpha,https://seekingalpha.com/news/3577565-lilly-partner-junshi-biosciences-advances-covidminus-19-antibody-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
783.0,5/27/2020 12:50:26 PM,7 Cheap Stocks to Buy With Great Potential,InvestorPlace,/news/stocks/7-cheap-stocks-buy-great-potential-now-1029238272
784.0,5/29/2020 2:36:45 AM,FDA approves Eli Lilly Alzheimer's diagnosis drug,Seeking Alpha,https://seekingalpha.com/news/3578522-fda-approves-eli-lilly-alzheimers-diagnosis-drug?utm_source=markets.businessinsider.com&utm_medium=referral
785.0,5/29/2020 3:18:05 AM,FDA Oks Lilly's Drug To Image Tau Pathology In Patients Being Evaluated For Alzheimer's Disease ,RTTNews,/news/stocks/fda-oks-lilly-s-drug-to-image-tau-pathology-in-patients-being-evaluated-for-alzheimer-s-disease-1029261468
786.0,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral
787.0,5/30/2020 5:08:49 AM,FDA Approves Lilly's Cyramza To Treat Metastatic EGFR-Mutated Non-Small Cell Lung Cancer ,RTTNews,/news/stocks/fda-approves-lilly-s-cyramza-to-treat-metastatic-egfr-mutated-non-small-cell-lung-cancer-1029265038
788.0,6/1/2020 5:32:10 AM,Innovent Announces Results Of TYVYT In Treatment Of Locally Advanced Or Metastatic ESCC ,RTTNews,/news/stocks/innovent-announces-results-of-tyvyt-in-treatment-of-locally-advanced-or-metastatic-escc-1029267350
789.0,6/3/2020 9:16:46 AM,Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk,InvestorPlace,/news/stocks/abbv-stock-an-oil-yield-without-oil-1029275806
790.0,6/3/2020 1:10:28 PM,Eli Lilly: Taltz Shows Consistent Efficacy In Psoriatic Arthritis - Quick Facts ,RTTNews,/news/stocks/eli-lilly-taltz-shows-consistent-efficacy-in-psoriatic-arthritis-quick-facts-1029276056
791.0,6/6/2020 1:18:27 PM,"The Week That Was In COVID: Russia Approves 1st COVID-19 Drug, INO Sues Vaccine Supplier... ",RTTNews,/news/stocks/the-week-that-was-in-covid-russia-approves-1st-covid-19-drug-ino-sues-vaccine-supplier-1029286233
792.0,6/7/2020 5:55:53 PM,Early-stage study underway in China for Junshi SARS-CoV-2 antibody,Seeking Alpha,https://seekingalpha.com/news/3580971-early-stage-study-underway-in-china-for-junshi-sars-covminus-2-antibody?utm_source=markets.businessinsider.com&utm_medium=referral
793.0,6/9/2020 3:10:56 PM,Aggressive Investors Can Do Much Better Than Merck Stock,InvestorPlace,/news/stocks/aggressive-investors-better-mrk-stock-1029293865
794.0,6/10/2020 7:59:09 PM,Lilly's baricitinib shows sustained benefit in rheumatoid arthritis study,Seeking Alpha,https://seekingalpha.com/news/3582063-lillys-baricitinib-shows-sustained-benefit-in-rheumatoid-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral
795.0,6/12/2020 8:09:14 PM,Lilly's lebrikizumab shows encouraging action in dermatitis study,Seeking Alpha,https://seekingalpha.com/news/3582761-lillys-lebrikizumab-shows-encouraging-action-in-dermatitis-study?utm_source=markets.businessinsider.com&utm_medium=referral
796.0,6/15/2020 11:45:59 AM,Lilly launches late-stage study of baricitinib in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3582916-lilly-launches-late-stage-study-of-baricitinib-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
797.0,6/15/2020 12:34:51 PM,Eli Lilly Is a Big Pharma Play With Big Potential,InvestorPlace,/news/stocks/eli-lilly-lly-stock-big-pharma-coronavirus-potential-1029308833
798.0,6/15/2020 1:00:05 PM,Lilly Starts Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients ,RTTNews,/news/stocks/lilly-starts-phase-3-clinical-trial-with-baricitinib-for-hospitalized-covid-19-patients-1029307552
799.0,6/16/2020 5:02:26 AM,FDA Approves Lilly's New Rapid-acting Insulin Lyumjev ,RTTNews,/news/stocks/fda-approves-lilly-s-new-rapid-acting-insulin-lyumjev-1029310459
800.0,6/16/2020 12:59:01 PM,Eli Lilly Reports Positive Results From Interim Analysis Of Phase 3 MonarchE Study ,RTTNews,/news/stocks/eli-lilly-reports-positive-results-from-interim-analysis-of-phase-3-monarche-study-1029311906
801.0,6/16/2020 5:49:43 PM,Pfizer and Merck's diabetes med Steglatro shows mixed results in cardiovascular outcomes study,Seeking Alpha,https://seekingalpha.com/news/3583523-pfizer-and-mercks-diabetes-med-steglatro-shows-mixed-results-in-cardiovascular-outcomes-study?utm_source=markets.businessinsider.com&utm_medium=referral
802.0,6/16/2020 6:54:03 PM,"Eli Lilly soars 15% after its breast cancer drug shows efficacy where a treatment from Pfizer failed (LLY, PFE)",Business Insider,https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-after-successful-drug-trial-breast-cancer-2020-6-1029314306
803.0,6/16/2020 7:06:23 PM,Eli Lilly News: LLY Stock Soars 15% on Successful Breast Cancer Drug Trial,InvestorPlace,/news/stocks/eli-lilly-breast-cancer-news-boosts-lly-stock-1029314839
804.0,6/17/2020 7:25:36 AM,"AMRN Makes Peace With Apotex, IDYA Cuts Deal With GSK, SLRX On Watch, NBIX, TAK Ink $2Bln Pact ",RTTNews,/news/stocks/amrn-makes-peace-with-apotex-idya-cuts-deal-with-gsk-slrx-on-watch-nbix-tak-ink-2bln-pact-1029315680
805.0,6/18/2020 2:31:38 PM,Lilly Begins Phase 3 Study To Evaluate Baricitinib In Hospitalized Adults With COVID-19 ,RTTNews,/news/stocks/lilly-begins-phase-3-study-to-evaluate-baricitinib-in-hospitalized-adults-with-covid-19-1029321737
806.0,7/14/2020 3:37:23 PM,The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase,InvestorPlace,/news/stocks/the-7-best-pharmaceutical-stocks-that-go-beyond-the-covid-19-chase-1029393527
807.0,7/15/2020 11:36:51 AM,Novavax Stock Has Probably Topped Out Until Successful Clinical Trials,InvestorPlace,/news/stocks/nvax-stock-topped-out-clinical-trials-1029397795
808.0,7/17/2020 1:02:22 PM,Eli Lilly Says Mirikizumab Superior To Cosentyx In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-mirikizumab-superior-to-cosentyx-in-phase-3-study-quick-facts-1029404743
809.0,7/27/2020 6:12:59 PM,Science Is the Reason to Invest in Neurotez Stock,InvestorPlace,/news/stocks/science-is-the-reason-to-invest-in-neurotez-stock-1029435254
810.0,7/29/2020 3:03:03 PM,Eli Lilly and earnings: here's what to expect,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q2-earnings-preview-1029445764
811.0,7/30/2020 12:29:22 PM,Eli Lilly And Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-beat-estimates-1029449986
812.0,7/30/2020 12:42:52 PM,Eli Lilly Boost FY20 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-boost-fy20-adj-eps-outlook-quick-facts-1029450071
813.0,7/30/2020 1:23:44 PM,Eli Lilly Announces Positive Top-line Results From EMPEROR-Reduced Phase III Trial ,RTTNews,/news/stocks/eli-lilly-announces-positive-top-line-results-from-emperor-reduced-phase-iii-trial-1029450334
814.0,8/3/2020 1:36:54 PM,Lilly Initiates Phase 3 COVID-19 Trial Of LY-CoV555 At Long-Term Care Facilities ,RTTNews,/news/stocks/lilly-initiates-phase-3-covid-19-trial-of-ly-cov555-at-long-term-care-facilities-1029461133
815.0,8/5/2020 1:59:32 PM,Novavax Stock Needs Solid Results Beyond Headlines,InvestorPlace,/news/stocks/nvax-stock-needs-solid-results-beyond-headlines-1029473742
816.0,8/5/2020 3:09:42 PM,Lilly : Empagliflozin Reduces Risk Of Cardiovascular Death Or Hospitalization For Heart Failure ,RTTNews,/news/stocks/lilly-empagliflozin-reduces-risk-of-cardiovascular-death-or-hospitalization-for-heart-failure-1029473363
817.0,8/7/2020 1:36:32 PM,This Company is the Landlord of Life Sciences,InvestorPlace,/news/stocks/this-company-is-the-landlord-of-life-sciences-1029482490
818.0,8/8/2020 9:44:59 PM,Lilly's sintilimab shows treatment benefit in first-line lung cancer,Seeking Alpha,https://seekingalpha.com/news/3603108-lillys-sintilimab-shows-treatment-benefit-in-first-line-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
819.0,8/18/2020 12:57:51 PM,Lilly Obtains License For TYVYT From Innovent For Geographies Outside Of China ,RTTNews,/news/stocks/lilly-obtains-license-for-tyvyt-from-innovent-for-geographies-outside-of-china-1029511945
820.0,8/18/2020 5:17:26 PM,Hold Eli Lilly as Mobile Covid-19 Labs Address Critical Needs,InvestorPlace,/news/stocks/hold-lly-stock-as-mobile-covid-19-labs-address-critical-needs-1029514261
821.0,8/20/2020 4:37:00 PM,Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-rates-eli-lilly-s-notes-a2-stable-outlook-1029521357
822.0,8/21/2020 3:31:12 PM,Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma,InvestorPlace,/news/stocks/lly-stock-still-looks-like-best-buy-large-cap-pharma-1029524567
823.0,9/8/2020 5:54:15 PM,6 of the Best Pharmaceutical Stocks to Buy Today,InvestorPlace,/news/stocks/6-of-the-best-pharmaceutical-stocks-to-buy-today-1029571607
824.0,9/9/2020 12:45:05 PM,Eli Lilly Promotes Ilya Yuffa To SVP & President Of Lilly Bio-Medicines ,RTTNews,/news/stocks/eli-lilly-promotes-ilya-yuffa-to-svp-president-of-lilly-bio-medicines-1029572815
825.0,9/10/2020 12:58:59 PM,Eli Lilly To Present Clinically Meaningful Results From MonarchE Phase 3 Study At ESMO ,RTTNews,/news/stocks/eli-lilly-to-present-clinically-meaningful-results-from-monarche-phase-3-study-at-esmo-1029577187
826.0,9/11/2020 1:27:54 PM,Eli Lilly: REYVOW Meets All 18 Gated Endpoints In New Phase 3 Study ,RTTNews,/news/stocks/eli-lilly-reyvow-meets-all-18-gated-endpoints-in-new-phase-3-study-1029581535
827.0,9/14/2020 1:19:20 PM,"Lilly, Incyte Announce Initial Data From Adaptive COVID-19 Treatment Trial - Quick Facts ",RTTNews,/news/stocks/lilly-incyte-announce-initial-data-from-adaptive-covid-19-treatment-trial-quick-facts-1029585401
828.0,9/15/2020 2:50:18 PM,"Eli Lilly, Boehringer Ingelheim: FDA Grants Fast Track Designation To Jardiance ",RTTNews,/news/stocks/eli-lilly-boehringer-ingelheim-fda-grants-fast-track-designation-to-jardiance-1029590187
829.0,9/16/2020 1:38:25 PM,Lilly: BLAZE-1 Interim Data Show LY-CoV555 Antibody Reduces COVID-related Hospitalizations ,RTTNews,/news/stocks/lilly-blaze-1-interim-data-show-ly-cov555-antibody-reduces-covid-related-hospitalizations-1029594017
830.0,9/16/2020 5:35:56 PM,Eli Lilly Stock Looks Hot on New Antibody Drug Evidence,InvestorPlace,/news/stocks/eli-lilly-stock-looks-hot-on-new-antibody-drug-evidence-1029596051
831.0,9/16/2020 10:56:34 PM,Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting,GlobeNewswire,/news/stocks/lilly-announces-proof-of-concept-data-for-neutralizing-antibody-ly-cov555-in-the-covid-19-outpatient-setting-1029596519
832.0,9/17/2020 12:56:42 PM,"Eli Lilly, Amgen Ink Antibody Manufacturing Deal To Boost Supply For COVID-19 Therapies ",RTTNews,/news/stocks/eli-lilly-amgen-ink-antibody-manufacturing-deal-to-boost-supply-for-covid-19-therapies-1029597997
833.0,9/17/2020 1:35:51 PM,SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials,InvestorPlace,/news/stocks/srne-stock-sorrento-therapeutics-pops-on-plans-to-launch-drug-trials-1029599296
834.0,9/17/2020 7:41:53 PM,Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial,GlobeNewswire,/news/stocks/baricitinib-in-combination-with-remdesivir-reduces-time-to-recovery-in-hospitalized-patients-with-covid-19-in-niaid-sponsored-actt-2-trial-1029600273
835.0,9/18/2020 2:04:17 PM,"Lilly, Incyte: CHMP Adopts Positive Opinion For Baricitinib In Treatment Of Atopic Dermatitis ",RTTNews,/news/stocks/lilly-incyte-chmp-adopts-positive-opinion-for-baricitinib-in-treatment-of-atopic-dermatitis-1029602319
836.0,9/21/2020 1:10:04 PM,Buy JetBlue Stock at These Levels and Sock It Away for the Recovery,InvestorPlace,/news/stocks/buy-jblu-stock-sock-it-away-recovery-1029607469
837.0,9/21/2020 5:10:56 PM,"Tread Carefully, But Sorrento Stock Could Continue to Bounce Back",InvestorPlace,/news/stocks/tread-carefully-buy-srne-stock-continue-bounce-back-1029608339
838.0,9/22/2020 3:29:36 PM,"Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have...",GlobeNewswire,/news/stocks/trulicity-dulaglutide-is-now-indicated-as-an-adjunct-to-diet-exercise-and-standard-of-care-therapy-to-reduce-the-risk-of-non-fatal-stroke-in-adults-with-type-2-diabetes-mellitus-who-have-1029611364
839.0,9/23/2020 12:05:31 PM,There Simply Isn’t Enough Good News for iBio,InvestorPlace,/news/stocks/simply-not-enough-good-news-ibio-stock-1029615057
840.0,10/6/2020 1:14:28 PM,Eli Lilly: REYVOW Shows Superiority Over Placebo In Migraine Pain Relief At 2 Hours ,RTTNews,/news/stocks/eli-lilly-reyvow-shows-superiority-over-placebo-in-migraine-pain-relief-at-2-hours-1029651591
841.0,10/7/2020 4:38:23 AM,Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective,Seeking Alpha,https://seekingalpha.com/news/3620325-innovent-bios-expanded-collaboration-lilly-for-tyvyt-now-effective?utm_source=markets.businessinsider.com&utm_medium=referral
842.0,10/7/2020 10:54:16 AM,Lilly teams up with DexCom for diabetes management,Seeking Alpha,https://seekingalpha.com/news/3620364-lilly-teams-up-dexcom-for-diabetes-management?utm_source=markets.businessinsider.com&utm_medium=referral
843.0,10/7/2020 1:01:10 PM,Lilly files for emergency use authorization in U.S. for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3620445-lilly-files-for-emergency-use-authorization-in-u-s-for-covidminus-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral
844.0,10/7/2020 3:15:56 PM,Eli Lilly Submits Initial Request For Emergency Use Authorization To Treat COVID-19 ,RTTNews,/news/stocks/eli-lilly-submits-initial-request-for-emergency-use-authorization-to-treat-covid-19-1029657413
845.0,10/7/2020 10:06:46 PM,Regeneron +2.3% after Trump praises drug in new video,Seeking Alpha,https://seekingalpha.com/news/3620637-regeneronplus-2_3-after-trump-praises-drug-in-new-video?utm_source=markets.businessinsider.com&utm_medium=referral
846.0,10/8/2020 9:01:29 AM,"CDNA, OCUL Soar On Prelim Q3 Revenue, Lilly Seeks EUA For LY-CoV555 In COVID-19, ALKS On Watch ",RTTNews,/news/stocks/cdna-ocul-soar-on-prelim-q3-revenue-lilly-seeks-eua-for-ly-cov555-in-covid-19-alks-on-watch-1029660015
847.0,10/8/2020 11:10:58 AM,Lilly signs deal to supply COVID-19 antibody treatment to developing countries,Seeking Alpha,https://seekingalpha.com/news/3620710-lilly-signs-deal-to-supply-covidminus-19-antibody-treatment-to-developing-countries?utm_source=markets.businessinsider.com&utm_medium=referral
848.0,10/8/2020 12:22:49 PM,Regeneron and Lilly to get emergency approval for antibody treatments - Trump,Seeking Alpha,https://seekingalpha.com/news/3620753-regeneron-and-lilly-to-get-emergency-approval-for-antibody-treatments-trump?utm_source=markets.businessinsider.com&utm_medium=referral
849.0,10/8/2020 1:11:54 PM,"Lilly, Gates Foundation To Supply Potential COVID-19 Therapy For Low, Middle Income Countries ",RTTNews,/news/stocks/lilly-gates-foundation-to-supply-potential-covid-19-therapy-for-low-middle-income-countries-1029660842
850.0,10/8/2020 1:56:34 PM,REGN Stock: Regeneron Pops on Trump’s Antibody Support,InvestorPlace,/news/stocks/regn-stock-regeneron-pops-on-trumps-antibody-support-1029662216
851.0,10/8/2020 3:19:14 PM,Lilly doublet therapy for COVID-19 reduced hospitalizations in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3620846-lilly-doublet-therapy-for-covidminus-19-reduced-hospitalizations-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral
852.0,10/8/2020 4:20:17 PM,Lilly's baricitinib shows incremental benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3620863-lillys-baricitinib-shows-incremental-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral
853.0,10/9/2020 11:40:19 AM,Lilly/Innovent rituximab injection OK'd in China,Seeking Alpha,https://seekingalpha.com/news/3621048-lilly-innovent-rituximab-injection-okd-in-china?utm_source=markets.businessinsider.com&utm_medium=referral
854.0,10/9/2020 1:16:37 PM,Eli Lilly: Nearly 4 Out Of 5 People In OVERCOME Survey Report Improvement In Migraine ,RTTNews,/news/stocks/eli-lilly-nearly-4-out-of-5-people-in-overcome-survey-report-improvement-in-migraine-1029665353
855.0,10/9/2020 1:29:30 PM,"Innovent, Eli Lilly Announce Approval Of HALPRYZA In China - Quick Facts ",RTTNews,/news/stocks/innovent-eli-lilly-announce-approval-of-halpryza-in-china-quick-facts-1029665370
856.0,10/9/2020 4:37:25 PM,Covid-19 Therapeutics May Push Novavax Out of the Spotlight,InvestorPlace,/news/stocks/covid-19-therapeutics-may-push-nvax-stock-out-of-the-spotlight-cseo-1029666747
857.0,10/9/2020 8:25:25 PM,COVID-19 drug developer Atea Pharmaceuticals files for IPO,Seeking Alpha,https://seekingalpha.com/news/3621228-covidminus-19-drug-developer-atea-pharmaceuticals-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
858.0,10/12/2020 12:12:15 PM,Lilly's mirikizumab shows sustained benefit in mid-stage Crohn's study,Seeking Alpha,https://seekingalpha.com/news/3621322-lillys-mirikizumab-shows-sustained-benefit-in-mid-stage-crohns-study?utm_source=markets.businessinsider.com&utm_medium=referral
859.0,10/12/2020 1:02:47 PM,Eli Lilly Reports Data From Phase 2 SERENITY Study Evaluating Mirikizumab ,RTTNews,/news/stocks/eli-lilly-reports-data-from-phase-2-serenity-study-evaluating-mirikizumab-1029669444
860.0,10/12/2020 3:33:55 PM,7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote,InvestorPlace,/news/stocks/7-election-stocks-you-definitely-want-to-avoid-leading-up-to-the-election-1029670817
861.0,10/12/2020 8:58:31 PM,7 Highly Rated Pharmaceutical Stocks for Q4,InvestorPlace,/news/stocks/7-highly-rated-pharmaceutical-stocks-for-q4-1029679826
862.0,10/13/2020 6:46:50 PM,Eli Lilly's Covid-19 antibody trial paused over safety concerns,Seeking Alpha,https://seekingalpha.com/news/3621824-eli-lillys-covidminus-19-antibody-trial-paused-over-safety-concerns?utm_source=markets.businessinsider.com&utm_medium=referral
863.0,10/13/2020 6:54:32 PM,7 Pet Stocks to Adopt Today ,InvestorPlace,/news/stocks/7-pet-stocks-to-adopt-today-1029676172
864.0,10/14/2020 7:06:20 AM,Quality control lapses at plant making Eli Lilly COVID drug,Seeking Alpha,https://seekingalpha.com/news/3621925-quality-control-lapses-plant-making-eli-lilly-covid-drug?utm_source=markets.businessinsider.com&utm_medium=referral
865.0,10/14/2020 8:31:39 AM,"LLY Pauses COVID-19 Antibody Trial, JNJ Boosts Annual Outlook, Double Whammy For GOSS ",RTTNews,/news/stocks/lly-pauses-covid-19-antibody-trial-jnj-boosts-annual-outlook-double-whammy-for-goss-1029677498
866.0,10/14/2020 1:03:22 PM,Health care holding up despite COVID setbacks: At the Open,Seeking Alpha,https://seekingalpha.com/news/3622071-health-care-holding-up-despite-covid-setbacks-open?utm_source=markets.businessinsider.com&utm_medium=referral
867.0,10/14/2020 7:23:24 PM,Eli Lilly says other COVID-19 antibody drug trials ongoing after study halted for safety concern - Reuters,Seeking Alpha,https://seekingalpha.com/news/3622224-eli-lilly-says-covidminus-19-antibody-drug-trials-ongoing-after-study-halted-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral
868.0,10/14/2020 7:35:36 PM,Don’t Give Up on Sorrento Therapeutics Stock Just Yet,InvestorPlace,/news/stocks/dont-give-up-on-sorrento-srne-stock-just-yet-1029681139
869.0,10/15/2020 12:37:15 PM,"Carnival Stock Is Far from Recovered, But the Worst Is Behind",InvestorPlace,/news/stocks/carnival-stock-is-far-from-recovered-but-the-worst-is-behind-1029684755
870.0,10/15/2020 1:53:03 PM,Eli Lilly scoops up Disarm Therapeutics for $135M upfront,Seeking Alpha,https://seekingalpha.com/news/3622494-eli-lilly-scoops-up-disarm-therapeutics-for-135m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral
871.0,10/15/2020 3:51:22 PM,Lilly To Buy Disarm Therapeutics For Upfront Payment Of $135.0 Mln ,RTTNews,/news/stocks/lilly-to-buy-disarm-therapeutics-for-upfront-payment-of-135-0-mln-1029684606
872.0,10/16/2020 8:37:24 AM,"SNY/TBIO Move COVID-19 Vaccine Into Clinic, AVXL's PDD Study Promising, EIGR On Watch ",RTTNews,/news/stocks/sny-tbio-move-covid-19-vaccine-into-clinic-avxl-s-pdd-study-promising-eigr-on-watch-1029687214
873.0,10/16/2020 11:58:35 AM,Biden Town Hall: 4 Key Investing Takeaways,InvestorPlace,/news/stocks/biden-town-hall-4-key-investing-takeaways-1029688135
874.0,10/16/2020 1:03:00 PM,7 Short-Term Stocks to Make a Quick Buck,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-quick-buck-1029688757
875.0,10/16/2020 5:53:26 PM,Can Cytonics Pivot Successfully to Covid-19 Therapeutics?,InvestorPlace,/news/stocks/cytonics-stock-pivot-coronavirus-therapeutics-1029689508
876.0,10/16/2020 5:53:36 PM,Novavax Stock Looks Volatile As Vaccine Enthusiasm Wanes,InvestorPlace,/news/stocks/nvax-stock-looks-volatile-as-vaccine-enthusiasm-wanes-1029689507
877.0,10/16/2020 7:30:50 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3622976-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
878.0,10/16/2020 8:03:31 PM,Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3623006-lilly-incytes-baricitinib-shows-additional-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral
879.0,10/16/2020 11:02:00 PM,JPM picks big pharma names to benefit with busy catalyst calendar ahead,Seeking Alpha,https://seekingalpha.com/news/3623038-jpm-picks-big-pharma-names-to-benefit-busy-catalyst-calendar-ahead?utm_source=markets.businessinsider.com&utm_medium=referral
880.0,10/19/2020 12:28:44 PM,Lilly's Taltz OK'd in Canada for arthritis of the spine,Seeking Alpha,https://seekingalpha.com/news/3623179-lillys-taltz-okd-in-canada-for-arthritis-of-spine?utm_source=markets.businessinsider.com&utm_medium=referral
881.0,10/19/2020 4:24:41 PM,Eli Lilly declares $0.74 dividend,Seeking Alpha,https://seekingalpha.com/news/3623314-eli-lilly-declares-0_74-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
882.0,10/19/2020 5:25:37 PM,Why the FDA’s Inquiry of Inovio Is More Critical Than You Think,InvestorPlace,/news/stocks/why-fda-inquiry-very-critical-ino-stock-1029694935
883.0,10/19/2020 5:50:56 PM,The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio,InvestorPlace,/news/stocks/ibio-stock-no-more-low-hanging-fruit-1029694932
884.0,10/21/2020 9:48:02 AM,Lilly taps outside advisor for problems at COVID drug plant,Seeking Alpha,https://seekingalpha.com/news/3624057-lilly-taps-outside-advisor-for-problems-covid-drug-plant?utm_source=markets.businessinsider.com&utm_medium=referral
885.0,10/21/2020 7:50:43 PM,Sorrento Therapeutics Is a Vaccine Movie That Investors Have Already Seen,InvestorPlace,/news/stocks/lack-of-covid-19-focus-could-hinder-srne-stock-1029706960
886.0,10/22/2020 5:31:38 PM,Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?,InvestorPlace,/news/stocks/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine-1029712056
887.0,10/22/2020 9:37:48 PM,GILD News: Gilead Stock Pops as FDA Approves Remdesivir Treatment,InvestorPlace,/news/stocks/gild-news-gilead-stock-pops-as-fda-approves-remdesivir-treatment-1029712808
888.0,10/24/2020 4:30:00 AM,Gilead solidifies leadership in COVID-19 treatments with FDA remdesivir nod,Seeking Alpha,https://seekingalpha.com/news/3625261-gilead-solidifies-leadership-in-covidminus-19-treatments-fda-remdesivir-nod?utm_source=markets.businessinsider.com&utm_medium=referral
889.0,10/26/2020 1:33:08 PM,10 Robinhood Stocks to Buy From the Top 100,InvestorPlace,/news/stocks/10-robinhood-stocks-to-buy-from-top-100-1029721869
890.0,10/26/2020 3:01:39 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-q3-earnings-preview-stock-1029721393
891.0,10/26/2020 4:13:39 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3625836-notable-earnings-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
892.0,10/26/2020 6:17:42 PM,Eli Lilly Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3625964-eli-lilly-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
893.0,10/27/2020 4:04:29 AM,Eli Lilly Ends Late-stage Covid-19 Antibody Trial In U.S. Due To Insufficient Data ,RTTNews,/news/stocks/eli-lilly-ends-late-stage-covid-19-antibody-trial-in-u-s-due-to-insufficient-data-1029723434
894.0,10/27/2020 6:48:04 AM,Lilly ends COVID-19 antibody trial after lack of improvement,Seeking Alpha,https://seekingalpha.com/news/3626170-lilly-ends-covidminus-19-antibody-trial-after-lack-of-improvement?utm_source=markets.businessinsider.com&utm_medium=referral
895.0,10/27/2020 10:32:15 AM,"Eli Lilly EPS misses by $0.17, misses on revenue",Seeking Alpha,https://seekingalpha.com/news/3626213-eli-lilly-eps-misses-0_17-misses-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
896.0,10/27/2020 11:00:07 AM,"Lilly slips 5% on Q3 miss, GAAP EPS  guidance lowered",Seeking Alpha,https://seekingalpha.com/news/3626249-lilly-slips-5-on-q3-miss-gaap-eps-guidance-lowered?utm_source=markets.businessinsider.com&utm_medium=referral
897.0,10/27/2020 11:05:34 AM,Lilly COVID-19 antibody treatment comes up empty in NIAID study,Seeking Alpha,https://seekingalpha.com/news/3626261-lilly-covidminus-19-antibody-treatment-comes-up-empty-in-niaid-study?utm_source=markets.businessinsider.com&utm_medium=referral
898.0,10/27/2020 11:42:27 AM,Eli Lilly And Co. Q3 adjusted earnings Miss Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q3-adjusted-earnings-miss-estimates-1029725667
899.0,10/27/2020 12:10:27 PM,Eli Lilly Q3 Profit Misses Estimates; Revenue Up 5% ,RTTNews,/news/stocks/eli-lilly-q3-profit-misses-estimates-revenue-up-5-1029725848
900.0,10/28/2020 10:59:13 AM,Lilly inks U.S. deal to supply 300K vials of LY-CoV555 for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3627067-lilly-inks-u-s-deal-to-supply-300k-vials-of-ly-cov555-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
901.0,10/28/2020 12:14:31 PM,"Lilly In Deal To Supply 300,000 Vials Of COVID-19 Drug Bamlanivimab To U.S. Govt For $375 Mln ",RTTNews,/news/stocks/lilly-in-deal-to-supply-300-000-vials-of-covid-19-drug-bamlanivimab-to-u-s-govt-for-375-mln-1029733057
902.0,10/28/2020 11:00:20 PM,Eli Lilly's Bamlanivimab Phase 2 Study Data Shows Treatment May Be Effective Against COVID-19 ,RTTNews,/news/stocks/eli-lilly-s-bamlanivimab-phase-2-study-data-shows-treatment-may-be-effective-against-covid-19-1029737260
903.0,10/29/2020 10:37:34 PM,Eli Lilly secures $312.5M U.S. Army contract for LY-CoV555 procurement,Seeking Alpha,https://seekingalpha.com/news/3628859-eli-lilly-secures-312_5m-u-s-army-contract-for-ly-cov555-procurement?utm_source=markets.businessinsider.com&utm_medium=referral
904.0,10/30/2020 12:26:12 PM,"Lilly, Incyte Report Positive New Data For Baricitinib In Adult Patients With Alopecia Areata ",RTTNews,/news/stocks/lilly-incyte-report-positive-new-data-for-baricitinib-in-adult-patients-with-alopecia-areata-1029745907
905.0,11/2/2020 1:14:27 PM,A Lot of News Isn’t Necessarily Good News for Sorrento Therapeutics,InvestorPlace,/news/stocks/lot-news-good-news-srne-stock-1029754095
906.0,11/3/2020 1:04:10 PM,Sorrento Therapeutics Is Charming But Read the Label,InvestorPlace,/news/stocks/srne-stock-charming-but-read-label-1029758584
907.0,11/4/2020 7:50:27 AM,Lilly updates on FDA surveillance inspections,Seeking Alpha,https://seekingalpha.com/news/3630908-lilly-updates-on-fda-surveillance-inspections?utm_source=markets.businessinsider.com&utm_medium=referral
908.0,11/4/2020 5:12:44 PM,Healthcare rallies as Presidential vote count continues,Seeking Alpha,https://seekingalpha.com/news/3631239-healthcare-rallies-presidential-vote-count-continues?utm_source=markets.businessinsider.com&utm_medium=referral
909.0,11/5/2020 8:06:56 PM,Cytonics: Invest In A Startup That’s Targeting Osteoarthritis,InvestorPlace,/news/stocks/cytonics-invest-in-a-startup-thats-targeting-osteoarthritis-1029772608
910.0,11/7/2020 5:30:00 AM,Biogen's long and winding road in Alzheimer's hits wall,Seeking Alpha,https://seekingalpha.com/news/3633230-biogens-long-and-winding-road-in-alzheimers-hits-wall?utm_source=markets.businessinsider.com&utm_medium=referral
911.0,11/9/2020 4:55:35 PM,COVID-19 treatment developers under pressure on positive COVID-19 vaccine data,Seeking Alpha,https://seekingalpha.com/news/3633767-covidminus-19-treatment-developers-under-pressure-on-positive-covidminus-19-vaccine-data?utm_source=markets.businessinsider.com&utm_medium=referral
912.0,11/9/2020 11:42:39 PM,Eli Lilly gets emergency OK for COVID-19 treatment bamlanivimab; shares +4.7%,Seeking Alpha,https://seekingalpha.com/news/3634128-eli-lilly-gets-emergency-ok-for-covidminus-19-treatment-bamlanivimab-sharesplus-4_7?utm_source=markets.businessinsider.com&utm_medium=referral
913.0,11/10/2020 4:38:24 AM,Lilly's COVID-19 Antibody Drug Gets FDA Emergency Use Authorization For Non-hospitalized Patients ,RTTNews,/news/stocks/lilly-s-covid-19-antibody-drug-gets-fda-emergency-use-authorization-for-non-hospitalized-patients-1029783969
914.0,11/10/2020 8:35:00 AM,"ARNA Falls Short Of ADVICE, PFE's COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy ",RTTNews,/news/stocks/arna-falls-short-of-advice-pfe-s-covid-19-vaccine-shows-90-efficacy-supn-hit-by-double-whammy-1029784994
915.0,11/10/2020 1:52:47 PM,Lilly chief defends need for antibody treatment despite availability of vaccine,Seeking Alpha,https://seekingalpha.com/news/3634346-lilly-chief-defends-need-for-antibody-treatment-despite-availability-of-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral
916.0,11/10/2020 10:32:33 PM,Market Insight: What’s Behind Monday’s Huge Rally,InvestorPlace,/news/stocks/market-insight-whats-behind-mondays-huge-rally-1029789442
917.0,11/11/2020 4:50:34 PM,7 Biotech Penny Stocks Worth a Gamble,InvestorPlace,/news/stocks/7-biotech-stocks-to-gamble-with-1029793010
918.0,11/11/2020 9:46:42 PM,Lilly webcast on late-stage tirzepatide program in T2D November 20,Seeking Alpha,https://seekingalpha.com/news/3635197-lilly-webcast-on-late-stage-tirzepatide-program-in-t2d-november-20?utm_source=markets.businessinsider.com&utm_medium=referral
919.0,11/12/2020 9:31:59 PM,"With Pfizer Winning the Vaccine Race, Novavax Is a Strong Sell",InvestorPlace,/news/stocks/with-pfizer-winning-the-vaccine-race-nvax-stock-is-a-strong-sell-1029799195
920.0,11/13/2020 12:13:55 PM,Beyond Spring teams up with Lilly to develop protein degraders,Seeking Alpha,https://seekingalpha.com/news/3636038-beyond-spring-teams-up-lilly-to-develop-protein-degraders?utm_source=markets.businessinsider.com&utm_medium=referral
921.0,11/13/2020 8:00:17 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3636251-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
922.0,11/13/2020 9:25:41 PM,3 Oil Stocks To Buy And Bull Trade For Big Gains,InvestorPlace,/news/stocks/3-oil-stocks-to-buy-and-bull-trade-for-big-gains-1029802756
923.0,11/16/2020 4:31:37 PM,Dicerna earns $10M in milestone from Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3636624-dicerna-earns-10m-in-milestone-from-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral
924.0,11/17/2020 2:28:04 PM,Samsung BioLogics mass producing Eli Lilly's COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3637101-samsung-biologics-mass-producing-eli-lillys-covidminus-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
925.0,11/18/2020 1:46:16 PM,Lilly's Jardiance reduced risk of cardiovascular events in adults with type 2 diabetes,Seeking Alpha,https://seekingalpha.com/news/3637472-lillys-jardiance-reduced-risk-of-cardiovascular-events-in-adults-type-2-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
926.0,11/18/2020 2:22:38 PM,Eli Lilly : Jardiance Reduces Risk Of First Plus Recurrent Cardiovascular Events ,RTTNews,/news/stocks/eli-lilly-jardiance-reduces-risk-of-first-plus-recurrent-cardiovascular-events-1029815923
927.0,11/19/2020 12:11:11 PM,Lilly and Ypsomed collaborate to advance automated insulin delivery system in diabetes,Seeking Alpha,https://seekingalpha.com/news/3637853-lilly-and-ypsomed-collaborate-to-advance-automated-insulin-delivery-system-in-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
928.0,11/19/2020 1:04:42 PM,Lilly Partners Ypsomed To Offer Automated Insulin Delivery System For Diabetes Patients ,RTTNews,/news/stocks/lilly-partners-ypsomed-to-offer-automated-insulin-delivery-system-for-diabetes-patients-1029819956
929.0,11/20/2020 2:57:39 AM,Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19,Seeking Alpha,https://seekingalpha.com/news/3638211-eli-lilly-arthritis-drug-gets-fda-ok-for-emergency-use-to-treat-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
930.0,11/20/2020 5:04:01 AM,FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment ,RTTNews,/news/stocks/fda-issues-emergency-approval-to-lilly-s-arthritis-drug-with-remdesivir-for-covid-19-treatment-1029823536
931.0,11/20/2020 7:46:37 AM,"AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B ",RTTNews,/news/stocks/azn-s-covid-jab-immunosenescence-pfe-bntx-to-seek-emergency-nod-for-vaccine-qure-aces-hope-b-1029823800
932.0,11/20/2020 12:17:09 PM,Precision BioSciences up more than 20% after gene therapy pact with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3638267-precision-biosciences-up-20-after-gene-therapy-pact-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral
933.0,11/20/2020 1:26:01 PM,"Lilly, Precision BioSciences Reach Genome Editing Research Collaboration And License Deal ",RTTNews,/news/stocks/lilly-precision-biosciences-reach-genome-editing-research-collaboration-and-license-deal-1029824716
934.0,11/20/2020 1:50:00 PM,Oil fighting $42 and still responding better to vaccine news: At the Open,Seeking Alpha,https://seekingalpha.com/news/3638317-oil-fighting-42-and-still-responding-better-to-vaccine-news-open?utm_source=markets.businessinsider.com&utm_medium=referral
935.0,11/22/2020 2:53:22 AM,FDA grants emergency clearance for Regeneron's COVID-19 threapy,Seeking Alpha,https://seekingalpha.com/news/3638520-fda-grants-emergency-clearance-for-regenerons-covidminus-19-threapy?utm_source=markets.businessinsider.com&utm_medium=referral
936.0,11/23/2020 3:52:03 PM,REGN Stock: 11 Things for Investors to Know About Regeneron Approval,InvestorPlace,/news/stocks/regn-stock-11-things-for-investors-to-know-about-regeneron-approval-1029830793
937.0,12/1/2020 6:01:43 PM,4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains-1029854808
938.0,12/2/2020 5:30:54 PM,CVS picked to administer Eli Lilly Covid-19 treatment in nursing homes and long-term care facilities,Seeking Alpha,https://seekingalpha.com/news/3640922-cvs-picked-to-administer-eli-lilly-covidminus-19-treatment-in-nursing-homes-and-long-term?utm_source=markets.businessinsider.com&utm_medium=referral
939.0,12/2/2020 9:44:17 PM,Feds buy another 650K doses of Lilly COVID-19 med bamlanivimab,Seeking Alpha,https://seekingalpha.com/news/3641135-feds-buy-another-650k-doses-of-lilly-covidminus-19-med-bamlanivimab?utm_source=markets.businessinsider.com&utm_medium=referral
940.0,12/4/2020 1:54:36 PM,"Lilly, UnitedHealth to study antibody treatment in high-risk COVID patients",Seeking Alpha,https://seekingalpha.com/news/3641704-lilly-unitedhealth-to-study-antibody-treatment-in-high-risk-covid-patients?utm_source=markets.businessinsider.com&utm_medium=referral
941.0,12/4/2020 1:57:53 PM,Lilly partners with UnitedHealth on real-world study of COVID-19 med in diverse high-risk population,Seeking Alpha,https://seekingalpha.com/news/3641707-lilly-partners-unitedhealth-on-real-world-study-of-covidminus-19-med-in-diverse-high-risk?utm_source=markets.businessinsider.com&utm_medium=referral
942.0,12/4/2020 2:12:12 PM,"Lilly, UnitedHealth Partner On Pragmatic Study Of Bamlanivimab For COVID-19 ",RTTNews,/news/stocks/lilly-unitedhealth-partner-on-pragmatic-study-of-bamlanivimab-for-covid-19-1029865109
943.0,12/7/2020 10:52:00 AM,Moody's - Outlook for global pharmaceutical industry revised to positive as COVID-19 vaccines and treatments boost earnings,Moodys,/news/bonds/moody-s-outlook-for-global-pharmaceutical-industry-revised-to-positive-as-covid-19-vaccines-and-treatments-boost-earnings-1029868484
944.0,12/7/2020 5:27:58 PM,Loxo Oncology Announces Data From The Phase 1/2 Trial For LOXO-305 In Chronic Lymphocytic Leukemia ,RTTNews,/news/stocks/loxo-oncology-announces-data-from-the-phase-1-2-trial-for-loxo-305-in-chronic-lymphocytic-leukemia-1029870137
945.0,12/9/2020 12:36:32 PM,Lilly's tirzepatide shows impressive A1C and weight reductions for people with type 2 diabetes,Seeking Alpha,https://seekingalpha.com/news/3642823-lillys-tirzepatide-shows-impressive-a1c-and-weight-reductions-for-people-type-2-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
946.0,12/9/2020 1:30:22 PM,Lilly's Tirzepatide Significantly Reduces A1C And Body Weight In People With Type 2 Diabetes ,RTTNews,/news/stocks/lilly-s-tirzepatide-significantly-reduces-a1c-and-body-weight-in-people-with-type-2-diabetes-1029876920
947.0,12/9/2020 3:39:55 PM,Lilly’s verzenio data shows decrease in breast cancer recurrence,Seeking Alpha,https://seekingalpha.com/news/3642951-lilly-s-verzenio-data-shows-decrease-in-breast-cancer-recurrence?utm_source=markets.businessinsider.com&utm_medium=referral
948.0,12/9/2020 4:12:09 PM,Lilly : Verzenio - Standard Endocrine Therapy Combination Reduces Breast Cancer Recurrence Risk ,RTTNews,/news/stocks/lilly-verzenio-standard-endocrine-therapy-combination-reduces-breast-cancer-recurrence-risk-1029878034
949.0,12/10/2020 11:01:11 AM,Government and Institutional Support Are Positives for Sorrento Stock,InvestorPlace,/news/stocks/government-institutional-support-sorrento-snre-stock-1029880666
950.0,12/11/2020 7:02:40 AM,COVID-19 antibody therapy developer AbCellera Bio prices IPO above range at $20,Seeking Alpha,https://seekingalpha.com/news/3643591-covidminus-19-antibody-therapy-developer-abcellera-bio-prices-ipo-above-range-20?utm_source=markets.businessinsider.com&utm_medium=referral
951.0,12/11/2020 7:45:03 PM,Eli Lilly/Incyte announce peer-reviewed publication of Baricitinib/remdesivir trial data,Seeking Alpha,https://seekingalpha.com/news/3643811-eli-lilly-incyte-announce-peer-reviewed-publication-of-baricitinib-remdesivir-trial-data?utm_source=markets.businessinsider.com&utm_medium=referral
952.0,12/11/2020 8:30:29 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3643803-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
953.0,12/14/2020 10:31:06 AM,The 7 Best Dow Jones Stocks to Buy Now As You Ready for the Coming Year,InvestorPlace,/news/stocks/7-best-dow-jones-stocks-to-buy-now-ibm-hd-mmm-aapl-msft-wmt-amgn-1029889146
954.0,12/14/2020 9:07:39 PM,Eli Lilly increases dividend by ~15% to $0.85,Seeking Alpha,https://seekingalpha.com/news/3644202-eli-lilly-increases-dividend-15-to-0_85?utm_source=markets.businessinsider.com&utm_medium=referral
955.0,12/15/2020 11:41:13 AM,Prevail Therapeutics rockets 85% on being acquired by Lilly for ~$1.04B,Seeking Alpha,https://seekingalpha.com/news/3644314-prevail-therapeutics-rockets-85-on-being-acquired-lilly-for-1_04b?utm_source=markets.businessinsider.com&utm_medium=referral
956.0,12/15/2020 12:09:39 PM,"Lilly lifts 2020 guidance, sets 2021 outlook ahead of consensus; shares rise premarket",Seeking Alpha,https://seekingalpha.com/news/3644332-lilly-lifts-2020-guidance-sets-2021-outlook-ahead-of-consensus-shares-rise-premarket?utm_source=markets.businessinsider.com&utm_medium=referral
957.0,12/15/2020 12:24:14 PM,Eli Lilly To Acquire Prevail Therapeutics - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-acquire-prevail-therapeutics-quick-facts-1029893140
958.0,12/15/2020 1:01:04 PM,Lilly Raises 2020 Outlook; Sees 2021 In Line With View - Quick Facts ,RTTNews,/news/stocks/lilly-raises-2020-outlook-sees-2021-in-line-with-view-quick-facts-1029893271
959.0,12/15/2020 2:51:14 PM,Prevail Therapeutics surges 86% on news of a $1 billion buyout by Eli Lilly,Business Insider,https://www.businessinsider.com/prevail-therapeutics-stock-price-eli-lilly-buyout-deal-billion-prvl-2020-12
960.0,12/15/2020 3:18:48 PM,PRVL Stock: Why Gene Therapy Play Prevail Therapeutics Is Rocketing Higher Tuesday,InvestorPlace,/news/stocks/prvl-stock-rises-on-prevail-therapeutics-lly-deal-1029895198
961.0,12/15/2020 3:52:00 PM,Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company,Moodys,/news/bonds/eli-lilly-and-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-eli-lilly-and-company-1029894439
962.0,12/16/2020 10:47:45 AM,Micro-cap oncology biotech Scopus Biopharma prices downsized $2.75M IPO,Seeking Alpha,https://seekingalpha.com/news/3644762-micro-cap-oncology-biotech-scopus-biopharma-prices-downsized-2_75m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
963.0,12/16/2020 3:42:52 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644938-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral
964.0,12/16/2020 3:43:17 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644940-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral
965.0,12/16/2020 3:43:50 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644941-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral
966.0,12/16/2020 3:43:59 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644942-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral
967.0,12/18/2020 7:41:39 PM,Vir Biotech’s COVID-19 agents could be ‘NPV negative’: Baird,Seeking Alpha,https://seekingalpha.com/news/3645867-vir-biotech-s-covidminus-19-agents-be-npv-negative-baird?utm_source=markets.businessinsider.com&utm_medium=referral
968.0,12/20/2020 4:02:46 PM,"The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 1 FDA Decision",Benzinga,/news/stocks/the-week-ahead-in-biotech-light-calendar-in-abbreviated-week-features-1-ipo-1-fda-decision-1029909484
969.0,12/21/2020 7:57:25 AM,Lilly to launch bamlanivimab study for COVID-19 in New Mexico,Seeking Alpha,https://seekingalpha.com/news/3646049-lilly-to-launch-bamlanivimab-study-for-covidminus-19-in-new-mexico?utm_source=markets.businessinsider.com&utm_medium=referral
970.0,12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral
971.0,12/28/2020 11:35:55 AM,"As Vaccine Excitement Fades, Buy the Pullback in Pfizer",InvestorPlace,/news/stocks/vaccine-excitement-fades-buy-pullback-pfizer-pfe-stock-1029921274
972.0,12/29/2020 8:03:33 AM,Amphastar Pharma gains 10% on FDA approval of generic glucagon in low blood sugar,Seeking Alpha,https://seekingalpha.com/news/3647627-amphastar-pharma-gains-10-on-fda-approval-of-generic-glucagon-in-low-blood-sugar?utm_source=markets.businessinsider.com&utm_medium=referral
973.0,12/29/2020 8:08:08 PM,COVID-19 antibody therapies left unused; developers carry on regardless,Seeking Alpha,https://seekingalpha.com/news/3647775-covidminus-19-antibody-therapies-left-unused-developers-carry-on-regardless?utm_source=markets.businessinsider.com&utm_medium=referral
974.0,1/5/2021 11:37:37 PM,"BofA's biopharma picks into 2021 set to build with new launches, 'beatable' expectations",Seeking Alpha,https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?utm_source=markets.businessinsider.com&utm_medium=referral
975.0,1/7/2021 12:41:34 PM,Precision Bio closes gene therapy deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3649546-precision-bio-closes-gene-therapy-deal-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral
976.0,1/8/2021 1:43:26 PM,Eli Lilly collaborates with Blacksmith Medicines in a deal worth $300M,Seeking Alpha,https://seekingalpha.com/news/3649921-eli-lilly-collaborates-blacksmith-medicines-in-deal-worth-300m?utm_source=markets.businessinsider.com&utm_medium=referral
977.0,1/11/2021 12:38:39 PM,Eli Lilly up 20% after Donanemab shows phase 2 positive result for Alzheimer's disease,Seeking Alpha,https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-phase-2-positive-result-for-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral
978.0,1/11/2021 12:45:09 PM,Lilly's Donanemab Slows Clinical Decline Of Alzheimer's Disease In Phase 2 Trial ,RTTNews,/news/stocks/lilly-s-donanemab-slows-clinical-decline-of-alzheimer-s-disease-in-phase-2-trial-1029946907
979.0,1/11/2021 1:28:59 PM,"LLY, GME, NIO and BNGO among notable premarket gainers",Seeking Alpha,https://seekingalpha.com/news/3650232-lly-gme-nio-and-bngo-among-notable-premarket-gainers?utm_source=markets.businessinsider.com&utm_medium=referral
980.0,1/11/2021 2:24:01 PM,Eli Lilly: FDA Accepts Supplemental New Drug Application For Jardiance - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fda-accepts-supplemental-new-drug-application-for-jardiance-quick-facts-1029955272
981.0,1/11/2021 2:33:36 PM,Alzheimer’s Drug News: Why Eli Lilly (LLY) Stock Is Soaring Today,InvestorPlace,/news/stocks/alzheimers-drug-news-why-eli-lilly-lly-stock-is-soaring-today-1029955967
982.0,1/11/2021 4:19:50 PM,Stocks That Hit 52-Week Highs On Monday,Benzinga,/news/stocks/stocks-that-hit-52-week-highs-on-monday-1029956096
983.0,1/11/2021 4:21:28 PM,Stock Alert: Eli Lilly And Company Jumps 11% ,RTTNews,/news/stocks/stock-alert-eli-lilly-and-company-jumps-11-1029956099
984.0,1/11/2021 5:32:08 PM,Alzheimer's peers jump after Eli Lilly's donanemab study meets endpoint,Seeking Alpha,https://seekingalpha.com/news/3650395-alzheimers-peers-jump-after-eli-lillys-donanemab-study-meets-endpoint?utm_source=markets.businessinsider.com&utm_medium=referral
985.0,1/11/2021 6:05:51 PM,63 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/63-stocks-moving-in-monday-s-mid-day-session-1029956505
986.0,1/11/2021 8:30:04 PM,Eli Lilly rockets 14% after experimental Alzheimer's drug slows rate of decline in trial,Business Insider,https://www.businessinsider.com/eli-lilly-stock-price-alzheimers-drug-trial-results-positive-lly-2021-1
987.0,1/11/2021 10:21:46 PM,"4 Top Stock Trades for Tuesday: LLY, GME, F, UPWK",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-lly-gme-f-upwk-1029957365
988.0,1/12/2021 6:24:05 AM,Lilly and Innovent Bio's application for Tyvyt  as second-line therapy for lung cancer OK'd in China,Seeking Alpha,https://seekingalpha.com/news/3650563-lilly-and-innovent-bios-application-for-tyvyt-second-line-therapy-for-lung-cancer-okd-in?utm_source=markets.businessinsider.com&utm_medium=referral
989.0,1/12/2021 7:32:37 AM,"BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch ",RTTNews,/news/stocks/bgne-teams-up-with-nvs-editas-slumps-over-15-lly-s-drug-shines-in-trailblazer-alz-meso-on-watch-1029958073
990.0,1/12/2021 11:00:12 AM,84 Biggest Movers From Yesterday,Benzinga,/news/stocks/84-biggest-movers-from-yesterday-1029958576
991.0,1/12/2021 2:15:54 PM,"The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue",Benzinga,/news/stocks/the-daily-biotech-pulse-gsk-vir-to-start-covid-19-antibody-study-novartis-in-licenses-beigene-s-cancer-drug-earnings-preannouncements-continue-1029959657
992.0,1/12/2021 3:28:18 PM,Covid-19 South African variant could evade our medicines: Eli Lilly CEO,Seeking Alpha,https://seekingalpha.com/news/3650751-covidminus-19-south-african-variant-evade-medicines-eli-lilly-ceo?utm_source=markets.businessinsider.com&utm_medium=referral
993.0,1/13/2021 8:42:34 PM,Lilly and Innovent Bio's application for Tyvyt combo as first-line therapy for liver cancer OK'd in China,Seeking Alpha,https://seekingalpha.com/news/3651248-lilly-and-innovent-bios-application-for-tyvyt-combo-first-line-therapy-for-liver-cancer-okd?utm_source=markets.businessinsider.com&utm_medium=referral
994.0,1/15/2021 12:55:23 PM,Eli Lilly Invests In Unseen Capital Health Fund As Part Of Racial Justice Efforts ,RTTNews,/news/stocks/eli-lilly-invests-in-unseen-capital-health-fund-as-part-of-racial-justice-efforts-1029972387
995.0,1/15/2021 2:40:13 PM,Lilly invests $30M in Unseen Capital Health Fund,Seeking Alpha,https://seekingalpha.com/news/3651837-lilly-invests-30m-in-unseen-capital-health-fund?utm_source=markets.businessinsider.com&utm_medium=referral
996.0,1/18/2021 9:38:34 AM,New drugs and injections to overcome challenges in COVID-19 antibody therapies - WSJ,Seeking Alpha,https://seekingalpha.com/news/3652061-new-drugs-and-injections-to-overcome-challenges-in-covidminus-19-antibody-therapies-wsj?utm_source=markets.businessinsider.com&utm_medium=referral
997.0,1/19/2021 12:47:46 PM,"Lilly, Merus Collaborate To Discover T-Cell Re-Directing Bispecific Antibodies ",RTTNews,/news/stocks/lilly-merus-collaborate-to-discover-t-cell-re-directing-bispecific-antibodies-1029980302
998.0,1/19/2021 1:32:22 PM,Lilly teams up with Merus to discover T-cell re-directing antibody therapies,Seeking Alpha,https://seekingalpha.com/news/3652204-?utm_source=markets.businessinsider.com&utm_medium=referral
999.0,1/19/2021 4:04:22 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-19-2021-1029982130
1000.0,1/19/2021 4:50:45 PM,"Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today",Benzinga,/news/stocks/why-aclaris-tenax-gritstone-merus-minerva-and-celyad-are-rallying-today-1029982313
1001.0,1/19/2021 8:42:32 PM,"Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade",Benzinga,/news/stocks/lilly-awash-in-catalysts-pipeline-updates-mizuho-says-in-upgrade-1029983120
1002.0,1/19/2021 8:44:04 PM,Eli Lilly upgraded to buy at Mizuho on positive donanemab data,Seeking Alpha,https://seekingalpha.com/news/3652410-eli-lilly-upgraded-to-buy-on-positive-donanemab-data?utm_source=markets.businessinsider.com&utm_medium=referral
1003.0,1/20/2021 1:32:35 PM,"The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-greenlights-merck-s-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study-1029985849
1004.0,1/20/2021 3:24:21 PM,The 7 Best Healthcare Stocks to Buy for 2021,InvestorPlace,/news/stocks/the-7-best-healthcare-stocks-to-buy-for-2021-1029987247
1005.0,1/21/2021 1:30:41 PM,Eli Lilly's bamlanivimab effective in reducing COVID-19 risk in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/3653068-?utm_source=markets.businessinsider.com&utm_medium=referral
1006.0,1/21/2021 2:05:24 PM,"The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping",Benzinga,/news/stocks/the-daily-biotech-pulse-addex-jumps-on-positive-data-for-out-licensed-drug-covid-19-vaccine-developer-inovio-announces-150m-follow-on-offering-boston-scientific-goes-shopping-1029990203
1007.0,1/21/2021 2:25:22 PM,Eli Lilly: Bamlanivimab Reduced Risk Of Contracting COVID-19 At Nursing Homes By Up To 80% ,RTTNews,/news/stocks/eli-lilly-bamlanivimab-reduced-risk-of-contracting-covid-19-at-nursing-homes-by-up-to-80-1029990290
1008.0,1/21/2021 4:25:23 PM,Biden Stocks: 16 Stocks to Watch for a Defense Production Act Boost,InvestorPlace,/news/stocks/biden-stocks-16-stocks-to-watch-for-a-defense-production-act-boost-1029991455
1009.0,1/22/2021 6:43:01 AM,"ADMP's Symjepi Hits Walgreen's Shelves, LLY's Antibody Cuts COVID-19 Risk By 80%, FLDM On Watch ",RTTNews,/news/stocks/admp-s-symjepi-hits-walgreen-s-shelves-lly-s-antibody-cuts-covid-19-risk-by-80-fldm-on-watch-1029992967
1010.0,1/22/2021 1:22:34 PM,"The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa",Benzinga,/news/stocks/the-daily-biotech-pulse-fluidigm-s-saliva-based-covid-test-approved-in-europe-china-backs-amarin-s-vascepa-1029993832
1011.0,1/22/2021 2:06:53 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1029993983
1012.0,1/22/2021 3:05:53 PM,Lilly Closes Acquisition Of Prevail Therapeutics ,RTTNews,/news/stocks/lilly-closes-acquisition-of-prevail-therapeutics-1029994268
1013.0,1/23/2021 3:14:04 PM,"The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-24-30-j-j-lilly-to-kickstart-big-pharma-earnings-amgen-fda-decision-and-more-1029996049
1014.0,1/25/2021 3:46:00 PM,Eli Lilly shares up as it completes Prevail Therapeutics deal,Seeking Alpha,https://seekingalpha.com/news/3653940-eli-lilly-shares-up-as-it-completes-prevail-therapeutics-deal?utm_source=markets.businessinsider.com&utm_medium=referral
1015.0,1/25/2021 6:04:14 PM,Adocia announces positive results from BioChaperone Lispro Diabetes study,Seeking Alpha,https://seekingalpha.com/news/3653986-adocia-announces-positive-results-from-biochaperone-bc-lispro-diabetes-study?utm_source=markets.businessinsider.com&utm_medium=referral
1016.0,1/25/2021 10:29:05 PM,Germany to become first in EU to use COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3654167-germany-to-become-first-in-eu-to-use-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1017.0,1/26/2021 1:51:34 PM,Eli Lilly: Phase 3 BLAZE-1 Trial Meets Primary And Secondary Endpoints ,RTTNews,/news/stocks/eli-lilly-phase-3-blaze-1-trial-meets-primary-and-secondary-endpoints-1030003776
1018.0,1/26/2021 2:07:40 PM,"The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-misses-j-j-beats-in-big-pharma-earnings-vaccine-developer-curevac-taps-equity-market-1030004007
1019.0,1/26/2021 2:42:06 PM,"Lilly bamlanivimab combo therapy lowers COVID-19 hospitalizations, death by 70%",Seeking Alpha,https://seekingalpha.com/news/3654378-lilly-combo-therapy-reduced-covid-hospitalizations-death-by-70?utm_source=markets.businessinsider.com&utm_medium=referral
1020.0,1/27/2021 12:07:25 PM,Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3654808-lilly-teams-up-with-vir-biogsk-to-evaluate-bamlanivimab-with-vir-7831-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1021.0,1/27/2021 12:40:52 PM,Regeneron’s antibody cocktail neutralizes new COVID-19 variants,Seeking Alpha,https://seekingalpha.com/news/3654838-regenerons-antibody-cocktail-neutralizes-new-covid-19-variants?utm_source=markets.businessinsider.com&utm_medium=referral
1022.0,1/27/2021 1:03:05 PM,"Lilly, Vir Biotechnology, GSK Say First Patient Dosed In Expanded BLAZE-4 Trial - Quick Facts ",RTTNews,/news/stocks/lilly-vir-biotechnology-gsk-say-first-patient-dosed-in-expanded-blaze-4-trial-quick-facts-1030009053
1023.0,1/27/2021 1:35:59 PM,"The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement",Benzinga,/news/stocks/the-daily-biotech-pulse-sorrento-immutep-surge-on-covid-19-study-data-t2-biosystems-sinks-on-preannouncement-1030009241
1024.0,1/27/2021 3:02:36 PM,Eli Lilly and is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-stock-quarter-earnings-preview-q4-1030010033
1025.0,1/27/2021 8:30:44 PM,Pfizer’s setback can hurt others with JAK inhibitors,Seeking Alpha,https://seekingalpha.com/news/3655131-pfizers-setback-can-hurt-others-with-jak-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral
1026.0,1/27/2021 10:23:39 PM,Eli Lilly secures $625M Army contract modification for 50K doses of LY-CoV555,Seeking Alpha,https://seekingalpha.com/news/3655282-eli-lilly-secures-625m-army-contract-modification-for-50k-doses-of-ly-cov555?utm_source=markets.businessinsider.com&utm_medium=referral
1027.0,1/28/2021 8:49:22 AM,"AGTC Sheds Light On Achromatopsia Trials, LLY, VIR And GSK Team Up, CVM Turns Head As It Awaits Data ",RTTNews,/news/stocks/agtc-sheds-light-on-achromatopsia-trials-lly-vir-and-gsk-team-up-cvm-turns-head-as-it-awaits-data-1030013470
1028.0,1/28/2021 12:16:55 PM,"Eli Lilly, Asahi Kasei Pharma inks licensing pact for chronic pain drug candidate",Seeking Alpha,https://seekingalpha.com/news/3655445-eli-lilly-asahi-kasei-pharma-inks-licensing-pact-for-chronic-pain-drug-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
1029.0,1/28/2021 12:51:57 PM,Lilly To Buy Exclusive Rights For Chronic Pain Drug Candidate From Asahi Kasei Pharma ,RTTNews,/news/stocks/lilly-to-buy-exclusive-rights-for-chronic-pain-drug-candidate-from-asahi-kasei-pharma-1030014281
1030.0,1/28/2021 2:03:49 PM,"The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-decision-day-for-amgen-zymeworks-sinks-on-data-ortho-clinical-diagnostics-ipo-1030014922
1031.0,1/28/2021 4:59:28 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3655663-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1032.0,1/28/2021 6:15:24 PM,Eli Lilly Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3655696-eli-lilly-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
1033.0,1/29/2021 12:02:52 AM,"Major pharma set for strong 2021, and trading at a 35% discount to market - J.P. Morgan",Seeking Alpha,https://seekingalpha.com/news/3655985-major-pharma-set-for-strong-2021-and-trading-at-a-35-discount-to-market-jp-morgan?utm_source=markets.businessinsider.com&utm_medium=referral
1034.0,1/29/2021 11:21:57 AM,"Eli Lilly EPS beats by $0.36, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3656047-eli-lilly-eps-beats-0_36-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
1035.0,1/29/2021 11:58:10 AM,"Lilly tops Q4 forecast, Trulicity sales up 24%, GAAP EPS guidance lowered",Seeking Alpha,https://seekingalpha.com/news/3656066-lilly-tops-q4-forecast-trulicity-sales-up-24-gaap-eps-guidance-lowered?utm_source=markets.businessinsider.com&utm_medium=referral
1036.0,1/29/2021 12:33:15 PM,Eli Lilly And Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q4-adjusted-earnings-beat-estimates-1030019303
1037.0,1/29/2021 1:00:55 PM,Eli Lilly Q4 Results Top Estimates; Backs FY21 Outlook ,RTTNews,/news/stocks/eli-lilly-q4-results-top-estimates-backs-fy21-outlook-1030019411
1038.0,1/29/2021 1:45:44 PM,"The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-readout-clinical-hold-on-bellicum-study-lifted-lilly-earnings-nls-pharma-ipo-1030019600
1039.0,1/29/2021 7:19:02 PM,Biogen’s FDA review extension: ‘a positive for Lilly’s Alzheimer perception' – MS,Seeking Alpha,https://seekingalpha.com/news/3656321-biogens-fda-review-extension-a-positive-for-lillys-alzheimer-perception-ms?utm_source=markets.businessinsider.com&utm_medium=referral
1040.0,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250
1041.0,1/31/2021 3:35:05 PM,3 Recent Earnings Stocks Worth Buying Today,InvestorPlace,/news/stocks/3-recent-earnings-stocks-worth-buying-today-1030023479
1042.0,2/2/2021 2:30:28 PM,Cassava surges after favorable trial data for simufilam in Alzheimer’s disease,Seeking Alpha,https://seekingalpha.com/news/3657220-cassava-surges-after-favorable-results-for-simufilam-in-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral
1043.0,2/3/2021 5:33:40 AM,"Lilly, Innovent Bio's Tyvyt + chemotherapy OK'd in China for lung cancer",Seeking Alpha,https://seekingalpha.com/news/3657589-lilly-innovent-bios-tyvyt-chemotherapy-okd-in-china-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1044.0,2/4/2021 3:00:00 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030043861
1045.0,2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
1046.0,2/9/2021 1:19:15 PM,Eli Lilly Appoints Anat Ashkenazi To Succeed Josh Smiley As CFO - Quick Facts ,RTTNews,/news/stocks/eli-lilly-appoints-anat-ashkenazi-to-succeed-josh-smiley-as-cfo-quick-facts-1030059967
1047.0,2/9/2021 2:58:26 PM,Lilly taps Anat Ashkenazi as new CFO,Seeking Alpha,https://seekingalpha.com/news/3659911-lilly-picks-internal-candidate-for-cfo-position?utm_source=markets.businessinsider.com&utm_medium=referral
1048.0,2/10/2021 2:20:40 AM,Lilly's COVID-19 Antibody Combination Receives Emergency Use Authorization In U.S. ,RTTNews,/news/stocks/lilly-s-covid-19-antibody-combination-receives-emergency-use-authorization-in-u-s-1030063212
1049.0,2/10/2021 4:59:02 AM,FDA grants EUA for Lilly COVID-19 monoclonal antibody combo,Seeking Alpha,https://seekingalpha.com/news/3660349-fda-grants-emergency-use-authorization-lilly-covid-19-monoclonal-antibody-combo?utm_source=markets.businessinsider.com&utm_medium=referral
1050.0,2/10/2021 8:53:35 AM,"GMDA On Track, GNFT Soars, HTBX Sparkles, LLY's Neutralizing Antibody Therapies Get FDA  Nod ",RTTNews,/news/stocks/gmda-on-track-gnft-soars-htbx-sparkles-lly-s-neutralizing-antibody-therapies-get-fda-nod-1030065055
1051.0,2/10/2021 1:34:43 PM,"The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-covid-19-antibody-cocktail-approved-for-emergency-use-gamida-genfit-jump-on-data-2-ipos-1030066164
1052.0,2/10/2021 1:51:54 PM,AbCellera shares jump after bamlanivimab combo nabs FDA's EUA for COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3660525-abcellera-shares-jump-after-bamlanivimab-combo-nabs-fdas-eua-for-covid-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
1053.0,2/11/2021 3:14:41 PM,ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today,InvestorPlace,/news/stocks/aciu-stock-why-ac-immune-shares-are-rocketing-higher-today-1030073976
1054.0,2/13/2021 9:00:00 PM,"Pharmas engaged in Alzheimer's, the 'holy grail' of drug development",Seeking Alpha,https://seekingalpha.com/news/3661766-pharmas-engaged-in-alzheimers-the-holy-grail-of-drug-development?utm_source=markets.businessinsider.com&utm_medium=referral
1055.0,2/17/2021 1:04:31 PM,Eli Lilly: Tirzepatide Significantly Reduced A1C And Body Weight In Two Phase 3 SURPASS Trials ,RTTNews,/news/stocks/eli-lilly-tirzepatide-significantly-reduced-a1c-and-body-weight-in-two-phase-3-surpass-trials-1030091441
1056.0,2/17/2021 2:40:46 PM,Lilly’s Tirzepatide studies achieve primary and secondary endpoints,Seeking Alpha,https://seekingalpha.com/news/3662856-lillys-tirzepatide-studies-achieve-primary-and-secondary-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral
1057.0,2/18/2021 11:47:33 AM,Rigel shares surge 41% on RIPK1 inhibitors deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3663357-eli-lilly-rigel-team-up-to-develop-ripk1-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral
1058.0,2/18/2021 12:53:14 PM,"Lilly, Rigel To Develop RIPK1 Inhibitors For Treatment Of Immunological & Neurodegenerative Diseases ",RTTNews,/news/stocks/lilly-rigel-to-develop-ripk1-inhibitors-for-treatment-of-immunological-neurodegenerative-diseases-1030096390
1059.0,2/18/2021 2:14:38 PM,"The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-lily-rigel-licensing-deal-vtv-starts-early-stage-psoriasis-study-immunic-data-readout-1030097072
1060.0,2/18/2021 4:47:21 PM,"Lilly Strikes Licensing Deal With Rigel In Push Toward Neurological, Immunological Therapies",Benzinga,/news/stocks/lilly-strikes-licensing-deal-with-rigel-in-push-toward-neurological-immunological-therapies-1030098049
1061.0,2/18/2021 7:48:55 PM,RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today,InvestorPlace,/news/stocks/rigl-stock-why-rigel-pharmaceuticals-is-climbing-today-1030099041
1062.0,2/19/2021 7:02:13 AM,"FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLY ",RTTNews,/news/stocks/flxn-on-track-imnm-discovers-antibodies-to-fight-s-african-variant-rigl-in-deal-with-lly-1030100306
1063.0,2/19/2021 1:25:51 PM,"The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-supply-deal-orphan-drug-designation-for-travere-covid-19-boost-for-quidel-opko-1030101326
1064.0,2/19/2021 2:32:59 PM,"Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows",Benzinga,/news/stocks/precision-bio-s-arcus-gene-editing-platform-is-safe-durable-long-term-animal-study-shows-1030101589
1065.0,2/19/2021 8:30:27 PM,Avidity Biosciences shares soar 18% in afternoon trading,Seeking Alpha,https://seekingalpha.com/news/3664079-avidity-biosciences-shares-soar-18-in-afternoon-trading?utm_source=markets.businessinsider.com&utm_medium=referral
1066.0,2/22/2021 2:07:58 PM,Six stocks hedge funds and mutual funds love (and 20 they don't): At the Open,Seeking Alpha,https://seekingalpha.com/news/3664311-six-stocks-hedge-funds-and-mutual-funds-love?utm_source=markets.businessinsider.com&utm_medium=referral
1067.0,2/23/2021 5:21:45 PM,Veru Files US Application For TADFIN Combo For Prostate Enlargement,Benzinga,/news/stocks/veru-files-us-application-for-tadfin-combo-for-prostate-enlargement-1030114252
1068.0,2/24/2021 1:17:19 PM,RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today,InvestorPlace,/news/stocks/rlftf-why-little-known-relief-therapeutics-is-climbing-today-brpa-stock-1030119085
1069.0,2/24/2021 10:57:00 PM,"Alvogen Pharma US, Inc. -- Moody's affirms Alvogen's ratings; outlook revised to negative",Moodys,/news/bonds/alvogen-pharma-us-inc-moody-s-affirms-alvogen-s-ratings-outlook-revised-to-negative-1030120543
1070.0,2/25/2021 7:50:23 PM,Lilly's migraine med approved in Canada for episodic cluster headache,Seeking Alpha,https://seekingalpha.com/news/3666622-lillys-migraine-med-approved-in-canada-for-episodic-cluster-headache?utm_source=markets.businessinsider.com&utm_medium=referral
1071.0,2/26/2021 12:15:26 PM,U.S. to buy 100K doses of Lilly's bamlanivimab combo for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3667055-us-to-buy-100k-doses-of-lillys-bamlanivimab-combo-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1072.0,2/26/2021 1:14:22 PM,"Eli Lilly: U.S. Govt. To Buy Min. 100K Doses Of Bamlanivimab 700 Mg, Etesevimab 1400 Mg Together ",RTTNews,/news/stocks/eli-lilly-u-s-govt-to-buy-min-100k-doses-of-bamlanivimab-700-mg-etesevimab-1400-mg-together-1030129089
1073.0,2/26/2021 2:16:52 PM,"The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-test-awaits-j-j-s-covid-19-vaccine-lilly-to-supply-additional-antibody-therapy-doses-to-us-regulatory-setback-for-tricida-1030129439
1074.0,2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296
1075.0,3/1/2021 8:40:13 PM,Eli Lilly secures $2.52B Army contract for LY-CoV555 and LY-CoV016,Seeking Alpha,https://seekingalpha.com/news/3667860-eli-lilly-secures-252b-army-contract-for-ly-cov555-and-ly-cov016?utm_source=markets.businessinsider.com&utm_medium=referral
1076.0,3/3/2021 12:04:43 PM,"Lilly, Incyte's baricitinib shows hair regrowth in late-stage alopecia areata study",Seeking Alpha,https://seekingalpha.com/news/3668631-lilly-incytes-baricitinib-successful-in-alopecia-areata-study?utm_source=markets.businessinsider.com&utm_medium=referral
1077.0,3/3/2021 1:04:01 PM,Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth ,RTTNews,/news/stocks/lilly-phase-3-study-on-baricitinib-meets-primary-endpoint-of-hair-regrowth-1030144664
1078.0,3/3/2021 1:34:53 PM,"Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment- Quick Facts ",RTTNews,/news/stocks/eli-lilly-incyte-report-positive-results-for-baricitinib-in-alopecia-areata-treatment-quick-facts-1030144848
1079.0,3/4/2021 12:28:41 PM,Lilly's tirzepatide improves blood glucose and weight loss vs. semaglutide in diabetes,Seeking Alpha,https://seekingalpha.com/news/3669286-lillys-tirzepatide-shows-superiority-over-semaglutide-in-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
1080.0,3/4/2021 2:04:33 PM,Eli Lilly Announces Positive Topline Results From Late-stage Study Of Tirzepatide- Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-positive-topline-results-from-late-stage-study-of-tirzepatide-quick-facts-1030150027
1081.0,3/4/2021 2:12:10 PM,"The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-pfizer-kiniksa-rises-on-commercialization-pact-with-regeneron-bio-techne-to-buy-diagnostic-company-1030150188
1082.0,3/4/2021 5:06:51 PM,9 Cheap Stocks That Look Like a Bargain,InvestorPlace,/news/stocks/9-cheap-stocks-look-like-bargain-1030151715
1083.0,3/5/2021 5:15:16 PM,Eli Lilly’s antibody combo wins positive opinion in Europe against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3669986-eli-lillys-antibody-combo-wins-positive-opinion-in-europe-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1084.0,3/5/2021 8:45:57 PM,AbCellera's bamlanivimab wins EMA's positive recommendation,Seeking Alpha,https://seekingalpha.com/news/3670026-abcelleras-bamlanivimab-wins-emas-positive-recommendation?utm_source=markets.businessinsider.com&utm_medium=referral
1085.0,3/8/2021 1:13:12 PM,Struggling defensive sectors losing even more appeal ahead of more stimulus: At the Open,Seeking Alpha,https://seekingalpha.com/news/3670158-struggling-defensive-sectors-losing-even-more-appeal?utm_source=markets.businessinsider.com&utm_medium=referral
1086.0,3/8/2021 10:20:04 PM,Lilly to collaborate with Biolojic Design to develop diabetes antibody therapies,Seeking Alpha,https://seekingalpha.com/news/3670507-lilly-to-collaborate-with-biolojic-design-to-develop-diabetes-antibody-therapies?utm_source=markets.businessinsider.com&utm_medium=referral
1087.0,3/9/2021 12:53:49 PM,Eli Lilly: Myles O'Neill And Melissa Barnes To Retire - Quick Facts ,RTTNews,/news/stocks/eli-lilly-myles-o-neill-and-melissa-barnes-to-retire-quick-facts-1030163056
1088.0,3/9/2021 2:08:24 PM,"The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data",Benzinga,/news/stocks/the-daily-biotech-pulse-regulatory-setback-for-acadia-lilly-forges-diabetes-antibody-treatment-collaboration-aytu-s-positive-covid-19-data-1030163477
1089.0,3/10/2021 1:22:28 PM,Lilly's (LLY) COVID-19 antibody combo reduced hospitalization and death by 87%,Seeking Alpha,https://seekingalpha.com/news/3671153-lillys-covid-19-combo-therapy-reduced-covid-hospitalizationby-87?utm_source=markets.businessinsider.com&utm_medium=referral
1090.0,3/10/2021 1:25:59 PM,"The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link",Benzinga,/news/stocks/the-daily-biotech-pulse-medicinova-bags-barda-contract-lilly-s-covid-19-antibody-cocktail-data-bluebird-bio-refutes-blood-cancer-link-1030168202
1091.0,3/10/2021 1:27:12 PM,Lilly' Bamlanivimab & Etesevimab Reduce Hospitalizations & Death In Phase 3 Trial For Early COVID-19 ,RTTNews,/news/stocks/lilly-bamlanivimab-etesevimab-reduce-hospitalizations-death-in-phase-3-trial-for-early-covid-19-1030168188
1092.0,3/10/2021 4:37:41 PM,AbCellera-discovered bamlanivimab combo shows promise in late-stage COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3671258-abcellera-discovered-bamlanivimab-combo-shows-promise-in-late-stage-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1093.0,3/10/2021 4:54:25 PM,8 Biotech Penny Stocks for Investors to Watch,InvestorPlace,/news/stocks/eight-biotech-penny-stocks-investors-to-watch-1030169900
1094.0,3/10/2021 5:30:16 PM,Adocia initiates mid-stage M1pram diabetes trial,Seeking Alpha,https://seekingalpha.com/news/3671288-adocia-initiates-mid-stage-m1pram-diabetes-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1095.0,3/11/2021 9:44:40 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-cpng-stock-ocgn-stock-stimulus-1030175736
1096.0,3/12/2021 8:30:12 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3672347-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
1097.0,3/13/2021 2:20:32 PM,Full phase 2 data of Lilly's donanemab for Alzheimer's offers mixed bag,Seeking Alpha,https://seekingalpha.com/news/3672430-full-phase-2-data-of-lilly-donanemab-for-alzheimers-offers-mixed-bag?utm_source=markets.businessinsider.com&utm_medium=referral
1098.0,3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral
1099.0,3/14/2021 1:14:58 PM,"Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations",Benzinga,/news/stocks/week-ahead-in-biotech-march-14-20-update-on-fibrogen-astrazeneca-s-anemia-drug-earnings-and-presentations-1030194424
1100.0,3/15/2021 12:23:11 PM,"Eli Lilly, Magnite leads the premarket losers' pack",Seeking Alpha,https://seekingalpha.com/news/3672572-eli-lilly-magnite-leads-the-premarket-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral
1101.0,3/15/2021 12:49:00 PM,Eli Lilly viewed with interest at Citi despite ‘zero’ chance of approval for donanemab,Seeking Alpha,https://seekingalpha.com/news/3672599-eli-lilly-viewed-with-interest-at-citi-despite-donanemab-results?utm_source=markets.businessinsider.com&utm_medium=referral
1102.0,3/15/2021 4:35:15 PM,Lilly charts course for second donanemab pivotal trial in Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3672720-lilly-charts-course-for-second-donanemab-pivotal-trial-in-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral
1103.0,3/15/2021 4:55:51 PM,Lilly's bamlanivimab combo cuts hospitalizations and death in phase 3 early COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3672747-lillys-bamlanivimab-combo-cuts-hospitalizations-and-death-in-phase-3-early-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1104.0,3/15/2021 5:04:34 PM,Mid-Day Market Update: Intec Pharma Jumps Following Merger News; HighPoint Resources Shares Plunge,Benzinga,/news/stocks/mid-day-market-update-intec-pharma-jumps-following-merger-news-highpoint-resources-shares-plunge-1030206136
1105.0,3/15/2021 5:36:28 PM,42 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/42-stocks-moving-in-monday-s-mid-day-session-1030206348
1106.0,3/15/2021 6:06:24 PM,Biogen nears session lows as Jefferies holds call on Alzheimer's drugs,Seeking Alpha,https://seekingalpha.com/news/3672776-biogen-nears-session-lows-as-jefferies-holds-call-on-alzheimers-drugs?utm_source=markets.businessinsider.com&utm_medium=referral
1107.0,3/16/2021 11:29:14 AM,65 Biggest Movers From Yesterday,Benzinga,/news/stocks/65-biggest-movers-from-yesterday-1030213887
1108.0,3/16/2021 12:35:22 PM,Lilly's mirikizumab meets endpoints in late-stage ulcerative colitis study,Seeking Alpha,https://seekingalpha.com/news/3673072-lillys-mirikizumab-meets-endpoints-in-ulcerative-colitis-study?utm_source=markets.businessinsider.com&utm_medium=referral
1109.0,3/17/2021 7:18:58 AM,"CELC Inks Breast Cancer Trial Collaboration, CANF Soars On Deal With Ewopharma, MRUS On Watch ",RTTNews,/news/stocks/celc-inks-breast-cancer-trial-collaboration-canf-soars-on-deal-with-ewopharma-mrus-on-watch-1030217968
1110.0,3/17/2021 12:00:17 PM,FTC moves to hinder cross-border pharma mergers; CVS cut to neutral at Guggenheim and more in today’s analyst action,Seeking Alpha,https://seekingalpha.com/news/3673529-ftc-moves-to-hinder-cross-border-pharma-mergers-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
1111.0,3/17/2021 12:02:41 PM,Lilly Reports Patient-Reported Outcomes From Phase 3 MonarchE Trial For Verzenio ,RTTNews,/news/stocks/lilly-reports-patient-reported-outcomes-from-phase-3-monarche-trial-for-verzenio-1030218745
1112.0,3/17/2021 12:22:17 PM,Lilly presents favorable patient reported outcomes in late-stage trial for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3673543-lilly-presents-favorable-patient-reported-outcomes-in-late-stage-trial-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1113.0,3/20/2021 2:52:32 PM,"FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings",Benzinga,/news/stocks/fda-decisions-for-pfizer-eli-lilly-and-bluebird-bio-bristol-meyers-squibb-plus-new-data-and-earnings-1030229632
1114.0,3/21/2021 4:18:05 PM,"Barron's Latest Picks And Pans: Space Race Picks, Eli Lilly, GameStop, Splunk And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-space-race-picks-eli-lilly-gamestop-splunk-and-more-1030230109
1115.0,3/22/2021 2:23:40 PM,FDA briefing documents released ahead of AdCom meeting on Pfizer’s BLA for tanezumab,Seeking Alpha,https://seekingalpha.com/news/3674809-fda-briefing-documents-released-ahead-of-adcom-meeting-on-pfizers-tanezumab?utm_source=markets.businessinsider.com&utm_medium=referral
1116.0,3/23/2021 6:31:22 AM,"AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA Approval, AdComm To Review Osteoarthritis Drug ",RTTNews,/news/stocks/azn-s-covid-19-jab-shows-79-efficacy-zeal-wins-fda-approval-adcomm-to-review-osteoarthritis-drug-1030234460
1117.0,3/24/2021 1:59:18 PM,"The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping",Benzinga,/news/stocks/the-daily-biotech-pulse-dynavax-clover-start-phase-2-3-vaccine-study-brainstorm-reports-positive-ms-readout-neogenomics-goes-shopping-1030241020
1118.0,3/25/2021 12:58:24 PM,"The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-squibb-s-skin-cancer-readout-cellect-strikes-reverse-merger-deal-lava-therapeutics-makes-nasdaq-debut-1030245316
1119.0,3/25/2021 4:30:01 PM,Pfizer’s tanezumab in osteoarthritis turned down by FDA expert panel (updated),Seeking Alpha,https://seekingalpha.com/news/3676348-pfizers-marketing-application-on-tanezumab-fails-in-adcom-vote?utm_source=markets.businessinsider.com&utm_medium=referral
1120.0,3/26/2021 9:38:09 AM,"5 Stocks To Watch For March 26, 2021",Benzinga,/news/stocks/5-stocks-to-watch-for-march-26-2021-1030249063
1121.0,3/26/2021 10:57:30 AM,A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Reports,Benzinga,/news/stocks/a-peek-into-the-markets-us-stock-futures-gain-ahead-of-economic-reports-1030249240
1122.0,3/26/2021 12:20:54 PM,Aspira extends gains as analysts weigh in; Flexion to benefit from Pfizer’s failure in osteoarthritis drug and more in today’s analyst action,Seeking Alpha,https://seekingalpha.com/news/3676731-aspira-extends-gains-as-analysts-weigh-in-flexion-to-benefit-from-pfizers-failure?utm_source=markets.businessinsider.com&utm_medium=referral
1123.0,3/29/2021 12:50:46 PM,"Lilly, Vir Bio, GSK's cocktail antibody shows positive action in COVID-19",Seeking Alpha,https://seekingalpha.com/news/3677146-lilly-vir-bio-gsks-cocktail-antibody-shows-positive-action-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1124.0,3/29/2021 2:58:45 PM,"Lilly, Vir And GSK Announce Positive Data From Phase 2 BLAZE-4 Trial On COVID-19 ",RTTNews,/news/stocks/lilly-vir-and-gsk-announce-positive-data-from-phase-2-blaze-4-trial-on-covid-19-1030254696
1125.0,3/30/2021 2:06:26 PM,"The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-wave-life-sciences-pulls-plug-on-2-assets-amarin-s-vascepa-snags-european-approval-biocept-jumps-on-earnings-1030258478
1126.0,4/1/2021 3:02:28 PM,Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition,Benzinga,/news/stocks/fortress-biotech-s-partner-firm-expands-footprint-in-dermatology-with-qbrexza-acquisition-1030269030
1127.0,4/1/2021 7:40:39 PM,Eli Lilly subsidiary to divest Qbrexza to Journey Medical,Seeking Alpha,https://seekingalpha.com/news/3678822-eli-lilly-subsidiary-to-divest-qbrexza-to-journey-medical?utm_source=markets.businessinsider.com&utm_medium=referral
1128.0,4/3/2021 3:11:24 PM,"The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-regeneron-supernus-fda-decisions-cancer-conference-presentations-in-the-spotlight-1030272481
1129.0,4/5/2021 6:42:13 AM,Health Canada approves Lilly's Taltz for plaque psoriasis in pediatric patients,Seeking Alpha,https://seekingalpha.com/news/3679018-health-canada-approves-lillys-taltz-for-plaque-psoriasis-in-pediatric-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1130.0,4/6/2021 2:29:11 PM,JP Morgan physician survey finds support for Lilly's donanemab in Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3679541-jp-morgan-physician-survey-finds-support-for-lilly-donanemab-in-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral
1131.0,4/6/2021 2:55:42 PM,Is Silicon Valley Replacing Big Pharma In Neuroscience?,Benzinga,/news/stocks/is-silicon-valley-replacing-big-pharma-in-neuroscience-1030277135
1132.0,4/6/2021 8:39:09 PM,"FDA extends review period for Eli Lilly, Incyte's baricitinib atopic dermatitis sNDA",Seeking Alpha,https://seekingalpha.com/news/3679664-fda-extends-review-period-for-eli-lilly-incytes-baricitinib-atopic-dermatitis-snda?utm_source=markets.businessinsider.com&utm_medium=referral
1133.0,4/7/2021 1:57:58 PM,"The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award",Benzinga,/news/stocks/the-daily-biotech-pulse-fibrogen-fudges-safety-data-novartis-strikes-cancer-drug-collaboration-immutep-gains-on-patent-award-1030280866
1134.0,4/8/2021 11:23:22 AM,"Lilly, Incyte's COV-BARRIER study fails to meet primary endpoint in COVID-19",Seeking Alpha,https://seekingalpha.com/news/3680241-lilly-incytes-cov-barrier-study-fails-to-meet-primary-endpoint-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1135.0,4/8/2021 1:26:43 PM,"Lilly woes provide buying opportunity, Danaher a buy with likely earnings beat, and more in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3680280-lilly-woes-provide-buying-opportunity-danaher-a-buy-with-likely-earnings-beat-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
1136.0,4/8/2021 1:41:24 PM,Eli Lilly Says Late-stage Study Of Baricitinib In Hospitalized Covid Patients Didn't Meet Main Goal ,RTTNews,/news/stocks/eli-lilly-says-late-stage-study-of-baricitinib-in-hospitalized-covid-patients-didn-t-meet-main-goal-1030285100
1137.0,4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466
1138.0,4/9/2021 12:30:56 PM,Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes,Benzinga,/news/stocks/provention-bio-stock-craters-after-fda-flags-deficiencies-in-pk-profiles-from-teplizumab-trials-for-diabetes-1030288688
1139.0,4/9/2021 1:26:03 PM,"The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-negative-regulatory-tidings-for-provention-bio-celcuity-soars-on-in-licensing-deal-2-ipos-1030288848
1140.0,4/10/2021 3:20:43 PM,The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight,Benzinga,/news/stocks/the-week-ahead-in-biotech-april-11-17-avenue-therapeutics-fda-decision-and-conference-presentations-in-the-spotlight-1030290858
1141.0,4/11/2021 3:38:21 PM,Healthcare momentum struggling with UnitedHealth set to report: Sector Watch,Seeking Alpha,https://seekingalpha.com/news/3680852-healthcare-stocks-momentum-stalling?utm_source=markets.businessinsider.com&utm_medium=referral
1142.0,4/12/2021 9:06:47 AM,Lilly's retevmo shows antitumor activity in solid tumors,Seeking Alpha,https://seekingalpha.com/news/3680871-lillys-retevmo-shows-antitumor-activity-in-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
1143.0,4/12/2021 11:21:17 AM,Eli Lilly and U.S. government amend supply agreement for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3680902-eli-lilly-and-us-government-amend-supply-agreement-for-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1144.0,4/12/2021 12:58:46 PM,"Eli Lilly, U.S. Government Amend Purchase Agreements For Neutralizing Antibody Therapies ",RTTNews,/news/stocks/eli-lilly-u-s-government-amend-purchase-agreements-for-neutralizing-antibody-therapies-1030293179
1145.0,4/13/2021 3:51:18 AM,Lilly : Phase 3 Study Shows Sintilimab Improves OS For Squamous Non-small Cell Lung Cancer Patients ,RTTNews,/news/stocks/lilly-phase-3-study-shows-sintilimab-improves-os-for-squamous-non-small-cell-lung-cancer-patients-1030295802
1146.0,4/13/2021 6:53:37 AM,Lilly's Tyvyt 'significantly improves' overall survival as a second-line treatment for lung cancer,Seeking Alpha,https://seekingalpha.com/news/3681219-lillys-tyvyt-significantly-improves-overall-survival-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1147.0,4/13/2021 12:43:44 PM,Eli Lilly Appoints Diogo Rau To Head Information Technology And Digital Capabilities ,RTTNews,/news/stocks/eli-lilly-appoints-diogo-rau-to-head-information-technology-and-digital-capabilities-1030297649
1148.0,4/13/2021 2:16:36 PM,"The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-leadership-transition-at-amarin-vaccine-setback-for-j-j-fda-nod-for-label-expansion-of-roche-s-asthma-drug-1030298345
1149.0,4/14/2021 11:35:37 AM,Eli Lilly and SciNeuro Pharmaceuticals ink exclusive license agreement,Seeking Alpha,https://seekingalpha.com/news/3681646-eli-lilly-and-scineuro-pharmaceuticals-ink-exclusive-license-agreement?utm_source=markets.businessinsider.com&utm_medium=referral
1150.0,4/14/2021 1:51:00 PM,"The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-cfo-departs-zai-lab-inks-cancer-drug-collaboration-fda-nod-for-gilead-1030303096
1151.0,4/15/2021 5:39:05 PM,Merck hurt by another setback in its battle against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682287-merck-hurt-by-another-setback-in-its-battle-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1152.0,4/16/2021 10:52:08 AM,Lilly requests withdrawal of emergency use nod of bamlanivimab alone in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682491-lilly-requests-withdrawal-of-emergency-use-nod-of-bamlanivimab-alone-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1153.0,4/16/2021 12:50:40 PM,Eli Lilly Requests FDA Revoke EUA For Bamlanivimab 700 Mg Alone - Quick Facts ,RTTNews,/news/stocks/eli-lilly-requests-fda-revoke-eua-for-bamlanivimab-700-mg-alone-quick-facts-1030312052
1154.0,4/16/2021 2:00:59 PM,"The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-precision-biosciences-regains-rights-to-car-t-candidates-cfo-changes-2-ipos-1030312278
1155.0,4/16/2021 8:47:11 PM,Lilly and Incyte's baricitinib fails to meet main goal in late-stage COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3682728-lilly-and-incytes-baricitinib-fails-to-meet-main-goal-in-late-stage-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1156.0,4/18/2021 1:18:56 AM,AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy,Seeking Alpha,https://seekingalpha.com/news/3682763-eli-lillys-kras-battle-affimeds-new-cell-therapy-graced-aacr-2021?utm_source=markets.businessinsider.com&utm_medium=referral
1157.0,4/19/2021 4:58:40 PM,Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19,Seeking Alpha,https://seekingalpha.com/news/3683056-large-nih-funded-study-to-explore-repurposed-drugs-for-mild-to-moderate-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1158.0,4/20/2021 11:11:34 AM,"Lilly, Incyte's second baricitinib study shows improvement in hair regrowth in alopecia areata patients",Seeking Alpha,https://seekingalpha.com/news/3683289-lilly-incytes-second-baricitinib-study-shows-improvement-in-hair-regrowth-in-alopecia-areata-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1159.0,4/20/2021 1:51:46 PM,Eli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal- Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-2nd-late-stage-study-of-baricitinib-achieved-main-goal-quick-facts-1030322410
1160.0,4/20/2021 2:06:58 PM,"The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex",Benzinga,/news/stocks/the-daily-biotech-pulse-q1-beat-from-johnson-johnson-kalvista-study-placed-on-hold-european-label-expansion-for-gw-pharma-s-epidiolex-1030322640
1161.0,4/21/2021 1:31:27 PM,"The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-to-supply-variant-specific-vaccine-to-israel-roche-s-diagnostics-business-comes-to-rescue-1030327873
1162.0,4/23/2021 3:52:51 PM,Incyte presents more data from positive late-stage studies for ruxolitinib in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3685158-incyte-presents-more-data-from-late-stage-studies-for-ruxolitinib-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
1163.0,4/23/2021 4:44:02 PM,Incyte : Olumiant Shows Improvements In Severity And Extent Of Atopic Dermatitis ,RTTNews,/news/stocks/incyte-olumiant-shows-improvements-in-severity-and-extent-of-atopic-dermatitis-1030339129
1164.0,4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692
1165.0,4/25/2021 3:01:40 PM,Eli Lilly and is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/eli_lilly-q1-quarterly-earnings-preview-1030341714
1166.0,4/26/2021 4:36:08 PM,Eli Lilly Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3685577-eli-lilly-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
1167.0,4/26/2021 4:42:37 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3685586-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1168.0,4/27/2021 10:26:27 AM,"Eli Lilly EPS misses by $0.23, misses on revenue",Seeking Alpha,https://seekingalpha.com/news/3685930-eli-lilly-eps-misses-0_23-misses-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
1169.0,4/27/2021 11:08:52 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-morning-3-1030351233
1170.0,4/27/2021 11:17:05 AM,Lilly slips 4% as Q4 trails estimates; Guidance lags consensus; COVID-19 antibody revenues of $810M,Seeking Alpha,https://seekingalpha.com/news/3685967-lilly-slips-4-as-q4-trails-estimates-and-guidance-lags-consensus-covid-19-antibody-revenues-of-810m?utm_source=markets.businessinsider.com&utm_medium=referral
1171.0,4/27/2021 12:30:23 PM,Eli Lilly And Co. Q1 adjusted earnings of $1.87 per share,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-of-1-87-per-share-1030350476
1172.0,4/27/2021 1:05:22 PM,24 Stocks Moving in Tuesday's Pre-Market Session,Benzinga,/news/stocks/24-stocks-moving-in-tuesday-s-pre-market-session-1030350694
1173.0,4/27/2021 1:25:45 PM,Lilly Q1 Profit Down; Cuts FY Profit View ,RTTNews,/news/stocks/lilly-q1-profit-down-cuts-fy-profit-view-1030350841
1174.0,4/28/2021 1:51:14 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1030357518
1175.0,4/29/2021 2:39:08 PM,Lilly’s Olumiant undergoes European review for hospitalized  COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3687965-lillys-olumiant-undergoes-european-review-for-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1176.0,5/1/2021 5:43:35 PM,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates-1030373547
1177.0,5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608
1178.0,5/4/2021 1:28:54 PM,"Lilly donates 400,000 baricitinib tablets to India for use as COVID-19 therapy",Seeking Alpha,https://seekingalpha.com/news/3690156-lilly-donates-400000-baricitinib-tablets-to-india-for-use-as-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1179.0,5/4/2021 1:38:50 PM,Lilly To Donate COVID-19 Treatment Baricitinib To India - Quick Facts ,RTTNews,/news/stocks/lilly-to-donate-covid-19-treatment-baricitinib-to-india-quick-facts-1030383661
1180.0,5/4/2021 2:19:15 PM,Lilly-AbCellera collaboration develops new antibody that can neutralize COVID-19 variants,Seeking Alpha,https://seekingalpha.com/news/3690194-lilly-abcellera-collaboration-develops-new-antibody-that-can-neutralize-covid-19-variants?utm_source=markets.businessinsider.com&utm_medium=referral
1181.0,5/4/2021 2:34:49 PM,Lilly Outlines Plans To Strengthen ESG Commitments ,RTTNews,/news/stocks/lilly-outlines-plans-to-strengthen-esg-commitments-1030384194
1182.0,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral
1183.0,5/5/2021 5:22:43 PM,Lilly implicated in production lapses at two of its plants,Seeking Alpha,https://seekingalpha.com/news/3691282-lilly-implicated-in-production-lapses-at-two-of-its-plants?utm_source=markets.businessinsider.com&utm_medium=referral
1184.0,5/7/2021 7:30:30 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3693377-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
1185.0,5/8/2021 6:10:15 PM,"The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More",Benzinga,/news/stocks/the-past-week-s-notable-insider-buys-amphenol-aldeyra-werewolf-therapeutics-and-more-1030404834
1186.0,5/11/2021 11:02:42 AM,"Lilly, MiNA Therapeutics ink saRNA research collaboration",Seeking Alpha,https://seekingalpha.com/news/3694429-lilly-mina-therapeutics-ink-sarna-research-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral
1187.0,5/11/2021 1:03:18 PM,"Eli Lilly, MiNA Therapeutics To Collaborate On Research Using MiNA's SaRNA Technology - Quick Facts ",RTTNews,/news/stocks/eli-lilly-mina-therapeutics-to-collaborate-on-research-using-mina-s-sarna-technology-quick-facts-1030413814
1188.0,5/11/2021 1:54:31 PM,"The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-pfizer-biontech-covid-19-vaccine-for-adolescents-lilly-strikes-r-d-collaboration-vaccine-stocks-novavax-inovio-sink-on-earnings-1030414147
1189.0,5/11/2021 5:50:08 PM,Dr Reddy's strikes licensing deal with Lilly for Baricitinib,Seeking Alpha,https://seekingalpha.com/news/3694741-dr-reddys-strikes-licensing-deal-with-lilly-for-baricitinib?utm_source=markets.businessinsider.com&utm_medium=referral
1190.0,5/18/2021 4:32:53 AM,"FDA accepts Lilly, Innovent's sintilimab + chemotherapy application in lung cancer",Seeking Alpha,https://seekingalpha.com/news/3697564-fda-accepts-lilly-innovents-sintilimab-chemotherapy-application-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1191.0,5/18/2021 1:44:45 PM,"The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO",Benzinga,/news/stocks/the-daily-biotech-pulse-spero-secures-niaid-funding-glaxosmithkline-releases-covid-19-data-biontech-gets-new-cfo-1030440714
1192.0,5/18/2021 3:16:29 PM,Hershey To Buy Lily's Confectionery Brand - Quick Facts ,RTTNews,/news/stocks/hershey-to-buy-lily-s-confectionery-brand-quick-facts-1030441609
1193.0,5/18/2021 7:54:31 PM,Why Zomedica Doesn’t Need Reddit,InvestorPlace,/news/stocks/zom-stock-why-zomedica-doesnt-need-reddit-1030443399
1194.0,5/19/2021 9:01:32 AM,7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage,InvestorPlace,/news/stocks/7-best-biotech-stocks-to-buy-in-2021-as-innovation-takes-center-stage-1030445426
1195.0,5/20/2021 11:37:10 AM,Lilly’s Tirzepatide reaches endpoints in open label study for patients with type 2 diabetes,Seeking Alpha,https://seekingalpha.com/news/3698580-lillys-tirzepatide-reaches-endpoints-in-open-label-study-for-patients-with-type-2-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
1196.0,5/20/2021 1:49:56 PM,Lilly's Diabetes Drug Candidate Tirzepatide Meets Primary Study Outcome In Surpass-4 Trial ,RTTNews,/news/stocks/lilly-s-diabetes-drug-candidate-tirzepatide-meets-primary-study-outcome-in-surpass-4-trial-1030450418
1197.0,5/20/2021 2:27:03 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-order-flow-abounds-voyager-ceo-cmo-to-depart-decision-day-for-bristol-myers-squibb-asco-abstracts-move-stocks-1030450798
1198.0,5/21/2021 6:37:07 PM,FDA approves J&J's Rybrevant as targeted therapy for NSCLC patient subset,Seeking Alpha,https://seekingalpha.com/news/3699217-fda-approves-johnson-johnson-rybrevant-as-targeted-therapy-for-nsclc-patient-subset?utm_source=markets.businessinsider.com&utm_medium=referral
1199.0,5/23/2021 4:05:56 PM,"The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-23-29-eton-lantheus-fda-decisions-adcom-test-for-provention-chiasma-data-presentation-1030457244
1200.0,5/24/2021 6:31:26 PM,3 Healthcare Stocks to Buy as the Sector Breaks Out,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-as-the-sector-breaks-out-1030459870
1201.0,5/25/2021 1:53:39 PM,"The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-in-vaccine-supply-talks-with-india-provention-in-focus-ahead-of-briefing-doc-neurorx-to-list-via-spac-deal-1030461990
1202.0,5/27/2021 3:12:17 AM,GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization; Vir up 9%,Seeking Alpha,https://seekingalpha.com/news/3700603-gsk-vir-covid-19-biologic-wins-fda-emergency-use-authorization-vir-up-9?utm_source=markets.businessinsider.com&utm_medium=referral
1203.0,5/27/2021 11:37:19 AM,FDA accepts Lilly and Dicerna's cardiometabolic diseases IND,Seeking Alpha,https://seekingalpha.com/news/3700702-fda-accepts-lilly-and-dicernas-cardiometabolic-diseases-ind?utm_source=markets.businessinsider.com&utm_medium=referral
1204.0,5/27/2021 3:17:34 PM,Eli Lilly Reveals Receipt Of Subpoena From DoJ On Branchburg Manufacturing Facility - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reveals-receipt-of-subpoena-from-doj-on-branchburg-manufacturing-facility-quick-facts-1030471647
1205.0,5/27/2021 4:45:07 PM,Eli Lilly under probe over alleged manufacturing lapses at New Jersey plant: Reuters,Seeking Alpha,https://seekingalpha.com/news/3700900-eli-lilly-under-probe-over-alleged-manufacturing-lapses-at-new-jersey-plant-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
1206.0,5/28/2021 7:00:20 PM,Amgen's Lumakras can target 13% of the NSCLC market,Seeking Alpha,https://seekingalpha.com/news/3701338-amgen-mirati-lumakras-can-target-13-of-the-nsclc-market?utm_source=markets.businessinsider.com&utm_medium=referral
1207.0,6/2/2021 2:20:24 PM,"The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-novartis-irhythm-ceo-quits-abruptly-moderna-inks-vaccine-supply-agreements-1030486987
1208.0,6/3/2021 9:13:31 AM,"Lilly, Innovent Bio's Tyvyt combo OK'd in China for lung cancer",Seeking Alpha,https://seekingalpha.com/news/3702755-lilly-innovent-bios-tyvyt-combo-okd-in-china-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1209.0,6/4/2021 9:37:08 PM,Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers,Benzinga,/news/stocks/merus-reveals-new-data-from-zeno-program-in-nrg1-fusion-cancers-1030496448
1210.0,6/7/2021 6:34:19 PM,Eli Lilly hits 52-week high after Biogen wins FDA approval for Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3703836-eli-lilly-hits-52-week-high-after-biogen-won-fda-approval-for-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1211.0,6/7/2021 7:21:42 PM,Biogen CEO: committed to gathering new data on FDA-approved Alzheimer's drug,Seeking Alpha,https://seekingalpha.com/news/3703844-biogen-ceo-committed-to-gathering-new-data-on-fda-approved-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral
1212.0,6/8/2021 3:17:38 PM,"The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex",Benzinga,/news/stocks/the-daily-biotech-pulse-hookipa-pds-biotech-report-positive-data-ironwood-cfo-to-depart-decision-day-for-vertex-1030503836
1213.0,6/8/2021 3:18:10 PM,"Could Lilly's donanemab, others for Alzheimer's get a boost from Biogen approval?",Seeking Alpha,https://seekingalpha.com/news/3704152-could-lilly-donanemab-others-for-alzheimers-get-a-boost-from-biogen-approval?utm_source=markets.businessinsider.com&utm_medium=referral
1214.0,6/8/2021 4:09:35 PM,"Biogen, Eisai and other Alzheimer's players cool off in afternoon trading",Seeking Alpha,https://seekingalpha.com/news/3704216-biogen-eisai-and-other-alzheimers-players-cool-off-in-afternoon-trading?utm_source=markets.businessinsider.com&utm_medium=referral
1215.0,6/8/2021 6:51:45 PM,"5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing",Benzinga,/news/stocks/5-biogen-analysts-on-fda-approval-of-alzheimer-s-drug-aduhelm-broad-label-pricing-1030504841
1216.0,6/10/2021 11:05:59 AM,"Lilly, ALX Oncology collaborate in gastric or gastroesophageal cancer",Seeking Alpha,https://seekingalpha.com/news/3704911-lilly-alx-oncology-collaborate-in-gastric-or-gastroesophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1217.0,6/10/2021 1:30:22 PM,ALX Oncology Inks Clinical Trial Collaboration Supply Deal With Eli Lilly For ALX148 Combination ,RTTNews,/news/stocks/alx-oncology-inks-clinical-trial-collaboration-supply-deal-with-eli-lilly-for-alx148-combination-1030511170
1218.0,6/10/2021 2:13:41 PM,"The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-us-to-procure-500m-pfizer-biontech-vaccine-doses-for-donation-verona-out-licenses-copd-drug-nautilus-lists-through-spac-deal-1030511571
1219.0,6/10/2021 2:49:41 PM,Biogen Gets an Unearned Rip on an Unproven Drug,InvestorPlace,/news/stocks/biib-stock-an-unearned-rip-on-an-unproven-drug-1030512916
1220.0,6/10/2021 4:43:14 PM,UBS sees $13B in peak Biogen Aduhelm sales for Alzheimer's based on doc checks,Seeking Alpha,https://seekingalpha.com/news/3705125-ubs-sees-13b-in-peak-biogen-aduhelm-sales-for-alzheimers-based-on-doc-checks?utm_source=markets.businessinsider.com&utm_medium=referral
1221.0,6/11/2021 2:05:19 PM,"The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-vertex-shelves-mid-stage-study-precigen-novan-jump-on-data-hematology-conference-janux-debuts-1030515558
1222.0,6/11/2021 7:00:00 PM,Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA,PR Newswire,/news/stocks/lilly-announces-webcast-to-provide-diabetes-portfolio-update-at-ada-1030516583
1223.0,6/12/2021 8:00:43 PM,The road -- and obstacles -- ahead for Biogen's Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3705833-the-road-and-obstacles-ahead-for-biogens-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral
1224.0,6/14/2021 4:00:00 PM,Lilly to Participate in Guggenheim Biopharma Strategy Series,PR Newswire,/news/stocks/lilly-to-participate-in-guggenheim-biopharma-strategy-series-1030520135
1225.0,6/15/2021 9:59:16 AM,AstraZeneca’s STORM CHASER trial in COVID-19 misses primary endpoint of preventing COVID-19,Seeking Alpha,https://seekingalpha.com/news/3706281-astrazenecas-storm-chaser-trial-in-covid-19-misses-primary-endpoint-of-preventing-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1226.0,6/15/2021 11:20:12 AM,Eli Lilly to start head-to-head study comparing two approved migraine therapies,Seeking Alpha,https://seekingalpha.com/news/3706320-eli-lilly-to-start-head-to-head-study-comparing-two-approved-migraine-therapies?utm_source=markets.businessinsider.com&utm_medium=referral
1227.0,6/15/2021 12:45:00 PM,Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine,PR Newswire,/news/stocks/lilly-announces-head-to-head-study-comparing-once-monthly-emgality-with-every-other-day-nurtec-odt-for-the-preventive-treatment-of-migraine-1030522796
1228.0,6/15/2021 1:07:41 PM,Eli Lilly To Launch Head-to-head Study Comparing Once-monthly Injectable Emgality With Nurtec ODT ,RTTNews,/news/stocks/eli-lilly-to-launch-head-to-head-study-comparing-once-monthly-injectable-emgality-with-nurtec-odt-1030522928
1229.0,6/15/2021 3:36:14 PM,Alzheimer's-focused Anavex takes a breather day after gaining 35%,Seeking Alpha,https://seekingalpha.com/news/3706529-alzheimers-focused-anavex-takes-a-breather-day-after-gaining-35?utm_source=markets.businessinsider.com&utm_medium=referral
1230.0,6/15/2021 4:10:47 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1030524490
1231.0,6/15/2021 7:05:41 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030525266
1232.0,6/16/2021 2:02:10 PM,"Cramer Shares His Thoughts On Vertex Pharma, Snap And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-vertex-pharma-snap-and-more-1030527592
1233.0,6/16/2021 2:06:24 PM,"Eli Lilly, Sanofi, and Novo Nordisk sued over insulin prices",Seeking Alpha,https://seekingalpha.com/news/3706905-eli-lilly-sanofi-and-novo-nordisk-sued-over-insulin-prices?utm_source=markets.businessinsider.com&utm_medium=referral
1234.0,6/17/2021 2:00:00 PM,Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine,PR Newswire,/news/stocks/lilly-launches-think-talk-treat-migraine-to-help-improve-diagnosis-and-treatment-of-migraine-1030531801
1235.0,6/18/2021 2:55:08 PM,Biohaven gains on takeover speculation following board appointment,Seeking Alpha,https://seekingalpha.com/news/3707709-biohaven-gains-on-takeover-speculation-following-board-appointment?utm_source=markets.businessinsider.com&utm_medium=referral
1236.0,6/18/2021 6:00:30 PM,"4 Top Stock Trades for Monday: MSFT, TWLO, LLY, GE",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-msft-twlo-lly-ge-1030536281
1237.0,6/21/2021 7:35:35 PM,3 Top Stock Trades of the Week,InvestorPlace,/news/stocks/3-top-stock-trades-of-the-week-1030540695
1238.0,6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral
1239.0,6/24/2021 7:42:17 AM,Biotech Stocks Facing FDA Decision In July 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2021-1030549382
1240.0,6/24/2021 10:59:56 AM,Eli Lilly to file marketing application for Alzheimer’s therapy this year,Seeking Alpha,https://seekingalpha.com/news/3709448-eli-lilly-says-it-plans-to-file-marketing-application-for-alzheimers-therapy-this-year?utm_source=markets.businessinsider.com&utm_medium=referral
1241.0,6/24/2021 12:26:43 PM,"FSLR, LLY, SNDL and BBBY among premarket gainers",Seeking Alpha,https://seekingalpha.com/news/3709505-fslr-lly-sndl-and-bbby-among-premarket-gainers?utm_source=markets.businessinsider.com&utm_medium=referral
1242.0,6/24/2021 12:45:00 PM,Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease,PR Newswire,/news/stocks/lilly-s-donanemab-receives-u-s-fda-s-breakthrough-therapy-designation-for-treatment-of-alzheimer-s-disease-1030550392
1243.0,6/24/2021 1:38:12 PM,Lilly's Donanemab For Alzheimer's Disease Gets Breakthrough Therapy Designation ,RTTNews,/news/stocks/lilly-s-donanemab-for-alzheimer-s-disease-gets-breakthrough-therapy-designation-1030550648
1244.0,6/24/2021 2:00:00 PM,Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin,PR Newswire,/news/stocks/lilly-announces-call-for-leonard-award-nominations-as-part-of-global-initiative-celebrating-100-years-of-insulin-1030550851
1245.0,6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889
1246.0,6/24/2021 2:59:27 PM,LLY Stock: The Alzheimer’s Drug News Sending Eli Lilly Higher Today,InvestorPlace,/news/stocks/lly-stock-the-alzheimers-drug-news-sending-eli-lilly-higher-today-1030551951
1247.0,6/24/2021 3:18:48 PM,ENFA Stock: 10 Things Potential Investors Should Know About the BuzzFeed SPAC Merger,InvestorPlace,/news/stocks/enfa-stock-10-things-potential-investors-should-know-about-the-buzzfeed-spac-merger-1030552091
1248.0,6/24/2021 3:42:34 PM,LAZR Stock: The Volvo News That Has Luminar Technologies Investors Smiling Today,InvestorPlace,/news/stocks/lazr-stock-the-volvo-news-that-has-luminar-technologies-investors-smiling-today-1030552154
1249.0,6/24/2021 4:00:54 PM,Midday Market Update: 10 Biggest Stocks Gainers Today,InvestorPlace,/news/stocks/midday-market-update-10-biggest-stocks-gainers-today-1030552204
1250.0,6/24/2021 4:58:13 PM,PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday,Benzinga,/news/stocks/premarket-prep-recap-the-4-stocks-dennis-dick-bought-yesterday-1030551973
1251.0,6/24/2021 6:04:24 PM,Mizuho enthusiasm for Eli Lilly tempered after talk with company,Seeking Alpha,https://seekingalpha.com/news/3709766-mizuho-enthusiasm-for-eli-lilly-alzheimers-drug-tempered-after-talk-with-company?utm_source=markets.businessinsider.com&utm_medium=referral
1252.0,6/24/2021 6:10:26 PM,36 Stocks Moving In Thursday's Mid-Day Session,Benzinga,/news/stocks/36-stocks-moving-in-thursday-s-mid-day-session-1030552259
1253.0,6/24/2021 9:22:04 PM,"Biogen shares hit by Lilly donanemab Breakthrough Therapy designation, filing plans",Seeking Alpha,https://seekingalpha.com/news/3709984-biogen-shares-hit-by-lilly-donanemab-breakthrough-therapy-designation-filing-plans?utm_source=markets.businessinsider.com&utm_medium=referral
1254.0,6/25/2021 11:20:52 AM,45 Biggest Movers From Yesterday,Benzinga,/news/stocks/45-biggest-movers-from-yesterday-1030554190
1255.0,6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577
1256.0,6/25/2021 5:30:00 PM,Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type ...,PR Newswire,/news/stocks/lilly-s-surpass-2-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-superior-a1c-and-body-weight-reductions-compared-to-injectable-semaglutide-in-adults-with-type-1030555443
1257.0,6/25/2021 6:39:42 PM,Eli Lilly COVID-19 antibody shipments halted in the U.S. citing prevalence of variants,Seeking Alpha,https://seekingalpha.com/news/3710240-eli-lilly-covid-19-antibody-shipments-halted-in-the-us-citing-prevalence-of-variants?utm_source=markets.businessinsider.com&utm_medium=referral
1258.0,6/26/2021 10:15:00 PM,Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes,PR Newswire,/news/stocks/lilly-s-surpass-1-results-published-in-the-lancet-show-tirzepatide-s-superior-a1c-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes-1030556609
1259.0,6/27/2021 6:02:12 AM,"Eli Lilly, BioMarin and Seagen among top large-cap biopharma names at BofA",Seeking Alpha,https://seekingalpha.com/news/3710326-eli-lilly-biomarin-and-seagen-among-top-large-cap-biopharma-names-at-bofa?utm_source=markets.businessinsider.com&utm_medium=referral
1260.0,6/27/2021 6:55:52 PM,"The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus",Benzinga,/news/stocks/the-week-ahead-in-biotech-mediwound-provention-fda-decisions-ipos-pending-clinical-readouts-in-focus-1030556958
1261.0,6/28/2021 7:39:58 AM,Lilly's tirzepatide shows superior A1C and body weight reductions in late-stage diabetes study,Seeking Alpha,https://seekingalpha.com/news/3710338-lillys-tirzepatide-shows-superior-a1c-and-body-weight-reductions-in-late-stage-type-2-diabetes-study?utm_source=markets.businessinsider.com&utm_medium=referral
1262.0,6/28/2021 8:51:40 AM,"Lilly's tirzepatide showed superior blood glucose, weight reductions compared to semaglutide in SURPASS-2 trial",Seeking Alpha,https://seekingalpha.com/news/3710340-lillys-tirzepatide-showed-superior-blood-glucose-and-weight-reductions-compared-to-semaglutide-in-surpass-2-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1263.0,6/28/2021 10:41:55 AM,"Pre-market Movers: NTLA, ABUS, ATOS, GTEC... ",RTTNews,/news/stocks/pre-market-movers-ntla-abus-atos-gtec-1030557805
1264.0,6/29/2021 3:54:15 PM,Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3711042-lilly-and-regeneron-monoclonal-antibodies-among-preferred-therapies-in-eu-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1265.0,6/29/2021 4:20:34 PM,3 Better Alzheimer’s Drug Stocks to Buy Instead of Biogen,InvestorPlace,/news/stocks/3-better-alzheimers-drug-stocks-to-buy-instead-of-biogen-1030564044
1266.0,6/29/2021 6:02:16 PM,Walmart looks for healthcare advantage with insulin push,Seeking Alpha,https://seekingalpha.com/news/3711072-walmart-looks-for-healthcare-advantage-with-insulin-push?utm_source=markets.businessinsider.com&utm_medium=referral
1267.0,6/29/2021 10:27:00 PM,Lilly Declares Third-Quarter 2021 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2021-dividend-1030564583
1268.0,7/1/2021 6:50:48 PM,Eisai and Lilly among top H1 gainers in big pharma; Viatris and Merck trail,Seeking Alpha,https://seekingalpha.com/news/3712052-eisai-and-lilly-among-top-h1-gainers-in-big-pharma-as-viatris-and-merck-trail?utm_source=markets.businessinsider.com&utm_medium=referral
1269.0,7/1/2021 11:07:05 PM,Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-july-pdufa-dates-1030573631
1270.0,7/2/2021 4:27:11 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1030575765
1271.0,7/2/2021 7:06:16 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030576232
1272.0,7/4/2021 2:00:00 PM,"Pharmas, payers to meet at Duke to hash out how to pay for Alzheimer's drugs - Endpoints",Seeking Alpha,https://seekingalpha.com/news/3712734-pharmas-payers-to-meet-at-duke-to-hash-out-how-to-pay-for-alzheimers-drugs-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral
1273.0,7/6/2021 11:20:35 AM,Lilly's Jardiance successful in late-stage EMPEROR-Preserved trial for cardiovascular diseaase,Seeking Alpha,https://seekingalpha.com/news/3712811-lillys-jardiance-successful-in-late-stage-emperor-preserved-trial-for-cardiovascular-diseaase?utm_source=markets.businessinsider.com&utm_medium=referral
1274.0,7/6/2021 12:25:00 PM,Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction,PR Newswire,/news/stocks/breakthrough-results-for-jardiance-empagliflozin-confirm-emperor-preserved-as-first-and-only-successful-trial-for-heart-failure-with-preserved-ejection-fraction-1030581158
1275.0,7/6/2021 12:55:24 PM,Eli Lilly Says EMPEROR-Preserved Phase III Trial Of Jardiance Met Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-emperor-preserved-phase-iii-trial-of-jardiance-met-primary-endpoint-quick-facts-1030581226
1276.0,7/7/2021 10:49:38 AM,Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year,Seeking Alpha,https://seekingalpha.com/news/3713185-mid-size-pharmaceutical-firms-lead-bigger-rivals-in-acquisitions-this-year?utm_source=markets.businessinsider.com&utm_medium=referral
1277.0,7/7/2021 8:05:41 PM,Big pharma outperforms smaller rivals to lead second quarter gains: Evaluate,Seeking Alpha,https://seekingalpha.com/news/3713436-big-pharma-outperforms-smaller-rivals-to-lead-second-quarter-gains-evaluate?utm_source=markets.businessinsider.com&utm_medium=referral
1278.0,7/8/2021 11:20:05 AM,Eli Lilly in pact with Verge Genomics for treatments in amyotrophic lateral sclerosis,Seeking Alpha,https://seekingalpha.com/news/3713541-eli-lilly-in-pact-with-verge-genomics-for-treatments-in-amyotrophic-lateral-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral
1279.0,7/8/2021 1:45:17 PM,"The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test",Benzinga,/news/stocks/the-daily-biotech-pulse-priority-review-for-amgen-s-asthma-treatment-evaxion-reports-positive-skin-cancer-readout-quidel-recalls-lyra-covid-19-test-1030589266
1280.0,7/8/2021 7:38:27 PM,"House Oversight report says pharmas spend more on buybacks, dividends than R&D",Seeking Alpha,https://seekingalpha.com/news/3713778-house-oversight-report-says-pharmas-spend-more-on-buybacks-dividends-than-research-development?utm_source=markets.businessinsider.com&utm_medium=referral
1281.0,7/9/2021 11:16:57 AM,Lilly's mirikizumab up-regulates genes related with mucosal healing in UC for up to one year,Seeking Alpha,https://seekingalpha.com/news/3713912-lillys-mirikizumab-up-regulates-genes-related-with-mucosal-healing-in-uc-for-up-to-one-year?utm_source=markets.businessinsider.com&utm_medium=referral
1282.0,7/9/2021 12:31:00 PM,Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study,PR Newswire,/news/stocks/mirikizumab-up-regulates-genes-associated-with-mucosal-healing-in-ulcerative-colitis-for-up-to-one-year-in-phase-2-study-1030592567
1283.0,7/9/2021 1:24:08 PM,Lilly: Mirikizumab In Trial Up-Regulates Genes Associated With Mucosal Healing In UC For Upto 1 Year ,RTTNews,/news/stocks/lilly-mirikizumab-in-trial-up-regulates-genes-associated-with-mucosal-healing-in-uc-for-upto-1-year-1030592704
1284.0,7/9/2021 1:36:16 PM,"The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-morphic-s-positive-data-at-ecco-humanigen-s-covid-treatment-gets-expedited-review-in-uk-transcode-ipo-1030592766
1285.0,7/9/2021 6:39:01 PM,"Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714076-biogen-fda-probe-on-alzheimers-drug-unlikely-to-have-tangible-impact-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral
1286.0,7/14/2021 10:57:55 AM,Lilly acquires Protomer Technologies for potential deal value of more than $1B,Seeking Alpha,https://seekingalpha.com/news/3715004-lilly-acquires-protomer-technologies?utm_source=markets.businessinsider.com&utm_medium=referral
1287.0,7/14/2021 12:45:00 PM,Lilly Announces Acquisition of Protomer Technologies,PR Newswire,/news/stocks/lilly-announces-acquisition-of-protomer-technologies-1030605671
1288.0,7/14/2021 1:37:11 PM,Eli Lilly Buys Protomer Technologies For Value That Could Be Above $1 Bln ,RTTNews,/news/stocks/eli-lilly-buys-protomer-technologies-for-value-that-could-be-above-1-bln-1030605961
1289.0,7/14/2021 1:48:12 PM,"The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues",Benzinga,/news/stocks/the-daily-biotech-pulse-scpharma-s-positive-data-lilly-goes-shopping-lemaitre-pre-announces-q2-revenues-1030605990
1290.0,7/15/2021 2:22:54 PM,Eli Lilly in pact with Banner Alzheimer's Institute for donanemab late-stage trial,Seeking Alpha,https://seekingalpha.com/news/3715574-eli-lilly-in-pact-with-banner-alzheimers-institute-for-donanemab-late-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1291.0,7/15/2021 2:38:54 PM,"FDA, Alzheimer's stakeholders look at expediting post-marketing confirmatory trials",Seeking Alpha,https://seekingalpha.com/news/3715573-fda-alzheimers-stakeholders-look-at-expediting-post-marketing-confirmatory-trials?utm_source=markets.businessinsider.com&utm_medium=referral
1292.0,7/15/2021 4:00:00 PM,Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab,PR Newswire,/news/stocks/lilly-and-banner-alzheimer-s-institute-collaborate-on-planned-phase-3-prevention-trial-of-donanemab-1030611798
1293.0,7/15/2021 4:28:56 PM,"Lilly, Banner Alzheimer's Institute Collaborate On Phase 3 Trial Of Donanemab On Alzheimer's Disease ",RTTNews,/news/stocks/lilly-banner-alzheimer-s-institute-collaborate-on-phase-3-trial-of-donanemab-on-alzheimer-s-disease-1030611987
1294.0,7/16/2021 2:09:18 PM,Lilly and Incyte provide update on FDA regulatory timeline for baricitinib,Seeking Alpha,https://seekingalpha.com/news/3715993-lilly-and-incyte-provide-update-on-fda-regulatory-timeline-for-baricitinib?utm_source=markets.businessinsider.com&utm_medium=referral
1295.0,7/16/2021 4:00:00 PM,Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis,PR Newswire,/news/stocks/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-1030615435
1296.0,7/16/2021 4:33:50 PM,Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis ,RTTNews,/news/stocks/lilly-fda-delays-review-of-baricitinib-snda-on-atopic-dermatitis-1030615528
1297.0,7/18/2021 4:25:56 PM,"The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-earnings-kickstart-with-j-j-and-biogen-albireo-awaits-fda-decisions-more-ipos-1030617574
1298.0,7/20/2021 3:09:13 AM,Common cholesterol drugs may lower death risk from COVID-19,Seeking Alpha,https://seekingalpha.com/news/3716662-common-cholesterol-drugs-statins-may-lower-death-risk-from-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1299.0,7/22/2021 4:00:00 PM,Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-second-quarter-2021-financial-results-announcement-1030635625
1300.0,7/23/2021 1:45:07 PM,"The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-acorda-spikes-on-distribution-deal-alzamend-soars-on-data-pfizer-biontech-to-supply-more-vaccine-doses-3-ipos-1030638740
1301.0,7/27/2021 1:48:33 PM,"The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-obseva-surges-on-out-licensing-deal-eyegate-appoints-new-ceo-2-positive-catalysts-for-merck-candel-therapeutics-debuts-1030649705
1302.0,7/29/2021 12:45:00 PM,Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses,PR Newswire,/news/stocks/lilly-and-kumquat-biosciences-announce-collaboration-to-discover-and-develop-novel-small-molecules-that-stimulate-tumor-specific-immune-responses-1030661500
1303.0,7/29/2021 1:28:19 PM,"Eli Lilly, Kumquat in immuno-oncology collaboration potentially worth more than $2B",Seeking Alpha,https://seekingalpha.com/news/3721524-eli-lilly-kumquat-in-immuno-oncology-collaboration-potentially-worth-more-than-2b?utm_source=markets.businessinsider.com&utm_medium=referral
1304.0,7/29/2021 1:55:42 PM,"Lilly, Kumquat To Develop Novel Small Molecules That Stimulate Tumor-Specific Immune Responses ",RTTNews,/news/stocks/lilly-kumquat-to-develop-novel-small-molecules-that-stimulate-tumor-specific-immune-responses-1030661995
1305.0,7/29/2021 1:59:04 PM,"FDA broadens EUA for Lilly, Incyte's baricitinib for COVID-19",Seeking Alpha,https://seekingalpha.com/news/3721602-fda-broadens-eua-for-lilly-incytes-baricitinib-olumiant-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1306.0,7/29/2021 3:26:00 PM,FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen,PR Newswire,/news/stocks/fda-broadens-existing-emergency-use-of-lilly-and-incyte-s-baricitinib-in-patients-hospitalized-with-covid-19-requiring-oxygen-1030662816
1307.0,7/29/2021 3:45:21 PM,Lilly : FDA Broadens Emergency Use Of Baricitinib In Patients Hospitalized With COVID-19 ,RTTNews,/news/stocks/lilly-fda-broadens-emergency-use-of-baricitinib-in-patients-hospitalized-with-covid-19-1030662943
1308.0,7/29/2021 7:35:13 PM,Eli Lilly releases data showing potential of donanemab in lowering Alzheimer’s pathology,Seeking Alpha,https://seekingalpha.com/news/3721791-eli-lilly-releases-data-showing-potential-of-donanemab-in-lowering-alzheimers-pathology?utm_source=markets.businessinsider.com&utm_medium=referral
1309.0,7/29/2021 9:00:00 PM,Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline,PR Newswire,/news/stocks/lilly-releases-donanemab-data-that-demonstrated-relationship-between-reduction-of-amyloid-plaque-and-slowing-of-cognitive-decline-1030664072
1310.0,7/30/2021 5:21:53 PM,Biogen: Does Aduhelm Make it the Next Dendreon?,InvestorPlace,/news/stocks/biib-stock-does-aduhelm-make-it-the-next-dendreon-1030669123
1311.0,8/1/2021 3:01:51 PM,Eli Lilly and earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-stock-quarter-earnings-preview-q2-1030671386
1312.0,8/2/2021 10:00:07 AM,Investors Should Avoid High-Risk Atossa Therapeutics,InvestorPlace,/news/stocks/investors-should-avoid-high-risk-atos-stock-1030675492
1313.0,8/2/2021 2:02:49 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3722982-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1314.0,8/3/2021 10:31:12 AM,"Eli Lilly EPS misses by $0.02, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3723637-eli-lilly-eps-misses-0_02-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
1315.0,8/3/2021 10:53:35 AM,"Eli Lilly posts Q2 topline beat on Trulicity, Humalog strength; updates FY forecast",Seeking Alpha,https://seekingalpha.com/news/3723669-eli-lilly-posts-q2-topline-beat-on-trulicity-humalog-strength-updates-fy-forecast?utm_source=markets.businessinsider.com&utm_medium=referral
1316.0,8/3/2021 10:55:42 AM,"Lilly, Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation",Seeking Alpha,https://seekingalpha.com/news/3723668-lilly-incytes-baricitinib-reduces-deaths-among-covid-19-patients-on-mechanical-ventilation?utm_source=markets.businessinsider.com&utm_medium=referral
1317.0,8/3/2021 12:00:00 PM,Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation,PR Newswire,/news/stocks/lilly-and-incyte-s-baricitinib-reduced-deaths-among-patients-with-covid-19-receiving-invasive-mechanical-ventilation-1030681949
1318.0,8/3/2021 12:25:00 PM,"Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance",PR Newswire,/news/stocks/lilly-delivers-strong-second-quarter-2021-financial-results-updates-2021-financial-guidance-1030682047
1319.0,8/3/2021 12:28:52 PM,Eli Lilly And Co. Q2 adjusted earnings of $1.87 per share,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-of-1-87-per-share-1030682051
1320.0,8/3/2021 12:36:53 PM,"Lilly, Incyte: Baricitinib Reduced Deaths In COVID-19 Patients Under Invasive Mechanical Ventilation ",RTTNews,/news/stocks/lilly-incyte-baricitinib-reduced-deaths-in-covid-19-patients-under-invasive-mechanical-ventilation-1030682109
1321.0,8/3/2021 1:19:34 PM,"Lilly Q2 Profit Down; Cuts FY21 EPS, Margin View; Backs Adj. Earnings Forecast ",RTTNews,/news/stocks/lilly-q2-profit-down-cuts-fy21-eps-margin-view-backs-adj-earnings-forecast-1030682446
1322.0,8/3/2021 1:55:12 PM,"The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-buys-translate-bio-in-3-2b-deal-lilly-s-q2-earnings-disappoint-bausch-to-spin-off-medical-aesthetics-business-1030682672
1323.0,8/3/2021 8:07:45 PM,"4 Top Stock Trades for Wednesday: Ethereum, Bitcoin, LLY, HOOD",InvestorPlace,/news/stocks/4-top-stock-trades-for-wednesday-ethereum-bitcoin-lly-hood-1030685426
1324.0,8/4/2021 1:52:10 PM,"The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-s-positive-readout-nrx-strikes-r-d-collaboration-with-mannkind-cerus-invitae-jump-on-earnings-1030688766
1325.0,8/4/2021 4:40:12 PM,"Eisai, Biogen will push for fast approval of another Alzheimer's candidate, lecanemab",Seeking Alpha,https://seekingalpha.com/news/3725115-eisai-biogen-will-push-for-fast-approval-of-another-alzheimers-candidate-lecanemab?utm_source=markets.businessinsider.com&utm_medium=referral
1326.0,8/5/2021 2:07:56 PM,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-positive-keytruda-readout-moderna-slips-despite-q2-beat-bayer-to-buy-vividion-for-up-to-2b-glycomimetics-gets-new-ceo-1030695873
1327.0,8/5/2021 4:07:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-august-5-2021-1030696756
1328.0,8/5/2021 6:19:51 PM,Analyst Ratings For Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1030697230
1329.0,8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral
1330.0,8/10/2021 1:55:36 PM,"The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-arcturus-soars-on-covid-19-vaccine-updates-merck-s-keytruda-on-track-for-more-label-expansions-eliem-debuts-1030712978
1331.0,8/13/2021 3:31:47 PM,AbCellera rises over 15% most since March despite revenue miss,Seeking Alpha,https://seekingalpha.com/news/3730374-abcellera-rises-over-15-most-since-march-despite-revenue-miss?utm_source=markets.businessinsider.com&utm_medium=referral
1332.0,8/16/2021 8:00:00 AM,Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials,PR Newswire,/news/stocks/lilly-s-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-phase-3-trials-1030733039
1333.0,8/16/2021 8:31:10 AM,"Lilly: Lebrikizumab Meets Primary, Secondary Goals In ADvocate 1, ADvocate 2 Phase 3 Trials ",RTTNews,/news/stocks/lilly-lebrikizumab-meets-primary-secondary-goals-in-advocate-1-advocate-2-phase-3-trials-1030733102
1334.0,8/16/2021 1:00:00 PM,FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps,PR Newswire,/news/stocks/fda-approves-lyumjev-insulin-lispro-aabc-injection-100-units-ml-for-use-in-insulin-pumps-1030733732
1335.0,8/16/2021 1:21:46 PM,FDA Approves Pump Use For Lilly's Insulin ,RTTNews,/news/stocks/fda-approves-pump-use-for-lilly-s-insulin-1030733801
1336.0,8/17/2021 12:30:00 PM,Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units,PR Newswire,/news/stocks/lilly-announces-leadership-changes-and-formation-of-neuroscience-and-immunology-business-units-1030737422
1337.0,8/17/2021 1:09:38 PM,Eli Lilly Creates Separate Divisions For Neuroscience And Immunology - Quick Facts ,RTTNews,/news/stocks/eli-lilly-creates-separate-divisions-for-neuroscience-and-immunology-quick-facts-1030737607
1338.0,8/17/2021 2:28:53 PM,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-reorganizes-business-units-in-neuroscience-focus-helius-medical-spikes-on-breakthrough-designation-ra-medical-sells-dermatology-business-1030738023
1339.0,8/18/2021 1:37:56 PM,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",Benzinga,/news/stocks/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-for-priority-review-fda-nod-for-glaxosmithkline-1030741574
1340.0,8/18/2021 7:30:00 PM,US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction,PR Newswire,/news/stocks/us-fda-approves-jardiance-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction-1030743128
1341.0,8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral
1342.0,8/20/2021 12:12:31 PM,Spotify To Buy Back Up To $1.0 Bln Of Stock ,RTTNews,/news/stocks/spotify-to-buy-back-up-to-1-0-bln-of-stock-1030748433
1343.0,8/22/2021 3:01:25 PM,"The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-cara-fda-decision-ascendis-earnings-aileron-data-presentation-and-more-1030750711
1344.0,8/23/2021 1:27:52 PM,COVID-19 vaccinations pick up as some states face with a ‘tsunami of patients’,Seeking Alpha,https://seekingalpha.com/news/3733039-covid-19-vaccinations-pick-up-as-some-states-face-with-a-tsunami-of-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1345.0,8/23/2021 2:15:21 PM,Medigen Vaccine Biologics Announces Rollout Of COVID-19 Vaccine In Taiwan ,RTTNews,/news/stocks/medigen-vaccine-biologics-announces-rollout-of-covid-19-vaccine-in-taiwan-1030752207
1346.0,8/25/2021 12:45:00 PM,Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders,PR Newswire,/news/stocks/lilly-and-lycia-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-novel-lysosomal-targeting-chimera-lytac-degraders-1030757201
1347.0,8/25/2021 12:45:00 PM,Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors,PR Newswire,/news/stocks/lilly-announces-that-professor-carolyn-bertozzi-has-resigned-from-its-board-of-directors-1030757200
1348.0,8/25/2021 12:58:14 PM,Lilly Says Carolyn Bertozzi Resigns From Board - Quick Facts ,RTTNews,/news/stocks/lilly-says-carolyn-bertozzi-resigns-from-board-quick-facts-1030757231
1349.0,8/25/2021 1:07:21 PM,Eli Lilly To Utilize Lycia's LYTAC Platform To Treat Challenging Disease Areas ,RTTNews,/news/stocks/eli-lilly-to-utilize-lycia-s-lytac-platform-to-treat-challenging-disease-areas-1030757293
1350.0,8/25/2021 1:30:14 PM,"The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-strikes-1-6b-r-d-collaboration-fsd-pulls-plug-on-covid-19-program-cassava-sinks-on-questions-about-alzheimer-s-drug-1030757345
1351.0,8/27/2021 1:06:42 PM,"CBO: Drug pricing bill could stymie pharma, biotech R&D",Seeking Alpha,https://seekingalpha.com/news/3734838-cbo-drug-pricing-bill-could-stymie-pharma-biotech-research-development?utm_source=markets.businessinsider.com&utm_medium=referral
1352.0,8/27/2021 5:25:00 PM,Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction,PR Newswire,/news/stocks/landmark-trial-demonstrates-jardiance-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction-1030763952
1353.0,8/30/2021 12:22:55 PM,"A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs",Benzinga,/news/stocks/a-peek-into-the-markets-us-stock-futures-edge-higher-after-s-p-500-nasdaq-hit-record-highs-1030766402
1354.0,8/30/2021 7:06:05 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030767628
1355.0,8/31/2021 8:00:00 PM,Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference,PR Newswire,/news/stocks/lilly-to-participate-in-citi-s-16th-annual-biopharma-virtual-conference-1030770980
1356.0,9/1/2021 2:21:43 PM,Avidity Biosciences drops over 10% on resignation of chief medical officer,Seeking Alpha,https://seekingalpha.com/news/3736123-avidity-biosciences-drops-over-10-on-resignation-of-chief-medical-officer?utm_source=markets.businessinsider.com&utm_medium=referral
1357.0,9/1/2021 3:50:24 PM,Healthcare groups ask Democrats to back drug pricing reforms in reconciliation package,Seeking Alpha,https://seekingalpha.com/news/3736163-healthcare-groups-ask-democrats-to-back-drug-pricing-reforms-in-reconciliation-package?utm_source=markets.businessinsider.com&utm_medium=referral
1358.0,9/3/2021 4:00:00 PM,Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-1030779892
1359.0,9/3/2021 4:17:20 PM,AbCellera Biologics gains as COVID-19 antibody shipments resume,Seeking Alpha,https://seekingalpha.com/news/3737227-abcellera-biologics-gains-as-covid-19-antibody-shipments-resume?utm_source=markets.businessinsider.com&utm_medium=referral
1360.0,9/3/2021 6:50:43 PM,Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal,Benzinga,/news/stocks/wall-street-crime-and-punishment-martha-stewart-s-perfectly-ridiculous-stock-scandal-1030780207
1361.0,9/7/2021 12:00:00 PM,Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities,PR Newswire,/news/stocks/lilly-announces-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-1030783374
1362.0,9/7/2021 12:16:34 PM,Eli Lilly Begins Cash Tender Offer Of Specified Series Of Outstanding Debt Securities ,RTTNews,/news/stocks/eli-lilly-begins-cash-tender-offer-of-specified-series-of-outstanding-debt-securities-1030783447
1363.0,9/7/2021 3:00:00 PM,"Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to ""Type 1 Diabetes Camps Initiative""",PR Newswire,/news/stocks/lilly-diabetes-joins-the-leona-m-and-harry-b-helmsley-charitable-trust-to-pledge-significant-funding-to-type-1-diabetes-camps-initiative-1030784208
1364.0,9/8/2021 12:07:00 PM,Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-rates-eli-lilly-s-notes-a2-stable-outlook-1030786393
1365.0,9/8/2021 8:09:21 PM,ProQR Therapeutics teams up with Eli Lilly in potential $1.25B research collaboration,Seeking Alpha,https://seekingalpha.com/news/3738081-proqr-therapeutics-teams-up-with-eli-lilly-in-potential-125b-research-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral
1366.0,9/8/2021 9:13:32 PM,BeyondSpring gains as Baird sees FDA approval for its lead asset,Seeking Alpha,https://seekingalpha.com/news/3738143-beyondspring-gains-as-baird-sees-fda-approval-for-its-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral
1367.0,9/9/2021 11:24:06 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-sept-9-1030789643
1368.0,9/9/2021 12:58:03 PM,"Eli Lilly Inks Another RNA Collab, This Time With ProQR",Benzinga,/news/stocks/eli-lilly-inks-another-rna-collab-this-time-with-proqr-1030789543
1369.0,9/9/2021 2:00:00 PM,FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction,PR Newswire,/news/stocks/fda-grants-jardiance-breakthrough-therapy-designation-for-heart-failure-with-preserved-ejection-fraction-1030789842
1370.0,9/9/2021 2:17:07 PM,"The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization",Benzinga,/news/stocks/the-daily-biotech-pulse-proqr-lilly-r-d-partnership-sanofi-s-pemphigus-trial-disappointment-humanigen-s-covid-19-drug-denied-emergency-use-authorization-1030789942
1371.0,9/9/2021 2:46:51 PM,Eli Lilly Reports Breakthrough Therapy Designation For Jardiance - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-breakthrough-therapy-designation-for-jardiance-quick-facts-1030790074
1372.0,9/9/2021 8:00:00 PM,Lilly Prices First Sustainability Bond to Advance Global ESG Strategy,PR Newswire,/news/stocks/lilly-prices-first-sustainability-bond-to-advance-global-esg-strategy-1030791057
1373.0,9/10/2021 12:08:22 AM,Baird Initiates BeyondSpring With Outperform On Plinabulin Potential,Benzinga,/news/stocks/baird-initiates-beyondspring-with-outperform-on-plinabulin-potential-1030791416
1374.0,9/13/2021 2:00:00 PM,Lilly to Present New Data from Oncology Portfolio at ESMO Congress,PR Newswire,/news/stocks/lilly-to-present-new-data-from-oncology-portfolio-at-esmo-congress-1030795660
1375.0,9/13/2021 4:00:00 PM,Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-1030796058
1376.0,9/15/2021 12:45:00 PM,"Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19",PR Newswire,/news/stocks/lilly-to-supply-388-000-doses-of-etesevimab-to-u-s-government-for-treatment-of-covid-19-1030801008
1377.0,9/15/2021 1:04:48 PM,"Lilly To Supply 388,000 Doses Of Etesevimab To U.S. For Treatment Of COVID-19 ",RTTNews,/news/stocks/lilly-to-supply-388-000-doses-of-etesevimab-to-u-s-for-treatment-of-covid-19-1030801074
1378.0,9/15/2021 1:38:39 PM,"The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-calliditas-theravance-to-cut-75-jobs-4-ipos-1030801226
1379.0,9/15/2021 8:23:34 PM,Narrower drug pricing bill introduced in House by centrist Democrats,Seeking Alpha,https://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats?utm_source=markets.businessinsider.com&utm_medium=referral
1380.0,9/15/2021 9:20:09 PM,House committee approves portion of spending package that includes drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?utm_source=markets.businessinsider.com&utm_medium=referral
1381.0,9/16/2021 9:56:00 PM,Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19,PR Newswire,/news/stocks/emergency-use-authorization-for-lilly-s-bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-covid-19-1030805731
1382.0,9/16/2021 11:26:24 PM,"FDA Expands EUA For Lilly's Bamlanivimab, Etesevimab To Include Post-exposure Prophylaxis For COVID ",RTTNews,/news/stocks/fda-expands-eua-for-lilly-s-bamlanivimab-etesevimab-to-include-post-exposure-prophylaxis-for-covid-1030805886
1383.0,9/17/2021 1:36:08 PM,"The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-tryst-for-pfizer-biontech-booster-shot-abcellera-s-covid-antibody-treatment-gets-expanded-use-protagonist-slapped-with-clinical-hold-1030806977
1384.0,9/17/2021 5:18:04 PM,"Powell, two Fed presidents owned securities the Fed was buying last year - CNBC",Seeking Alpha,https://seekingalpha.com/news/3740916-powell-two-fed-presidents-owned-securities-the-fed-was-buying-last-year?utm_source=markets.businessinsider.com&utm_medium=referral
1385.0,9/21/2021 1:00:00 PM,Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps...,PR Newswire,/news/stocks/lilly-announces-the-early-tender-results-of-its-pending-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-and-removal-of-the-note-caps-1030812258
1386.0,9/21/2021 7:37:00 PM,Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19,PR Newswire,/news/stocks/lilly-announces-procurement-agreement-with-european-commission-to-supply-bamlanivimab-and-etesevimab-together-for-the-treatment-of-confirmed-covid-19-1030813862
1387.0,9/21/2021 10:15:00 PM,Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities,PR Newswire,/news/stocks/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-1030814168
1388.0,9/25/2021 2:04:00 AM,Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency,PR Newswire,/news/stocks/eli-lilly-and-company-issues-voluntary-nationwide-recall-of-one-lot-of-glucagon-emergency-kit-due-to-loss-of-potency-1030822884
1389.0,9/27/2021 8:07:55 AM,Lilly Recalls One Lot Of GLUCAGON Emergency Kit ,RTTNews,/news/stocks/lilly-recalls-one-lot-of-glucagon-emergency-kit-1030824532
1390.0,9/27/2021 2:00:00 PM,New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary,PR Newswire,/news/stocks/new-data-from-verzenio-abemaciclib-monarche-study-to-be-featured-in-esmo-virtual-plenary-1030825427
1391.0,9/28/2021 12:30:00 PM,Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options,PR Newswire,/news/stocks/lilly-again-reduces-list-price-of-insulin-lispro-injection-as-latest-change-to-affordability-options-1030827465
1392.0,9/28/2021 12:59:27 PM,"Lilly Cuts List Price Of Insulin Lispro Injection In U.S. Again, Effective Jan. 1 ",RTTNews,/news/stocks/lilly-cuts-list-price-of-insulin-lispro-injection-in-u-s-again-effective-jan-1-1030827509
1393.0,9/28/2021 7:30:23 PM,7 Biotech Stocks Entering the Golden Boom Phase,InvestorPlace,/news/stocks/7-biotech-stocks-entering-the-golden-boom-phase-1030829968
1394.0,9/28/2021 11:45:00 PM,FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy,PR Newswire,/news/stocks/fda-expands-lilly-s-erbitux-cetuximab-label-with-combination-of-braftovi-encorafenib-for-the-treatment-of-braf-v600e-mutation-positive-metastatic-colorectal-cancer-crc-after-prior-therapy-1030829222
1395.0,9/29/2021 4:27:13 AM,FDA Expands Lilly's Erbitux Label With Braftovi For Treatment Of Metastatic Colorectal Cancer ,RTTNews,/news/stocks/fda-expands-lilly-s-erbitux-label-with-braftovi-for-treatment-of-metastatic-colorectal-cancer-1030829333
1396.0,9/29/2021 1:36:38 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1030830738
1397.0,9/29/2021 2:13:41 PM,"The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-abbvie-s-migraine-drug-ok-d-by-fda-amicus-spins-off-gene-therapy-business-geovax-in-licenses-cancer-drug-1030831016
1398.0,9/29/2021 4:00:00 PM,Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women,PR Newswire,/news/stocks/lilly-and-susan-g-komen-partner-to-address-disparities-in-breast-cancer-outcomes-experienced-by-black-women-1030831411
1399.0,9/29/2021 4:11:58 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-29-2021-1030831447
1400.0,9/29/2021 9:09:33 PM,Why Eli Lilly Shares Are Moving Higher Today,Benzinga,/news/stocks/why-eli-lilly-shares-are-moving-higher-today-1030832108
1401.0,9/29/2021 10:30:09 PM,Citi Upgrades This Big Pharma Stock On Positive Alzheimer's Expectations,Benzinga,/news/stocks/citi-upgrades-this-big-pharma-stock-on-positive-alzheimer-s-expectations-1030832239
1402.0,9/30/2021 10:30:00 AM,Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study,PR Newswire,/news/stocks/lilly-s-tirzepatide-led-to-greater-time-in-range-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-surpass-3-cgm-sub-study-1030833217
1403.0,9/30/2021 10:40:00 AM,Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study,PR Newswire,/news/stocks/lilly-s-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-surpass-3-mri-sub-study-1030833229
1404.0,9/30/2021 11:37:54 AM,Lilly Reports Positive Results From Two SURPASS-3 Sub-studies Of Tirzepatide In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-reports-positive-results-from-two-surpass-3-sub-studies-of-tirzepatide-in-type-2-diabetes-1030833366
1405.0,9/30/2021 11:56:00 AM,OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata,PR Newswire,/news/stocks/olumiant-significantly-improved-hair-regrowth-to-at-least-80-scalp-coverage-as-early-as-24-weeks-across-first-completed-phase-3-studies-for-alopecia-areata-1030833394
1406.0,9/30/2021 12:40:08 PM,"Lilly, Incyte Present Detailed Results From OLUMIANT BRAVE-AA1, BRAVE-AA2 Trials In Alopecia Areata ",RTTNews,/news/stocks/lilly-incyte-present-detailed-results-from-olumiant-brave-aa1-brave-aa2-trials-in-alopecia-areata-1030833516
1407.0,9/30/2021 1:43:13 PM,"The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-confirms-acceleron-purchase-regeneron-touts-covid-19-antibody-cocktail-data-takeda-in-licenses-huntington-s-disease-drug-1030833761
1408.0,9/30/2021 6:01:30 PM,House Judiciary Committee approves bill to expedite biosimilar drugs to market,Seeking Alpha,https://seekingalpha.com/news/3746703-house-judiciary-committee-approves-bill-to-expedite-biosimilar-drugs-to-market?utm_source=markets.businessinsider.com&utm_medium=referral
1409.0,10/1/2021 3:00:00 PM,"At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study",PR Newswire,/news/stocks/at-week-104-75-of-patients-with-ulcerative-colitis-taking-mirikizumab-maintained-symptomatic-remission-in-phase-2-study-1030837268
1410.0,10/4/2021 3:00:00 PM,Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals,PR Newswire,/news/stocks/ready-for-the-challenge-boehringer-ingelheim-and-eli-lilly-and-company-launch-first-ever-online-game-on-cardio-renal-metabolic-conditions-for-healthcare-professionals-1030840780
1411.0,10/7/2021 1:36:16 PM,Sonoco To Implement Price Increase For Uncoated Recycled Paperboard ,RTTNews,/news/stocks/sonoco-to-implement-price-increase-for-uncoated-recycled-paperboard-1030849920
1412.0,10/7/2021 3:00:00 PM,Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics,PR Newswire,/news/stocks/loxo-oncology-at-lilly-announces-details-of-presentations-at-2021-aacr-nci-eortc-virtual-international-conference-on-molecular-targets-and-cancer-therapeutics-1030850358
1413.0,10/11/2021 1:35:40 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030855838
1414.0,10/11/2021 4:51:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-11-2021-1030856429
1415.0,10/11/2021 7:03:01 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030856715
1416.0,10/12/2021 3:30:41 PM,COVAX Exercises Option To Purchase 176.5 Mln Addl Doses Of Moderna COVID-19 Vaccine In H1 2022 ,RTTNews,/news/stocks/covax-exercises-option-to-purchase-176-5-mln-addl-doses-of-moderna-covid-19-vaccine-in-h1-2022-1030859372
1417.0,10/12/2021 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2021-financial-results-announcement-1030859524
1418.0,10/13/2021 12:45:00 PM,FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer,PR Newswire,/news/stocks/fda-approves-verzenio-abemaciclib-as-the-first-and-only-cdk4-6-inhibitor-for-certain-people-with-hr-her2-high-risk-early-breast-cancer-1030862350
1419.0,10/13/2021 1:01:36 PM,Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer ,RTTNews,/news/stocks/eli-lilly-fda-approves-verzenio-in-adjuvant-treatment-of-hr-her2-early-breast-cancer-1030862398
1420.0,10/13/2021 1:46:14 PM,"The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-lilly-regulus-slumps-on-study-discontinuation-obseva-strikes-linzagolix-commercialization-deal-1030862589
1421.0,10/13/2021 8:24:22 PM,Agilent gets FDA companion diagnostic approval for Ki-67 IHC MIB-1 pharmDx,Seeking Alpha,https://seekingalpha.com/news/3752596-agilent-gets-fda-companion-diagnostic-approval-for-ki-67-ihc-mib-1-pharmdx?utm_source=markets.businessinsider.com&utm_medium=referral
1422.0,10/14/2021 5:15:16 PM,White House eyeing former FDA commissioner Robert Califf for FDA top spot -- WaPo,Seeking Alpha,https://seekingalpha.com/news/3752938-white-house-eyeing-former-commissioner-robert-califf-for-fda-top-spot-wapo?utm_source=markets.businessinsider.com&utm_medium=referral
1423.0,10/14/2021 7:30:00 PM,Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology,PR Newswire,/news/stocks/lilly-announces-updated-verzenio-abemaciclib-phase-3-monarche-trial-data-presented-at-esmo-virtual-plenary-and-simultaneously-published-in-the-annals-of-oncology-1030867519
1424.0,10/16/2021 10:15:09 PM,"Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-amazon-apple-chevron-citigroup-dell-and-more-1030870768
1425.0,10/18/2021 2:47:35 PM,Quest to provide companion diagnostic for Lilly's breast cancer drug Verzenio,Seeking Alpha,https://seekingalpha.com/news/3754112-quest-to-provide-companion-diagnostic-for-lillys-breast-cancer-drug-verzenio?utm_source=markets.businessinsider.com&utm_medium=referral
1426.0,10/18/2021 8:52:00 PM,Lilly Declares Fourth-Quarter 2021 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2021-dividend-1030874735
1427.0,10/19/2021 12:45:00 PM,Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk,PR Newswire,/news/stocks/tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk-1030876763
1428.0,10/19/2021 1:00:51 PM,Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-phase-3-tirzepatide-results-show-superior-a1c-and-body-weight-reductions-in-type-2-diabetes-1030876853
1429.0,10/19/2021 6:10:09 PM,Abbott Laboratories Q3 earnings preview and review,Seeking Alpha,https://seekingalpha.com/news/3755153-abbott-laboratories-q3-earnings-preview-and-review?utm_source=markets.businessinsider.com&utm_medium=referral
1430.0,10/19/2021 9:10:23 PM,3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat,Benzinga,/news/stocks/3-biopharma-stocks-to-watch-following-johnson-johnson-s-earnings-beat-1030878749
1431.0,10/20/2021 12:45:09 PM,"28 Stocks To Benefit From Inflation, According To Jim Cramer",Benzinga,/news/stocks/28-stocks-to-benefit-from-inflation-according-to-jim-cramer-1030881145
1432.0,10/24/2021 3:01:33 PM,What Wall Street expects from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-q3-quarterly-earnings-preview-stock-1030891515
1433.0,10/24/2021 3:02:41 PM,Eli Lilly hosts conference call for investors,Markets Insider Automation,/news/stocks/eli_lilly_conference-1029887223
1434.0,10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741
1435.0,10/25/2021 3:00:12 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3757513-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1436.0,10/26/2021 12:25:00 PM,Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential,PR Newswire,/news/stocks/lilly-reports-robust-third-quarter-2021-financial-results-as-pipeline-success-strengthens-future-growth-potential-1030898889
1437.0,10/26/2021 12:29:31 PM,Eli Lilly And Co. Profit Drops In Q3,RTTNews,/news/stocks/eli-lilly-and-co-profit-drops-in-q3-1030898896
1438.0,10/26/2021 1:08:46 PM,"Lilly Lifts FY21 Adj. EPS, Revenue View Above Market - Quick Facts ",RTTNews,/news/stocks/lilly-lifts-fy21-adj-eps-revenue-view-above-market-quick-facts-1030899109
1439.0,10/26/2021 2:30:47 PM,"The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-gains-on-vaccine-news-novartis-reports-q3-beat-adcom-reviews-authorization-of-pfizer-biontech-s-vaccine-for-children-1030899570
1440.0,10/26/2021 4:13:44 PM,Teva Pharmaceutical falls 6% on eve of Q3 earnings show,Seeking Alpha,https://seekingalpha.com/news/3758203-teva-pharmaceutical-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
1441.0,10/28/2021 1:15:01 PM,"Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022",Benzinga,/news/stocks/inventiva-plans-to-start-lanifibranor-combo-study-in-nash-diabetes-in-2022-1030909822
1442.0,10/28/2021 10:00:00 PM,Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology,PR Newswire,/news/stocks/additional-verzenio-abemaciclib-phase-3-monarche-trial-data-published-in-the-annals-of-oncology-1030911942
1443.0,10/30/2021 8:00:00 PM,"BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards",Seeking Alpha,https://seekingalpha.com/news/3761145-biontech-gsk-top-pharma-performers-in-october-bristol-amgen-biggest-laggards?utm_source=markets.businessinsider.com&utm_medium=referral
1444.0,11/1/2021 5:00:00 PM,Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bernstein-s-second-annual-operational-decisions-conference-1030922462
1445.0,11/2/2021 11:28:40 AM,Eli Lilly gets additional U.S. government order for bamlanivimab/etesevimab combo,Seeking Alpha,https://seekingalpha.com/news/3762716-eli-lilly-gets-additional-us-government-order-for-bamlanivimabetesevimab-combo?utm_source=markets.businessinsider.com&utm_medium=referral
1446.0,11/2/2021 11:45:00 AM,"Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19",PR Newswire,/news/stocks/lilly-to-supply-614-000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-u-s-government-for-the-treatment-or-post-exposure-prevention-of-covid-19-1030925254
1447.0,11/2/2021 12:52:53 PM,"The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-solid-q3-earnings-regulatory-setback-for-legend-lilly-to-supply-additional-covid-19-antibody-cocktails-to-us-1030925781
1448.0,11/2/2021 1:23:24 PM,Lilly To Supply 614K Additional Doses Of Bamlanivimab And Etesevimab To The US ,RTTNews,/news/stocks/lilly-to-supply-614k-additional-doses-of-bamlanivimab-and-etesevimab-to-the-us-1030926030
1449.0,11/2/2021 5:42:57 PM,Eli Lilly pulls rolling submission seeking EU nod for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3763177-eli-lilly-pulls-rolling-submission-seeking-eu-nod-for-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1450.0,11/3/2021 12:14:31 PM,Democrats finally hammer out prescription drug pricing plan,Seeking Alpha,https://seekingalpha.com/news/3763812-democrats-finally-hammer-out-prescription-drug-pricing-plan?utm_source=markets.businessinsider.com&utm_medium=referral
1451.0,11/4/2021 2:00:00 PM,Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting,PR Newswire,/news/stocks/loxo-oncology-at-lilly-announces-details-of-presentations-at-the-2021-american-society-of-hematology-ash-annual-meeting-1030937395
1452.0,11/5/2021 8:00:00 PM,Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status,PR Newswire,/news/stocks/jardiance-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status-1030943568
1453.0,11/9/2021 2:30:00 PM,"OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis",PR Newswire,/news/stocks/olumiant-long-term-safety-profile-established-up-to-9-3-years-in-integrated-analysis-of-more-than-3-700-patients-with-rheumatoid-arthritis-1030953796
1454.0,11/9/2021 8:00:00 PM,Lilly to Participate in Wolfe Research Virtual Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-wolfe-research-virtual-healthcare-conference-1030955245
1455.0,11/11/2021 2:30:00 PM,"Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care",PR Newswire,/news/stocks/lilly-announces-winners-of-inaugural-leonard-award-a-global-program-celebrating-100-years-of-innovation-in-diabetes-care-1030965166
1456.0,11/11/2021 7:30:00 PM,US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction,PR Newswire,/news/stocks/us-fda-accepts-supplemental-new-drug-application-and-grants-priority-review-for-jardiance-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction-1030966505
1457.0,11/11/2021 8:01:30 PM,Eli Lilly - Boehringer Ingelheim granted FDA’s priority review for heart failure drug,Seeking Alpha,https://seekingalpha.com/news/3769661-eli-lilly-boehringer-ingelheim-granted-fdas-priority-review-for-heart-failure-drug?utm_source=markets.businessinsider.com&utm_medium=referral
1458.0,11/16/2021 2:04:33 PM,Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower,Seeking Alpha,https://seekingalpha.com/news/3771400-pfizer-moves-to-allow-cheaper-covid-19-pills-sending-shares-of-rivals-lower?utm_source=markets.businessinsider.com&utm_medium=referral
1459.0,11/17/2021 1:24:59 PM,Jim Cramer Likes This Stock Over Cassava Sciences And Biogen,Benzinga,/news/stocks/jim-cramer-likes-this-stock-over-cassava-sciences-and-biogen-1030983909
1460.0,11/17/2021 4:00:00 PM,Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/lilly-to-participate-in-fourth-annual-evercore-isi-healthconx-conference-1030984856
1461.0,11/18/2021 1:43:31 PM,Enrollment underway in Eli Lilly' Emgality vs. Nurtec ODT trial in migraine,Seeking Alpha,https://seekingalpha.com/news/3772399-enrollment-underway-in-eli-lilly-emgality-vs-nurtec-odt-trial-in-migraine?utm_source=markets.businessinsider.com&utm_medium=referral
1462.0,11/18/2021 2:00:00 PM,Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients,PR Newswire,/news/stocks/emgality-versus-nurtec-odt-head-to-head-migraine-preventive-treatment-study-now-enrolling-patients-1030987910
1463.0,11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825
1464.0,11/23/2021 7:18:02 PM,"Jim Cramer Weighs In On Cano Health, Moderna And More",Benzinga,/news/stocks/jim-cramer-weighs-in-on-cano-health-moderna-and-more-1030998921
1465.0,11/23/2021 10:28:21 PM,Eli Lilly and Company bags $525M US Army contract for combination therapeutic doses,Seeking Alpha,https://seekingalpha.com/news/3774061-eli-lilly-and-company-bags-535m-us-army-contract-for-combination-therapeutic-doses?utm_source=markets.businessinsider.com&utm_medium=referral
1466.0,11/29/2021 12:58:31 PM,Tetra Announces Positive Initial Data From Phase 2 Trials Of QIXLEEF For Cancer Pain ,RTTNews,/news/stocks/tetra-announces-positive-initial-data-from-phase-2-trials-of-qixleef-for-cancer-pain-1031008379
1467.0,11/29/2021 2:21:46 PM,"Moderna, Pfizer, and Adagio likely to benefit from Omicron variant - Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3774880-moderna-pfizer-and-adagio-likely-to-benefit-from-omicron-covid-variant-morgan-stanley?utm_source=markets.businessinsider.com&utm_medium=referral
1468.0,11/29/2021 6:58:45 PM,3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries,Benzinga,/news/stocks/3-pharma-stocks-morgan-stanley-says-will-be-omicron-variant-beneficiaries-1031009763
1469.0,11/29/2021 9:57:43 PM,ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential,InvestorPlace,/news/stocks/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential-1031010138
1470.0,11/30/2021 12:17:53 PM,Moderna CEO warns “material drop” in vaccine efficacy against new COVID-19 variant,Seeking Alpha,https://seekingalpha.com/news/3775258-moderna-ceo-warns-material-drop-in-vaccine-efficacy-against-new-covid-19-variant?utm_source=markets.businessinsider.com&utm_medium=referral
1471.0,12/1/2021 4:00:00 PM,Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting,PR Newswire,/news/stocks/lilly-to-announce-initial-2022-financial-guidance-provide-r-d-overview-at-investment-community-meeting-1031016499
1472.0,12/3/2021 1:40:11 PM,"The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-protagonist-pulls-plug-on-phase-1-asset-xenon-aces-mid-stage-epilepsy-study-esperion-prices-offering-1031022833
1473.0,12/3/2021 7:02:42 PM,House Oversight Committee schedules Dec. 9 hearing on prescription drug prices,Seeking Alpha,https://seekingalpha.com/news/3777032-house-oversight-committee-schedules-dec-9-hearing-on-prescription-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
1474.0,12/3/2021 7:59:59 PM,Eli Lilly COVID-19 antibody cocktail is now FDA authorized for use in newborns,Seeking Alpha,https://seekingalpha.com/news/3777059-eli-lilly-covid-19-antibody-cocktail-is-now-fda-authorized-for-use-in-newborns?utm_source=markets.businessinsider.com&utm_medium=referral
1475.0,12/3/2021 8:51:00 PM,Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12,PR Newswire,/news/stocks/lilly-s-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-covid-19-patients-under-the-age-of-12-1031023920
1476.0,12/3/2021 9:40:58 PM,AbCellera rises 9% after hours as beneficiary of COVID antibody cocktail EUA expansion,Seeking Alpha,https://seekingalpha.com/news/3777091-abcellera-rises-9-after-hours-as-beneficiary-of-covid-antibody-cocktail-eua-expansion?utm_source=markets.businessinsider.com&utm_medium=referral
1477.0,12/3/2021 9:43:36 PM,AbbVie updates U.S. labeling info for RINVOQ in rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3777094-abbvie-updates-us-labeling-info-for-rinvoq-in-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral
1478.0,12/6/2021 3:16:26 AM,FDA Expands Authorization For Lilly's COVID-19 Antibody Therapy To Include Young Children & Infants ,RTTNews,/news/stocks/fda-expands-authorization-for-lilly-s-covid-19-antibody-therapy-to-include-young-children-infants-1031024713
1479.0,12/6/2021 8:50:20 PM,Biden calls on Senate to pass legislation to tackle 'outrageously expensive' drug prices,Seeking Alpha,https://seekingalpha.com/news/3777526-biden-call-on-senate-to-pass-legislation-to-tackle-outrageously-expensive-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
1480.0,12/9/2021 1:38:59 PM,"AbbVie is Wells Fargo's top pick in large biotech, pharma sectors; sees 35% upside",Seeking Alpha,https://seekingalpha.com/news/3778670-abbvie-is-wells-fargo-top-pick-in-large-biotech-pharma-sectors-sees-35-upside?utm_source=markets.businessinsider.com&utm_medium=referral
1481.0,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161
1482.0,12/9/2021 4:29:00 PM,New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients,PR Newswire,/news/stocks/new-lilly-study-reveals-underappreciation-of-bowel-urgency-as-a-symptom-of-ulcerative-colitis-and-highlights-communication-gap-between-healthcare-providers-and-patients-1031036142
1483.0,12/10/2021 11:57:48 AM,Lilly collaborates with Regor Therapeutics to develop therapies for metabolic disorders,Seeking Alpha,https://seekingalpha.com/news/3779072-lilly-collaborates-with-regor-therapeutics-to-develop-therapies-for-metabolic-disorders?utm_source=markets.businessinsider.com&utm_medium=referral
1484.0,12/10/2021 12:30:00 PM,Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders,PR Newswire,/news/stocks/lilly-and-regor-therapeutics-group-enter-into-strategic-collaboration-to-discover-and-develop-novel-therapies-for-metabolic-disorders-1031038298
1485.0,12/10/2021 12:38:59 PM,"Lilly, Regor Collaborates To Discover & Develop Novel Therapies For Metabolic Disorders ",RTTNews,/news/stocks/lilly-regor-collaborates-to-discover-develop-novel-therapies-for-metabolic-disorders-1031038320
1486.0,12/10/2021 1:50:11 PM,"The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-sings-metabolic-disorder-drug-pact-moderna-reports-positive-flu-vaccine-data-halozyme-to-buy-back-shares-1031038565
1487.0,12/10/2021 8:00:40 PM,"Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings",Seeking Alpha,https://seekingalpha.com/news/3779254-catalyst-watch-for-next-week-fomc-drama-events-for-lowes-and-delta-air-lines-rivian-earnings?utm_source=markets.businessinsider.com&utm_medium=referral
1488.0,12/12/2021 3:30:00 PM,Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting,PR Newswire,/news/stocks/loxo-oncology-at-lilly-announces-updated-data-from-the-phase-1-2-bruin-clinical-trial-for-pirtobrutinib-at-the-american-society-of-hematology-annual-meeting-1031040264
1489.0,12/13/2021 8:48:32 AM,Lilly unit Loxo Oncology reports updated pirtobrutinib data from Phase 1/2 BRUIN trial at ASH2021,Seeking Alpha,https://seekingalpha.com/news/3779376-lilly-unit-loxo-oncology-reports-updated-pirtobrutinib-data-from-phase-12-bruin-trial-at-ash2021?utm_source=markets.businessinsider.com&utm_medium=referral
1490.0,12/13/2021 11:44:13 AM,Foghorn jumps 36% after collaborating with Lilly in oncology medicines,Seeking Alpha,https://seekingalpha.com/news/3779408-foghorn-jumps-36-after-collaborating-with-lilly-in-oncology-medicines?utm_source=markets.businessinsider.com&utm_medium=referral
1491.0,12/13/2021 12:00:00 PM,Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform,PR Newswire,/news/stocks/lilly-and-foghorn-announce-strategic-collaboration-for-novel-oncology-targets-using-foghorn-s-proprietary-gene-traffic-control-platform-1031045742
1492.0,12/13/2021 12:19:21 PM,Why Foghorn Therapeutics Is Rising In Pre-market? ,RTTNews,/news/stocks/why-foghorn-therapeutics-is-rising-in-pre-market-1031041276
1493.0,12/13/2021 12:31:03 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-december-13-1031041442
1494.0,12/13/2021 2:57:32 PM,Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly,Benzinga,/news/stocks/foghorn-therapeutics-stock-surges-after-1-5b-cancer-pact-with-eli-lilly-1031041669
1495.0,12/13/2021 4:02:55 PM,Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals,Benzinga,/news/stocks/mid-morning-market-update-markets-open-lower-pfizer-to-acquire-arena-pharmaceuticals-1031041800
1496.0,12/13/2021 7:08:16 PM,40 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/40-stocks-moving-in-monday-s-mid-day-session-1031042190
1497.0,12/13/2021 7:08:33 PM,Mid-Day Market Update: Nasdaq Drops Over 100 Points;  Foghorn Therapeutics Shares Surge,Benzinga,/news/stocks/mid-day-market-update-nasdaq-drops-over-100-points-foghorn-therapeutics-shares-surge-1031042189
1498.0,12/13/2021 8:36:34 PM,Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher,Benzinga,/news/stocks/mid-afternoon-market-update-dow-tumbles-over-200-points-bellus-health-shares-spike-higher-1031042273
1499.0,12/13/2021 8:39:59 PM,Eli Lilly raises dividend by 15% to $0.98,Seeking Alpha,https://seekingalpha.com/news/3779650-eli-lilly-raises-dividend-by-15-to-098?utm_source=markets.businessinsider.com&utm_medium=referral
1500.0,12/13/2021 8:41:07 PM,How Eli Lilly's potential ~$1.7B partnership with Foghorn bolsters its oncology portfolio,Seeking Alpha,https://seekingalpha.com/news/3779440-how-eli-lillys-17b-partnership-with-foghorn-bolsters-its-oncology-portfolio?utm_source=markets.businessinsider.com&utm_medium=referral
1501.0,12/13/2021 8:45:54 PM,FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn Today,InvestorPlace,/news/stocks/fhtx-stock-alert-7-things-to-know-about-the-partnership-lifting-foghorn-today-1031042345
1502.0,12/13/2021 9:35:00 PM,"Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend",PR Newswire,/news/stocks/lilly-announces-15-percent-dividend-increase-first-quarter-2022-dividend-1031046031
1503.0,12/14/2021 11:15:51 AM,59 Biggest Movers From Yesterday,Benzinga,/news/stocks/58-biggest-movers-from-yesterday-1031043167
1504.0,12/14/2021 12:35:38 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-dec-14-1031043500
1505.0,12/14/2021 4:27:45 PM,"Eli Lilly, Regeneron COVID-19 antibody therapies lose effectiveness against Omicron - study",Seeking Alpha,https://seekingalpha.com/news/3780004-eli-lilly-regeneron-covid-19-antibody-therapies-lose-effectiveness-against-omicron-study?utm_source=markets.businessinsider.com&utm_medium=referral
1506.0,12/14/2021 10:36:19 PM,Eli Lilly's mirikizumab meets primary endpoint in late-stage ulcerative colitis trial,Seeking Alpha,https://seekingalpha.com/news/3780169-eli-lilly-mirikizumab-meets-primary-endpoint-in-late-stage-ulcerative-colitis-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1507.0,12/14/2021 11:00:00 PM,"Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022",PR Newswire,/news/stocks/mirikizumab-demonstrates-superiority-over-placebo-in-phase-3-maintenance-study-in-ulcerative-colitis-supporting-regulatory-submissions-in-2022-1031046538
1508.0,12/15/2021 12:12:15 PM,Lilly gains 5% after providing financial guidance above consensus; raised 2021 outlook,Seeking Alpha,https://seekingalpha.com/news/3780258-lilly-gains-5-after-providing-financial-guidance-above-consensus-raised-2021-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
1509.0,12/15/2021 12:45:00 PM,Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting,PR Newswire,/news/stocks/lilly-highlights-innovation-based-growth-strategy-and-pipeline-developments-announces-2022-financial-guidance-at-investment-community-meeting-1031046703
1510.0,12/15/2021 1:15:13 PM,Eli Lilly Increases 2021 Adj. Earnings Guidance; Announces 2022 Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-increases-2021-adj-earnings-guidance-announces-2022-outlook-quick-facts-1031046822
1511.0,12/15/2021 3:44:01 PM,Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis ,RTTNews,/news/stocks/nektar-announces-positive-phase-1b-data-for-nktr-358-in-patients-with-atopic-dermatitis-1031047588
1512.0,12/15/2021 6:40:47 PM,36 Stocks Moving In Wednesday's Mid-Day Session,Benzinga,/news/stocks/36-stocks-moving-in-wednesday-s-mid-day-session-1031048166
1513.0,12/16/2021 10:42:57 AM,46 Biggest Movers From Yesterday,Benzinga,/news/stocks/46-biggest-movers-from-yesterday-1031049509
1514.0,12/16/2021 1:32:45 PM,Eli Lilly price target upped at Cantor following new closing high; sees 22% upside,Seeking Alpha,https://seekingalpha.com/news/3780737-eli-lilly-price-target-upped-at-cantor-following-new-closing-high-sees-22-upside?utm_source=markets.businessinsider.com&utm_medium=referral
1515.0,12/16/2021 8:22:33 PM,Cantor raises Pfizer price target ahead of company event highlighting COVID treatments,Seeking Alpha,https://seekingalpha.com/news/3781034-cantor-raises-pfizer-price-target-ahead-of-company-event-highlighting-covid-treatments?utm_source=markets.businessinsider.com&utm_medium=referral
1516.0,12/17/2021 3:37:09 PM,What 5 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-5-analyst-ratings-have-to-say-about-eli-lilly-1031053521
1517.0,12/17/2021 4:17:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-17-2021-1031053650
1518.0,12/20/2021 12:50:30 PM,5 Stocks Insiders Are Selling,Benzinga,/news/stocks/5-stocks-insiders-are-selling-1031055900
1519.0,12/21/2021 6:01:00 AM,Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study,PR Newswire,/news/stocks/lilly-s-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combined-with-topical-corticosteroids-in-people-with-atopic-dermatitis-in-third-phase-3-study-1031057941
1520.0,12/21/2021 7:15:30 AM,Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals ,RTTNews,/news/stocks/lilly-s-phase-3-study-of-lebrikizumab-in-atopic-dermatitis-meets-all-goals-1031058037
1521.0,12/21/2021 9:33:37 AM,Lilly's late-stage lebrikizumab study in atopic dermatitis met all endpoints,Seeking Alpha,https://seekingalpha.com/news/3782200-lillys-late-stage-lebrikizumab-study-in-atopic-dermatitis-met-all-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral
1522.0,12/23/2021 1:23:04 PM,Biogen price target cut at BofA on Japan refusing to approve Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3782992-biogen-price-target-cut-at-bofa-on-japan-refusing-to-approve-aduhelm-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral
1523.0,12/24/2021 11:06:44 AM,Innovent Biologics : China Accepts SNDA Of TYVYT On Lung-cancer ,RTTNews,/news/stocks/innovent-biologics-china-accepts-snda-of-tyvyt-on-lung-cancer-1031065384
1524.0,12/29/2021 11:00:41 AM,Stock Market Crash Coming? 7 Wall Street Pros Make Their Predictions,InvestorPlace,/news/stocks/stock-market-crash-coming-7-wall-street-pros-make-their-predictions-1031069368
1525.0,1/4/2022 1:18:53 PM,5 Stocks Insiders Are Selling,Benzinga,/news/stocks/5-stocks-insiders-are-selling-1031075865
1526.0,1/4/2022 7:12:11 PM,Califf FDA commissioner nomination to go before Senate Health Committee Jan. 12,Seeking Alpha,https://seekingalpha.com/news/3785167-califf-fda-commissioner-nomination-to-go-before-senate-health-committee-jan-12?utm_source=markets.businessinsider.com&utm_medium=referral
1527.0,1/6/2022 12:13:18 PM,Lilly collaborates with Entos Pharma to develop therapies in multiple neurologic indications,Seeking Alpha,https://seekingalpha.com/news/3785729-lilly-collaborates-with-entos-pharma-to-develop-therapies-in-multiple-neurologic-indications?utm_source=markets.businessinsider.com&utm_medium=referral
1528.0,1/6/2022 12:45:00 PM,Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications,PR Newswire,/news/stocks/lilly-and-entos-pharmaceuticals-enter-into-research-and-collaboration-agreement-to-support-the-development-of-innovative-therapies-in-multiple-neurologic-indications-1031081137
1529.0,1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342
1530.0,1/6/2022 1:36:56 PM,Lilly Buys Exclusive Rights Of Entos' Fusogenix Nucleic Acid Technology ,RTTNews,/news/stocks/lilly-buys-exclusive-rights-of-entos-fusogenix-nucleic-acid-technology-1031081273
1531.0,1/6/2022 2:24:12 PM,"The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-strikes-neurological-r-d-collaboration-valneva-confirms-vaccine-timelines-biohaven-gains-on-strong-migraine-drug-sales-1031081477
1532.0,1/6/2022 8:00:00 PM,Lilly to Participate in the J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-j-p-morgan-healthcare-conference-1031082374
1533.0,1/7/2022 6:17:06 PM,Biden administration to ask Congress for more COVID funding - WaPo,Seeking Alpha,https://seekingalpha.com/news/3786338-biden-administration-to-ask-congress-for-more-covid-funding?utm_source=markets.businessinsider.com&utm_medium=referral
1534.0,1/11/2022 4:43:14 PM,Two Lilly candidates make Clarivate 'drugs to watch'; total sales of $9B in 2026,Seeking Alpha,https://seekingalpha.com/news/3787184-two-lilly-candidates-make-clarivate-drugs-to-watch-total-sales-of-9b-2022?utm_source=markets.businessinsider.com&utm_medium=referral
1535.0,1/11/2022 4:43:14 PM,Three Lilly candidates make Clarivate 'drugs to watch'; total sales of $10.75B in 2026,Seeking Alpha,https://seekingalpha.com/news/3787184-three-lilly-candidates-make-clarivate-drugs-to-watch-total-sales-of-1075b-2022?utm_source=markets.businessinsider.com&utm_medium=referral
1536.0,1/11/2022 9:34:29 PM,Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall,Seeking Alpha,https://seekingalpha.com/news/3787286-cms-severely-limits-coverage-for-biogens-controversial-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral
1537.0,1/11/2022 9:52:04 PM,Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall,Seeking Alpha,https://seekingalpha.com/news/3787286-medicare-severely-limits-coverage-for-biogen-controversial-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral
1538.0,1/12/2022 11:00:23 AM,The 10 Best Performing Stocks in the S&P 500 for 2021,InvestorPlace,/news/stocks/the-10-best-performing-stocks-in-the-sp-500-for-2021-1031096258
1539.0,1/12/2022 12:25:56 PM,Biogen extends losses as Wall Street weighs in on Medicare decision on Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3787408-biogen-extends-losses-as-wall-street-weighs-in-on-medicare-decision-on-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral
1540.0,1/12/2022 8:20:01 PM,Vir extends gains as Needham lifts sales outlook for COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3787638-vir-extends-gains-as-needham-lifts-sales-outlook-for-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1541.0,1/13/2022 8:52:18 AM,Calls grow to treat COVID like an 'endemic' illness,Seeking Alpha,https://seekingalpha.com/news/3787737-calls-grow-to-treat-covid-like-an-endemic-illness?utm_source=markets.businessinsider.com&utm_medium=referral
1542.0,1/13/2022 2:52:59 PM,Why Jim Cramer Prefers This Mining Stock Over Vale,Benzinga,/news/stocks/why-jim-cramer-prefers-this-mining-stock-over-vale-1031100220
1543.0,1/13/2022 8:28:29 PM,Lilly's diabetes therapy Baqsimi gets coverage in all federal benefit programs in Canada,Seeking Alpha,https://seekingalpha.com/news/3788056-lillys-diabetes-therapy-baqsimi-gets-coverage-in-all-federal-benefit-programs-in-canada?utm_source=markets.businessinsider.com&utm_medium=referral
1544.0,1/14/2022 11:51:18 AM,Eli Lilly and GlaxoSmithKline/Vir COVID-19 therapies get WHO backing,Seeking Alpha,https://seekingalpha.com/news/3788201-eli-lilly-and-glaxosmithklinevir-covid-19-therapies-get-who-backing?utm_source=markets.businessinsider.com&utm_medium=referral
1545.0,1/14/2022 1:26:21 PM,Pieris Pharmaceuticals begins dosing in phase 2 gastric cancer study,Seeking Alpha,https://seekingalpha.com/news/3788254-pieris-pharmaceuticals-begins-dosing-in-phase-2-gastric-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral
1546.0,1/18/2022 7:52:12 AM,Evotec Enters Research Partnership With Lilly - Quick Facts ,RTTNews,/news/stocks/evotec-enters-research-partnership-with-lilly-quick-facts-1031107647
1547.0,1/18/2022 12:02:56 PM,Eli Lilly signs drug discovery collaboration with Evotec in a deal valued up to $5B,Seeking Alpha,https://seekingalpha.com/news/3788584-eli-lilly-signs-drug-discovery-collaboration-with-evotec-in-a-deal-valued-up-to-5b?utm_source=markets.businessinsider.com&utm_medium=referral
1548.0,1/18/2022 7:27:13 PM,7 of the Top-Rated Pharmaceutical Stocks for Q1,InvestorPlace,/news/stocks/7-of-the-top-rated-pharmaceutical-stocks-for-q1-1031110217
1549.0,1/20/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2021-financial-results-announcement-1031116590
1550.0,1/21/2022 4:04:17 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-21-2022-1031119319
1551.0,1/21/2022 6:01:35 PM,Expert Ratings For Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031119590
1552.0,1/21/2022 7:09:36 PM,GlaxoSmithKline and Vir to boost U.S. output of COVID-19 antibody - Reuters,Seeking Alpha,https://seekingalpha.com/news/3790412-glaxosmithkline-and-vir-to-boost-us-output-of-covid-19-antibody-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
1553.0,1/24/2022 10:52:04 AM,"Innovent, Lilly report final results of Phase ib study of Tyvyt + bevacizumab biosimilar in liver cancer",Seeking Alpha,https://seekingalpha.com/news/3790540-innovent-lilly-report-final-results-of-phase-ib-study-of-tyvyt-bevacizumab-biosimilar-in-liver-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1554.0,1/25/2022 6:17:15 PM,"CBO report finds skyrocketing price increases for brand Rx drugs for Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/3791432-cbo-report-finds-skyrocketing-price-increases-for-brand-rx-drugs-for-medicare-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral
1555.0,1/27/2022 1:47:08 PM,Health Canada authorizes Lilly's Verzenio for HR+ HER2- early breast cancer patients,Seeking Alpha,https://seekingalpha.com/news/3792441-health-canada-authorizes-lillys-verzenio-for-hr-her2-early-breast-cancer-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1556.0,1/27/2022 6:50:00 PM,ALX Oncology gastric cancer candidate granted Orphan Drug Designation,Seeking Alpha,https://seekingalpha.com/news/3792646-alx-oncology-gastric-cancer-candidate-granted-orphan-drug-designation?utm_source=markets.businessinsider.com&utm_medium=referral
1557.0,1/28/2022 2:00:00 PM,Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis,PR Newswire,/news/stocks/updates-on-olumiant-baricitinib-phase-3-lupus-program-and-fda-review-for-atopic-dermatitis-1031139169
1558.0,1/28/2022 2:16:35 PM,Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts ,RTTNews,/news/stocks/lilly-to-discontinue-phase-3-development-program-for-olumiant-in-lupus-quick-facts-1031139271
1559.0,1/28/2022 5:24:38 PM,Eli Lilly to invest $1B to set up manufacturing site in North Carolina,Seeking Alpha,https://seekingalpha.com/news/3793173-eli-lilly-to-invest-1b-to-set-up-manufacturing-site-in-north-carolina?utm_source=markets.businessinsider.com&utm_medium=referral
1560.0,1/28/2022 6:15:00 PM,Lilly announces $1 billion investment in new manufacturing facility in North Carolina,PR Newswire,/news/stocks/lilly-announces-1-billion-investment-in-new-manufacturing-facility-in-north-carolina-1031140038
1561.0,1/29/2022 12:37:14 AM,Eli Lilly To Invest $1 Bln To Build New Plant In Concord ,RTTNews,/news/stocks/eli-lilly-to-invest-1-bln-to-build-new-plant-in-concord-1031140494
1562.0,1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral
1563.0,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306
1564.0,2/1/2022 3:22:51 PM,Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-key-february-pdufa-dates-1031149588
1565.0,2/1/2022 8:00:00 PM,Lilly to Participate in Guggenheim Oncology Conference,PR Newswire,/news/stocks/lilly-to-participate-in-guggenheim-oncology-conference-1031150571
1566.0,2/2/2022 12:11:22 PM,What's in store for Eli Lilly's Q4 earnings?,Seeking Alpha,https://seekingalpha.com/news/3794751-whats-in-store-for-eli-lillys-q4-earnings?utm_source=markets.businessinsider.com&utm_medium=referral
1567.0,2/2/2022 3:00:35 PM,Novo Nordisk challenges House report it collaborated with competitors on insulin prices,Seeking Alpha,https://seekingalpha.com/news/3794874-novo-nordisk-challenges-house-report-it-collaborated-with-competitors-on-insulin-prices?utm_source=markets.businessinsider.com&utm_medium=referral
1568.0,2/2/2022 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-quarter-earnings-preview-q4-1031154281
1569.0,2/2/2022 3:47:17 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3794923-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1570.0,2/2/2022 4:00:00 PM,UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents,PR Newswire,/news/stocks/unicef-and-lilly-collaborate-to-help-improve-health-outcomes-for-10-million-children-and-adolescents-1031154595
1571.0,2/3/2022 11:27:13 AM,"Eli Lilly Non-GAAP EPS of $2.49 misses by $0.02, revenue of $8B beats by $110M",Seeking Alpha,https://seekingalpha.com/news/3795356-eli-lilly-non-gaap-eps-of-2_49-misses-0_02-revenue-of-8b-beats-110m?utm_source=markets.businessinsider.com&utm_medium=referral
1572.0,2/3/2022 12:25:00 PM,"Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients",PR Newswire,/news/stocks/lilly-reports-solid-fourth-quarter-and-full-year-2021-financial-results-recent-late-stage-pipeline-successes-set-up-next-wave-of-innovative-medicines-for-patients-1031158104
1573.0,2/3/2022 12:27:39 PM,Eli Lilly tops Q4 revenue estimates as sales of COVID-19 antibodies exceed $1B,Seeking Alpha,https://seekingalpha.com/news/3795434-eli-lilly-tops-q4-revenue-estimates-as-sales-of-covid-19-antibodies-exceed-1b?utm_source=markets.businessinsider.com&utm_medium=referral
1574.0,2/3/2022 12:28:37 PM,Eli Lilly And Co. Profit Declines In Q4,RTTNews,/news/stocks/eli-lilly-and-co-profit-declines-in-q4-1031158111
1575.0,2/3/2022 12:58:21 PM,Eli Lilly Q4 Results Top Estimates; Reaffirms FY22 Outlook ,RTTNews,/news/stocks/eli-lilly-q4-results-top-estimates-reaffirms-fy22-outlook-1031158235
1576.0,2/3/2022 2:13:03 PM,"The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation",Benzinga,/news/stocks/the-daily-biotech-pulse-big-pharma-earnings-prove-lackluster-mersana-inks-1b-adc-r-d-deal-syros-gets-orphan-drug-designation-1031158702
1577.0,2/3/2022 6:10:08 PM,Eli Lilly pushes back regulatory submissions for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3795666-eli-lilly-pushes-back-regulatory-submissions-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral
1578.0,2/4/2022 4:36:55 PM,5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-to-benefit-from-bidens-new-cancer-cabinet-1031163083
1579.0,2/8/2022 8:58:39 PM,"Eli Lilly, Innovent draw negative FDA comments for cancer drug ahead of AdCom meeting",Seeking Alpha,https://seekingalpha.com/news/3797458-eli-lilly-innovent-draw-negative-fda-comments-for-cancer-drug-ahead-of-adcom-meeting?utm_source=markets.businessinsider.com&utm_medium=referral
1580.0,2/10/2022 2:29:52 PM,"The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-q4-gets-covid-boost-seagen-plunges-on-earnings-adcom-test-awaits-lilly-1031182008
1581.0,2/10/2022 7:58:22 PM,Eli Lilly/ Innovent cancer drug rebuked at FDA AdCom meeting (updated),Seeking Alpha,https://seekingalpha.com/news/3798772-eli-lilly-innovent-cancer-drug-rebuked-at-fda-adcom-meeting?utm_source=markets.businessinsider.com&utm_medium=referral
1582.0,2/10/2022 11:01:00 PM,"Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options",PR Newswire,/news/stocks/lilly-will-supply-up-to-600-000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-effort-to-provide-covid-19-treatment-options-1031183803
1583.0,2/11/2022 2:55:23 AM,"Lilly Reaches Deal With U.S. To Supply Up To 600,000 Doses Of Bebtelovimab For COVID-19 Treatment ",RTTNews,/news/stocks/lilly-reaches-deal-with-u-s-to-supply-up-to-600-000-doses-of-bebtelovimab-for-covid-19-treatment-1031184003
1584.0,2/11/2022 11:00:03 AM,Lilly inks deal to supply 600K doses of COVID drug bebtelovimab to US for $720M,Seeking Alpha,https://seekingalpha.com/news/3799043-lilly-inks-deal-to-supply-600k-doses-of-covid-drug-bebtelovimab-to-us-for-720m?utm_source=markets.businessinsider.com&utm_medium=referral
1585.0,2/11/2022 1:22:42 PM,FDA Panel Votes Against Lilly's Lung Cancer Drug For China-only Trial ,RTTNews,/news/stocks/fda-panel-votes-against-lilly-s-lung-cancer-drug-for-china-only-trial-1031186334
1586.0,2/11/2022 2:08:16 PM,Journey Medical to get $2.5M as Rapifort gets approval in Japan,Seeking Alpha,https://seekingalpha.com/news/3799171-journey-medical-to-get-25m-as-rapifort-gets-approval-in-japan?utm_source=markets.businessinsider.com&utm_medium=referral
1587.0,2/11/2022 7:53:41 PM,Eli Lilly granted FDA nod for new COVID-19 antibody therapy with efficacy against Omicron,Seeking Alpha,https://seekingalpha.com/news/3799324-eli-lilly-granted-fda-nod-for-new-covid-19-antibody-therapy-with-efficacy-against-omicron?utm_source=markets.businessinsider.com&utm_medium=referral
1588.0,2/11/2022 9:08:00 PM,Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19,PR Newswire,/news/stocks/lilly-s-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19-1031187477
1589.0,2/11/2022 11:02:34 PM,FDA Issues Emergency Use Authorization For Eli Lilly's Covid-19 Treatment ,RTTNews,/news/stocks/fda-issues-emergency-use-authorization-for-eli-lilly-s-covid-19-treatment-1031187655
1590.0,2/12/2022 9:00:00 PM,Cassava Sciences citizen petition saga shines light on alleged abuse of FDA program,Seeking Alpha,https://seekingalpha.com/news/3799281-cassava-sciences-citizen-petition-saga-shines-light-on-alleged-abuse-of-fda-program?utm_source=markets.businessinsider.com&utm_medium=referral
1591.0,2/15/2022 12:21:20 PM,ImmunoGen gains on pact with Eli Lilly for antibody-drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3799985-immunogen-gains-on-pact-with-eli-lilly-for-antibody-drug-conjugates?utm_source=markets.businessinsider.com&utm_medium=referral
1592.0,2/15/2022 5:19:07 PM,Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B,Benzinga,/news/stocks/lilly-unites-with-immunogen-in-adc-deal-worth-up-to-1-7b-1031196711
1593.0,2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral
1594.0,2/16/2022 2:21:33 PM,"Eli Lilly diabetes drug tirzepatide isn't better than other meds, ICER says",Seeking Alpha,https://seekingalpha.com/news/3800715-eli-lilly-diabetes-drug-tirzepatide-isnt-better-than-other-meds-icer-says?utm_source=markets.businessinsider.com&utm_medium=referral
1595.0,2/16/2022 3:00:00 PM,Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence,PR Newswire,/news/stocks/lilly-and-breast-cancer-advocacy-organizations-collaborate-to-drive-awareness-of-the-complexities-of-early-breast-cancer-and-the-risk-of-recurrence-1031200904
1596.0,2/17/2022 9:47:49 PM,NexImmune promotes chief operating officer to lead the company as CEO departs,Seeking Alpha,https://seekingalpha.com/news/3801729-neximmune-promotes-chief-operating-officer-to-lead-the-company-as-ceo-departs?utm_source=markets.businessinsider.com&utm_medium=referral
1597.0,2/18/2022 4:45:00 PM,Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study,PR Newswire,/news/stocks/nearly-two-thirds-of-patients-respond-to-mirikizumab-treatment-at-12-weeks-in-lilly-s-first-in-class-ulcerative-colitis-phase-3-lucent-1-study-1031208982
1598.0,2/22/2022 12:45:00 PM,Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site,PR Newswire,/news/stocks/lilly-announces-the-institute-for-genetic-medicine-and-700-million-investment-in-boston-seaport-site-1031215311
1599.0,2/22/2022 1:24:52 PM,Lilly Launches Institute For Genetic Medicine; Invests $700 Mln ,RTTNews,/news/stocks/lilly-launches-institute-for-genetic-medicine-invests-700-mln-1031215534
1600.0,2/22/2022 1:29:32 PM,Lilly launches Institute for Genetic Medicine; $700M for new facility at Boston Seaport,Seeking Alpha,https://seekingalpha.com/news/3802420-lilly-launches-institute-for-genetic-medicine-700m-for-new-facility-at-boston-seaport?utm_source=markets.businessinsider.com&utm_medium=referral
1601.0,2/24/2022 8:24:04 PM,Lilly-Boehringer Ingelheim's Jardiance granted expanded indication in heart failure,Seeking Alpha,https://seekingalpha.com/news/3805360-lilly-boehringer-ingelheims-jardiance-granted-expanded-indication-in-heart-failure?utm_source=markets.businessinsider.com&utm_medium=referral
1602.0,2/24/2022 10:15:00 PM,US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction,PR Newswire,/news/stocks/us-fda-approves-jardiance-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction-1031228735
1603.0,2/25/2022 11:31:07 AM,FDA Approves Jardiance To Treat Adults With Heart Failure ,RTTNews,/news/stocks/fda-approves-jardiance-to-treat-adults-with-heart-failure-1031231393
1604.0,2/25/2022 2:02:25 PM,"The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-s-jardiance-gets-nod-for-heart-failure-pulmatrix-announces-reverse-split-reata-awaits-fda-decision-1031231988
1605.0,2/25/2022 4:46:48 PM,Healthcare leads a rally in S&P 500 amid hopes of Russia - Ukraine talks,Seeking Alpha,https://seekingalpha.com/news/3806014-healthcare-leads-a-rally-in-sp-500-amid-hopes-of-russia-ukraine-talks?utm_source=markets.businessinsider.com&utm_medium=referral
1606.0,2/27/2022 3:26:47 PM,"The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-27-march-5-earnings-multiple-regulatory-decisions-take-the-spotlight-1031235310
1607.0,2/28/2022 7:41:42 AM,Biotech Stocks Facing FDA Decision In March 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2022-1031236842
1608.0,2/28/2022 8:00:00 PM,Lilly to Participate in Cowen Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-cowen-health-care-conference-1031239581
1609.0,2/28/2022 8:34:39 PM,Why did Vir Biotechnology stock drop today?,Seeking Alpha,https://seekingalpha.com/news/3807154-why-did-vir-stock-drop-today-falling-covid-19-cases?utm_source=markets.businessinsider.com&utm_medium=referral
1610.0,3/1/2022 4:06:00 PM,Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial,PR Newswire,/news/stocks/jardiance-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-following-acute-heart-failure-in-empulse-phase-iii-trial-1031243500
1611.0,3/1/2022 5:07:10 PM,Eli Lilly's Jardiance provides benefit for acute heart failure patients,Seeking Alpha,https://seekingalpha.com/news/3807867-eli-lilly-jardiance-provides-benefit-for-acute-heart-failure-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1612.0,3/1/2022 9:05:19 PM,Eli Lilly Says Jardiance Provides Significant Benefit In Adults Following Acute Heart Failure ,RTTNews,/news/stocks/eli-lilly-says-jardiance-provides-significant-benefit-in-adults-following-acute-heart-failure-1031244507
1613.0,3/2/2022 1:00:40 PM,ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer,Seeking Alpha,https://seekingalpha.com/news/3808374-alx-oncology-begins-dosing-in-phase-23-trial-of-evorpacept-in-gastric-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1614.0,3/2/2022 1:35:33 PM,"Biden pushes for insulin price cap, Medicare drug negotiations in SOTU",Seeking Alpha,https://seekingalpha.com/news/3808400-biden-pushes-for-insulin-price-cap-medicare-drug-negotiations-in-sotu?utm_source=markets.businessinsider.com&utm_medium=referral
1615.0,3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946
1616.0,3/3/2022 3:57:17 PM,U.S. to share government-backed COVID-19 tech with WHO - Washington Post,Seeking Alpha,https://seekingalpha.com/news/3809199-us-to-share-government-backed-covid-19-tech-with-who-washington-post?utm_source=markets.businessinsider.com&utm_medium=referral
1617.0,3/3/2022 8:00:00 PM,Lilly to Participate in Barclays Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-barclays-global-healthcare-conference-1031252743
1618.0,3/4/2022 9:48:01 AM,Lilly/Incyte's baricitinib reduces risk of death in COVID patients in UK study- Reuters,Seeking Alpha,https://seekingalpha.com/news/3809478-lillyincytes-baricitinib-reduces-risk-of-death-in-covid-patients-in-uk-study-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
1619.0,3/6/2022 12:16:50 PM,Johnson & Johnson is in talks for biotech deals in China - FT,Seeking Alpha,https://seekingalpha.com/news/3809928-johnson-johnson-is-in-talks-for-biotech-deals-in-china-ft?utm_source=markets.businessinsider.com&utm_medium=referral
1620.0,3/8/2022 10:42:21 AM,"Lilly, Boehringer Ingelheim's Jardiance gets EU approval for expanded use in heart failure",Seeking Alpha,https://seekingalpha.com/news/3810496-lilly-boehringer-ingelheims-jardiance-gets-eu-approval-for-expanded-use-in-heart-failure?utm_source=markets.businessinsider.com&utm_medium=referral
1621.0,3/8/2022 10:30:00 PM,Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR),PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2022-american-association-for-cancer-research-aacr-1031264187
1622.0,3/9/2022 1:47:19 PM,Push to curb insulin costs reemerges for Senate action,Seeking Alpha,https://seekingalpha.com/news/3811093-push-to-curb-insulin-costs-reemerges-for-senate-action?utm_source=markets.businessinsider.com&utm_medium=referral
1623.0,3/10/2022 2:25:03 PM,"Eli Lilly, Erasca ink clinical trial/supply agreement",Seeking Alpha,https://seekingalpha.com/news/3812163-eli-lilly-erasca-ink-clinical-trialsupply-agreement?utm_source=markets.businessinsider.com&utm_medium=referral
1624.0,3/11/2022 4:56:36 PM,"Foghorn Therapeutics buoyed by 2021 annual report, 2022 outlook",Seeking Alpha,https://seekingalpha.com/news/3812790-foghorn-therapeutics-buoyed-by-earnings-2022-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
1625.0,3/12/2022 7:20:14 PM,Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict,Seeking Alpha,https://seekingalpha.com/news/3812903-drugmakers-face-clinical-trial-disruptions-amid-russia-ukraine-conflict?utm_source=markets.businessinsider.com&utm_medium=referral
1626.0,3/13/2022 2:24:45 PM,Biogen awaits Medicare decision on Alzheimer’s drug amid public pressure for coverage,Seeking Alpha,https://seekingalpha.com/news/3812913-biogen-awaits-medicare-decision-on-alzheimers-drug-amid-public-pressure-for-coverage?utm_source=markets.businessinsider.com&utm_medium=referral
1627.0,3/14/2022 3:22:48 PM,Boeing : Arajet Orders 20 737 MAX Aircraft ,RTTNews,/news/stocks/boeing-arajet-orders-20-737-max-aircraft-1031278248
1628.0,3/15/2022 12:51:10 PM,Executives Sell More Than $25M Of 4 Stocks,Benzinga,/news/stocks/executives-sell-more-than-25m-of-4-stocks-1031280885
1629.0,3/15/2022 2:49:24 PM,Eli Lilly to halt exporting “non-essential” medicines to Russia,Seeking Alpha,https://seekingalpha.com/news/3813665-eli-lilly-to-halt-exporting-non-essential-medicines-to-russia-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
1630.0,3/15/2022 5:19:52 PM,U.S. faces a shortage of COVID-19 antibody therapies without more funds - White House,Seeking Alpha,https://seekingalpha.com/news/3813747-us-risks-shortage-of-covid-19-antibody-therapies-without-more-funds?utm_source=markets.businessinsider.com&utm_medium=referral
1631.0,3/16/2022 1:00:00 PM,Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease,PR Newswire,/news/stocks/jardiance-phase-iii-empa-kidney-trial-will-stop-early-due-to-clear-positive-efficacy-in-people-with-chronic-kidney-disease-1031284743
1632.0,3/16/2022 1:47:00 PM,Eli Lilly: EMPA-KIDNEY Trial Shows Efficacy For Jardiance At Early Stage; Trial To Stop ,RTTNews,/news/stocks/eli-lilly-empa-kidney-trial-shows-efficacy-for-jardiance-at-early-stage-trial-to-stop-1031285003
1633.0,3/17/2022 8:53:55 AM,"Lilly, Boehringer to stop Jardiance's kidney disease trial early due to 'clear efficacy'",Seeking Alpha,https://seekingalpha.com/news/3814437-lilly-boehringer-to-stop-jardiances-kidney-disease-trial-early-due-to-clear-efficacy?utm_source=markets.businessinsider.com&utm_medium=referral
1634.0,3/17/2022 3:03:13 PM,Eli Lilly extends gains as BofA raises target citing prospects in weight loss space,Seeking Alpha,https://seekingalpha.com/news/3814645-eli-lilly-extends-gains-as-bofa-raises-target-citing-prospects-in-weight-loss?utm_source=markets.businessinsider.com&utm_medium=referral
1635.0,3/24/2022 11:00:13 AM,Eli Lilly says lung cancer drug rejected by FDA citing need for a diverse trial,Seeking Alpha,https://seekingalpha.com/news/3816811-eli-lilly-says-lung-cancer-drug-rejected-by-fda-citing-need-for-a-diverse-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1636.0,3/24/2022 11:45:00 AM,Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer,PR Newswire,/news/stocks/lilly-announces-complete-response-letter-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-nonsquamous-non-small-cell-lung-cancer-1031304269
1637.0,3/24/2022 11:55:44 AM,Eli Lilly: FDA Issues CRL For BLA For Sintilimab; Unable To Approve Application In Its Current Form ,RTTNews,/news/stocks/eli-lilly-fda-issues-crl-for-bla-for-sintilimab-unable-to-approve-application-in-its-current-form-1031304295
1638.0,3/24/2022 1:10:16 PM,"The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-prostate-cancer-drug-lands-fda-approval-ligand-announces-spac-deal-to-spin-off-antibody-business-lilly-s-lung-cancer-therapy-hit-with-crl-1031304689
1639.0,3/26/2022 2:20:00 PM,Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies,PR Newswire,/news/stocks/majority-of-patients-treated-with-lebrikizumab-achieved-skin-clearance-in-lilly-s-pivotal-phase-3-atopic-dermatitis-studies-1031309481
1640.0,3/26/2022 4:20:00 PM,Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies,PR Newswire,/news/stocks/nearly-40-of-adults-with-alopecia-areata-taking-olumiant-4-mg-saw-at-least-80-scalp-hair-coverage-at-52-weeks-in-lilly-s-pivotal-phase-3-studies-1031309584
1641.0,3/28/2022 2:00:00 AM,Innovent and Lilly Expand Strategic Partnership in Oncology,PR Newswire,/news/stocks/innovent-and-lilly-expand-strategic-partnership-in-oncology-1031310210
1642.0,3/28/2022 3:44:01 AM,"Innovent Biologics, Lilly Expand Partnership In Oncology ",RTTNews,/news/stocks/innovent-biologics-lilly-expand-partnership-in-oncology-1031310225
1643.0,3/28/2022 9:51:19 AM,"Lilly, Biologics expand collaboration over cancer drugs in China",Seeking Alpha,https://seekingalpha.com/news/3817853-lilly-biologics-expand-collaboration-over-cancer-drugs-in-china?utm_source=markets.businessinsider.com&utm_medium=referral
1644.0,3/28/2022 10:51:53 AM,"Eli Lilly, Incyte present late-stage 52-week data for hair loss therapy",Seeking Alpha,https://seekingalpha.com/news/3817874-eli-lilly-incy-present-late-stage-52-week-data-for-hair-loss-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1645.0,3/29/2022 8:47:27 AM,"US agency pauses distribution of GSK, Vir's COVID-19 therapy sotrovimab in certain states",Seeking Alpha,https://seekingalpha.com/news/3818262-us-agency-pauses-distribution-of-gsk-virs-covid-19-antibody-therapy-in-certain-states?utm_source=markets.businessinsider.com&utm_medium=referral
1646.0,3/29/2022 2:53:29 PM,J&J to suspend supply of personal care products in Russia,Seeking Alpha,https://seekingalpha.com/news/3818471-jj-to-suspend-supply-of-personal-care-products-in-russia?utm_source=markets.businessinsider.com&utm_medium=referral
1647.0,4/1/2022 12:01:26 PM,Lilly reports new data from phase 1/2 trial of Retevmo in advanced lung cancer,Seeking Alpha,https://seekingalpha.com/news/3819786-lilly-reports-new-data-from-phase-12-trial-of-retevmo-in-advanced-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1648.0,4/1/2022 12:45:00 PM,Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress,PR Newswire,/news/stocks/lilly-presents-updated-data-on-retevmo-selpercatinib-in-advanced-ret-fusion-positive-non-small-cell-lung-cancer-nsclc-at-the-2022-european-lung-cancer-congress-1031325951
1649.0,4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374
1650.0,4/1/2022 10:56:45 PM,4 Stocks Reporting Earnings the Week of April 4,InvestorPlace,/news/stocks/4-stocks-reporting-earnings-the-week-of-april-4-1031327553
1651.0,4/4/2022 9:00:38 PM,Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated),Seeking Alpha,https://seekingalpha.com/news/3820489-lawmakers-set-to-announce-10-billion-additional-funding-for-us-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral
1652.0,4/6/2022 1:33:41 AM,"GlaxoSmithKline, Vir COVID-19 therapy is no longer authorized in U.S. - FDA",Seeking Alpha,https://seekingalpha.com/news/3820993-glaxosmithkline-vir-covid-19-therapy-is-no-longer-authorized-in-us-fda?utm_source=markets.businessinsider.com&utm_medium=referral
1653.0,4/6/2022 2:33:34 PM,Eli Lilly price target raised at Morgan Stanley on robust product outlook,Seeking Alpha,https://seekingalpha.com/news/3821186-eli-lilly-price-target-raised-at-morgan-stanley-on-robust-product-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
1654.0,4/6/2022 5:05:03 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1031337266
1655.0,4/7/2022 7:43:39 PM,"House, Senate Democrats introduce bills targeting 'abusive' pharma business practices",Seeking Alpha,https://seekingalpha.com/news/3821821-house-senate-democrats-introduce-bills-targeting-abusive-pharma-business-practices?utm_source=markets.businessinsider.com&utm_medium=referral
1656.0,4/8/2022 2:01:42 PM,Why Is Biogen (BIIB) Stock in the Spotlight Today?,InvestorPlace,/news/stocks/why-is-biogen-biib-stock-in-the-spotlight-today-1031343182
1657.0,4/9/2022 4:00:14 PM,Healthcare stocks outperform as investors look for safety,Seeking Alpha,https://seekingalpha.com/news/3822171-healthcare-stocks-outperform-as-investors-look-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral
1658.0,4/10/2022 10:42:49 PM,"The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-10-april-16-regeneron-fda-decision-cancer-conference-presentations-and-more-1031344759
1659.0,4/11/2022 4:15:00 PM,Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis,PR Newswire,/news/stocks/lilly-s-lebrikizumab-combined-with-topical-corticosteroids-showed-significant-improvements-in-disease-severity-for-atopic-dermatitis-1031346782
1660.0,4/11/2022 4:45:23 PM,Lilly atopic dermatitis candidate lebrikizumab shows improvement in disease severity,Seeking Alpha,https://seekingalpha.com/news/3822353-lilly-atopic-dermatitis-candidate-lebrikizumab-shows-improvement-in-disease-severity?utm_source=markets.businessinsider.com&utm_medium=referral
1661.0,4/11/2022 4:47:41 PM,Lilly's Lebrikizumab - Corticosteroids Show Improvements In Disease Severity For Atopic Dermatitis ,RTTNews,/news/stocks/lilly-s-lebrikizumab-corticosteroids-show-improvements-in-disease-severity-for-atopic-dermatitis-1031346873
1662.0,4/15/2022 11:03:38 AM,3 Mutual Funds to Buy for April,InvestorPlace,/news/stocks/3-mutual-funds-to-buy-for-april-1031358654
1663.0,4/18/2022 11:59:23 AM,Eli Lilly expects $165 million in charges related to in-process R&D projects,Seeking Alpha,https://seekingalpha.com/news/3823792-eli-lilly-to-recognize-165-million-in-charges-related-to-in-process-rd-projects?utm_source=markets.businessinsider.com&utm_medium=referral
1664.0,4/19/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2022-financial-results-announcement-1031364440
1665.0,4/20/2022 3:00:00 PM,Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care,PR Newswire,/news/stocks/tackling-health-disparities-and-inequities-for-women-with-heart-failure-new-program-encourages-black-and-latina-women-to-demand-more-from-their-care-1031368129
1666.0,4/21/2022 12:10:33 PM,7 Potential Biotech Stocks Buyout Targets in 2022,InvestorPlace,/news/stocks/7-potential-biotech-stocks-targets-in-2022-1031371733
1667.0,4/22/2022 4:32:49 PM,EMA panel recommends extending indication for Lilly's cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3825852-ema-panel-recommends-extending-indication-for-lillys-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1668.0,4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral
1669.0,4/25/2022 7:48:12 PM,Pfizer and Gilead earn preferred status for COVID-19 antivirals in new CDC advisory,Seeking Alpha,https://seekingalpha.com/news/3826382-pfe-gild-stocks-up-on-preferred-status-for-covid-19-antivirals-in-cdc-advisory?utm_source=markets.businessinsider.com&utm_medium=referral
1670.0,4/25/2022 9:26:09 PM,"Nektar Therapeutics unveils restructuring plan, laying off 70% of its workforce",Seeking Alpha,https://seekingalpha.com/news/3826475-nektar-therapeutics-unveils-restructuring-plan-laying-off-70-of-its-workforce?utm_source=markets.businessinsider.com&utm_medium=referral
1671.0,4/27/2022 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q1-earnings-preview-1031391569
1672.0,4/27/2022 3:25:48 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3827680-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1673.0,4/27/2022 5:22:22 PM,"Eli Lilly Q1 result to focus on COVID-19 therapies sales, comments on Alzheimer's drug",Seeking Alpha,https://seekingalpha.com/news/3827833-eli-lilly-q1-result-to-focus-on-covid-19-therapies-sales-comments-on-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral
1674.0,4/28/2022 10:26:24 AM,"Eli Lilly Non-GAAP EPS of $2.62 beats by $0.32, revenue of $7.81B beats by $520M",Seeking Alpha,https://seekingalpha.com/news/3828363-eli-lilly-non-gaap-eps-of-2_62-beats-0_32-revenue-of-7_81b-beats-520m?utm_source=markets.businessinsider.com&utm_medium=referral
1675.0,4/28/2022 11:55:30 AM,"Lilly Q1 revenue soars on COVID antibodies, Trulicity; raises FY22 revenue outlook, cuts EPS guidance",Seeking Alpha,https://seekingalpha.com/news/3828506-lilly-q1-revenue-soars-on-covid-antibodies-trulicity-raises-fy22-revenue-outlook-cuts-eps-guidance?utm_source=markets.businessinsider.com&utm_medium=referral
1676.0,4/28/2022 12:15:00 PM,Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1,PR Newswire,/news/stocks/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-surmount-1-1031396399
1677.0,4/28/2022 12:25:00 PM,Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022,PR Newswire,/news/stocks/solid-first-quarter-financial-results-reflect-lilly-s-continued-momentum-into-2022-1031396440
1678.0,4/28/2022 12:30:18 PM,Eli Lilly And Co. Reveals Increase In Q1 Profit,RTTNews,/news/stocks/eli-lilly-and-co-reveals-increase-in-q1-profit-1031396489
1679.0,4/28/2022 12:52:39 PM,Eli Lilly Q1 Results Top Estimates; Boosts FY22 Revenue Outlook ,RTTNews,/news/stocks/eli-lilly-q1-results-top-estimates-boosts-fy22-revenue-outlook-1031396555
1680.0,4/28/2022 1:28:07 PM,Lilly's tirzepatide shows weight loss benefit in adults without diabetes,Seeking Alpha,https://seekingalpha.com/news/3828625-eli-lilly-tirzepatide-shows-weight-loss-benefit-in-adults-without-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral
1681.0,4/28/2022 2:04:49 PM,Lilly: Tirzepatide In SURMOUNT-1 Trial Delivers Superior Weight Loss In Adults ,RTTNews,/news/stocks/lilly-tirzepatide-in-surmount-1-trial-delivers-superior-weight-loss-in-adults-1031397022
1682.0,4/28/2022 2:52:43 PM,"The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-seeks-fda-approval-for-covid-19-shot-for-children-2-6-tax-disclosure-for-amgen-fast-track-tags-for-sqz-biotech-timber-pharma-candidates-1031397312
1683.0,4/29/2022 5:02:56 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1031403053
1684.0,4/30/2022 8:00:00 PM,U.S. pharmaceutical sector fails to spring higher amid lackluster April performance,Seeking Alpha,https://seekingalpha.com/news/3829651-us-pharmaceutical-sector-fails-to-spring-higher-amid-lackluster-april-performance?utm_source=markets.businessinsider.com&utm_medium=referral
1685.0,5/2/2022 10:15:00 AM,Morgan Stanley issues list of 45 highest conviction stock picks,Seeking Alpha,https://seekingalpha.com/news/3829447-morgan-stanley-issues-list-of-45-highest-conviction-stock-picks?utm_source=markets.businessinsider.com&utm_medium=referral
1686.0,5/2/2022 7:01:26 PM,Eli Lilly declares $0.98 dividend,Seeking Alpha,https://seekingalpha.com/news/3830361-eli-lilly-and-company-declares-0_98-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
1687.0,5/2/2022 8:26:00 PM,Lilly Declares Second-Quarter 2022 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2022-dividend-1031410053
1688.0,5/3/2022 3:07:41 PM,Lilly partners with AI-focused Genesis Therapeutics in up to $670M deal,Seeking Alpha,https://seekingalpha.com/news/3831062-lilly-partners-with-ai-artifical-intelligence-focused-genesis-therapeutics-in-up-to-670m-deal?utm_source=markets.businessinsider.com&utm_medium=referral
1689.0,5/3/2022 8:00:00 PM,Lilly to Participate in Bank of America Securities 2022 Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bank-of-america-securities-2022-healthcare-conference-1031415107
1690.0,5/4/2022 10:39:59 AM,"Starbucks, Meta, Exxon among many stocks dropping off BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3831217-starbucks-meta-exxon-among-many-stocks-dropping-off-bofas-alpa-surprise-screen?utm_source=markets.businessinsider.com&utm_medium=referral
1691.0,5/5/2022 7:32:41 PM,Biogen spat with SEC over accounting impacting other pharmas' quarterly reports - MarketWatch,Seeking Alpha,https://seekingalpha.com/news/3833608-biogen-spat-with-sec-over-accounting-impacting-other-pharmas-quarterly-reports-marketwatch?utm_source=markets.businessinsider.com&utm_medium=referral
1692.0,5/6/2022 8:00:00 PM,Mary Lynne Hedley Elected to Lilly Board of Directors,PR Newswire,/news/stocks/mary-lynne-hedley-elected-to-lilly-board-of-directors-1031431727
1693.0,5/9/2022 9:15:08 AM,Adocia to get $5M as Chinese partner Tonghua begins dosing of insulin BioChaperone in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3834787-adocia-to-get-5m-as-chinese-partner-tonghua-begins-dosing-of-insulin-biochaperone-in-phase-3-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1694.0,5/11/2022 10:35:43 AM,7 Biotech Stocks With Key Catalysts for May,InvestorPlace,/news/stocks/7-biotech-stocks-with-key-catalysts-for-may-1031447419
1695.0,5/11/2022 11:16:47 AM,"Lilly, Incyte get FDA approval of Olumiant to treat certain hospitalized COVID-19 patients",Seeking Alpha,https://seekingalpha.com/news/3836682-lilly-incyte-get-fda-approval-of-olumiant-to-treat-certain-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1696.0,5/11/2022 12:45:00 PM,FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19,PR Newswire,/news/stocks/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-for-the-treatment-of-certain-hospitalized-patients-with-covid-19-1031447417
1697.0,5/11/2022 1:04:22 PM,"Eli Lilly, Incyte Announce FDA Approval Of OLUMIANT For Hospitalized Patients With COVID-19 ",RTTNews,/news/stocks/eli-lilly-incyte-announce-fda-approval-of-olumiant-for-hospitalized-patients-with-covid-19-1031447512
1698.0,5/11/2022 3:37:50 PM,"The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine",Benzinga,/news/stocks/the-daily-biotech-pulse-veru-shares-up-on-covid-candidate-update-fda-approves-lilly-s-covid-treatment-latest-on-sanofi-astrazeneca-rsv-vaccine-1031448828
1699.0,5/12/2022 2:14:54 PM,Federal flags to fly at half-staff to mark one million COVID deaths,Seeking Alpha,https://seekingalpha.com/news/3837849-federal-flags-to-fly-at-half-staff-to-mark-one-million-covid-deaths?utm_source=markets.businessinsider.com&utm_medium=referral
1700.0,5/13/2022 5:55:52 PM,"Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas",Benzinga,/news/stocks/amid-slowing-sales-at-home-innovent-biologics-stumbles-overseas-1031459391
1701.0,5/13/2022 7:44:06 PM,Eli Lilly's dual-receptor diabetes drug tirzepatide granted FDA approval,Seeking Alpha,https://seekingalpha.com/news/3838811-eli-lilly-dual-receptor-diabetes-drug-tirzepatide-mounjaro-granted-fda-approval?utm_source=markets.businessinsider.com&utm_medium=referral
1702.0,5/13/2022 11:54:00 PM,"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes",PR Newswire,/news/stocks/fda-approves-lilly-s-mounjaro-tirzepatide-injection-the-first-and-only-gip-and-glp-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes-1031459853
1703.0,5/14/2022 3:58:03 AM,FDA Approves Lilly's Mounjaro Injection For Type 2 Diabetes Treatment ,RTTNews,/news/stocks/fda-approves-lilly-s-mounjaro-injection-for-type-2-diabetes-treatment-1031459884
1704.0,5/14/2022 8:00:00 PM,Why the approval of Eli Lilly's tirzepatide for diabetes will lead to blockbuster sales,Seeking Alpha,https://seekingalpha.com/news/3838865-why-the-approval-of-eli-lilly-tirzepatide-mounjaro-for-diabetes-will-lead-to-blockbuster-sales?utm_source=markets.businessinsider.com&utm_medium=referral
1705.0,5/16/2022 6:04:27 PM,FDA rejects old antidepressant Luvox as COVID treatment citing lack of evidence,Seeking Alpha,https://seekingalpha.com/news/3839377-fda-rejects-old-antidepressant-luvox-fluvoxamine-as-covid-treatment-citing-lack-of-evidence?utm_source=markets.businessinsider.com&utm_medium=referral
1706.0,5/16/2022 8:00:00 PM,Lilly to Participate in UBS Global Healthcare Conference 2022,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-global-healthcare-conference-2022-1031465541
1707.0,5/18/2022 6:37:57 PM,Eli Lilly says COVID therapy bebtelovimab effective against dominant U.S. COVID strain,Seeking Alpha,https://seekingalpha.com/news/3840595-eli-lilly-says-covid-therapy-bebtelovimab-effective-against-dominant-us-covid-strain?utm_source=markets.businessinsider.com&utm_medium=referral
1708.0,5/19/2022 12:44:29 PM,PepsiCo And 3 Other Stocks Insiders Are Selling,Benzinga,/news/stocks/pepsico-and-3-other-stocks-insiders-are-selling-1031475155
1709.0,5/19/2022 6:49:20 PM,Eli Lilly oncologic selpercatinib granted Orphan Drug status for solid tumors,Seeking Alpha,https://seekingalpha.com/news/3841094-eli-lilly-oncologic-selpercatinib-retevmo-granted-orphan-drug-status-for-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
1710.0,5/20/2022 2:11:00 PM,CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA),PR Newswire,/news/stocks/chmp-recommends-approval-of-lilly-and-incyte-s-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata-aa-1031478443
1711.0,5/20/2022 2:29:07 PM,Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-for-olumiant-for-severe-alopecia-areata-treatment-1031478481
1712.0,5/20/2022 8:19:36 PM,Eli Lilly's new diabetes drug Mounjaro priced below Novo Nordisk's Wegovy,Seeking Alpha,https://seekingalpha.com/news/3841486-eli-lilly-new-diabetes-drug-mounjaro-tirzepatidepriced-below-novo-nordisk-wegovy-semaglutide?utm_source=markets.businessinsider.com&utm_medium=referral
1713.0,5/23/2022 2:18:39 PM,"AstraZeneca, Eli Lilly in focus as U.S. panel weighs routine kidney disease screening",Seeking Alpha,https://seekingalpha.com/news/3841740-lly-azn-stocks-in-focus-as-us-panel-weighs-kidney-disease-screening?utm_source=markets.businessinsider.com&utm_medium=referral
1714.0,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320
1715.0,5/23/2022 8:08:01 PM,What 7 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-eli-lilly-1031482764
1716.0,5/23/2022 8:44:09 PM,The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma,Benzinga,/news/stocks/the-analyst-says-impressive-phase-3-data-highlight-best-in-class-opportunity-for-concert-pharma-1031482839
1717.0,5/23/2022 11:00:00 PM,Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA,PR Newswire,/news/stocks/lilly-announces-webcast-to-provide-diabetes-and-obesity-portfolio-update-at-ada-1031483078
1718.0,5/24/2022 9:01:00 AM,Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study,PR Newswire,/news/stocks/fifty-percent-of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lilly-s-pivotal-phase-3-study-1031483807
1719.0,5/24/2022 9:38:02 AM,Lilly mirikizumab helps reduce ulcerative colitis symptoms in 50% patients at 1 year in trial,Seeking Alpha,https://seekingalpha.com/news/3842076-lilly-mirikizumab-helps-reduce-ulcerative-colitis-symptoms-in-50-patients-at-1-year-in-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1720.0,5/24/2022 10:20:00 AM,Lilly: One-half Of Mirikizumab Patients Achieves Clinical Remission At One Year In Phase 3 Study ,RTTNews,/news/stocks/lilly-one-half-of-mirikizumab-patients-achieves-clinical-remission-at-one-year-in-phase-3-study-1031483947
1721.0,5/24/2022 1:29:05 PM,COVID-19 sales boom for vaccine and drug makers might be over - analysts,Seeking Alpha,https://seekingalpha.com/news/3842211-covid-19-sales-boom-for-vaccine-and-drug-makers-might-be-over?utm_source=markets.businessinsider.com&utm_medium=referral
1722.0,5/25/2022 2:10:21 PM,Executives Sell Around $207M Of 5 Stocks,Benzinga,/news/stocks/executives-sell-around-207m-of-5-stocks-1031488093
1723.0,5/25/2022 4:58:45 PM,AbbVie trails Lilly despite a 30% bigger ex-Humira business - Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3842736-abbvie-stock-gains-as-wells-fargo-backs-ex-humira-business?utm_source=markets.businessinsider.com&utm_medium=referral
1724.0,5/25/2022 5:52:58 PM,Eli Lilly allocates $2.1 billion to expand production footprint in Indiana,Seeking Alpha,https://seekingalpha.com/news/3842765-eli-lilly-allocates-21-billion-to-expand-production-footprint-in-indiana?utm_source=markets.businessinsider.com&utm_medium=referral
1725.0,5/25/2022 7:15:00 PM,Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana,PR Newswire,/news/stocks/lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-indiana-1031489204
1726.0,5/26/2022 3:23:32 AM,Lilly To Invest $2.1 Bln In New Manufacturing Sites In Indiana ,RTTNews,/news/stocks/lilly-to-invest-2-1-bln-in-new-manufacturing-sites-in-indiana-1031489755
1727.0,5/26/2022 2:45:54 PM,"The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review",Benzinga,/news/stocks/the-daily-biotech-pulse-setback-for-nrx-pharma-s-covid-study-fast-track-tag-for-pfizer-s-nash-combo-therapy-reata-s-ataxia-drug-in-fda-review-1031490976
1728.0,5/26/2022 3:41:44 PM,Pfizer's Paxlovid by far the most administered COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3843162-pfizer-paxlovid-by-far-the-most-administered-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1729.0,5/26/2022 7:30:04 PM,Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness,Benzinga,/news/stocks/mizuho-sees-compelling-risk-reward-for-this-schizophrenia-stock-despite-recent-weakness-1031491666
1730.0,5/26/2022 11:00:00 PM,Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2022-american-society-of-clinical-oncology-asco-annual-meeting-1031491995
1731.0,5/30/2022 12:52:39 PM,Sanofi trial for over-the-counter Cialis put on hold by FDA,Seeking Alpha,https://seekingalpha.com/news/3843681-sanofi-trial-for-over-the-counter-cialis-put-on-hold-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral
1732.0,5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral
1733.0,6/1/2022 2:44:41 PM,Executives Sell Over $100M Of 4 Stocks,Benzinga,/news/stocks/executives-sell-over-100m-of-4-stocks-1031501797
1734.0,6/3/2022 4:00:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1031508671
1735.0,6/4/2022 4:02:00 PM,Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight,PR Newswire,/news/stocks/lilly-s-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight-1031509535
1736.0,6/4/2022 5:00:00 PM,Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo,PR Newswire,/news/stocks/lilly-s-award-peds-trial-investigating-use-of-trulicity-dulaglutide-in-youth-and-adolescents-with-type-2-diabetes-showed-superiority-in-a1c-reduction-vs-placebo-1031509542
1737.0,6/5/2022 10:09:23 PM,"The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnings-and-more-1031509946
1738.0,6/5/2022 10:30:00 PM,Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world eviden...,PR Newswire,/news/stocks/jardiance-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-dpp-4-inhibitors-and-by-30-versus-glp-1-receptor-agonists-in-adults-with-type-2-diabetes-in-real-world-eviden-1031509950
1739.0,6/6/2022 5:19:22 AM,Lilly : Jardiance Decreases Risk Of Hospitalization For Heart Failure By 50% In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-jardiance-decreases-risk-of-hospitalization-for-heart-failure-by-50-in-type-2-diabetes-1031509998
1740.0,6/6/2022 10:45:52 AM,Lilly/Boehringer Jardiance cuts risk of heart failure hospitalization for diabetes patients in 5-year data,Seeking Alpha,https://seekingalpha.com/news/3845812-lillyboehringer-jardiance-cuts-risk-of-heart-failure-hospitalization-for-diabetes-patients-in-5-year-data?utm_source=markets.businessinsider.com&utm_medium=referral
1741.0,6/6/2022 6:31:15 PM,Eli Lilly rebounds as analysts cheer newly published data for weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/3846046-lly-stock-rebounds-as-analysts-cheer-newly-published-weight-loss-therapy-data?utm_source=markets.businessinsider.com&utm_medium=referral
1742.0,6/7/2022 1:00:00 AM,New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®,PR Newswire,/news/stocks/new-analyses-of-mounjaro-tirzepatide-injection-for-the-treatment-of-adults-with-type-2-diabetes-presented-at-the-american-diabetes-association-s-82nd-scientific-sessions-1031511962
1743.0,6/7/2022 6:01:00 AM,Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials,PR Newswire,/news/stocks/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lilly-s-lebrikizumab-atopic-dermatitis-monotherapy-trials-1031512139
1744.0,6/7/2022 7:14:10 AM,Lilly Reports Positive Data From Lebrikizumab Atopic Dermatitis Monotherapy Trials ,RTTNews,/news/stocks/lilly-reports-positive-data-from-lebrikizumab-atopic-dermatitis-monotherapy-trials-1031512313
1745.0,6/7/2022 10:13:51 AM,Lilly/Almirall drug maintains clearer skin in eczema patients in trials; Lilly plans FDA filing,Seeking Alpha,https://seekingalpha.com/news/3846159-lillyalmirall-drug-maintains-clearer-skin-in-eczema-patients-in-trials-lilly-plans-fda-filing?utm_source=markets.businessinsider.com&utm_medium=referral
1746.0,6/9/2022 6:49:28 PM,Amphastar crashes 22% as FDA rejects generic for osteoporosis drug,Seeking Alpha,https://seekingalpha.com/news/3847440-amph-stock-crashes-as-fda-rejects-generic-for-osteoporosis-drug?utm_source=businessinsider&utm_medium=referral
1747.0,6/10/2022 2:57:48 PM,7 Great ETFs to Buy Now for Momentum in Q2,InvestorPlace,/news/stocks/7-great-etfs-to-buy-now-for-momentum-in-q2-1031522477
1748.0,6/10/2022 9:53:38 PM,Goldman Sachs comes under SEC civil probe over ESG funds - WSJ,Seeking Alpha,https://seekingalpha.com/news/3847829-goldman-sachs-comes-under-sec-probe-on-esg-funds-wsj?utm_source=businessinsider&utm_medium=referral
1749.0,6/13/2022 7:31:49 PM,Eli Lilly wins FDA label expansion for Olumiant in hair-loss disorder,Seeking Alpha,https://seekingalpha.com/news/3848167-eli-lilly-wins-fda-label-expansion-for-olumiant-in-hair-loss-disorder?utm_source=businessinsider&utm_medium=referral
1750.0,6/14/2022 3:50:00 AM,FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata,PR Newswire,/news/stocks/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-as-first-and-only-systemic-medicine-for-adults-with-severe-alopecia-areata-1031526339
1751.0,6/14/2022 7:47:24 AM,FDA Approves Lilly's Olumiant As First Systemic Treatment For Alopecia ,RTTNews,/news/stocks/fda-approves-lilly-s-olumiant-as-first-systemic-treatment-for-alopecia-1031526677
1752.0,6/14/2022 9:39:14 AM,FDA Approves First Medicine Ever For Alopecia Areata ,RTTNews,/news/stocks/fda-approves-first-medicine-ever-for-alopecia-areata-1031526865
1753.0,6/14/2022 2:37:49 PM,"Morning Brief: Top Financial Stories Dominating on Tuesday, June 14",Benzinga,/news/stocks/morning-brief-top-financial-stories-dominating-on-tuesday-june-14-1031527745
1754.0,6/14/2022 8:09:00 PM,Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock,Benzinga,/news/stocks/approval-of-baricitinib-for-patchy-baldness-validates-clinical-patch-for-this-small-cap-stock-1031528830
1755.0,6/16/2022 2:32:22 PM,Jim Cramer Says This Company Is A Great One,Benzinga,/news/stocks/jim-cramer-says-this-company-is-a-great-one-1031533078
1756.0,6/16/2022 5:26:53 PM,Lilly partnering with Sidekick Health for breast cancer digital therapeutic app,Seeking Alpha,https://seekingalpha.com/news/3849343-lilly-partnering-with-sidekick-health-for-breast-cancer-digital-therapeutic-app?utm_source=businessinsider&utm_medium=referral
1757.0,6/17/2022 3:03:44 AM,FTC votes unanimously to increase scrutiny over pharmacy agent fees,Seeking Alpha,https://seekingalpha.com/news/3849443-ftc-votes-unanimously-to-increase-scrutiny-over-rebates-paid-to-pbms?utm_source=businessinsider&utm_medium=referral
1758.0,6/17/2022 6:30:21 PM,BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock,Benzinga,/news/stocks/bmo-sees-differentiated-gene-editing-platform-for-this-small-cap-stock-1031536035
1759.0,6/21/2022 3:25:07 AM,Innovent : China Approves TYVYT Combination As Treatment For Esophageal Squamous Cell Carcinoma ,RTTNews,/news/stocks/innovent-china-approves-tyvyt-combination-as-treatment-for-esophageal-squamous-cell-carcinoma-1031538652
1760.0,6/21/2022 10:35:05 AM,Lilly/Innovent Tyvyt gets approval in China for expanded use in esophagus cancer,Seeking Alpha,https://seekingalpha.com/news/3849948-lillyinnovent-tyvyt-gets-approval-in-china-for-expanded-use-in-esophagus-cancer?utm_source=businessinsider&utm_medium=referral
1761.0,6/21/2022 12:12:02 PM,Top stocks insulated from risk with recession not fully priced in - Morgan Stanley,Seeking Alpha,https://seekingalpha.com/news/3849977-top-stocks-insulated-from-risk-with-recession-not-fully-priced-in-morgan-stanley?utm_source=businessinsider&utm_medium=referral
1762.0,6/22/2022 1:34:57 PM,AVEO Oncology partners with Eli Lilly to develop and supply head and neck cancer combo therapy,Seeking Alpha,https://seekingalpha.com/news/3850765-aveo-oncology-partners-with-eli-lilly-to-develop-and-supply-head-and-neck-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral
1763.0,6/24/2022 12:43:55 PM,Lilly's migraine therapy Rayvow gets EMA panel nod for EU approval,Seeking Alpha,https://seekingalpha.com/news/3851498-lillys-migraine-therapy-rayvow-gets-ema-panel-nod-for-eu-approval?utm_source=businessinsider&utm_medium=referral
1764.0,6/27/2022 3:09:10 AM,Lilly : China Approves TYVYT Combination For Treatment Of Gastric Cancer ,RTTNews,/news/stocks/lilly-china-approves-tyvyt-combination-for-treatment-of-gastric-cancer-1031550439
1765.0,6/27/2022 5:37:12 PM,Eli Lilly declares $0.98 dividend,Seeking Alpha,https://seekingalpha.com/news/3852172-eli-lilly-and-company-declares-0_98-dividend?utm_source=businessinsider&utm_medium=referral
1766.0,6/27/2022 7:26:00 PM,Lilly Declares Third-Quarter 2022 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2022-dividend-1031552633
1767.0,6/27/2022 10:04:34 PM,7 Defensive Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/defensive-stocks-to-buy-for-a-bear-market-1031557948
1768.0,6/27/2022 10:04:38 PM,7 Defensive Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/7-defensive-stocks-to-buy-for-a-bear-market-1031552985
1769.0,6/29/2022 11:10:12 AM,Lilly to supply additional 150K doses of COVID-19 antibody therapy to U.S.,Seeking Alpha,https://seekingalpha.com/news/3852750-lly-stock-on-watch-after-deal-to-supply-covid-19-antibody-therapy?utm_source=businessinsider&utm_medium=referral
1770.0,6/29/2022 12:45:00 PM,"Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options",PR Newswire,/news/stocks/lilly-will-supply-an-additional-150-000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-effort-to-provide-covid-19-treatment-options-1031556993
1771.0,6/29/2022 12:57:33 PM,Lilly To Supply Addl. 150K Doses Of Bebtelovimab To U.S. Government For About $275 Mln ,RTTNews,/news/stocks/lilly-to-supply-addl-150k-doses-of-bebtelovimab-to-u-s-government-for-about-275-mln-1031557022
1772.0,6/29/2022 3:50:08 PM,5 S&P 500 Stocks Ready to Break Out,InvestorPlace,/news/stocks/sp-500-stocks-ready-to-break-out-1031558401
1773.0,6/29/2022 6:06:23 PM,"The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data",Benzinga,/news/stocks/the-daily-biotech-pulse-eli-lilly-modifies-covid-19-treatment-pact-oyster-point-outlines-restructuring-plan-icosavax-posts-interim-rsv-vaccine-data-1031558382
1774.0,7/2/2022 6:00:00 PM,"As amyloid-targeting therapies for Alzheimer's fail, where might success lie?",Seeking Alpha,https://seekingalpha.com/news/3853361-as-amyloid-targeting-therapies-for-alzheimers-fail-where-might-success-lie?utm_source=businessinsider&utm_medium=referral
1775.0,7/6/2022 3:00:44 PM,Eli Lilly hits new all-time high buoyed by recent drug approvals; up 21% YTD,Seeking Alpha,https://seekingalpha.com/news/3854637-eli-lilly-hits-new-all-time-high-buoyed-by-recent-drug-approvals-up-21-ytd?utm_source=businessinsider&utm_medium=referral
1776.0,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral
1777.0,7/7/2022 1:53:40 PM,This Analyst Cuts Price Target On Microsoft; Here's The Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/this-analyst-cuts-price-target-on-microsoft-here-s-the-biggest-price-target-changes-for-thursday-1031572813
1778.0,7/7/2022 10:27:17 PM,What 8 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-eli-lilly-1031574128
1779.0,7/11/2022 3:29:42 PM,Goldman screens stocks most and least vulnerable to recession margin pressure,Seeking Alpha,https://seekingalpha.com/news/3855643-goldman-screens-stocks-most-ane-least-vulnerable-to-recession-margin-pressure?utm_source=businessinsider&utm_medium=referral
1780.0,7/12/2022 7:33:16 PM,Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?,Benzinga,/news/stocks/incyte-incy-outperforms-industry-ytd-what-lies-ahead-1031582179
1781.0,7/15/2022 9:41:21 PM,Eli Lilly (again) hits a new 52-week high; up 22% YTD,Seeking Alpha,https://seekingalpha.com/news/3857334-eli-lilly-again-hits-a-new-52-week-high-up-22-ytd?utm_source=businessinsider&utm_medium=referral
1782.0,7/17/2022 4:00:59 PM,"Novo, Eli Lilly to dominate >$50B obesity market - Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3857375-lly-nvo-stocks-in-focus-as-morgan-stanley-projects-over-50b-obesity-market?utm_source=businessinsider&utm_medium=referral
1783.0,7/18/2022 1:18:25 PM,"Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers",Seeking Alpha,https://seekingalpha.com/news/3857560-erasca-eli-lilly-to-collaborate-on-trial-to-evaluate-combo-treatment-for-two-cancers?utm_source=businessinsider&utm_medium=referral
1784.0,7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral
1785.0,7/20/2022 10:00:43 PM,7 Best Pharmaceutical Stocks to Buy Now,InvestorPlace,/news/stocks/best-pharmaceutical-stocks-1031602627
1786.0,7/21/2022 3:49:50 PM,AstraZeneca COVID-19 therapy less effective against new Omicron strains: study,Seeking Alpha,https://seekingalpha.com/news/3859171-astrazeneca-covid-19-therapy-less-protection-against-new-omicron-strains?utm_source=businessinsider&utm_medium=referral
1787.0,7/21/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-second-quarter-2022-financial-results-announcement-1031605059
1788.0,7/21/2022 7:03:18 PM,"New Indication Approval For Incyte ""To Usher New Growth Avenue""",Benzinga,/news/stocks/new-indication-approval-for-incyte-to-usher-new-growth-avenue-1031605581
1789.0,7/21/2022 9:05:24 PM,Scientist casts doubt on amyloid theory for Alzheimer's; sees issues with Cassava images,Seeking Alpha,https://seekingalpha.com/news/3859403-scientist-casts-doubt-on-amyloid-theory-for-alzheimers-sees-issues-with-cassava-images?utm_source=businessinsider&utm_medium=referral
1790.0,7/22/2022 1:13:06 PM,"EMA panel recommends approval of Lilly drug Mounjaro, extension of indication for Retsevmo",Seeking Alpha,https://seekingalpha.com/news/3859615-ema-panel-recommends-approval-of-lilly-drug-mounjaro-extension-of-indication-for-retsevmo?utm_source=businessinsider&utm_medium=referral
1791.0,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral
1792.0,7/26/2022 10:37:23 AM,"China clears HIV pill for COVID-19, marking 1st home-made pill against coronavirus",Seeking Alpha,https://seekingalpha.com/news/3860382-china-clears-hiv-pill-for-covid-19-marking-1st-home-made-pill-against-coronavirus?utm_source=businessinsider&utm_medium=referral
1793.0,7/26/2022 8:16:10 PM,Surge in use of Pfizer's COVID antiviral Paxlovid since May,Seeking Alpha,https://seekingalpha.com/news/3860833-nearly-28m-courses-of-pfizer-covid-antiviral-paxlovid-administered-so-far?utm_source=businessinsider&utm_medium=referral
1794.0,7/28/2022 8:20:28 PM,Senate Democrats propose $21B funding for next phase of COVID-19 response,Seeking Alpha,https://seekingalpha.com/news/3862718-senate-democrats-propose-21b-funding-for-next-phase-of-covid-19-response?utm_source=businessinsider&utm_medium=referral
1795.0,7/29/2022 4:41:48 PM,"Earnings Week Ahead: Starbucks, Caterpillar, AMD, Uber, Moderna, JetBlue, and more",Seeking Alpha,https://seekingalpha.com/news/3863301-earnings-week-ahead-starbucks-caterpillar-amd-uber-moderna-jetblue-and-more?utm_source=businessinsider&utm_medium=referral
1796.0,8/1/2022 10:16:04 AM,Innate stock slumps 16% as AstraZeneca pulls plug on monalizumab in head/neck cancer after trial failure,Seeking Alpha,https://seekingalpha.com/news/3863571-innate-stock-slumps-16-as-astrazeneca-pulls-plug-on-monalizumab-in-headneck-cancer-after-trial-failure?utm_source=businessinsider&utm_medium=referral
1797.0,8/3/2022 2:45:21 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3865794-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral
1798.0,8/3/2022 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q2-earnings-preview-1031645714
1799.0,8/3/2022 5:43:40 PM,What to expect from Eli Lilly Q2 2022 earnings?,Seeking Alpha,https://seekingalpha.com/news/3866097-what-to-expect-from-eli-lilly-q2-2022-earnings?utm_source=businessinsider&utm_medium=referral
1800.0,8/4/2022 10:26:56 AM,"Eli Lilly Non-GAAP EPS of $1.71 in-line, revenue of $6.48B misses by $370M, cuts FY22 EPS guidance",Seeking Alpha,https://seekingalpha.com/news/3866905-eli-lilly-non-gaap-eps-of-1_71-in-line-revenue-of-6_48b-misses-370m?utm_source=businessinsider&utm_medium=referral
1801.0,8/4/2022 11:10:11 AM,Eli Lilly slips as quarterly revenue declines for the first time in two years,Seeking Alpha,https://seekingalpha.com/news/3866996-lly-stock-slips-as-quarterly-revenue-declines-for-the-first-time-in-two-years?utm_source=businessinsider&utm_medium=referral
1802.0,8/4/2022 12:25:00 PM,"Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements",PR Newswire,/news/stocks/lilly-reports-second-quarter-financial-results-highlights-momentum-of-new-medicines-and-pipeline-advancements-1031650013
1803.0,8/4/2022 12:30:33 PM,Eli Lilly And Co. Profit Declines In Q2,RTTNews,/news/stocks/eli-lilly-and-co-profit-declines-in-q2-1031650064
1804.0,8/4/2022 12:58:11 PM,Eli Lilly Reduces FY22 Earnings Guidance; Revenue Outlook Remains Unchanged ,RTTNews,/news/stocks/eli-lilly-reduces-fy22-earnings-guidance-revenue-outlook-remains-unchanged-1031650211
1805.0,8/4/2022 3:06:29 PM,"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",Benzinga,/news/stocks/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazeneca-s-lynparza-in-early-stage-breast-cancer-decision-day-for-alzheimer-s-associated-hallucinations-candidate-1031651306
1806.0,8/4/2022 3:52:00 PM,Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results,PR Newswire,/news/stocks/lilly-updates-conference-call-start-time-for-second-quarter-2022-financial-results-1031651514
1807.0,8/4/2022 5:18:38 PM,Eli Lilly ordered to pay $183M in whistleblower Medicaid fraud case - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3867381-eli-lilly-ordered-to-pay-183m-in-whistleblower-medicaid-fraud-case-bloomberg?utm_source=businessinsider&utm_medium=referral
1808.0,8/7/2022 8:39:37 PM,The 7 Best Fidelity Funds for Retirees,InvestorPlace,/news/stocks/best-fidelity-funds-for-retirees-1031657952
1809.0,8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral
1810.0,8/8/2022 7:35:46 AM,HUTCHMED Stock Up As Fruquintinib Global Phase III FRESCO-2 Study In CRC Meets Primary Goal ,RTTNews,/news/stocks/hutchmed-stock-up-as-fruquintinib-global-phase-iii-fresco-2-study-in-crc-meets-primary-goal-1031660134
1811.0,8/8/2022 9:38:29 AM,What companies are most exposed to the Inflation Reduction Act?,Seeking Alpha,https://seekingalpha.com/news/3868607-what-companies-are-most-exposed-to-the-inflation-reduction-act?utm_source=businessinsider&utm_medium=referral
1812.0,8/8/2022 9:55:13 AM,"Hutchmed fruquintinib improves survival, meets main goal of colorectal cancer study",Seeking Alpha,https://seekingalpha.com/news/3868609-hutchmed-fruquintinib-improves-survival-meets-main-goal-of-colorectal-cancer-study?utm_source=businessinsider&utm_medium=referral
1813.0,8/8/2022 11:31:00 AM,Lilly arthritis/psoriasis drug Taltz's citrate-free formulation becomes available in US,Seeking Alpha,https://seekingalpha.com/news/3868675-lilly-arthritispsoriasis-drug-taltzs-citrate-free-formulation-becomes-available-in-us?utm_source=businessinsider&utm_medium=referral
1814.0,8/8/2022 12:45:00 PM,"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience",PR Newswire,/news/stocks/lilly-s-taltz-ixekizumab-now-available-in-new-citrate-free-formulation-to-reduce-injection-site-pain-for-improved-patient-experience-1031660650
1815.0,8/8/2022 1:51:11 PM,Eli Lilly Says New Formulation Of Taltz Injection Available Across US ,RTTNews,/news/stocks/eli-lilly-says-new-formulation-of-taltz-injection-available-across-us-1031660874
1816.0,8/8/2022 3:44:30 PM,Nektar downgraded at JPMorgan citing setup after end to anti-cancer program,Seeking Alpha,https://seekingalpha.com/news/3868851-nektar-downgraded-at-jpmorgan-citing-setup-after-end-to-anti-cancer-program?utm_source=businessinsider&utm_medium=referral
1817.0,8/9/2022 1:38:04 AM,The 3 Best Vanguard Funds to Buy in August,InvestorPlace,/news/stocks/best-vanguard-funds-1031663161
1818.0,8/9/2022 3:26:35 PM,Lilly picks AmerisourceBergen for U.S. commercial rollout of COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3869877-lilly-picks-amerisourcebergen-for-commercial-rollout-of-covid-antibody-therapy?utm_source=businessinsider&utm_medium=referral
1819.0,8/10/2022 5:48:21 PM,AbCellera stock rises ~17% as continued strength from COVID royalties overshadows Q2 miss,Seeking Alpha,https://seekingalpha.com/news/3870902-abcellera-stock-rises-17-as-continued-strength-from-covid-royalties-overshadows-q2-miss?utm_source=businessinsider&utm_medium=referral
1820.0,8/11/2022 2:30:00 PM,Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly,PR Newswire,/news/stocks/lilly-announces-leadership-transition-in-human-resources-and-new-chief-commercial-officer-for-loxo-lilly-1031675758
1821.0,8/11/2022 4:52:13 PM,ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off,Benzinga,/news/stocks/alx-oncology-shares-climb-as-mid-stage-triple-combination-colorectal-cancer-study-kicks-off-1031676485
1822.0,8/11/2022 7:26:06 PM,CDC eases COVID guidance for unvaccinated people,Seeking Alpha,https://seekingalpha.com/news/3871779-cdc-eases-covid-guidance-for-unvaccinated-people?utm_source=businessinsider&utm_medium=referral
1823.0,8/12/2022 12:07:01 AM,Recap Of Thursday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-thursday-s-biotech-catalysts---end-of-the-day-summary-1031677667
1824.0,8/12/2022 8:05:42 PM,Raymond James Bullish On This Penny Stock's Reprioritized Pipeline,Benzinga,/news/stocks/raymond-james-bullish-on-this-penny-stock-s-reprioritized-pipeline-1031680579
1825.0,8/13/2022 1:13:36 AM,"House clears bill on climate change, drug prices",Seeking Alpha,https://seekingalpha.com/news/3872584-house-clears-bill-on-climate-change-drug-prices?utm_source=businessinsider&utm_medium=referral
1826.0,8/17/2022 10:54:23 AM,"U.S. govt. to stop buying COVID-19 vaccines, therapies, tests from this fall – Jha",Seeking Alpha,https://seekingalpha.com/news/3874012-us-govt-to-stop-buying-covid-19-vaccines-therapies-tests-from-this-fall-jha?utm_source=businessinsider&utm_medium=referral
1827.0,8/17/2022 5:10:23 PM,CDC seeks reforms to correct COVID missteps,Seeking Alpha,https://seekingalpha.com/news/3874241-cdc-to-implement-reforms-to-correct-covid-missteps?utm_source=businessinsider&utm_medium=referral
1828.0,8/18/2022 3:13:59 PM,"Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity",Seeking Alpha,https://seekingalpha.com/news/3874688-alnylam-discovery-of-genetic-mutations-could-lead-to-therapies-for-diabetes-obesity?utm_source=businessinsider&utm_medium=referral
1829.0,8/19/2022 12:31:52 PM,"HHS sets Aug. 30 meeting as costs for COVID products to shift to payors, individuals – WSJ",Seeking Alpha,https://seekingalpha.com/news/3875015-hhs-sets-aug-meeting-as-covid-products-head-for-commercialization-wsj?utm_source=businessinsider&utm_medium=referral
1830.0,8/19/2022 6:44:30 PM,10 Best Fidelity Funds to Buy Now,InvestorPlace,/news/stocks/best-fidelity-funds-1031695976
1831.0,8/25/2022 1:03:42 PM,"Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata",Seeking Alpha,https://seekingalpha.com/news/3876632-aclaris-lilly-ink-patent-license-deal-for-olumiant-to-treat-alopecia-areata?utm_source=businessinsider&utm_medium=referral
1832.0,8/25/2022 2:40:47 PM,Jim Cramer Says He's Passing On This $10 Social Media Stock As It's 'Losing Money',Benzinga,/news/stocks/jim-cramer-says-he-s-passing-on-this-10-social-media-stock-as-it-s-losing-money-1031705774
1833.0,8/25/2022 2:40:57 PM,Citi bullish on Eli Lilly as it significantly boosts price target; sees 16% upside,Seeking Alpha,https://seekingalpha.com/news/3876692-citi-bullish-on-eli-lilly-as-it-significantly-boosts-price-target-sees-16-upside?utm_source=businessinsider&utm_medium=referral
1834.0,8/25/2022 4:00:00 PM,Lilly to Participate in Citi's 17th Annual BioPharma Conference,PR Newswire,/news/stocks/lilly-to-participate-in-citi-s-17th-annual-biopharma-conference-1031706171
1835.0,8/25/2022 8:45:32 PM,Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate,Benzinga,/news/stocks/citi-is-bullish-on-this-large-pharma-stock-on-upcoming-data-readout-from-diabetes-candidate-1031706767
1836.0,8/31/2022 2:27:50 PM,"U.S. outlines plans to move COVID-19 drugs, vaccines to commercial market",Seeking Alpha,https://seekingalpha.com/news/3878943-us-outlines-plans-to-move-covid-19-drugs-vaccines-to-commercial-market?utm_source=businessinsider&utm_medium=referral
1837.0,8/31/2022 4:00:00 PM,Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-morgan-stanley-20th-annual-global-healthcare-conference-1031716507
1838.0,9/2/2022 10:00:00 PM,"Micron, Intel among new ideas in BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3879926-micron-intel-among-new-ideas-in-bofas-alpha-surprise-screen?utm_source=businessinsider&utm_medium=referral
1839.0,9/6/2022 2:16:31 PM,"This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%",Benzinga,/news/stocks/this-analyst-predicts-396-for-eli-lilly-plus-raymond-james-slashes-pt-on-this-stock-by-over-73-1031726123
1840.0,9/6/2022 5:24:31 PM,Why Eli Lilly Stock Is Rising Today,Benzinga,/news/stocks/why-eli-lilly-stock-is-rising-today-1031726838
1841.0,9/7/2022 8:06:21 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031730199
1842.0,9/7/2022 10:05:54 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1031730392
1843.0,9/8/2022 12:05:00 AM,Lilly Announces Details of Presentations at ESMO Congress 2022,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-esmo-congress-2022-1031730623
1844.0,9/8/2022 2:15:00 PM,Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials,PR Newswire,/news/stocks/lebrikizumab-dosed-every-four-weeks-maintained-durable-skin-clearance-in-lilly-s-phase-3-monotherapy-atopic-dermatitis-trials-1031731845
1845.0,9/8/2022 3:40:48 PM,Eli Lilly: Late-breaking Lebrikizumab Data Shows Long-lasting Results In Atopic Dermatitis ,RTTNews,/news/stocks/eli-lilly-late-breaking-lebrikizumab-data-shows-long-lasting-results-in-atopic-dermatitis-1031732361
1846.0,9/9/2022 12:17:21 AM,"Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-8-2022---end-of-the-day-summary-1031733508
1847.0,9/9/2022 1:14:39 PM,Tesla Fame's Robot-Run ETF Sold Its Entire Apple Stake In August — Here's What It Bought,Benzinga,/news/etf/tesla-fame-s-robot-run-etf-sold-its-entire-apple-stake-in-august-—-here-s-what-it-bought-1031734407
1848.0,9/12/2022 8:49:32 PM,Biotech Stocks Stand to Benefit as Biden Announces Support for Industry,InvestorPlace,/news/stocks/biotech-stocks-stand-to-benefit-as-biden-announces-support-for-industry-1031738367
1849.0,9/14/2022 2:18:38 PM,"End in sight for COVID-19 pandemic, WHO chief says",Seeking Alpha,https://seekingalpha.com/news/3882728-end-in-sight-for-covid-19-pandemic-who-chief-says?utm_source=businessinsider&utm_medium=referral
1850.0,9/14/2022 3:02:28 PM,Piper Sandler sees Altimmune liver/obesity drug competitive despite weight loss data,Seeking Alpha,https://seekingalpha.com/news/3882751-piper-sandler-sees-altimmune-liverobesity-drug-as-competitive-despite-weight-loss-data?utm_source=businessinsider&utm_medium=referral
1851.0,9/17/2022 8:14:23 PM,7 Blue-Chip Stocks to Buy for Safety in This Volatile Market,InvestorPlace,/news/stocks/7-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market-1031749158
1852.0,9/20/2022 8:18:52 PM,3 Stocks That Could Rocket on Biden’s Cancer Moonshot,InvestorPlace,/news/stocks/3-stocks-that-could-rocket-on-bidens-cancer-moonshot-1031754919
1853.0,9/22/2022 1:12:00 AM,"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type",PR Newswire,/news/stocks/fda-approves-lilly-s-retevmo-selpercatinib-the-first-and-only-ret-inhibitor-for-adults-with-advanced-or-metastatic-solid-tumors-with-a-ret-gene-fusion-regardless-of-type-1031757905
1854.0,9/22/2022 2:47:16 AM,Lilly : FDA Approves Retevmo For Adult Patients With Locally Advanced Or Metastatic Solid Tumors ,RTTNews,/news/stocks/lilly-fda-approves-retevmo-for-adult-patients-with-locally-advanced-or-metastatic-solid-tumors-1031757926
1855.0,9/22/2022 10:58:30 AM,Eli Lilly wins FDA approval for solid tumor therapy,Seeking Alpha,https://seekingalpha.com/news/3885170-lly-stock-gains-after-fda-approval-for-solid-tumor-therapy?utm_source=businessinsider&utm_medium=referral
1856.0,9/22/2022 1:35:19 PM,Eli Lilly raised to Buy at UBS; named top large cap pick,Seeking Alpha,https://seekingalpha.com/news/3885286-lly-stock-raised-to-buy-at-ubs-named-top-large-cap-pick?utm_source=businessinsider&utm_medium=referral
1857.0,9/22/2022 3:55:15 PM,"WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed",Seeking Alpha,https://seekingalpha.com/news/3885339-who-chief-reiterates-belief-that-covid-19-pandemic-end-near-says-work-still-needed?utm_source=businessinsider&utm_medium=referral
1858.0,9/22/2022 4:38:31 PM,Why Eli Lilly Is This Analyst's 'New Top Large Cap Pick',Benzinga,/news/stocks/why-eli-lilly-is-this-analyst-s-new-top-large-cap-pick-1031759769
1859.0,9/22/2022 7:25:05 PM,Healthcare outperforms S&P 500 as large cap pharma rebounds,Seeking Alpha,https://seekingalpha.com/news/3885399-healthcare-outperforms-sp-500-as-large-cap-pharma-rebounds?utm_source=businessinsider&utm_medium=referral
1860.0,9/22/2022 8:55:50 PM,7 Stocks to Buy That Can Soar in Good Times or in Bad,InvestorPlace,/news/stocks/7-stocks-to-buy-that-can-soar-in-good-times-or-in-bad-1031760580
1861.0,9/23/2022 6:48:02 PM,BlackRock Says Buy High-Quality Healthcare Stocks to Weather a Recession; Here Are 2 Names That Analysts Like,TipRanks,/news/stocks/blackrock-says-buy-high-quality-healthcare-stocks-to-weather-a-recession-here-are-2-names-that-analysts-like-1031762647
1862.0,9/26/2022 1:50:20 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbCellera Biologics (ABCL)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-abcellera-biologics-abcl-1031764942
1863.0,9/26/2022 10:29:08 PM,"EEOC sues Lilly USA, alleging nationwide age discrimination",Seeking Alpha,https://seekingalpha.com/news/3886177-eeoc-sues-lilly-usa-alleging-nationwide-age-discrimination?utm_source=businessinsider&utm_medium=referral
1864.0,9/27/2022 9:04:58 PM,Thermo Fisher wins FDA OK of Oncomine Dx Target test to aid in cancer therapy selection,Seeking Alpha,https://seekingalpha.com/news/3886564-thermo-fisher-wins-fda-ok-of-oncomine-dx-target-test-to-aid-in-cancer-therapy-selection?utm_source=businessinsider&utm_medium=referral
1865.0,9/28/2022 10:43:14 AM,"Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial",Seeking Alpha,https://seekingalpha.com/news/3886651-biogen-eisai-spark-rally-in-alzheimers-stocks-on-late-stage-lecanemab-data?utm_source=businessinsider&utm_medium=referral
1866.0,9/28/2022 12:09:47 PM,2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data,Benzinga,/news/stocks/2-sympathy-plays-to-watch-for-in-the-wake-of-biogen-s-positive-alzheimer-s-drug-data-1031769371
1867.0,9/28/2022 12:13:38 PM,"Biogen, Eli Lilly And Some Other Big Stocks Moving Higher In Today's Pre-Market Session",Benzinga,/news/stocks/biogen-eli-lilly-and-some-other-big-stocks-moving-higher-in-today-s-pre-market-session-1031769388
1868.0,9/28/2022 12:53:05 PM,"Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… ",RTTNews,/news/stocks/pre-market-movers-silo-prta-biib-nxpl-abos-1031769509
1869.0,9/28/2022 1:17:23 PM,Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket,Benzinga,/news/stocks/why-mindmed-is-trading-lower-by-around-35-here-are-31-stocks-moving-premarket-1031769653
1870.0,9/28/2022 2:22:32 PM,Prothena climbs 80% as Bofa upgrades after rivals’ Alzheimer’s data,Seeking Alpha,https://seekingalpha.com/news/3886766-prothena-climbs-80-as-bofa-upgrades-after-rivals-alzheimers-data?utm_source=businessinsider&utm_medium=referral
1871.0,9/28/2022 3:02:10 PM,Why Is Cassava Sciences (SAVA) Stock Heating Up Today?,InvestorPlace,/news/stocks/why-is-cassava-sciences-sava-stock-heating-up-today-1031770608
1872.0,9/28/2022 3:54:55 PM,"Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval",Seeking Alpha,https://seekingalpha.com/news/3886771-eisai-biogens-lecanemab-cognitive-improvement-bodes-well-for-alzheimers-approval?utm_source=businessinsider&utm_medium=referral
1873.0,9/28/2022 4:04:37 PM,"Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval",Seeking Alpha,https://seekingalpha.com/news/3886771-eisai-biogen-lecanemab-cognitive-improvement-bodes-well-for-alzheimers-approval?utm_source=businessinsider&utm_medium=referral
1874.0,9/28/2022 5:39:12 PM,"Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results",InvestorPlace,/news/stocks/biotech-stocks-lly-esaly-biib-gain-on-biogen-positive-trial-results-1031771015
1875.0,9/28/2022 6:30:05 PM,This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval,Benzinga,/news/stocks/this-analyst-believes-biogen-s-lecanemab-data-not-slam-dunk-for-complete-cms-approval-1031770867
1876.0,9/28/2022 6:40:47 PM,"Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session",Benzinga,/news/stocks/why-prothena-corporation-shares-are-trading-higher-by-76-here-are-53-stocks-moving-in-wednesday-s-mid-day-session-1031770887
1877.0,9/28/2022 10:01:13 PM,"Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data",Seeking Alpha,https://seekingalpha.com/news/3886925-many-alzheimers-drug-developers-close-significantly-higher-thanks-to-biogen-eisai-data?utm_source=businessinsider&utm_medium=referral
1878.0,9/28/2022 10:17:23 PM,These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win,Benzinga,/news/stocks/these-stocks-are-on-the-radar-after-biogen-eisai-s-surprising-alzheimer-s-trial-win-1031771238
1879.0,9/29/2022 12:43:06 AM,7 Growth Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/7-growth-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031771484
1880.0,9/29/2022 9:45:49 AM,"Netflix, Biogen And Other Big Gainers From Wednesday",Benzinga,/news/stocks/netflix-biogen-and-other-big-gainers-from-wednesday-1031771992
1881.0,9/29/2022 11:09:35 AM,Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-nls-pharmaceutics-shares-tumbled-over-66-here-are-68-biggest-movers-from-yesterday-1031772129
1882.0,9/29/2022 6:07:42 PM,"Biogen, Eisai cool off after massive run-up following lecanemab Alzheimer's data",Seeking Alpha,https://seekingalpha.com/news/3887223-biogen-eisai-cool-off-after-massive-run-up-following-lecanemab-alzheimers-data?utm_source=businessinsider&utm_medium=referral
1883.0,10/2/2022 4:00:31 PM,COVID stocks lag U.S. biopharma in Q3; Alzheimer’s theme regains focus,Seeking Alpha,https://seekingalpha.com/news/3887740-covid-stocks-lag-us-biopharma-in-q3-alzheimers-theme-regains-focus?utm_source=businessinsider&utm_medium=referral
1884.0,10/3/2022 2:10:59 PM,Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY) and Alnylam Pharma (ALNY),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-and-alnylam-pharma-alny-1031779181
1885.0,10/3/2022 7:23:24 PM,AstraZeneca COVID-19 antibodies unlikely to protect against new Omicron subvariant,Seeking Alpha,https://seekingalpha.com/news/3888160-astrazeneca-covid-19-antibody-unlikely-to-act-against-new-omicron-subvariant?utm_source=businessinsider&utm_medium=referral
1886.0,10/4/2022 4:30:31 AM,"LLY, ISRG, or BMY: Which Healthcare Stock Could Yield Better Returns?",TipRanks,/news/stocks/lly-isrg-or-bmy-which-healthcare-stock-could-yield-better-returns-1031780497
1887.0,10/5/2022 12:15:30 PM,"Use short-term rallies to boost high-momentum stock exposure, Wells Fargo says",Seeking Alpha,https://seekingalpha.com/news/3888434-use-short-term-rallies-to-bost-high-momentum-stock-exposure?utm_source=businessinsider&utm_medium=referral
1888.0,10/6/2022 9:51:10 AM,Adocia M1Pram shows weight loss benefit vs Lilly's Humalog in obese diabetic patients in trial,Seeking Alpha,https://seekingalpha.com/news/3889114-adocia-m1pram-shows-weight-loss-benefit-vs-lillys-humalog-in-obese-diabetic-patients-in-trial?utm_source=businessinsider&utm_medium=referral
1889.0,10/6/2022 11:10:06 AM,Lilly's tirzepatide gets FDA fast track status to treat obesity,Seeking Alpha,https://seekingalpha.com/news/3889141-lillys-tirzepatide-gets-fda-fast-track-status-to-treat-obesity?utm_source=businessinsider&utm_medium=referral
1890.0,10/6/2022 12:35:11 PM,FDA agrees to single phase 3 trial by Entera for bone disorder drug EB613 to support approval,Seeking Alpha,https://seekingalpha.com/news/3889191-fda-agrees-to-single-phase-3-trial-by-entera-for-bone-disorder-drug-eb613-to-support-approval?utm_source=businessinsider&utm_medium=referral
1891.0,10/6/2022 12:45:00 PM,"Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities",PR Newswire,/news/stocks/lilly-receives-u-s-fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity-or-overweight-with-weight-related-comorbidities-1031786861
1892.0,10/6/2022 1:21:43 PM,Eli Lilly Gets Fast Track Status For Its Tirzepatide To Treat Obesity ,RTTNews,/news/stocks/eli-lilly-gets-fast-track-status-for-its-tirzepatide-to-treat-obesity-1031786970
1893.0,10/6/2022 2:58:18 PM,Bipartisan bill aims to get CMS to cover Alzheimer's antibody treatments,Seeking Alpha,https://seekingalpha.com/news/3889267-bipartisan-bill-aims-to-gets-cms-to-cover-alzheimers-antibody-treatments?utm_source=businessinsider&utm_medium=referral
1894.0,10/10/2022 3:11:37 AM,Innovent Biologics: China Oks Selpercatinib NDA For Treatment Of RET-driven Lung And Thyroid Cancers ,RTTNews,/news/stocks/innovent-biologics-china-oks-selpercatinib-nda-for-treatment-of-ret-driven-lung-and-thyroid-cancers-1031791613
1895.0,10/10/2022 3:18:05 AM,Innovent Biologics : China Approves SNDA For CYRAMZA For Hepatocellular Carcinoma Treatment ,RTTNews,/news/stocks/innovent-biologics-china-approves-snda-for-cyramza-for-hepatocellular-carcinoma-treatment-1031791615
1896.0,10/10/2022 8:34:09 AM,"Lilly, Innovent's Cyramza gets approval in China to treat liver cancer",Seeking Alpha,https://seekingalpha.com/news/3889903-lilly-innovents-cyramza-gets-approval-in-china-to-treat-liver-cancer?utm_source=businessinsider&utm_medium=referral
1897.0,10/10/2022 10:15:48 AM,These 7 Biotech Stocks Are Set to Boom in 2023,InvestorPlace,/news/stocks/7-biotech-stocks-set-to-boom-2023-1031792647
1898.0,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral
1899.0,10/11/2022 9:01:54 AM,"Analysts Are Bullish on Top Healthcare Stocks: Avenue Therapeutics (ATXI), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-avenue-therapeutics-atxi-eli-lilly-co-lly-1031795182
1900.0,10/11/2022 4:08:51 PM,"Amgen up 6%, leading S&P 500, following bullish call from Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3890404-amgen-up-6-leading-sp-500-following-bullish-call-from-morgan-stanley?utm_source=businessinsider&utm_medium=referral
1901.0,10/11/2022 7:18:00 PM,Lilly in license agreement with Nimbus Therapeutics for metabollc disease treatments,Seeking Alpha,https://seekingalpha.com/news/3890460-lilly-in-license-agreement-with-nimbus-therapeutics-for-metabollc-disease-treatments?utm_source=businessinsider&utm_medium=referral
1902.0,10/12/2022 8:23:13 PM,What 4 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-4-analyst-ratings-have-to-say-about-eli-lilly-1031800702
1903.0,10/12/2022 8:47:17 PM,Lilly Q3 results will be impacted by 6-cent charge to GAAP and adjusted EPS,Seeking Alpha,https://seekingalpha.com/news/3890851-eli-lilly-q3-results-will-be-impacted-by-6-cent-charge-to-gaap-and-adjusted-eps?utm_source=businessinsider&utm_medium=referral
1904.0,10/13/2022 3:27:17 PM,Biogen upgraded to buy at Stifel on lecanemab Alzheimer's treatment,Seeking Alpha,https://seekingalpha.com/news/3891135-biogen-upgraded-to-buy-at-stifel-on-lecanemab-alzheimers-treatment?utm_source=businessinsider&utm_medium=referral
1905.0,10/13/2022 7:45:04 PM,"Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts",Benzinga,/news/stocks/analyst-upgrades-biogen-citing-upcoming-conference-competitive-readouts-1031804196
1906.0,10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral
1907.0,10/14/2022 1:28:20 PM,Lilly's Lyumjev gets EMA panel backing for use in children with diabetes,Seeking Alpha,https://seekingalpha.com/news/3891425-lillys-lyumjev-gets-ema-panel-backing-for-use-in-children-with-diabetes?utm_source=businessinsider&utm_medium=referral
1908.0,10/14/2022 4:45:44 PM,CDC data shows that cases of new COVID 'escape variants' on the rise,Seeking Alpha,https://seekingalpha.com/news/3891468-cdc-data-shows-that-cases-of-new-covid-escape-variants-on-the-rise?utm_source=businessinsider&utm_medium=referral
1909.0,10/15/2022 12:15:27 PM,Eli Lilly & Co (LLY) Gets a Buy from J.P. Morgan,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-j-p-morgan-1031807379
1910.0,10/17/2022 4:09:15 PM,Eli Lilly declares $0.98 dividend,Seeking Alpha,https://seekingalpha.com/news/3891896-eli-lilly-and-company-declares-0_98-dividend?utm_source=businessinsider&utm_medium=referral
1911.0,10/17/2022 6:04:00 PM,Lilly Declares Fourth-Quarter 2022 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2022-dividend-1031810669
1912.0,10/18/2022 11:25:10 AM,Akouos soars 87% as Lilly nabs hearing loss gene therapy developer,Seeking Alpha,https://seekingalpha.com/news/3892121-akouos-soars-87-as-lilly-nabs-hearing-loss-gene-therapy-developer?utm_source=businessinsider&utm_medium=referral
1913.0,10/18/2022 12:50:00 PM,Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss,PR Newswire,/news/stocks/lilly-to-acquire-akouos-to-discover-and-develop-treatments-for-hearing-loss-1031812818
1914.0,10/18/2022 1:20:23 PM,Eli Lilly To Buy Akouos For Up To $610 Mln ,RTTNews,/news/stocks/eli-lilly-to-buy-akouos-for-up-to-610-mln-1031812953
1915.0,10/18/2022 2:46:47 PM,Why Is Akouos (AKUS) Stock Up 85% Today?,InvestorPlace,/news/stocks/why-is-akouos-akus-stock-up-85-today-1031814104
1916.0,10/18/2022 3:30:49 PM,Decibel Therapeutics hears it may be a takeout target after Lilly acquisition of Akouos,Seeking Alpha,https://seekingalpha.com/news/3892281-decibel-therapeutics-hears-it-may-be-a-takeou-ttarget-after-eli-lilly-acquisition-of-akouos?utm_source=businessinsider&utm_medium=referral
1917.0,10/18/2022 4:14:25 PM,US Stocks Extend Monday's Gains; Dow Jumps Over 500 Points,Benzinga,/news/stocks/us-stocks-extend-monday-s-gains-dow-jumps-over-500-points-1031813982
1918.0,10/18/2022 6:43:40 PM,Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-akouos-shares-are-trading-sharply-higher-here-are-36-stocks-moving-in-tuesday-s-mid-day-session-1031814418
1919.0,10/18/2022 6:54:57 PM,Nasdaq Rises Over 100 Points; Goldman Sachs Tops Q3 Views,Benzinga,/news/stocks/nasdaq-rises-over-100-points-goldman-sachs-tops-q3-views-1031814476
1920.0,10/18/2022 8:43:41 PM,Crude Oil Drops Over 2%; Akouos Shares Spike Higher,Benzinga,/news/stocks/crude-oil-drops-over-2-akouos-shares-spike-higher-1031814653
1921.0,10/19/2022 10:18:19 AM,"Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday",Benzinga,/news/stocks/carnival-amazon-iamgold-and-other-big-gainers-from-tuesday-1031816461
1922.0,10/19/2022 11:10:26 AM,Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-quoin-pharmaceuticals-shares-jumped-by-more-than-44-here-are-57-biggest-movers-from-yesterday-1031816546
1923.0,10/19/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2022-financial-results-announcement-1031817838
1924.0,10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral
1925.0,10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral
1926.0,10/26/2022 12:10:43 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Masimo (MASI) and Teleflex (TFX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-masimo-masi-and-teleflex-tfx-1031837891
1927.0,10/26/2022 2:39:42 PM,Biogen raised to Buy at Goldman Sachs as Alzheimer’s prospects return,Seeking Alpha,https://seekingalpha.com/news/3895547-biib-stock-gains-as-goldman-sachs-upgrades-on-alzheimers-prospects?utm_source=businessinsider&utm_medium=referral
1928.0,10/27/2022 4:00:00 PM,Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration,PR Newswire,/news/stocks/lilly-commits-92-5-million-to-purdue-to-establish-an-innovative-pharmaceutical-manufacturing-scholarship-program-and-to-extend-research-collaboration-1031844055
1929.0,10/28/2022 5:30:56 PM,"Earnings week ahead: Uber, Pfizer, Peloton, Paramount Global, BP and more",Seeking Alpha,https://seekingalpha.com/news/3897313-earnings-week-ahead-uber-pfizer-peloton-paramount-global-bp-and-more?utm_source=businessinsider&utm_medium=referral
1930.0,10/28/2022 6:30:28 PM,"Catalyst watch: FOMC jitters, Starbucks and Pfizer earnings, Boeing and AMD events",Seeking Alpha,https://seekingalpha.com/news/3897337-catalyst-watch-fomc-jitters-starbucks-and-pfizer-earnings-boeing-and-amd-events?utm_source=businessinsider&utm_medium=referral
1931.0,10/31/2022 1:21:04 PM,Amgen downgraded at Barclays citing rally fueled by weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/3897732-amgn-stock-downgraded-at-barclays-citing-rally-fueled-by-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral
1932.0,10/31/2022 2:12:40 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-abbvie-abbv-1031854099
1933.0,10/31/2022 2:38:59 PM,What to expect from Eli Lilly Q3 2022 Earnings,Seeking Alpha,https://seekingalpha.com/news/3897794-what-to-expect-from-eli-lilly-q3-2022-earnings?utm_source=businessinsider&utm_medium=referral
1934.0,10/31/2022 3:01:13 PM,Eli Lilly and is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-quarter-earnings-preview-q3-1031853955
1935.0,10/31/2022 3:21:29 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3897806-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral
1936.0,11/1/2022 10:27:00 AM,"Eli Lilly Non-GAAP EPS of $2.04 beats by $0.11, revenue of $6.94B beats by $30M, cuts FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3898329-eli-lilly-non-gaap-eps-of-204-beats-by-011-revenue-of-694b-beats-by-30m-cuts-fy22-outlook?utm_source=businessinsider&utm_medium=referral
1937.0,11/1/2022 11:19:39 AM,"Lilly falls as FY22 outlook cut on forex impact, Trulicity drives Q3 sales",Seeking Alpha,https://seekingalpha.com/news/3898399-lilly-falls-as-fy22-outlook-cut-on-forex-impact-trulicity-drives-q3-sales?utm_source=businessinsider&utm_medium=referral
1938.0,11/1/2022 11:25:00 AM,Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress,PR Newswire,/news/stocks/lilly-reports-solid-third-quarter-2022-financial-results-and-continued-pipeline-progress-1031857552
1939.0,11/1/2022 11:34:21 AM,Eli Lilly And Co. Q3 Income Rises,RTTNews,/news/stocks/eli-lilly-and-co-q3-income-rises-1031857587
1940.0,11/1/2022 12:00:42 PM,Lilly Cuts FY22 Earnings Outlook Again - Update ,RTTNews,/news/stocks/lilly-cuts-fy22-earnings-outlook-again-update-1031857729
1941.0,11/1/2022 4:30:59 PM,AnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonists,Seeking Alpha,https://seekingalpha.com/news/3898656-anab-stock-raised-to-buy-at-guggenheim-on-checkpoint-agonists?utm_source=businessinsider&utm_medium=referral
1942.0,11/1/2022 7:57:55 PM,Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast,Benzinga,/news/stocks/nasdaq-down-60-points-eli-lilly-lowers-earnings-forecast-1031859928
1943.0,11/2/2022 4:45:52 AM,SVB Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1031860929
1944.0,11/2/2022 12:43:36 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Idexx Laboratories (IDXX) and Waters (WAT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-idexx-laboratories-idxx-and-waters-wat-1031863998
1945.0,11/2/2022 1:53:58 PM,Jim Cramer Says These 2 ‘Strong Buy’ Stocks Could Be Among the New Market Leaders,TipRanks,/news/stocks/jim-cramer-says-these-2-strong-buy-stocks-could-be-among-the-new-market-leaders-1031864877
1946.0,11/2/2022 7:07:52 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031865815
1947.0,11/3/2022 2:00:00 PM,Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting,PR Newswire,/news/stocks/loxo-lilly-announces-details-of-presentations-at-the-2022-american-society-of-hematology-annual-meeting-1031870510
1948.0,11/4/2022 3:30:00 PM,Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease,PR Newswire,/news/stocks/landmark-empa-kidney-trial-showed-significant-benefit-of-jardiance-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease-1031876269
1949.0,11/4/2022 3:31:28 PM,Eli Lilly COVID-19 therapy unlikely to neutralize new Omicron subvariants - FDA,Seeking Alpha,https://seekingalpha.com/news/3902025-eli-lilly-covid-19-therapy-unlikely-to-neutralize-new-omicron-subvariants?utm_source=businessinsider&utm_medium=referral
1950.0,11/4/2022 4:12:00 PM,Lilly : Phase III Trial Shows Benefit Of Jardiance In Reducing Kidney Disease Progression In CKD ,RTTNews,/news/stocks/lilly-phase-iii-trial-shows-benefit-of-jardiance-in-reducing-kidney-disease-progression-in-ckd-1031876429
1951.0,11/4/2022 5:26:53 PM,Eli Lilly heart disease therapy meets main goal in Phase 3 kidney disease trial,Seeking Alpha,https://seekingalpha.com/news/3902191-eli-lilly-heart-disease-therapy-meets-main-goal-in-phase-3-kidney-disease-trial?utm_source=businessinsider&utm_medium=referral
1952.0,11/6/2022 5:00:24 PM,"Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report",Seeking Alpha,https://seekingalpha.com/news/3902378-off-patent-drugs-make-up-91-of-prescriptions-18-of-spending?utm_source=businessinsider&utm_medium=referral
1953.0,11/7/2022 2:50:55 PM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), ImmunoGen (IMGN) and Bausch Health Companies (BHC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-immunogen-imgn-and-bausch-health-companies-bhc-1031881979
1954.0,11/7/2022 5:30:00 PM,Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform,PR Newswire,/news/stocks/lilly-to-begin-rollout-of-tempo-personalized-diabetes-management-platform-1031882320
1955.0,11/8/2022 7:04:04 PM,The 7 Best Pharma Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-best-pharma-stocks-to-buy-now-1031893081
1956.0,11/8/2022 7:47:03 PM,"Eli Lilly, Merck reach new 52-week highs",Seeking Alpha,https://seekingalpha.com/news/3903867-eli-lilly-merck-reach-new-52-week-highs?utm_source=businessinsider&utm_medium=referral
1957.0,11/10/2022 10:23:43 AM,Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit,Seeking Alpha,https://seekingalpha.com/news/3905343-boston-jury-orders-lilly-to-pay-1765m-to-teva-in-migraine-drug-patent-suit?utm_source=businessinsider&utm_medium=referral
1958.0,11/11/2022 8:16:39 PM,"Healthcare stocks come off lows, worst performing sector among defensive losers (update)",Seeking Alpha,https://seekingalpha.com/news/3906637-healthcare-stocks-fall-across-the-board-as-traders-move-out-of-defensive-sectors?utm_source=businessinsider&utm_medium=referral
1959.0,11/11/2022 9:31:43 PM,Why Are Healthcare Stocks Down Today?,InvestorPlace,/news/stocks/why-are-healthcare-stocks-down-today-1031905660
1960.0,11/12/2022 9:00:00 PM,"Novo Nordisk expected to maintain lead in diabetes market over Eli Lilly, report finds",Seeking Alpha,https://seekingalpha.com/news/3906692-novo-nordisk-expected-to-maintain-lead-in-diabetes-market-over-eli-lilly-report-finds?utm_source=businessinsider&utm_medium=referral
1961.0,11/13/2022 1:17:33 AM,Fake tweets from ‘verified’ Twitter accounts spur real losses for Lilly and Lockheed stock,Seeking Alpha,https://seekingalpha.com/news/3906751-fake-tweets-from-verified-twitter-accounts-spur-real-losses-for-lilly-and-lockheed-stock?utm_source=businessinsider&utm_medium=referral
1962.0,11/13/2022 1:59:54 AM,U.S. COVID health emergency to stay in place,Seeking Alpha,https://seekingalpha.com/news/3906753-us-covid-health-emergency-to-stay-in-place?utm_source=businessinsider&utm_medium=referral
1963.0,11/14/2022 2:11:59 AM,HUTCHMED Reports Mixed Results In Fruquintinib PhaseIII Study In Second-Line Gastric Cancer In China ,RTTNews,/news/stocks/hutchmed-reports-mixed-results-in-fruquintinib-phaseiii-study-in-second-line-gastric-cancer-in-china-1031907090
1964.0,11/14/2022 11:47:20 AM,Hutchmed stock rises 15% as fruquintinib meets one main goal in gastric cancer trial,Seeking Alpha,https://seekingalpha.com/news/3906919-hutchmed-stock-rises-15-as-fruquintinib-meets-one-main-goal-in-gastric-cancer-trial?utm_source=businessinsider&utm_medium=referral
1965.0,11/14/2022 1:17:31 PM,"Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus",Benzinga,/news/stocks/nasdaq-s-p-500-futures-pullback-at-start-of-new-trading-week-as-rate-fears-return-to-haunt-amd-tesla-biogen-eli-lilly-jd-in-focus-1031909736
1966.0,11/14/2022 1:40:23 PM,Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study,Benzinga,/news/stocks/hutchmed-lilly-partnered-gastric-cancer-drug-shows-mixed-results-in-phase-3-study-1031909859
1967.0,11/14/2022 2:51:28 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-crispr-therapeutics-ag-crsp-1031910665
1968.0,11/14/2022 4:59:20 PM,"Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback",Seeking Alpha,https://seekingalpha.com/news/3907250-cassava-biogen-lead-alzheimers-stocks-higher-following-roches-gantenerumab-setback?utm_source=businessinsider&utm_medium=referral
1969.0,11/14/2022 9:02:09 PM,"Druckenmiller's Duquesne adds Amazon, exits Westlake, lowers Microsoft stake",Seeking Alpha,https://seekingalpha.com/news/3907390-druckenmillers-duquesne-adds-amazon-exits-westlake-lowers-microsoft-stake?utm_source=businessinsider&utm_medium=referral
1970.0,11/14/2022 9:08:32 PM,Fake free insulin Tweet leads Eli Lilly to pull advertising from Twitter - WaPo,Seeking Alpha,https://seekingalpha.com/news/3907399-fake-free-insulin-tweet-leads-eli-lilly-to-pull-advertising-from-twitter-wapo?utm_source=businessinsider&utm_medium=referral
1971.0,11/15/2022 11:04:32 PM,Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage,Benzinga,/news/stocks/successful-alzheimer-s-data-would-have-placed-roche-at-two-year-competitive-advantage-1031916589
1972.0,11/16/2022 7:51:07 AM,"Analysts’ Top Healthcare Picks: Lineage Cell Therapeutics (LCTX), Compugen (CGEN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-lineage-cell-therapeutics-lctx-compugen-cgen-1031917474
1973.0,11/16/2022 4:00:00 PM,Lilly to Participate in Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/lilly-to-participate-in-evercore-isi-healthconx-conference-1031919113
1974.0,11/16/2022 5:17:42 PM,"Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors",Seeking Alpha,https://seekingalpha.com/news/3908715-pfizer-roche-lilly-covid-treatments-get-draft-recommendation-from-uk-nhs-advisors?utm_source=businessinsider&utm_medium=referral
1975.0,11/17/2022 4:40:49 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Gossamer Bio (GOSS) and Alcon (ALC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-gossamer-bio-goss-and-alcon-alc-1031924296
1976.0,11/18/2022 2:03:01 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1031925085
1977.0,11/18/2022 3:03:49 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031925440
1978.0,11/18/2022 4:03:30 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1031925614
1979.0,11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925
1980.0,11/18/2022 8:22:36 PM,"Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage",Benzinga,/news/stocks/eli-lilly-is-best-in-class-growth-says-analyst-while-initiating-coverage-1031926179
1981.0,11/21/2022 3:00:00 PM,Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2022-san-antonio-breast-cancer-symposium-1031928665
1982.0,11/23/2022 3:35:18 AM,SVB Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1031932748
1983.0,11/25/2022 11:00:46 AM,3 Reasons to Turn Any LLY Stock Skeptic Into a Believer,InvestorPlace,/news/stocks/3-reasons-to-turn-any-lly-stock-skeptic-into-a-believer-1031937458
1984.0,11/28/2022 3:00:48 PM,"Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Spectrum Pharmaceuticals (SPPI) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-arcus-biosciences-rcus-spectrum-pharmaceuticals-sppi-and-eli-lilly-co-lly-1031940203
1985.0,11/28/2022 5:23:11 PM,7 Beaten-Down Stocks That Can Make You a Millionaire by 2030,InvestorPlace,/news/stocks/7-beaten-down-stocks-that-can-make-you-a-millionaire-by-2030-1031942973
1986.0,11/28/2022 10:28:43 PM,Wall Street Loves These 4 “Strong Buy” Stocks Right Now,TipRanks,/news/stocks/wall-street-loves-these-4-strong-buy-stocks-right-now-1031940806
1987.0,11/29/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-2023-financial-guidance-announcement-1031942466
1988.0,11/30/2022 12:50:00 PM,Lilly and Akouos Announce Expiration of Akouos Tender Offer,PR Newswire,/news/stocks/lilly-and-akouos-announce-expiration-of-akouos-tender-offer-1031944475
1989.0,12/1/2022 12:00:00 AM,Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease,PR Newswire,/news/stocks/lilly-shares-positive-donanemab-data-in-first-active-comparator-study-in-early-symptomatic-alzheimer-s-disease-1031946402
1990.0,12/1/2022 2:20:39 AM,FDA Pulls Emergency Use Authorization For Lilly's COVID-19 Antibody Drug ,RTTNews,/news/stocks/fda-pulls-emergency-use-authorization-for-lilly-s-covid-19-antibody-drug-1031946501
1991.0,12/1/2022 2:32:41 AM,Lilly Reports Positive Donanemab Data In Comparator Study In Early Symptomatic Alzheimer's Disease ,RTTNews,/news/stocks/lilly-reports-positive-donanemab-data-in-comparator-study-in-early-symptomatic-alzheimer-s-disease-1031946506
1992.0,12/1/2022 2:41:00 PM,Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases,PR Newswire,/news/stocks/lilly-completes-acquisition-of-akouos-expanding-efforts-to-help-people-with-genetic-diseases-1031947790
1993.0,12/2/2022 3:10:33 AM,"Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-1031949326
1994.0,12/2/2022 2:20:00 PM,3 Analyst-Loved Healthcare Stocks for a Recession,TipRanks,/news/stocks/3-analyst-loved-healthcare-stocks-for-a-recession-1031950786
1995.0,12/2/2022 2:50:09 PM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Rigel (RIGL)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-rigel-rigl-1031950666
1996.0,12/5/2022 11:15:30 AM,"Even After This Year’s Melt-Up, Runway Remains for LLY Stock",InvestorPlace,/news/stocks/even-after-this-years-melt-up-runway-remains-for-lly-stock-1031952582
1997.0,12/5/2022 6:06:27 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031953622
1998.0,12/5/2022 8:04:55 PM,What 12 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-12-analyst-ratings-have-to-say-about-eli-lilly-1031953824
1999.0,12/5/2022 10:02:23 PM,12 Analysts Have This to Say About Eli Lilly,Benzinga,/news/stocks/12-analysts-have-this-to-say-about-eli-lilly-1031953925
2000.0,12/6/2022 2:44:39 PM,Eli Lilly sees “unprecedented” demand for its diabetes drugs,Seeking Alpha,https://seekingalpha.com/news/3914335-lly-stock-company-sees-unprecedented-demand-for-diabetes-drugs?utm_source=businessinsider&utm_medium=referral
2001.0,12/6/2022 4:30:59 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbbVie (ABBV) and Mirati Therapeutics (MRTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-abbvie-abbv-and-mirati-therapeutics-mrtx-1031956241
2002.0,12/6/2022 9:00:00 PM,Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology,PR Newswire,/news/stocks/lilly-announces-updated-data-from-the-verzenio-abemaciclib-phase-3-monarche-trial-presented-at-sabcs-and-simultaneously-published-in-the-lancet-oncology-1031956359
2003.0,12/7/2022 1:48:23 PM,"Lilly, Boehringer diabetes drug meets main goal in patients aged 10-17",Seeking Alpha,https://seekingalpha.com/news/3914862-lly-stock-on-watch-as-diabetes-drug-meets-main-goal-in-young-patients?utm_source=businessinsider&utm_medium=referral
2004.0,12/7/2022 2:00:00 PM,Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes,PR Newswire,/news/stocks/phase-iii-trial-demonstrated-jardiance-is-the-first-sglt2-inhibitor-to-show-statistically-significant-reduction-in-blood-sugar-levels-in-children-and-adolescents-with-type-2-diabetes-1031957696
2005.0,12/7/2022 2:31:23 PM,Eli Lilly: Jardiance Improves Overall Blood Sugar Control In Children With Type 2 Diabetes ,RTTNews,/news/stocks/eli-lilly-jardiance-improves-overall-blood-sugar-control-in-children-with-type-2-diabetes-1031957845
2006.0,12/7/2022 9:38:11 PM,"These 2 Stocks Can Easily Survive a Recession, Analysts Believe",TipRanks,/news/stocks/these-2-stocks-can-easily-survive-a-recession-analysts-believe-1031959029
2007.0,12/8/2022 2:40:55 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-crispr-therapeutics-ag-crsp-1031960877
2008.0,12/9/2022 10:27:28 AM,Innovent's drug shows promise in advanced lung cancer patients in early-stage trial,Seeking Alpha,https://seekingalpha.com/news/3915620-innovent-drug-shows-promise-in-advanced-lung-cancer-patients-in-early-stage-trial?utm_source=businessinsider&utm_medium=referral
2009.0,12/9/2022 7:30:48 PM,"Catalyst Watch: FOMC, CPI print and spotlight on Yum Brands",Seeking Alpha,https://seekingalpha.com/news/3915821-stocks-to-watch-fomc-cpi-print-and-spotlight-on-yum-brands?utm_source=businessinsider&utm_medium=referral
2010.0,12/11/2022 5:00:50 PM,"Lilly, Novo dominance in weight loss market intact despite Amgen entry – BofA",Seeking Alpha,https://seekingalpha.com/news/3915950-lly-stock-novo-nordisk-to-dominate-obesity-despite-amgen-entry?utm_source=businessinsider&utm_medium=referral
2011.0,12/12/2022 11:15:21 AM,Eli Lilly Stock Is a Mega-Blockbuster Buy,InvestorPlace,/news/stocks/lly-stock-is-a-mega-blockbuster-buy-1031964937
2012.0,12/12/2022 8:57:53 PM,Eli Lilly raises dividend by 15% to $1.13,Seeking Alpha,https://seekingalpha.com/news/3916279-eli-lilly-raises-dividend-by-15-to-113?utm_source=businessinsider&utm_medium=referral
2013.0,12/12/2022 9:26:00 PM,"Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend",PR Newswire,/news/stocks/lilly-announces-15-dividend-increase-first-quarter-2023-dividend-1031967641
2014.0,12/12/2022 11:30:00 PM,Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting,PR Newswire,/news/stocks/loxo-lilly-presents-updated-pirtobrutinib-data-from-the-phase-1-2-bruin-clinical-trial-at-the-2022-american-society-of-hematology-annual-meeting-1031967801
2015.0,12/13/2022 12:45:00 PM,"Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines",PR Newswire,/news/stocks/lilly-announces-2023-financial-guidance-plans-to-launch-up-to-four-new-medicines-1031968733
2016.0,12/13/2022 12:57:25 PM,Eli Lilly dips after issuing underwhelming 2023 guidance,Seeking Alpha,https://seekingalpha.com/news/3916459-lly-stock-dips-after-issuing-underwhelming-2023-guidance-?utm_source=businessinsider&utm_medium=referral
2017.0,12/13/2022 1:11:29 PM,Eli Lilly Issues FY23 Guidance; Reaffirms FY22 Outlook ,RTTNews,/news/stocks/eli-lilly-issues-fy23-guidance-reaffirms-fy22-outlook-1031968824
2018.0,12/13/2022 7:04:10 PM,"mRNA cancer vaccines could be in greater focus after Moderna, Merck candidate shines",Seeking Alpha,https://seekingalpha.com/news/3916642-mrna-cancer-vaccines-could-be-in-greater-focus-after-moderna-merck-candidate-shines?utm_source=businessinsider&utm_medium=referral
2019.0,12/13/2022 7:53:12 PM,Our Top 10 Stock Picks for 2023,InvestorPlace,/news/stocks/our-top-10-stock-picks-for-2023-1031970169
2020.0,12/14/2022 3:55:31 AM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1031970545
2021.0,12/14/2022 10:15:00 AM,Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa,PR Newswire,/news/stocks/lilly-and-eva-pharma-announce-collaboration-to-enhance-sustainable-access-to-affordable-insulin-in-africa-1031971102
2022.0,12/14/2022 10:27:01 AM,Lilly teams up with Eva to make and provide affordable insulin in Africa,Seeking Alpha,https://seekingalpha.com/news/3916824-lilly-teams-up-with-eva-to-make-and-provide-affordable-insulin-in-africa?utm_source=businessinsider&utm_medium=referral
2023.0,12/14/2022 12:10:29 PM,"Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Eli Lilly & Co (LLY) and Irhythm Technologies (IRTC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-conmed-cnmd-eli-lilly-co-lly-and-irhythm-technologies-irtc-1031971458
2024.0,12/14/2022 2:40:39 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ligand Pharma (LGND),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-ligand-pharma-lgnd-1031971993
2025.0,12/14/2022 4:25:25 PM,Morgan Stanley Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1031972299
2026.0,12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral
2027.0,12/15/2022 2:05:56 PM,Carnival To Rally Over 36%? Here Are 10 Other Price Target Changes For Thursday,Benzinga,/news/stocks/carnival-to-rally-over-36-here-are-10-other-price-target-changes-for-thursday-1031974554
2028.0,12/16/2022 9:34:17 AM,"Sosei to get $37M upfront from Lilly in pact to discover drugs for diabetes, metabolic diseases",Seeking Alpha,https://seekingalpha.com/news/3917900-sosei-to-get-37m-upfront-from-lilly-in-pact-to-discover-drugs-for-diabetes-metabolic-diseases?utm_source=businessinsider&utm_medium=referral
2029.0,12/16/2022 11:25:27 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/large-cap-stocks-to-buy-and-hold-1031827937
2030.0,12/16/2022 12:30:27 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), HCA Healthcare (HCA)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-hca-healthcare-hca-1031977178
2031.0,12/16/2022 1:27:21 PM,Lilly withdraws Olumiant filing in EU for COVID; gets EMA panel nod for Adcirca's use in kids,Seeking Alpha,https://seekingalpha.com/news/3917969-lilly-withdraws-olumiant-filing-in-eu-for-covid-gets-ema-panel-nod-for-adcircas-use-in-kids?utm_source=businessinsider&utm_medium=referral
2032.0,12/16/2022 5:36:44 PM,Eli Lilly diabetes drugs in shortage due to rising demand,Seeking Alpha,https://seekingalpha.com/news/3918115-eli-lilly-diabetes-drugs-in-shortage-due-to-rising-demand?utm_source=businessinsider&utm_medium=referral
2033.0,12/18/2022 2:04:41 PM,The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond,InvestorPlace,/news/stocks/the-7-hottest-healthcare-stocks-to-own-for-2023-and-beyond-1031978729
2034.0,12/18/2022 9:34:20 PM,The 7 Best Retirement Stocks to Buy Now,InvestorPlace,/news/stocks/best-retirement-stocks-1031562793
2035.0,12/20/2022 2:35:26 PM,BMO Capital Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-eli-lilly-co-lly-1031982614
2036.0,12/20/2022 5:00:22 PM,The 7 Best Bear Market Stocks to Buy Now,InvestorPlace,/news/stocks/best-bear-market-stocks-1031573318
2037.0,12/20/2022 9:00:54 PM,"Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says",Benzinga,/news/stocks/top-m-a-target-madrigal-pharmaceuticals-could-be-next-after-successful-nash-data-analyst-says-1031983372
2038.0,12/21/2022 5:21:22 PM,Halozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology,Seeking Alpha,https://seekingalpha.com/news/3919530-halozyme-therapeutics-overweight-at-morgan-stanley-on-enhanze-subcutaneous-technology?utm_source=businessinsider&utm_medium=referral
2039.0,12/22/2022 11:42:33 AM,Eli Lilly sends ProQR 35% higher after expanding RNA editing deal,Seeking Alpha,https://seekingalpha.com/news/3919739-prqr-stock-surges-as-eli-lilly-expands-rna-editing-deal?utm_source=businessinsider&utm_medium=referral
2040.0,12/22/2022 12:00:00 PM,Lilly and ProQR to Expand RNA Editing Collaboration,PR Newswire,/news/stocks/lilly-and-proqr-to-expand-rna-editing-collaboration-1031986680
2041.0,12/22/2022 12:20:36 PM,"Lilly, ProQR To Expand Licensing And Collaboration Deal For New Genetic Medicines ",RTTNews,/news/stocks/lilly-proqr-to-expand-licensing-and-collaboration-deal-for-new-genetic-medicines-1031986721
2042.0,12/22/2022 5:48:44 PM,"Biogen, Lilly potential Alzheimer's drugs given lukewarm review by drug evaluation group",Seeking Alpha,https://seekingalpha.com/news/3919908-biogen-lilly-potential-alzheimers-drugs-given-lukewarm-review-by-drug-evaluation-group?utm_source=businessinsider&utm_medium=referral
2043.0,12/22/2022 5:51:29 PM,Why Is ProQR (PRQR) Stock Up 83% Today?,InvestorPlace,/news/stocks/why-is-proqr-prqr-stock-up-83-today-1031987573
2044.0,12/22/2022 6:18:16 PM,ProQR adds 75% as Cantor upgrades on expanded deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3919928-prqr-stock-climbs-cantor-upgrades-expanded-eli-lilly-deal?utm_source=businessinsider&utm_medium=referral
2045.0,12/23/2022 4:51:10 PM,Immune-evasive Omicron subvariant XBB rapidly gaining ground in U.S.,Seeking Alpha,https://seekingalpha.com/news/3920398-immune-evasive-omicron-subvariant-xbb-rapidly-gaining-ground-in-us?utm_source=businessinsider&utm_medium=referral
2046.0,12/25/2022 5:00:44 PM,Goldman Sachs highlights key healthcare themes for 2023,Seeking Alpha,https://seekingalpha.com/news/3920634-goldman-sachs-micro-over-macro-healthcare-themes-2023?utm_source=businessinsider&utm_medium=referral
2047.0,12/26/2022 11:15:34 AM,Why Eli Lilly Stock Will Stay Strong in 2023,InvestorPlace,/news/stocks/why-lly-stock-will-stay-strong-in-2023-1031990189
2048.0,12/27/2022 2:12:49 PM,PeptiDream signs licensing deal with Lilly for peptide drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3920726-peptidream-signs-licensing-deal-with-lilly-for-peptide-drug-conjugates?utm_source=businessinsider&utm_medium=referral
2049.0,12/29/2022 10:14:33 AM,"Adocia, Tonghua's BioChaperone Lispro insulin shows promise in phase 1 trial",Seeking Alpha,https://seekingalpha.com/news/3921073-adocia-tonghuas-biochaperone-lispro-insulin-shows-promise-in-phase-1-trial?utm_source=businessinsider&utm_medium=referral
2050.0,12/30/2022 12:28:33 PM,7 Cheap Large-Cap Stocks to Buy Before They Surge Higher,InvestorPlace,/news/stocks/cheap-large-cap-stocks-1031607723
2051.0,12/30/2022 5:11:21 PM,Diabetes rates in children set to skyrocket by 2060 - study,Seeking Alpha,https://seekingalpha.com/news/3921303-diabetes-rates-in-children-set-to-skyrocket-by-2060-study?utm_source=businessinsider&utm_medium=referral
2052.0,12/30/2022 5:45:22 PM,Merck is best performing large U.S. pharma of 2022,Seeking Alpha,https://seekingalpha.com/news/3921306-merck-is-best-performing-large-us-pharma-of-2022?utm_source=businessinsider&utm_medium=referral
2053.0,12/31/2022 2:37:49 PM,The 7 Best Retirement Stocks for Investors Over 50,InvestorPlace,/news/stocks/best-retirement-stocks-for-investors-over-50-1031581892
2054.0,1/2/2023 12:00:59 PM,Why LLY Stock Could Meet (or Beat!) 2022’s Stellar Performance,InvestorPlace,/news/stocks/lly-stock-could-meet-or-beat-2022-stellar-performance-1031996431
2055.0,1/3/2023 7:53:16 PM,10 Best Stock Traders In Congress In 2022 (Spoiler: Nancy Pelosi Isn't No. 1),Benzinga,/news/stocks/10-best-stock-traders-in-congress-in-2022-spoiler-nancy-pelosi-isn-t-no-1-1031998484
2056.0,1/4/2023 4:00:00 PM,Lilly to Participate in the J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-j-p-morgan-healthcare-conference-1032000138
2057.0,1/4/2023 5:30:15 PM,The 10 Best Dividend Stocks of All Time ,InvestorPlace,/news/stocks/best-dividend-stocks-of-all-time-1031596593
2058.0,1/5/2023 4:35:57 PM,Jim Cramer Says Avoid This Stock: 'Too Expensive',Benzinga,/news/stocks/jim-cramer-says-avoid-this-stock-too-expensive-1032002488
2059.0,1/6/2023 8:19:28 PM,"Lilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approval",Seeking Alpha,https://seekingalpha.com/news/3922771-lilly-roche-other-alzheimers-drug-developer-rise-modestly-on-biogen-lecanemab-approval?utm_source=businessinsider&utm_medium=referral
2060.0,1/6/2023 8:47:34 PM,"SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday",Benzinga,/news/stocks/sava-lly-ibb-why-these-alzheimer-s-related-stocks-are-volatile-on-friday-1032005036
2061.0,1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182
2062.0,1/9/2023 3:00:58 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Alnylam Pharma (ALNY) and G1 Therapeutics (GTHX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-alnylam-pharma-alny-and-g1-therapeutics-gthx-1032007403
2063.0,1/10/2023 12:29:26 PM,7 Long-Term Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/long-term-stocks-to-buy-and-hold-1031656398
2064.0,1/11/2023 12:22:40 AM,Lilly could launch tirzepatide as obesity treatment by end of the year,Seeking Alpha,https://seekingalpha.com/news/3923535-lilly-could-launch-tirzepatide-as-obesity-treatment-by-end-of-the-year?utm_source=businessinsider&utm_medium=referral
2065.0,1/11/2023 6:06:37 PM,7 Hot Healthcare Stocks to Watch in 2023,InvestorPlace,/news/stocks/7-hot-healthcare-stocks-to-watch-in-2023-1032013193
2066.0,1/11/2023 9:55:36 PM,"Eli Lilly says Q4 results will be impacted by $240M in IPR&D, development milestone charges",Seeking Alpha,https://seekingalpha.com/news/3923934-eli-lilly-says-q4-results-will-be-impacted-by-240m-in-iprd-development-milestone-charges?utm_source=businessinsider&utm_medium=referral
2067.0,1/12/2023 4:19:04 PM,"Medications appropriate for obese teens, new guideline says",Seeking Alpha,https://seekingalpha.com/news/3924214-medications-appropriate-for-obese-teens-new-guideline-says?utm_source=businessinsider&utm_medium=referral
2068.0,1/12/2023 7:44:45 PM,"Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices",Seeking Alpha,https://seekingalpha.com/news/3924281-eli-lilly-novo-sanofi-leading-pbms-accused-in-california-over-insulin-prices?utm_source=businessinsider&utm_medium=referral
2069.0,1/14/2023 7:54:32 PM,Gamechanging Weight Loss Drug Could Send LLY Stock Soaring,InvestorPlace,/news/stocks/lly-stock-recent-sideways-movement-belies-mounjaro-progress-1032018570
2070.0,1/14/2023 9:00:00 PM,"Type 2 diabetes market to surpass $136B in 2029 from new therapies, increased diagnoses",Seeking Alpha,https://seekingalpha.com/news/3924584-type-2-diabetes-market-to-surpass-136b-in-2029-from-new-therapies-increased-diagnoses?utm_source=businessinsider&utm_medium=referral
2071.0,1/15/2023 5:00:03 PM,Drugmakers welcome new year with 450 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/3924676-pfizer-abbvie-gsk-eli-lilly-among-drugmakers-to-raise-prices?utm_source=businessinsider&utm_medium=referral
2072.0,1/16/2023 12:15:26 PM,AbbVie and Lilly leave U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3924704-abbvie-and-lilly-leave-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral
2073.0,1/16/2023 2:55:12 PM,BMO Capital Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-eli-lilly-co-lly-1032020613
2074.0,1/17/2023 6:36:59 PM,Bristol-Myers earns bullish views at Cantor on breakout potential,Seeking Alpha,https://seekingalpha.com/news/3925135-bmy-stock-earns-bullish-views-cantor-breakout-potential?utm_source=businessinsider&utm_medium=referral
2075.0,1/19/2023 1:10:49 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Roche Holding AG (OtherRHHVF) and Avidity Biosciences (RNA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eli-lilly-co-lly-roche-holding-ag-otherrhhvf-and-avidity-biosciences-rna-1032028292
2076.0,1/19/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-fourth-quarter-2022-financial-results-announcement-1032028718
2077.0,1/19/2023 6:19:18 PM,Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide,Benzinga,/news/stocks/analyst-views-novo-nordisk-s-upcoming-obesity-drug-data-to-lay-grounds-for-eli-lilly-s-tirzepatide-1032029171
2078.0,1/19/2023 11:12:42 PM,Eli Lilly shares fall 3% after hours as FDA rejects submission for Alzheimer's treatment,Seeking Alpha,https://seekingalpha.com/news/3926184-eli-lilly-shares-fall-3-after-hours-as-fda-rejects-submission-for-alzheimers-treatment?utm_source=businessinsider&utm_medium=referral
2079.0,1/20/2023 12:00:00 AM,U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab,PR Newswire,/news/stocks/u-s-food-and-drug-administration-issues-complete-response-letter-for-accelerated-approval-of-donanemab-1032029712
2080.0,1/20/2023 2:03:10 AM,FDA Declines To Grant Accelerated Approval To Lilly's Alzheimer's Drug ,RTTNews,/news/stocks/fda-declines-to-grant-accelerated-approval-to-lilly-s-alzheimer-s-drug-1032029741
2081.0,1/20/2023 3:00:00 PM,US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease,PR Newswire,/news/stocks/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-adults-with-chronic-kidney-disease-1032030902
2082.0,1/20/2023 3:02:47 PM,Lilly's diabetes drug Jardiance to get FDA review for chronic kidney disease indication,Seeking Alpha,https://seekingalpha.com/news/3926360-lillys-diabetes-drug-jardiance-to-get-fda-review-for-chronic-kidney-disease-indication?utm_source=businessinsider&utm_medium=referral
2083.0,1/20/2023 3:24:40 PM,Eli Lilly Announces FDA Acceptance Of SNDA For Jardiance For Chronic Kidney Disease ,RTTNews,/news/stocks/eli-lilly-announces-fda-acceptance-of-snda-for-jardiance-for-chronic-kidney-disease-1032030968
2084.0,1/20/2023 3:49:19 PM,Eli Lilly slips while Street defends FDA setback for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3926378-lly-stock-slips-as-street-defends-alzheimers-setback?utm_source=businessinsider&utm_medium=referral
2085.0,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral
2086.0,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral
2087.0,1/23/2023 9:49:07 AM,Takeda to acquire rights to Hutchmed's cancer drug fruquintinib for $400M upfront,Seeking Alpha,https://seekingalpha.com/news/3926597-takeda-to-acquire-rights-to-hutchmeds-cancer-drug-fruquintinib-for-400m-upfront?utm_source=businessinsider&utm_medium=referral
2088.0,1/23/2023 2:35:16 PM,Eli Lilly & Co (LLY) Gets a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bmo-capital-1032034183
2089.0,1/23/2023 3:03:07 PM,3 Drug Stocks With Promising Pipelines for 2023,InvestorPlace,/news/stocks/3-drug-stocks-with-promising-pipelines-for-2023-1032034241
2090.0,1/24/2023 12:27:58 PM,Lilly to invest $450M to expand production of diabetes meds,Seeking Alpha,https://seekingalpha.com/news/3927076-lly-stock-amid-plans-expand-production-diabetes-meds?utm_source=businessinsider&utm_medium=referral
2091.0,1/24/2023 12:30:00 PM,Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park,PR Newswire,/news/stocks/lilly-plans-to-invest-additional-450-million-at-manufacturing-site-in-research-triangle-park-1032036356
2092.0,1/24/2023 12:40:39 PM,Lilly To Expand Manufacturing Facility In North Carolina ,RTTNews,/news/stocks/lilly-to-expand-manufacturing-facility-in-north-carolina-1032036401
2093.0,1/24/2023 6:22:14 PM,Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results,Benzinga,/news/stocks/cassava-sciences-shares-fall-as-alzheimer-s-candidate-worsens-patients-with-moderate-disease-1032037660
2094.0,1/26/2023 4:00:00 PM,Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity,PR Newswire,/news/stocks/lilly-supports-direct-relief-s-efforts-to-expand-access-to-medicines-by-improving-cold-chain-capacity-1032044178
2095.0,1/26/2023 11:06:46 PM,The 3 Best Biotech Stocks Under $1 to Buy for January,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-under-1-to-buy-for-january-1032045234
2096.0,1/27/2023 11:00:21 AM,"Good News, LLY Stock Invetors! Eli Lilly Is Poised for a Promising 2023.",InvestorPlace,/news/stocks/lly-stock-is-poised-for-a-promising-2023-1032046341
2097.0,1/27/2023 12:14:02 PM,Lilly's diabetes drug Trulicity gets EMA committee nod for use in adolescents,Seeking Alpha,https://seekingalpha.com/news/3928883-lillys-diabetes-drug-trulicity-gets-ema-committee-nod-for-use-in-adolescents?utm_source=businessinsider&utm_medium=referral
2098.0,1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral
2099.0,1/27/2023 7:15:05 PM,"Catalyst watch: Eyes on tech earnings, Chinese EV stocks, Peloton and Church & Dwight",Seeking Alpha,https://seekingalpha.com/news/3929095-catalyst-watch-eyes-on-tech-earnings-chinese-ev-stocks-peloton-and-church-dwight?utm_source=businessinsider&utm_medium=referral
2100.0,1/27/2023 7:42:05 PM,Eli Lilly wins FDA accelerated approval for lymphoma therapy,Seeking Alpha,https://seekingalpha.com/news/3929112-lly-stock-wins-fda-accelerated-approval-lymphoma-therapy?utm_source=businessinsider&utm_medium=referral
2101.0,1/27/2023 8:07:00 PM,"U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Line...",PR Newswire,/news/stocks/u-s-fda-approves-jaypirca-pirtobrutinib-the-first-and-only-non-covalent-reversible-btk-inhibitor-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-after-at-least-two-line-1032047471
2102.0,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678
2103.0,1/30/2023 12:00:56 PM,WHO maintains public health emergency on COVID but sees pandemic at 'transition point',Seeking Alpha,https://seekingalpha.com/news/3929274-who-maintains-public-health-emergency-on-covid-with-3-years-into-pandemic?utm_source=businessinsider&utm_medium=referral
2104.0,1/31/2023 3:06:19 PM,7 Healthcare Stocks That Will Be Big Winners in 2023,InvestorPlace,/news/stocks/7-healthcare-stocks-that-will-be-big-winners-in-2023-1032054711
2105.0,1/31/2023 4:35:10 PM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1032055024
2106.0,1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559
2107.0,1/31/2023 11:22:27 PM,Diabetes drug developer Structure Therapeutics sets terms for $125M US IPO,Seeking Alpha,https://seekingalpha.com/news/3930220-diabetes-drug-developer-structure-therapeutics-sets-terms-for-125m-us-ipo?utm_source=businessinsider&utm_medium=referral
2108.0,2/1/2023 1:47:08 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), HCA Healthcare (HCA) and Spectrum Pharmaceuticals (SPPI)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-hca-healthcare-hca-and-spectrum-pharmaceuticals-sppi-1032058779
2109.0,2/1/2023 3:01:13 PM,Here's what to expect from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-stock-quarter-earnings-preview-q4-1032058988
2110.0,2/1/2023 3:44:59 PM,"Eli Lilly to report Q4 earnings amid forex headwinds, loss of COVID-19 antibody revenue",Seeking Alpha,https://seekingalpha.com/news/3930493-eli-lilly-to-report-q4-earnings-amid-forex-headwinds-loss-of-covid-19-antibody-revenue?utm_source=businessinsider&utm_medium=referral
2111.0,2/1/2023 3:55:38 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3930495-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral
2112.0,2/2/2023 11:49:05 AM,"Eli Lilly Non-GAAP EPS of $2.09 beats by $0.24, revenue of $7.3B misses by $90M",Seeking Alpha,https://seekingalpha.com/news/3931105-eli-lilly-non-gaap-eps-of-2_09-beats-0_24-revenue-of-7_3b-misses-90m?utm_source=businessinsider&utm_medium=referral
2113.0,2/2/2023 12:34:23 PM,"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",Benzinga,/news/stocks/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-line-1032062305
2114.0,2/2/2023 12:41:59 PM,Eli Lilly slips as falling demand for COVID therapy hurts topline,Seeking Alpha,https://seekingalpha.com/news/3931176-lly-stock-slips-falling-demand-covid-therapy-hurts-topline?utm_source=businessinsider&utm_medium=referral
2115.0,2/2/2023 12:45:00 PM,"Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook",PR Newswire,/news/stocks/lilly-reports-fourth-quarter-2022-financial-results-core-business-growth-and-pipeline-advancements-support-strong-long-term-outlook-1032062351
2116.0,2/2/2023 12:48:23 PM,Eli Lilly And Co. Reveals Rise In Q4 Bottom Line,RTTNews,/news/stocks/eli-lilly-and-co-reveals-rise-in-q4-bottom-line-1032062364
2117.0,2/2/2023 1:07:35 PM,Lilly Lifts FY23 Earnings View Above Market On Updated Tax Rate - Update ,RTTNews,/news/stocks/lilly-lifts-fy23-earnings-view-above-market-on-updated-tax-rate-update-1032062448
2118.0,2/2/2023 6:49:16 PM,Lilly's quarterly results impacted by less than expected growth in diabetes drug Mounjaro,Seeking Alpha,https://seekingalpha.com/news/3931468-lillys-quarterly-results-impacted-by-less-than-expected-growth-in-diabetes-drug-mounjaro?utm_source=businessinsider&utm_medium=referral
2119.0,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral
2120.0,2/2/2023 8:20:04 PM,"Nasdaq, S&P off session highs but on track to extend post-Fed rally; Dow in the red",Seeking Alpha,https://seekingalpha.com/news/3931346-sp500-nasdaq-dow-jones-stock-market-meta-earnings-post-fed-rally?utm_source=businessinsider&utm_medium=referral
2121.0,2/3/2023 11:10:26 AM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-humana-hum-1032065666
2122.0,2/3/2023 12:30:25 PM,"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-and-merck-company-mrk-1032066009
2123.0,2/3/2023 4:00:00 PM,Lilly to Participate in Guggenheim Oncology Conference,PR Newswire,/news/stocks/lilly-to-participate-in-guggenheim-oncology-conference-1032066381
2124.0,2/3/2023 4:58:11 PM,Erasca rises as Morgan Stanley upgrades on newly added asset,Seeking Alpha,https://seekingalpha.com/news/3931908-eras-stock-rises-as-morgan-stanley-upgrades-on-newly-added-asset?utm_source=businessinsider&utm_medium=referral
2125.0,2/3/2023 9:14:45 PM,Diabetes drug developer Structure Therapeutics stock soars 73% in debut (update),Seeking Alpha,https://seekingalpha.com/news/3932013-diabetes-drug-developer-structure-therapeutics-stock-soars-72-in-market-debut?utm_source=businessinsider&utm_medium=referral
2126.0,2/3/2023 10:00:31 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1032067123
2127.0,2/6/2023 9:30:23 AM,"Analysts Conflicted on These Healthcare Names: Mednax (MD), Aclaris Therapeutics (ACRS) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-mednax-md-aclaris-therapeutics-acrs-and-eli-lilly-co-lly-1032069702
2128.0,2/6/2023 4:31:12 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-regeneron-regn-and-seagen-sgen-1032070948
2129.0,2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral
2130.0,2/7/2023 11:30:10 AM,7 A-Rated Stocks to Buy for February 2023,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-for-february-2023-1032073457
2131.0,2/7/2023 12:16:26 PM,Ten top growth stocks and 10 top value stocks from BofA's screens,Seeking Alpha,https://seekingalpha.com/news/3932604-ten-top-growth-stocks-and-10-top-value-stocks-from-bofas-screens?utm_source=businessinsider&utm_medium=referral
2132.0,2/7/2023 4:00:00 PM,Lilly to Participate in SVB Securities Global Biopharma Conference,PR Newswire,/news/stocks/lilly-to-participate-in-svb-securities-global-biopharma-conference-1032074441
2133.0,2/8/2023 3:54:52 PM,The 7 Best Dividend Stocks to Buy for February 2023,InvestorPlace,/news/stocks/the-7-best-dividend-stocks-to-buy-for-february-2023-1032079245
2134.0,2/10/2023 11:00:07 AM,Ignore the Worrywarts! Snap Up Eli Lilly Stock on Sale,InvestorPlace,/news/stocks/ignore-the-worrywarts-snap-up-lly-stock-on-sale-1032085942
2135.0,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral
2136.0,2/12/2023 3:56:18 PM,7 A-Rated Healthcare Stocks to Buy for the Future of Medicine,InvestorPlace,/news/stocks/7-a-rated-healthcare-stocks-to-buy-for-the-future-of-medicine-1032088046
2137.0,2/13/2023 11:15:28 AM,"Lilly, IABL team up to provide affordable insulin in Bangladesh",Seeking Alpha,https://seekingalpha.com/news/3935095-lilly-iabl-team-up-to-provide-affordable-insulin-in-bangladesh?utm_source=businessinsider&utm_medium=referral
2138.0,2/13/2023 11:40:05 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), IQVIA Holdings (IQV) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-iqvia-holdings-iqv-and-viatris-vtrs-1032090836
2139.0,2/13/2023 12:00:00 PM,Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh,PR Newswire,/news/stocks/lilly-and-iabl-collaborate-to-ensure-patient-access-to-high-quality-affordable-insulin-in-bangladesh-1032090726
2140.0,2/14/2023 11:00:30 AM,7 Great Growth Stocks to Buy in February,InvestorPlace,/news/stocks/ceg-csgp-hal-lly-meli-tmus-uri-7-great-growth-stocks-to-buy-in-february-1032094204
2141.0,2/14/2023 9:05:22 PM,Which Healthcare Stock Is a Better Pick in 2023?,InvestorPlace,/news/stocks/which-healthcare-stock-is-a-better-pick-in-2023-1032095959
2142.0,2/14/2023 9:54:34 PM,"Druckenmiller's Duquesne adds Nvidia, AMD, exits Amazon, Microsoft",Seeking Alpha,https://seekingalpha.com/news/3936047-druckenmillers-duquesne-adds-nvidia-amd-exits-amazon-microsoft?utm_source=businessinsider&utm_medium=referral
2143.0,2/15/2023 4:09:25 PM,Entera Bio up 9% after FDA agrees to review design for phase 3 osteoporosis candidate,Seeking Alpha,https://seekingalpha.com/news/3936418-entera-bio-up-9-after-fda-agrees-to-review-design-for-phase-3-osteoporosis-candidate?utm_source=businessinsider&utm_medium=referral
2144.0,2/15/2023 6:14:14 PM,Eli Lilly downgraded to sell at Societe Generale on lack of potential upside,Seeking Alpha,https://seekingalpha.com/news/3936538-eli-lilly-downgraded-to-sell-at-societe-generale-on-lack-of-potential-upside?utm_source=businessinsider&utm_medium=referral
2145.0,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral
2146.0,2/15/2023 6:54:20 PM,Concert retains breakthrough status for hair loss therapy despite rival entry,Seeking Alpha,https://seekingalpha.com/news/3936569-concert-retains-breakthrough-status-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral
2147.0,2/15/2023 7:11:38 PM,7 Hot Healthcare Stocks With the Potential to Outperform,InvestorPlace,/news/stocks/7-hot-healthcare-stocks-with-the-potential-to-outperform-1032103825
2148.0,2/16/2023 1:34:25 AM,Eli Lilly’s (NYSE:LLY) Growth Slowdown Doesn’t Take Away from Its Bull Case,TipRanks,/news/stocks/eli-lilly-s-nyse-lly-growth-slowdown-doesn-t-take-away-from-its-bull-case-1032100627
2149.0,2/16/2023 12:30:46 PM,"US Stocks' Resilience Faces Test As Traders Await Flurry Of Economic Data: Fed May 'Surprise To The Upside' On Rates Again In 2023, Says Analyst",Benzinga,/news/stocks/us-stocks-resilience-faces-test-as-traders-await-flurry-of-economic-data-fed-may-surprise-to-the-upside-on-rates-again-in-2023-says-analyst-1032102212
2150.0,2/17/2023 5:54:00 PM,Senators urge swift action to expand Medicare coverage for Alzheimer’s therapies,Seeking Alpha,https://seekingalpha.com/news/3937793-senators-urge-expand-medicare-coverage-for-alzheimers-therapies?utm_source=businessinsider&utm_medium=referral
2151.0,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral
2152.0,2/21/2023 8:31:09 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Phibro Animal Health (PAHC) and Elanco Animal Health (ELAN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-phibro-animal-health-pahc-and-elanco-animal-health-elan-1032110756
2153.0,2/21/2023 12:40:57 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Teladoc (TDOC) and Apellis Pharmaceuticals (APLS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-teladoc-tdoc-and-apellis-pharmaceuticals-apls-1032111359
2154.0,2/21/2023 4:00:00 PM,Lilly to Participate in Cowen's 43rd Annual Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-cowen-s-43rd-annual-health-care-conference-1032112115
2155.0,2/23/2023 11:53:25 AM,Medicare says coverage limits on Alzheimer’s drugs is not under review,Seeking Alpha,https://seekingalpha.com/news/3939776-medicare-says-coverage-limits-on-alzheimers-drugs-is-not-under-review?utm_source=businessinsider&utm_medium=referral
2156.0,2/24/2023 1:11:22 AM,Nektar Therapeutics plunges 29% after hours on mid-stage lupus treatment failure,Seeking Alpha,https://seekingalpha.com/news/3940432-nektar-therapeutics-plunges-29-after-hours-on-mid-stage-lupus-treatment-failure?utm_source=businessinsider&utm_medium=referral
2157.0,2/24/2023 12:10:54 PM,US Stocks Stare At More Losses In a Lackluster Week: Can Inflation Data Salvage Year's Rally?,Benzinga,/news/stocks/us-stocks-stare-at-more-losses-in-a-lackluster-week-can-inflation-data-salvage-year-s-rally-1032123114
2158.0,2/24/2023 2:23:12 PM,Why Nektar Therapeutics Stock Is Plunging Today,Benzinga,/news/stocks/why-nektar-therapeutics-stock-is-plunging-today-1032123579
2159.0,2/24/2023 5:03:36 PM,Nektar sheds 45% as trial setback prompts Jefferies downgrade,Seeking Alpha,https://seekingalpha.com/news/3940735-nktr-stock-plunges-as-trial-setback-prompts-jefferies-downgrade?utm_source=businessinsider&utm_medium=referral
2160.0,2/24/2023 5:46:09 PM,7 Dynamite Dividend Stocks for Income and Growth in 2023,InvestorPlace,/news/stocks/7-dynamite-dividend-stocks-for-income-and-growth-in-2023-1032124388
2161.0,2/24/2023 6:29:49 PM,3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End,InvestorPlace,/news/stocks/lly-nams-sava-3-drug-stocks-to-watch-as-alzheimers-disease-drugs-clinical-trials-end-1032124474
2162.0,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral
2163.0,2/26/2023 2:45:56 PM,7 Mega-Cap Stocks to Buy for the Long Haul,InvestorPlace,/news/stocks/7-mega-cap-stocks-to-buy-for-the-long-haul-1032125500
2164.0,2/27/2023 10:50:27 AM,Analysts Conflicted on These Healthcare Names: Personalis (PSNL) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-personalis-psnl-and-eli-lilly-co-lly-1032127148
2165.0,2/28/2023 11:30:12 AM,Stocks most and least liked by hedge funds and mutual funds -  Goldman,Seeking Alpha,https://seekingalpha.com/news/3941168-stocks-most-and-least-liked-by-hedge-funds-and-mutual-funds-goldman?utm_source=businessinsider&utm_medium=referral
2166.0,2/28/2023 12:20:08 PM,"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-and-viatris-vtrs-1032131149
2167.0,2/28/2023 8:27:27 PM,"Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race",Benzinga,/news/stocks/analysts-sees-over-50-upside-opportunity-for-this-newly-listed-obesity-player-stock-participating-in-big-pharma-race-1032133040
2168.0,3/1/2023 11:39:48 AM,FBI Director says novel coronavirus likely originated from China lab leak,Seeking Alpha,https://seekingalpha.com/news/3942433-fbi-director-says-novel-coronavirus-likely-originated-from-china-lab-leak?utm_source=businessinsider&utm_medium=referral
2169.0,3/1/2023 2:00:00 PM,Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month,PR Newswire,/news/stocks/lilly-cuts-insulin-prices-by-70-and-caps-patient-insulin-out-of-pocket-costs-at-35-per-month-1032136009
2170.0,3/1/2023 2:00:08 PM,"Eli Lilly slashes insulin prices by 70%, places $35 monthly out-of-pocket cap",Seeking Alpha,https://seekingalpha.com/news/3942564-eli-lilly-slashes-insulin-prices-by-70-places-35-monthly-out-of-pocket-cap?utm_source=businessinsider&utm_medium=referral
2171.0,3/1/2023 2:40:49 PM,Eli Lilly Announces Aggressive Price Cuts For Insulins; Announces Expansion Of Insulin Value Program ,RTTNews,/news/stocks/eli-lilly-announces-aggressive-price-cuts-for-insulins-announces-expansion-of-insulin-value-program-1032136245
2172.0,3/1/2023 3:51:26 PM,China PMI Surprises To Upside,Benzinga,/news/stocks/china-pmi-surprises-to-upside-1032136732
2173.0,3/1/2023 4:25:28 PM,Morgan Stanley Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-keeps-their-buy-rating-on-eli-lilly-co-lly-1032137112
2174.0,3/1/2023 4:38:51 PM,"LLY Stock Alert: Eli Lilly Slashes Insulin Prices, Caps Patient Costs",InvestorPlace,/news/stocks/lly-stock-alert-eli-lilly-slashes-insulin-prices-caps-patient-costs-1032137149
2175.0,3/1/2023 8:04:43 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032137520
2176.0,3/2/2023 1:27:22 PM,Eli Lilly licenses non opioid pain med for $40M upfront,Seeking Alpha,https://seekingalpha.com/news/3943220-eli-lilly-licenses-non-opioid-pain-med-for-40m-upfront?utm_source=businessinsider&utm_medium=referral
2177.0,3/3/2023 12:20:56 PM,Viatris joins AbbVie and Lilly in protesting against U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3943792-viatris-joins-abbvie-and-lilly-in-protesting-against-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral
2178.0,3/3/2023 4:30:35 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Innoviva (INVA) and Alector (ALEC)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-innoviva-inva-and-alector-alec-1032144359
2179.0,3/3/2023 8:08:25 PM,Wegovy CV risk reduction data in obesity could help both Novo Nordisk and Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3944109-wegovy-cv-risk-reduction-data-in-obesity-could-help-both-novo-nordisk-and-eli-lilly?utm_source=businessinsider&utm_medium=referral
2180.0,3/3/2023 8:20:28 PM,Eli Lilly wins additional breast cancer indication for Verzenio,Seeking Alpha,https://seekingalpha.com/news/3944114-eli-lilly-wins-additional-breast-cancer-indication-for-verzenio?utm_source=businessinsider&utm_medium=referral
2181.0,3/3/2023 8:58:00 PM,"U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer",PR Newswire,/news/stocks/u-s-fda-broadens-indication-for-verzenio-abemaciclib-in-hr-her2-node-positive-high-risk-early-breast-cancer-1032144778
2182.0,3/5/2023 4:19:39 PM,7 High-Growth Stocks for ESG-Oriented Investors,InvestorPlace,/news/stocks/7-high-growth-stocks-for-esg-oriented-investors-1032145717
2183.0,3/6/2023 11:50:15 AM,"Analysts’ Top Healthcare Picks: Abbott Labs (ABT), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-abbott-labs-abt-eli-lilly-co-lly-1032146876
2184.0,3/6/2023 12:36:50 PM,"US Stocks Could Consolidate As S&P 500, Nasdaq Futures Tick Up Ahead Of Fed Chair Powell's Congressional Testimony",Benzinga,/news/stocks/us-stocks-could-consolidate-as-s-p-500-nasdaq-futures-tick-up-ahead-of-fed-chair-powell-s-congressional-testimony-1032146852
2185.0,3/6/2023 4:00:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-6-2023-1032147650
2186.0,3/6/2023 4:30:00 PM,"Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according t...",PR Newswire,/news/stocks/intensive-education-at-clinics-about-multidisciplinary-care-improved-likelihood-that-adults-with-type-2-diabetes-and-cardiovascular-disease-were-receiving-guideline-directed-medicines-according-t-1032147710
2187.0,3/6/2023 6:50:03 PM,Eli Lilly granted Hold rating at Jefferies as shares look “priced to perfection”,Seeking Alpha,https://seekingalpha.com/news/3944576-eli-lilly-granted-hold-rating-jefferies-shares-look-priced-to-perfection?utm_source=businessinsider&utm_medium=referral
2188.0,3/6/2023 9:51:01 PM,WW buying telehealth provider Sequence; provides easier access to obesity drugs,Seeking Alpha,https://seekingalpha.com/news/3944657-weight-watchers-buys-telehealth-provider-sequence-provides-easier-access-to-obesity-drugs?utm_source=businessinsider&utm_medium=referral
2189.0,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral
2190.0,3/7/2023 4:24:57 PM,Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin,Seeking Alpha,https://seekingalpha.com/news/3944959-lexicon-initiated-at-buy-at-jefferies-on-uptake-of-heart-failure-candidate-sotagliflozin?utm_source=businessinsider&utm_medium=referral
2191.0,3/8/2023 1:34:07 AM,Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason,Benzinga,/news/stocks/health-care-etfs-have-lost-in-the-last-month---these-top-pharma-stocks-are-the-reason-1032151775
2192.0,3/8/2023 2:38:05 PM,"Boehringer, Lilly get FDA review for expanded use of Jardiance in adolescents",Seeking Alpha,https://seekingalpha.com/news/3945363-boehringer-lilly-get-fda-review-for-expanded-use-of-jardiance-in-adolescents?utm_source=businessinsider&utm_medium=referral
2193.0,3/8/2023 3:00:00 PM,US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes,PR Newswire,/news/stocks/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-children-10-years-and-older-with-type-2-diabetes-1032153748
2194.0,3/8/2023 3:36:12 PM,Lilly : FDA Accepts SNDA For Jardiance For Children 10 Years & Older With Type 2 Diabetes ,RTTNews,/news/stocks/lilly-fda-accepts-snda-for-jardiance-for-children-10-years-older-with-type-2-diabetes-1032153943
2195.0,3/8/2023 10:33:01 PM,Lilly ends development of Alzheimer's candidate solanezumab after study failure,Seeking Alpha,https://seekingalpha.com/news/3945692-lilly-ends-development-of-alzheimers-candidate-solanezumab-after-study-failure?utm_source=businessinsider&utm_medium=referral
2196.0,3/8/2023 11:00:00 PM,Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease,PR Newswire,/news/stocks/lilly-provides-update-on-a4-study-of-solanezumab-for-preclinical-alzheimer-s-disease-1032154925
2197.0,3/9/2023 2:41:44 AM,Lilly's Solanezumab Fails In Alzheimer's Prevention Trial ,RTTNews,/news/stocks/lilly-s-solanezumab-fails-in-alzheimer-s-prevention-trial-1032155097
2198.0,3/9/2023 6:07:49 PM,Sanders unveils bill to cap insulin price at $20 per vial,Seeking Alpha,https://seekingalpha.com/news/3946076-sanders-unveils-bill-to-cap-insulin-price-at-20-per-vial?utm_source=businessinsider&utm_medium=referral
2199.0,3/10/2023 7:10:43 PM,"Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs",Benzinga,/news/stocks/hefty-listing-price-of-new-drugs-for-cancer-rare-diseases-put-pressure-on-annual-hike-for-older-drugs-1032160689
2200.0,3/12/2023 5:00:16 PM,New weight loss therapies can burden Medicare - experts,Seeking Alpha,https://seekingalpha.com/news/3946678-new-weight-loss-therapies-can-burden-medicare?utm_source=businessinsider&utm_medium=referral
2201.0,3/13/2023 9:50:23 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Axsome Therapeutics (AXSM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-axsome-therapeutics-axsm-1032162619
2202.0,3/13/2023 11:55:12 AM,Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows,Benzinga,/news/stocks/nasdaq-futures-climb-solidly-after-past-week-s-rout-analyst-flags-key-s-p-500-support-to-stay-above-october-lows-1032162772
2203.0,3/13/2023 12:20:01 PM,"3 Stocks to Buy Today, 3/13/2023, According to Top Analysts",TipRanks,/news/stocks/3-stocks-to-buy-today-3-13-2023-according-to-top-analysts-1032163130
2204.0,3/13/2023 4:00:45 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-13-2023-1032163649
2205.0,3/13/2023 4:35:00 PM,Eli Lilly upgraded at Wells Fargo citing opportunity after recent weakness,Seeking Alpha,https://seekingalpha.com/news/3946916-lly-stock-upgraded-wells-fargo-opportunity-weakness?utm_source=businessinsider&utm_medium=referral
2206.0,3/14/2023 12:38:36 PM,"Eli Lilly, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling",Benzinga,/news/stocks/eli-lilly-hewlett-packard-enterprise-and-2-other-stocks-insiders-are-selling-1032165906
2207.0,3/14/2023 12:45:58 PM,Novo Nordisk to bring down insulin prices by up to 75% - WSJ,Seeking Alpha,https://seekingalpha.com/news/3947235-novo-nordisk-to-bring-down-insulin-prices-by-up-to-75?utm_source=businessinsider&utm_medium=referral
2208.0,3/14/2023 9:30:00 PM,Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2023-american-association-for-cancer-research-aacr-annual-meeting-1032167521
2209.0,3/15/2023 2:03:35 PM,"Eli Lilly, Novo could make more money on insulin despite price reductions - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3947677-eli-lilly-novo-could-make-more-money-on-insulin-despite-price-reductions-bloomberg?utm_source=businessinsider&utm_medium=referral
2210.0,3/16/2023 9:41:10 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Halozyme (HALO) and 9 Meters Biopharma (NMTR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-halozyme-halo-and-9-meters-biopharma-nmtr-1032172053
2211.0,3/16/2023 6:15:32 PM,Medicare publishes initial guidance on drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3948265-medicare-publishes-initial-guidance-on-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
2212.0,3/17/2023 3:26:18 AM,Sanofi To Cut U.S. List Price Of Its Most-prescribed Insulin By 78% ,RTTNews,/news/stocks/sanofi-to-cut-u-s-list-price-of-its-most-prescribed-insulin-by-78-1032174315
2213.0,3/19/2023 4:00:30 PM,Pfizer CEO pockets $33M for 2022 after 36% pay hike,Seeking Alpha,https://seekingalpha.com/news/3948694-pfizer-ceo-pockets-33m-for-2022-after-36-percent-pay-hike?utm_source=businessinsider&utm_medium=referral
2214.0,3/20/2023 10:45:56 AM,Takeda hits main goals in mid-stage trial for plaque psoriasis therapy,Seeking Alpha,https://seekingalpha.com/news/3948751-takeda-hits-main-goals-mid-stage-trial-plaque-psoriasis-therapy?utm_source=businessinsider&utm_medium=referral
2215.0,3/20/2023 11:15:08 AM,BMO Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032178534
2216.0,3/21/2023 9:41:13 AM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-humana-hum-1032181184
2217.0,3/21/2023 6:58:24 PM,Altimmune leads obesity drug developers lower after data for lead asset,Seeking Alpha,https://seekingalpha.com/news/3949662-altimmune-leads-obesity-drug-developers-lower-after-data-for-lead-asset?utm_source=businessinsider&utm_medium=referral
2218.0,3/21/2023 7:34:59 PM,Eli Lilly experiencing shortages of diabetes med Trulicity,Seeking Alpha,https://seekingalpha.com/news/3949668-eli-lilly-experiencing-shortages-diabetes-med-trulicity?utm_source=businessinsider&utm_medium=referral
2219.0,3/21/2023 8:13:55 PM,7 Healthcare Stocks to Buy for Long-Term Growth and Stability,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-for-long-term-growth-and-stability-1032183221
2220.0,3/22/2023 7:26:26 AM,"Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease ",RTTNews,/news/stocks/roche-lilly-to-develop-elecsys-amyloid-plasma-panel-to-boost-early-diagnosis-of-alzheimer-s-disease-1032183853
2221.0,3/22/2023 9:12:23 AM,"Lilly, Roche team up to develop blood test for Alzheimer's disease",Seeking Alpha,https://seekingalpha.com/news/3949789-lilly-roche-team-up-to-develop-blood-test-for-alzheimers-disease?utm_source=businessinsider&utm_medium=referral
2222.0,3/22/2023 9:51:19 PM,"7 Hot Stocks To Turn $1,000 Into $10,000 By 2030",InvestorPlace,/news/stocks/7-hot-stocks-to-turn-1000-into-10000-by-2030-1032191126
2223.0,3/23/2023 1:59:14 PM,‘Our Best Long-Term Picks’: Morgan Stanley Suggests 3 High-Quality Stocks to Buy Now,TipRanks,/news/stocks/our-best-long-term-picks-morgan-stanley-suggests-3-high-quality-stocks-to-buy-now-1032188153
2224.0,3/23/2023 6:33:09 PM,White House seeking alternative supply chains for pharmaceutical ingredients,Seeking Alpha,https://seekingalpha.com/news/3950575-white-house-alternative-supply-chains-pharmaceutical-ingredients-drug-shortages?utm_source=businessinsider&utm_medium=referral
2225.0,3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral
2226.0,3/24/2023 7:13:32 PM,California to produce state-label low-cost insulin,Seeking Alpha,https://seekingalpha.com/news/3951103-california-to-produce-state-label-low-cost-insulin?utm_source=businessinsider&utm_medium=referral
2227.0,3/27/2023 12:20:41 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV), Eli Lilly & Co (LLY) and Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-elevance-health-elv-eli-lilly-co-lly-and-johnson-johnson-jnj-1032193916
2228.0,3/28/2023 9:00:00 PM,"Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says",Benzinga,/news/stocks/viking-therapeutics-initial-vk2735-data-resoundingly-beat-expectations-analyst-says-1032198283
2229.0,3/28/2023 9:53:02 PM,Mid-Cap Monday: ETF Fund Flows,Benzinga,/news/etf/mid-cap-monday-etf-fund-flows-1032198343
2230.0,3/29/2023 2:50:46 PM,WHO to weigh adding obesity therapies to 'essential' medicines list – Reuters,Seeking Alpha,https://seekingalpha.com/news/3952303-who-to-weigh-adding-obesity-therapies-to-essential-medicines-list-reuters?utm_source=businessinsider&utm_medium=referral
2231.0,3/30/2023 10:37:24 AM,"Stopping Novo Nordisk's Wegovy, Ozempic may lead to regaining weight - report",Seeking Alpha,https://seekingalpha.com/news/3952594-stopping-novo-nordisks-wegovy-ozempic-may-lead-to-regaining-weight?utm_source=businessinsider&utm_medium=referral
2232.0,3/31/2023 12:02:14 PM,Lilly's ulcerative colitis drug Omvoh inches closer to EU approval with EMA nod,Seeking Alpha,https://seekingalpha.com/news/3953087-lillys-ulcerative-colitis-drug-omvoh-inches-closer-eu-approval?utm_source=businessinsider&utm_medium=referral
2233.0,3/31/2023 2:55:02 PM,Eli Lilly says new Alzheimer’s drug showed dose-dependent effect,Seeking Alpha,https://seekingalpha.com/news/3953216-eli-lilly-stock-shows-early-effect-of-alzheimers-therapy?utm_source=businessinsider&utm_medium=referral
2234.0,4/3/2023 10:15:22 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032210142
2235.0,4/3/2023 11:31:23 AM,"Analysts’ Top Healthcare Picks: Legend Biotech (LEGN), Y-Mabs Therapeutics (YMAB)",TipRanks,/news/stocks/analysts-top-healthcare-picks-legend-biotech-legn-y-mabs-therapeutics-ymab-1032210419
2236.0,4/3/2023 10:52:51 PM,7 Spectacular Growth Stocks to Buy in April,InvestorPlace,/news/stocks/7-spectacular-growth-stocks-to-buy-in-april-1032212167
2237.0,4/3/2023 11:01:46 PM,8 Analysts Have This to Say About Eli Lilly,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-eli-lilly-1032212036
2238.0,4/6/2023 3:09:09 PM,"Morgan Stanley cuts Comcast, adds Becton Dickinson to its model portfolio",Seeking Alpha,https://seekingalpha.com/news/3954991-morgan-stanley-cuts-comcast-adds-becton-dickinson-to-its-model-portfolio?utm_source=businessinsider&utm_medium=referral
2239.0,4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral
2240.0,4/6/2023 9:20:22 PM,What To Expect When Merus Presents Petosemtamab Data Update At AACR,Benzinga,/news/stocks/what-to-expect-when-merus-presents-petosemtamab-data-update-at-aacr-1032219940
2241.0,4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral
2242.0,4/7/2023 7:50:36 PM,6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative',Benzinga,/news/stocks/6-questions-with-rocket-pharma-s-ceo-on-world-health-day-how-the-biotech-is-changing-the-narrative-1032220849
2243.0,4/9/2023 4:00:00 PM,"Premier cancer research event, AACR is starting this week; Here is what to expect",Seeking Alpha,https://seekingalpha.com/news/3955202-aacr-2023-is-starting-this-week-here-is-what-to-expect?utm_source=businessinsider&utm_medium=referral
2244.0,4/10/2023 8:05:16 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1032221717
2245.0,4/11/2023 2:25:44 AM,U.S. launches $5B program to speed up development of next-gen COVID vaccines,Seeking Alpha,https://seekingalpha.com/news/3955481-us-launches-5b-program-develop-next-gen-covid-vaccines?utm_source=businessinsider&utm_medium=referral
2246.0,4/11/2023 11:05:05 AM,Eli Lilly & Co (LLY) Receives a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-bmo-capital-1032223998
2247.0,4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral
2248.0,4/12/2023 6:13:04 PM,Bernie Sanders weighs Senate hearing for largest insulin makers – Stat News,Seeking Alpha,https://seekingalpha.com/news/3956054-bernie-sanders--senate-hearing-insulin-makers?utm_source=businessinsider&utm_medium=referral
2249.0,4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral
2250.0,4/13/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2023-financial-results-announcement-1032230447
2251.0,4/13/2023 8:51:21 PM,FDA rejects Eli Lilly's license application for ulcerative colitis treatment mirikizumab,Seeking Alpha,https://seekingalpha.com/news/3956434-fda-rejects-eli-lillys-license-application-for-ulcerative-colitis-treatment-mirikizumab?utm_source=businessinsider&utm_medium=referral
2252.0,4/13/2023 10:30:00 PM,U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab,PR Newswire,/news/stocks/u-s-food-and-drug-administration-issues-complete-response-letter-for-mirikizumab-1032231292
2253.0,4/14/2023 8:30:53 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cigna-ci-eli-lilly-co-lly-and-teva-pharmaceutical-teva-1032232189
2254.0,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral
2255.0,4/14/2023 9:35:12 AM,Bank of America Securities Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032232290
2256.0,4/14/2023 9:45:07 AM,Morgan Stanley Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-remains-a-buy-on-eli-lilly-co-lly-1032232335
2257.0,4/14/2023 3:28:52 PM,WeightWatchers Latest Strategic Acquisition: Simplify Insurance Reimbursement For Costly Weight-Loss Drugs,Benzinga,/news/stocks/weightwatchers-latest-strategic-acquisition-simplify-insurance-reimbursement-for-costly-weight-loss-drugs-1032232977
2258.0,4/14/2023 4:01:32 PM,"Big Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top Stories",Benzinga,/news/stocks/big-bank-s-big-q1-performance-florida-gov-quietly-slips-6-week-abortion-ban-into-law-subway-sandwich-seeks-10b-sale-today-s-top-stories-1032233074
2259.0,4/15/2023 12:20:12 AM,"Merus' Petosemtamab Abstract Hits Upside Scenario For Overall Response Rate, Duration Of Response: Analyst",Benzinga,/news/stocks/merus-petosemtamab-abstract-hits-upside-scenario-for-overall-response-rate-duration-of-response-analyst-1032233789
2260.0,4/16/2023 12:30:06 PM,Get In Now. 3 Stocks That Are Set to Soar.,InvestorPlace,/news/stocks/3-stocks-to-buy-stocks-that-are-set-to-soar-1032234461
2261.0,4/17/2023 11:45:08 AM,Eli Lilly & Co (LLY) Gets a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bmo-capital-1032236121
2262.0,4/17/2023 5:00:00 PM,Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities,PR Newswire,/news/stocks/lilly-to-make-record-breaking-investment-in-indiana-manufacturing-facilities-1032236845
2263.0,4/17/2023 5:28:30 PM,Eli Lilly to boost investment in Indiana manufacturing facilities,Seeking Alpha,https://seekingalpha.com/news/3956981-eli-lilly-boost-investment-indiana-manufacturing-facilities?utm_source=businessinsider&utm_medium=referral
2264.0,4/17/2023 6:12:49 PM,"Eli Lilly To Invest Additional $1.6 Bln, Commits 200 New Jobs At LEAP Innovation Park ",RTTNews,/news/stocks/eli-lilly-to-invest-additional-1-6-bln-commits-200-new-jobs-at-leap-innovation-park-1032237074
2265.0,4/17/2023 9:46:12 PM,Nektar Therapeutics up 7% after hours on restructuring plan,Seeking Alpha,https://seekingalpha.com/news/3957126-nektar-therapeutics-up-7-after-hours-on-restructuring-plan?utm_source=businessinsider&utm_medium=referral
2266.0,4/18/2023 1:20:41 PM,Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions,Benzinga,/news/stocks/analyst-says-nektar-therapeutics-rezpeg-prioritization-likely-to-spark-investor-questions-1032239294
2267.0,4/18/2023 5:23:54 PM,"Teladoc up 8% on expansion into weight management, diabetes",Seeking Alpha,https://seekingalpha.com/news/3957412-teladoc-up-8-expansion-into-weight-management-diabetes?utm_source=businessinsider&utm_medium=referral
2268.0,4/18/2023 7:19:36 PM,Why Is Teladoc (TDOC) Stock Up 6% Today?,InvestorPlace,/news/stocks/why-is-teladoc-tdoc-stock-up-6-today-1032240941
2269.0,4/21/2023 8:30:57 AM,"Analysts Are Bullish on These Healthcare Stocks: AmerisourceBergen (ABC), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amerisourcebergen-abc-eli-lilly-co-lly-1032249192
2270.0,4/21/2023 12:30:10 PM,Eli Lilly expects Medicare coverage for Alzheimer's drugs - Reuters,Seeking Alpha,https://seekingalpha.com/news/3958637-eli-lilly-expects-medicare-coverage-alzheimers-drugs-reuters?utm_source=businessinsider&utm_medium=referral
2271.0,4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral
2272.0,4/21/2023 7:00:36 PM,"Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut",Seeking Alpha,https://seekingalpha.com/news/3958768-catalyst-watch-earnings-blitz-mobileye-lockup-expiration-and-the-new-one-day-vix-debut?utm_source=businessinsider&utm_medium=referral
2273.0,4/22/2023 8:00:00 PM,Ulcerative colitis market set to hit $9.6B by 2031,Seeking Alpha,https://seekingalpha.com/news/3958777-ulcerative-colitis-market-set-to-hit-96b-by-2031?utm_source=businessinsider&utm_medium=referral
2274.0,4/24/2023 9:40:07 AM,Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-procept-biorobotics-prct-and-eli-lilly-co-lly-1032253421
2275.0,4/24/2023 11:31:21 AM,Eli Lilly to divest diabetes therapy Baqsimi to Amphastar,Seeking Alpha,https://seekingalpha.com/news/3958992-eli-lilly-stock-divest-diabetes-therapy-baqsimi-amphastar?utm_source=businessinsider&utm_medium=referral
2276.0,4/24/2023 12:45:00 PM,Lilly to Divest BAQSIMI to Amphastar,PR Newswire,/news/stocks/lilly-to-divest-baqsimi-to-amphastar-1032253594
2277.0,4/24/2023 1:39:39 PM,Lilly To Sell BAQSIMI For At Least $500 Mln In Cash ,RTTNews,/news/stocks/lilly-to-sell-baqsimi-for-at-least-500-mln-in-cash-1032253742
2278.0,4/24/2023 3:46:03 PM,Eli Lilly to conduct Mounjaro head-to-head trial against Novo Nordisk's Wegovy,Seeking Alpha,https://seekingalpha.com/news/3959125-eli-lilly-conduct-mounjaro-head-to-head-trial-against-novo-nordisk-wegovy?utm_source=businessinsider&utm_medium=referral
2279.0,4/24/2023 7:37:37 PM,Weight-loss drugmakers push for Medicare coverage,Seeking Alpha,https://seekingalpha.com/news/3959326-weight-loss-drugmakers-push-medicare-coverage?utm_source=businessinsider&utm_medium=referral
2280.0,4/25/2023 3:38:42 PM,Bipartisan agreement reached in Senate prescription drug price legislation,Seeking Alpha,https://seekingalpha.com/news/3959793-bipartisan-agreement-reached-senate-prescription-drug-price-legislation?utm_source=businessinsider&utm_medium=referral
2281.0,4/25/2023 5:35:06 PM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1032259613
2282.0,4/26/2023 3:01:13 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q1-earnings-preview-1032263654
2283.0,4/26/2023 3:07:35 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3960517-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral
2284.0,4/26/2023 3:32:44 PM,Lilly to report Q1 2023 results with pipeline updates in spotlight,Seeking Alpha,https://seekingalpha.com/news/3960530-lilly-stock-report-q1-2023-results-wth-pipeline-updates-focus?utm_source=businessinsider&utm_medium=referral
2285.0,4/26/2023 8:05:11 PM,Biogen gains as Medicare to cover new Alzheimer’s drug with full FDA approval,Seeking Alpha,https://seekingalpha.com/news/3960780-biogen-stock-gains-medicare-cover-new-alzheimers-drug?utm_source=businessinsider&utm_medium=referral
2286.0,4/27/2023 10:45:09 AM,7 Healthcare Stocks With Huge Return Potential for Long-Term Investors,InvestorPlace,/news/stocks/7-healthcare-stocks-with-huge-return-potential-for-long-term-investors-1032267993
2287.0,4/27/2023 10:48:16 AM,"Eli Lilly Non-GAAP EPS of $1.62 misses by $0.11, revenue of $6.96B beats by $90M",Seeking Alpha,https://seekingalpha.com/news/3961164-eli-lilly-non-gaap-eps-of-1_62-misses-0_11-revenue-of-6_96b-beats-90m?utm_source=businessinsider&utm_medium=referral
2288.0,4/27/2023 10:55:09 AM,Lilly obesity therapy shows ~16% weight loss in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3961177-lilly-stock-obesity-therapy-shows-weight-loss?utm_source=businessinsider&utm_medium=referral
2289.0,4/27/2023 12:15:00 PM,Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2,PR Newswire,/news/stocks/lilly-s-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-surmount-2-1032267820
2290.0,4/27/2023 12:29:50 PM,Eli Lilly: Tirzepatide Achieves Up To 15.7% Weight Loss In Results From SURMOUNT-2 ,RTTNews,/news/stocks/eli-lilly-tirzepatide-achieves-up-to-15-7-weight-loss-in-results-from-surmount-2-1032267884
2291.0,4/27/2023 12:45:00 PM,"Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum",PR Newswire,/news/stocks/lilly-reports-first-quarter-2023-financial-results-highlights-continued-core-business-growth-and-pipeline-momentum-1032267967
2292.0,4/27/2023 1:01:01 PM,"Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Eli Lilly & Co (LLY) and Universal Health (UHS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-edwards-lifesciences-ew-eli-lilly-co-lly-and-universal-health-uhs-1032269007
2293.0,4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050
2294.0,4/27/2023 1:07:20 PM,"Eli Lilly And Co. Q1 Profit Decreases, misses estimates",RTTNews,/news/stocks/eli-lilly-and-co-q1-profit-decreases-misses-estimates-1032268069
2295.0,4/27/2023 1:10:44 PM,"Lilly Q1 Profit Down, Misses View; Lifts FY23 Forecast; Stock Up In Pre Market ",RTTNews,/news/stocks/lilly-q1-profit-down-misses-view-lifts-fy23-forecast-stock-up-in-pre-market-1032268066
2296.0,4/27/2023 1:24:55 PM,Eli Lilly posts Q1 contraction amid hit to COVID sales,Seeking Alpha,https://seekingalpha.com/news/3961359-eli-lilly-stock-posts-q1-contraction-amid-hit-to-covid-sales?utm_source=businessinsider&utm_medium=referral
2297.0,4/27/2023 2:13:09 PM,LLY Stock Alert: Mounjaro Takes Eli Lilly to the Next Level,InvestorPlace,/news/stocks/lly-stock-alert-mounjaro-takes-eli-lilly-to-the-next-level-1032269314
2298.0,4/27/2023 2:14:00 PM,Nektar regains rights to atopic dermatitis candidate from Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3961402-nektar-regains-rights-atopic-dermatitis-candidate-rezpeg-eli-lilly?utm_source=businessinsider&utm_medium=referral
2299.0,4/27/2023 2:53:44 PM,Cathie Wood Doubles Down on Tesla (TSLA) Stock After Earnings,InvestorPlace,/news/stocks/cathie-wood-doubles-down-on-tesla-tsla-stock-after-earnings-1032269413
2300.0,4/27/2023 3:12:38 PM,Zura to license autoimmune disease drug from Lilly; plans $80M private offering,Seeking Alpha,https://seekingalpha.com/news/3961450-zura-to-license-autoimmune-disease-drug-lilly-plans-80m-private-offering?utm_source=businessinsider&utm_medium=referral
2301.0,4/27/2023 3:19:42 PM,Why Are Stocks Up Today?,InvestorPlace,/news/stocks/why-are-stocks-up-today-april-27th-1032269539
2302.0,4/27/2023 3:46:08 PM,Eli Lilly to use priority review voucher for Mounjaro weight loss indication,Seeking Alpha,https://seekingalpha.com/news/3961462-eli-lilly-priority-review-voucher-mounjaro-weight-loss-indication?utm_source=businessinsider&utm_medium=referral
2303.0,4/27/2023 5:01:56 PM,"Hot Stocks: TDOC, LLY, ROKU and CMCSA rises on earnings; DBX falls on layoffs; LUV, CAT and BMY slides",Seeking Alpha,https://seekingalpha.com/news/3961499-hot-stocks-tdoc-lly-roku-and-cmcsa-rises-on-earnings-dbx-fallss-on-layoffs-luv-cat-and-bmy-slides?utm_source=businessinsider&utm_medium=referral
2304.0,4/28/2023 8:15:08 AM,Goldman Sachs Sticks to Their Hold Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-hold-rating-for-eli-lilly-co-lly-1032272692
2305.0,4/28/2023 8:25:44 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1032272677
2306.0,4/28/2023 8:59:59 AM,Lilly's blood cancer drug Jaypirca gets EMA greenlight for conditional approval,Seeking Alpha,https://seekingalpha.com/news/3961899-lillys-blood-cancer-drug-jaypirca-gets-ema-greenlight-conditional-approval?utm_source=businessinsider&utm_medium=referral
2307.0,4/28/2023 9:30:31 AM,"Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Eli Lilly & Co (LLY) and Quest Diagnostics (DGX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-baxter-international-bax-eli-lilly-co-lly-and-quest-diagnostics-dgx-1032272923
2308.0,4/28/2023 2:40:41 PM,Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/mastercard-to-rally-over-18-here-are-10-other-analyst-forecasts-for-friday-1032273736
2309.0,4/28/2023 4:12:21 PM,ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug,Benzinga,/news/stocks/immunogen-boosts-annual-guidance-on-upbeat-uptake-of-newly-approved-ovarian-cancer-drug-1032274159
2310.0,4/29/2023 8:00:00 PM,"Pfizer, GSK, AbbVie among pharmas set to rise with May catalysts",Seeking Alpha,https://seekingalpha.com/news/3962345-pfizer-gsk-abbvie-among-pharmas-rise-may-catalysts?utm_source=businessinsider&utm_medium=referral
2311.0,4/29/2023 11:19:13 PM,Here Are The Best Sector ETFs And Major Sector-Moving Stocks In April,Benzinga,/news/etf/here-are-the-best-sector-etfs-and-major-sector-moving-stocks-in-april-1032275372
2312.0,5/1/2023 9:25:16 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1032277525
2313.0,5/1/2023 11:10:34 AM,Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-immunogen-imgn-and-eli-lilly-co-lly-1032277746
2314.0,5/1/2023 11:26:37 AM,Eli Lilly posts additional late-stage data for eczema therapy,Seeking Alpha,https://seekingalpha.com/news/3962508-eli-lilly-stock-posts-late-stage-data-eczema-therapy?utm_source=businessinsider&utm_medium=referral
2315.0,5/1/2023 12:45:00 PM,Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis,PR Newswire,/news/stocks/up-to-73-of-atopic-dermatitis-patients-taking-lilly-s-lebrikizumab-had-improved-or-cleared-skin-on-face-or-hands-in-new-analysis-1032277699
2316.0,5/1/2023 1:35:57 PM,Lilly Says Lebrikizumab Improved 'face Or Hand Dermatitis' At 16 Weeks ,RTTNews,/news/stocks/lilly-says-lebrikizumab-improved-face-or-hand-dermatitis-at-16-weeks-1032277786
2317.0,5/1/2023 5:26:39 PM,Eli Lilly declares $1.13 dividend,Seeking Alpha,https://seekingalpha.com/news/3962738-eli-lilly-and-company-declares-1_13-dividend?utm_source=businessinsider&utm_medium=referral
2318.0,5/1/2023 7:02:00 PM,Lilly Declares Second-Quarter 2023 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2023-dividend-1032278949
2319.0,5/2/2023 5:12:33 PM,"Eli Lilly, Sanofi to cap insulin prices at $35 per month for uninsured New Yorkers",Seeking Alpha,https://seekingalpha.com/news/3963574-lilly-sanofi-cap-monthly-insulin-prices-uninsured-in-new-york?utm_source=businessinsider&utm_medium=referral
2320.0,5/2/2023 6:25:36 PM,"Eli Lilly, Merck hit new 52-week highs",Seeking Alpha,https://seekingalpha.com/news/3963709-eli-lilly-merck-hit-new-52-week-highs?utm_source=businessinsider&utm_medium=referral
2321.0,5/2/2023 8:09:10 PM,Bipartisan prescription drug price legislation hits snag - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3963865-bipartisan-prescription-drug-price-legislation-hits-snag-bloomberg?utm_source=businessinsider&utm_medium=referral
2322.0,5/3/2023 10:00:58 AM,3 Stocks Quietly Hitting All-Time Highs (and Can Continue Higher) ,InvestorPlace,/news/stocks/3-stocks-quietly-hitting-all-time-highs-and-can-continue-higher-1032286732
2323.0,5/3/2023 10:08:01 AM,"Fentanyl overdose deaths rose 279%, oxycodone deaths fell in 5 years",Seeking Alpha,https://seekingalpha.com/news/3964240-fentanyl-overdose-deaths-rose-279-oxycodone-deaths-fell-in-5-years?utm_source=businessinsider&utm_medium=referral
2324.0,5/3/2023 11:13:53 AM,"Lilly stock surges after Alzheimer's drug donanemab slows cognitive decline by 35%, brain swelling seen in some",Seeking Alpha,https://seekingalpha.com/news/3964326-lilly-stock-rises-after-alzheimers-drug-donanemab-slows-cognitive-decline?utm_source=businessinsider&utm_medium=referral
2325.0,5/3/2023 12:19:32 PM,Eli Lilly: Donanemab Meets Primary Endpoint In Phase 3 Study Of Early Alzheimer's Disease ,RTTNews,/news/stocks/eli-lilly-donanemab-meets-primary-endpoint-in-phase-3-study-of-early-alzheimer-s-disease-1032286779
2326.0,5/3/2023 12:49:51 PM,"Eli Lilly, Livent, Super Micro Computer And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session",Benzinga,/news/stocks/eli-lilly-livent-super-micro-computer-and-other-big-stocks-moving-higher-in-wednesday-s-pre-market-session-1032286905
2327.0,5/3/2023 1:44:52 PM,LLY Stock Alert: Eli Lilly Announces Positive Alzheimer’s Drug Data,InvestorPlace,/news/stocks/lly-stock-alert-eli-lilly-announces-positive-alzheimers-drug-data-1032288023
2328.0,5/3/2023 2:04:45 PM,Why Is ImmunoGen (IMGN) Stock Up 125% Today?,InvestorPlace,/news/stocks/why-is-immunogen-imgn-stock-up-125-today-1032288066
2329.0,5/3/2023 5:13:59 PM,Novo Nordisk to report Q1 2023 results with Wegovy sales in focus,Seeking Alpha,https://seekingalpha.com/news/3964707-novo-nordisk-q1-2023-earnings-preview-wegovy-sales?utm_source=businessinsider&utm_medium=referral
2330.0,5/3/2023 5:31:14 PM,"Hot Stocks: GOLD rises on earnings; EL, AMCR fall on guidance cut; PSO gains on upgrade; LLY on strong clinical data; IEP slides",Seeking Alpha,https://seekingalpha.com/news/3964740-hot-stocks-gold-rise-on-earnings-el-amcr-fall-on-guidance-cut-pso-gain-on-upgrade-lly-on-strong-clinical-data-iep-slide?utm_source=businessinsider&utm_medium=referral
2331.0,5/3/2023 7:37:28 PM,Lilly sends Alzheimer’s drug developers higher after trial data,Seeking Alpha,https://seekingalpha.com/news/3964896-lilly-stock-sends-alzheimers-drug-developers-higher-after-trial-data?utm_source=businessinsider&utm_medium=referral
2332.0,5/4/2023 10:10:46 AM,7 A-Rated Stocks to Buy for May 2023,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-for-may-2023-1032291725
2333.0,5/4/2023 11:35:13 AM,BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032292212
2334.0,5/4/2023 12:25:54 PM,Credit Suisse Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/credit-suisse-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032292508
2335.0,5/4/2023 12:50:30 PM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), United Therapeutics (UTHR) and Bausch + Lomb Corporation (BLCO)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-united-therapeutics-uthr-and-bausch-+-lomb-corporation-blco-1032292666
2336.0,5/4/2023 7:29:16 PM,Which Healthcare Stock Is a Compelling Pick for the Long Haul?,InvestorPlace,/news/stocks/which-healthcare-stock-is-a-compelling-pick-for-the-long-haul-1032294048
2337.0,5/4/2023 8:34:50 PM,Mastercard To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Thursday,Benzinga,/news/stocks/mastercard-to-rally-around-27-here-are-10-other-analyst-forecasts-for-thursday-1032293945
2338.0,5/4/2023 9:06:04 PM,"Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen",Benzinga,/news/stocks/analysts-say-eli-lilly-s-donanemab-in-alzheimer-s-is-encouraging-outline-potential-implications-for-biogen-1032294014
2339.0,5/5/2023 11:46:28 AM,"Dividend Roundup: Apple, PepsiCo, UPS, Visa and more",Seeking Alpha,https://seekingalpha.com/news/3965910-dividend-roundup-pepsico-ups-visa-and-more?utm_source=businessinsider&utm_medium=referral
2340.0,5/6/2023 8:00:00 PM,"Eli Lilly, Humana among best health care names in defensive environment - BofA",Seeking Alpha,https://seekingalpha.com/news/3966792-eli-lilly-humana-among-best-health-care-names-defensive-environment?utm_source=businessinsider&utm_medium=referral
2341.0,5/7/2023 4:00:27 PM,Spending on weight loss drugs to rise 378% in 2023 – 2027: report,Seeking Alpha,https://seekingalpha.com/news/3966814-spending-weight-loss-drugs-wegovy-mounjaro-2023-2027?utm_source=businessinsider&utm_medium=referral
2342.0,5/9/2023 10:45:43 AM,3 Dividend Stocks to Buy as the Healthcare Sector Booms in 2023,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-as-the-healthcare-sector-booms-in-2023-1032306053
2343.0,5/9/2023 11:32:42 AM,Lilly touts more data for ulcerative colitis therapy mirikizumab,Seeking Alpha,https://seekingalpha.com/news/3967871-lilly-touts-more-data-for-ulcerative-colitis-therapy-mirikizumab?utm_source=businessinsider&utm_medium=referral
2344.0,5/9/2023 12:45:00 PM,"Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis",PR Newswire,/news/stocks/lilly-discloses-first-in-class-interim-phase-2-data-in-pediatric-patients-and-new-analysis-from-phase-3-program-in-adult-patients-for-mirikizumab-in-ulcerative-colitis-1032306025
2345.0,5/9/2023 2:13:37 PM,Eli Lilly Reports Interim Results From The Phase 2 Study Of Mirikizumab ,RTTNews,/news/stocks/eli-lilly-reports-interim-results-from-the-phase-2-study-of-mirikizumab-1032306523
2346.0,5/9/2023 3:00:00 PM,Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation,PR Newswire,/news/stocks/lilly-s-social-impact-venture-capital-portfolio-poised-to-grow-to-300-million-with-new-50-million-allocation-1032307047
2347.0,5/10/2023 9:25:43 AM,Bank of America Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032311424
2348.0,5/10/2023 9:54:01 AM,"Boehringer, Zealand's drug helps cut weight up to 14.9%, meets phase 2 trial's goal",Seeking Alpha,https://seekingalpha.com/news/3968883-boehringer-zealands-drug-helps-cut-weight-by-149-in-trial?utm_source=businessinsider&utm_medium=referral
2349.0,5/10/2023 5:27:29 PM,"Obesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly",Benzinga,/news/stocks/obesity-drug-achieves-~15-weight-loss---zealand-pharma-boehringer-ingelheim-partnered-drug-may-compete-with-novo-nordisk-eli-lilly-1032313298
2350.0,5/10/2023 9:47:30 PM,ELi Lilly won't raise prices of its currently marketed insulins - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3969678-eli-lilly-wont-raise-prices-of-currently-marketed-insulin?utm_source=businessinsider&utm_medium=referral
2351.0,5/11/2023 9:56:21 AM,"Lundbeck, Otsuka's Rexulti wins FDA approval for agitation linked with Alzheimer's",Seeking Alpha,https://seekingalpha.com/news/3969842-lundbeck-otsukas-rexulti-wins-fda-nod-for-alzheimers-agitation?utm_source=businessinsider&utm_medium=referral
2352.0,5/11/2023 10:09:45 AM,The 3 Best MedTech Stocks to Watch in May 2023,InvestorPlace,/news/stocks/the-3-best-medtech-stocks-to-watch-in-may-2023-1032317056
2353.0,5/11/2023 4:00:00 PM,Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting,PR Newswire,/news/stocks/loxo-lilly-announces-details-of-presentations-at-2023-european-hematology-association-eha-annual-meeting-1032318365
2354.0,5/12/2023 8:40:50 AM,Obesity review: World Health Organization weighs in on weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3970649-obesity-review-world-health-organization-weighs-in-on-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
2355.0,5/12/2023 5:11:43 PM,AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market,Benzinga,/news/etf/ai-run-etf-dumps-apple-in-favor-of-this-chip-stock-and-hints-at-new-opportunity-brewing-in-market-1032323317
2356.0,5/14/2023 4:00:49 PM,Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study,Seeking Alpha,https://seekingalpha.com/news/3971102-biogen-new-alzheimers-drug-leqembi-raise-medicare-costs?utm_source=businessinsider&utm_medium=referral
2357.0,5/15/2023 1:25:15 PM,Eli Lilly & Co (LLY) Gets a Buy from Morgan Stanley,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-morgan-stanley-1032327631
2358.0,5/15/2023 7:01:51 PM,What 20 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-20-analyst-ratings-have-to-say-about-eli-lilly-1032328277
2359.0,5/15/2023 10:03:22 PM,"Druckenmiller's Duquesne adds Microsoft, IQVIA, exits Cenovus Energy, Lennar",Seeking Alpha,https://seekingalpha.com/news/3971810-druckenmillers-duquesne-adds-microsoft-iqvia-exits-cenovus-energy-lennar?utm_source=businessinsider&utm_medium=referral
2360.0,5/16/2023 1:07:42 PM,"Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront  cash/equity deal",Seeking Alpha,https://seekingalpha.com/news/3972036-lilly-scribe-team-up-for-neuro-diseases-crispr-therapies?utm_source=businessinsider&utm_medium=referral
2361.0,5/17/2023 12:30:41 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Compugen (CGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-compugen-cgen-and-eli-lilly-co-lly-1032332838
2362.0,5/17/2023 8:47:25 PM,Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs,InvestorPlace,/news/stocks/shhh-3-healthcare-stocks-quietly-hitting-52-week-highs-1032336112
2363.0,5/18/2023 11:35:07 AM,Lilly's rheumatoid arthritis drug peresolimab shows promise in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3972930-lillys-rheumatoid-arthritis-drug-peresolimab-shows-promise-in-trial?utm_source=businessinsider&utm_medium=referral
2364.0,5/18/2023 12:45:00 PM,Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine,PR Newswire,/news/stocks/lilly-s-peresolimab-phase-2a-rheumatoid-arthritis-trial-published-in-the-new-england-journal-of-medicine-1032337009
2365.0,5/18/2023 3:30:11 PM,Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer’s study,Seeking Alpha,https://seekingalpha.com/news/3973090-cognition-stock-rises-after-ct1812-shows-promise-in-alzheimers?utm_source=businessinsider&utm_medium=referral
2366.0,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral
2367.0,5/18/2023 7:30:02 PM,"Sen. Wyden presses HHS, CMS on access to new Alzheimer's therapies",Seeking Alpha,https://seekingalpha.com/news/3973210-sen-ron-wyden-presses-hhs-cms-access-new-alzheimers-therapies?utm_source=businessinsider&utm_medium=referral
2368.0,5/19/2023 4:51:21 PM,"WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake",Benzinga,/news/stocks/who-recommends-new-covid-booster-shots-to-target-xbb-variants-despite-slower-uptake-1032340045
2369.0,5/20/2023 8:00:39 PM,Novo Nordisk Ozempic sales expected to reach $17B in 2029,Seeking Alpha,https://seekingalpha.com/news/3973617-novo-nordisk-ozempic-sales-expected-reach-17b-2029?utm_source=businessinsider&utm_medium=referral
2370.0,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral
2371.0,5/22/2023 10:23:17 AM,Novo Nordisk gains as study shows cardiovascular benefits of obesity drug,Seeking Alpha,https://seekingalpha.com/news/3973701-novo-nordisk-obesity-drug-linked-heart-health?utm_source=businessinsider&utm_medium=referral
2372.0,5/22/2023 11:25:05 AM,BMO Capital Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-eli-lilly-co-lly-1032342314
2373.0,5/22/2023 1:05:48 PM,The 3 Best Momentum Stocks to Buy in May 2023,InvestorPlace,/news/stocks/momentum-stocks-to-buy-1032342750
2374.0,5/22/2023 4:00:00 PM,Lilly ESG Report Highlights Progress Towards Sustainability Goals,PR Newswire,/news/stocks/lilly-esg-report-highlights-progress-towards-sustainability-goals-1032342887
2375.0,5/22/2023 4:30:42 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Bausch Health Companies (BHC) and Resmed (RMD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-bausch-health-companies-bhc-and-resmed-rmd-1032343304
2376.0,5/23/2023 3:25:08 AM,Bank of America Securities Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032343912
2377.0,5/23/2023 1:49:23 PM,Microsoft To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday,Benzinga,/news/stocks/microsoft-to-rally-around-25-here-are-10-other-analyst-forecasts-for-tuesday-1032345031
2378.0,5/23/2023 2:51:44 PM,Pfizer stock yet to imply obesity drug’s blockbuster potential – Cantor,Seeking Alpha,https://seekingalpha.com/news/3974223-pfizer-stock-to-imply-obesity-drugs-potential-cantor?utm_source=businessinsider&utm_medium=referral
2379.0,5/24/2023 12:18:40 AM,7 Stocks That Could Be the Next $2 Trillion-Dollar Companies,InvestorPlace,/news/stocks/7-stocks-that-could-be-the-next-2-trillion-dollar-companies-1032346826
2380.0,5/24/2023 2:00:57 PM,Zura Bio soars 37% as Raymond James starts with Strong Buy,Seeking Alpha,https://seekingalpha.com/news/3974613-zura-bio-stock-soars-raymond-james-strong-buy?utm_source=businessinsider&utm_medium=referral
2381.0,5/24/2023 8:42:38 PM,"Zura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upside",Benzinga,/news/stocks/zura-bio-s-veteran-leadership-eyes-repeat-success-confident-analyst-sees-150-upside-1032349587
2382.0,5/25/2023 4:29:40 PM,7 Top Stock Tips for June 2023,InvestorPlace,/news/stocks/7-top-stock-tips-for-june-2023-1032352462
2383.0,5/26/2023 10:19:56 AM,3 Biotech Stocks Sitting on Huge-Upside Catalysts,InvestorPlace,/news/stocks/3-biotech-stocks-sitting-on-huge-upside-catalysts-1032353942
2384.0,5/26/2023 10:38:37 AM,Elon Musk's Neuralink gets FDA nod to start human trial of brain implant,Seeking Alpha,https://seekingalpha.com/news/3975338-elon-musks-neuralink-gets-fda-nod-to-start-human-trial-of-brain-implant?utm_source=businessinsider&utm_medium=referral
2385.0,5/26/2023 12:30:32 PM,"Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-allogene-therapeutics-allo-eli-lilly-co-lly-1032354317
2386.0,5/26/2023 4:30:27 PM,"Analysts Offer Insights on Healthcare Companies: Centene (CNC), Eli Lilly & Co (LLY) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-centene-cnc-eli-lilly-co-lly-and-sarepta-therapeutics-srpt-1032354885
2387.0,5/27/2023 6:04:05 PM,3 High-Growth Stocks to Buy Before They Join the Trillion-Dollar Club,InvestorPlace,/news/stocks/3-high-growth-stocks-to-buy-before-they-join-the-trillion-dollar-club-1032355503
2388.0,5/28/2023 10:27:56 PM,7 Overvalued Value Stocks to Sell Before June 2023,InvestorPlace,/news/stocks/7-overvalued-value-stocks-to-sell-before-june-2023-1032355835
2389.0,5/29/2023 6:05:36 PM,SVB Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032356756
2390.0,5/30/2023 2:23:23 AM,"LLY, DXCM, or ISRG: Which Healthcare Stock is the Most Attractive Pick?",TipRanks,/news/stocks/lly-dxcm-or-isrg-which-healthcare-stock-is-the-most-attractive-pick-1032356958
2391.0,5/30/2023 4:00:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1032358529
2392.0,5/30/2023 7:30:57 PM,Eli Lilly partners with XtalPi on AI drug discovery in up to $250M deal,Seeking Alpha,https://seekingalpha.com/news/3975939-eli-lilly-partners-xtalpi-artificial-intelligence-drug-discovery-250m-deal?utm_source=businessinsider&utm_medium=referral
2393.0,6/1/2023 2:33:27 PM,Medicare to cover Alzheimer's drugs granted full FDA approval,Seeking Alpha,https://seekingalpha.com/news/3976628-medicare-cover-alzheimers-drugs-granted-full-fda-approval?utm_source=businessinsider&utm_medium=referral
2394.0,6/1/2023 5:01:15 PM,Eli Lilly beats Johnson & Johnson to become world's most valuable drugmaker,Seeking Alpha,https://seekingalpha.com/news/3976741-lilly-stock-pips-jnj-stock-become-most-valuable-pharma?utm_source=businessinsider&utm_medium=referral
2395.0,6/2/2023 2:00:00 PM,Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting,PR Newswire,/news/stocks/lilly-highlights-verzenio-abemaciclib-and-jaypirca-pirtobrutinib-data-at-2023-asco-annual-meeting-1032367099
2396.0,6/3/2023 4:00:00 PM,ASCO 2023: What to look for at oncology's biggest meeting,Seeking Alpha,https://seekingalpha.com/news/3976898-asco-2023-what-look-for-oncology-biggest-meeting?utm_source=businessinsider&utm_medium=referral
2397.0,6/4/2023 4:00:08 PM,Morgan Stanley sees broader MedTech impact from weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3977410-morgan-stanley-sees-medtech-impact-from-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
2398.0,6/4/2023 6:53:53 PM,"Novo Nordisk, Lilly facing increased competition in obesity drug market",Seeking Alpha,https://seekingalpha.com/news/3977415-novo-nordisk-lilly-facing-increased-competition-in-obesity-drug-market?utm_source=businessinsider&utm_medium=referral
2399.0,6/5/2023 9:02:14 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032369720
2400.0,6/5/2023 11:15:09 AM,BMO Capital Gives a Buy Rating to Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-gives-a-buy-rating-to-eli-lilly-co-lly-1032369990
2401.0,6/5/2023 11:31:25 AM,Akero gains 15% on potential of liver disease drug and weight loss therapy combo,Seeking Alpha,https://seekingalpha.com/news/3977502-akero-posts-data-liver-disease-drug-glp-1-combo?utm_source=businessinsider&utm_medium=referral
2402.0,6/6/2023 12:48:16 AM,7 Growth Stocks to Sell in June Before They Crash and Burn,InvestorPlace,/news/stocks/7-growth-stocks-to-sell-in-june-before-they-crash-and-burn-1032371563
2403.0,6/7/2023 8:45:27 AM,Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bank-of-america-securities-1032375162
2404.0,6/7/2023 9:55:24 AM,SVB Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032375300
2405.0,6/7/2023 10:50:17 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Oscar Health (OSCR) and Doximity (DOCS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-oscar-health-oscr-and-doximity-docs-1032375473
2406.0,6/7/2023 7:46:56 PM,"Eli Lilly, Takeda must face racketeering claims over Actos diabetes drug, judge rules",Seeking Alpha,https://seekingalpha.com/news/3978336-eli-lilly-takeda-hit-with-racketeering-class-action-lawsuit?utm_source=businessinsider&utm_medium=referral
2407.0,6/7/2023 10:30:39 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Guardant Health (GH) and Coya Therapeutics, Inc. (COYA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-guardant-health-gh-and-coya-therapeutics-inc-coya-1032377089
2408.0,6/9/2023 1:21:31 AM,Want to Invest in Republican or Democratic Stocks? Check Out These 2 ETFs,TipRanks,/news/stocks/want-to-invest-in-republican-or-democratic-stocks-check-out-these-2-etfs-1032379619
2409.0,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral
2410.0,6/11/2023 4:00:02 PM,Alzheimer’s disease market expected to reach $14B globally in 2030,Seeking Alpha,https://seekingalpha.com/news/3979065-biogens-leqembi-drive-alzheimers-market-2030?utm_source=businessinsider&utm_medium=referral
2411.0,6/12/2023 11:50:11 AM,"Analysts Are Bullish on These Healthcare Stocks: Intellia Therapeutics (NTLA), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-intellia-therapeutics-ntla-eli-lilly-co-lly-1032383274
2412.0,6/14/2023 12:12:36 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032387458
2413.0,6/15/2023 10:56:49 AM,Verve teams with Lilly to advance vivo gene editing program targeting Lp(a),Seeking Alpha,https://seekingalpha.com/news/3980078-verve-teams-with-lilly-to-advance-vivo-gene-editing-program-targeting-lpa?utm_source=businessinsider&utm_medium=referral
2414.0,6/16/2023 2:47:23 PM,Eli Lilly diabetes med Mounjaro on intermittent backorder,Seeking Alpha,https://seekingalpha.com/news/3980497-eli-lilly-diabetes-med-mounjaro-intermittent-backorder?utm_source=businessinsider&utm_medium=referral
2415.0,6/16/2023 5:21:44 PM,Eli Lilly migraine drug Emgality fails to beat Pfizer's Nurtec,Seeking Alpha,https://seekingalpha.com/news/3980545-eli-lilly-migraine-drug-emgality-fails-beat-pfizer-nurtec?utm_source=businessinsider&utm_medium=referral
2416.0,6/16/2023 6:00:00 PM,First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention,PR Newswire,/news/stocks/first-of-its-kind-head-to-head-clinical-trial-reaffirms-the-efficacy-of-emgality-in-episodic-migraine-prevention-1032394793
2417.0,6/19/2023 11:05:11 AM,BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-keeps-their-buy-rating-on-eli-lilly-co-lly-1032396626
2418.0,6/20/2023 11:03:12 AM,Eli Lilly to acquire oral drug developer Dice Therapeutics for over $2B,Seeking Alpha,https://seekingalpha.com/news/3980764-eli-lilly-stock-to-buy-dice-therapeutics-for-over-2b?utm_source=businessinsider&utm_medium=referral
2419.0,6/20/2023 12:45:00 PM,Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology,PR Newswire,/news/stocks/lilly-to-acquire-dice-therapeutics-to-advance-innovation-in-immunology-1032398451
2420.0,6/20/2023 12:59:48 PM,Eli Lilly To Acquire DICE Therapeutics For $48/share All-cash Deal ,RTTNews,/news/stocks/eli-lilly-to-acquire-dice-therapeutics-for-48-share-all-cash-deal-1032398495
2421.0,6/20/2023 1:21:21 PM,"4 stocks to watch on Tuesday: FedEx, AT&T and more",Seeking Alpha,https://seekingalpha.com/news/3980909-4-stocks-to-watch-on-tuesday-fedex-att-and-more?utm_source=businessinsider&utm_medium=referral
2422.0,6/20/2023 1:31:08 PM,Why Is Dice Therapeutics (DICE) Stock Up 38% Today?,InvestorPlace,/news/stocks/why-is-dice-therapeutics-dice-stock-up-38-today-1032399204
2423.0,6/20/2023 2:00:00 PM,"Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch ""Tap the Cap""",PR Newswire,/news/stocks/lilly-teams-up-with-the-american-diabetes-association-and-adam-duvall-to-launch-tap-the-cap-1032398651
2424.0,6/20/2023 2:18:17 PM,"Biggest stock movers today: Nikola, Avis Budget, DICE Therapeutics, Faraday Future and more",Seeking Alpha,https://seekingalpha.com/news/3980740-biggest-stock-movers-today-nikola-arcellx-beam-global-and-more?utm_source=businessinsider&utm_medium=referral
2425.0,6/20/2023 3:16:39 PM,Why DICE Therapeutics Stock Is Soaring Tuesday,Benzinga,/news/stocks/why-dice-therapeutics-stock-is-soaring-tuesday-1032399129
2426.0,6/20/2023 3:51:59 PM,Eli Lilly To Acquire Small Company DICE Therapeutics Focused On Autoimmune Diseases For $2B,Benzinga,/news/stocks/eli-lilly-to-acquire-small-company-dice-therapeutics-focused-on-autoimmune-diseases-for-2b-1032399256
2427.0,6/20/2023 4:31:26 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), RegenXBio (RGNX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-regenxbio-rgnx-1032399915
2428.0,6/20/2023 4:36:03 PM,"Alexandria Research completes sale of five facilities, reiterates 2023 guidance",Seeking Alpha,https://seekingalpha.com/news/3981077-alexandria-research-completes-sale-of-five-facilities-reiterates-2023-guidance?utm_source=businessinsider&utm_medium=referral
2429.0,6/20/2023 7:37:00 PM,Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions,PR Newswire,/news/stocks/lilly-to-present-new-research-in-the-treatment-of-diabetes-and-obesity-at-the-american-diabetes-association-s-83rd-scientific-sessions-1032400003
2430.0,6/20/2023 9:02:27 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032400114
2431.0,6/21/2023 4:34:09 AM,FDA Approves Boehringer Ingelheim' Jardiance And Synjardy To Treat Pediatric Type 2 Diabetes ,RTTNews,/news/stocks/fda-approves-boehringer-ingelheim-jardiance-and-synjardy-to-treat-pediatric-type-2-diabetes-1032400467
2432.0,6/21/2023 11:53:36 AM,Eli Lilly and partner win FDA nod to include children for diabetes drugs,Seeking Alpha,https://seekingalpha.com/news/3981352-eli-lilly-partner-win-fda-nod-childrens-diabetes-drugs?utm_source=businessinsider&utm_medium=referral
2433.0,6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral
2434.0,6/21/2023 5:17:16 PM,Key Data On Novo Nordisk's Weight Loss Drug Wegovy Due In July: Biotech Analyst Details Likely Impact On Lilly's Stock,Benzinga,/news/stocks/key-data-on-novo-nordisk-s-weight-loss-drug-wegovy-due-in-july-biotech-analyst-details-likely-impact-on-lilly-s-stock-1032402337
2435.0,6/21/2023 7:15:00 PM,US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older,PR Newswire,/news/stocks/us-fda-approves-jardiance-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older-1032402663
2436.0,6/22/2023 9:55:37 AM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1032403901
2437.0,6/22/2023 11:03:39 AM,Novo Nordisk falls after safety signal linked to weight loss drug class,Seeking Alpha,https://seekingalpha.com/news/3981844-novo-nordisk-stock-falls-safety-signal-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
2438.0,6/22/2023 8:54:22 PM,"Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation",Benzinga,/news/stocks/terns-pharma-has-35-upside-according-to-this-analyst-nash-asset-to-drive-valuation-1032405573
2439.0,6/24/2023 3:50:00 AM,"Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we...",PR Newswire,/news/stocks/lilly-s-phase-2-results-published-in-the-new-england-journal-of-medicine-show-orforglipron-a-once-daily-oral-nonpeptide-glp-1-receptor-agonist-achieved-up-to-14-7-mean-weight-reduction-at-36-we-1032407804
2440.0,6/24/2023 11:48:37 AM,Eli Lilly says oral obesity therapy caused up to 15% weight loss,Seeking Alpha,https://seekingalpha.com/news/3982546-eli-lilly-oral-obesity-drug-cut-15-percent-weight?utm_source=businessinsider&utm_medium=referral
2441.0,6/24/2023 5:18:00 PM,Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes,PR Newswire,/news/stocks/lilly-s-surmount-2-results-published-in-the-lancet-show-tirzepatide-achieved-a-mean-weight-reduction-of-15-7-at-the-highest-dose-15-mg-in-adults-with-obesity-or-overweight-and-type-2-diabetes-1032408028
2442.0,6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral
2443.0,6/26/2023 7:10:14 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), MoonLake Immunotherapeutics (MLTX) and Jazz Pharmaceuticals (JAZZ)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-moonlake-immunotherapeutics-mltx-and-jazz-pharmaceuticals-jazz-1032408813
2444.0,6/26/2023 9:20:36 AM,Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-eli-lilly-co-lly-1032409063
2445.0,6/26/2023 10:11:55 AM,Pills for obesity: Novo Nordisk records success in late-stage trials,Seeking Alpha,https://seekingalpha.com/news/3982632-novo-nordisk-high-dose-weight-loss-pills?utm_source=businessinsider&utm_medium=referral
2446.0,6/26/2023 1:01:33 PM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), CymaBay Therapeutics (CBAY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-cymabay-therapeutics-cbay-1032409777
2447.0,6/26/2023 1:38:25 PM,ALX Oncology gastric cancer candidate wins orphan drug status from EC,Seeking Alpha,https://seekingalpha.com/news/3982736-alx-oncology-gastric-cancer-candidate-evorpacept-orphan-drug-european-commission?utm_source=businessinsider&utm_medium=referral
2448.0,6/26/2023 2:28:42 PM,Pfizer to drop studies for weight-loss pill,Seeking Alpha,https://seekingalpha.com/news/3982779-pfizer-stock-falls-plans-discontinue-weight-loss-pill?utm_source=businessinsider&utm_medium=referral
2449.0,6/26/2023 3:27:00 PM,Eli Lilly declares $1.13 dividend,Seeking Alpha,https://seekingalpha.com/news/3982806-eli-lilly-and-company-declares-1_13-dividend?utm_source=businessinsider&utm_medium=referral
2450.0,6/26/2023 4:36:33 PM,Pfizer wins FDA approval for oral hair loss therapy,Seeking Alpha,https://seekingalpha.com/news/3982832-pfizer-wins-fda-nod-oral-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral
2451.0,6/26/2023 5:06:00 PM,Lilly Declares Third-Quarter 2023 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2023-dividend-1032410144
2452.0,6/26/2023 11:15:58 PM,Lilly says patients saw mean weight reduction of 58 lbs on retatrutide,Seeking Alpha,https://seekingalpha.com/news/3983017-lilly-says-patients-saw-mean-weight-reduction-of-58-lbs-on-retatrutide?utm_source=businessinsider&utm_medium=referral
2453.0,6/27/2023 12:00:00 AM,Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity...,PR Newswire,/news/stocks/lilly-s-phase-2-retatrutide-results-published-in-the-new-england-journal-of-medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-1032410879
2454.0,6/27/2023 4:27:43 AM,Eli Lilly's Obesity Drug Retatrutide Leads To 24.2% Weight Loss In Phase 2 Trial ,RTTNews,/news/stocks/eli-lilly-s-obesity-drug-retatrutide-leads-to-24-2-weight-loss-in-phase-2-trial-1032410968
2455.0,6/27/2023 8:50:47 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Amedisys (AMED),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-amedisys-amed-1032411532
2456.0,6/27/2023 4:25:25 PM,Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032413085
2457.0,6/27/2023 5:03:37 PM,Eli Lilly highlights weight loss agent’s potential in fatty liver,Seeking Alpha,https://seekingalpha.com/news/3983279-eli-lilly-shows-weight-loss-agents-potential-fatty-liver?utm_source=businessinsider&utm_medium=referral
2458.0,6/27/2023 8:52:55 PM,Why did Madrigal Pharma stock drop today? Lilly fatty liver data,Seeking Alpha,https://seekingalpha.com/news/3983432-why-did-madrigal-pharma-stock-drop-today-eli-lilly-fatty-liver-data?utm_source=businessinsider&utm_medium=referral
2459.0,6/27/2023 9:13:52 PM,Here’s 2023’s Best-Performing Actively-Managed ETF,TipRanks,/news/stocks/here-s-2023-s-best-performing-actively-managed-etf-1032413585
2460.0,6/28/2023 1:45:33 PM,Eli Lilly & Co (LLY) Receives a Buy from SVB Securities,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-svb-securities-1032415335
2461.0,6/28/2023 8:53:46 PM,"Terns Pharmaceuticals Is ""Attractively Priced"" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says",Benzinga,/news/stocks/terns-pharmaceuticals-is-attractively-priced-despite-pressure-from-eli-lilly-s-obesity-data-analyst-says-1032416121
2462.0,6/29/2023 1:26:45 AM,Looking for a Market-Beating Growth ETF? Check Out VUG,TipRanks,/news/stocks/looking-for-a-market-beating-growth-etf-check-out-vug-1032416446
2463.0,6/29/2023 11:11:28 AM,Sigilon stock skyrockets 650% on buyout deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3984041-sigilon-stock-skyrockets-buyout-deal-eli-lilly?utm_source=businessinsider&utm_medium=referral
2464.0,6/29/2023 11:27:32 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-29th-1032417552
2465.0,6/29/2023 11:59:44 AM,Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?,InvestorPlace,/news/stocks/why-is-sigilon-therapeutics-sgtx-stock-up-691-today-1032417665
2466.0,6/29/2023 12:45:00 PM,Lilly to Acquire Sigilon Therapeutics,PR Newswire,/news/stocks/lilly-to-acquire-sigilon-therapeutics-1032417388
2467.0,6/29/2023 1:06:41 PM,Eli Lilly To Acquire Sigilon Therapeutics ,RTTNews,/news/stocks/eli-lilly-to-acquire-sigilon-therapeutics-1032417474
2468.0,6/29/2023 2:48:14 PM,Viking Therapeutics gains as Street defends after selloff,Seeking Alpha,https://seekingalpha.com/news/3984135-viking-therapeutics-stock-gains-street-defends-post-selloff?utm_source=businessinsider&utm_medium=referral
2469.0,6/29/2023 6:00:35 PM,The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-now-june-2023-1032418755
2470.0,6/30/2023 10:25:17 AM,3 Dividend Stocks That Have Insiders Running for the Exit,InvestorPlace,/news/stocks/3-dividend-stocks-to-avoid-as-insiders-head-for-the-exits-1032420229
2471.0,6/30/2023 11:48:19 AM,"Dividend Roundup: General Mills, Mastercard, JPMorgan, Verizon, and more",Seeking Alpha,https://seekingalpha.com/news/3984403-dividend-roundup-general-mills-mastercard-jpmorgan-verizon-and-more?utm_source=businessinsider&utm_medium=referral
2472.0,6/30/2023 4:39:00 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023,InvestorPlace,/news/stocks/pharma-stocks-to-buy-1032421255
2473.0,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
2474.0,7/1/2023 8:00:00 PM,"Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst",Seeking Alpha,https://seekingalpha.com/news/3984694-lilly-vertex-top-pharma-performers-h1-moderna-pfizer-worst?utm_source=businessinsider&utm_medium=referral
2475.0,7/3/2023 10:05:15 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032423088
2476.0,7/3/2023 11:35:08 AM,BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-keeps-their-buy-rating-on-eli-lilly-co-lly-1032423316
2477.0,7/5/2023 7:38:26 PM,Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results,InvestorPlace,/news/stocks/cassava-sciences-sava-stock-drops-despite-positive-trial-results-1032428453
2478.0,7/6/2023 1:45:00 PM,New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-bruin-phase-1-2-trial-data-for-pirtobrutinib-in-btk-inhibitor-pre-treated-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-1032429845
2479.0,7/6/2023 6:30:39 PM,Novo Nordisk sues Florida pharmacy for allegedly selling Wegovy copycat,Seeking Alpha,https://seekingalpha.com/news/3986050-novo-nordisk-sues-florida-pharmacy-allegedly-selling-wegovy-copycat?utm_source=businessinsider&utm_medium=referral
2480.0,7/7/2023 6:16:21 PM,FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline,Benzinga,/news/stocks/fda-approves-biogen-s-alzheimer-s-drug-here-are-other-companies-with-treatments-in-the-pipeline-1032432660
2481.0,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral
2482.0,7/9/2023 7:34:36 PM,The 7 Best Value Stocks to Buy in July,InvestorPlace,/news/stocks/the-7-best-value-stocks-to-buy-in-july-1032433488
2483.0,7/10/2023 8:20:06 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Syndax Pharmaceuticals (SNDX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-syndax-pharmaceuticals-sndx-1032434231
2484.0,7/11/2023 4:00:00 PM,Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC,PR Newswire,/news/stocks/lilly-announces-webcast-to-provide-alzheimer-s-disease-update-at-aaic-1032438083
2485.0,7/11/2023 5:31:05 PM,EU expands probe into suicide risk linked to weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3986847-eu-widens-probe-suicide-risk-linked-weight-loss-meds?utm_source=businessinsider&utm_medium=referral
2486.0,7/11/2023 8:00:37 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032438698
2487.0,7/12/2023 10:17:56 PM,Eli Lilly sees IPR&D charges negatively impacting Q2 EPS,Seeking Alpha,https://seekingalpha.com/news/3987245-eli-lilly-sees-iprd-charges-negatively-impacting-q2-eps?utm_source=businessinsider&utm_medium=referral
2488.0,7/13/2023 7:24:22 AM,"Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Replimune Group (REPL)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-alnylam-pharma-alny-replimune-group-repl-1032443396
2489.0,7/13/2023 7:25:08 AM,Eli Lilly & Co (LLY) Receives a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-barclays-1032443395
2490.0,7/14/2023 12:20:11 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Humana (HUM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-humana-hum-1032445940
2491.0,7/14/2023 12:38:01 PM,Eli Lilly to acquire Versanis Bio in ~$2B deal to boost weight loss franchise,Seeking Alpha,https://seekingalpha.com/news/3987685-eli-lilly-buy-versanis-bio-boost-weight-loss-franchise?utm_source=businessinsider&utm_medium=referral
2492.0,7/14/2023 2:00:00 PM,Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases,PR Newswire,/news/stocks/lilly-to-acquire-versanis-to-improve-patient-outcomes-in-cardiometabolic-diseases-1032447238
2493.0,7/14/2023 2:09:44 PM,Eli Lilly To Acquire Versanis Bio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-acquire-versanis-bio-quick-facts-1032447269
2494.0,7/14/2023 2:29:26 PM,LLY Stock Alert: What to Know as Eli Lilly Acquires Versanis Bio,InvestorPlace,/news/stocks/lly-stock-alert-what-to-know-as-eli-lilly-acquires-versanis-bio-1032447923
2495.0,7/14/2023 2:48:42 PM,PRGO Stock Alert: Perrigo Climbs on Landmark FDA Birth Control Decision,InvestorPlace,/news/stocks/prgo-stock-alert-perrigo-climbs-on-landmark-fda-birth-control-decision-1032447956
2496.0,7/14/2023 5:02:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-14-2023-1032447974
2497.0,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral
2498.0,7/17/2023 12:14:12 AM,"HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna",Seeking Alpha,https://seekingalpha.com/news/3987876-hsbc-bullish-on-roche-lonza-bearish-on-bristol-myers-gsk-moderna?utm_source=businessinsider&utm_medium=referral
2499.0,7/17/2023 11:20:11 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Apellis Pharmaceuticals (APLS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-apellis-pharmaceuticals-apls-1032450987
2500.0,7/17/2023 2:42:39 PM,Sangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus Capsids ,RTTNews,/news/stocks/sangamo-inks-evaluation-and-option-agreement-with-lilly-s-prevail-for-adeno-associated-virus-capsids-1032451234
2501.0,7/17/2023 4:15:00 PM,Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA,PR Newswire,/news/stocks/results-from-lilly-s-landmark-phase-3-trial-of-donanemab-presented-at-alzheimer-s-association-conference-and-published-in-jama-1032451878
2502.0,7/17/2023 5:21:00 PM,Eli Lilly full phase 3 data confirms benefit of Alzheimer's asset donanemab,Seeking Alpha,https://seekingalpha.com/news/3988105-eli-lilly-full-phase-3-data-confirms-benefit-alzheimers-donanemab?utm_source=businessinsider&utm_medium=referral
2503.0,7/18/2023 4:20:07 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), UnitedHealth (UNH) and Caliber Imaging & Diagnostic (OtherLCDX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-unitedhealth-unh-and-caliber-imaging-diagnostic-otherlcdx-1032453288
2504.0,7/18/2023 5:35:12 AM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1032453528
2505.0,7/18/2023 9:05:11 AM,Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline ,RTTNews,/news/stocks/lilly-says-its-alzheimer-s-drug-significantly-slowed-cognitive-and-functional-decline-1032453676
2506.0,7/18/2023 9:10:33 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Argenx Se (ARGX) and Alector (ALEC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-argenx-se-argx-and-alector-alec-1032454094
2507.0,7/18/2023 10:22:03 AM,3 Biotech Stocks for Getting Rich in 2023,InvestorPlace,/news/stocks/3-biotech-stocks-for-getting-rich-in-2023-1032454309
2508.0,7/18/2023 3:27:28 PM,Sanofi expands collaboration with Scribe on CRISPR genome editing,Seeking Alpha,https://seekingalpha.com/news/3988429-sanofi-expands-collaboration-scribe-crispr-genome-editing?utm_source=businessinsider&utm_medium=referral
2509.0,7/20/2023 5:58:57 PM,Lawmakers reintroduce bill to offer Medicare coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3989310-bill-offer-medicare-coverage-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
2510.0,7/20/2023 7:36:44 PM,Eli Lilly's Solid Portfolio Alzheimer's & Diabetes Drugs To Aid Sales Growth: Analyst,Benzinga,/news/stocks/eli-lilly-s-solid-portfolio-alzheimer-s-diabetes-drugs-to-aid-sales-growth-analyst-1032463634
2511.0,7/21/2023 7:31:28 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-now-july-2023-1032466871
2512.0,7/21/2023 8:45:52 PM,WINN ETF: Can You Really Win with This ETF?,TipRanks,/news/stocks/winn-etf-can-you-really-win-with-this-etf-1032466949
2513.0,7/24/2023 11:50:28 AM,"Analysts Are Bullish on These Healthcare Stocks: Thorne HealthTech (THRN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-thorne-healthtech-thrn-eli-lilly-co-lly-1032469817
2514.0,7/25/2023 12:55:00 PM,Lilly Announces Extension of Tender Offer to Acquire DICE,PR Newswire,/news/stocks/lilly-announces-extension-of-tender-offer-to-acquire-dice-1032473843
2515.0,7/25/2023 1:30:57 PM,Lilly Extends Tender Offer To Acquire DICE ,RTTNews,/news/stocks/lilly-extends-tender-offer-to-acquire-dice-1032473982
2516.0,7/25/2023 1:33:48 PM,Eli Lilly extends tender offer to acquire Dice,Seeking Alpha,https://seekingalpha.com/news/3990559-eli-lilly-extends-tender-offer-acquire-dice?utm_source=businessinsider&utm_medium=referral
2517.0,7/25/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-second-quarter-2023-financial-results-announcement-1032474853
2518.0,7/25/2023 5:46:10 PM,"Lilly, Novo Nordisk diabetes and weight loss drug shortages persist",Seeking Alpha,https://seekingalpha.com/news/3990724-eli-lilly-novo-nordisk-diabetes-weight-loss-drug-shortages-persist?utm_source=businessinsider&utm_medium=referral
2519.0,7/26/2023 4:50:29 PM,Probe over suicide risk linked to weight loss drugs expands to U.K. – Reuters,Seeking Alpha,https://seekingalpha.com/news/3991362-uk-probes-suicide-risk-linked-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
2520.0,7/26/2023 6:26:37 PM,3 Risky Stocks to Avoid at All Costs in 2023,InvestorPlace,/news/stocks/3-risky-stocks-to-avoid-at-all-costs-in-2023-1032481132
2521.0,7/27/2023 12:04:51 AM,VTI ETF’s Simple but Powerful Strategy is a Long-Term Winner,TipRanks,/news/stocks/vti-etf-s-simple-but-powerful-strategy-is-a-long-term-winner-1032481766
2522.0,7/27/2023 11:39:24 AM,Eli Lilly updates Phase 3 data for obesity drug indicating up to 26% of weight loss,Seeking Alpha,https://seekingalpha.com/news/3992014-eli-lilly-obesity-drug-indicates-26-weight-loss?utm_source=businessinsider&utm_medium=referral
2523.0,7/27/2023 12:48:00 PM,Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies,PR Newswire,/news/stocks/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-1032483877
2524.0,7/27/2023 1:42:27 PM,7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes,InvestorPlace,/news/stocks/7-millionaire-maker-healthcare-stocks-to-buy-before-the-window-closes-1032484989
2525.0,7/27/2023 3:48:50 PM,Lilly's Diabetes Drug Tirzepatide Demonstrates Significant And Superior Weight Loss In Two Studies ,RTTNews,/news/stocks/lilly-s-diabetes-drug-tirzepatide-demonstrates-significant-and-superior-weight-loss-in-two-studies-1032484975
2526.0,7/28/2023 9:03:18 AM,Analysts Offer Insights on Healthcare Companies: Laboratory (LH) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-laboratory-lh-and-eli-lilly-co-lly-1032489117
2527.0,7/31/2023 8:41:24 AM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Idexx Laboratories (IDXX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-idexx-laboratories-idxx-1032494416
2528.0,7/31/2023 11:11:04 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and 4D Molecular Therapeutics (FDMT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-4d-molecular-therapeutics-fdmt-1032494909
2529.0,7/31/2023 9:50:57 PM,NULG: Check Out This Large-Cap Growth ETF’s Strong Performance,TipRanks,/news/stocks/nulg-check-out-this-large-cap-growth-etf-s-strong-performance-1032497282
2530.0,8/2/2023 7:35:39 PM,Dice Therapeutics gains amid Nasdaq delisting notice for Eli Lilly deal,Seeking Alpha,https://seekingalpha.com/news/3995698-dice-therapeutics-gains-amid-nasdaq-delisting-notice-for-eli-lilly-deal?utm_source=businessinsider&utm_medium=referral
2531.0,8/4/2023 1:45:00 PM,Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Adva...,PR Newswire,/news/stocks/lilly-s-retevmo-selpercatinib-is-the-first-targeted-therapy-to-demonstrate-superior-progression-free-survival-compared-to-a-pd-1-inhibitor-plus-chemotherapy-for-adults-with-newly-diagnosed-adva-1032517655
2532.0,8/4/2023 2:54:59 PM,Eli Lilly: LIBRETTO-431 Study Meets Primary Endpoint ,RTTNews,/news/stocks/eli-lilly-libretto-431-study-meets-primary-endpoint-1032517948
2533.0,8/4/2023 6:41:33 PM,"ETF Winners And Losers: Micro-Cap Fund Flows - Innovative AUSF, With Annualized Returns Of 17.19% Over Last 3 Years, Adds $159.87 Million",Benzinga,/news/etf/etf-winners-and-losers-micro-cap-fund-flows---innovative-ausf-with-annualized-returns-of-17-19-over-last-3-years-adds-159-87-million-1032518855
2534.0,8/4/2023 7:00:42 PM,"Catalyst Watch: Wayfair and Kellogg events, Alibaba earnings and AI hacking test at Def Con",Seeking Alpha,https://seekingalpha.com/news/3997605-catalyst-watch-wayfair-and-kellogg-events-alibaba-earnings-and-ai-hacking-test-at-def-con?utm_source=businessinsider&utm_medium=referral
2535.0,8/6/2023 4:00:54 PM,Nearly half of U.S. adults want weight-loss drugs – KFF poll,Seeking Alpha,https://seekingalpha.com/news/3997955-nearly-half-of-americans-want-weight-loss-drugs-kff-poll?utm_source=businessinsider&utm_medium=referral
2536.0,8/7/2023 9:16:06 AM,Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-eli-lilly-co-lly-1032523200
2537.0,8/7/2023 11:20:34 AM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-alnylam-pharma-alny-1032523487
2538.0,8/7/2023 3:01:13 PM,Eli Lilly and earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q2-quarterly-earnings-preview-1032524059
2539.0,8/7/2023 3:20:35 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3998171-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral
2540.0,8/7/2023 5:29:20 PM,Nektar reportedly sues Lilly for bungling clinical data on dermo drug,Seeking Alpha,https://seekingalpha.com/news/3998390-nektar-reportedly-sues-lilly-for-bungling-clinical-data-on-dermo-drug?utm_source=businessinsider&utm_medium=referral
2541.0,8/7/2023 7:08:21 PM,"Eli Lilly, up 24% YTD, looks to Q2 results beats",Seeking Alpha,https://seekingalpha.com/news/3998430-eli-lilly-up-24-ytd-looks-q2-results-beats?utm_source=businessinsider&utm_medium=referral
2542.0,8/8/2023 1:20:07 AM,"Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-eli-lilly-co-lly-1032525803
2543.0,8/8/2023 10:18:50 AM,"Eli Lilly, Beyond Meat And 3 Stocks To Watch Heading Into Tuesday",Benzinga,/news/stocks/eli-lilly-beyond-meat-and-3-stocks-to-watch-heading-into-tuesday-1032527715
2544.0,8/8/2023 10:47:52 AM,Eli Lilly beats Q2 top and bottom line estimates; raises FY23 EPS outlook,Seeking Alpha,https://seekingalpha.com/news/3998862-eli-lilly-beats-q2-top-and-bottom-line-estimates-raises-fy23-eps-outlook?utm_source=businessinsider&utm_medium=referral
2545.0,8/8/2023 10:52:00 AM,Novo Nordisk weight loss drug cuts heart disease risk by 20%,Seeking Alpha,https://seekingalpha.com/news/3998866-novo-nordisk-weight-loss-drug-cuts-heart-disease-risk?utm_source=businessinsider&utm_medium=referral
2546.0,8/8/2023 11:28:24 AM,Eli Lilly Q2 beat driven by Mounjaro and growth products,Seeking Alpha,https://seekingalpha.com/news/3998931-eli-lilly-q2-beat-driven-mounjaro-and-growth-products?utm_source=businessinsider&utm_medium=referral
2547.0,8/8/2023 12:45:00 PM,"Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements",PR Newswire,/news/stocks/lilly-reports-second-quarter-2023-financial-results-highlights-accelerating-revenue-growth-and-key-pipeline-advancements-1032528235
2548.0,8/8/2023 12:50:33 PM,"Eli Lilly And Co. Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/eli-lilly-and-co-q2-profit-increases-beats-estimates-1032528243
2549.0,8/8/2023 12:59:23 PM,Eli Lilly Boosts FY23 Outlook - Update ,RTTNews,/news/stocks/eli-lilly-boosts-fy23-outlook-update-1032528292
2550.0,8/8/2023 2:24:46 PM,"Biggest stock movers today: Medical Properties Trust, Novavax, Eli Lilly, Tilray Brands, and more",Seeking Alpha,https://seekingalpha.com/news/3998776-biggest-stock-movers-today-tilray-brands-beyond-meat-and-more?utm_source=businessinsider&utm_medium=referral
2551.0,8/8/2023 2:26:14 PM,"Lilly reaches all-time high on Q2 results, 2023 guidance boost",Seeking Alpha,https://seekingalpha.com/news/3999097-lilly-reaches-all-time-high-q2-results-2023-guidance-boost?utm_source=businessinsider&utm_medium=referral
2552.0,8/8/2023 2:47:02 PM,Watch weight loss stocks after cardiovascular data for Wegovy,Seeking Alpha,https://seekingalpha.com/news/3999115-watch-weight-loss-stocks-cardiovascular-data-for-wegovy?utm_source=businessinsider&utm_medium=referral
2553.0,8/8/2023 3:28:34 PM,"Eli Lilly Up Over 11% In Pre-market After Increased Q2 Profit, Outlook ",RTTNews,/news/stocks/eli-lilly-up-over-11-in-pre-market-after-increased-q2-profit-outlook-1032529321
2554.0,8/8/2023 3:31:32 PM,Eli Lilly Boosts Outlook As Q2 Results Top Estimates; Stock Up 11% ,RTTNews,/news/stocks/eli-lilly-boosts-outlook-as-q2-results-top-estimates-stock-up-11-1032529342
2555.0,8/8/2023 4:15:25 PM,"Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy",Seeking Alpha,https://seekingalpha.com/news/3999177-stifel-guggenheim-jefferies-wedbush-start-apogee-therapeutics-at-buy?utm_source=businessinsider&utm_medium=referral
2556.0,8/8/2023 4:35:25 PM,"Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday",Benzinga,/news/stocks/fox-warner-music-eli-lilly-chegg-and-other-big-stocks-moving-higher-on-tuesday-1032529860
2557.0,8/8/2023 6:06:59 PM,Dow Falls 1%; Eli Lilly Raises Annual Guidance,Benzinga,/news/stocks/dow-falls-1-eli-lilly-raises-annual-guidance-1032530154
2558.0,8/8/2023 6:16:56 PM,Eli Lilly (LLY) Stock Just Reached a New All-Time High,InvestorPlace,/news/stocks/eli-lilly-lly-stock-just-reached-a-new-all-time-high-1032530411
2559.0,8/8/2023 7:13:13 PM,Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-energizer-holdings-shares-are-trading-lower-by-13-here-are-other-stocks-moving-in-tuesday-s-mid-day-session-1032530289
2560.0,8/9/2023 4:55:06 AM,Eli Lilly & Co (LLY) Gets a Hold from Goldman Sachs,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-hold-from-goldman-sachs-1032532701
2561.0,8/9/2023 7:32:29 AM,"Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO), Elevance Health (ELV) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sangamo-biosciences-sgmo-elevance-health-elv-and-eli-lilly-co-lly-1032533583
2562.0,8/9/2023 11:41:19 AM,CBOE Volatility Index Increases Ahead Of Inflation Data,Benzinga,/news/stocks/cboe-volatility-index-increases-ahead-of-inflation-data-1032534093
2563.0,8/9/2023 2:30:03 PM,Eli Lilly upgraded at Jefferies on Mounjaro sales and Wegovy data (update),Seeking Alpha,https://seekingalpha.com/news/4000027-eli-lilly-stock-upgraded-jefferies-mounjaro-sales?utm_source=businessinsider&utm_medium=referral
2564.0,8/9/2023 3:02:00 PM,Lilly Completes Acquisition of DICE Therapeutics,PR Newswire,/news/stocks/lilly-completes-acquisition-of-dice-therapeutics-1032535172
2565.0,8/9/2023 4:03:13 PM,"Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth",Benzinga,/news/stocks/eli-lilly-analysts-bump-up-forecasts-on-q2-print-beyond-mounjaro-alzheimer-s-franchise-remains-a-key-pillar-to-future-growth-1032535647
2566.0,8/9/2023 5:00:38 PM,"Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-august-9-2023-1032535842
2567.0,8/9/2023 9:51:42 PM,3 Growth Stocks to Sell in August Before They Crash and Burn,InvestorPlace,/news/stocks/3-growth-stocks-to-sell-in-august-before-they-crash-and-burn-1032536926
2568.0,8/9/2023 10:43:54 PM,"Stifel cuts Morphic to hold, doesn't see it as near-term M&A target",Seeking Alpha,https://seekingalpha.com/news/4000665-stifel-cuts-morphic-to-hold-doesnt-see-it-as-near-term-takeover-target?utm_source=businessinsider&utm_medium=referral
2569.0,8/10/2023 3:00:00 PM,Medicare Part D drug price increases far exceed inflation - AARP,Seeking Alpha,https://seekingalpha.com/news/4000101-medicare-part-d-drug-price-increases-far-exceed-inflation?utm_source=businessinsider&utm_medium=referral
2570.0,8/10/2023 4:01:10 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032541047
2571.0,8/10/2023 5:51:32 PM,Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results,Benzinga,/news/stocks/novo-nordisk-soars-to-new-high-on-weight-loss-drug-trial-results-1032541453
2572.0,8/11/2023 8:52:36 AM,"Uber Crowded, Battleground and Sweet 16 stock portfolios from Jefferies",Seeking Alpha,https://seekingalpha.com/news/3999208-uber-crowded-battleground-and-sweet-16-stock-portfolios-from-jefferies?utm_source=businessinsider&utm_medium=referral
2573.0,8/11/2023 6:47:04 PM,5 ETFs Responding To PPI Surge And Consumer Sentiment Dip On Friday,Benzinga,/news/etf/5-etfs-responding-to-ppi-surge-and-consumer-sentiment-dip-on-friday-1032547560
2574.0,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
2575.0,8/14/2023 1:25:00 PM,Lilly Completes Acquisition of Sigilon Therapeutics,PR Newswire,/news/stocks/lilly-completes-acquisition-of-sigilon-therapeutics-1032550835
2576.0,8/14/2023 1:30:42 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Y-Mabs Therapeutics (YMAB)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-y-mabs-therapeutics-ymab-1032551662
2577.0,8/14/2023 2:03:16 PM,"Eli Lilly closes Sigilon, Versanis buyouts boosting diabetes/ obesity franchise",Seeking Alpha,https://seekingalpha.com/news/4002290-eli-lilly-closes-sigilon-versanis-buyouts?utm_source=businessinsider&utm_medium=referral
2578.0,8/14/2023 2:19:11 PM,Eli Lilly Concludes Acquisition Of Sigilon Therapeutics ,RTTNews,/news/stocks/eli-lilly-concludes-acquisition-of-sigilon-therapeutics-1032551055
2579.0,8/14/2023 3:09:00 PM,Lilly Completes Acquisition of Versanis Bio,PR Newswire,/news/stocks/lilly-completes-acquisition-of-versanis-bio-1032551486
2580.0,8/14/2023 3:21:40 PM,Eli Lilly Completes Acquisition Of Versanis Bio ,RTTNews,/news/stocks/eli-lilly-completes-acquisition-of-versanis-bio-1032551535
2581.0,8/14/2023 7:06:48 PM,"Tiger Global reduces holdings in tech, boosts stakes in Grab, Apollo, adds Eli Lilly",Seeking Alpha,https://seekingalpha.com/news/4002479-tiger-global-reduces-holdings-in-tech-boosts-stakes-in-grab-apollo-adds-eli-lilly?utm_source=businessinsider&utm_medium=referral
2582.0,8/15/2023 7:06:54 PM,"Coatue Management takes new stake in Oracle, exits GameStop, trims Tesla, adds to Amazon",Seeking Alpha,https://seekingalpha.com/news/4003164-coatue-management-takes-new-stake-in-oracle-exits-gamestop-trims-tesla-adds-to-amazon?utm_source=businessinsider&utm_medium=referral
2583.0,8/16/2023 11:07:03 PM,The 7 Most Undervalued Healthcare Stocks to Buy Now: August 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-healthcare-stocks-to-buy-now-august-2023-1032561356
2584.0,8/17/2023 10:40:49 AM,7 A-Rated Biotech Stocks for Your August Buy List,InvestorPlace,/news/stocks/7-a-rated-biotech-stocks-for-your-august-buy-list-1032562826
2585.0,8/17/2023 12:11:53 PM,"Eli Lilly's Stock Spikes, Yet Team Jim Cramer Holds Back On Recommending Immediate Buying: 'Wait For A Pullback'",Benzinga,/news/stocks/eli-lilly-s-stock-spikes-yet-team-jim-cramer-holds-back-on-recommending-immediate-buying-wait-for-a-pullback-1032562599
2586.0,8/17/2023 6:19:02 PM,Fitch Flags Major Credit Risks Amid Sticky Inflation and High Interest Rates: Bond Market Turmoil Persists,Benzinga,/news/etf/fitch-flags-major-credit-risks-amid-sticky-inflation-and-high-interest-rates-bond-market-turmoil-persists-1032564234
2587.0,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral
2588.0,8/21/2023 10:20:07 AM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Brainsway (BWAY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-brainsway-bway-1032569197
2589.0,8/21/2023 11:26:04 AM,BMO Capital Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032569373
2590.0,8/21/2023 3:28:18 PM,5 Safe Stocks Under $40 to Buy Immediately,InvestorPlace,/news/stocks/5-safe-stocks-under-40-to-buy-immediately-1032570520
2591.0,8/21/2023 4:09:36 PM,Insulet downgraded at Baird; upgraded at Citi amid GLP1-linked selloff,Seeking Alpha,https://seekingalpha.com/news/4004840-insulet-downgraded-baird-upgraded-citi-amid-glp1-linked-selloff?utm_source=businessinsider&utm_medium=referral
2592.0,8/21/2023 7:53:10 PM,Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed,Benzinga,/news/etf/value-stocks-outshine-growth-amidst-rising-treasury-yields-key-sectors-and-stocks-analyzed-1032570802
2593.0,8/21/2023 7:58:31 PM,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",Seeking Alpha,https://seekingalpha.com/news/4004913-lillys-market-cap-soared-in-q2-eclipsing-jnj-merck-novo-nordisk?utm_source=businessinsider&utm_medium=referral
2594.0,8/22/2023 1:28:26 PM,Eli Lilly succeeds in Phase 3 thyroid cancer trial for Retevmo,Seeking Alpha,https://seekingalpha.com/news/4005158-eli-lilly-phase-3-thyroid-cancer-trial-retevmo-succeeds?utm_source=businessinsider&utm_medium=referral
2595.0,8/22/2023 1:45:00 PM,Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer,PR Newswire,/news/stocks/lilly-s-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer-1032572662
2596.0,8/22/2023 1:59:38 PM,Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint ,RTTNews,/news/stocks/eli-lilly-says-libretto-531-study-evaluating-retevmo-meets-primary-endpoint-1032572689
2597.0,8/23/2023 8:25:24 AM,Cantor Fitzgerald Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032575471
2598.0,8/24/2023 11:10:36 AM,7 A-Rated Growth Stocks to Grab Up Now,InvestorPlace,/news/stocks/7-a-rated-growth-stocks-to-grab-up-now-1032579326
2599.0,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral
2600.0,8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
2601.0,8/28/2023 9:58:12 AM,Want to Get Rich? 3 Game-Changing Growth Stocks to Buy Right Now,InvestorPlace,/news/stocks/want-to-get-rich-3-game-changing-growth-stocks-to-buy-right-now-1032585368
2602.0,8/28/2023 10:35:42 AM,Hedge and mutual funds rotate from tech; see the stocks they love and shun,Seeking Alpha,https://seekingalpha.com/news/4006637-hedge-and-mutual-funds-rotate-from-tech-see-the-stocks-they-love-and-shun?utm_source=businessinsider&utm_medium=referral
2603.0,8/28/2023 12:10:38 PM,The 3 Blue-Chip Stocks Every Investor Needs to Own Today,InvestorPlace,/news/stocks/the-3-blue-chip-stocks-every-investor-needs-to-own-today-1032585783
2604.0,8/28/2023 1:50:15 PM,"Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Eli Lilly & Co (LLY) and Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-privia-health-group-prva-eli-lilly-co-lly-and-alnylam-pharma-alny-1032586152
2605.0,8/28/2023 4:37:09 PM,"Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories",Benzinga,/news/stocks/hawaiian-electric-says-power-lines-not-responsible-for-deadly-lahaina-fire-china-targets-stock-market-revival-ftc-pauses-legal-battle-with-amgen-s-28b-horizon-deal-today-s-top-stories-1032586588
2606.0,8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral
2607.0,8/29/2023 4:00:00 PM,Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-morgan-stanley-21st-annual-global-healthcare-conference-1032589333
2608.0,8/29/2023 7:29:57 PM,Republicans say Medicare drug negotiations will mean fewer new meds,Seeking Alpha,https://seekingalpha.com/news/4007245-republicans-say-medicare-drug-negotiations-fewer-new-meds?utm_source=businessinsider&utm_medium=referral
2609.0,8/30/2023 12:58:15 AM,SPLG: The Market’s Lowest-Cost S&P 500 ETF,TipRanks,/news/stocks/splg-the-market-s-lowest-cost-s-p-500-etf-1032590792
2610.0,8/30/2023 9:20:13 AM,The 3 Most Promising Pharma Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-pharma-stocks-to-own-now-1032591971
2611.0,8/30/2023 12:54:37 PM,3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of,InvestorPlace,/news/stocks/3-biotech-stocks-that-wall-street-analysts-cant-get-enough-of-1032592710
2612.0,8/30/2023 11:17:20 PM,7 Stocks Sitting At 52-Week Highs Right Now,InvestorPlace,/news/stocks/stocks-at-52-week-highs-1032594399
2613.0,8/31/2023 11:10:56 AM,7 A-Rated Blue-Chip Stocks to Secure Your Financial Future,InvestorPlace,/news/stocks/7-a-rated-blue-chip-stocks-to-secure-your-financial-future-1032595839
2614.0,8/31/2023 8:35:18 PM,"Senators ask Novo Nordisk, Lilly, Sanofi for details on discount insulin programs",Seeking Alpha,https://seekingalpha.com/news/4008203-senators-ask-novo-nordisk-lilly-sanofi-for-details-on-discount-insulin-programs?utm_source=businessinsider&utm_medium=referral
2615.0,8/31/2023 9:18:56 PM,Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects,Benzinga,/news/stocks/why-abcellera-biologics-is-still-a-buy-despite-dropping-royalties-analyst-on-long-term-prospects-1032597681
2616.0,9/1/2023 1:38:50 AM,"Vanguard Mega Cap Growth ETF (MGK): Go Big, or Go Home",TipRanks,/news/stocks/vanguard-mega-cap-growth-etf -mgk-go-big-or-go-home-1032598019
2617.0,9/1/2023 10:00:11 PM,The 3 Most Promising Healthcare Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-healthcare-stocks-to-own-now-1032600808
2618.0,9/2/2023 6:00:00 PM,"Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag",Seeking Alpha,https://seekingalpha.com/news/4008548-lilly-novo-nordisk-top-pharma-performers-august-astrazeneca-roche-lag?utm_source=businessinsider&utm_medium=referral
2619.0,9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral
2620.0,9/4/2023 2:47:20 PM,Nestle-partnered weight loss capsule succeeds in pivotal trial,Seeking Alpha,https://seekingalpha.com/news/4008913-nestle-partnered-weight-loss-capsule-succeeds-trial?utm_source=businessinsider&utm_medium=referral
2621.0,9/5/2023 9:41:15 AM,S&P 500 (SPY) ETF: What’s in the Cards?,TipRanks,/news/stocks/s-p-500-spy-etf-what-s-in-the-cards-1032604500
2622.0,9/5/2023 11:25:04 AM,BMO Capital Releases a Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-releases-a-buy-rating-on-eli-lilly-co-lly-1032604871
2623.0,9/5/2023 10:00:25 PM,The Latest Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/the-latest-analyst-ratings-for-eli-lilly-1032606748
2624.0,9/6/2023 12:26:49 AM,Cantor Fitzgerald Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-eli-lilly-co-lly-1032607024
2625.0,9/6/2023 5:47:07 PM,DexCom cites rising glucose monitor use amid weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4009594-dexcom-stock-gains-cgm-use-rises-amid-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2626.0,9/7/2023 1:55:26 AM,Berenberg Bank Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/berenberg-bank-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032610948
2627.0,9/7/2023 11:08:02 AM,7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth,InvestorPlace,/news/stocks/7-pharma-stocks-to-buy-for-groundbreaking-treatments-and-robust-revenue-growth-1032612381
2628.0,9/7/2023 12:41:19 PM,3 Nasdaq Stocks to Sell in September Before They Crash & Burn,InvestorPlace,/news/stocks/3-nasdaq-stocks-to-sell-in-september-before-they-crash-burn-1032612766
2629.0,9/7/2023 3:04:48 PM,Researchers study weight loss drugs in dementia and addiction,Seeking Alpha,https://seekingalpha.com/news/4009962-researchers-test-weight-loss-drugs-dementia-addiction?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2630.0,9/8/2023 11:14:27 AM,Eli Lilly wins U.K. backing for diabetes drug Mounjaro,Seeking Alpha,https://seekingalpha.com/news/4010163-eli-lilly-wins-uk-backing-for-diabetes-drug-mounjaro?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2631.0,9/10/2023 4:00:00 PM,"Eli Lilly, Novo to lead $100B weight loss drug market in 2030: JPMorgan",Seeking Alpha,https://seekingalpha.com/news/4010426-eli-lilly-novo-lead-weight-loss-drug-market-jpmorgan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2632.0,9/12/2023 1:59:15 AM,Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold,InvestorPlace,/news/stocks/pound-for-pound-3-buzzworthy-drug-stocks-worth-their-weight-in-gold-1032621509
2633.0,9/13/2023 5:55:35 AM,Eli Lilly & Co (LLY) Gets a Buy from DBS,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-dbs-1032625517
2634.0,9/15/2023 9:26:39 PM,"VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks",TipRanks,/news/stocks/vti-etf-this-diversified-powerhouse-owns-over-3-800-stocks-1032634771
2635.0,9/18/2023 11:30:27 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Precision BioSciences (DTIL),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-precision-biosciences-dtil-1032636638
2636.0,9/20/2023 2:17:37 PM,Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale ,RTTNews,/news/stocks/eli-lilly-sues-clinics-over-unauthorized-mounjaro-drug-sale-1032643266
2637.0,9/20/2023 5:03:50 PM,The 7 Most Hated Stocks by Institutional Traders,InvestorPlace,/news/stocks/the-7-most-hated-stocks-by-institutional-traders-1032644534
2638.0,9/22/2023 2:33:00 PM,US FDA approves Jardiance® for the treatment of adults with chronic kidney disease,PR Newswire,/news/stocks/us-fda-approves-jardiance-for-the-treatment-of-adults-with-chronic-kidney-disease-1032649564
2639.0,9/22/2023 2:53:39 PM,Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Disease ,RTTNews,/news/stocks/eli-lilly-fda-approves-jardiance-in-treatment-of-chronic-kidney-disease-1032649637
2640.0,9/22/2023 4:46:19 PM,'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase,Benzinga,/news/stocks/stocks-in-monopolistic-bull-market-wall-street-analyst-contemplates-a-bright-future-for-next-phase-1032650182
2641.0,9/22/2023 9:05:52 PM,Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend,InvestorPlace,/news/stocks/immunomics-stocks-3-ways-to-play-this-massive-ai-biotech-megatrend-1032650707
2642.0,9/23/2023 8:00:05 PM,David vs. Goliath: 3 Stocks Poised to Challenge the ‘Magnificent 7′,InvestorPlace,/news/stocks/david-vs-goliath-3-stocks-poised-to-challenge-the-magnificent-7-1032650929
2643.0,9/25/2023 11:10:48 AM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Centessa Pharmaceuticals (CNTA)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-centessa-pharmaceuticals-cnta-1032652558
2644.0,9/26/2023 5:00:53 PM,Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher,InvestorPlace,/news/stocks/dont-miss-the-boom-3-biotech-stocks-set-to-explode-higher-1032657128
2645.0,9/28/2023 12:45:04 PM,3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals,InvestorPlace,/news/stocks/3-biotech-stocks-to-watch-ahead-of-potential-obesity-drug-approvals-1032662925
2646.0,9/29/2023 1:52:14 AM,SCHX ETF: A Large-Cap ETF for Large Gains,TipRanks,/news/stocks/schx-etf-a-large-cap-etf-for-large-gains-1032664747
2647.0,10/1/2023 2:32:42 AM,"LLY, ISRG, or JNJ: Which Healthcare Stock Could Generate the Best Returns?",TipRanks,/news/stocks/lly-isrg-or-jnj-which-healthcare-stock-could-generate-the-best-returns-1032668067
2648.0,10/2/2023 12:45:00 PM,U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer,PR Newswire,/news/stocks/u-s-food-and-drug-administration-issues-complete-response-letter-for-lebrikizumab-based-on-inspection-findings-at-third-party-manufacturer-1032669811
2649.0,10/2/2023 12:58:07 PM,Eli Lilly: FDA Issues CRL For Lebrikizumab BLA Related To Third-party Manufacturing Organization ,RTTNews,/news/stocks/eli-lilly-fda-issues-crl-for-lebrikizumab-bla-related-to-third-party-manufacturing-organization-1032669837
2650.0,10/2/2023 1:20:21 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Abbott Labs (ABT), Eli Lilly & Co (LLY) and Rocket Pharmaceuticals (RCKT)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-abbott-labs-abt-eli-lilly-co-lly-and-rocket-pharmaceuticals-rckt-1032670481
2651.0,10/2/2023 3:28:42 PM,Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns,InvestorPlace,/news/stocks/stable-giants-3-bigwig-biotech-stocks-for-consistent-returns-1032671153
2652.0,10/2/2023 3:32:07 PM,Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024,InvestorPlace,/news/stocks/q4-stock-predictions-3-pharma-stocks-ready-to-roar-into-2024-1032671152
2653.0,10/2/2023 11:00:46 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1032671752
2654.0,10/3/2023 8:25:29 AM,Cantor Fitzgerald Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032672635
2655.0,10/3/2023 12:45:00 PM,Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies,PR Newswire,/news/stocks/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-1032673889
2656.0,10/3/2023 12:55:09 PM,Why Is Point Biopharma (PNT) Stock Up 84% Today?,InvestorPlace,/news/stocks/why-is-point-biopharma-pnt-stock-up-84-today-1032674584
2657.0,10/3/2023 1:23:12 PM,Lilly To Acquire POINT Biopharma For $1.4 Bln In Cash; POINT Up In Pre Market ,RTTNews,/news/stocks/lilly-to-acquire-point-biopharma-for-1-4-bln-in-cash-point-up-in-pre-market-1032674015
2658.0,10/3/2023 2:58:30 PM,Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?,Benzinga,/news/stocks/why-cancer-focused-alx-oncology-stock-gained-over-100-today-1032674452
2659.0,10/3/2023 3:03:07 PM,Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today?,Benzinga,/news/stocks/why-is-cancer-treatment-focused-point-biopharma-stock-trading-higher-today-1032674451
2660.0,10/3/2023 3:42:06 PM,Dow Falls Over 100 Points; McCormick Sales Miss Views,Benzinga,/news/stocks/dow-falls-over-100-points-mccormick-sales-miss-views-1032674679
2661.0,10/3/2023 4:09:54 PM,"Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday",Benzinga,/news/stocks/vericity-point-biopharma-global-oddity-tech-and-other-big-stocks-moving-higher-on-tuesday-1032675118
2662.0,10/3/2023 4:11:21 PM,"'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories",Benzinga,/news/stocks/airbnb-has-foundational-cracks-disney+-follows-netflix-on-subscription-sharing-crackdown-microsoft-s-nadella-criticizes-google-s-exclusive-content-deals-today-s-top-stories-1032675117
2663.0,10/3/2023 6:20:54 PM,Nasdaq Down Over 200 Points; US Job Openings Rise In August,Benzinga,/news/stocks/nasdaq-down-over-200-points-us-job-openings-rise-in-august-1032675501
2664.0,10/3/2023 7:26:04 PM,"Wall Street Sell-Off Worsens, VIX Spikes As Bond Yields Rise Further, Dollar Strengthens: What's Driving Markets Tuesday?",Benzinga,/news/etf/wall-street-sell-off-worsens-vix-spikes-as-bond-yields-rise-further-dollar-strengthens-what-s-driving-markets-tuesday-1032675610
2665.0,10/3/2023 7:33:22 PM,Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-getty-images-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-tuesday-s-mid-day-session-1032675609
2666.0,10/3/2023 8:36:40 PM,Crude Oil Moves Higher; POINT Biopharma Global Shares Jump,Benzinga,/news/stocks/crude-oil-moves-higher-point-biopharma-global-shares-jump-1032675711
2667.0,10/4/2023 11:16:07 AM,Strategic Pipeline Progression and Growth Prospects Affirm Buy Rating for Lilly: An Analysis,TipRanks,/news/stocks/strategic-pipeline-progression-and-growth-prospects-affirm-buy-rating-for-lilly-an-analysis-1032677501
2668.0,10/4/2023 12:45:00 PM,Lilly Announces Leadership Transitions,PR Newswire,/news/stocks/lilly-announces-leadership-transitions-1032677321
2669.0,10/4/2023 6:05:00 PM,Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,PR Newswire,/news/stocks/loxo-lilly-unveils-three-new-oncology-programs-at-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-1032678907
2670.0,10/6/2023 11:10:46 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Apellis Pharmaceuticals (APLS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-apellis-pharmaceuticals-apls-1032684257
2671.0,10/6/2023 1:45:00 PM,Lilly Announces Details of Presentations at ESMO Congress 2023,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-esmo-congress-2023-1032684340
2672.0,10/6/2023 6:23:48 PM,"Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst",Benzinga,/news/stocks/eli-lilly-s-upcoming-obesity-drugs-highlight-bright-future-says-optimistic-analyst-1032685329
2673.0,10/6/2023 10:01:38 PM,"Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise",Benzinga,/news/stocks/snacks-in-the-ozempic-era-food-beverage-stocks-crash-with-weight-loss-drugs-on-the-rise-1032685569
2674.0,10/6/2023 10:14:50 PM,"Shutdown Averted, Treasury Yields Flirt With 5%, Strong Payrolls Add to Fed Tightening Risk: The Week In The Markets",Benzinga,/news/etf/shutdown-averted-treasury-yields-flirt-with-5-strong-payrolls-add-to-fed-tightening-risk-the-week-in-the-markets-1032685594
2675.0,10/7/2023 1:00:48 PM,3 Biotech Stocks Ready to Break Out in 2024,InvestorPlace,/news/stocks/3-biotech-stocks-ready-to-break-out-in-2024-1032685969
2676.0,10/9/2023 10:42:41 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032688302
2677.0,10/10/2023 8:20:10 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-bristol-myers-squibb-bmy-1032691280
2678.0,10/10/2023 2:06:15 PM,Obesity Medication Insurance Coverage? Employers Embrace the Inclusion of Novo Nordisk's Wegovy in Health Coverage,Benzinga,/news/stocks/obesity-medication-insurance-coverage-employers-embrace-the-inclusion-of-novo-nordisk-s-wegovy-in-health-coverage-1032692132
2679.0,10/10/2023 9:06:49 PM,"RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan",Benzinga,/news/stocks/rayzebio-is-a-new-contender-in-radiopharmaceutical-arena-will-attract-prominent-entities-jp-morgan-1032693787
2680.0,10/11/2023 6:16:04 PM,What's Going On With Eli Lilly Stock Wednesday?,Benzinga,/news/stocks/what-s-going-on-with-eli-lilly-stock-wednesday-1032697667
2681.0,10/11/2023 7:10:15 PM,"Stocks In The Red, Bonds On The Rise As Investors Brace for FOMC Minutes, Crucial CPI Report: What's Driving Markets Wednesday?",Benzinga,/news/etf/stocks-in-the-red-bonds-on-the-rise-as-investors-brace-for-fomc-minutes-crucial-cpi-report-what-s-driving-markets-wednesday-1032697769
2682.0,10/12/2023 10:43:42 AM,Could Eli Lilly (NYSE:LLY) Stock Hit $1 Trillion in Market Cap?,TipRanks,/news/stocks/could-eli-lilly-nyse-lly-stock-hit-1-trillion-in-market-cap-1032699932
2683.0,10/12/2023 12:45:00 PM,Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial,PR Newswire,/news/stocks/lilly-s-mirikizumab-helped-patients-with-crohn-s-disease-achieve-long-term-remission-in-phase-3-trial-1032699918
2684.0,10/12/2023 1:29:43 PM,Lilly: Mirikizumab Phase 3 Trial In Adults With Crohn's Disease Meets Coprimary Endpoints ,RTTNews,/news/stocks/lilly-mirikizumab-phase-3-trial-in-adults-with-crohn-s-disease-meets-coprimary-endpoints-1032700070
2685.0,10/12/2023 10:53:43 PM,7 Stocks to Buy With Your 2024 Social Security Increase,InvestorPlace,/news/stocks/stocks-to-buy-with-social-security-increases-1032702135
2686.0,10/16/2023 12:00:00 AM,"Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks",PR Newswire,/news/stocks/lilly-s-tirzepatide-shows-additional-21-1-weight-loss-after-12-weeks-of-intensive-lifestyle-intervention-for-a-total-mean-weight-loss-of-26-6-from-study-entry-over-84-weeks-1032706040
2687.0,10/16/2023 3:30:31 AM,Lilly's Tirzepatide Shows Addl 21.1% Weight Loss After 12 Weeks Of Intensive Lifestyle Intervention ,RTTNews,/news/stocks/lilly-s-tirzepatide-shows-addl-21-1-weight-loss-after-12-weeks-of-intensive-lifestyle-intervention-1032706077
2688.0,10/16/2023 11:30:33 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AstraZeneca (AZN) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-astrazeneca-azn-and-ultragenyx-pharmaceutical-rare-1032708087
2689.0,10/16/2023 8:43:28 PM,Food and Beverage Stocks Look Appetizing After Ozempic Selloff,InvestorPlace,/news/stocks/food-and-beverage-stocks-look-appetizing-after-ozempic-selloff-1032709959
2690.0,10/16/2023 10:16:41 PM,7 Cutting-Edge Stocks That Could Change Humanity as We Know It,InvestorPlace,/news/stocks/7-cutting-edge-stocks-that-could-change-humanity-as-we-know-it-1032710031
2691.0,10/18/2023 10:51:54 PM,The Next Trillion-Dollar Companies: 3 Stocks to Buy Now,InvestorPlace,/news/stocks/the-next-trillion-dollar-companies-3-stocks-to-buy-now-1032718562
2692.0,10/19/2023 11:58:05 AM,Optimistic Future for Eli Lilly: Potential Approval and Impact of Mounjaro in Obstructive Sleep Apnea Treatment Landscape,TipRanks,/news/stocks/optimistic-future-for-eli-lilly-potential-approval-and-impact-of-mounjaro-in-obstructive-sleep-apnea-treatment-landscape-1032720635
2693.0,10/19/2023 8:11:36 PM,7 Healthcare Stocks That Can Cure a Lackluster Portfolio,InvestorPlace,/news/stocks/healthcare-stocks-to-buy-4-1032722294
2694.0,10/20/2023 3:42:15 AM,"NVO, LLY, AZN: 3 “Strong Buy” Stocks to Bet on Weight-Loss Drugs",TipRanks,/news/stocks/nvo-lly-azn-3-strong-buy-stocks-to-bet-on-weight-loss-drugs-1032722680
2695.0,10/20/2023 4:25:32 AM,LLY vs. PFE: Which Pharma Stock is the Better Buy?,TipRanks,/news/stocks/lly-vs-pfe-which-pharma-stock-is-the-better-buy-1032722758
2696.0,10/20/2023 12:45:00 PM,Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years,PR Newswire,/news/stocks/nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-clear-skin-with-lilly-s-lebrikizumab-monthly-maintenance-dosing-at-two-years-1032723948
2697.0,10/20/2023 2:00:00 PM,Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer,PR Newswire,/news/stocks/landmark-5-year-monarche-outcome-data-demonstrate-verzenio-abemaciclib-s-long-term-impact-on-cancer-recurrence-in-high-risk-early-breast-cancer-1032724130
2698.0,10/20/2023 2:24:43 PM,Eli Lilly Reports Five-year Outcomes From Pre-planned Analysis Of Phase 3 MonarchE Study ,RTTNews,/news/stocks/eli-lilly-reports-five-year-outcomes-from-pre-planned-analysis-of-phase-3-monarche-study-1032724188
2699.0,10/20/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2023-financial-results-announcement-1032724483
2700.0,10/20/2023 11:00:23 PM,What 23 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-23-analyst-ratings-have-to-say-about-eli-lilly-1032725257
2701.0,10/21/2023 1:42:20 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Intuitive Surgical (ISRG),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-intuitive-surgical-isrg-1032725606
2702.0,10/21/2023 4:31:00 PM,Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and...,PR Newswire,/news/stocks/lilly-s-retevmo-selpercatinib-phase-3-results-in-ret-fusion-positive-non-small-cell-lung-cancer-and-ret-mutant-medullary-thyroid-cancer-both-published-in-the-new-england-journal-of-medicine-and-1032725643
2703.0,10/26/2023 12:16:41 PM,Wells Fargo Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032746054
2704.0,10/26/2023 12:19:29 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Alnylam Pharma (ALNY) and Thermo Fisher (TMO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-alnylam-pharma-alny-and-thermo-fisher-tmo-1032746041
2705.0,10/26/2023 4:00:00 PM,Lilly to Participate in UBS Biopharma Conference 2023,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-biopharma-conference-2023-1032744299
2706.0,10/26/2023 11:41:57 PM,CGDG: This New Dividend Growth ETF Looks Promising,TipRanks,/news/stocks/cgdg-this-new-dividend-growth-etf-looks-promising-1032748443
2707.0,10/27/2023 12:24:00 AM,"FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis",PR Newswire,/news/stocks/fda-approves-lilly-s-omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis-1032745805
2708.0,10/27/2023 5:11:57 AM,FDA Approves Lilly's Omvoh For Ulcerative Colitis Treatment ,RTTNews,/news/stocks/fda-approves-lilly-s-omvoh-for-ulcerative-colitis-treatment-1032746241
2709.0,10/27/2023 10:33:58 PM,"Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets",Benzinga,/news/etf/bears-roam-wall-street-as-middle-east-conflict-earnings-outlook-raise-concerns-despite-strong-q3-us-economic-growth-this-week-in-markets-1032749881
2710.0,10/30/2023 10:02:53 AM,Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032755904
2711.0,10/31/2023 1:52:54 PM,Why Beam Therapeutics Stock Is Getting Bought Today,Benzinga,/news/stocks/why-beam-therapeutics-stock-is-getting-bought-today-1032759115
2712.0,10/31/2023 8:48:26 PM,AI-Powered Investing: 3 Promising Stocks for 2024,InvestorPlace,/news/stocks/ai-powered-investing-3-promising-stocks-for-2024-1032761245
2713.0,11/1/2023 1:48:01 AM,7 A-Rated Stocks to Buy in Q4,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-in-q4-1032761726
2714.0,11/1/2023 9:40:00 AM,Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On,InvestorPlace,/news/stocks/inside-cathie-woods-portfolio-3-stocks-she-is-betting-millions-on-1032764221
2715.0,11/1/2023 11:55:00 AM,Lilly Declares Fourth-Quarter 2023 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2023-dividend-1032764380
2716.0,11/1/2023 1:00:00 PM,"Hip-Hop Classic ""It Takes Two"" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease",PR Newswire,/news/stocks/hip-hop-classic-it-takes-two-takes-on-new-meaning-in-remix-to-elevate-importance-of-testing-for-kidney-disease-1032764655
2717.0,11/1/2023 3:01:13 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-q3-earnings-preview-1032765587
2718.0,11/2/2023 5:31:20 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Eli Lilly & Co (LLY) and Repligen (RGEN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-eli-lilly-co-lly-and-repligen-rgen-1032771764
2719.0,11/2/2023 10:40:00 AM,7 A-Rated Tech Stocks to Buy for November,InvestorPlace,/news/stocks/7-a-rated-tech-stocks-to-buy-for-november-1032769617
2720.0,11/2/2023 11:30:00 AM,"Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity",PR Newswire,/news/stocks/lilly-reports-third-quarter-2023-financial-results-highlights-strong-sales-growth-and-business-development-activity-1032769525
2721.0,11/2/2023 11:34:22 AM,Eli Lilly And Co. Q3 Earnings Summary,RTTNews,/news/stocks/eli-lilly-and-co-q3-earnings-summary-1032769550
2722.0,11/2/2023 12:25:46 PM,Eli Lilly Cuts Annual Earnings Outlook Below View - Update ,RTTNews,/news/stocks/eli-lilly-cuts-annual-earnings-outlook-below-view-update-1032769848
2723.0,11/2/2023 2:00:00 PM,Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting,PR Newswire,/news/stocks/lilly-announces-details-of-pirtobrutinib-presentations-in-b-cell-malignancies-at-2023-ash-annual-meeting-1032770295
2724.0,11/2/2023 6:24:15 PM,Positive Growth Prospects and Strategic Opportunities Bolster Buy Rating for Eli Lilly & Co: An Analyst’s Perspective,TipRanks,/news/stocks/positive-growth-prospects-and-strategic-opportunities-bolster-buy-rating-for-eli-lilly-co-an-analyst-s-perspective-1032774901
2725.0,11/2/2023 6:58:06 PM,"Green Wave Boosts Stocks, Bonds As Traders Embrace Fed's Stance, Await Apple Earnings: What's Driving Markets Thursday?",Benzinga,/news/etf/green-wave-boosts-stocks-bonds-as-traders-embrace-fed-s-stance-await-apple-earnings-what-s-driving-markets-thursday-1032771843
2726.0,11/3/2023 3:50:06 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and Seres Therapeutics (MCRB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-irhythm-technologies-irtc-and-seres-therapeutics-mcrb-1032776998
2727.0,11/3/2023 12:32:34 PM,"Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Stryker (SYK) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-moderna-mrna-stryker-syk-and-eli-lilly-co-lly-1032778033
2728.0,11/3/2023 4:56:15 PM,The Importance of Brand Power: 3 Stocks to Consider,InvestorPlace,/news/stocks/the-importance-of-brand-power-3-stocks-to-consider-1032777152
2729.0,11/6/2023 1:10:55 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Rani Therapeutics Holdings (RANI) and Crispr Therapeutics AG (CRSP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-rani-therapeutics-holdings-rani-and-crispr-therapeutics-ag-crsp-1032784199
2730.0,11/8/2023 10:20:12 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-crispr-therapeutics-ag-crsp-1032796758
2731.0,11/8/2023 6:22:00 PM,"FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems",PR Newswire,/news/stocks/fda-approves-lilly-s-zepbound-tirzepatide-for-chronic-weight-management-a-powerful-new-option-for-the-treatment-of-obesity-or-overweight-with-weight-related-medical-problems-1032795836
2732.0,11/8/2023 9:50:07 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1032799748
2733.0,11/8/2023 10:56:00 PM,Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma,PR Newswire,/news/stocks/lilly-announces-extension-of-tender-offer-to-acquire-point-biopharma-1032796691
2734.0,11/9/2023 2:35:46 AM,Buy Rating for Eli Lilly & Co. Driven by Zepbound’s Potential Success in Obesity Market,TipRanks,/news/stocks/buy-rating-for-eli-lilly-co-driven-by-zepbound-s-potential-success-in-obesity-market-1032801132
2735.0,11/9/2023 4:46:15 AM,"Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity ",RTTNews,/news/stocks/lilly-fda-approves-zepbound-for-chronic-weight-management-new-option-for-treatment-of-obesity-1032797295
2736.0,11/9/2023 4:58:34 AM,Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16 ,RTTNews,/news/stocks/lilly-extends-tender-offer-for-point-biopharma-global-until-nov-16-1032797306
2737.0,11/9/2023 8:25:47 AM,J.P. Morgan Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/j-p-morgan-remains-a-buy-on-eli-lilly-co-lly-1032802437
2738.0,11/9/2023 1:35:46 PM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), Stryker (SYK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-stryker-syk-1032803039
2739.0,11/9/2023 2:16:01 PM,Eli Lilly & Co (LLY) Receives a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-bmo-capital-1032803082
2740.0,11/10/2023 12:00:00 PM,7 Biotech Stocks to Buy for Big-Time Gains,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-big-time-gains-1032806584
2741.0,11/10/2023 3:01:42 PM,"'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer",Benzinga,/news/stocks/i-want-you-to-buy-it-and-every-time-it-dips-i-want-you-to-buy-more-cramer-hypes-up-auto-parts-retailer-1032806934
2742.0,11/10/2023 5:20:06 PM,3 Stocks to Buy for Retirees Looking to Beat Inflation,InvestorPlace,/news/stocks/3-stocks-to-buy-for-retirees-looking-to-beat-inflation-1032807707
2743.0,11/12/2023 11:50:44 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BridgeBio Pharma (BBIO) and Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-bridgebio-pharma-bbio-and-boston-scientific-bsx-1032812570
2744.0,11/13/2023 8:07:30 AM,"Up 65% YTD, Is Eli Lilly (NYSE:LLY) Stock Worth Buying?  ",TipRanks,/news/stocks/up-65-ytd-is-eli-lilly-nyse-lly-stock-worth-buying- -1032814439
2745.0,11/13/2023 12:06:31 PM,Eli Lilly & Co’s Stock Earns Buy Rating: Promising Obesity Treatment Results and Cardiovascular Benefits Beyond Weight Loss,TipRanks,/news/stocks/eli-lilly-co-s-stock-earns-buy-rating-promising-obesity-treatment-results-and-cardiovascular-benefits-beyond-weight-loss-1032814856
2746.0,11/13/2023 12:45:33 PM,Hold Rating for Eli Lilly & Co: A Mixed Outlook Amid Promising Clinical Results and Potential Market Challenges,TipRanks,/news/stocks/hold-rating-for-eli-lilly-co-a-mixed-outlook-amid-promising-clinical-results-and-potential-market-challenges-1032814950
2747.0,11/13/2023 1:06:08 PM,Potential Synergies of Combined Treatment for T2D and Albuminuria Drive Buy Rating for Eli Lilly & Co,TipRanks,/news/stocks/potential-synergies-of-combined-treatment-for-t2d-and-albuminuria-drive-buy-rating-for-eli-lilly-co-1032814964
2748.0,11/13/2023 1:56:07 PM,The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight’,InvestorPlace,/news/stocks/the-magnificent-seven-7-stocks-that-could-make-it-the-elite-eight-1032813036
2749.0,11/13/2023 3:06:28 PM,"‘Hold Your Horses,’ Says Goldman Sachs About Eli Lilly Stock",TipRanks,/news/stocks/hold-your-horses-says-goldman-sachs-about-eli-lilly-stock-1032815036
2750.0,11/13/2023 3:40:17 PM,"Analysts Conflicted on These Healthcare Names: Inogen (INGN), Eli Lilly & Co (LLY) and Celcuity (CELC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-inogen-ingn-eli-lilly-co-lly-and-celcuity-celc-1032815047
2751.0,11/13/2023 8:00:11 PM,"Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly",Benzinga,/news/stocks/is-there-room-for-improvement-in-weight-loss-arena-analysts-evaluate-novo-nordisk-data-emphasize-opportunities-for-eli-lilly-1032814358
2752.0,11/14/2023 12:50:39 AM,"Analysts Conflicted on These Healthcare Names: Vertex (VERX), Eli Lilly & Co (LLY) and Mirum Pharmaceuticals (MIRM)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-vertex-verx-eli-lilly-co-lly-and-mirum-pharmaceuticals-mirm-1032817492
2753.0,11/14/2023 2:48:37 AM,Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.,InvestorPlace,/news/stocks/royal-rule-buy-these-3-dividend-aristocrats-on-every-single-dip-1032815027
2754.0,11/14/2023 4:00:00 PM,Lilly to Participate in Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/lilly-to-participate-in-evercore-isi-healthconx-conference-1032818227
2755.0,11/14/2023 9:06:08 PM,Why It’s Time to Sell These 3 Hot Stocks,InvestorPlace,/news/stocks/why-its-time-to-sell-these-3-hot-stocks-1032819466
2756.0,11/14/2023 10:33:00 PM,Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma,PR Newswire,/news/stocks/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of-point-biopharma-1032819518
2757.0,11/15/2023 4:33:23 AM,Lilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharma ,RTTNews,/news/stocks/lilly-receives-nrc-consent-in-connection-with-proposed-acquisition-of-point-biopharma-1032819978
2758.0,11/16/2023 8:25:29 AM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1032829152
2759.0,11/16/2023 9:51:17 PM,Goldman Sachs' 2024 Equity Outlook: Winning Stocks And Sectors To Watch,Benzinga,/news/stocks/goldman-sachs-2024-equity-outlook-winning-stocks-and-sectors-to-watch-1032829179
2760.0,11/17/2023 12:45:00 PM,"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023",PR Newswire,/news/stocks/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-1-2023-1032830849
2761.0,11/17/2023 2:00:00 PM,Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany,PR Newswire,/news/stocks/lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-germany-1032831044
2762.0,11/17/2023 2:09:47 PM,"Eli Lilly To Construct A New $2.5 Billion High-tech Manufacturing Site In Alzey, Germany ",RTTNews,/news/stocks/eli-lilly-to-construct-a-new-2-5-billion-high-tech-manufacturing-site-in-alzey-germany-1032831103
2763.0,11/17/2023 5:23:20 PM,The Relative Strength Index (RSI) Indicator: Does It Work?,InvestorPlace,/news/stocks/the-relative-strength-index-rsi-indicator-does-it-work-1032832168
2764.0,11/19/2023 3:51:26 PM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Karuna Therapeutics (KRTX) and Masimo (MASI)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-karuna-therapeutics-krtx-and-masimo-masi-1032833752
2765.0,11/20/2023 12:35:42 PM,"Eli Lilly & Co: A Bullish Outlook Based on Robust Growth Potential, Strong Financial Performance, and Promising Pipeline Strategy",TipRanks,/news/stocks/eli-lilly-co-a-bullish-outlook-based-on-robust-growth-potential-strong-financial-performance-and-promising-pipeline-strategy-1032837224
2766.0,11/20/2023 8:00:42 PM,Analyst Expectations for Eli Lilly's Future,Benzinga,/news/stocks/analyst-expectations-for-eli-lilly-s-future-1032836776
2767.0,11/21/2023 8:25:44 AM,Cantor Fitzgerald Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-eli-lilly-co-lly-1032840641
2768.0,11/21/2023 2:55:13 PM,Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?,Benzinga,/news/etf/can-weight-loss-drug-ozempic-tip-the-scales-for-tema-s-new-healthcare-etf-1032839197
2769.0,11/21/2023 9:16:25 PM,"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others",Benzinga,/news/stocks/alzheimer-s-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-others-1032840637
2770.0,11/22/2023 6:13:03 PM,3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape,InvestorPlace,/news/stocks/3-healthcare-stocks-to-scoop-up-as-they-change-the-medical-landscape-1032843890
2771.0,11/26/2023 11:45:31 PM,Robust Demand and Promising Forecasts Reinforce Buy Rating for Eli Lilly & Co,TipRanks,/news/stocks/robust-demand-and-promising-forecasts-reinforce-buy-rating-for-eli-lilly-co-1032850866
2772.0,11/28/2023 2:00:00 PM,"Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego",PR Newswire,/news/stocks/alexandria-real-estate-equities-inc-announces-exclusive-partnership-with-lilly-to-expand-lilly-gateway-labs-to-san-diego-1032854533
2773.0,11/28/2023 2:00:00 PM,Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego,PR Newswire,/news/stocks/lilly-announces-plans-to-open-its-first-ever-gateway-labs-site-in-san-diego-1032854501
2774.0,11/28/2023 2:15:03 PM,Lilly To Open New Gateway Labs Location In Partnership With Alexandria Real Estate Equities ,RTTNews,/news/stocks/lilly-to-open-new-gateway-labs-location-in-partnership-with-alexandria-real-estate-equities-1032854638
2775.0,11/30/2023 2:25:31 AM,Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032862775
2776.0,12/1/2023 2:10:12 PM,Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-and-eli-lilly-co-lly-1032867939
2777.0,12/1/2023 4:55:50 PM,"Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst",Benzinga,/news/stocks/weight-loss-drugs---novo-nordisk-a-primary-beneficiary-in-obesity-space-currently-controlled-by-two-players-says-analyst-1032867014
2778.0,12/1/2023 11:22:00 PM,Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Thera...,PR Newswire,/news/stocks/jaypirca-pirtobrutinib-now-approved-by-u-s-fda-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-who-have-received-at-least-two-lines-of-thera-1032867707
2779.0,12/2/2023 5:46:20 PM,Lilly's Jaypirca Gets Second Approval From FDA ,RTTNews,/news/stocks/lilly-s-jaypirca-gets-second-approval-from-fda-1032868093
2780.0,12/4/2023 12:45:00 PM,"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023",PR Newswire,/news/stocks/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-15-2023-1032869940
2781.0,12/4/2023 12:50:33 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032872254
2782.0,12/4/2023 1:10:30 PM,"VICI, LLY, ET Stocks: 3 Analyst Favorites with “Strong Buy” Technical Indicators",TipRanks,/news/stocks/vici-lly-et-stocks-3-analyst-favorites-with-strong-buy-technical-indicators-1032872275
2783.0,12/4/2023 1:17:32 PM,Lilly Says Tender Offer Expiration Extended Related To POINT Biopharma Acquisition ,RTTNews,/news/stocks/lilly-says-tender-offer-expiration-extended-related-to-point-biopharma-acquisition-1032870079
2784.0,12/4/2023 10:20:13 PM,"Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market",Benzinga,/news/etf/roche-pfizer-race-to-find-next-ozempic-as-pharma-giants-hustle-to-join-obesity-treatment-market-1032871966
2785.0,12/5/2023 1:38:00 PM,Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity,PR Newswire,/news/stocks/zepbound-tirzepatide-is-now-available-in-u-s-pharmacies-for-adults-living-with-obesity-1032873874
2786.0,12/5/2023 2:01:57 PM,Eli Lilly Announces Availability Of Zepbound In U.S. Pharmacies - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-availability-of-zepbound-in-u-s-pharmacies-quick-facts-1032874006
2787.0,12/5/2023 2:15:00 PM,Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer S...,PR Newswire,/news/stocks/lilly-to-present-final-overall-survival-analysis-from-the-monarch-3-study-of-verzenio-abemaciclib-and-additional-results-from-its-breast-cancer-portfolio-at-the-2023-san-antonio-breast-cancer-s-1032874088
2788.0,12/5/2023 3:24:03 PM,Eli Lilly To Present Final Survival Results Of MONARCH 3 Trial Of Verzenio In Breast Cancer ,RTTNews,/news/stocks/eli-lilly-to-present-final-survival-results-of-monarch-3-trial-of-verzenio-in-breast-cancer-1032874543
2789.0,12/6/2023 5:23:37 PM,"JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities",Benzinga,/news/stocks/jnj-ceo-signals-no-rush-into-weight-loss-drug-realm-emphasizes-different-priorities-1032879077
2790.0,12/8/2023 10:15:00 AM,Challenging the Magnificent 7: 3 Stocks on the Rise,InvestorPlace,/news/stocks/challenging-the-magnificent-7-3-stocks-on-the-rise-1032885008
2791.0,12/8/2023 5:25:00 PM,"Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend",PR Newswire,/news/stocks/lilly-announces-15-dividend-increase-first-quarter-2024-dividend-1032886280
2792.0,12/11/2023 12:20:57 PM,"Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Legend Biotech (LEGN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-healthequity-hqy-legend-biotech-legn-and-eli-lilly-co-lly-1032891195
2793.0,12/11/2023 4:54:00 PM,"Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks",PR Newswire,/news/stocks/lilly-s-zepbound-tirzepatide-achieved-additional-6-7-weight-loss-following-a-36-week-open-label-lead-in-period-for-a-total-mean-weight-loss-of-26-0-from-study-entry-over-88-weeks-1032890271
2794.0,12/12/2023 1:30:00 AM,Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting,PR Newswire,/news/stocks/updated-data-from-the-bruin-phase-1-2-study-of-pirtobrutinib-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-presented-at-the-2023-ash-annual-meeting-1032891215
2795.0,12/12/2023 12:20:23 PM,"Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Eli Lilly & Co (LLY) and Disc Medicine (IRON)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-centessa-pharmaceuticals-cnta-eli-lilly-co-lly-and-disc-medicine-iron-1032895160
2796.0,12/12/2023 4:30:26 PM,"Did Eli Lilly Stock Rally Too Far, Too Fast? Goldman Sachs Weighs In",TipRanks,/news/stocks/did-eli-lilly-stock-rally-too-far-too-fast-goldman-sachs-weighs-in-1032895363
2797.0,12/13/2023 7:13:00 AM,"ABBV, NVO, or LLY: Which Healthcare Stock Could Generate the Highest Returns?",TipRanks,/news/stocks/abbv-nvo-or-lly-which-healthcare-stock-could-generate-the-highest-returns-1032898484
2798.0,12/14/2023 7:14:00 PM,Billionaire Ken Griffin Bets Big on 2 ‘Strong Buy’ Stocks — Eli Lilly and Microsoft,TipRanks,/news/stocks/billionaire-ken-griffin-bets-big-on-2-strong-buy-stocks-—-eli-lilly-and-microsoft-1032903660
2799.0,12/15/2023 1:55:17 PM,The New Magnificent 7: 7 Stocks Rising to Prominence,InvestorPlace,/news/stocks/the-new-magnificent-7-stocks-7-more-players-rising-to-prominence-1032904774
2800.0,12/15/2023 3:51:25 PM,3 Stocks Wall Street Bulls Are Betting On Big-Time,InvestorPlace,/news/stocks/3-stocks-wall-street-bulls-are-betting-on-big-time-1032905400
2801.0,12/17/2023 6:46:58 PM,Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?,InvestorPlace,/news/stocks/are-novembers-3-biggest-stock-losers-worth-snapping-up-now-1032907117
2802.0,12/18/2023 10:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Elevance Health (ELV) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-elevance-health-elv-and-eli-lilly-co-lly-1032910493
2803.0,12/18/2023 12:25:58 PM,Eli Lilly & Co: A Strong Buy on Robust Diabetes and Oncology Growth Prospects,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-diabetes-and-oncology-growth-prospects-1032910579
2804.0,12/18/2023 12:45:00 PM,"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023",PR Newswire,/news/stocks/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-22-2023-1032908517
2805.0,12/18/2023 8:39:37 PM,Obesity/Diabetes Drug Class GLP-1s' Cost-Saving Potential: Decoding Impact on Healthcare Spending,Benzinga,/news/stocks/obesity-diabetes-drug-class-glp-1s-cost-saving-potential-decoding-impact-on-healthcare-spending-1032910224
2806.0,12/19/2023 6:03:48 AM,Goldman Sachs: Eli Lilly's Shares May Surge By 140% With GLP-1 Drug Boom,Benzinga,/news/stocks/goldman-sachs-eli-lilly-s-shares-may-surge-by-140-with-glp-1-drug-boom-1032910837
2807.0,12/21/2023 2:00:45 PM,What Analysts Are Saying About Eli Lilly Stock,Benzinga,/news/stocks/what-analysts-are-saying-about-eli-lilly-stock-1032919073
2808.0,12/22/2023 12:51:10 PM,Looking Beyond Tech: 7 High-Growth Stocks for Substantial Returns,InvestorPlace,/news/stocks/looking-beyond-tech-7-high-growth-stocks-for-substantial-returns-1032922090
2809.0,12/22/2023 9:21:22 PM,7 Small-Cap Stocks That Wall Street Loves for Good Reason ,InvestorPlace,/news/stocks/7-small-cap-stocks-that-analysts-are-upgrading-1032923323
2810.0,12/26/2023 8:02:49 PM,Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst,Benzinga,/news/stocks/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-karxt-analyst-1032926298
2811.0,12/27/2023 2:31:00 PM,Lilly Completes Acquisition of POINT Biopharma,PR Newswire,/news/stocks/lilly-completes-acquisition-of-point-biopharma-1032927846
2812.0,12/27/2023 3:11:10 PM,Lilly Acquires Point Biopharma For Approx. $1.4 Bln ,RTTNews,/news/stocks/lilly-acquires-point-biopharma-for-approx-1-4-bln-1032927941
2813.0,12/27/2023 6:42:14 PM,"Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned",Benzinga,/news/stocks/recent-m-a-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-analyst-say-astrazeneca-is-favorably-positioned-1032928584
2814.0,12/28/2023 2:54:49 AM,"Innovent Biologics, Xuanzhu Collaborate On Clinical Trial For Advanced Solid Tumors In China ",RTTNews,/news/stocks/innovent-biologics-xuanzhu-collaborate-on-clinical-trial-for-advanced-solid-tumors-in-china-1032928924
2815.0,12/28/2023 1:33:14 PM,"Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts",Benzinga,/news/stocks/eli-lilly-johnson-johnson-and-other-health-care-stocks-from-wall-street-s-most-accurate-analysts-1032929866
2816.0,12/29/2023 12:22:40 AM,Top 3 Large-Cap Growth Stock Picks for the New Year,InvestorPlace,/news/stocks/top-3-large-cap-growth-stock-picks-for-the-new-year-1032931106
2817.0,12/30/2023 9:00:00 PM,3 Ken Griffin Stocks to Invest Like Citadel,InvestorPlace,/news/stocks/3-ken-griffin-stocks-to-invest-like-citadel-1032933562
2818.0,1/1/2024 1:56:17 PM,2024’s Power Players: 7 Stocks Racing to a Trillion Valuation,InvestorPlace,/news/stocks/2024s-power-players-7-stocks-racing-to-a-trillion-valuation-1032934899
2819.0,1/2/2024 2:51:46 PM,"Analysts Conflicted on These Healthcare Names: Staar Surgical (STAA), Venus Concept (VERO) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-staar-surgical-staa-venus-concept-vero-and-eli-lilly-co-lly-1032938548
2820.0,1/2/2024 4:00:00 PM,Lilly to Participate in J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-j-p-morgan-healthcare-conference-1032937015
2821.0,1/3/2024 10:42:40 PM,The 7 Best Meme Stocks to Buy Now,InvestorPlace,/news/stocks/best-meme-stocks-1031269612
2822.0,1/4/2024 2:02:53 PM,"Eli Lilly Launches LillyDirect To Help Patients Manage Health, Access Medicines ",RTTNews,/news/stocks/eli-lilly-launches-lillydirect-to-help-patients-manage-health-access-medicines-1032942973
2823.0,1/4/2024 8:29:37 PM,"EXCLUSIVE: Buy The Dip — There's A Lot More Upside To Come, Says Marc Chaikin",Benzinga,/news/stocks/exclusive-buy-the-dip-—-there-s-a-lot-more-upside-to-come-says-marc-chaikin-1032944300
2824.0,1/4/2024 11:53:24 PM,Global Giants: 3 Multinational Corporations to Outperform in 2024,InvestorPlace,/news/stocks/global-giants-3-multinational-corporations-to-outperform-in-2024-1032944623
2825.0,1/5/2024 3:25:22 PM,Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge,Benzinga,/news/etf/short-sellers-nightmare-195b-evaporates-in-2023-s-market-surge-1032946074
2826.0,1/5/2024 6:20:23 PM,Dry January Investing: Trading Pints For Portfolio Growth,Benzinga,/news/etf/dry-january-investing-trading-pints-for-portfolio-growth-1032946780
2827.0,1/5/2024 6:30:11 PM,Why Is WeightWatchers (WW) Stock Down 5% Today?,InvestorPlace,/news/stocks/why-is-weightwatchers-ww-stock-down-5-today-1032946887
2828.0,1/5/2024 9:21:16 PM,3 Stocks to Make You the Millionaire Next Door: 2024 Edition,InvestorPlace,/news/stocks/3-stocks-to-make-you-the-millionaire-next-door-2024-edition-1032947071
2829.0,1/8/2024 7:28:48 PM,Q1’s Rising Stars: 3 Dividend Stocks with Massive Upside,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-for-upside-in-2024-1032951464
2830.0,1/9/2024 6:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), InflaRx (IFRX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-walgreens-boots-alliance-wba-inflarx-ifrx-and-eli-lilly-co-lly-1032954795
2831.0,1/9/2024 11:19:15 AM,Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/9/2024,TipRanks,/news/stocks/analysts-and-technical-indicators-agree-these-3-stocks-are-strong-buys-–-1-9-2024-1032955265
2832.0,1/10/2024 2:05:20 AM,Goldman Sachs Sticks to Its Hold Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/goldman-sachs-sticks-to-its-hold-rating-for-eli-lilly-co-lly-1032956046
2833.0,1/10/2024 11:00:21 AM,Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ardelyx-ardx-and-eli-lilly-co-lly-1032957350
2834.0,1/11/2024 2:15:56 PM,Pfizer’s 2024 Outlook: Is PFE Stock Poised for a Major Rebound?,InvestorPlace,/news/stocks/pfizers-2024-outlook-is-pfe-stock-poised-for-a-major-rebound-1032960713
2835.0,1/11/2024 5:40:37 PM,"Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance",Benzinga,/news/stocks/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lilly-s-dominance-1032961467
2836.0,1/11/2024 9:38:39 PM,3 Stocks to Buy in the Booming Field of Gene Editing,InvestorPlace,/news/stocks/3-gene-editing-stocks-to-profit-from-the-coming-boom-1032962080
2837.0,1/12/2024 7:21:55 PM,Portfolio Protection: 7 Risky Stocks to Drop Right Now,InvestorPlace,/news/stocks/portfolio-protection-7-risky-stocks-to-drop-right-now-1032964859
2838.0,1/19/2024 1:05:15 PM,Senate panel to consider subpoenas for J&J and Merck CEOs,Seeking Alpha,https://seekingalpha.com/news/4056351-sen-bernie-sanders-weighs-subpoenas-jj-merck-ceos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2839.0,1/19/2024 4:18:03 PM,Eli Lilly production plant said to be under renewed FDA scrutiny,Seeking Alpha,https://seekingalpha.com/news/4056498-eli-lilly-plant-renewed-fda-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2840.0,1/19/2024 10:03:58 PM,S&P 500 Shatters Records: The Top-Performing Stocks In January 2024,Benzinga,/news/etf/s-p-500-shatters-records-the-top-performing-stocks-in-january-2024-1032981017
2841.0,1/21/2024 5:00:01 PM,Anti-obesity meds can expand the market for weight loss surgery: Bernstein,Seeking Alpha,https://seekingalpha.com/news/4056663-glp-1s-can-expand-market-weight-loss-surgery-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2842.0,1/23/2024 8:31:16 AM,"Analysts Offer Insights on Healthcare Companies: Kineta (KA), Eli Lilly & Co (LLY) and Iovance Biotherapeutics (IOVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-kineta-ka-eli-lilly-co-lly-and-iovance-biotherapeutics-iova-1032987150
2843.0,1/23/2024 3:00:20 PM,The Latest Analyst Ratings For Eli Lilly,Benzinga,/news/stocks/the-latest-analyst-ratings-for-eli-lilly-1032987935
2844.0,1/24/2024 4:20:18 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032990859
2845.0,1/24/2024 6:53:17 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crispr Therapeutics AG (CRSP) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-crispr-therapeutics-ag-crsp-and-gilead-sciences-gild-1032991442
2846.0,1/24/2024 7:16:06 PM,Eli Lilly gene therapy restores hearing in Phase 1/2 trial,Seeking Alpha,https://seekingalpha.com/news/4058092-eli-lilly-gene-therapy-restores-hearing-phase-12-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2847.0,1/25/2024 11:35:07 AM,Eli Lilly's Mounjaro dose available in limited amounts through February,Seeking Alpha,https://seekingalpha.com/news/4058355-eli-lillys-mounjaro-dose-available-in-limited-amounts-through-february?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2848.0,1/25/2024 6:01:15 PM,5 Mega-Cap Stocks Ready to Make the Magnificent 7 a Dynamic Dozen,InvestorPlace,/news/stocks/5-mega-cap-stocks-ready-to-make-the-magnificent-7-a-dynamic-dozen-1032998173
2849.0,1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2850.0,1/26/2024 7:15:39 PM,Perspective gains as B. Riley sees over 100% upside on radiopharma prospects,Seeking Alpha,https://seekingalpha.com/news/4059244-perspective-stock-gains-b-riley-starts-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2851.0,1/26/2024 8:57:19 PM,3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024,InvestorPlace,/news/stocks/biotech-breakthroughs-in-2024-and-the-3-stocks-that-can-benefit-1033002304
2852.0,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2853.0,1/29/2024 11:05:27 AM,Eli Lilly: Expanding Market Reach with KwikPen for Zepbound – A Buy Rating Review,TipRanks,/news/stocks/eli-lilly-expanding-market-reach-with-kwikpen-for-zepbound-–-a-buy-rating-review-1033005772
2854.0,1/29/2024 12:20:49 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-regeneron-regn-1033006315
2855.0,1/29/2024 3:20:11 PM,Eli Lilly said to be in talks with Germany to win coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4059549-eli-lilly-talks-win-german-coverage-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2856.0,1/29/2024 8:13:38 PM,Karuna’s KarXT tops Evaluate’s most anticipated drug list,Seeking Alpha,https://seekingalpha.com/news/4059673-karuna-karxt-tops-evaluate-most-anticipated-drug-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2857.0,1/30/2024 7:30:47 AM,HUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong Kong ,RTTNews,/news/stocks/hutchmed-announces-marketing-approval-for-elunate-by-pharmacy-and-poisons-board-of-hong-kong-1033008450
2858.0,1/30/2024 1:59:38 PM,Eli Lilly wins Canada approval for severe hair loss therapy,Seeking Alpha,https://seekingalpha.com/news/4060020-eli-lilly-wins-canada-approval-for-severe-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2859.0,1/30/2024 3:45:12 PM,"Tech Giants' Market Concentration Echoes Dot-Com Bubble Peak, Analysts Warn",Benzinga,/news/stocks/tech-giants-market-concentration-echoes-dot-com-bubble-peak-analysts-warn-1033010437
2860.0,1/31/2024 3:56:09 PM,Abbott launches nutritional brand for GLP-1 users (update),Seeking Alpha,https://seekingalpha.com/news/4060732-abbott-launches-nutritional-product-brand-for-glp-1-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2861.0,1/31/2024 5:03:34 PM,Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-january-2024-1033016369
2862.0,1/31/2024 5:32:57 PM,"Lilly, Novo could be first trillion-dollar health stocks: world's largest sovereign wealth fund",Seeking Alpha,https://seekingalpha.com/news/4060795-lilly-novo-first-trillion-dollar-health-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2863.0,1/31/2024 11:03:00 PM,"LLY, ABT, CVS: Which Healthcare Stock Do Analysts Prefer?",TipRanks,/news/stocks/lly-abt-cvs-which-healthcare-stock-do-analysts-prefer-1033017434
2864.0,2/1/2024 2:38:18 PM,NeuroBo to begin Phase 1 testing of potential Wegovy rival,Seeking Alpha,https://seekingalpha.com/news/4061296-neurobo-to-begin-phase-1-testing-of-potential-wegovy-rival?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2865.0,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2866.0,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2867.0,2/1/2024 4:28:24 PM,The Road to a Trillion: 3 Stocks Next in Line for the Mega Milestone,InvestorPlace,/news/stocks/the-road-to-a-trillion-3-stocks-next-in-line-for-the-mega-milestone-1033021784
2868.0,2/1/2024 6:22:16 PM,"Lilly, Zoetis, Abbott least shorted stocks in S&P 500 health sector in mid-Jan",Seeking Alpha,https://seekingalpha.com/news/4061498-lilly-zoetis-abbott-least-shorted-stocks-in-health-sector-till-mid-jan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2869.0,2/2/2024 4:15:43 AM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1033023698
2870.0,2/2/2024 6:06:23 PM,AbbVie cites tailwinds to Botox business from weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4062286-abbvie-cites-tailwinds-botox-sales-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2871.0,2/2/2024 6:29:10 PM,What's Going On With Eli Lilly Stock Today?,Benzinga,/news/stocks/what-s-going-on-with-eli-lilly-stock-today-1033026202
2872.0,2/2/2024 7:39:14 PM,3 Pharma Stocks to Sell in February Before They Crash and Burn,InvestorPlace,/news/stocks/3-pharma-stocks-to-sell-in-february-before-they-crash-and-burn-1033026411
2873.0,2/2/2024 8:00:00 PM,"Catalyst watch: Alibaba earnings, World Defense Show, Fed speakers unleashed and Super Bowl buzz",Seeking Alpha,https://seekingalpha.com/news/4060879-catalyst-watch-alibaba-earnings-world-defense-show-fed-speakers-unleashed-and-super-bowl-buzz?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2874.0,2/3/2024 6:49:12 PM,7 Mutual Funds That Will Outperform in Any Market,InvestorPlace,/news/stocks/7-mutual-funds-that-will-outperform-in-any-market-1033026808
2875.0,2/4/2024 1:45:00 PM,"Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more",Seeking Alpha,https://seekingalpha.com/news/4062246-earnings-week-ahead-alibaba-pepsico-disney-palantir-mcdonalds-philip-morris-ford-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2876.0,2/5/2024 8:10:43 AM,"Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Eli Lilly & Co (LLY) and Idexx Laboratories (IDXX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-roche-holding-ag-otherrhhvf-eli-lilly-co-lly-and-idexx-laboratories-idxx-1033029408
2877.0,2/5/2024 11:35:53 AM,Amgen weight loss drug shows promising early data,Seeking Alpha,https://seekingalpha.com/news/4062458-amgen-weight-loss-drug-shows-promising-early-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2878.0,2/5/2024 12:59:52 PM,Eli Lilly & Co: A Buy Rating Anchored in Growth Prospects and Innovative Pipeline,TipRanks,/news/stocks/eli-lilly-co-a-buy-rating-anchored-in-growth-prospects-and-innovative-pipeline-1033031053
2879.0,2/5/2024 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-q4-quarterly-earnings-preview-stock-1033030181
2880.0,2/5/2024 3:51:44 PM,Eli Lilly sees highest intraday trade since November ahead of earnings,Seeking Alpha,https://seekingalpha.com/news/4062641-eli-lilly-sees-highest-intraday-trade-since-november-ahead-of-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2881.0,2/5/2024 4:04:02 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4062654-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2882.0,2/5/2024 4:32:52 PM,"Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday",Benzinga,/news/stocks/estée-lauder-posts-upbeat-earnings-joins-on-semiconductor-tyson-foods-and-other-big-stocks-moving-higher-on-monday-1033030909
2883.0,2/5/2024 5:38:30 PM,Eli Lilly Q4 results to highlight Zepbound uptake,Seeking Alpha,https://seekingalpha.com/news/4062717-eli-lilly-q4-results-highlight-zepbound-uptake?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2884.0,2/5/2024 6:56:50 PM,Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-air-products-and-chemicals-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-monday-s-mid-day-session-1033031395
2885.0,2/5/2024 7:18:07 PM,"NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?",InvestorPlace,/news/stocks/nvo-lly-or-azn-which-pharma-stock-is-the-best-weight-loss-investment-1033031555
2886.0,2/5/2024 9:14:41 PM,3 High-Octane Growth Stocks Not Slowing Down Any Time Soon,InvestorPlace,/news/stocks/3-high-octane-growth-stocks-not-slowing-down-any-time-soon-1033031767
2887.0,2/6/2024 1:31:38 AM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Premier (PINC) and Idexx Laboratories (IDXX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-premier-pinc-and-idexx-laboratories-idxx-1033032171
2888.0,2/6/2024 4:20:10 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Vertex Pharmaceuticals (VRTX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-vertex-pharmaceuticals-vrtx-1033033385
2889.0,2/6/2024 7:05:41 AM,Eli Lilly Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/eli-lilly-likely-to-report-higher-q4-earnings-here-are-the-recent-forecast-changes-from-wall-street-s-most-accurate-analysts-1033033240
2890.0,2/6/2024 11:47:47 AM,Eli Lilly beats top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4063010-eli-lilly-beats-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2891.0,2/6/2024 12:25:47 PM,Eli Lilly beats in Q4 as obesity drug sales blow past estimates,Seeking Alpha,https://seekingalpha.com/news/4063037-eli-lilly-stock-gains-q4-beats-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2892.0,2/6/2024 12:28:18 PM,"Eli Lilly in charts: Verzenio and Mounjaro drive revenue growth, while Humalog and Trulicity decline",Seeking Alpha,https://seekingalpha.com/news/4063035-eli-lilly-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2893.0,2/6/2024 12:49:11 PM,"Eli Lilly And Co. Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/eli-lilly-and-co-q4-profit-increases-beats-estimates-1033034264
2894.0,2/6/2024 1:03:29 PM,Eli Lilly Guides FY24 Revenues Above Estimates - Update ,RTTNews,/news/stocks/eli-lilly-guides-fy24-revenues-above-estimates-update-1033034314
2895.0,2/6/2024 2:15:00 PM,"6 stocks to watch on Tuesday: Spotify, Eli Lilly, Chipotle, DocuSign and more",Seeking Alpha,https://seekingalpha.com/news/4063134-6-stocks-to-watch-on-tuesday-spotify-eli-lilly-chipotle-docusign-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2896.0,2/6/2024 2:55:15 PM,"Biggest stock movers today: DocuSign, BP, Palantir Technologies, and more",Seeking Alpha,https://seekingalpha.com/news/4062976-biggest-stock-movers-today-palantir-technologies-chegg-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2897.0,2/6/2024 3:06:14 PM,Eli Lilly Q4 Results Top Estimates ,RTTNews,/news/stocks/eli-lilly-q4-results-top-estimates-1033035398
2898.0,2/6/2024 5:58:10 PM,Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy,Seeking Alpha,https://seekingalpha.com/news/4063338-nash-drug-developers-drop-trial-win-lilly-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2899.0,2/6/2024 6:23:49 PM,Lilly reportedly worried about impact of Catalent/Novo deal,Seeking Alpha,https://seekingalpha.com/news/4063363-lilly-reportedly-worried-about-impact-of-catalent-novo-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2900.0,2/6/2024 7:48:01 PM,"Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks",InvestorPlace,/news/stocks/eli-lilly-novo-nordisk-could-be-first-trillion-dollar-drug-stocks-1033036679
2901.0,2/6/2024 8:24:05 PM,"Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?",Benzinga,/news/etf/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-what-s-driving-markets-tuesday-1033036589
2902.0,2/6/2024 8:33:01 PM,"Move Over, Tesla: 5 Stocks That Could Take Its Place in the Magnificent Seven",InvestorPlace,/news/stocks/move-over-tesla-5-stocks-that-could-take-its-place-in-the-magnificent-seven-1033036706
2903.0,2/6/2024 9:16:24 PM,Catalent ticks lower amid report Indiana plant may have quality issues,Seeking Alpha,https://seekingalpha.com/news/4063443-catalent-ticks-lower-amid-report-indiana-plant-may-have-quality-issues?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2904.0,2/6/2024 9:31:15 PM,The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition,InvestorPlace,/news/stocks/the-top-25-stocks-to-buy-immediately-according-to-ai-february-2024-edition-1033036939
2905.0,2/7/2024 4:15:53 AM,Wells Fargo Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-remains-a-buy-on-eli-lilly-co-lly-1033039021
2906.0,2/7/2024 10:15:43 AM,Eli Lilly & Co.: A Balanced Outlook with Hold Rating Amid Growth and Uncertainties,TipRanks,/news/stocks/eli-lilly-co-a-balanced-outlook-with-hold-rating-amid-growth-and-uncertainties-1033040694
2907.0,2/7/2024 10:21:13 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Impedimed Limited (OtherIPDQF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-exelixis-exel-and-impedimed-limited-otheripdqf-1033040645
2908.0,2/7/2024 12:21:04 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Exelixis (EXEL),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-exelixis-exel-1033041729
2909.0,2/7/2024 1:37:02 PM,Eli Lilly: Strong Q4 Performance and Promising Tirzepatide Trials Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-strong-q4-performance-and-promising-tirzepatide-trials-justify-buy-rating-1033042113
2910.0,2/7/2024 2:34:00 PM,Amgen cut at Leerink on heavy obesity expectations,Seeking Alpha,https://seekingalpha.com/news/4063851-amgen-stock-cut-leerink-obesity-prospects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2911.0,2/7/2024 8:49:42 PM,"Analysts Boost Eli Lilly's Forecast With High Hopes On Mounjaro, Zepbound Performance",Benzinga,/news/stocks/analysts-boost-eli-lilly-s-forecast-with-high-hopes-on-mounjaro-zepbound-performance-1033042624
2912.0,2/7/2024 10:43:49 PM,EU drug regulators to assess potential impact of Catalent-Novo merger,Seeking Alpha,https://seekingalpha.com/news/4064289-eu-drug-regulators-to-assess-potential-impact-of-catalent-novo-merger?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2913.0,2/8/2024 3:06:41 AM,"Apple, Chipotle And Eli Lilly Stocks Baffle Jim Cramer With Unusual Moves: 'Authentic Stupidity Is A Perfectly Plausible Explanation'",Benzinga,/news/stocks/apple-chipotle-and-eli-lilly-stocks-baffle-jim-cramer-with-unusual-moves-authentic-stupidity-is-a-perfectly-plausible-explanation-1033043234
2914.0,2/8/2024 12:41:07 PM,Foghorn says Eli Lilly picked lung cancer candidate for further studies,Seeking Alpha,https://seekingalpha.com/news/4064506-foghorn-stock-gains-eli-lilly-picks-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2915.0,2/8/2024 6:15:00 PM,The 3 Most Undervalued Biotech Stocks to Buy in February 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-february-2024-1033047922
2916.0,2/8/2024 10:33:09 PM,"S&P 500 Hits 5,000 Milestone, Yet Concerns Of Overvaluation Versus Its Equal-Weight Counterpart Mount",Benzinga,/news/etf/s-p-500-hits-5-000-milestone-yet-concerns-of-overvaluation-versus-its-equal-weight-counterpart-mount-1033048271
2917.0,2/9/2024 3:39:53 PM,Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies,Benzinga,/news/stocks/is-tesla-still-a-magnificent-7-stock-ev-maker-could-get-bumped-by-these-companies-1033051308
2918.0,2/9/2024 4:25:25 PM,Eli Lilly & Co: Strong Growth Trajectory Prompts Buy Rating and Raised EPS Forecasts Through 2030,TipRanks,/news/stocks/eli-lilly-co-strong-growth-trajectory-prompts-buy-rating-and-raised-eps-forecasts-through-2030-1033052408
2919.0,2/9/2024 5:20:31 PM,3 Stocks to Sell Immediately Before the Bubble Bursts: February 2024,InvestorPlace,/news/stocks/3-stocks-to-sell-immediately-before-the-bubble-bursts-february-2024-1033052201
2920.0,2/9/2024 6:21:35 PM,AstraZeneca looking to ramp up in-house production amid Catalent deal,Seeking Alpha,https://seekingalpha.com/news/4065249-astrazeneca-looking-to-ramp-up-in-house-production-amid-catalent-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2921.0,2/9/2024 6:39:14 PM,FTC likely to look at Catalent alternatives in review of Novo deal - report,Seeking Alpha,https://seekingalpha.com/news/4065255-ftc-likely-to-look-at-catalent-alternatives-in-review-of-novo-deal-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2922.0,2/9/2024 10:08:19 PM,"S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets",Benzinga,/news/etf/s-p-500-hits-5-000-magnificent-7-tops-13-trillion-commercial-real-estate-cracks-emerge-the-week-in-the-markets-1033052503
2923.0,2/10/2024 9:16:57 AM,Eli Lilly Secures $6 Billion in Underwritten Notes,TipRanks,/news/stocks/eli-lilly-secures-6-billion-in-underwritten-notes-1033052803
2924.0,2/11/2024 5:00:03 PM,Booming weight-loss drug market to lift “pick-and-shovel” plays: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4065355-weight-loss-drug-market-lifts-pick-and-shovel-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2925.0,2/12/2024 1:41:44 PM,Novo Nordisk’s parent eyes $7B annual investments by 2030: FT,Seeking Alpha,https://seekingalpha.com/news/4065481-novo-nordisks-parent-eyes-7b-annual-investments-2030?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2926.0,2/12/2024 3:32:46 PM,Coca-Cola Q4 earnings ahead: Will the beverage giant continue to fizz?,Seeking Alpha,https://seekingalpha.com/news/4065558-coca-cola-q4-earnings-ahead-will-the-beverage-giant-continue-to-fizz?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2927.0,2/12/2024 8:55:20 PM,"Eli Lilly's Weight Loss Drug Tirzepatide Is Expanding Market Share, Analyst Outlines What Lies Ahead (CORRECTED)",Benzinga,/news/stocks/eli-lilly-s-weight-loss-drug-tripeptide-is-expanding-market-share-analyst-outlines-what-lies-ahead-1033058372
2928.0,2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2929.0,2/13/2024 10:36:01 AM,Eli Lilly’s Tirzepatide Poised for Success: Buy Rating Affirmed Amid Anticipated Clinical Advancements,TipRanks,/news/stocks/eli-lilly-s-tirzepatide-poised-for-success-buy-rating-affirmed-amid-anticipated-clinical-advancements-1033060981
2930.0,2/13/2024 10:43:53 AM,Eli Lilly & Co (LLY) Receives a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-jefferies-1033061078
2931.0,2/13/2024 6:07:35 PM,Eli Lilly partner BioAge wins $170M to study Zepbound combo,Seeking Alpha,https://seekingalpha.com/news/4066258-eli-lilly-partner-bioage-wins-170m-zepbound-combo-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2932.0,2/13/2024 8:07:53 PM,Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report,InvestorPlace,/news/stocks/kerrisdale-capital-slams-altimmune-alt-stock-in-new-short-report-1033062803
2933.0,2/14/2024 7:43:49 PM,7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution,InvestorPlace,/news/stocks/7-must-buy-pharma-stocks-amid-the-weight-loss-drug-revolution-1033068096
2934.0,2/15/2024 12:53:06 PM,Eli Lilly obesity therapy tirzepatide being rolled out in the U.K.,Seeking Alpha,https://seekingalpha.com/news/4067537-eli-lilly-obesity-therapy-launched-uk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2935.0,2/15/2024 3:38:38 PM,Meet the Next Trillion-Dollar Companies: Our Top 7 Picks,InvestorPlace,/news/stocks/meet-the-next-trillion-dollar-companies-our-top-7-picks-1033072617
2936.0,2/16/2024 12:15:34 PM,Could Eli Lilly be the first $1T biopharma stock? Morgan Stanley asks,Seeking Alpha,https://seekingalpha.com/news/4068101-could-eli-lilly-be-first-1t-biopharma-morgan-stanley?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2937.0,2/16/2024 3:29:22 PM,Novartis aiming to develop next-generation weight-loss drugs,Seeking Alpha,https://seekingalpha.com/news/4068274-novartis-aiming-to-develop-next-generation-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2938.0,2/16/2024 5:13:28 PM,My Top 3 Stock Candidates to Replace Tesla in the Magnificent 7,InvestorPlace,/news/stocks/my-top-3-stock-candidates-to-replace-tesla-in-the-magnificent-7-1033077042
2939.0,2/16/2024 5:34:51 PM,Viking Therapeutics gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4068347-viking-therapeutics-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2940.0,2/18/2024 11:29:58 PM,Weight-loss drugs cut grocery bills by up to 9% - Morgan Stanley,Seeking Alpha,https://seekingalpha.com/news/4068526-weight-loss-drugs-cut-grocery-bill-by-up-to-9-percent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2941.0,2/19/2024 11:21:00 AM,3 Stocks Primed to Reach Trillion-Dollar Valuation,InvestorPlace,/news/stocks/3-stocks-primed-to-reach-trillion-dollar-valuation-1033079746
2942.0,2/20/2024 4:39:42 AM,"LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?",TipRanks,/news/stocks/lly-cvs-exas-which-strong-buy-rated-healthcare-stock-is-the-better-buy-1033081825
2943.0,2/20/2024 6:54:06 PM,Top 7 Contenders to Join the Trillion-Dollar Club,InvestorPlace,/news/stocks/top-7-contenders-to-join-the-trillion-dollar-club-1033084666
2944.0,2/20/2024 8:36:00 PM,3 Cheap Dividend Stocks to Snatch Up Now,InvestorPlace,/news/stocks/3-cheap-dividend-stocks-to-snatch-up-now-1033085289
2945.0,2/20/2024 8:45:00 PM,3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024,InvestorPlace,/news/stocks/3-top-sectors-investment-dollars-are-pouring-into-now-february-2024-1033084786
2946.0,2/21/2024 2:02:21 PM,"Jazz Pharma Names Eli Lilly's Philip Johnson CFO, Effective March 1 ",RTTNews,/news/stocks/jazz-pharma-names-eli-lilly-s-philip-johnson-cfo-effective-march-1-1033087458
2947.0,2/21/2024 4:26:20 PM,Ventyx surges as Piper highlights potential against obesity,Seeking Alpha,https://seekingalpha.com/news/4069678-ventyx-stock-surges-piper-cites-obesity-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2948.0,2/21/2024 6:02:57 PM,Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7,Benzinga,/news/stocks/health-care-becomes-most-overweighted-sector-as-hedge-funds-crowd-into-magnificent-7-1033089072
2949.0,2/21/2024 7:03:43 PM,3 Stocks With the Potential to Knock Tesla Out of the Magnificent 7,InvestorPlace,/news/stocks/3-stocks-with-the-potential-to-knock-tesla-out-of-the-magnificent-7-1033089430
2950.0,2/21/2024 7:32:41 PM,Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for February 2024,InvestorPlace,/news/stocks/wall-street-favorites-7-growth-stocks-with-strong-buy-ratings-for-february-2024-1033089466
2951.0,2/22/2024 7:41:34 PM,Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/4070545-obesity-drugs-expand-us-gdp-goldman-sachs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2952.0,2/23/2024 11:01:36 AM,"Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Eli Lilly & Co (LLY) and Irhythm Technologies (IRTC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-c4-therapeutics-cccc-eli-lilly-co-lly-and-irhythm-technologies-irtc-1033097545
2953.0,2/23/2024 1:30:26 PM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Icon (ICLR)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-icon-iclr-1033098488
2954.0,2/23/2024 4:49:56 PM,Weight Watchers weighed down by fallout from 'GLP-1 House' - report,Seeking Alpha,https://seekingalpha.com/news/4069831-weight-watchers-weighed-down-fallout-from-glp-1-house?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2955.0,2/25/2024 5:00:00 PM,Radiopharmaceutical market expected to reach ~$14B by 2032,Seeking Alpha,https://seekingalpha.com/news/4071376-radiopharmaceutical-market-reach-14b-by-2032?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2956.0,2/26/2024 8:50:36 AM,"Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Bausch + Lomb Corporation (BLCO) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-idexx-laboratories-idxx-bausch-+-lomb-corporation-blco-and-eli-lilly-co-lly-1033101988
2957.0,2/26/2024 11:55:00 AM,3 Highly Rated Biotech Stocks to Buy for 300% Gains,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-to-buy-for-300-gains-1033102093
2958.0,2/26/2024 12:30:21 PM,"Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-c4-therapeutics-cccc-halozyme-halo-and-eli-lilly-co-lly-1033103492
2959.0,2/26/2024 4:29:29 PM,3 Top Pharma Stocks for Investors Betting on a Biotech Boom,InvestorPlace,/news/stocks/3-top-pharma-stocks-for-investors-betting-on-a-biotech-boom-1033103696
2960.0,2/26/2024 5:31:36 PM,"Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors",Benzinga,/news/etf/eli-lilly-novo-nordisk-s-strategies-against-new-weight-loss-drug-competitors-1033103712
2961.0,2/26/2024 7:10:07 PM,Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now,InvestorPlace,/news/stocks/future-juggernauts-the-next-7-trillion-dollar-companies-to-buy-now-1033104208
2962.0,2/26/2024 7:12:31 PM,The 3 Hottest Healthcare ETFs to Buy in 2024,InvestorPlace,/news/stocks/the-3-hottest-healthcare-etfs-to-buy-in-2024-1033104224
2963.0,2/26/2024 7:25:33 PM,"Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs",Benzinga,/news/stocks/amgen-s-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-goldman-sachs-1033104128
2964.0,2/27/2024 1:11:23 PM,Viking Therapeutics surges 80% on phase 2 obesity drug results,Seeking Alpha,https://seekingalpha.com/news/4072194-viking-therapeutics-surges-80-phase-2-obesity-drug-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2965.0,2/27/2024 1:52:11 PM,"Novo Nordisk, Lilly fall premarket on Viking's obesity drug gains",Seeking Alpha,https://seekingalpha.com/news/4072227-novo-nordisk-lilly-fall-premarket-viking-obesity-drug-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2966.0,2/27/2024 2:10:06 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-day-one-biopharmaceuticals-dawn-eli-lilly-co-lly-and-sanofi-othersnynf-1033108809
2967.0,2/27/2024 2:19:00 PM,"4 stocks to watch on Tuesday: Viking Therapeutics, Macy's and more",Seeking Alpha,https://seekingalpha.com/news/4072259-4-stocks-to-watch-on-tuesday-viking-therapeutics-macys-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2968.0,2/27/2024 5:24:52 PM,Eli Lilly talks with Viking Therapeutics may have stalled - report,Seeking Alpha,https://seekingalpha.com/news/4072391-eli-lilly-talks-with-viking-therapeutics-may-have-stalled-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2969.0,2/27/2024 5:45:21 PM,Beam stock jumps as Eli Lilly deal drives Q4 beat,Seeking Alpha,https://seekingalpha.com/news/4072415-beam-stock-jumps-as-eli-lilly-deal-brings-q4-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2970.0,2/27/2024 6:22:55 PM,Stock Spotlight: 3 Picks ChatGPT Urges You Not to Miss,InvestorPlace,/news/stocks/stock-spotlight-3-picks-chatgpt-urges-you-not-to-miss-1033109018
2971.0,2/27/2024 6:34:20 PM,Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect,Benzinga,/news/stocks/beyond-tech-and-ai-why-the-sector-hedge-funds-prefer-is-not-the-one-you-d-expect-1033108902
2972.0,2/27/2024 9:00:02 PM,"Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end",Seeking Alpha,https://seekingalpha.com/news/4072568-waters-moderna-most-shorted-stocks-in-sp-500-health-sector-till-jan-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2973.0,2/27/2024 9:06:43 PM,"BMO starts Korro at outperform, cites upcoming data for AATD drug",Seeking Alpha,https://seekingalpha.com/news/4072585-bmo-starts-korro-at-outperform-cites-upcoming-data-for-aatd-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2974.0,2/28/2024 8:40:26 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ligand Pharma (LGND), Agilent (A) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ligand-pharma-lgnd-agilent-a-and-eli-lilly-co-lly-1033112061
2975.0,2/28/2024 10:38:13 AM,Eli Lilly Maintains Strong Market Position Despite Viking’s Phase 2 Data: A Buy Rating,TipRanks,/news/stocks/eli-lilly-maintains-strong-market-position-despite-viking-s-phase-2-data-a-buy-rating-1033112663
2976.0,2/28/2024 11:51:11 AM,Beam reverses gains after mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/4072881-beam-stock-slips-mixed-shelf-offering?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2977.0,2/28/2024 12:40:51 PM,"Analysts’ Top Healthcare Picks: Alphatec Holdings (ATEC), PROCEPT BioRobotics (PRCT)",TipRanks,/news/stocks/analysts-top-healthcare-picks-alphatec-holdings-atec-procept-biorobotics-prct-1033113823
2978.0,2/28/2024 1:50:24 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Radnet (RDNT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-radnet-rdnt-1033114205
2979.0,2/28/2024 6:05:35 PM,"Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say",Benzinga,/news/stocks/viking-therapeutics-weight-loss-study-data-outperformed-novo-nordisk-eli-lilly-studies-analysts-say-1033114321
2980.0,2/28/2024 10:20:55 PM,Stock Splits Watch: 3 Likely Candidates to Keep on Your Radar in 2024,InvestorPlace,/news/stocks/stock-splits-watch-3-likely-candidates-to-keep-on-your-radar-in-2024-1033115164
2981.0,2/29/2024 2:34:38 PM,NeuroBo stock jumps 14% on weight-loss drug update,Seeking Alpha,https://seekingalpha.com/news/4073921-neurobo-stock-jumps-on-weight-loss-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2982.0,2/29/2024 8:23:07 PM,5 Investors Betting Big on Weight Watchers (WW) Stock as Oprah Backs Out,InvestorPlace,/news/stocks/5-investors-betting-big-on-weight-watchers-ww-stock-as-oprah-backs-out-1033120364
2983.0,2/29/2024 11:00:45 PM,Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit),Benzinga,/news/stocks/top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-here-s-what-investors-think-about-them-wall-street-vs-reddit-1033120683
2984.0,3/1/2024 11:33:35 AM,"Over a billion people worldwide living with obesity, study finds",Seeking Alpha,https://seekingalpha.com/news/4074466-over-a-billion-people-worldwide-living-with-obesity-study-finds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2985.0,3/1/2024 11:40:24 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033123671
2986.0,3/1/2024 12:30:00 PM,The Hot List: 3 AI Stocks Worth Buying on Weakness,InvestorPlace,/news/stocks/the-hot-list-3-ai-stocks-worth-buying-on-weakness-1033123124
2987.0,3/1/2024 1:19:15 PM,Eli Lilly gains as Bank of America renews bullish narrative,Seeking Alpha,https://seekingalpha.com/news/4074523-lilly-stock-gains-bank-of-america-raises-target?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2988.0,3/1/2024 2:03:00 PM,"4 stocks to watch on Friday: Plug Power, Eli Lilly and more",Seeking Alpha,https://seekingalpha.com/news/4074559-4-stocks-to-watch-on-friday-plug-power-eli-lilly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2989.0,3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2990.0,3/1/2024 9:02:26 PM,A Closer Look at 18 Analyst Recommendations For Eli Lilly and Co,Benzinga,/news/stocks/a-closer-look-at-18-analyst-recommendations-for-eli-lilly-and-co-1033125113
2991.0,3/1/2024 9:45:00 PM,"Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets",Benzinga,/news/stocks/eli-lilly-s-commercial-moat-competitor-landscape-bofa-emphasizes-strength-in-incretin-space-undervalued-assets-1033125178
2992.0,3/1/2024 10:05:12 PM,"Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla",Benzinga,/news/etf/record-high-s-p-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-surpasses-tesla-1033125195
2993.0,3/2/2024 3:10:00 PM,The $1T club could soon have its first non-tech members: Berkshire Hathaway & Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/4074979-the-1t-club-could-soon-have-its-first-non-tech-members-berkshire-hathaway-eli-lilly?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2994.0,3/3/2024 7:08:04 PM,Biggest contributors and detractors to the S&P's run,Seeking Alpha,https://seekingalpha.com/news/4075016-biggest-contributors-and-detractors-to-the-sps-run?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2995.0,3/4/2024 12:30:45 PM,"Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Eli Lilly & Co (LLY) and 4D Molecular Therapeutics (FDMT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-y-mabs-therapeutics-ymab-eli-lilly-co-lly-and-4d-molecular-therapeutics-fdmt-1033129294
2996.0,3/4/2024 3:06:12 PM,It’s Time! 3 Dodgy Pharma Stocks to Sell in February,InvestorPlace,/news/stocks/its-time-3-dodgy-pharma-stocks-to-sell-in-february-1033129175
2997.0,3/4/2024 4:07:52 PM,Eli Lilly price target upped at UBS on GLP-1 survey,Seeking Alpha,https://seekingalpha.com/news/4075349-eli-lilly-price-target-upped-ubs-glp-1-survey?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2998.0,3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2999.0,3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3000.0,3/5/2024 12:30:03 PM,"Novo Nordisk slips, dialysis stocks gain after kidney disease data for Ozempic",Seeking Alpha,https://seekingalpha.com/news/4075853-novo-stock-lilly-stock-slip-ozempic-kidney-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3001.0,3/5/2024 6:02:26 PM,"Eli Lilly said to have tapped National Resilience, BSP for Zepbound production",Seeking Alpha,https://seekingalpha.com/news/4076137-eli-lilly-taps-national-resilience-bsp-make-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3002.0,3/5/2024 7:42:07 PM,Amphastar a new overweight at J.P. Morgan on diverse asset portfolio,Seeking Alpha,https://seekingalpha.com/news/4076207-amphastar-new-overweight-jp-morgan-diverse-asset-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3003.0,3/6/2024 4:31:43 PM,"Eli Lilly likely won't meet demand for weight loss, diabetes drugs in 2024",Seeking Alpha,https://seekingalpha.com/news/4076590-eli-lilly-likely-wont-meet-demand-weight-loss-diabetes-drugs-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3004.0,3/6/2024 6:12:14 PM,Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise,InvestorPlace,/news/stocks/trillion-dollar-threshold-the-next-3-stocks-ready-to-rise-1033139066
3005.0,3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3006.0,3/7/2024 11:43:36 AM,"Cigna in pact with Novo, Eli Lilly to widen obesity coverage",Seeking Alpha,https://seekingalpha.com/news/4077029-cigna-pact-novo-eli-lilly-widen-obesity-coverage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3007.0,3/7/2024 2:33:18 PM,Labcorp introduces weight loss management portfolio,Seeking Alpha,https://seekingalpha.com/news/4077193-labcorp-introduces-weight-loss-management-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3008.0,3/7/2024 2:34:17 PM,Novo Nordisk hits all-time high as oral obesity drug shows promising early results,Seeking Alpha,https://seekingalpha.com/news/4077048-novo-nordisk-stock-jumps-as-experimental-obesity-drug-shows-promising-early-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3009.0,3/7/2024 6:43:42 PM,The Top 3 ETFs to Buy in March 2024,InvestorPlace,/news/stocks/the-top-3-etfs-to-buy-in-march-2024-1033143692
3010.0,3/7/2024 10:45:00 PM,3 Stocks Mario Gabelli Is Betting on Big,InvestorPlace,/news/stocks/3-stocks-mario-gabelli-is-betting-on-big-1033144221
3011.0,3/8/2024 12:06:31 AM,Novo Nordisk expects Wegovy approval in China this year: report,Seeking Alpha,https://seekingalpha.com/news/4077511-novo-nordisk-expects-wegovy-approval-in-china-this-year-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3012.0,3/8/2024 10:21:53 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033146221
3013.0,3/8/2024 10:41:35 AM,"Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-rapt-therapeutics-rapt-eli-lilly-co-lly-and-sight-sciences-sght-1033146290
3014.0,3/8/2024 12:07:44 PM,Eli Lilly slips as FDA delays decision on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4077577-eli-lilly-stock-slips-fda-decision-alzheimers-drug-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3015.0,3/8/2024 1:20:04 PM,FDA Delays Decision On Lilly's Alzheimer's Drug ,RTTNews,/news/stocks/fda-delays-decision-on-lilly-s-alzheimer-s-drug-1033146031
3016.0,3/8/2024 2:25:22 PM,Eli Lilly & Co. Maintains Hold Rating Amidst Unexpected FDA Scrutiny on Alzheimer’s Drug Donanemab,TipRanks,/news/stocks/eli-lilly-co-maintains-hold-rating-amidst-unexpected-fda-scrutiny-on-alzheimer-s-drug-donanemab-1033147376
3017.0,3/8/2024 4:25:31 PM,Novo Nordisk sees launching new obesity drugs before Wegovy patent expires,Seeking Alpha,https://seekingalpha.com/news/4077692-novo-nordisk-sees-launching-new-obesity-drugs-before-wegovy-patent-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3018.0,3/8/2024 5:10:25 PM,Novo Nordisk not planning more supply chain acquisitions: report,Seeking Alpha,https://seekingalpha.com/news/4077703-novo-nordisk-not-planning-more-supply-chain-acquisitions-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3019.0,3/8/2024 7:28:57 PM,FDA approves Wegovy for reduction of cardiovascular risks,Seeking Alpha,https://seekingalpha.com/news/4077743-fda-approves-wegovy-for-reduction-of-cardiovascular-risks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3020.0,3/9/2024 6:00:00 PM,The Top 3 Pharma Stocks to Buy in March 2024,InvestorPlace,/news/stocks/the-top-3-pharma-stocks-to-buy-in-march2024-1033148079
3021.0,3/11/2024 2:02:22 AM,Lilly: Majority Of People With AD & Skin Of Color Experienced Skin Improvement In Lebrikizumab Study ,RTTNews,/news/stocks/lilly-majority-of-people-with-ad-skin-of-color-experienced-skin-improvement-in-lebrikizumab-study-1033148751
3022.0,3/11/2024 6:35:09 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033150000
3023.0,3/11/2024 9:53:32 AM,Eli Lilly eczema drug shows robust efficacy in people of color,Seeking Alpha,https://seekingalpha.com/news/4077872-eli-lilly-eczema-drug-shows-robust-efficacy-in-people-of-color?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3024.0,3/11/2024 11:10:33 AM,"Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ocuphire-pharma-ocup-merus-mrus-and-eli-lilly-co-lly-1033151121
3025.0,3/11/2024 11:40:36 AM,"Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-eli-lilly-co-lly-1033151280
3026.0,3/11/2024 5:22:56 PM,Eli Lilly Stock Drops 4% ,RTTNews,/news/stocks/eli-lilly-stock-drops-4-1033151956
3027.0,3/12/2024 5:11:55 PM,"Wedbush raises AnaptysBio to outperform, cites upcoming data",Seeking Alpha,https://seekingalpha.com/news/4078536-wedbush-raises-anaptysbio-to-outperform-cites-upcoming-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3028.0,3/12/2024 7:48:53 PM,Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers,Benzinga,/news/stocks/skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clinical-triggers-1033156516
3029.0,3/13/2024 6:40:07 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Axsome Therapeutics (AXSM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-axsome-therapeutics-axsm-1033158619
3030.0,3/13/2024 11:47:31 AM,Eli Lilly in pact with Amazon to deliver Zepbound and other medicines,Seeking Alpha,https://seekingalpha.com/news/4078790-eli-lilly-amazon-pharmacy-deliver-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3031.0,3/13/2024 1:26:44 PM,LLY Stock Alert: You Can Now Get Eli Lilly’s Weight Loss Drugs on Amazon,InvestorPlace,/news/stocks/lly-stock-alert-you-can-now-get-eli-lillys-weight-loss-drugs-on-amazon-1033159632
3032.0,3/13/2024 2:17:18 PM,Why Is MicroCloud Hologram (HOLO) Stock Up 31% Today?,InvestorPlace,/news/stocks/why-is-microcloud-hologram-holo-stock-up-31-today-1033159925
3033.0,3/13/2024 2:36:34 PM,Why Is Gaxos.ai (GXAI) Stock Up 134% Today?,InvestorPlace,/news/stocks/why-is-gaxos-ai-gxai-stock-up-134-today-1033160005
3034.0,3/13/2024 3:07:00 PM,Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio,InvestorPlace,/news/stocks/billionaires-biotech-bets-3-stocks-dominating-bill-gates-portfolio-1033161056
3035.0,3/13/2024 5:29:04 PM,Liver drug developers outperform as U.S. awaits first NASH drug,Seeking Alpha,https://seekingalpha.com/news/4079090-liver-drug-developers-gain-us-awaits-first-nash-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3036.0,3/13/2024 5:37:06 PM,Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks,Benzinga,/news/stocks/top-7-biotech-winners-of-novo-nordisk-eli-lilly-s-outsourcing-strategy-for-weight-loss-drugs-goldman-sachs-1033160762
3037.0,3/13/2024 7:30:57 PM,WW slumps amid report of lenders hiring lawyers for debt talks,Seeking Alpha,https://seekingalpha.com/news/4079134-ww-slumps-amid-report-of-report-lenders-hiring-lawyers-for-debt-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3038.0,3/13/2024 9:16:40 PM,Eli Lilly Strikes Deal With Amazon Pharmacy To Deliver Prescription Drugs ,RTTNews,/news/stocks/eli-lilly-strikes-deal-with-amazon-pharmacy-to-deliver-prescription-drugs-1033161271
3039.0,3/14/2024 10:50:00 AM,7 Delightful Dividend Stocks to Put Some Spring in Your Step,InvestorPlace,/news/stocks/7-delightful-dividend-stocks-to-put-some-spring-in-your-step-1033163248
3040.0,3/14/2024 11:20:30 AM,Biotech group backs anti-China bill; part ways with WuXi AppTec,Seeking Alpha,https://seekingalpha.com/news/4079392-biotech-group-backs-anti-china-bill-splits-wuxi-apptec?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3041.0,3/14/2024 1:45:32 PM,Is WW Stock on the Brink of Bankruptcy?,InvestorPlace,/news/stocks/is-ww-stock-on-the-brink-of-bankruptcy-1033164175
3042.0,3/14/2024 2:23:45 PM,7 Growth Stocks to Sell in March Before They Crash & Burn,InvestorPlace,/news/stocks/7-growth-stocks-to-sell-in-march-before-they-crash-burn-1033164348
3043.0,3/14/2024 3:44:36 PM,UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates,Seeking Alpha,https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3044.0,3/14/2024 7:45:17 PM,Madrigal granted FDA approval for NASH therapy,Seeking Alpha,https://seekingalpha.com/news/4079638-madrigal-stock-focus-fda-clears-nash-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3045.0,3/14/2024 10:49:54 PM,3 Pharma Stocks to Sell in March Before They Crash & Burn,InvestorPlace,/news/stocks/3-pharma-stocks-to-sell-in-march-before-they-crash-burn-1033165973
3046.0,3/14/2024 11:23:16 PM,Terns to report Phase 1 data on GLP-1 drug in 2H 2024,Seeking Alpha,https://seekingalpha.com/news/4079774-terns-to-report-phase-1-data-on-glp-1-drug-in-2h-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3047.0,3/15/2024 9:17:03 AM,Wells Fargo Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033167891
3048.0,3/15/2024 11:08:11 AM,Truist Financial Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033168311
3049.0,3/15/2024 12:15:00 PM,3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold,InvestorPlace,/news/stocks/3-weight-loss-stocks-to-buy-as-glp-1-mania-takes-hold-1033167937
3050.0,3/15/2024 12:19:55 PM,Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades,Seeking Alpha,https://seekingalpha.com/news/4079886-madrigal-stock-climbs-fda-nod-nash-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3051.0,3/15/2024 1:29:14 PM,"Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end",Seeking Alpha,https://seekingalpha.com/news/4079885-johnson-johnson-boston-scientific-least-shorted-stocks-in-sp-500-healthcare-sector-for-feb-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3052.0,3/15/2024 7:38:23 PM,Eli Lilly Zepbound prescriptions exceed Novo’s Wegovy for the first time in U.S.,Seeking Alpha,https://seekingalpha.com/news/4080150-eli-lilly-zepbound-prescriptions-exceed-novos-wegovy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3053.0,3/16/2024 4:57:30 PM,NASH drug market expected to surpass $48B by 2035,Seeking Alpha,https://seekingalpha.com/news/4080234-nash-drug-market-expected-top-48b-2035?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3054.0,3/16/2024 6:00:00 PM,The Trillion-Dollar Crystal Ball: 3 Companies Next in Line for the Market Milestone,InvestorPlace,/news/stocks/the-trillion-dollar-crystal-ball-3-companies-next-in-line-for-the-market-milestone-1033169865
3055.0,3/17/2024 5:00:00 PM,"The $1 Trillion Question: Will LLY, TSMC or TSLA Be Wall Street’s Next Nvidia?",InvestorPlace,/news/stocks/the-1-trillion-question-will-lly-tsmc-or-tsla-be-wall-streets-next-nvidia-1033170285
3056.0,3/17/2024 9:09:16 PM,Survey finds GLP-1 users more inclined to get aesthetic procedures,Seeking Alpha,https://seekingalpha.com/news/4080286-survey-finds-glp-1-users-more-inclined-to-get-aesthetic-procedures?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3057.0,3/18/2024 7:10:16 AM,"Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Eli Lilly & Co (LLY) and Globus Medical (GMED)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-hca-healthcare-hca-eli-lilly-co-lly-and-globus-medical-gmed-1033171716
3058.0,3/18/2024 4:17:28 PM,AstraZeneca to cap costs of inhalers at $35 per month,Seeking Alpha,https://seekingalpha.com/news/4080619-astrazeneca-to-cap-costs-of-inhalers-at-35-per-month?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3059.0,3/18/2024 5:31:24 PM,Oprah expected to endorse WeightWatchers Clinic on ABC special,Seeking Alpha,https://seekingalpha.com/news/4080683-oprah-expected-endorse-weightwatchers-clinic-abc-special?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3060.0,3/18/2024 8:10:58 PM,Wall Street’s Favorite Growth Stocks? 7 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-growth-stocks-7-names-that-could-make-you-filthy-rich-1033174061
3061.0,3/18/2024 9:45:43 PM,Inventiva Phase 2 study for MASH drug meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4080815-inventiva-phase-2-study-for-mash-drug-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3062.0,3/19/2024 12:19:47 PM,AstraZeneca-Fusion deal reignites radiopharma space,Seeking Alpha,https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3063.0,3/19/2024 2:55:15 PM,"Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'",Benzinga,/news/stocks/cramer-calls-datadog-dynamite-puts-sofi-in-dog-house-what-the-heck-is-going-on-1033176692
3064.0,3/19/2024 5:57:51 PM,What Retail Apocalypse? 7 Stocks Proving the Doomsayers Wrong.,InvestorPlace,/news/stocks/what-retail-apocalypse-7-stocks-proving-the-doomsayers-wrong-1033177900
3065.0,3/19/2024 9:07:51 PM,3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50,InvestorPlace,/news/stocks/3-juicy-stocks-serving-up-5-dividends-that-you-can-snag-for-50-1033178210
3066.0,3/20/2024 10:00:00 AM,3 Stocks Ready to Ride the Bull Higher,InvestorPlace,/news/stocks/3-stocks-ready-to-ride-the-bull-higher-1033179637
3067.0,3/20/2024 1:00:32 PM,Labcorp expands Alzheimer's testing portfolio with new diagnostic,Seeking Alpha,https://seekingalpha.com/news/4081545-labcorp-expands-alzheimers-test-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3068.0,3/20/2024 5:09:31 PM,Medicare coverage for obesity drugs could strain federal budget: CBO,Seeking Alpha,https://seekingalpha.com/news/4081689-weight-loss-drug-coverage-could-strain-federal-budget-cbo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3069.0,3/20/2024 5:38:58 PM,Wall Street’s Favorite Tech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-tech-stocks-3-names-that-could-make-you-filthy-rich-1033181883
3070.0,3/21/2024 10:25:00 AM,Amazon’s 1-2 Punch: AI-Powered Listings and Eli Lilly Deal Make AMZN a Must-Buy,InvestorPlace,/news/stocks/amazons-1-2-punch-ai-powered-listings-and-eli-lilly-deal-make-amzn-a-must-buy-1033183881
3071.0,3/21/2024 5:35:23 PM,Medicare expands coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4082299-medicare-expands-coverage-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3072.0,3/22/2024 11:10:32 AM,"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-dianthus-therapeutics-dnth-and-eli-lilly-co-lly-1033188793
3073.0,3/22/2024 1:41:41 PM,"Argus cuts Pfizer to hold, cites concerns about topline growth",Seeking Alpha,https://seekingalpha.com/news/4082673-argus-cuts-pfizer-to-hold-cites-concerns-about-topline-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3074.0,3/22/2024 9:07:27 PM,Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs,InvestorPlace,/news/stocks/hot-stocks-the-3-best-opportunities-for-investing-in-weight-loss-drugs-1033190216
3075.0,3/24/2024 7:41:46 PM,Hedge Funds Are Fleeing Tech: 7 Stocks They’re Buying Instead,InvestorPlace,/news/stocks/hedge-funds-are-fleeing-tech-7-stocks-theyre-buying-instead-1033191198
3076.0,3/25/2024 7:32:21 AM,Analysts Offer Insights on Healthcare Companies: Sotera Health (SHC) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sotera-health-shc-and-eli-lilly-co-lly-1033192497
3077.0,3/25/2024 10:00:00 AM,Amazon’s AI Awakening: Why AMZN Stock Is the Magnificent Seven’s Sleeping Giant,InvestorPlace,/news/stocks/amazons-ai-awakening-why-amzn-stock-is-the-magnificent-sevens-sleeping-giant-1033192426
3078.0,3/25/2024 2:05:49 PM,"Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'",Benzinga,/news/stocks/cramer-isn-t-knocking-this-pharma-firm-anymore-as-a-matter-of-fact-i-m-going-in-1033193181
3079.0,3/25/2024 7:00:00 PM,Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-biotech-stocks-3-names-that-could-make-you-filthy-rich-1033194514
3080.0,3/26/2024 11:37:54 AM,Viking Therapeutics gains on early data for oral weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4083623-viking-therapeutics-stock-gains-data-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3081.0,3/26/2024 3:43:00 PM,Biotech Roundtable: Is CRISPR all it's cracked up to be?,Seeking Alpha,https://seekingalpha.com/news/4083198-biotech-roundtable-is-crispr-all-its-cracked-up-to-be?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3082.0,3/26/2024 6:01:03 PM,Cytokinetics gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4083918-cytokinetics-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3083.0,3/26/2024 6:15:37 PM,Amazon reportedly leaning on weight loss frenzy to boost pharmacy unit,Seeking Alpha,https://seekingalpha.com/news/4083927-amazon-expects-weight-loss-frenzy-boost-pharmacy-unit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3084.0,3/27/2024 9:54:19 AM,The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months,InvestorPlace,/news/stocks/the-2025-double-3-stocks-poised-to-deliver-100-gains-in-just-12-months-1033200341
3085.0,3/27/2024 12:26:15 PM,Altimmune falls after Q4 results; obesity drug data released,Seeking Alpha,https://seekingalpha.com/news/4084241-altimmune-stock-falls-obesity-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3086.0,3/27/2024 12:36:10 PM,Eli Lilly & Co (LLY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-truist-financial-1033202073
3087.0,3/27/2024 6:59:41 PM,US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar,Benzinga,/news/etf/us-companies-in-japan-wary-on-market-intervention-as-yen-hits-34-year-low-vs-dollar-1033202545
3088.0,3/27/2024 9:02:39 PM,Sen. Sanders goes after Novo Nordisk on a study on Ozempic low manufacture cost,Seeking Alpha,https://seekingalpha.com/news/4084693-sanders-goes-after-novo-nordisk-study-ozempic-low-manufacture-cost?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3089.0,3/28/2024 2:00:53 PM,"CVS, Elevance Health to cover Novo Nordisk’s Wegovy: WSJ",Seeking Alpha,https://seekingalpha.com/news/4084965-cvs-elevance-cover-novo-nordisks-wegovy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3090.0,3/29/2024 10:40:00 AM,The 3 Best Biotech Stocks to Buy in Q2 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-q2-2024-1033208071
3091.0,3/30/2024 4:13:00 PM,Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues,Seeking Alpha,https://seekingalpha.com/news/4084974-eli-lilly-tops-the-growth-chart-for-the-sp-500-index-in-q1-as-the-sector-gains-momentum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3092.0,4/1/2024 3:00:49 PM,What Analysts Are Saying About Eli Lilly and Co Stock,Benzinga,/news/stocks/what-analysts-are-saying-about-eli-lilly-and-co-stock-1033210971
3093.0,4/2/2024 9:07:25 AM,Eli Lilly Poised for Market Dominance Amid Positive orforglipron Trial Results and Legislative Tailwinds,TipRanks,/news/stocks/eli-lilly-poised-for-market-dominance-amid-positive-orforglipron-trial-results-and-legislative-tailwinds-1033214650
3094.0,4/2/2024 10:00:00 AM,Buy Amazon Stock Now for Continued Growth and Diversification,InvestorPlace,/news/stocks/buy-amazon-stock-now-for-continued-growth-and-diversification-1033214034
3095.0,4/2/2024 11:34:50 AM,Verve drops after pausing trial enrollments for lead asset,Seeking Alpha,https://seekingalpha.com/news/4086152-verve-stock-drops-setback-lead-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3096.0,4/2/2024 4:13:19 PM,Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts,InvestorPlace,/news/stocks/merger-mania-3-potential-takeover-targets-to-watch-for-lucrative-buyouts-1033216143
3097.0,4/2/2024 5:39:43 PM,Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience,Benzinga,/news/stocks/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience-1033215940
3098.0,4/2/2024 8:30:04 PM,5 Healthcare Stocks to Buy for 2024,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-2024-1033216722
3099.0,4/2/2024 8:41:50 PM,"Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand",Benzinga,/news/stocks/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-leadership-and-expand-1033216480
3100.0,4/3/2024 9:40:11 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Glaukos (GKOS) and Omnicell (OMCL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-glaukos-gkos-and-omnicell-omcl-1033218769
3101.0,4/3/2024 11:01:03 AM,Novo’s Ozempic to face copycats as Chinese firm seeks biosimilar nod,Seeking Alpha,https://seekingalpha.com/news/4086664-novos-ozempic-face-biosimilar-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3102.0,4/3/2024 4:05:29 PM,Zepbound shortage: Eli Lilly's weight-loss drug in limited availability through April-end,Seeking Alpha,https://seekingalpha.com/news/4086918-zepbound-shortage-eli-lillys-weight-loss-drug-in-limited-availability-through-april-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3103.0,4/3/2024 8:09:31 PM,The 3 Best Healthcare Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-april-2024-1033220393
3104.0,4/3/2024 11:03:07 PM,"LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?",TipRanks,/news/stocks/lly-regn-bhvn-which-biotech-stock-offers-the-most-upside-1033220670
3105.0,4/4/2024 10:55:00 AM,7 A-Rated Stocks to Buy in April,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-in-april-1033221911
3106.0,4/4/2024 1:33:00 PM,3 Growth Stocks with Even Greater Potential Than the Magnificent 7,InvestorPlace,/news/stocks/3-growth-stocks-with-even-greater-potential-than-the-magnificent-7-1033222646
3107.0,4/4/2024 5:15:40 PM,"Baird puts Inspire on top idea list, sees limited impact by GLP-1s",Seeking Alpha,https://seekingalpha.com/news/4087357-baird-puts-inspire-on-top-idea-list-sees-limited-impact-by-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3108.0,4/4/2024 11:40:25 PM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), UnitedHealth (UNH)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-unitedhealth-unh-1033224162
3109.0,4/5/2024 6:24:15 PM,Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds,Benzinga,/news/stocks/wondering-where-to-find-an-over-7-annual-return-check-out-these-10-investment-grade-corporate-bonds-1033226605
3110.0,4/5/2024 9:58:39 PM,Lilly to record $111M pre-tax IPR&D charges in Q1,Seeking Alpha,https://seekingalpha.com/news/4087706-lilly-to-record-111m-pre-tax-iprd-charges-in-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3111.0,4/5/2024 10:23:33 PM,"Traders Rethink Interest Rate Cuts, Labor Market Heats Up, Oil Prices Quietly Reach 6-Month High: This Week In The Markets",Benzinga,/news/etf/traders-rethink-interest-rate-cuts-labor-market-heats-up-oil-prices-quietly-reach-6-month-high-this-week-in-the-markets-1033226941
3112.0,4/6/2024 4:20:25 AM,"Analysts’ Top Healthcare Picks: Pfizer (PFE), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-pfizer-pfe-eli-lilly-co-lly-1033227104
3113.0,4/8/2024 9:50:54 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Medtronic (MDT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-ionis-pharmaceuticals-ions-and-medtronic-mdt-1033229651
3114.0,4/8/2024 5:43:58 PM,ProfoundBio Discovers The Joys Of Having A Wealthy Owner,Benzinga,/news/stocks/profoundbio-discovers-the-joys-of-having-a-wealthy-owner-1033230521
3115.0,4/8/2024 7:11:44 PM,"EMA to discuss possible link between GLP-1s, suicidal thoughts: report",Seeking Alpha,https://seekingalpha.com/news/4088011-ema-to-discuss-possible-link-between-glp-1s-suicidal-thoughts-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3116.0,4/9/2024 11:00:00 AM,3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April,InvestorPlace,/news/stocks/3-high-growth-biotech-stocks-investors-shouldnt-sleep-on-in-april-1033232893
3117.0,4/9/2024 2:03:48 PM,Madrigal announces US launch of NASH/MASH drug Rezdiffra,Seeking Alpha,https://seekingalpha.com/news/4088257-madrigal-announces-us-launch-of-nashmash-drug-rezdiffra?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3118.0,4/9/2024 4:37:13 PM,"Cantor starts Structure at overweight, sees positive data for GLP-1 drug",Seeking Alpha,https://seekingalpha.com/news/4088314-cantor-starts-structure-at-overweight-sees-positive-data-for-glp-1-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3119.0,4/9/2024 5:06:07 PM,Eli Lilly launches construction of $2.5B plant to meet obesity drug demand,Seeking Alpha,https://seekingalpha.com/news/4088326-eli-lilly-eyes-25b-plant-make-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3120.0,4/9/2024 8:25:52 PM,MarketMasterAI’s Top 500 Stocks: April 2024,InvestorPlace,/news/stocks/marketmasterais-top-500-stocks-april-2024-1033234851
3121.0,4/10/2024 9:46:07 AM,Eli Lilly & Co: Strong Buy Rating on Robust ‘Diabesity’ Portfolio and Key Product Outperformance,TipRanks,/news/stocks/eli-lilly-co-strong-buy-rating-on-robust-diabesity-portfolio-and-key-product-outperformance-1033237131
3122.0,4/10/2024 6:56:07 PM,Top 10 best performing S&P 500 health care stocks of 2024,Seeking Alpha,https://seekingalpha.com/news/4088691-top-10-best-performing-sp-500-health-care-stocks-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3123.0,4/10/2024 7:41:00 PM,3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild,InvestorPlace,/news/stocks/3-obesity-drug-stocks-set-to-skyrocket-as-demand-goes-wild-1033238954
3124.0,4/10/2024 9:23:59 PM,Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies,Benzinga,/news/stocks/amphastar-pharmaceuticals-interested-in-potential-acquisitions-in-endocrinology-focused-companies-1033238698
3125.0,4/11/2024 7:22:29 AM,Roche's Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimer's Detection ,RTTNews,/news/stocks/roche-s-elecsys-ptau217-blood-test-receives-fda-breakthrough-designation-for-alzheimer-s-detection-1033239569
3126.0,4/11/2024 10:20:37 AM,"Roche, Eli Lilly gain FDA breakthrough device tag for Alzheimer's blood test",Seeking Alpha,https://seekingalpha.com/news/4088828-roche-eli-lilly-gain-fda-breakthrough-device-tag-for-alzheimers-blood-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3127.0,4/11/2024 7:55:19 PM,Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone,InvestorPlace,/news/stocks/trillion-dollar-trajectories-3-billion-dollar-stocks-with-the-potential-to-hit-the-next-milestone-1033242439
3128.0,4/11/2024 8:30:00 PM,Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-healthcare-stocks-with-strong-buy-ratings-for-april-2024-1033242568
3129.0,4/12/2024 10:25:00 AM,"Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027",InvestorPlace,/news/stocks/shed-the-fat-gain-the-profits-3-weight-loss-stocks-to-own-until-2027-1033243810
3130.0,4/12/2024 10:40:00 AM,7 A-Rated Aggressive Biotech Stocks to Bet On in 2024,InvestorPlace,/news/stocks/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024-1033243804
3131.0,4/12/2024 11:05:43 AM,"No link between weight loss drugs and suicidal thoughts, EU regulator concludes",Seeking Alpha,https://seekingalpha.com/news/4089182-no-link-weight-loss-drugs-suicidal-thoughts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3132.0,4/12/2024 4:02:53 PM,GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma,Seeking Alpha,https://seekingalpha.com/news/4089307-glp-1s-benefit-parkinsons-barclays-sees-biopharma-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3133.0,4/12/2024 5:17:44 PM,"Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in March",Seeking Alpha,https://seekingalpha.com/news/4089272-short-interest-in-sp-500-healthcare-sector-rises-lilly-least-shorted-industry-at-march-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3134.0,4/14/2024 9:56:08 PM,"Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down",Seeking Alpha,https://seekingalpha.com/news/4089446-needham-sees-bsx-cnmd-rmd-beating-street-despite-medtech-slow-down?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3135.0,4/15/2024 8:20:06 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), PolyPid (PYPD) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-hca-healthcare-hca-polypid-pypd-and-eli-lilly-co-lly-1033248808
3136.0,4/15/2024 6:19:53 PM,BTIG Research Predicts Over 118% Rally for These 3 Stocks,InvestorPlace,/news/stocks/btig-research-predicts-over-118-rally-for-these-3-stocks-1033250641
3137.0,4/16/2024 4:20:14 AM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), McKesson (MCK)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-mckesson-mck-1033251959
3138.0,4/16/2024 6:35:28 AM,Eli Lilly & Co: A Strong Buy on Robust Incretin Franchise Prospects and Positive Market Trends,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-incretin-franchise-prospects-and-positive-market-trends-1033252465
3139.0,4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3140.0,4/16/2024 4:23:16 PM,Bayer dethroned as Germany’s top drugmaker,Seeking Alpha,https://seekingalpha.com/news/4090165-bayer-beaten-top-german-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3141.0,4/16/2024 4:38:35 PM,Lexaria gets ethics board okay for oral GLP-1 study,Seeking Alpha,https://seekingalpha.com/news/4090172-lexaria-gets-ethics-board-okay-for-oral-glp-1-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3142.0,4/16/2024 5:19:09 PM,These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?,InvestorPlace,/news/stocks/these-3-biotech-stocks-are-up-269-in-2024-is-there-more-to-come-1033254629
3143.0,4/16/2024 8:25:01 PM,"Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades",Benzinga,/news/stocks/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-hidradenitis-suppurativa-market-analyst-upgrades-1033254721
3144.0,4/16/2024 8:59:57 PM,"Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration",Seeking Alpha,https://seekingalpha.com/news/4090270-eli-lilly-subsidiary-precision-biosciences-end-gene-therapy-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3145.0,4/17/2024 8:30:36 AM,3 Weight-Loss ETFs to Profit From the Obesity Drug Boom,InvestorPlace,/news/stocks/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom-1033256825
3146.0,4/17/2024 11:04:07 AM,Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder,Seeking Alpha,https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3147.0,4/17/2024 12:58:25 PM,Lilly's Tirzepatide To Treat Sleep Apnea Meets Primary Goals In Late-stage Studies ,RTTNews,/news/stocks/lilly-s-tirzepatide-to-treat-sleep-apnea-meets-primary-goals-in-late-stage-studies-1033257233
3148.0,4/17/2024 1:22:00 PM,"5 stocks to watch on Wednesday: LLY, ABT and more",Seeking Alpha,https://seekingalpha.com/news/4090463-5-stocks-to-watch-on-wednesday-lly-abt-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3149.0,4/17/2024 2:30:28 PM,Inspire Medical rebounds as J.P. Morgan defends after Lilly sleep data,Seeking Alpha,https://seekingalpha.com/news/4090500-inspire-medical-stock-spikes-jp-morgan-defends?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3150.0,4/17/2024 4:02:34 PM,"Eli Lilly's Mounjaro, Zepbound to remain in shortage through end of Q2",Seeking Alpha,https://seekingalpha.com/news/4090552-eli-lilly-mounjaro-zepbound-remain-shortage-through-end-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3151.0,4/17/2024 7:45:55 PM,Eli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea ,RTTNews,/news/stocks/eli-lilly-s-weight-loss-drug-zepbound-shows-promise-in-reducing-sleep-apnea-1033259201
3152.0,4/18/2024 9:32:38 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-zoetis-zts-and-tscan-therapeutics-tcrx-1033261988
3153.0,4/18/2024 10:00:59 AM,"Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-abbott-labs-abt-us-physical-therapy-usph-1033262193
3154.0,4/18/2024 11:20:37 AM,Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pacific-biosciences-pacb-and-eli-lilly-co-lly-1033262781
3155.0,4/18/2024 11:30:18 AM,"Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-inspire-medical-systems-insp-eli-lilly-co-lly-1033262875
3156.0,4/18/2024 12:20:54 PM,"Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-intra-cellular-therapies-itci-eli-lilly-co-lly-and-sanofi-othersnynf-1033263051
3157.0,4/18/2024 1:30:39 PM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-tg-therapeutics-tgtx-1033263410
3158.0,4/18/2024 2:23:15 PM,Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.,InvestorPlace,/news/stocks/want-to-double-your-tax-refund-in-2024-7-stocks-to-buy-now-1033262864
3159.0,4/19/2024 11:30:00 AM,Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now,InvestorPlace,/news/stocks/strong-buy-alert-7-no-brainer-stocks-to-scoop-up-now-1033265717
3160.0,4/19/2024 9:10:14 PM,Hepion ends Phase 2 study for NASH drug due to cash restraints,Seeking Alpha,https://seekingalpha.com/news/4091671-hepion-ends-phase-2-study-for-nash-drug-due-to-cash-restraints?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3161.0,4/21/2024 6:42:04 PM,Goldman picks top capex and R&D stocks,Seeking Alpha,https://seekingalpha.com/news/4091724-goldman-picks-top-capex-and-rd-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3162.0,4/22/2024 12:04:07 AM,13 new obesity drugs could hit the market by 2029 amid surging demand,Seeking Alpha,https://seekingalpha.com/news/4091726-13-new-obesity-drugs-could-hit-the-market-by-2029-amid-surging-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3163.0,4/22/2024 7:50:34 AM,Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbott-labs-abt-and-eli-lilly-co-lly-1033270364
3164.0,4/22/2024 2:35:45 PM,Eli Lilly buys injectable medicine manufacturing facility in Wisconsin,Seeking Alpha,https://seekingalpha.com/news/4091934-eli-lilly-buys-injectable-medicine-manufacturing-facility-in-wisconsin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3165.0,4/22/2024 5:43:04 PM,7 High-Flying Stocks That Are Majorly Overdue for a Pullback,InvestorPlace,/news/stocks/7-high-flying-stocks-that-are-majorly-overdue-for-a-pullback-1033272415
3166.0,4/23/2024 11:00:00 AM,3 Stocks With the Potential to Surpass Analyst Expectations for 2024,InvestorPlace,/news/stocks/3-stocks-with-the-potential-to-surpass-analyst-expectations-for-2024-1033275494
3167.0,4/23/2024 7:23:33 PM,TikTok to restrict weight loss drug promotion (updated),Seeking Alpha,https://seekingalpha.com/news/4092598-tiktok-restrict-weight-loss-drug-promotion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3168.0,4/24/2024 10:33:00 AM,3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains,InvestorPlace,/news/stocks/3-speculative-weight-loss-drug-stocks-to-bet-on-for-big-gains-1033280935
3169.0,4/24/2024 2:27:55 PM,3.6M Medicare patients could qualify for Wegovy coverage: report,Seeking Alpha,https://seekingalpha.com/news/4093197-36m-medicare-patients-could-qualify-for-wegovy-coverage-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3170.0,4/24/2024 6:51:49 PM,Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses,InvestorPlace,/news/stocks/which-companies-will-join-the-trillion-dollar-team-in-2024-our-3-best-guesses-1033283869
3171.0,4/24/2024 7:42:21 PM,Novo Nordisk comes under Senate probe over pricing for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4093539-novo-nordisk-senate-probe-wegovy-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3172.0,4/24/2024 10:40:03 PM,Surprise! These 3 Dividend Giants Are at 52-Week Lows. Buy Them Before They Soar,InvestorPlace,/news/stocks/surprise-these-3-dividend-giants-are-at-52-week-lows-buy-them-before-they-soar-1033284469
3173.0,4/25/2024 10:04:00 AM,Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List,InvestorPlace,/news/stocks/dont-miss-out-3-top-tier-blue-chip-growth-stocks-for-your-must-buy-list-1033286956
3174.0,4/25/2024 4:07:32 PM,Dividend Legends: 3 Stocks With Over 100 Years of Payouts,InvestorPlace,/news/stocks/dividend-legends-3-stocks-with-over-100-years-of-payouts-1033289488
3175.0,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3176.0,4/26/2024 7:00:06 PM,"Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day",Seeking Alpha,https://seekingalpha.com/news/4094989-catalyst-watch-apple-earnings-viking-ipo-chinese-ev-deliveries-and-russell-indices-rank-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3177.0,4/26/2024 7:11:32 PM,More than half of the S&P 500 names that reported results this week beat top and bottom line - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095089-more-than-half-of-the-sp-500-names-that-reported-results-this-week-beat-top-and-bottom-line-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3178.0,4/28/2024 12:00:00 PM,"Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more",Seeking Alpha,https://seekingalpha.com/news/4094953-earnings-week-ahead-amazon-apple-pfizer-amd-qualcomm-coca-cola-starbucks-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3179.0,4/28/2024 2:34:47 PM,What do weight-loss drugs mean for the diet industry?,Seeking Alpha,https://seekingalpha.com/news/4095227-what-do-weight-loss-drugs-mean-for-the-diet-industry?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3180.0,4/29/2024 9:46:53 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033300080
3181.0,4/29/2024 3:01:13 PM,Eli Lilly and earnings: here's what to expect,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-quarter-earnings-preview-q1-1033300228
3182.0,4/29/2024 3:15:34 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4095553-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3183.0,4/29/2024 5:13:13 PM,Eli Lilly Q1 Earnings Preview: Weight loss therapies to drive quarterly growth,Seeking Alpha,https://seekingalpha.com/news/4095722-eli-lilly-q1-earnings-preview-weight-loss-therapies-to-drive-quarterly-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3184.0,4/30/2024 10:47:16 AM,"Eli Lilly Non-GAAP EPS of $2.58 beats by $0.09, revenue of $8.77B misses by $160M",Seeking Alpha,https://seekingalpha.com/news/4096067-eli-lilly-non-gaap-eps-of-2_58-beats-0_09-revenue-of-8_77b-misses-160m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3185.0,4/30/2024 11:03:41 AM,"Eli Lilly in charts: Mounjaro, Zepbound, Verzenio, and Jardiance drive revenue growth in Q1; Trulicity declines 26%",Seeking Alpha,https://seekingalpha.com/news/4096088-eli-lilly-in-charts-mounjaro-zepbound-verzenio-and-jardiance-drive-revenue-growth-in-q1-trulicity-declines-26?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3186.0,4/30/2024 11:31:21 AM,Eli Lilly raises guidance on weight loss momentum,Seeking Alpha,https://seekingalpha.com/news/4096119-eli-lilly-stock-gains-weight-loss-momentum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3187.0,4/30/2024 12:48:23 PM,"Eli Lilly And Co. Q1 Profit Increases, beats estimates",RTTNews,/news/stocks/eli-lilly-and-co-q1-profit-increases-beats-estimates-1033305281
3188.0,4/30/2024 1:02:03 PM,Eli Lilly Boosts FY24 Outlook - Update ,RTTNews,/news/stocks/eli-lilly-boosts-fy24-outlook-update-1033305347
3189.0,4/30/2024 1:18:00 PM,"5 stocks to watch on Tuesday: KO, MCD, AMZN and more",Seeking Alpha,https://seekingalpha.com/news/4096254-5-stocks-to-watch-on-tuesday-ko-mcd-amzn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3190.0,4/30/2024 1:30:01 PM,Bank of America Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1033308261
3191.0,4/30/2024 1:32:37 PM,"Analysts’ Top Healthcare Picks: Qiagen (QGEN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-qiagen-qgen-eli-lilly-co-lly-1033308254
3192.0,4/30/2024 2:41:18 PM,"Biggest stock movers today: LLY, NXPI, MSTR, ST, and more",Seeking Alpha,https://seekingalpha.com/news/4095999-biggest-stock-movers-today-nxpi-mstr-st-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3193.0,4/30/2024 2:53:01 PM,"LLY Stock Earnings: Eli Lilly Beats EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/lly-stock-earnings-eli-lilly-for-q1-of-2024-1033307499
3194.0,4/30/2024 7:35:14 PM,"Stocks Dive On Fears Of Hawkish Fed; Treasury Yields Rise, Bitcoin Tumbles To $60,000: What's Driving Markets Tuesday?",Benzinga,/news/stocks/stocks-dive-on-fears-of-hawkish-fed-treasury-yields-rise-bitcoin-tumbles-to-60-000-what-s-driving-markets-tuesday-1033308411
3195.0,4/30/2024 9:11:33 PM,"Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs",Benzinga,/news/stocks/goldman-scrutinizes-hits-misses-and-growth-trajectory-concerns-for-eli-lilly-and-its-its-obesity-and-diabetes-drugs-1033308604
3196.0,5/1/2024 10:01:13 AM,"Pfizer plans direct-to-consumer platform to sell Covid, migraine drugs - report",Seeking Alpha,https://seekingalpha.com/news/4097035-pfizer-plans-direct-to-consumer-platform-to-sell-covid-migraine-drugs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3197.0,5/1/2024 10:14:21 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033313537
3198.0,5/1/2024 10:42:18 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-exelixis-exel-and-zynex-zyxi-1033313579
3199.0,5/1/2024 10:50:23 AM,"Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-10x-genomics-txg-axonics-modulation-technologies-axnx-and-eli-lilly-co-lly-1033313676
3200.0,5/1/2024 11:15:39 AM,Truist Financial Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-eli-lilly-co-lly-1033314141
3201.0,5/1/2024 2:47:16 PM,3 Healthcare Stocks With the Potential to Triple Your Investment by 2026,InvestorPlace,/news/stocks/3-healthcare-stocks-with-the-potential-to-triple-your-investment-by-2026-1033314236
3202.0,5/1/2024 3:59:48 PM,Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge,InvestorPlace,/news/stocks/stock-market-crash-alert-3-must-buy-biotech-stocks-when-prices-plunge-1033314585
3203.0,5/1/2024 4:01:09 PM,What 23 Analyst Ratings Have To Say About Eli Lilly and Co,Benzinga,/news/stocks/what-23-analyst-ratings-have-to-say-about-eli-lilly-and-co-1033313991
3204.0,5/1/2024 4:38:01 PM,Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.,InvestorPlace,/news/stocks/stock-market-crash-warning-dont-get-caught-holding-these-3-consumer-stocks-1033314760
3205.0,5/1/2024 5:41:56 PM,Profit from the Panic: 3 Stocks to Pounce on When They Become Steals,InvestorPlace,/news/stocks/profit-from-the-panic-3-stocks-to-pounce-on-when-they-become-steals-1033314988
3206.0,5/1/2024 7:36:03 PM,Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers),InvestorPlace,/news/stocks/q1-earnings-seasons-picks-pans-the-4-biggest-stock-winners-and-3-losers-1033315221
3207.0,5/1/2024 9:26:50 PM,"Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'",Benzinga,/news/stocks/eli-lilly-on-its-way-to-1-trillion-market-cap-analysts-say-it-s-a-have-in-a-sea-of-have-nots-1033315206
3208.0,5/2/2024 6:31:05 AM,Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tandem-diabetes-care-tndm-and-eli-lilly-co-lly-1033318536
3209.0,5/2/2024 8:11:57 AM,"Novo Nordisk lifts guidance as Ozempic, Wegovy sales surge; but stock falls 3%",Seeking Alpha,https://seekingalpha.com/news/4098171-novo-nordisk-stock-guidance-earnings-weight-loss-drug-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3210.0,5/2/2024 1:17:44 PM,"Novo Nordisk says prices dropping for Wegovy, Ozempic: report",Seeking Alpha,https://seekingalpha.com/news/4098574-novo-nordisk-says-prices-dropping-for-wegovy-ozempic-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3211.0,5/2/2024 1:58:32 PM,"GLP-1 drug prices falling at UK pharmacies, clinics: report",Seeking Alpha,https://seekingalpha.com/news/4098637-glp-1-drug-prices-falling-at-uk-pharmacies-clinics-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3212.0,5/2/2024 2:00:00 PM,3 Stocks Gunning for Trillion-Dollar Status: The Players to Own Now,InvestorPlace,/news/stocks/3-stocks-gunning-for-trillion-dollar-status-the-players-to-own-now-1033320626
3213.0,5/2/2024 6:31:50 PM,Radiopharma stocks higher as sector welcomes the latest M&A deal,Seeking Alpha,https://seekingalpha.com/news/4099035-novartis-mariana-oncology-deal-drives-radiopharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3214.0,5/2/2024 7:10:06 PM,Palatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatide,Seeking Alpha,https://seekingalpha.com/news/4099046-palatin-stock-spikes-fda-clears-obesity-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3215.0,5/2/2024 9:40:21 PM,"Amgen stock rallies 13% amid weight-loss drug updates, tweaked guidance",Seeking Alpha,https://seekingalpha.com/news/4099298-amgen-stock-rallies-on-weight-loss-drug-updates-tweaked-guidanace?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3216.0,5/3/2024 2:28:54 PM,Amgen stock rallies 13% on GLP-1 weight-loss drug update,Seeking Alpha,https://seekingalpha.com/news/4099749-amgen-stock-rallies-on-glp-1-weight-loss-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3217.0,5/3/2024 6:39:42 PM,3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030,InvestorPlace,/news/stocks/3-under-the-radar-stocks-that-could-be-worth-over-1-trillion-by-2030-1033328193
3218.0,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3219.0,5/4/2024 8:47:00 PM,16 out of 24 health care companies beat topline numbers this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4099757-16-out-of-24-health-care-companies-beat-topline-numbers-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3220.0,5/5/2024 8:08:00 PM,About 79% of the S&P 500 names beat on EPS during the busiest week of Q1 reporting - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4099902-about-79-of-the-sp-500-names-beat-on-eps-during-the-busiest-week-of-q1-reporting-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3221.0,5/6/2024 8:37:45 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033332480
3222.0,5/6/2024 3:38:47 PM,Eli Lilly declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/4100436-eli-lilly-declares-130-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3223.0,5/6/2024 6:30:17 PM,3 Biotech Stocks to Double Your Money in the Next 24 Months,InvestorPlace,/news/stocks/3-biotech-stocks-to-double-your-money-in-the-next-24-months-1033334986
3224.0,5/7/2024 1:38:29 PM,Eli Lilly Alzheimer’s therapy set for June FDA AdCom meeting,Seeking Alpha,https://seekingalpha.com/news/4101160-eli-lilly-alzheimers-drug-set-june-fda-adcom?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3225.0,5/7/2024 5:24:47 PM,Fresenius down 6% despite bottom-line beat,Seeking Alpha,https://seekingalpha.com/news/4101564-fresenius-down-6-despite-bottom-line-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3226.0,5/7/2024 5:28:03 PM,FDA Advisory Committee To Convene Meeting To Discuss On Eli Lilly's Alzheimer's Drug ,RTTNews,/news/stocks/fda-advisory-committee-to-convene-meeting-to-discuss-on-eli-lilly-s-alzheimer-s-drug-1033340860
3227.0,5/7/2024 6:04:24 PM,Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare,InvestorPlace,/news/stocks/biotech-breakthroughs-7-stocks-driving-the-next-wave-in-healthcare-1033341676
3228.0,5/9/2024 5:30:47 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033354744
3229.0,5/9/2024 2:34:23 PM,7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025,InvestorPlace,/news/stocks/7-weight-loss-drug-stocks-poised-for-explosive-growth-by-2025-1033357058
3230.0,5/9/2024 4:40:14 PM,Lilly next-generation diabetes drug mazdutide meets primary goal in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/4103883-lilly-next-generation-diabetes-drug-mazdutide-meets-primary-goal-phase-3-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3231.0,5/9/2024 4:41:08 PM,A Look at Pharma ETFs Post Q1 Earnings,Benzinga,/news/etf/a-look-at-pharma-etfs-post-q1-earnings-1033357001
3232.0,5/9/2024 5:22:28 PM,"Novo Nordisk, Flagship to develop next-generation obesity drugs",Seeking Alpha,https://seekingalpha.com/news/4103937-novo-nordisk-flagship-to-develop-next-generation-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3233.0,5/10/2024 10:30:00 AM,3 Biotech Stocks to Sell in May Before They Crash & Burn,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-in-may-before-they-crash-burn-1033362353
3234.0,5/10/2024 12:18:46 PM,"Dividend Roundup: Eli Lilly, American Express, Microsoft, Delta Air Lines, and more",Seeking Alpha,https://seekingalpha.com/news/4104536-dividend-roundup-eli-lilly-american-express-microsoft-delta-air-lines-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3235.0,5/10/2024 2:16:35 PM,One in eight U.S. adults admits to GLP-1 usage as public awareness climbs,Seeking Alpha,https://seekingalpha.com/news/4104648-one-in-eight-us-adults-admits-glp-1-usage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3236.0,5/10/2024 5:01:03 PM,Lilly could partner with Cipla to market GLP-1 drugs in India - report,Seeking Alpha,https://seekingalpha.com/news/4104762-lilly-could-partner-cipla-market-glp-1-drugs-india?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3237.0,5/10/2024 6:13:46 PM,AI-discovered drugs have an 80%–90% success rate: study,Seeking Alpha,https://seekingalpha.com/news/4104786-ai-discovered-drugs-have-an-8090-success-rate-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3238.0,5/13/2024 7:51:10 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eli-lilly-co-lly-trubridge-tbrg-and-ligand-pharma-lgnd-1033370083
3239.0,5/13/2024 11:00:00 AM,The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory,InvestorPlace,/news/stocks/the-must-watch-list-3-stocks-to-snap-up-as-soon-as-they-hit-bargain-territory-1033370214
3240.0,5/13/2024 3:48:17 PM,BoA raises 2024 Novo Nordisk Wegovy sales estimates on prescription trends,Seeking Alpha,https://seekingalpha.com/news/4105273-boa-raises-2024-novo-nordisk-wegovy-sales-estimates-prescription-trends?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3241.0,5/14/2024 10:30:00 AM,Biotech Behemoths: 3 Giants Set to Dominate the Health Scene,InvestorPlace,/news/stocks/biotech-behemoths-3-giants-set-to-dominate-the-health-scene-1033375431
3242.0,5/14/2024 2:39:47 PM,"Lilly target price raised at Argus on Mounjaro, Zepbound sales",Seeking Alpha,https://seekingalpha.com/news/4105874-lilly-target-price-raised-argus-mounjaro-zepbound-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3243.0,5/15/2024 2:21:25 PM,"Short interest in S&P 500 healthcare sector dips in April, biotechnology companies most shorted",Seeking Alpha,https://seekingalpha.com/news/4106501-short-interest-in-sp-500-healthcare-sector-dips-in-april-biotechnology-companies-most-shorted?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3244.0,5/15/2024 5:09:04 PM,Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-growth-stocks-with-strong-buy-ratings-for-may-2024-1033386011
3245.0,5/15/2024 8:27:14 PM,"Duquesne Family Office top Q1 buys, cuts: Coherent, Eli Lilly, others",Seeking Alpha,https://seekingalpha.com/news/4106936-duquesne-family-office-top-q1-buys-cuts-coherent-eli-lilly-others?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3246.0,5/15/2024 9:43:25 PM,Should You Hold Viking Therapeutics in Your Portfolio?,Benzinga,/news/stocks/should-you-hold-viking-therapeutics-in-your-portfolio-1033386466
3247.0,5/16/2024 10:15:00 AM,Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade,InvestorPlace,/news/stocks/patent-peril-3-stocks-at-risk-from-the-ftcs-drug-crusade-1033392050
3248.0,5/16/2024 10:48:39 AM,Roche obesity therapy leads to ~19% weight loss in Phase 1 trial,Seeking Alpha,https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3249.0,5/16/2024 11:15:00 AM,7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs,InvestorPlace,/news/stocks/7-pharma-stocks-harnessing-ai-brainpower-for-big-breakthroughs-1033392344
3250.0,5/16/2024 11:21:56 AM,Eli Lilly once-weekly insulin hits main goal in late-stage trials,Seeking Alpha,https://seekingalpha.com/news/4107209-eli-lilly-weekly-insulin-hits-main-goal-late-stage-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3251.0,5/16/2024 12:13:38 PM,The Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024,InvestorPlace,/news/stocks/the-dividend-investors-playbook-3-stocks-for-consistent-cash-flow-in-2024-1033392689
3252.0,5/16/2024 1:10:28 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-celcuity-celc-and-89bio-etnb-1033394380
3253.0,5/16/2024 2:30:33 PM,Novo Nordisk falls on reports of fire at construction site (update),Seeking Alpha,https://seekingalpha.com/news/4107388-novo-nordisk-stock-falls-construction-site-fire?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3254.0,5/16/2024 3:31:52 PM,Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint ,RTTNews,/news/stocks/lilly-says-phase-3-trials-of-once-weekly-insulin-in-type-2-diabetes-meets-primary-endpoint-1033393113
3255.0,5/16/2024 4:40:29 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Arvinas Holding Company (ARVN) and Progyny (PGNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-arvinas-holding-company-arvn-and-progyny-pgny-1033394933
3256.0,5/16/2024 6:37:18 PM,Viking falls after Roche’s obesity drug data; RayJay upgrades (update),Seeking Alpha,https://seekingalpha.com/news/4107654-viking-stock-falls-roche-obesity-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3257.0,5/17/2024 11:10:11 AM,"Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amgen-amgn-eli-lilly-co-lly-1033399669
3258.0,5/17/2024 6:44:34 PM,Rally Rockets: 3 Stocks Benefitting From the Market’s Unstoppable Surge,InvestorPlace,/news/stocks/rally-rockets-3-stocks-benefitting-from-the-markets-unstoppable-surge-1033400584
3259.0,5/17/2024 7:02:01 PM,Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?,InvestorPlace,/news/stocks/pharma-stocks-outlook-where-are-2024s-top-performers-headed-next-1033400641
3260.0,5/17/2024 9:04:43 PM,"EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga",Benzinga,/news/etf/exclusive-gamestop-amc-buzz-may-prove-to-be-short-lived-ceo-of-company-behind-meme-etf-tells-benzinga-1033400602
3261.0,5/17/2024 9:24:26 PM,"4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly",Benzinga,/news/stocks/4-stocks-that-could-break-novo-nordisk-lilly-s-obesity-duopoly-1033400634
3262.0,5/18/2024 5:35:22 AM,AstraZeneca Sharpens Focus on Innovation,TipRanks,/news/stocks/astrazeneca-sharpens-focus-on-innovation-1033400908
3263.0,5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3264.0,5/19/2024 7:05:03 PM,SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?,Seeking Alpha,https://seekingalpha.com/news/4108152-sa-roundtable-are-eli-lilly-and-novo-nordisk-overvalued?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3265.0,5/20/2024 10:02:10 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-johnson-johnson-jnj-eli-lilly-co-lly-and-coherus-biosciences-chrs-1033403373
3266.0,5/20/2024 2:15:35 PM,Hims & Hers surges on cheap compounded versions of Novo Nordisk's semaglutide,Seeking Alpha,https://seekingalpha.com/news/4108357-hims-hers-surges-cheap-compounded-versions-novo-nordisk-semaglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3267.0,5/20/2024 7:16:21 PM,HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections,InvestorPlace,/news/stocks/hims-stock-alert-hims-hers-shares-rocket-on-weight-loss-injections-1033404593
3268.0,5/20/2024 7:18:17 PM,Should You Invest in the Vanguard Health Care ETF?,Benzinga,/news/etf/should-you-invest-in-the-vanguard-health-care-etf-1033404417
3269.0,5/21/2024 10:43:02 AM,Eli Lilly’s tirzepatide cleared for diabetes treatment in China,Seeking Alpha,https://seekingalpha.com/news/4108665-eli-lillys-tirzepatide-cleared-for-diabetes-treatment-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3270.0,5/21/2024 11:20:00 AM,3 S&P 500 Stocks to Buy in May Before They Rocket Higher,InvestorPlace,/news/stocks/3-sp-500-stocks-to-buy-in-may-before-they-rocket-higher-1033406733
3271.0,5/21/2024 12:06:41 PM,Eli Lilly & Co.: A Strong Buy on Robust Pipeline and Financial Health,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-pipeline-and-financial-health-1033408148
3272.0,5/21/2024 1:13:41 PM,Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis,Seeking Alpha,https://seekingalpha.com/news/4108774-eli-lilly-inks-radiopharma-deal-aktis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3273.0,5/21/2024 1:21:57 PM,Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds,Seeking Alpha,https://seekingalpha.com/news/4108784-microcap-mangoceuticals-doubles-on-plan-to-sell-cheap-oral-glp-1-weight-loss-meds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3274.0,5/21/2024 1:44:06 PM,7 Reliable Blue-Chip Stocks That Cannot Miss,InvestorPlace,/news/stocks/7-reliable-blue-chip-stocks-that-cannot-miss-1033407489
3275.0,5/21/2024 2:29:09 PM,Roundhill Investment launches GLP-1 & Weight Loss ETF,Seeking Alpha,https://seekingalpha.com/news/4108849-roundhill-investment-launches-glp-1-weight-loss-etf?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3276.0,5/21/2024 3:13:11 PM,Lilly Reports Positive Phase 3 Trial Results Of Mirikizumab In Crohn's Disease ,RTTNews,/news/stocks/lilly-reports-positive-phase-3-trial-results-of-mirikizumab-in-crohn-s-disease-1033407307
3277.0,5/21/2024 3:50:45 PM,Novo Nordisk unsure when it will meet obesity drug demand: report,Seeking Alpha,https://seekingalpha.com/news/4108910-novo-nordisk-unsure-when-it-will-meet-obesity-drug-demand-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3278.0,5/21/2024 6:06:23 PM,"Study finds 30% of Wegovy, Saxenda users quit within 4 weeks",Seeking Alpha,https://seekingalpha.com/news/4108986-study-finds-30-percent-of-wegovy-saxenda-users-quit-within-4-weeks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3279.0,5/21/2024 6:36:28 PM,3 Growth Stocks That Could Be Millionaire-Makers: May Edition,InvestorPlace,/news/stocks/3-growth-stocks-that-could-be-millionaire-makers-may-edition-1033408725
3280.0,5/21/2024 10:35:00 PM,EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic,Benzinga,/news/stocks/exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-ozempic-1033408932
3281.0,5/22/2024 11:14:37 AM,Australia to ban copycat versions of weight loss drugs like Ozempic,Seeking Alpha,https://seekingalpha.com/news/4109205-australia-ban-compounded-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3282.0,5/22/2024 1:58:49 PM,Retire Rich: 3 Game-Changing Stocks to Own for the Next 10 Years,InvestorPlace,/news/stocks/retire-rich-3-game-changing-stocks-to-own-for-the-next-10-years-1033412253
3283.0,5/22/2024 3:11:31 PM,"The 500 Top Stocks to Buy in May, According to AI",InvestorPlace,/news/stocks/the-500-top-stocks-to-buy-in-may-according-to-ai-1033412478
3284.0,5/22/2024 3:25:25 PM,FDA reviewers voice concerns over hypoglycemia with Novo Nordisk weekly insulin,Seeking Alpha,https://seekingalpha.com/news/4109381-fda-reviewers-voice-concerns-hypoglycemia-novo-nordisk-weekly-insulin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3285.0,5/23/2024 10:50:00 AM,Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.,InvestorPlace,/news/stocks/move-over-ozempic-3-new-glp-1-drugs-and-products-coming-soon-1033415366
3286.0,5/23/2024 1:03:35 PM,"Analysts’ Top Healthcare Picks: Silk Road Medical (SILK), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-silk-road-medical-silk-eli-lilly-co-lly-1033416866
3287.0,5/23/2024 6:01:14 PM,3 Biotech Stocks to Buy on the Dip: May 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-on-the-dip-may-2024-1033417162
3288.0,5/23/2024 6:07:59 PM,SA Asks: Is Eli Lilly or Novo Nordisk a better investment?,Seeking Alpha,https://seekingalpha.com/news/4109962-sa-asks-is-eli-lilly-or-novo-nordisk-a-better-investment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3289.0,5/24/2024 10:00:00 AM,7 Stocks to Buy if the Market Ends Up Plunging,InvestorPlace,/news/stocks/7-stocks-to-buy-if-the-market-ends-up-plunging-1033419330
3290.0,5/24/2024 11:00:00 AM,Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now,InvestorPlace,/news/stocks/stocks-to-buy-7-undeniable-dow-darlings-to-pile-into-now-1033419440
3291.0,5/24/2024 11:06:38 AM,Novo weight loss therapy cuts mortality risk in kidney disease,Seeking Alpha,https://seekingalpha.com/news/4110177-novo-ozempic-cuts-death-risk-kidney-patient?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3292.0,5/24/2024 2:10:36 PM,"Eli Lilly to spend another $5.3B on production site for Mounjaro, Zepbound",Seeking Alpha,https://seekingalpha.com/news/4110256-eli-lilly-spend-another-53b-production-site-mounjaro-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3293.0,5/24/2024 2:40:44 PM,Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide,Seeking Alpha,https://seekingalpha.com/news/4110248-zealand-pharma-releases-top-line-phase-1-results-weight-loss-asset-dapiglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3294.0,5/24/2024 4:06:22 PM,"Lilly Increases Investment In Indiana-Based Unit To Enhance Production Of Zepbound, Mounjaro ",RTTNews,/news/stocks/lilly-increases-investment-in-indiana-based-unit-to-enhance-production-of-zepbound-mounjaro-1033420251
3295.0,5/24/2024 8:16:00 PM,Novo Nordisk once weekly insulin fails to get thumbs up from majority of FDA advisors,Seeking Alpha,https://seekingalpha.com/news/4110352-novo-nordisk-once-weekly-insulin-fails-get-thumbs-up-majority-fda-advisors?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3296.0,5/25/2024 12:41:46 PM,Novo Nordisk’s Wegovy improves kidney health in addition to weight loss: study,Seeking Alpha,https://seekingalpha.com/news/4110469-novo-nordisks-wegovy-kidney-health-in-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3297.0,5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3298.0,5/26/2024 5:36:00 PM,SA Asks: Who will launch the next big weight-loss drug?,Seeking Alpha,https://seekingalpha.com/news/4110093-sa-asks-who-will-launch-the-next-big-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3299.0,5/27/2024 6:56:31 PM,The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop,InvestorPlace,/news/stocks/the-penny-stock-prophecy-3-overlooked-stocks-primed-to-pop-1033424976
3300.0,5/28/2024 9:41:05 AM,Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY) and Veeva Systems (VEEV),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-and-veeva-systems-veev-1033426901
3301.0,5/28/2024 11:50:00 AM,The Dividend Acceleration Squad: 3 Stocks With Rapidly Rising Yields,InvestorPlace,/news/stocks/the-dividend-acceleration-squad-3-stocks-with-rapidly-rising-yields-1033426687
3302.0,5/28/2024 3:32:01 PM,OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF,InvestorPlace,/news/stocks/ozem-etf-7-things-to-know-about-the-new-roundhill-glp-1-weight-loss-etf-1033427842
3303.0,5/29/2024 10:30:00 AM,"If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-in-may-it-better-be-one-of-these-3-names-1033431002
3304.0,5/29/2024 2:01:00 PM,3 Sorry Pharma Stocks to Sell in May While You Still Can,InvestorPlace,/news/stocks/3-sorry-pharma-stocks-to-sell-in-may-while-you-still-can-1033433603
3305.0,5/29/2024 4:11:20 PM,"Ro provides supply tracking feature for Lilly, Novo Nordisk weight loss drugs",Seeking Alpha,https://seekingalpha.com/news/4111188-ro-provides-supply-tracking-feature-lilly-novo-nordisk-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3306.0,5/29/2024 4:32:44 PM,Lilly's Retevmo gains approval for children as young as two with thyroid cancer,Seeking Alpha,https://seekingalpha.com/news/4111200-lilly-retevmo-gains-approval-children-as-young-as-two-thyroid-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3307.0,5/29/2024 11:56:12 PM,"Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker",Benzinga,/news/stocks/nvidia-is-up-186-from-a-year-ago-yet-these-7-stocks-have-more-than-doubled-their-returns-over-the-ai-chipmaker-1033433492
3308.0,5/30/2024 11:30:00 AM,Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit,InvestorPlace,/news/stocks/blue-chip-bubble-trouble-7-stocks-to-short-as-valuations-stretch-to-the-limit-1033435720
3309.0,5/30/2024 11:31:44 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and VolitionRX (VNRX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-volitionrx-vnrx-1033436798
3310.0,5/30/2024 11:55:49 AM,Biotech Stocks Facing FDA Decision In June 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2024-1033435348
3311.0,5/30/2024 3:22:06 PM,Goldman Sachs raises obesity drug market estimate to $130B,Seeking Alpha,https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3312.0,5/30/2024 5:17:07 PM,"Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs",Benzinga,/news/stocks/weight-loss-drug-market-to-rocket-to-130b-by-2030-with-eli-lilly-novo-nordisk-in-lead-goldman-sachs-1033436939
3313.0,5/30/2024 7:03:57 PM,Should You Invest in the iShares U.S. Healthcare ETF?,Benzinga,/news/stocks/should-you-invest-in-the-ishares-u-s-healthcare-etf-1033437375
3314.0,5/30/2024 9:36:44 PM,"New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk",Benzinga,/news/etf/new-weight-loss-etf-is-essentially-a-play-on-eli-lilly-novo-nordisk-1033437704
3315.0,5/30/2024 9:37:15 PM,Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year,InvestorPlace,/news/stocks/institutional-bets-7-stocks-the-big-money-will-send-higher-this-year-1033437969
3316.0,5/31/2024 1:01:10 AM,"ZTS, SYK, LLY: Which Healthcare Stock Is the Best Buy?",TipRanks,/news/stocks/zts-syk-lly-which-healthcare-stock-is-the-best-buy-1033438317
3317.0,5/31/2024 3:04:41 AM,Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033439807
3318.0,5/31/2024 10:00:00 AM,Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential,InvestorPlace,/news/stocks/aristocrats-in-disguise-3-blue-chip-stocks-with-stealth-growth-potential-1033440553
3319.0,5/31/2024 10:00:00 AM,Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing,InvestorPlace,/news/stocks/unearthing-unknown-stocks-3-picks-that-could-be-the-next-big-thing-1033440550
3320.0,5/31/2024 2:02:26 PM,Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda (update),Seeking Alpha,https://seekingalpha.com/news/4111919-summit-stock-falls-despite-data-beating-merck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3321.0,5/31/2024 7:00:19 PM,"Catalyst Watch: Nvidia stock split buzz, COMPUTEX, Walmart's annual meeting, and REITs on display",Seeking Alpha,https://seekingalpha.com/news/4111995-catalyst-watch-nvidia-stock-split-buzz-computex-walmarts-annual-meeting-and-reits-on-display?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3322.0,6/1/2024 3:53:31 PM,Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors ,RTTNews,/news/stocks/lilly-announces-updated-data-from-phase-1-2-study-of-olomorasib-in-advanced-solid-tumors-1033442941
3323.0,6/1/2024 6:44:45 PM,FDA oncology chief says international clinical trials should be priority,Seeking Alpha,https://seekingalpha.com/news/4112136-fda-oncology-chief-international-clinical-trials-priority?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3324.0,6/2/2024 2:00:00 PM,SA Asks: Which weight-loss stocks should investors be watching?,Seeking Alpha,https://seekingalpha.com/news/4112116-sa-asks-which-weight-loss-stocks-should-investors-be-watching?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3325.0,6/3/2024 8:41:06 AM,"Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Eli Lilly & Co (LLY) and Envista Holdings (NVST)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-werewolf-therapeutics-howl-eli-lilly-co-lly-and-envista-holdings-nvst-1033445307
3326.0,6/3/2024 11:29:07 AM,Eli Lilly: A Strong Buy on Oncology Overhaul and Expanding Pipeline,TipRanks,/news/stocks/eli-lilly-a-strong-buy-on-oncology-overhaul-and-expanding-pipeline-1033446442
3327.0,6/3/2024 2:41:18 PM,Eli Lilly granted exclusive license to QurAlis candidate for neurodegenerative diseases,Seeking Alpha,https://seekingalpha.com/news/4112353-eli-lilly-granted-exclusive-license-quralis-candidate-neurodegenerative-diseases?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3328.0,6/3/2024 9:15:12 PM,"Structure Therapeutics Obesity Candidate Is 'Very Competitive' To Eli Lilly's Orforglipron, Analyst Says",Benzinga,/news/stocks/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lilly-s-orforglipron-analyst-says-1033447122
3329.0,6/4/2024 11:40:13 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eledon Pharmaceuticals (ELDN), BioNTech SE (BNTX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eledon-pharmaceuticals-eldn-biontech-se-bntx-and-eli-lilly-co-lly-1033450204
3330.0,6/4/2024 12:46:53 PM,"Largest companies in the Russell 3000 Index by size: NVDA, LLY, AVGO make huge leaps",Seeking Alpha,https://seekingalpha.com/news/4112667-largest-companies-in-the-russell-3000-index-by-size-nvda-lly-avgo-make-huge-leaps?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3331.0,6/4/2024 2:37:18 PM,Eli Lilly sees improving availability of GLP-1 drugs Mounjaro and Zepbound,Seeking Alpha,https://seekingalpha.com/news/4112744-eli-lilly-sees-improving-availability-of-glp-1-drugs-mounjaro-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3332.0,6/4/2024 6:57:26 PM,Eli Lilly wins favorable terms for obesity drug use in U.K.,Seeking Alpha,https://seekingalpha.com/news/4112822-eli-lilly-obesity-drug-recommended-use-uk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3333.0,6/4/2024 7:40:11 PM,Viking falls despite positive mid-stage data for liver drug,Seeking Alpha,https://seekingalpha.com/news/4112830-viking-stock-falls-positive-nash-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3334.0,6/5/2024 10:13:00 AM,AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight,InvestorPlace,/news/stocks/amzn-buy-alert-why-amazon-stock-is-a-bargain-hiding-in-plain-sight-1033452716
3335.0,6/5/2024 12:00:24 PM,Eli Lilly CFO Anat Ashkenazi to resign,Seeking Alpha,https://seekingalpha.com/news/4113047-eli-lilly-cfo-anat-ashkenazi-to-resign?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3336.0,6/5/2024 12:10:19 PM,Eli Lilly details NASH effects of weight loss drug,Seeking Alpha,https://seekingalpha.com/news/4113054-eli-lilly-details-nash-effects-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3337.0,6/5/2024 12:21:51 PM,Alphabet taps Eli Lilly executive as new CFO,Seeking Alpha,https://seekingalpha.com/news/4113065-alphabet-taps-eli-lilly-executive-as-new-cfo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3338.0,6/5/2024 1:20:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), LENSAR (LNSR)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-lensar-lnsr-1033454760
3339.0,6/5/2024 2:12:36 PM,Eli Lilly CFO Anat Ashkenazi Resigns ,RTTNews,/news/stocks/eli-lilly-cfo-anat-ashkenazi-resigns-1033453239
3340.0,6/5/2024 5:10:12 PM,Biogen favored at RBC as Eli Lilly awaits FDA AdCom on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4113279-biogen-stock-favored-rbc-lilly-awaits-alzheimers-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3341.0,6/5/2024 5:44:31 PM,LifeMD gains as KeyBanc issues bullish view on weight loss program,Seeking Alpha,https://seekingalpha.com/news/4113285-lifemd-stock-gains-keybanc-bullish-view?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3342.0,6/6/2024 10:00:00 AM,Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition,InvestorPlace,/news/stocks/growth-stock-goliaths-7-picks-that-will-tower-over-the-competition-1033456766
3343.0,6/6/2024 10:00:00 AM,Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half,InvestorPlace,/news/stocks/mid-year-momentum-plays-7-stocks-to-buy-for-the-second-half-1033456769
3344.0,6/6/2024 2:09:40 PM,FDA suggests safety warning for Eli Lilly Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4113676-eli-lilly-alzheimers-drug-should-come-safety-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3345.0,6/6/2024 9:23:47 PM,The 3 Most Undervalued Pharma Stocks to Buy in June 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-in-june-2024-1033459382
3346.0,6/6/2024 9:36:29 PM,Halozyme's ENHANZE Product Gets New Patent Grant in EU,Benzinga,/news/stocks/halozyme-s-enhanze-product-gets-new-patent-grant-in-eu-1033459113
3347.0,6/7/2024 12:10:56 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Qiagen (QGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-qiagen-qgen-and-eli-lilly-co-lly-1033461868
3348.0,6/7/2024 2:53:19 PM,Kroger follows Costco to offer GLP-1s as part of weight loss program,Seeking Alpha,https://seekingalpha.com/news/4114154-kroger-follows-costco-offer-glp-1-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3349.0,6/7/2024 4:42:12 PM,"ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential",Benzinga,/news/etf/etfs-bet-high-on-weight-loss-drugs-but-industry-observers-question-long-term-potential-1033461767
3350.0,6/7/2024 4:50:53 PM,Wall Street Reacts To Hot Jobs Report: Stocks Swing As Traders Abandon July Rate Cut Hopes,Benzinga,/news/etf/wall-street-reacts-to-hot-jobs-report-stocks-swing-as-traders-abandon-july-rate-cut-hopes-1033461780
3351.0,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3352.0,6/8/2024 11:40:00 AM,Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm,InvestorPlace,/news/stocks/profiting-from-the-crowd-3-stocks-set-to-surge-on-retail-investor-enthusiasm-1033462715
3353.0,6/8/2024 6:00:00 PM,"Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030",Seeking Alpha,https://seekingalpha.com/news/4114265-lillys-donanemeb-remternetug-set-dominate-alzheimers-treatment-2030?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3354.0,6/10/2024 10:45:00 AM,7 Blue-Chip Stocks to Add to Your June Buy List ,InvestorPlace,/news/stocks/7-blue-chip-stocks-to-add-to-your-june-buy-list-1033465204
3355.0,6/10/2024 10:45:28 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033465783
3356.0,6/10/2024 1:26:01 PM,Bank of America Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1033466595
3357.0,6/10/2024 4:09:47 PM,"Biogen, Eisai get January 2025 FDA action date for monthly Leqembi",Seeking Alpha,https://seekingalpha.com/news/4114537-biogen-eisai-get-january-2025-fda-action-date-monthly-leqembi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3358.0,6/10/2024 6:38:05 PM,Weight loss drugs other benefits could convince more men to use them - report,Seeking Alpha,https://seekingalpha.com/news/4114576-weight-loss-drugs-other-benefits-could-convince-more-men-use-them?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3359.0,6/10/2024 7:01:31 PM,7 Over-Hyped Stocks to Sell Before They Plunge: June Edition,InvestorPlace,/news/stocks/7-over-hyed-stocks-to-sell-before-they-plunge-june-edition-1033466884
3360.0,6/10/2024 7:35:10 PM,"Lilly's donanemab effective for Alzheimer's disease, FDA advisors say (updated)",Seeking Alpha,https://seekingalpha.com/news/4114590-lilly-donanemab-effective-alzheimers-disease-fda-advisors-say?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3361.0,6/11/2024 11:13:14 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033469525
3362.0,6/11/2024 11:33:22 AM,"Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-addus-homecare-adus-dianthus-therapeutics-dnth-and-eli-lilly-co-lly-1033469621
3363.0,6/11/2024 2:49:50 PM,Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer’s Drug,InvestorPlace,/news/stocks/eli-lilly-stock-hits-new-52-week-high-as-fda-panel-recommends-alzheimers-drug-1033469655
3364.0,6/11/2024 3:23:45 PM,Why Are Stocks Down Today?,InvestorPlace,/news/stocks/why-are-stocks-down-today-june-11th-1033469755
3365.0,6/11/2024 5:25:29 PM,"Wall Street’s most overbought stocks include NVDA, COST, LLY, and others",Seeking Alpha,https://seekingalpha.com/news/4114919-wall-streets-most-overbought-stocks-include-nvda-cost-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3366.0,6/11/2024 8:19:11 PM,"Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst",Benzinga,/news/stocks/eli-lilly-s-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-says-bofa-analyst-1033470262
3367.0,6/12/2024 6:26:26 AM,Eli Lilly: Strong Buy on Diverse Portfolio and Promising Alzheimer’s Pipeline Despite Donanemab’s Challenges,TipRanks,/news/stocks/eli-lilly-strong-buy-on-diverse-portfolio-and-promising-alzheimer-s-pipeline-despite-donanemab-s-challenges-1033471819
3368.0,6/12/2024 10:30:00 AM,3 Must-Buy Stocks Before the Third Quarter,InvestorPlace,/news/stocks/3-must-buy-stocks-before-the-third-quarter-1033472099
3369.0,6/12/2024 10:43:00 AM,7 Trending Stocks With Momentum on Their Side,InvestorPlace,/news/stocks/7-trending-stocks-with-momentum-on-their-side-1033472098
3370.0,6/12/2024 2:00:00 PM,3 Stocks Quietly Preparing for a 10X Surge: June Edition,InvestorPlace,/news/stocks/3-stocks-quietly-preparing-for-a-10x-surge-june-edition-1033473227
3371.0,6/12/2024 2:27:30 PM,Palatin starts Phase 2 obesity study of bremelanotide with Zepbound,Seeking Alpha,https://seekingalpha.com/news/4115213-palatin-starts-phase-2-obesity-study-of-bremelanotide-with-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3372.0,6/12/2024 4:33:43 PM,GLP-1 obesity drug coverage dropped by Blue Cross Michigan: report,Seeking Alpha,https://seekingalpha.com/news/4115246-glp-1-drug-coverage-dropped-by-blue-cross-michigan-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3373.0,6/12/2024 6:24:16 PM,4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024,InvestorPlace,/news/stocks/4-best-stocks-to-buy-and-3-best-stocks-to-sell-june-2024-1033474011
3374.0,6/12/2024 6:39:17 PM,Lilly's Retevmo gains traditional approval in thyroid cancer,Seeking Alpha,https://seekingalpha.com/news/4115326-lilly-retevmo-gains-traditional-approval-in-thyroid-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3375.0,6/12/2024 11:00:19 PM,Eli Lilly and Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings),Benzinga,/news/stocks/eli-lilly-and-co-stock-a-deep-dive-into-analyst-perspectives-17-ratings-1033474278
3376.0,6/13/2024 10:15:00 AM,3 Stocks to Buy as Ozempic Surges in Popularity,InvestorPlace,/news/stocks/3-stocks-to-buy-as-ozempic-surges-in-popularity-1033475495
3377.0,6/13/2024 10:30:00 AM,"3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years",InvestorPlace,/news/stocks/3-stocks-to-buy-if-you-want-to-turn-your-1000-into-10000-within-2-years-2-1033475586
3378.0,6/13/2024 11:40:34 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Cardinal Health (CAH),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-cardinal-health-cah-1033476821
3379.0,6/13/2024 1:49:40 PM,J.P. Morgan Private Capital raises over $500M for life sciences fund,Seeking Alpha,https://seekingalpha.com/news/4115629-jp-morgan-private-capital-raises-over-500m-for-life-sciences-fund?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3380.0,6/14/2024 10:37:00 AM,3 Stocks to Sell as Ozempic Surges in Popularity,InvestorPlace,/news/stocks/3-stocks-to-sell-as-ozempic-surges-in-popularity-1033479269
3381.0,6/14/2024 11:15:00 AM,7 A-Rated Biotech Stocks Worth Betting on in June,InvestorPlace,/news/stocks/7-a-rated-biotech-stocks-worth-betting-on-in-june-1033479361
3382.0,6/14/2024 12:01:46 PM,Employer coverage for GLP-1s rising amid FDA label expansions: survey,Seeking Alpha,https://seekingalpha.com/news/4116127-employer-coverage-for-glp-1s-rising-survey?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3383.0,6/14/2024 4:31:42 PM,U.S. sector and stock leaders and laggards as first half winds down,Seeking Alpha,https://seekingalpha.com/news/4116288-us-sector-and-stock-leaders-and-laggards-as-h1-winds-down?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3384.0,6/14/2024 7:39:10 PM,"Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails",Benzinga,/news/stocks/pharma-stock-roundup-fda-panel-endorses-lly-s-donanemab-pfe-s-dmd-therapy-study-fails-1033480819
3385.0,6/14/2024 10:24:23 PM,Employee benefits survey finds marked increase in GLP-1 coverage,Seeking Alpha,https://seekingalpha.com/news/4116449-employee-benefits-survey-finds-marked-increase-in-glp-1-coverage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3386.0,6/15/2024 10:12:00 AM,Exit Alert: 3 Stocks to Offload Before the Downturn,InvestorPlace,/news/stocks/exit-alert-3-stocks-to-offload-before-the-downturn-1033481227
3387.0,6/15/2024 3:19:01 PM,U.S. drug shortages worsen to reach a decade high: report,Seeking Alpha,https://seekingalpha.com/news/4116477-us-drug-shortages-reach-decade-high?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3388.0,6/16/2024 4:33:31 PM,"Ozempic drives more demand for smaller clothes, WSJ reports",Seeking Alpha,https://seekingalpha.com/news/4116505-ozempic-drives-more-demand-for-smaller-clothes-wsj-reports?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3389.0,6/17/2024 9:26:49 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033483419
3390.0,6/18/2024 10:00:45 AM,"Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Qiagen (QGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-qiagen-qgen-and-eli-lilly-co-lly-1033487105
3391.0,6/18/2024 2:34:48 PM,Least shorted S&P 500 stocks in May,Seeking Alpha,https://seekingalpha.com/news/4117019-least-shorted-sp-500-stocks-in-may?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3392.0,6/18/2024 5:49:28 PM,Eli Lilly oral weight-loss candidate orforglipron is potential winner: SA Investing Summit,Seeking Alpha,https://seekingalpha.com/news/4117103-eli-lilly-oral-weight-loss-candidate-orfoglipron-potential-winner-sa-summit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3393.0,6/20/2024 1:02:55 PM,Eli Lilly ramps up efforts against fake weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4117468-eli-lilly-ramps-up-efforts-against-fake-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3394.0,6/20/2024 3:58:22 PM,Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024 ,InvestorPlace,/news/stocks/wall-street-favorites-7-growth-stocks-with-strong-buy-ratings-for-june-2024-1033493767
3395.0,6/21/2024 4:25:41 AM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1033494967
3396.0,6/21/2024 10:22:00 AM,Hype Busters: 3 Overvalued Stocks Ready for a Reality Check,InvestorPlace,/news/stocks/hype-busters-3-overvalued-stocks-ready-for-a-reality-check-1033495538
3397.0,6/21/2024 12:20:43 PM,Zealand Pharma extends gains on early-stage data for weight loss drug,Seeking Alpha,https://seekingalpha.com/news/4117889-zealand-pharma-stock-gains-weight-loss-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3398.0,6/21/2024 1:44:16 PM,Hims & Hers defended at BofA as Lilly fights compounded GLP-1s,Seeking Alpha,https://seekingalpha.com/news/4117935-hims-stock-defended-lilly-fights-compounded-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3399.0,6/21/2024 2:12:29 PM,"Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss",Benzinga,/news/etf/move-aside-ozempic-wegovy-denmark-s-new-drug-just-showed-positive-results-for-weightloss-1033495776
3400.0,6/21/2024 6:00:00 PM,3 Biotech Stocks to Buy Now: June 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-now-june-2024-1033497074
3401.0,6/21/2024 8:24:19 PM,Lilly weight loss drug tirzepatide meets primary endpoint in sleep apnea study,Seeking Alpha,https://seekingalpha.com/news/4118034-lilly-weight-loss-drug-tirzepatide-meets-primary-endpoint-sleep-apnea-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3402.0,6/21/2024 8:33:06 PM,Takeda gets EU approval for Fruzaqla for colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/4118039-takeda-gets-eu-approval-for-fruzaqla-for-colorectal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3403.0,6/21/2024 9:31:14 PM,"The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",Benzinga,/news/stocks/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly-1033497156
3404.0,6/22/2024 12:27:42 PM,"ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug",Seeking Alpha,https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3405.0,6/22/2024 1:36:54 PM,"Eli Lilly’s Tirzepatide Shows Promising Results in Sleep Apnea Treatment, Justifying a Buy Rating",TipRanks,/news/stocks/eli-lilly-s-tirzepatide-shows-promising-results-in-sleep-apnea-treatment-justifying-a-buy-rating-1033497576
3406.0,6/22/2024 1:50:11 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Vertex Pharmaceuticals (VRTX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-vertex-pharmaceuticals-vrtx-1033497585
3407.0,6/22/2024 2:00:36 PM,"Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-vertex-pharmaceuticals-vrtx-eli-lilly-co-lly-1033497592
3408.0,6/22/2024 3:00:00 PM,GLP-1 drugs linked to reduced dementia risk: study,Seeking Alpha,https://seekingalpha.com/news/4118147-glp-1-drugs-linked-reduced-dementia-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3409.0,6/23/2024 6:00:00 PM,"Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit",Seeking Alpha,https://seekingalpha.com/news/4118072-lilly-novo-nordisk-dominate-weight-loss-therapy-sa-investing-summit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3410.0,6/24/2024 7:43:56 AM,Australian Stocks: ResMed Shares Tumble on Rival’s Weight-Loss Drug Results,TipRanks,/news/stocks/australian-stocks-resmed-shares-tumble-on-rival-s-weight-loss-drug-results-1033499433
3411.0,6/24/2024 10:18:49 AM,Buy Rating Affirmed for Eli Lilly on Tirzepatide’s Promise in OSA and Obesity Treatment,TipRanks,/news/stocks/buy-rating-affirmed-for-eli-lilly-on-tirzepatide-s-promise-in-osa-and-obesity-treatment-1033500010
3412.0,6/24/2024 11:55:51 AM,Eli Lilly & Co (LLY) Receives a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-jefferies-1033500655
3413.0,6/24/2024 12:26:03 PM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1033500767
3414.0,6/24/2024 1:21:19 PM,Altimmune jumps 13% on phase 2 pemvidutide results for obesity,Seeking Alpha,https://seekingalpha.com/news/4118343-altimmune-jumps-13-phase-2-pemvidutide-results-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3415.0,6/24/2024 2:56:49 PM,ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings,InvestorPlace,/news/stocks/alt-stock-alert-altimmune-pops-on-weight-loss-drug-findings-1033500759
3416.0,6/24/2024 3:14:09 PM,Top 10 performing S&P 500 names as first half looks to close out this week,Seeking Alpha,https://seekingalpha.com/news/4118379-top-10-performing-sp-500-names-as-h1-looks-to-close-out-this-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3417.0,6/24/2024 3:38:22 PM,Eli Lilly declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/4118430-eli-lilly-and-company-declares-1_30-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3418.0,6/24/2024 6:51:58 PM,Novo Nordisk to spend $4.1B to build new plant for obesity drugs in N.C.,Seeking Alpha,https://seekingalpha.com/news/4118545-novo-nordisk-spend-41b-build-new-plant-obesity-drugs-nc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3419.0,6/24/2024 7:17:13 PM,"Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data",Seeking Alpha,https://seekingalpha.com/news/4118548-inspire-medical-resmed-decline-following-lilly-tirzepatide-sleep-apnea-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3420.0,6/24/2024 7:56:56 PM,"Market shifting focus to softening growth from inflation, Morgan Stanley and BofA say",Seeking Alpha,https://seekingalpha.com/news/4118556-market-shifting-focus-to-softening-growth-from-inflation-morgan-stanley-and-bofa-say?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3421.0,6/25/2024 11:26:24 AM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033504439
3422.0,6/25/2024 1:29:33 PM,NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug,InvestorPlace,/news/stocks/nvo-stock-novo-nordisk-pops-as-china-approves-wegovy-weight-loss-drug-1033503921
3423.0,6/25/2024 3:08:09 PM,Eli Lilly collaborates with OpenAI for medicines against drug-resistant bacteria,Seeking Alpha,https://seekingalpha.com/news/4119028-eli-lilly-collaborates-with-openai-for-medicines-against-drug-resistant-bacteria?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3424.0,6/25/2024 4:12:34 PM,Lilly gains approval of lebrikizumab in Canada for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/4119066-lilly-gains-approval-lebrikizumab-canada-atopic-dermatitis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3425.0,6/25/2024 4:14:48 PM,Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials ,RTTNews,/news/stocks/eli-lilly-collaborates-with-openai-to-use-generative-ai-to-invent-novel-antimicrobials-1033504398
3426.0,6/25/2024 5:15:54 PM,GLP-1 weight loss meds + exercise seen preserving bone health,Seeking Alpha,https://seekingalpha.com/news/4119100-glp-1-weight-loss-meds-exercise-seen-preserving-bone-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3427.0,6/25/2024 5:37:45 PM,ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data,Seeking Alpha,https://seekingalpha.com/news/4119106-resmed-cut-at-oppenheimer-after-eli-lillys-tirzepatide-sleep-apnea-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3428.0,6/26/2024 7:33:34 AM,Augustine Therapeutics raises €17M in series A first closing,Seeking Alpha,https://seekingalpha.com/news/4119241-augustine-therapeutics-raises-17m-in-series-a-first-closing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3429.0,6/26/2024 11:50:00 AM,The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition,InvestorPlace,/news/stocks/the-next-7-trillion-dollar-stocks-to-buy-june-2024-edition-1033507334
3430.0,6/26/2024 1:26:08 PM,Augustine Therapeutics raises EUR 17M in Series A first closing,Seeking Alpha,https://seekingalpha.com/news/4119532-augustine-therapeutics-raises-eur-17m-in-series-a-first-closing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3431.0,6/27/2024 10:02:20 AM,3 Valuable Stocks That Are Worth the Expensive Price Tag,InvestorPlace,/news/stocks/3-valuable-stocks-that-are-worth-the-expensive-price-tag-1033510649
3432.0,6/27/2024 10:50:00 AM,7 A-Rated Stocks for Your June Buy List,InvestorPlace,/news/stocks/7-a-rated-stocks-for-your-june-buy-list-1033510905
3433.0,6/27/2024 11:15:00 AM,3 Promising Stocks That Can Turn $10K Into $1 Million,InvestorPlace,/news/stocks/3-promising-stocks-that-can-turn-10k-into-1-million-1033510940
3434.0,6/27/2024 1:36:33 PM,Hims & Hers down 6% following report on weight loss drug (updated),Seeking Alpha,https://seekingalpha.com/news/4120028-him-hers-down-6-following-report-shady-supplier-for-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3435.0,6/27/2024 6:21:43 PM,You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.,InvestorPlace,/news/stocks/youve-been-warned-3-biotech-stocks-to-buy-now-or-regret-forever-1033512850
3436.0,6/28/2024 10:00:00 AM,The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains,InvestorPlace,/news/stocks/the-top-3-weight-loss-drug-stocks-to-buy-for-huge-gains-1033514451
3437.0,6/28/2024 11:55:34 AM,"Dividend Roundup: Kroger, AT&T, Pfizer, JPMorgan, and more",Seeking Alpha,https://seekingalpha.com/news/4120524-dividend-roundup-kroger-att-pfizer-jpmorgan-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3438.0,6/28/2024 2:00:00 PM,The 3 Smartest Healthcare Stocks to Buy With $1K Right Now,InvestorPlace,/news/stocks/the-3-smartest-healthcare-stocks-to-buy-with-1k-right-now-1033515560
3439.0,6/28/2024 2:09:51 PM,The 3 Smartest Biotech Stocks to Buy With $5K Right Now,InvestorPlace,/news/stocks/the-3-smartest-biotech-stocks-to-buy-with-5k-right-now-1033515559
3440.0,6/29/2024 10:30:00 AM,3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt,InvestorPlace,/news/stocks/3-sectors-that-could-get-slammed-by-attempts-to-reduce-u-s-debt-1033516833
3441.0,6/29/2024 1:00:00 PM,Sound Investments: 3 Stocks to Buy for a Good Night’s Rest,InvestorPlace,/news/stocks/sound-investments-3-stocks-to-buy-for-a-good-nights-rest-1033516864
3442.0,6/29/2024 3:35:00 PM,Insulet tops S&P 500 growth chart for Q2 as it gains market share in the diabetes space,Seeking Alpha,https://seekingalpha.com/news/4120025-insulet-tops-sp-500-growth-chart-for-q2-as-it-gains-market-share-in-the-diabetes-space?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3443.0,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3444.0,7/1/2024 12:30:56 AM,"Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2",Seeking Alpha,https://seekingalpha.com/news/4120874-alnylam-lilly-astrzeneca-best-performing-pharmas-biotechs-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3445.0,7/1/2024 7:45:19 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033519052
3446.0,7/1/2024 5:36:30 PM,Lilly in deal with Radionetics Oncology on radiopharmaceuticals development,Seeking Alpha,https://seekingalpha.com/news/4121300-lilly-deal-radionetics-oncology-radiopharmaceuticals-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3447.0,7/2/2024 12:25:20 AM,Cantor Fitzgerald Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033521213
3448.0,7/2/2024 10:24:00 AM,3 Under-the-Radar Biotech Stocks With Blockbuster Potential,InvestorPlace,/news/stocks/3-under-the-radar-biotech-stocks-with-blockbuster-potential-1033522419
3449.0,7/2/2024 1:17:30 PM,"Eli Lilly, Novo under pressure as Biden urges lower drug prices",Seeking Alpha,https://seekingalpha.com/news/4121664-eli-lilly-novo-stocks-fall-biden-urges-lower-drug-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3450.0,7/2/2024 5:54:29 PM,Eli Lilly wins FDA approval of donanemab for Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/4121800-eli-lilly-wins-fda-approval-donanemab-alzheimers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3451.0,7/2/2024 7:11:24 PM,AMZN Stock Outlook: Amazon’s Next Growth Wave Could Make Early Investors Rich,InvestorPlace,/news/stocks/amzn-stock-outlook-amazons-next-growth-wave-could-make-early-investors-rich-1033524370
3452.0,7/3/2024 3:01:50 AM,FDA Approves Lilly's Kisunla To Treat Early Symptomatic Alzheimer's Disease ,RTTNews,/news/stocks/fda-approves-lilly-s-kisunla-to-treat-early-symptomatic-alzheimer-s-disease-1033524684
3453.0,7/3/2024 11:07:14 AM,Eli Lilly & Co (LLY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-truist-financial-1033527076
3454.0,7/3/2024 11:15:37 AM,Eli Lilly’s Kisunla Approval Spurs Buy Rating Amid Anticipated Revenue Boost and Alzheimer’s Treatment Paradigm Shift,TipRanks,/news/stocks/eli-lilly-s-kisunla-approval-spurs-buy-rating-amid-anticipated-revenue-boost-and-alzheimer-s-treatment-paradigm-shift-1033527131
3455.0,7/3/2024 12:16:06 PM,Eli Lilly’s Promising Alzheimer’s Treatment: A Buy Rating on Kisunla’s Market Potential and Clinical Benefits,TipRanks,/news/stocks/eli-lilly-s-promising-alzheimer-s-treatment-a-buy-rating-on-kisunla-s-market-potential-and-clinical-benefits-1033527318
3456.0,7/3/2024 12:55:31 PM,Eli Lilly & Co (LLY) Gets a Hold from Evercore ISI,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-hold-from-evercore-isi-1033527415
3457.0,7/3/2024 4:01:53 PM,"Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study",Seeking Alpha,https://seekingalpha.com/news/4122130-novo-nordisks-ozempic-linked-eye-disorder?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3458.0,7/3/2024 5:09:17 PM,Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst,Seeking Alpha,https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3459.0,7/3/2024 6:13:19 PM,Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst,Benzinga,/news/stocks/eli-lilly-s-alzheimer-s-therapy-s-broad-label-reflects-regulatory-confidence-in-anti-amyloid-antibodies-analyst-1033527516
3460.0,7/3/2024 7:04:02 PM,"S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?",Benzinga,/news/etf/s-p-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-what-s-driving-markets-wednesday-1033527636
3461.0,7/4/2024 7:05:46 AM,Eli Lilly’s Kisunla Launch: A Cautious Hold Amid Competitive and Logistical Uncertainties,TipRanks,/news/stocks/eli-lilly-s-kisunla-launch-a-cautious-hold-amid-competitive-and-logistical-uncertainties-1033529084
3462.0,7/4/2024 10:35:00 AM,The 3 Best Healthcare Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-july-2024-1033529151
3463.0,7/4/2024 7:45:11 PM,7 High Priced Stocks That Would Benefit From a Stock Split,InvestorPlace,/news/stocks/7-high-priced-stocks-that-would-benefit-from-a-stock-split-1033530303
3464.0,7/5/2024 10:20:00 AM,3 Highly Rated Biotech Stocks for Your July Buy List,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-for-your-july-buy-list-1033531559
3465.0,7/5/2024 7:04:46 PM,"Study links GLP-1 drugs, metformin to lower risk of certain cancers",Seeking Alpha,https://seekingalpha.com/news/4122404-study-links-glp-1-drugs-metformin-to-lower-risk-of-certain-cancers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3466.0,7/6/2024 12:00:00 PM,The 7 Best Under $10 Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-7-best-under-10-stocks-to-buy-in-july-2024-1033533214
3467.0,7/6/2024 6:00:00 PM,"Small, mid-size biotechs could see M&A action in H2 - PwC",Seeking Alpha,https://seekingalpha.com/news/4122402-small-mid-size-biotechs-could-see-ma-action-h2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3468.0,7/7/2024 3:39:52 PM,"EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",Benzinga,/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664
3469.0,7/8/2024 7:55:31 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033535320
3470.0,7/8/2024 11:05:08 AM,Eli Lilly to acquire Morphic for $57 a share in cash,Seeking Alpha,https://seekingalpha.com/news/4122514-eli-lilly-to-acquire-morphic-for-57-a-share-in-cash?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3471.0,7/8/2024 12:53:48 PM,Lilly To Acquire Morphic In Approx. $3.2 Bln Deal - Quick Facts ,RTTNews,/news/stocks/lilly-to-acquire-morphic-in-approx-3-2-bln-deal-quick-facts-1033535308
3472.0,7/8/2024 1:45:25 PM,"Biggest stock movers today: LCID, PARA, GRFS, and more",Seeking Alpha,https://seekingalpha.com/news/4122483-biggest-stock-movers-today-para-and-grfs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3473.0,7/8/2024 4:32:20 PM,3 Overlooked Giants-in-the-Making for Patient Investors,InvestorPlace,/news/stocks/3-overlooked-giants-in-the-making-for-patient-investors-1033536832
3474.0,7/8/2024 11:11:55 PM,Study finds patients lost more weight on Mounjaro than Ozempic,Seeking Alpha,https://seekingalpha.com/news/4122749-study-finds-patients-lost-more-weight-on-mounjaro-than-ozempic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3475.0,7/9/2024 9:27:08 AM,Eli Lilly’s Strategic Acquisition of MORF Bolsters Buy Rating Amid IBD Market Growth Opportunities,TipRanks,/news/stocks/eli-lilly-s-strategic-acquisition-of-morf-bolsters-buy-rating-amid-ibd-market-growth-opportunities-1033539140
3476.0,7/9/2024 10:42:00 AM,7 Bullish Stock Picks With the Potential to Turn $5K Into $50K,InvestorPlace,/news/stocks/7-bullish-stock-picks-with-the-potential-to-turn-5k-into-50k-1033538881
3477.0,7/9/2024 11:15:25 AM,Eli Lilly’s Strategic Expansion and Acquisition Synergy: A Buy Rating Analysis,TipRanks,/news/stocks/eli-lilly-s-strategic-expansion-and-acquisition-synergy-a-buy-rating-analysis-1033540059
3478.0,7/9/2024 6:24:24 PM,Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors,InvestorPlace,/news/stocks/hot-stocks-3-sleeping-giants-about-to-dominate-their-sectors-1033540831
3479.0,7/9/2024 7:00:45 PM,"BMO sees BMRN, LEGN, SLN as attractive M&A targets",Seeking Alpha,https://seekingalpha.com/news/4123073-bmo-sees-bmrn-legn-sln-as-attractive-ma-targets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3480.0,7/9/2024 9:00:47 PM,"Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst",Benzinga,/news/stocks/eli-lilly-s-3-2b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attention-on-obesity-analyst-1033540871
3481.0,7/10/2024 12:19:40 PM,"Most patients discontinue Novo’s Wegovy, Ozempic within two years: report",Seeking Alpha,https://seekingalpha.com/news/4123250-most-patients-stop-wegovy-ozempic-two-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3482.0,7/10/2024 1:05:53 PM,Eli Lilly names Gordon Brooks as interim CFO,Seeking Alpha,https://seekingalpha.com/news/4123281-eli-lilly-names-gordon-brooks-as-interim-cfo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3483.0,7/10/2024 1:10:28 PM,"Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Catalyst Pharma (CPRX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intuitive-surgical-isrg-catalyst-pharma-cprx-and-eli-lilly-co-lly-1033544298
3484.0,7/10/2024 6:34:38 PM,3 Pharma Stocks That Could Make Your Grandchildren Rich,InvestorPlace,/news/stocks/3-pharma-stocks-that-could-make-your-grandchildren-rich-1033544623
3485.0,7/11/2024 5:25:50 AM,Eli Lilly & Co (LLY) Receives a Buy from Berenberg Bank,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-berenberg-bank-1033546156
3486.0,7/11/2024 9:39:42 AM,Eli Lilly & Co: A Strong Buy on Robust Pipeline and Growth Prospects,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-pipeline-and-growth-prospects-1033546921
3487.0,7/11/2024 11:18:20 AM,Pfizer advances development of once-daily weight-loss pill,Seeking Alpha,https://seekingalpha.com/news/4123562-pfizer-advances-development-of-once-daily-weight-loss-pill?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3488.0,7/11/2024 11:56:06 AM,SA subscribers pitch stocks that could potentially replace Tesla in Magnificent 7,Seeking Alpha,https://seekingalpha.com/news/4123564-sa-subscribers-pitch-stocks-that-could-potentially-replace-tesla-in-magnificent-7?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3489.0,7/11/2024 1:00:20 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Biodesix (BDSX) and CVRx (CVRX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-biodesix-bdsx-and-cvrx-cvrx-1033548147
3490.0,7/11/2024 2:10:00 PM,3 Future Blue-Chip Stocks That Could Make You Rich,InvestorPlace,/news/stocks/3-future-blue-chip-stocks-that-could-make-you-rich-1033547734
3491.0,7/11/2024 3:17:00 PM,"Lilly, DaVita, Illumina among top healthcare Quant picks ahead of Q2 earnings",Seeking Alpha,https://seekingalpha.com/news/4123344-lilly-davita-illumina-among-top-healthcare-quant-picks-for-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3492.0,7/12/2024 8:12:28 AM,"This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment",Seeking Alpha,https://seekingalpha.com/news/4123754-weight-loss-amgen-stock-obesity-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3493.0,7/12/2024 10:08:00 AM,The 3 Most Undervalued Biotech Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-july-2024-1033549932
3494.0,7/12/2024 2:27:31 PM,Novo’s Ozempic linked to improved brain health: study,Seeking Alpha,https://seekingalpha.com/news/4123974-novos-ozempic-linked-to-improved-brain-health-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3495.0,7/12/2024 6:26:43 PM,"With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs",Benzinga,/news/stocks/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-presence---goldman-sachs-1033551299
3496.0,7/12/2024 7:57:37 PM,The Next Trillion-Dollar Stocks? 3 Top Contenders to Buy Now,InvestorPlace,/news/stocks/the-next-trillion-dollar-stocks-3-top-contenders-to-buy-now-1033551548
3497.0,7/12/2024 8:55:48 PM,Lilly expecting Q2 IPR&D pre-tax charge of around $0.14 per share: report,Seeking Alpha,https://seekingalpha.com/news/4124073-lilly-expecting-q2-iprd-pre-tax-charge-of-around-014-per-share-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3498.0,7/13/2024 11:30:00 AM,3 Powerful Stocks Worthy of Magnificent 7 Status,InvestorPlace,/news/stocks/3-powerful-stocks-worthy-of-magnificent-7-status-1033551774
3499.0,7/13/2024 1:00:00 PM,The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off,InvestorPlace,/news/stocks/the-7-most-important-stocks-to-watch-as-q2-earnings-season-kicks-off-1033551795
3500.0,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3501.0,7/13/2024 7:34:06 PM,Eli Lilly’s GLP-1 impact on ResMed is overblown: Barron’s,Seeking Alpha,https://seekingalpha.com/news/4124110-resmed-stock-a-buy-despite-lilly-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3502.0,7/14/2024 7:00:00 PM,3 Stocks for Patient Investors Looking to Build Generational Wealth,InvestorPlace,/news/stocks/3-stocks-for-patient-investors-looking-to-build-generational-wealth-1033552534
3503.0,7/15/2024 7:56:10 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033554852
3504.0,7/15/2024 10:58:00 AM,7 Billion-Dollar Stocks That Deserve a Spot in Your Portfolio,InvestorPlace,/news/stocks/7-billion-dollar-stocks-that-deserve-a-spot-in-your-portfolio-1033554910
3505.0,7/15/2024 5:00:00 PM,7 Top-Quality Stocks to Buy Now: July 2024,InvestorPlace,/news/stocks/7-top-quality-stocks-to-buy-now-july-2024-1033556432
3506.0,7/15/2024 7:13:12 PM,"This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges",Benzinga,/news/stocks/this-analyst-sees-potential-downside-in-eli-lilly-adjusts-model-for-acquired-ipr-d-charges-1033556441
3507.0,7/16/2024 5:01:00 PM,"Incyte, Moderna among most shorted S&P 500 healthcare stocks in June",Seeking Alpha,https://seekingalpha.com/news/4124310-incyte-moderna-among-most-shorted-sp-500-healthcare-stocks-in-june?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3508.0,7/16/2024 5:33:42 PM,3 Biotech Stocks to Buy in Case of Another Pandemic,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-in-case-of-another-pandemic-1033560541
3509.0,7/17/2024 5:43:26 AM,Aclaris Sells OLUMIANT Royalties & Milestones To OMERS For Up To $31.5 Mln; Stock Up In After-hours ,RTTNews,/news/stocks/aclaris-sells-olumiant-royalties-milestones-to-omers-for-up-to-31-5-mln-stock-up-in-after-hours-1033561114
3510.0,7/17/2024 10:06:00 AM,3 Moonshot Stocks With the Potential to Turn $10K Into $100K,InvestorPlace,/news/stocks/3-moonshot-stocks-with-the-potential-to-turn-10k-into-1-million-1033540783
3511.0,7/17/2024 11:36:37 AM,"Eli Lilly, Novo slip as Roche posts early-stage data for oral weight loss drug",Seeking Alpha,https://seekingalpha.com/news/4124932-eli-lilly-novo-slip-as-roche-posts-early-stage-data-for-oral-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3512.0,7/17/2024 6:09:20 PM,Big pharma rally after J&J earnings,Seeking Alpha,https://seekingalpha.com/news/4125149-big-pharma-rally-after-jj-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3513.0,7/17/2024 6:25:18 PM,Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio,InvestorPlace,/news/stocks/forget-boring-diversification-3-wild-card-stocks-to-spice-up-your-portfolio-1033565172
3514.0,7/18/2024 9:16:57 AM,Eli Lilly & Co: A Strong Buy on Orforglipron’s Market Lead and Promising Pipeline,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-orforglipron-s-market-lead-and-promising-pipeline-1033568222
3515.0,7/18/2024 9:25:17 AM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033568212
3516.0,7/18/2024 10:16:52 AM,Eli Lilly’s Market Position Challenged by Roche’s CT996: A Hold Rating Justified,TipRanks,/news/stocks/eli-lilly-s-market-position-challenged-by-roche-s-ct996-a-hold-rating-justified-1033568632
3517.0,7/18/2024 12:10:00 PM,"3 Reliable Blue-Chip Stocks to Buy, Hold and Never Let Go",InvestorPlace,/news/stocks/3-reliable-blue-chip-stocks-to-buy-hold-and-never-let-go-1033568295
3518.0,7/18/2024 1:33:46 PM,3 High-Flying Stocks That Show No Signs of Slowing Down,InvestorPlace,/news/stocks/3-high-flying-stocks-that-show-no-signs-of-slowing-down-1033568680
3519.0,7/18/2024 2:06:53 PM,Least shorted S&P 500 stocks in June,Seeking Alpha,https://seekingalpha.com/news/4125485-least-shorted-sp-500-stocks-in-june?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3520.0,7/18/2024 5:05:34 PM,"Eli Lilly, Novo extend muti-day decline in rare selloff",Seeking Alpha,https://seekingalpha.com/news/4125589-eli-lilly-stock-novo-stock-rare-selloff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3521.0,7/18/2024 8:05:29 PM,"VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?",Benzinga,/news/etf/vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-loss-giants-eli-lilly-novo-tumble-what-s-driving-markets-thursday-1033569954
3522.0,7/18/2024 8:51:35 PM,"Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst",Benzinga,/news/stocks/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-says-analyst-1033569993
3523.0,7/18/2024 10:59:13 PM,"EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'",Benzinga,/news/stocks/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-won-t-be-dominated-by-just-2-players-1033570253
3524.0,7/19/2024 11:21:36 AM,Eli Lilly weight loss drug approved in China,Seeking Alpha,https://seekingalpha.com/news/4125778-lilly-stock-gains-obesity-drug-cleared-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3525.0,7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3526.0,7/22/2024 1:02:13 AM,Kamala Harris' potential impact on health care stocks,Seeking Alpha,https://seekingalpha.com/news/4126065-kamala-harris-potential-impact-health-care-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3527.0,7/22/2024 7:52:23 PM,Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.,InvestorPlace,/news/stocks/dont-delay-3-stocks-to-buy-before-q2-earnings-1033579281
3528.0,7/22/2024 8:53:08 PM,AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst,Benzinga,/news/stocks/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lilly-s-analyst-1033579146
3529.0,7/23/2024 3:11:23 PM,U.K. regulators approve Wegovy for prevention of cardiac events,Seeking Alpha,https://seekingalpha.com/news/4126846-uk-regulators-approve-wegovy-for-prevention-of-cardiac-events?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3530.0,7/24/2024 7:40:28 PM,3 Fabulous Growth Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/3-fabulous-growth-stocks-to-buy-and-hold-forever-1033590657
3531.0,7/24/2024 10:00:33 PM,Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts,Benzinga,/news/stocks/expert-outlook-eli-lilly-and-co-through-the-eyes-of-25-analysts-1033590670
3532.0,7/25/2024 10:08:00 AM,Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks,InvestorPlace,/news/stocks/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks-1033593798
3533.0,7/25/2024 11:01:43 AM,"Viking sends Lilly, Novo lower as obesity drug enters late-stage program",Seeking Alpha,https://seekingalpha.com/news/4128191-viking-stock-climbs-obesity-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3534.0,7/25/2024 12:20:55 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-gilead-sciences-gild-1033595679
3535.0,7/25/2024 3:58:18 PM,3 Companies Gearing Up for a Stock Split,InvestorPlace,/news/stocks/3-companies-gearing-up-for-a-stock-split-1033595895
3536.0,7/25/2024 6:29:01 PM,3 Top-Performing Stocks Beating the Big Names in 2024,InvestorPlace,/news/stocks/3-top-performing-stocks-beating-the-big-names-in-2024-1033596309
3537.0,7/25/2024 9:17:16 PM,7 Explosive Growth Stocks Set to Soar in 2024,InvestorPlace,/news/stocks/7-explosive-growth-stocks-set-to-soar-in-2024-1033596726
3538.0,7/26/2024 11:22:32 AM,Biogen-partnered Alzheimer’s therapy fails to clear EU hurdle,Seeking Alpha,https://seekingalpha.com/news/4128882-biogen-stock-slips-lecanemab-rebuffed-eu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3539.0,7/26/2024 3:18:45 PM,AbbVie exits Alzheimer’s program on lack of differentiation,Seeking Alpha,https://seekingalpha.com/news/4129035-abbvie-axes-alzheimers-drug-mid-stage-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3540.0,7/26/2024 6:13:09 PM,FDA issues warning on compounded versions of Novo Nordisk's semaglutide,Seeking Alpha,https://seekingalpha.com/news/4129096-fda-issues-warning-compounded-versions-novo-nordisk-semaglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3541.0,7/28/2024 2:00:00 PM,Most U.S. pharmas don't pay any U.S. income tax,Seeking Alpha,https://seekingalpha.com/news/4129257-most-us-pharmas-dont-pay-any-us-income-tax?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3542.0,7/28/2024 5:00:41 PM,7 Smart Stocks to Buy BEFORE They Report Q2 Earnings,InvestorPlace,/news/stocks/7-smart-stocks-to-buy-before-they-report-q2-earnings-1033602806
3543.0,7/29/2024 8:16:46 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033605623
3544.0,7/29/2024 10:11:23 AM,Roche to fast-track weight loss drugs to compete with rivals - report,Seeking Alpha,https://seekingalpha.com/news/4129338-roche-to-fast-track-weight-loss-drugs-to-compete-with-rivals-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3545.0,7/29/2024 6:53:38 PM,3 Overlooked Stocks Poised for a Breakout Very Soon,InvestorPlace,/news/stocks/3-overlooked-stocks-poised-for-a-breakout-very-soon-1033607686
3546.0,7/30/2024 6:23:50 AM,"Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (AQST), Eli Lilly & Co (LLY) and Owens & Minor (OMI)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-aquestive-therapeutics-aqst-eli-lilly-co-lly-and-owens-minor-omi-1033610702
3547.0,7/30/2024 9:18:45 AM,Eli Lilly & Co Faces European Market Challenges; Analyst Maintains Hold Rating,TipRanks,/news/stocks/eli-lilly-co-faces-european-market-challenges-analyst-maintains-hold-rating-1033611546
3548.0,7/30/2024 10:50:00 AM,Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth,InvestorPlace,/news/stocks/healthy-profits-7-healthcare-stocks-to-build-a-lifetime-of-wealth-1033611118
3549.0,7/30/2024 11:45:00 AM,Unlocking the Next 3 Trillion-Dollar Stock Opportunities,InvestorPlace,/news/stocks/unlocking-the-next-3-trillion-dollar-stock-opportunities-1033611478
3550.0,7/30/2024 3:03:36 PM,Novo’s older obesity drug benefits Alzheimer’s patients in small trial,Seeking Alpha,https://seekingalpha.com/news/4130198-novos-obesity-drug-benefits-alzheimers-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3551.0,7/30/2024 3:54:32 PM,Fractyl gets FDA breakthrough device status for Revita,Seeking Alpha,https://seekingalpha.com/news/4130253-fractyl-gets-fda-breakthrough-device-status-for-revita?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3552.0,7/30/2024 7:07:52 PM,3 Biotech Stocks That Could Make Your Summer Unforgettable,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-make-your-summer-unforgettable-1033613685
3553.0,7/31/2024 11:00:00 AM,The Top 3 Healthcare Stocks to Buy Now: Summer 2024,InvestorPlace,/news/stocks/the-top-3-healthcare-stocks-to-buy-now-summer-2024-1033617324
3554.0,7/31/2024 2:54:40 PM,Vaccinex stock plunges 24% on mixed results for Alzheimer's study,Seeking Alpha,https://seekingalpha.com/news/4131127-vaccinex-stock-plunges-on-mixed-results-for-alzheimers-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3555.0,8/1/2024 11:31:41 AM,Eli Lilly stock rises as weight loss drug tirzepatide reduces heart failure risks in study,Seeking Alpha,https://seekingalpha.com/news/4132068-eli-lillys-weight-loss-drug-tirzepatide-reduces-heart-failure-risks-in-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3556.0,8/1/2024 1:40:27 PM,WW International shares crash as GLP-1 popularity weighs on Q2 profits,Seeking Alpha,https://seekingalpha.com/news/4132311-ww-international-shares-crash-glp-1-popularity-weighs-q2-profits?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3557.0,8/1/2024 2:26:09 PM,Lilly Reports Positive Topline Results From SUMMIT Phase 3 Study Of Tirzepatide ,RTTNews,/news/stocks/lilly-reports-positive-topline-results-from-summit-phase-3-study-of-tirzepatide-1033626313
3558.0,8/1/2024 4:19:01 PM,Morphic Holding ticks higher after HSR waiting period for Eli Lilly deal expires,Seeking Alpha,https://seekingalpha.com/news/4132424-morphic-holding-ticks-higher-after-hsr-waiting-period-for-eli-lilly-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3559.0,8/1/2024 5:06:01 PM,Eli Lilly CEO says weight loss drug shortage is ending,Seeking Alpha,https://seekingalpha.com/news/4132434-eli-lilly-weight-loss-drug-shortage-ending?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3560.0,8/1/2024 7:20:05 PM,What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.,InvestorPlace,/news/stocks/what-are-the-hottest-weight-loss-stocks-right-now-3-top-picks-1033628715
3561.0,8/2/2024 11:49:39 AM,Eli Lilly & Co (LLY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-truist-financial-1033633007
3562.0,8/2/2024 12:29:02 PM,Eli Lilly & Co: Set for Rebound as Analyst Maintains Buy Rating Amidst Potential Turnaround,TipRanks,/news/stocks/eli-lilly-co-set-for-rebound-as-analyst-maintains-buy-rating-amidst-potential-turnaround-1033633273
3563.0,8/2/2024 7:00:00 PM,"Catalyst Watch: Disney earnings, Costco sales update, MicroStrategy split, and eyes on AI patents",Seeking Alpha,https://seekingalpha.com/news/4132451-catalyst-watch-disney-earnings-costco-sales-update-microstrategy-split-and-eyes-on-ai-patents?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3564.0,8/2/2024 7:15:31 PM,Eli Lilly weight loss drug shortage is officially over,Seeking Alpha,https://seekingalpha.com/news/4133557-eli-lillys-zepbound-shortage-is-officially-over?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3565.0,8/3/2024 3:12:23 PM,Viking obesity drug could become direct rival to Eli Lilly’s: report,Seeking Alpha,https://seekingalpha.com/news/4133672-viking-obesity-drug-could-become-direct-rival-to-eli-lillys-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3566.0,8/4/2024 11:00:05 AM,"Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid ",RTTNews,/news/stocks/weekly-biotech-buzz-fgen-cuts-jobs-fda-oks-adap-s-groundbreaking-cell-therapy-me-rebuffs-ceo-bid-1033634796
3567.0,8/4/2024 12:00:00 PM,"Earnings week ahead: Disney, Duke Energy, Palantir, Shopify, Uber and more",Seeking Alpha,https://seekingalpha.com/news/4133349-earnings-week-ahead-disney-duke-energy-palantir-shopify-uber-plug-power-nikola-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3568.0,8/5/2024 6:22:24 AM,Eli Lilly Buy Rating Affirmed Amid Promising Alzheimer’s Treatment Advances,TipRanks,/news/stocks/eli-lilly-buy-rating-affirmed-amid-promising-alzheimer-s-treatment-advances-1033637852
3569.0,8/5/2024 7:40:51 AM,"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-eli-lilly-co-lly-and-teva-pharmaceutical-teva-1033638187
3570.0,8/5/2024 8:28:26 AM,Eli Lilly & Co.: Balancing Tirzepatide’s Supply Challenges with Fundamental Growth Prospects,TipRanks,/news/stocks/eli-lilly-co-balancing-tirzepatide-s-supply-challenges-with-fundamental-growth-prospects-1033638495
3571.0,8/5/2024 8:26:07 PM,"FDA indicates Lilly, Novo weight-loss drug shortages easing",Seeking Alpha,https://seekingalpha.com/news/4134422-fda-indicates-lilly-novo-weight-loss-drug-shortages-easing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3572.0,8/6/2024 10:21:22 PM,Novo Nordisk's Wegovy no longer in shortage,Seeking Alpha,https://seekingalpha.com/news/4135595-novo-nordisk-wegovy-no-longer-shortage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3573.0,8/7/2024 12:18:15 PM,Amgen cut at Wells Fargo; says obesity success is already priced in,Seeking Alpha,https://seekingalpha.com/news/4135878-amgen-stock-cut-wells-fargo-maritide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3574.0,8/7/2024 1:50:00 PM,Novo Nordisk stock falls as Wegovy Q2 sales miss the mark,Seeking Alpha,https://seekingalpha.com/news/4135735-novo-nordisk-boosts-sales-outlook-on-soaring-demand-for-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3575.0,8/7/2024 3:01:13 PM,Eli Lilly and is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-quarter-earnings-preview-q2-1033652826
3576.0,8/7/2024 3:46:20 PM,Eli Lilly Q2 2024 Earnings Preview: Overseas obesity drug approvals could boost guidance,Seeking Alpha,https://seekingalpha.com/news/4136157-eli-lilly-q2-2024-earnings-preview-overseas-obesity-drug-approvals-could-boost-guidance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3577.0,8/8/2024 10:46:13 AM,"Eli Lilly Non-GAAP EPS of $3.92 beats by $1.16, revenue of $11.3B beats by $1.33B",Seeking Alpha,https://seekingalpha.com/news/4136972-eli-lilly-non-gaap-eps-of-3_92-beats-1_16-revenue-of-11_3b-beats-1_33b?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3578.0,8/8/2024 11:02:02 AM,"Earnings Summary: Eli Lilly reports strong Q2, further boosts FY2024 outlook",Seeking Alpha,https://seekingalpha.com/news/4136996-earnings-summary-eli-lilly-reports-strong-q2-further-boosts-fy2024-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3579.0,8/8/2024 11:22:50 AM,Eli Lilly jumps after guidance raise on weight loss momentum,Seeking Alpha,https://seekingalpha.com/news/4137050-eli-lilly-stock-jumps-after-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3580.0,8/8/2024 11:32:12 AM,Eli Lilly Poised for Growth Amidst Sector Challenges: A Buy Rating Analysis,TipRanks,/news/stocks/eli-lilly-poised-for-growth-amidst-sector-challenges-a-buy-rating-analysis-1033661473
3581.0,8/8/2024 11:45:55 AM,"Eli Lilly in charts: Mounjaro, Zepbound, Verzenio, and Jardiance power Q2 performance",Seeking Alpha,https://seekingalpha.com/news/4137087-eli-lilly-in-charts-mounjaro-zepbound-verzenio-and-jardiance-power-q2-performance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3582.0,8/8/2024 12:50:27 PM,"Eli Lilly And Co. Q2 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/eli-lilly-and-co-q2-profit-increases-beats-estimates-1033659815
3583.0,8/8/2024 12:59:49 PM,Eli Lilly Again Boosts FY24 Outlook - Update ,RTTNews,/news/stocks/eli-lilly-again-boosts-fy24-outlook-update-1033659870
3584.0,8/8/2024 1:24:00 PM,"4 stocks to watch on Thursday: LLY, HOOD and more",Seeking Alpha,https://seekingalpha.com/news/4137228-4-stocks-to-watch-on-thursday-lly-hood-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3585.0,8/8/2024 1:28:17 PM,LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?,InvestorPlace,/news/stocks/lly-stock-alert-why-are-eli-lilly-shares-surging-today-1033660905
3586.0,8/8/2024 2:26:51 PM,"Biggest stock movers today: UAA, WBD, MNST, and more",Seeking Alpha,https://seekingalpha.com/news/4136848-biggest-stock-movers-today-wbd-mnst-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3587.0,8/8/2024 3:52:37 PM,"Volume Leaders: MCK, UAA, HOOD, LLY, and more",Seeking Alpha,https://seekingalpha.com/news/4137378-volume-leaders-mck-uaa-hood-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3588.0,8/8/2024 4:05:07 PM,Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook ,RTTNews,/news/stocks/eli-lilly-q2-results-top-estimates-boosts-fy24-outlook-1033661265
3589.0,8/8/2024 6:02:29 PM,Lilly Alzheimer's asset targeting tau protein fails in phase 2,Seeking Alpha,https://seekingalpha.com/news/4137445-lilly-alzheimers-asset-targeting-tau-protein-fails-phase-2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3590.0,8/9/2024 7:52:31 AM,Eli Lilly & Co (LLY) Receives a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-barclays-1033668437
3591.0,8/9/2024 10:00:39 AM,Eli Lilly & Co (LLY) Buy Rating Affirmed on Strong HFpEF Data and Competitive Edge Over Novo Nordisk (NVO),TipRanks,/news/stocks/eli-lilly-co-lly-buy-rating-affirmed-on-strong-hfpef-data-and-competitive-edge-over-novo-nordisk-nvo-1033669036
3592.0,8/9/2024 12:05:01 PM,"Dividend Roundup: Prudential Financial, Progressive, Alcoa, Eli Lilly, and more",Seeking Alpha,https://seekingalpha.com/news/4138000-dividend-roundup-prudential-financial-progressive-alcoa-eli-lilly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3593.0,8/9/2024 12:39:49 PM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033670004
3594.0,8/9/2024 12:46:04 PM,Eli Lilly & Co: Hold Recommendation Amid Robust Performance and Market Uncertainties,TipRanks,/news/stocks/eli-lilly-co-hold-recommendation-amid-robust-performance-and-market-uncertainties-1033670178
3595.0,8/9/2024 12:51:09 PM,"Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-crinetics-pharmaceuticals-crnx-eli-lilly-co-lly-1033670140
3596.0,8/9/2024 1:28:46 PM,Jefferies Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/jefferies-remains-a-buy-on-eli-lilly-co-lly-1033670514
3597.0,8/9/2024 3:13:39 PM,Eli Lilly & Co: A Balanced Hold Rating Amid Growth and Competitive Challenges,TipRanks,/news/stocks/eli-lilly-co-a-balanced-hold-rating-amid-growth-and-competitive-challenges-1033670887
3598.0,8/9/2024 4:02:42 PM,3 Healthcare Stocks to Sell in August Before They Crash & Burn,InvestorPlace,/news/stocks/3-healthcare-stocks-to-sell-in-august-before-they-crash-burn-1033670345
3599.0,8/9/2024 7:19:52 PM,Eli Lilly a new 'top pick' at Morgan Stanley following strong Q2 results,Seeking Alpha,https://seekingalpha.com/news/4138313-eli-lilly-new-top-pick-morgan-stanley-following-strong-q2-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3600.0,8/10/2024 10:32:00 AM,3 Stocks to Load-Up On Before Autumn Arrives,InvestorPlace,/news/stocks/3-stocks-to-load-up-on-before-autumn-arrives-2-1033671324
3601.0,8/11/2024 11:57:04 AM,About 73% of the S&P 500 names beat on EPS during the week - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4138410-about-73-of-the-sp-500-names-beat-on-eps-during-the-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3602.0,8/12/2024 7:50:47 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033676436
3603.0,8/12/2024 1:58:15 PM,Deutsche Bank calls Eli Lilly a ‘high growth unicorn’ in upgrade to Buy,Seeking Alpha,https://seekingalpha.com/news/4138646-deutsche-bank-calls-eli-lilly-high-growth-unicorn-in-upgrade-to-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3604.0,8/13/2024 12:09:50 PM,Eli Lilly opens R&D center in Boston Seaport,Seeking Alpha,https://seekingalpha.com/news/4139071-eli-lilly-opens-rd-center-in-boston-seaport?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3605.0,8/13/2024 2:08:54 PM,3 Stocks on the Rise After Stellar Q2 Earnings Results,InvestorPlace,/news/stocks/3-stocks-on-the-rise-after-stellar-q2-earnings-results-1033682606
3606.0,8/13/2024 6:17:41 PM,Eli Lilly & Co: A Strong Buy on Robust Pipeline and Market Leadership,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-pipeline-and-market-leadership-1033684030
3607.0,8/14/2024 5:16:22 AM,Berenberg Bank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/berenberg-bank-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033687043
3608.0,8/14/2024 10:01:18 PM,"Bridgewater adds to Amazon, Microsoft, exits Intel, Devon, others in Q2",Seeking Alpha,https://seekingalpha.com/news/4140130-bridgewater-adds-to-amazon-microsoft-exits-intel-devon-others-in-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3609.0,8/15/2024 1:31:20 AM,"LLY, NVO: Which GLP-1 Stock Is the Better Bet?",TipRanks,/news/stocks/lly-nvo-which-glp-1-stock-is-the-better-bet-1033692804
3610.0,8/15/2024 10:00:00 AM,3 Biotech Stocks to Buy on the Dip: August 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-on-the-dip-august-2024-1033694134
3611.0,8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3612.0,8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3613.0,8/15/2024 5:47:22 PM,Moderna was the most shorted S&P 500 healthcare stock in July,Seeking Alpha,https://seekingalpha.com/news/4139953-moderna-was-the-most-shorted-sp-500-healthcare-stock-in-july?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3614.0,8/15/2024 9:21:59 PM,Philippe Laffont's Coatue Management ups Nvidia stake by nearly tenfold among top Q2 moves,Seeking Alpha,https://seekingalpha.com/news/4140822-philippe-laffonts-coatue-management-ups-nvidia-stake-by-nearly-tenfold-among-top-q2-moves?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3615.0,8/17/2024 6:00:44 PM,"J&J, Roche come out on top in S&P ratings of strongest pharma companies",Seeking Alpha,https://seekingalpha.com/news/4141255-johnson-johnson-roche-come-out-top-in-ratings-strongest-pharma-companies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3616.0,8/17/2024 6:31:00 PM,"Notable analyst calls this week: WBD, Medtronic and Dell among top picks",Seeking Alpha,https://seekingalpha.com/news/4141124-notable-analyst-calls-this-week-wbd-medtronic-and-dell-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3617.0,8/19/2024 12:16:42 PM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033704774
3618.0,8/20/2024 11:12:49 AM,Eli Lilly’s tirzepatide cuts risk of diabetes by 94% in obese patients,Seeking Alpha,https://seekingalpha.com/news/4141781-lillys-tirzepatide-cuts-risk-of-diabetes-by-94-in-obese-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3619.0,8/20/2024 12:45:37 PM,"Eli Lilly, Organon expand distribution deal for migraine drug",Seeking Alpha,https://seekingalpha.com/news/4141846-eli-lilly-organon-expand-distribution-deal-for-migraine-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3620.0,8/20/2024 1:09:27 PM,Eli Lilly: Tirzepatide Lowers Risk Of Developing Type 2 Diabetes By 94% In 3-yr Study ,RTTNews,/news/stocks/eli-lilly-tirzepatide-lowers-risk-of-developing-type-2-diabetes-by-94-in-3-yr-study-1033706827
3621.0,8/20/2024 1:28:00 PM,"4 stocks to watch on Tuesday: LOW, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4141885-4-stocks-to-watch-on-tuesday-low-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3622.0,8/20/2024 1:50:43 PM,"Biggest stock movers today: LLY, PANW, FN, and more",Seeking Alpha,https://seekingalpha.com/news/4141719-biggest-stock-movers-today-panw-fn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3623.0,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3624.0,8/20/2024 7:01:10 PM,Eli Lilly to examine weight loss med Zepbound for immune disorders -- report,Seeking Alpha,https://seekingalpha.com/news/4142053-eli-lilly-weight-loss-med-zepbound-under-investigation-immune-disorders-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3625.0,8/20/2024 7:59:30 PM,Novo Nordisk weight loss med semaglutide linked to suicidal thoughts,Seeking Alpha,https://seekingalpha.com/news/4142061-novo-nordisk-weight-loss-med-semaglutide-linked-suicidal-thoughts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3626.0,8/21/2024 11:45:55 AM,Eli Lilly’s Tirzepatide Shows Promising Efficacy in T2D Prevention and Weight Loss: Buy Rating Justified,TipRanks,/news/stocks/eli-lilly-s-tirzepatide-shows-promising-efficacy-in-t2d-prevention-and-weight-loss-buy-rating-justified-1033711639
3627.0,8/22/2024 4:37:22 AM,"Eli Lilly’s Tirzepatide Shows Promise in Preventing Type 2 Diabetes, Earns Buy Rating",TipRanks,/news/stocks/eli-lilly-s-tirzepatide-shows-promise-in-preventing-type-2-diabetes-earns-buy-rating-1033713534
3628.0,8/24/2024 5:16:09 PM,Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report,Seeking Alpha,https://seekingalpha.com/news/4143531-eli-lilly-alzheimers-drug-face-uk-rejection?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3629.0,8/25/2024 6:00:00 PM,"Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market",Seeking Alpha,https://seekingalpha.com/news/4143506-eli-lilly-novo-nordisk-maintain-two-horse-race-glp-1-weight-loss-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3630.0,8/26/2024 7:45:11 AM,Eli Lilly & Co (LLY) Receives a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-barclays-1033721511
3631.0,8/27/2024 11:14:45 AM,"Pfizer launches direct sales website for common vaccines, medicines",Seeking Alpha,https://seekingalpha.com/news/4144069-pfizer-launches-direct-sales-website-for-common-vaccines-medicines?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3632.0,8/27/2024 11:35:14 AM,Eli Lilly Zepbound prices slashed by 50% for lowest doses,Seeking Alpha,https://seekingalpha.com/news/4144077-eli-lilly-zepbound-low-dose-price-cut-50?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3633.0,8/27/2024 12:55:26 PM,Eli Lilly’s Strategic Initiatives in Drug Accessibility Prompts Buy Rating,TipRanks,/news/stocks/eli-lilly-s-strategic-initiatives-in-drug-accessibility-prompts-buy-rating-1033726211
3634.0,8/27/2024 1:28:29 PM,Lilly Releases 2.5 Mg And 5 Mg Vials Of Obesity Drug Zepbound ,RTTNews,/news/stocks/lilly-releases-2-5-mg-and-5-mg-vials-of-obesity-drug-zepbound-1033725035
3635.0,8/27/2024 6:20:34 PM,"Walgreens, Hims stocks drop as Lilly rolls out cheap weight-loss drugs",Seeking Alpha,https://seekingalpha.com/news/4144270-walgreens-hims-stocks-drop-as-lilly-rolls-out-cheap-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3636.0,8/27/2024 7:00:55 PM,Weight loss drug developers slump as Eli Lilly slashes cost of some Zepbound doses,Seeking Alpha,https://seekingalpha.com/news/4144285-weight-loss-drug-developers-slump-eli-lilly-slashes-cost-some-zepbound-doses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3637.0,8/27/2024 9:12:01 PM,FDA approves Illumina's TruSight Oncology biomarker test,Seeking Alpha,https://seekingalpha.com/news/4144349-fda-approves-illumina-trusight-oncology-biomarker-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3638.0,8/27/2024 10:52:39 PM,Medicare coverage of Novo Nordisk's Wegovy could cost up to $145B annually,Seeking Alpha,https://seekingalpha.com/news/4144361-medicare-coverage-novo-nordisk-wegovy-could-cost-145b-annually?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3639.0,8/28/2024 12:05:54 PM,Eli Lilly & Co: Strategic Pricing and Market Expansion Fuel Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strategic-pricing-and-market-expansion-fuel-buy-rating-1033729591
3640.0,8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3641.0,8/29/2024 6:27:02 PM,Eli Lilly’s Zepbound price cut comes with shocker for those on patient assistance,Seeking Alpha,https://seekingalpha.com/news/4145247-eli-lilly-zepbound-price-cut-comes-with-shocker?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3642.0,9/3/2024 9:01:28 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033743264
3643.0,9/3/2024 9:02:35 AM,"Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-alnylam-pharma-alny-eli-lilly-co-lly-1033743259
3644.0,9/3/2024 11:14:01 AM,Novo Nordisk warns of continued Ozempic shortage in Q4,Seeking Alpha,https://seekingalpha.com/news/4146035-novo-nordisk-warns-of-continued-ozempic-shortage-in-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3645.0,9/4/2024 11:01:23 AM,Eli Lilly inks licensing deal to expand Olumiant access in Africa,Seeking Alpha,https://seekingalpha.com/news/4146624-eli-lilly-inks-licensing-deal-to-expand-olumiant-access-in-africa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3646.0,9/4/2024 12:34:09 PM,Lilly And EVA Pharma To Expand Access To Baricitinib In Low-to Middle-income Countries In Africa ,RTTNews,/news/stocks/lilly-and-eva-pharma-to-expand-access-to-baricitinib-in-low-to-middle-income-countries-in-africa-1033746475
3647.0,9/4/2024 12:56:11 PM,Novartis expands U.S. radiopharma production amid rising competition,Seeking Alpha,https://seekingalpha.com/news/4146729-novartis-expands-us-radiopharma-production-amid-rising-competition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3648.0,9/4/2024 2:55:22 PM,Eli Lilly’s quest for obesity drugs leads to $1B bet on dark genome,Seeking Alpha,https://seekingalpha.com/news/4146895-eli-lilly-bets-up-1b-haya-deal-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3649.0,9/4/2024 6:21:24 PM,"UK regulators find no link between certain GLP-1 drugs, suicidal thoughts",Seeking Alpha,https://seekingalpha.com/news/4147000-uk-regulators-find-no-link-between-certain-glp-1-drugs-suicidal-thoughts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3650.0,9/4/2024 6:36:05 PM,Inspire Medical gains on GLP-1 prospects,Seeking Alpha,https://seekingalpha.com/news/4147002-inspire-medical-stock-gains-glp-1-prospects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3651.0,9/4/2024 9:28:01 PM,"QIAGEN, Lilly to develop Alzheimer's risk detection test",Seeking Alpha,https://seekingalpha.com/news/4147100-qiagen-lilly-to-develop-alzheimers-risk-detection-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3652.0,9/5/2024 5:15:51 AM,"QIAGEN, Lilly To Develop QIAstat-Dx IVD Panel For Early Alzheimer's Disease Risk Identification ",RTTNews,/news/stocks/qiagen-lilly-to-develop-qiastat-dx-ivd-panel-for-early-alzheimer-s-disease-risk-identification-1033749015
3653.0,9/5/2024 11:27:49 AM,Eli Lilly marks late-stage trial win for once weekly insulin,Seeking Alpha,https://seekingalpha.com/news/4147209-eli-lilly-marks-trial-win-once-weekly-insulin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3654.0,9/5/2024 11:55:59 AM,Evercore ISI Keeps Their Hold Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/evercore-isi-keeps-their-hold-rating-on-eli-lilly-co-lly-1033751427
3655.0,9/5/2024 1:16:27 PM,"Lilly's QWINT-1, QWINT-3 Phase 3 Studies In Once Weekly Insulin Efsitora Alfa Meet Primary Goals ",RTTNews,/news/stocks/lilly-s-qwint-1-qwint-3-phase-3-studies-in-once-weekly-insulin-efsitora-alfa-meet-primary-goals-1033750183
3656.0,9/5/2024 5:16:14 PM,Perspective gets FDA fast track status for radiopharmaceutical VMT101,Seeking Alpha,https://seekingalpha.com/news/4147405-perspective-gets-fda-fast-track-status-for-radiopharmaceutical-vmt101?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3657.0,9/5/2024 5:16:14 PM,Perspective gets FDA fast track status for radiopharmaceutical VMT01,Seeking Alpha,https://seekingalpha.com/news/4147405-perspective-gets-fda-fast-track-status-for-radiopharmaceutical-vmt01?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3658.0,9/5/2024 6:41:56 PM,Eli Lilly bets $409M for AI-focused drug discovery,Seeking Alpha,https://seekingalpha.com/news/4147427-eli-lilly-bets-409m-for-ai-focused-drug-discovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3659.0,9/5/2024 9:25:20 PM,Eli Lilly: A Strong Buy on Promising Once-Weekly Insulin Efsitora and Positive Market Outlook,TipRanks,/news/stocks/eli-lilly-a-strong-buy-on-promising-once-weekly-insulin-efsitora-and-positive-market-outlook-1033752261
3660.0,9/9/2024 7:55:38 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033756800
3661.0,9/9/2024 10:55:02 AM,Eli Lilly taps veteran Lucas Montarce as new CFO,Seeking Alpha,https://seekingalpha.com/news/4147932-eli-lilly-taps-veteran-lucas-montarce-as-new-cfo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3662.0,9/9/2024 12:47:33 PM,Terns stock jumps as weight loss drug succeeds in early trial,Seeking Alpha,https://seekingalpha.com/news/4147984-terns-stock-jumps-as-weight-loss-drug-succeeds-in-early-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3663.0,9/9/2024 1:04:53 PM,Lilly Names Lucas Montarce EVP And CFO With Immediate Effect ,RTTNews,/news/stocks/lilly-names-lucas-montarce-evp-and-cfo-with-immediate-effect-1033756824
3664.0,9/10/2024 2:58:30 PM,Global stocks with the highest Triple Momentum analysis – BofA,Seeking Alpha,https://seekingalpha.com/news/4148393-global-stocks-with-the-highest-triple-momentum-analysis-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3665.0,9/10/2024 7:21:12 PM,UBS updates its ‘election watch’ stocks to match new winning probabilities,Seeking Alpha,https://seekingalpha.com/news/4148454-ubs-updates-its-election-watch-stocks-to-match-new-winning-probabilities?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3666.0,9/10/2024 7:47:02 PM,Altimmune spikes after presenting data for obesity drug,Seeking Alpha,https://seekingalpha.com/news/4148457-altimmune-stock-spikes-obesity-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3667.0,9/10/2024 10:56:30 PM,16 new GLP-1 weight-loss drugs could be launched by 2029: report,Seeking Alpha,https://seekingalpha.com/news/4148522-16-new-glp-1-weight-loss-drugs-could-be-launched-by-2029-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3668.0,9/11/2024 3:40:22 AM,Lilly's Weekly Efsitora Alfa Insulin Delivers A1C Reduction Consistent With Daily Insulin ,RTTNews,/news/stocks/lilly-s-weekly-efsitora-alfa-insulin-delivers-a1c-reduction-consistent-with-daily-insulin-1033762075
3669.0,9/11/2024 12:36:23 PM,Evercore ISI Reaffirms Their Hold Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/evercore-isi-reaffirms-their-hold-rating-on-eli-lilly-co-lly-1033764711
3670.0,9/11/2024 12:40:10 PM,Viking spikes as J.P. Morgan recommends ahead of key obesity drug readout,Seeking Alpha,https://seekingalpha.com/news/4148645-viking-stock-spikes-jp-morgan-recommends?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3671.0,9/11/2024 5:28:48 PM,"Roche falls while Novo, Lilly gain on weight-loss drug report",Seeking Alpha,https://seekingalpha.com/news/4148758-roche-falls-while-novo-lilly-gain-on-weight-loss-drug-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3672.0,9/12/2024 9:58:56 AM,Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland,Seeking Alpha,https://seekingalpha.com/news/4148911-eli-lilly-invests-18b-to-boost-manufacturing-footprint-in-ireland?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3673.0,9/12/2024 12:00:35 PM,Eli Lilly Lifts Manufacturing Investment In Limerick By $1 Bln - Quick Facts ,RTTNews,/news/stocks/eli-lilly-lifts-manufacturing-investment-in-limerick-by-1-bln-quick-facts-1033766242
3674.0,9/12/2024 4:57:26 PM,Each U.S. state has at least 20% of adults living with obesity: CDC,Seeking Alpha,https://seekingalpha.com/news/4149176-each-us-state-has-at-least-20-of-adults-living-with-obesity-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3675.0,9/12/2024 5:57:26 PM,Noom launches cheaper compounded version of Novo's semaglutide,Seeking Alpha,https://seekingalpha.com/news/4149198-noom-launches-cheaper-compounded-version-of-semaglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3676.0,9/13/2024 8:56:39 AM,Eli Lilly & Co (LLY) Gets a Buy from Citi,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-citi-1033769922
3677.0,9/13/2024 12:43:38 PM,Eli Lilly wins buy as Citi resumes coverage on obesity prospects,Seeking Alpha,https://seekingalpha.com/news/4149428-eli-lilly-stock-gains-citi-resumes-at-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3678.0,9/13/2024 12:56:51 PM,Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bank-of-america-securities-1033771009
3679.0,9/13/2024 8:38:21 PM,Lilly gains FDA approval for lebrikizumab for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/4149730-lilly-gains-fda-approval-for-lebrikizumab-atopic-dermatitis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3680.0,9/15/2024 1:36:00 PM,Least shorted S&P 500 stocks in August,Seeking Alpha,https://seekingalpha.com/news/4149788-least-shorted-sp-500-stocks-in-august?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3681.0,9/15/2024 2:07:52 PM,Do queasy side effects mean the end of weight-loss drug stock hype?,Seeking Alpha,https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3682.0,9/16/2024 7:25:20 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033773603
3683.0,9/16/2024 2:49:45 PM,Moderna was most shorted S&P 500 healthcare stock in August for second consecutive month,Seeking Alpha,https://seekingalpha.com/news/4149983-moderna-was-most-shorted-sp-500-healthcare-stock-in-august-for-second-consecutive-month?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3684.0,9/17/2024 5:20:43 PM,Rhythm Pharma draws bullish view at JMP on opportunity in rare genetic obesities,Seeking Alpha,https://seekingalpha.com/news/4150393-rhythm-pharma-stock-draws-bullish-view-at-jmp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3685.0,9/18/2024 4:56:58 PM,Sanders says generic drugmakers could sell Novo Nordisk Ozempic for less than $100,Seeking Alpha,https://seekingalpha.com/news/4150792-sen-sanders-claims-generic-drugmakers-sell-ozempic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3686.0,9/18/2024 6:05:40 PM,ResMed slips as Wolfe downgrades on GLP-1 threat from Lilly,Seeking Alpha,https://seekingalpha.com/news/4150858-resmed-stock-cut-wolfe-lilly-glp-1-threat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3687.0,9/19/2024 11:54:21 AM,Vanda slips as FDA rejects therapy for stomach condition,Seeking Alpha,https://seekingalpha.com/news/4151038-vanda-stock-slips-fda-snub-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3688.0,9/19/2024 3:15:37 PM,Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO,Seeking Alpha,https://seekingalpha.com/news/4151220-obesity-drug-developer-bioage-sets-ipo-terms?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3689.0,9/19/2024 4:42:16 PM,Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin,Seeking Alpha,https://seekingalpha.com/news/4151269-tandem-diabetes-rises-insulin-pump-cleared-use-eu-lilly-insulin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3690.0,9/20/2024 2:21:41 PM,Lilly asks people who took compounded tirzepatide for their medical records,Seeking Alpha,https://seekingalpha.com/news/4151567-lilly-asks-people-took-compounded-tirzepatide-medical-records?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3691.0,9/20/2024 3:35:17 PM,Eli Lilly’s Competitive Edge in Weight Loss Medication Market Bolstered by Orforglipron’s Promising Trial Results,TipRanks,/news/stocks/eli-lilly-s-competitive-edge-in-weight-loss-medication-market-bolstered-by-orforglipron-s-promising-trial-results-1033787597
3692.0,9/20/2024 3:49:22 PM,Novo Nordisk down 6% on data for oral weight loss drug onlunabant,Seeking Alpha,https://seekingalpha.com/news/4151646-novo-nordisk-down-6-data-oral-weight-loss-drug-onlunabant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3693.0,9/20/2024 4:09:55 PM,Novo Nordisk down 6% on data for oral weight loss drug monlunabant,Seeking Alpha,https://seekingalpha.com/news/4151646-novo-nordisk-down-6-data-oral-weight-loss-drug-monlunabant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3694.0,9/20/2024 5:17:34 PM,"UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices",Seeking Alpha,https://seekingalpha.com/news/4151680-unitedhealth-cigna-cvs-pbms-targeted-ftc-inflated-insulin-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3695.0,9/21/2024 11:45:40 AM,Eli Lilly & Co: Maintaining Market Dominance with Orforglipron Amid Competitor Challenges,TipRanks,/news/stocks/eli-lilly-co-maintaining-market-dominance-with-orforglipron-amid-competitor-challenges-1033787883
3696.0,9/21/2024 11:55:57 AM,Eli Lilly: A Strong Buy Amidst Obesity Treatment Market Dominance and Expanding Pipeline,TipRanks,/news/stocks/eli-lilly-a-strong-buy-amidst-obesity-treatment-market-dominance-and-expanding-pipeline-1033787873
3697.0,9/21/2024 8:00:07 PM,Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market,Seeking Alpha,https://seekingalpha.com/news/4151752-novartis-pluvicto-expected-dominate-prostate-cancer-radiopharmaceutical-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3698.0,9/23/2024 1:22:37 PM,Mizuho recommends buying Corbus following its drop post-Novo's obesity data,Seeking Alpha,https://seekingalpha.com/news/4151904-mizuho-recommends-buying-corbus-following-its-drop-post-novos-obesity-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3699.0,9/23/2024 5:30:12 PM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Aura Biosciences Inc (AURA)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-aura-biosciences-inc-aura-1033791834
3700.0,9/23/2024 5:47:31 PM,Morgan Stanley starts Structure Therapeutics at overweight,Seeking Alpha,https://seekingalpha.com/news/4152192-morgan-stanley-starts-structure-therapeutics-at-overweight?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3701.0,9/23/2024 7:17:40 PM,UCB gets expanded FDA approval for psoriasis drug Bimzelx,Seeking Alpha,https://seekingalpha.com/news/4152277-ucb-gets-expanded-fda-approval-for-psoriasis-drug-bimzelx?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3702.0,9/23/2024 8:26:47 PM,Senate HELP Committee hearing could get heated as Novo Nordisk CEO testifies,Seeking Alpha,https://seekingalpha.com/news/4152285-senate-help-committee-hearing-could-get-heated-novo-nordisk-ceo-testifies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3703.0,9/24/2024 10:22:45 AM,Eli Lilly's Alzheimer's therapy approved in Japan,Seeking Alpha,https://seekingalpha.com/news/4152449-eli-lillys-alzheimers-therapy-approved-in-japan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3704.0,9/24/2024 12:35:13 PM,Lilly Gets Approval For Its Alzheimer's Disease Drug Kisunla In Japan ,RTTNews,/news/stocks/lilly-gets-approval-for-its-alzheimer-s-disease-drug-kisunla-in-japan-1033793048
3705.0,9/24/2024 4:07:15 PM,Roche narrows pipeline to 11 disease areas amidst weight loss push - WSJ,Seeking Alpha,https://seekingalpha.com/news/4152759-roche-narrows-pipeline-11-disease-areas-amidst-weight-loss-push?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3706.0,9/25/2024 1:50:13 PM,Lilly Reports New Long-term Data For Its Atopic Dermatitis Treatment Ebglyss ,RTTNews,/news/stocks/lilly-reports-new-long-term-data-for-its-atopic-dermatitis-treatment-ebglyss-1033796465
3707.0,9/25/2024 2:48:47 PM,Lilly Ebglyss demonstrates durable disease control in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/4153146-lilly-ebglyss-demonstrates-durable-disease-control-in-atopic-dermatitis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3708.0,9/25/2024 3:47:35 PM,"Novo Nordisk, Lilly weight loss drugs poised for price reductions: Cantor's Louise Chen",Seeking Alpha,https://seekingalpha.com/news/4153231-novo-nordisk-lilly-weight-loss-drugs-poised--price-reductions-cantor-louise-chen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3709.0,9/25/2024 4:45:53 PM,Novo Nordisk's Ozempic could have another benefit: reducing opioid overdoses,Seeking Alpha,https://seekingalpha.com/news/4153287-novo-nordisk-ozempic-could-have-another-benefit-reducing-opioid-overdoses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3710.0,9/25/2024 5:06:51 PM,"BioAge, obesity drug developer, upsizes proposed IPO",Seeking Alpha,https://seekingalpha.com/news/4153310-bioage-obesity-drug-developer-upsizes-proposed-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3711.0,9/25/2024 6:29:49 PM,Amgen stock slides 5% as analysts weigh in on drug study results,Seeking Alpha,https://seekingalpha.com/news/4153393-amgen-stock-slides-as-analysts-weigh-in-on-drug-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3712.0,9/25/2024 6:55:41 PM,Next frontier in anti-obesity landscape: oral GLP-1s with potential OTC switch,Seeking Alpha,https://seekingalpha.com/news/4153415-next-frontier-in-anti-obesity-drugs-oral-glp-1s-with-otc-switch?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3713.0,9/26/2024 4:35:56 PM,BioAge stock rallies 29% following upsized $198M IPO,Seeking Alpha,https://seekingalpha.com/news/4153819-bioage-stock-rallies-following-upsized-198m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3714.0,9/26/2024 9:30:32 PM,"Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab ",RTTNews,/news/stocks/investigation-discloses-safety-efficacy-concerns-about-eli-lilly-s-donanemab-1033801945
3715.0,9/27/2024 5:59:43 PM,"Bristol Cobenfy approval draws optimism from Street, though with caveats",Seeking Alpha,https://seekingalpha.com/news/4154179-bristol-cobenfy-approval-draws-optimism-from-street-though-with-caveats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3716.0,9/27/2024 10:03:02 PM,Lilly gets traditional FDA approval for Retevmo for thyroid cancer,Seeking Alpha,https://seekingalpha.com/news/4154298-lilly-gets-traditional-fda-approval-for-retevmo-for-thyroid-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3717.0,9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3718.0,9/30/2024 7:15:25 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033806917
3719.0,9/30/2024 11:05:34 AM,Eli Lilly & Co: Strong Buy Rating Amid Robust Product Growth and Promising Pipeline,TipRanks,/news/stocks/eli-lilly-co-strong-buy-rating-amid-robust-product-growth-and-promising-pipeline-1033808038
3720.0,9/30/2024 3:25:11 PM,Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report,Seeking Alpha,https://seekingalpha.com/news/4154563-roche-sees-carmot-obesity-drugs-potential-peak-sales-at-4b-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3721.0,9/30/2024 7:23:25 PM,Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset,Seeking Alpha,https://seekingalpha.com/news/4154703-nektar-rises-11-btig-initiates-buy-rating-autoimmune-disorders-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3722.0,10/1/2024 2:22:33 PM,Lilly looking to test Zepbound as health maintenance drug: report,Seeking Alpha,https://seekingalpha.com/news/4155026-lilly-looking-to-test-zepbound-as-health-maintenance-drug-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3723.0,10/1/2024 7:35:29 PM,U.S. port strike expected to have limited impact on healthcare supply chain: HHS,Seeking Alpha,https://seekingalpha.com/news/4155196-us-port-strike-have-limited-impact-medical-supplies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3724.0,10/2/2024 11:55:06 AM,Eli Lilly announces $4.5B production/R&D site in Indiana,Seeking Alpha,https://seekingalpha.com/news/4155415-eli-lilly-announces-45b-site-indiana?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3725.0,10/2/2024 12:25:59 PM,Cantor Fitzgerald Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-remains-a-buy-on-eli-lilly-co-lly-1033815972
3726.0,10/2/2024 1:40:27 PM,Eli Lilly To Create Indiana Medicine Foundry For Advanced Manufacturing And Drug Development ,RTTNews,/news/stocks/eli-lilly-to-create-indiana-medicine-foundry-for-advanced-manufacturing-and-drug-development-1033814674
3727.0,10/2/2024 2:07:00 PM,Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3,Seeking Alpha,https://seekingalpha.com/news/4155316-bristol-myers-tops-growth-chart-among-sp-500-healthcare-stocks-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3728.0,10/3/2024 10:25:28 AM,Eli Lilly & Co: Resolution of Tirzepatide Supply Issue Bolsters Buy Rating,TipRanks,/news/stocks/eli-lilly-co-resolution-of-tirzepatide-supply-issue-bolsters-buy-rating-1033818218
3729.0,10/3/2024 11:16:47 AM,Eli Lilly & Co (LLY) Gets a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-truist-financial-1033818716
3730.0,10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3731.0,10/3/2024 12:59:00 PM,"4 stocks to watch on Thursday: STZ, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4155935-4-stocks-to-watch-on-thursday-stz-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3732.0,10/3/2024 1:46:03 PM,"Eli Lilly GLP-1 shortage officially ends, hurting Hims & Hers",Seeking Alpha,https://seekingalpha.com/news/4155847-eli-lillys-weight-loss-drug-no-longer-in-shortage-fda-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3733.0,10/3/2024 2:15:33 PM,Eli Lilly weight loss therapy on track for NHS rollout in England,Seeking Alpha,https://seekingalpha.com/news/4156017-eli-lilly-zepbound-track-nhs-rollout?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3734.0,10/3/2024 6:40:10 PM,Is Hims & Hers rally at risk as GLP-1 shortages ease?,Seeking Alpha,https://seekingalpha.com/news/4156219-can-hims-hers-stock-rally-glp-1-shortages?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3735.0,10/5/2024 5:45:56 PM,"Can Novo, Lilly take credit for U.S. obesity rate decline?",Seeking Alpha,https://seekingalpha.com/news/4156593-did-novo-lilly-cause-us-obesity-rate-decline?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3736.0,10/7/2024 7:26:37 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033824084
3737.0,10/7/2024 2:03:41 PM,Pfizer stock climbs 4% amid reports Starboard has taken $1B stake,Seeking Alpha,https://seekingalpha.com/news/4156751-pfizer-stock-climbs-amid-reports-starboard-has-taken-1b-stake?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3738.0,10/8/2024 7:51:12 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) and Aquestive Therapeutics (AQST)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-abivax-sa-sponsored-adr-abvx-and-aquestive-therapeutics-aqst-1033827450
3739.0,10/8/2024 12:00:54 PM,Eli Lilly obesity drug shortage ends fueling lawsuit against FDA,Seeking Alpha,https://seekingalpha.com/news/4156953-fda-sued-over-end-eli-lilly-zepbound-shortage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3740.0,10/8/2024 1:30:53 PM,"Lilly to take Q3 IPR&D charge of $2.83B, or $3.08 per share",Seeking Alpha,https://seekingalpha.com/news/4157008-lilly-to-take-q3-iprd-charge-of-283b-or-308-per-share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3741.0,10/8/2024 8:47:03 PM,"LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street’s “Strong Buy” Rating?",TipRanks,/news/stocks/lly-nvs-or-isrg-which-healthcare-stock-scores-wall-street-s-strong-buy-rating-1033829481
3742.0,10/9/2024 10:21:02 AM,Medicare coverage of obesity drugs could raise federal spending by $35B through 2034 - CBO,Seeking Alpha,https://seekingalpha.com/news/4157187-weight-loss-drugs-medicare-spending-cbo-analysis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3743.0,10/9/2024 5:43:52 PM,CBO report on projected Medicare spending on obesity drugs could jeopardize coverage,Seeking Alpha,https://seekingalpha.com/news/4157358-cbo-report-projected-medicare-spending-obesity-drugs-could-jeopardize-coverage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3744.0,10/9/2024 7:25:20 PM,Weight-loss drugs: How much should investors worry about side effects?,Seeking Alpha,https://seekingalpha.com/news/4157105-weight-loss-drugs-how-much-should-investors-worry-about-side-effects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3745.0,10/10/2024 2:16:51 PM,Lilly threatens legal action against copycat Zepbound providers: report,Seeking Alpha,https://seekingalpha.com/news/4157606-lilly-threatens-legal-action-against-copycat-zepbound-providers-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3746.0,10/10/2024 5:40:34 PM,Eli Lilly widens obesity reach with $1.4B KeyBioscience deal,Seeking Alpha,https://seekingalpha.com/news/4157666-eli-lilly-widens-obesity-reach-with-new-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3747.0,10/10/2024 6:20:58 PM,"WW surges after GLP-1 compounding announcement not justified after study, Barclays says",Seeking Alpha,https://seekingalpha.com/news/4157677-ww-surge-after-glp-1-compounding-announcement-not-justified-after-study-barclay-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3748.0,10/10/2024 7:39:30 PM,Will Pfizer transform in response to Starboard’s activism?,Seeking Alpha,https://seekingalpha.com/news/4157703-will-pfizer-transform-amid-starboards-activism?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3749.0,10/11/2024 8:56:04 AM,Eli Lilly & Co: Buy Rating Justified Despite Short-Term Sales Miss,TipRanks,/news/stocks/eli-lilly-co-buy-rating-justified-despite-short-term-sales-miss-1033838297
3750.0,10/11/2024 12:36:05 PM,Morgan Stanley Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1033839280
3751.0,10/11/2024 3:09:50 PM,Lilly expects Zepbound approval in Japan by mid-2025: report,Seeking Alpha,https://seekingalpha.com/news/4157926-lilly-expects-zepbound-approval-in-japan-by-mid-2025-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3752.0,10/12/2024 11:55:08 AM,FDA to review removal of Eli Lilly weight loss drug from shortage list,Seeking Alpha,https://seekingalpha.com/news/4158052-fda-to-review-decison-end-of-zepbound-shortage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3753.0,10/12/2024 5:58:03 PM,Weight loss drugs have one big issue; these companies want to fix it,Seeking Alpha,https://seekingalpha.com/news/4158061-these-companies-address-muscle-loss-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3754.0,10/14/2024 8:05:43 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033842579
3755.0,10/14/2024 1:24:40 PM,Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1 Study Of Mirikizumab In Crohn's Disease ,RTTNews,/news/stocks/lilly-reports-1-year-histologic-data-from-phase-3-vivid-1-study-of-mirikizumab-in-crohn-s-disease-1033842600
3756.0,10/14/2024 2:37:06 PM,Lilly reports positive data for Omvoh versus Stelara in Crohn's,Seeking Alpha,https://seekingalpha.com/news/4158237-lilly-reports-positive-data-for-omvoh-versus-stelara-in-crohns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3757.0,10/14/2024 3:04:13 PM,Hims & Hers up 10% as FDA reconsiders taking Lilly weight loss drug off shortage list,Seeking Alpha,https://seekingalpha.com/news/4158246-hims-hers-up-10-fda-reconsiders-taking-lilly-weight-loss-drugs-off-shortage-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3758.0,10/14/2024 3:56:46 PM,Eli Lilly & Co (LLY) Gets a Buy from TD Cowen,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-td-cowen-1033844066
3759.0,10/14/2024 5:20:25 PM,Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges ,RTTNews,/news/stocks/eli-lilly-to-invest-364-mln-in-uk-s-biotech-segment-to-tackle-health-challenges-1033843604
3760.0,10/15/2024 9:28:06 AM,Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential,TipRanks,/news/stocks/eli-lilly-a-strong-buy-on-robust-revenue-growth-and-expanding-market-potential-1033846639
3761.0,10/15/2024 6:35:59 PM,Moderna continues to be the most shorted S&P 500 healthcare stock in September,Seeking Alpha,https://seekingalpha.com/news/4162080-moderna-continues-to-be-the-most-shorted-sp-500-healthcare-stock-in-september?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3762.0,10/16/2024 4:21:34 PM,Least shorted S&P 500 stocks in September,Seeking Alpha,https://seekingalpha.com/news/4166027-least-shorted-sp-500-stocks-in-september?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3763.0,10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3764.0,10/19/2024 1:37:00 PM,"Notable analyst calls this week: Etsy, Zoom and Enphase among top picks",Seeking Alpha,https://seekingalpha.com/news/4175781-notable-analyst-calls-this-week-etsy-zoom-and-enphase-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3765.0,10/21/2024 9:17:01 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033864152
3766.0,10/21/2024 2:42:58 PM,Novo Nordisk semaglutide cut cardio risks by 14% in diabetics: study,Seeking Alpha,https://seekingalpha.com/news/4184024-novo-nordisk-semaglutide-cut-cardio-risks-by-14-percent-in-diabetics-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3767.0,10/21/2024 4:50:44 PM,"Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship",Seeking Alpha,https://seekingalpha.com/news/4185381-goldman-sachs-morgan-stanley-bullish-on-bioage-cite-lilly-relationship?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3768.0,10/21/2024 7:05:25 PM,"Lilly sues companies selling compounded Zepbound, Mounjaro",Seeking Alpha,https://seekingalpha.com/news/4186465-lilly-sues-companies-selling-compounded-zepbound-mounjaro?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3769.0,10/21/2024 8:35:44 PM,Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data,TipRanks,/news/stocks/morgan-stanley-names-amgen-catalyst-driven-idea-into-phase-2-maritide-data-1033866771
3770.0,10/21/2024 9:15:37 PM,Mangoceuticals ‘refutes’ claims by Eli Lilly regarding sale of tirzepatide,TipRanks,/news/stocks/mangoceuticals-refutes-claims-by-eli-lilly-regarding-sale-of-tirzepatide-1033866869
3771.0,10/21/2024 11:12:34 PM,Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit,Seeking Alpha,https://seekingalpha.com/news/4187735-mangoceuticals-refutes-claims-made-by-lilly-in-weight-loss-drug-lawsuit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3772.0,10/22/2024 5:31:19 AM,Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs ,RTTNews,/news/stocks/mangoceuticals-to-defend-against-eli-lilly-s-lawsuit-over-alleged-copying-of-weight-loss-drugs-1033867111
3773.0,10/22/2024 1:25:54 PM,"Pfizer, Lilly pressed about telehealth prescriber relationships, STAT reports",TipRanks,/news/stocks/pfizer-lilly-pressed-about-telehealth-prescriber-relationships-stat-reports-1033872465
3774.0,10/22/2024 4:01:16 PM,"GE Aerospace, GM report quarterly earnings beats: Morning Buzz",TipRanks,/news/stocks/ge-aerospace-gm-report-quarterly-earnings-beats-morning-buzz-1033873047
3775.0,10/22/2024 5:19:03 PM,"Pfizer, Lilly relationships with telehealth platforms draw Sen. Durbin's attention",Seeking Alpha,https://seekingalpha.com/news/4190392-pfizer-lilly-relationships-telehealth-platforms-draw-sen-durbin-attention?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3776.0,10/22/2024 10:48:32 PM,Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report,Seeking Alpha,https://seekingalpha.com/news/4192946-lilly-alzheimers-drug-not-to-be-covered-by-uks-nhs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3777.0,10/23/2024 9:10:26 AM,Eli Lilly announces MHRA grants marketing authorization for donanemab,TipRanks,/news/stocks/eli-lilly-announces-mhra-grants-marketing-authorization-for-donanemab-1033877923
3778.0,10/23/2024 10:05:20 AM,"Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports",TipRanks,/news/stocks/eli-lilly-alzheimer-s-drug-rejected-as-too-expensive-by-uk-s-nhs-ft-reports-1033878329
3779.0,10/23/2024 10:08:26 AM,Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use,Seeking Alpha,https://seekingalpha.com/news/4193722-eli-lillys-alzheimers-drug-donanemab-rejected-for-nhs-use?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3780.0,10/23/2024 1:28:16 PM,Novo tells FDA compounded semaglutide too difficult to make,Seeking Alpha,https://seekingalpha.com/news/4194796-novo-tells-fda-compounded-semaglutide-too-difficult-to-make?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3781.0,10/23/2024 4:06:12 PM,More states considering Medicaid coverage of GLP-1 weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4196032-more-states-considering-medicaid-coverage-glp-1-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3782.0,10/23/2024 4:26:42 PM,Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update),Seeking Alpha,https://seekingalpha.com/news/4195690-roche-ceo-says-antitrust-regulators-should-block-catalent-sale-to-novo-foundation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3783.0,10/23/2024 7:49:55 PM,"Him & Hers, WW down on Novo attempt to restrict compounded semaglutide",Seeking Alpha,https://seekingalpha.com/news/4196990-hims-and-hers-ww-down-novo-attempt-restrict-compounded-semagluti?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3784.0,10/24/2024 3:26:50 PM,Viking Therapeutics jumps as obesity updates outshine Q3 beat,Seeking Alpha,https://seekingalpha.com/news/4200535-viking-therapeutics-stock-jumps-post-q-3-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3785.0,10/24/2024 4:54:00 PM,Lilly to launch Mounjaro in rival Novo Nordisk's home country: report,Seeking Alpha,https://seekingalpha.com/news/4201290-lilly-to-launch-mounjaro-in-rival-novo-nordisks-home-country-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3786.0,10/24/2024 6:40:34 PM,"Study finds high costs, few benefits associated with GLP-1 weight loss drugs",Seeking Alpha,https://seekingalpha.com/news/4201472-study-finds-high-costs-few-benefits-associated-glp-1-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3787.0,10/25/2024 10:20:32 AM,"Eli Lilly price target raised to $1,250 from $1,060 at Citi",TipRanks,/news/stocks/eli-lilly-price-target-raised-to-1-250-from-1-060-at-citi-1033892717
3788.0,10/25/2024 10:56:31 AM,Eli Lilly presents new Ebglyss data at FCD Conference,TipRanks,/news/stocks/eli-lilly-presents-new-ebglyss-data-at-fcd-conference-1033892927
3789.0,10/25/2024 2:19:09 PM,Lilly's Ebglyss shown to be effective in former Dupixent users,Seeking Alpha,https://seekingalpha.com/news/4204992-lillys-ebglyss-shown-to-be-effective-in-former-dupixent-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3790.0,10/25/2024 7:00:00 PM,"Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting",Seeking Alpha,https://seekingalpha.com/news/4201499-catalyst-watch-eyes-on-tech-with-apple-amazon-alphabet-and-meta-reporting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3791.0,10/26/2024 5:46:00 PM,About 75% of companies that reported earnings this week delivered EPS wins-Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4205854-about-75-of-companies-that-reported-earnings-this-week-delivered-eps-wins-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3792.0,10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3793.0,10/28/2024 7:10:55 AM,Eli Lilly gets nod to sell weight-loss drug in Hong Kong by year-end - report,Seeking Alpha,https://seekingalpha.com/news/4212378-eli-lilly-gets-nod-to-sell-weight-loss-drug-in-hong-kong-by-year-end-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3794.0,10/28/2024 8:51:14 AM,"Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Eli Lilly & Co (LLY) and Ligand Pharma (LGND)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-eli-lilly-co-lly-and-ligand-pharma-lgnd-1033901057
3795.0,10/28/2024 10:56:43 AM,"Eli Lilly announces results from two, multi-year mirikizumab studies",TipRanks,/news/stocks/eli-lilly-announces-results-from-two-multi-year-mirikizumab-studies-1033901827
3796.0,10/28/2024 11:36:44 AM,"Eli Lilly’s Omvoh shows long-term effectiveness against UC, Crohn’s disease",Seeking Alpha,https://seekingalpha.com/news/4212961-eli-lillys-omvoh-shows-long-term-effectiveness-against-uc-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3797.0,10/28/2024 12:00:46 PM,Apogee Therapeutics price target raised to $100 from $81 at BTIG,TipRanks,/news/stocks/apogee-therapeutics-price-target-raised-to-100-from-81-at-btig-1033902665
3798.0,10/28/2024 12:15:19 PM,"Eli Lilly, ViaNautis sign collaboration agreement for polyNaut platform",TipRanks,/news/stocks/eli-lilly-vianautis-sign-collaboration-agreement-for-polynaut-platform-1033902742
3799.0,10/28/2024 12:17:03 PM,Eli Lilly’s Ebglyss: A Promising Alternative for Dupixent-Resistant Atopic Dermatitis Patients,TipRanks,/news/stocks/eli-lilly-s-ebglyss-a-promising-alternative-for-dupixent-resistant-atopic-dermatitis-patients-1033902726
3800.0,10/28/2024 12:24:42 PM,Investors eye earnings data volatility movements as it reflects highest levels in 15 years,Seeking Alpha,https://seekingalpha.com/news/4213053-investors-eye-earnings-data-as-volatility-movements-reflects-highest-levels-in-15-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3801.0,10/28/2024 12:46:03 PM,Eli Lilly tells Bloomberg approval received to launch Mounjaro in Hong Kong,TipRanks,/news/stocks/eli-lilly-tells-bloomberg-approval-received-to-launch-mounjaro-in-hong-kong-1033902907
3802.0,10/28/2024 1:58:49 PM,"ViaNautis Bio, Lilly Partner For ViaNautis' Drug Delivery Platform PolyNaut ",RTTNews,/news/stocks/vianautis-bio-lilly-partner-for-vianautis-drug-delivery-platform-polynaut-1033901523
3803.0,10/28/2024 2:03:34 PM,Evoke stock rockets 90% on study of Gimoti in GLP-1 users,Seeking Alpha,https://seekingalpha.com/news/4213544-evok-stock-rockets-on-study-of-gimoti-in-glp-1-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3804.0,10/28/2024 3:38:58 PM,Eli Lilly declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/4214160-eli-lilly-declares-130-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3805.0,10/28/2024 4:10:30 PM,"Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz",TipRanks,/news/stocks/boeing-to-offer-90m-common-shares-philips-reports-mixed-q3-morning-buzz-1033903631
3806.0,10/28/2024 6:45:12 PM,"Eli Lilly touts long-term data on Omvoh for ulcerative colitis, Crohn's",Seeking Alpha,https://seekingalpha.com/news/4215117-eli-lilly-touts-long-term-data-omvoh-ulcerative-colitis-crohns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3807.0,10/29/2024 4:20:15 PM,Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients,TipRanks,/news/stocks/eli-lilly-says-donanemab-redudced-aria-e-in-early-alzheimer-s-patients-1033911491
3808.0,10/29/2024 5:40:37 PM,Lilly reports positive Phase 3 results for modified Kisunla dosing,Seeking Alpha,https://seekingalpha.com/news/4220053-lilly-reports-positive-phase-3-results-for-modified-kisunla-dosing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3809.0,10/29/2024 6:00:55 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033911969
3810.0,10/29/2024 7:19:04 PM,"Eli Lilly Q3 2024 Earnings Preview: Focus on exit rate, fear of revenue miss on the horizon",Seeking Alpha,https://seekingalpha.com/news/4220488-eli-lilly-q3-2024-earnings-preview-focus-on-exit-rate-fear-of-revenue-miss-on-the-horizon?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3811.0,10/30/2024 10:46:08 AM,"Eli Lilly Non-GAAP EPS of $1.18 misses by $0.29, revenue of $11.44B misses by $680M",Seeking Alpha,https://seekingalpha.com/news/4222385-eli-lilly-non-gaap-eps-of-1_18-misses-0_29-revenue-of-11_44b-misses-680m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3812.0,10/30/2024 10:51:16 AM,"Eli Lilly reports Q3 EPS $1.18, consensus $1.47",TipRanks,/news/stocks/eli-lilly-reports-q3-eps-1-18-consensus-1-47-1033917917
3813.0,10/30/2024 10:57:34 AM,Eli Lilly cuts FY24 EPS view to $13.02-$13.52 from $16.10-$16.60,TipRanks,/news/stocks/eli-lilly-cuts-fy24-eps-view-to-13-02--13-52-from-16-10--16-60-1033917881
3814.0,10/30/2024 11:00:46 AM,"Earnings Snapshot: Eli Lilly falls short in Q3 results, lowers FY2024 outlook",Seeking Alpha,https://seekingalpha.com/news/4222460-earnings-snapshot-eli-lilly-falls-short-in-q3-results-lowers-fy2024-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3815.0,10/30/2024 11:17:23 AM,"Eli Lilly in charts: Mounjaro, Zepbound, and Humalog fuel Q3 sales growth",Seeking Alpha,https://seekingalpha.com/news/4222510-eli-lilly-in-charts-mounjaro-zepbound-and-humalog-fuel-q3-sales-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3816.0,10/30/2024 11:23:40 AM,"Eli Lilly drops, sending Novo lower after Q3 miss",Seeking Alpha,https://seekingalpha.com/news/4222515-eli-lilly-stock-drops-hurting-novo-after-q-3-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3817.0,10/30/2024 11:51:36 AM,Eli Lilly And Co. Q3 Earnings Summary ,RTTNews,/news/stocks/eli-lilly-and-co-q3-earnings-summary-1033916334
3818.0,10/30/2024 12:18:04 PM,"Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan",TipRanks,/news/stocks/eli-lilly-core-thesis-remains-intact-despite-q3-miss-says-jpmorgan-1033919156
3819.0,10/30/2024 12:18:05 PM,"Lilly Cuts FY24 Earnings, Revenue Outlook After Q3 Misses Street; Stock Down In Pre-market - Update ",RTTNews,/news/stocks/lilly-cuts-fy24-earnings-revenue-outlook-after-q3-misses-street-stock-down-in-pre-market-update-1033916486
3820.0,10/30/2024 12:46:43 PM,AnaptysBio plunges as Eli Lilly drops arthritis drug from pipeline,Seeking Alpha,https://seekingalpha.com/news/4222747-anaptys-bio-stock-falls-lilly-updates-pipeline?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3821.0,10/30/2024 12:50:24 PM,AnaptysBio sinks 30% after Lilly slides show PD-1 agonist pulled,TipRanks,/news/stocks/anaptysbio-sinks-30-after-lilly-slides-show-pd-1-agonist-pulled-1033919388
3822.0,10/30/2024 12:55:28 PM,"AnaptysBio to be weak on Lilly pulling peresolimab from pipeline, says Stifel",TipRanks,/news/stocks/anaptysbio-to-be-weak-on-lilly-pulling-peresolimab-from-pipeline-says-stifel-1033919373
3823.0,10/30/2024 1:01:23 PM,Morning Movers: Caterpillar and Eli Lilly sink following quarterly reports,TipRanks,/news/stocks/morning-movers-caterpillar-and-eli-lilly-sink-following-quarterly-reports-1033919565
3824.0,10/30/2024 1:20:00 PM,"5 stocks to watch on Wednesday: MSFT, META, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4223018-5-stocks-to-watch-on-wednesday-msft-meta-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3825.0,10/30/2024 1:50:35 PM,Eli Lilly falls -12.0%,TipRanks,/news/stocks/eli-lilly-falls--12-0-1033919816
3826.0,10/30/2024 2:00:35 PM,Eli Lilly falls -13.5%,TipRanks,/news/stocks/eli-lilly-falls--13-5-1033919999
3827.0,10/30/2024 2:15:22 PM,"Biggest stock movers Wednesday: SMCI, LLY, GOOG, SNAP, and more",Seeking Alpha,https://seekingalpha.com/news/4221935-biggest-stock-movers-wednesday-goog-snap-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3828.0,10/30/2024 2:20:13 PM,"AnaptysBio weakness on competitor news a buying opportunity, says Guggenheim",TipRanks,/news/stocks/anaptysbio-weakness-on-competitor-news-a-buying-opportunity-says-guggenheim-1033920029
3829.0,10/30/2024 3:45:40 PM,H.C. Wainwright still ‘optimistic’ on Phase 2 data for AnaptysBio’s rosnilimab,TipRanks,/news/stocks/h-c-wainwright-still-optimistic-on-phase-2-data-for-anaptysbio-s-rosnilimab-1033920348
3830.0,10/30/2024 4:15:41 PM,"Alphabet, AMD report Q3 earnings beats: Morning Buzz",TipRanks,/news/stocks/alphabet-amd-report-q3-earnings-beats-morning-buzz-1033920421
3831.0,10/30/2024 5:43:56 PM,"Eli Lilly had a strong Q3, so why is its stock falling?",Seeking Alpha,https://seekingalpha.com/news/4224905-eli-lilly-had-strong-q-3-so-why-is-its-stock-falling?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3832.0,10/30/2024 5:55:24 PM,Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update),Seeking Alpha,https://seekingalpha.com/news/4224998-hims-hers-stock-falls-after-novo-semaglutide-taken-off-shortage-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3833.0,10/31/2024 8:46:06 AM,Eli Lilly & Co: Buy Rating Affirmed Amidst U.S. Market Challenges and International Growth Potential,TipRanks,/news/stocks/eli-lilly-co-buy-rating-affirmed-amidst-u-s-market-challenges-and-international-growth-potential-1033927429
3834.0,10/31/2024 8:47:49 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033927409
3835.0,10/31/2024 9:56:08 AM,Eli Lilly’s Resilient Outlook: Buy Rating Affirmed Despite Q3 Challenges,TipRanks,/news/stocks/eli-lilly-s-resilient-outlook-buy-rating-affirmed-despite-q3-challenges-1033927923
3836.0,10/31/2024 12:37:07 PM,"Eli Lilly earnings selloff brings buying opportunity, says JPMorgan",TipRanks,/news/stocks/eli-lilly-earnings-selloff-brings-buying-opportunity-says-jpmorgan-1033929826
3837.0,10/31/2024 1:11:01 PM,"Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Ginkgo Bioworks Holdings (DNA) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bausch-+-lomb-corporation-blco-ginkgo-bioworks-holdings-dna-and-eli-lilly-co-lly-1033930018
3838.0,10/31/2024 1:26:00 PM,Jefferies Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/jefferies-remains-a-buy-on-eli-lilly-co-lly-1033930133
3839.0,11/1/2024 12:50:42 PM,Novo Nordisk posts Phase 3 win for obesity drug in MASH,Seeking Alpha,https://seekingalpha.com/news/4233438-novo-nordisk-wegovy-hits-main-goal-mash-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3840.0,11/1/2024 3:45:22 PM,"Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-1-015-from-1-025-at-deutsche-bank-1033938576
3841.0,11/1/2024 7:00:45 PM,"Catalyst Watch: Eyes on election bets, FOMC meeting, drug data, and NXP Semiconductors event",Seeking Alpha,https://seekingalpha.com/news/4234423-catalyst-watch-eyes-on-election-bets-fomc-meeting-drug-data-and-nxp-semiconductors-event?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3842.0,11/2/2024 7:36:20 PM,New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity,Seeking Alpha,https://seekingalpha.com/news/4238084-novo-nordisk’s-wegovy-can-heal-joint-pain?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3843.0,11/4/2024 9:17:24 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033943537
3844.0,11/4/2024 10:00:03 AM,"Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop",Seeking Alpha,https://seekingalpha.com/news/4241430-viking-shares-jump-after-positive-early-data-on-oral-obesity-pill-lilly-novo-drop?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3845.0,11/4/2024 10:40:34 AM,Viking Therapeutics surges after presenting ‘promising’ obesity drug data,TipRanks,/news/stocks/viking-therapeutics-surges-after-presenting-promising-obesity-drug-data-1033943945
3846.0,11/4/2024 2:07:37 PM,"Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-1-015-from-1-025-at-deutsche-bank-1033945960
3847.0,11/4/2024 4:26:04 PM,"AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports",TipRanks,/news/stocks/astrazeneca-says-experimental-obesity-pill-competitive-bloomberg-reports-1033946485
3848.0,11/4/2024 6:41:14 PM,New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity,Seeking Alpha,https://seekingalpha.com/news/4238084-novo-nordisk-wegovy-can-heal-joint-pain?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3849.0,11/4/2024 6:50:17 PM,"AstraZeneca oral GLP1 looks to be trailing Eli Lilly’s, says Deutsche Bank",TipRanks,/news/stocks/astrazeneca-oral-glp1-looks-to-be-trailing-eli-lilly-s-says-deutsche-bank-1033947020
3850.0,11/4/2024 8:40:58 PM,Viking stock drops 13% after jumping 9% on obesity drug data,Seeking Alpha,https://seekingalpha.com/news/4245047-viking-stock-drops-after-jumping-on-obesity-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3851.0,11/4/2024 8:42:07 PM,"How does Viking's weight loss med compare to ones from Novo, Eli Lilly?",Seeking Alpha,https://seekingalpha.com/news/4244507-how-viking-weight-loss-med-compares-ones-novo-eli-lilly?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3852.0,11/6/2024 2:32:58 AM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033957098
3853.0,11/6/2024 12:48:12 PM,Novo beats Eli Lilly in Q3 sales for obesity drug,Seeking Alpha,https://seekingalpha.com/news/4254529-novo-beats-eli-lilly-in-q3-sales-for-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3854.0,11/6/2024 3:29:57 PM,"Tango stock plunges 28% amid pipeline updates, Q3 earnings report",Seeking Alpha,https://seekingalpha.com/news/4255539-tango-stock-plunges-amid-pipeline-updates-q3-earnings-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3855.0,11/6/2024 8:17:19 PM,SA Asks: How will the U.S. election results impact healthcare stocks?,Seeking Alpha,https://seekingalpha.com/news/4257322-sa-asks-how-will-the-us-election-results-impact-healthcare-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3856.0,11/7/2024 9:01:04 PM,Eli Lilly snaps six straight sessions of losses,Seeking Alpha,https://seekingalpha.com/news/4262015-eli-lilly-set-to-snap-six-straight-sessions-of-losses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3857.0,11/8/2024 4:45:14 PM,Eli Lilly call volume above normal and directionally bullish,TipRanks,/news/stocks/eli-lilly-call-volume-above-normal-and-directionally-bullish-1033984770
3858.0,11/11/2024 8:10:20 AM,"Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Radnet (RDNT) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-radnet-rdnt-and-eli-lilly-co-lly-1033991070
3859.0,11/11/2024 7:15:37 PM,Tectonic Therapeutic price target raised to $69 from $49 at Leerink,TipRanks,/news/stocks/tectonic-therapeutic-price-target-raised-to-69-from-49-at-leerink-1033994544
3860.0,11/11/2024 9:21:12 PM,Needham biotech analysts hold an analyst/industry conference call,TipRanks,/news/stocks/needham-biotech-analysts-hold-an-analyst-industry-conference-call-1033994780
3861.0,11/12/2024 1:22:50 PM,Bristol-Myers upgraded at Leerink after AbbVie setback,Seeking Alpha,https://seekingalpha.com/news/4279606-bristol-myers-stock-upgraded-leerink?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3862.0,11/12/2024 8:32:02 PM,Amgen slips as Cantor cites safety concerns linked to obesity candidate,Seeking Alpha,https://seekingalpha.com/news/4281785-amgen-stock-slips-amid-risk-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3863.0,11/13/2024 7:13:36 PM,Hims & Hers launches GLP-1 drug shortage tracker,Seeking Alpha,https://seekingalpha.com/news/4286579-hims-hers-launches-glp-1-drug-shortage-tracker?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3864.0,11/13/2024 10:10:11 PM,Eli Lilly announces results from Phase 3 SURMOUNT-1 three-year study,TipRanks,/news/stocks/eli-lilly-announces-results-from-phase-3-surmount-1-three-year-study-1034011943
3865.0,11/13/2024 10:45:18 PM,"Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits",Seeking Alpha,https://seekingalpha.com/news/4287466-lilly-three-year-tirzepatide-results-show-sustained-weight-loss-diabetes-benefits?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3866.0,11/14/2024 4:46:23 PM,Global increase in diabetes indicates more room for GLP-1 meds to grow,Seeking Alpha,https://seekingalpha.com/news/4290949-global-increase-diabetes-indicates-more-room-for-glp-1-meds-grow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3867.0,11/14/2024 8:30:19 PM,Eli Lilly call volume above normal and directionally bullish,TipRanks,/news/stocks/eli-lilly-call-volume-above-normal-and-directionally-bullish-1034021054
3868.0,11/14/2024 9:15:11 PM,Eli Lilly initiated with an Outperform at Wolfe Research,TipRanks,/news/stocks/eli-lilly-initiated-with-an-outperform-at-wolfe-research-1034021192
3869.0,11/14/2024 10:48:03 PM,"Renaissance Tech adds Micron, exits Broadcom, among Q3 trades",Seeking Alpha,https://seekingalpha.com/news/4292581-renaissance-tech-adds-micron-exits-broadcom-among-q3-trades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3870.0,11/14/2024 11:27:00 PM,"Coatue Management top Q3 moves: cuts Nvidia, exits CRM & UNH, piles into Chinese stocks",Seeking Alpha,https://seekingalpha.com/news/4292784-coatue-management-top-q3-moves-cuts-nvidia-exits-crm-unh-piles-into-chinese-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3871.0,11/14/2024 11:45:10 PM,"Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform",TipRanks,/news/stocks/wolfe-sees-attractive-eli-lilly-opportunity-on-price-drop-starts-at-outperform-1034021615
3872.0,11/15/2024 12:19:45 PM,Eli Lilly follows JNJ in suing govt. over 340B drug-discount program,Seeking Alpha,https://seekingalpha.com/news/4294034-eli-lilly-follows-jnj-suing-over-340-b-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3873.0,11/15/2024 3:32:00 PM,Least shorted S&P 500 stocks in October,Seeking Alpha,https://seekingalpha.com/news/4294512-least-shorted-sp-500-stocks-in-october?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3874.0,11/15/2024 5:26:07 PM,"Eli Lilly sues to change hospital drug discount payments, WSJ reports",TipRanks,/news/stocks/eli-lilly-sues-to-change-hospital-drug-discount-payments-wsj-reports-1034026316
3875.0,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3876.0,11/15/2024 7:30:36 PM,"Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS",Seeking Alpha,https://seekingalpha.com/news/4296140-large-pharmas-biotechs-down-industries-grapple-with-rfk-jr-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3877.0,11/17/2024 3:30:13 AM,"Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity ",RTTNews,/news/stocks/lilly-tirzepatide-reduces-heart-failure-risk-improves-symptoms-in-hfpef-patients-with-obesity-1034027157
3878.0,11/18/2024 9:05:36 AM,Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-eli-lilly-co-lly-1034029862
3879.0,11/18/2024 11:45:58 AM,"Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients",Seeking Alpha,https://seekingalpha.com/news/4301465-eli-lillys-tirzepatide-cuts-risk-of-worsening-heart-failure-in-hfpef-obese-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3880.0,11/18/2024 12:55:48 PM,Eli Lilly & Co (LLY) Receives a Hold from Evercore ISI,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-hold-from-evercore-isi-1034031547
3881.0,11/18/2024 2:02:31 PM,"Incyclix Bio And Eli Lilly To Evaluate INX-315, Verzenio, And Fulvestrant In HR+/HER2- Breast Cancer ",RTTNews,/news/stocks/incyclix-bio-and-eli-lilly-to-evaluate-inx-315-verzenio-and-fulvestrant-in-hr-her2-breast-cancer-1034030088
3882.0,11/18/2024 6:26:46 PM,"Lilly, Incyclix to work on Verzenio combo treatment for breast cancer",Seeking Alpha,https://seekingalpha.com/news/4303653-lilly-incyclix-work-verzenio-combo-treatment-breast-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3883.0,11/18/2024 6:46:20 PM,Novo Nordisk reportedly launches Wegovy in China,Seeking Alpha,https://seekingalpha.com/news/4303757-novo-nordisk-reportedly-launches-wegovy-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3884.0,11/18/2024 7:55:17 PM,Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial,TipRanks,/news/stocks/lilly-s-muvalaplin-lowered-lipoprotein-a-levels-in-adults-in-phase-2-trial-1034033013
3885.0,11/18/2024 9:30:43 PM,Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels,Seeking Alpha,https://seekingalpha.com/news/4304285-lilly-heart-drug-muvalaplin-significantly-reduces-lipoprotein-levels?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3886.0,11/19/2024 6:55:56 AM,Eli Lilly’s Promising Prospects and New Product Pipeline Drive Buy Rating,TipRanks,/news/stocks/eli-lilly-s-promising-prospects-and-new-product-pipeline-drive-buy-rating-1034034992
3887.0,11/19/2024 5:50:15 PM,Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss,TipRanks,/news/stocks/eli-lilly-canada-disappointed-by-cda-amc-s-final-recommendation-for-ebglyss-1034038706
3888.0,11/19/2024 9:35:33 PM,Eli Lilly appoints Jon Moeller to board of directors,TipRanks,/news/stocks/eli-lilly-appoints-jon-moeller-to-board-of-directors-1034039124
3889.0,11/19/2024 10:20:38 PM,Eli Lilly & Co Appoints Procter & Gamble CEO to Board,TipRanks,/news/stocks/eli-lilly-co-appoints-procter-gamble-ceo-to-board-1034039234
3890.0,11/20/2024 10:15:31 AM,"Eli Lilly, Verge announce milestones in ALS collaboration",TipRanks,/news/stocks/eli-lilly-verge-announce-milestones-in-als-collaboration-1034041942
3891.0,11/20/2024 3:11:06 PM,Oppenheimer biotech analyst holds an analyst/industry conference call,TipRanks,/news/stocks/oppenheimer-biotech-analyst-holds-an-analyst-industry-conference-call-1034044058
3892.0,11/20/2024 4:14:55 PM,More companies covering weight loss drugs for their employees,Seeking Alpha,https://seekingalpha.com/news/4312209-more-companies-covering-weight-loss-drugs-employees?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3893.0,11/20/2024 5:45:21 PM,"Tectonic started at outperform by Raymond James, TX45 cited",Seeking Alpha,https://seekingalpha.com/news/4313083-tectonic-started-at-outperform-by-raymond-james-tx45-cited?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3894.0,11/20/2024 7:28:07 PM,Eli Lilly in pact with Chinese biotech for novel weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4313537-eli-lilly-in-pact-novel-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3895.0,11/20/2024 8:30:19 PM,Eli Lilly and China-based biotech Laekna team on obesity drug,TipRanks,/news/stocks/eli-lilly-and-china-based-biotech-laekna-team-on-obesity-drug-1034044779
3896.0,11/21/2024 11:06:58 AM,"Eli Lilly & Co: Buy Rating Amid Valuation, Growth Prospects, and IPI Concerns",TipRanks,/news/stocks/eli-lilly-co-buy-rating-amid-valuation-growth-prospects-and-ipi-concerns-1034048729
3897.0,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3898.0,11/21/2024 8:40:08 PM,Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s,TipRanks,/news/stocks/hims-hers-jumps-as-status-report-says-patients-unable-to-obtain-branded-glp-1s-1034051586
3899.0,11/21/2024 9:00:09 PM,"FDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi",TipRanks,/news/stocks/fda-tirzepatide-status-report-moderately-positive-for-hims-hers-says-citi-1034051677
3900.0,11/21/2024 9:09:46 PM,Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed,Seeking Alpha,https://seekingalpha.com/news/4318664-hims-hers-health-closes-up-10-lilly-tirzepatide-compounding-dispute-resolution-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3901.0,11/22/2024 12:25:48 PM,Protagonist Therapeutics price target raised to $67 from $51 at BTIG,TipRanks,/news/stocks/protagonist-therapeutics-price-target-raised-to-67-from-51-at-btig-1034055542
3902.0,11/22/2024 12:31:46 PM,Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens,Seeking Alpha,https://seekingalpha.com/news/4320724-novo-nordisk-contracts-ypsomed-to-make-cagrisema-pens?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3903.0,11/22/2024 4:35:10 PM,"Sanofi planning changes to 340B hospital drug discount plan, WSJ reports",TipRanks,/news/stocks/sanofi-planning-changes-to-340b-hospital-drug-discount-plan-wsj-reports-1034056551
3904.0,11/22/2024 4:50:49 PM,Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program,Seeking Alpha,https://seekingalpha.com/news/4322264-sanofi-becomes-latest-drugmakert-challenge-hhs-340-b-drug-discount-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3905.0,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3906.0,11/24/2024 12:05:06 PM,"Eli Lilly, others to buy after RFK-inspired drop, Barron’s says",TipRanks,/news/stocks/eli-lilly-others-to-buy-after-rfk-inspired-drop-barron-s-says-1034057659
3907.0,11/25/2024 5:46:13 PM,Hims & Hers up 18% amid optimism for compounders with Makary FDA pick,Seeking Alpha,https://seekingalpha.com/news/4330979-hims-hers-up-18-optimism-compounders-makary-fda-pick?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3908.0,11/26/2024 11:15:49 AM,"Biden admin proposes obesity drugs covered by Medicare, Medicaid, NYTimes says",TipRanks,/news/stocks/biden-admin-proposes-obesity-drugs-covered-by-medicare-medicaid-nytimes-says-1034065988
3909.0,11/26/2024 11:30:59 AM,"Biden administration proposes expanded obesity drug coverage under Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/4334040-biden-administration-proposes-expanded-obesity-drug-coverage-under-medicare-medicaid?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3910.0,11/26/2024 12:18:47 PM,Amgen posts mid-stage data for weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4334405-amgen-stock-slips-on-data-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3911.0,11/26/2024 1:55:40 PM,Anavex gains after seeking EU marketing nod for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4335176-anavex-gains-seeking-eu-marketing-nod-alzheimer-s-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3912.0,11/26/2024 2:00:20 PM,White House proposes Medicare and Medicaid cover weight loss drugs,TipRanks,/news/stocks/white-house-proposes-medicare-and-medicaid-cover-weight-loss-drugs-1034067371
3913.0,11/26/2024 2:20:33 PM,"Amgen’s MariTide only differentiation seems to be dosing frequency, says Leerink",TipRanks,/news/stocks/amgen-s-maritide-only-differentiation-seems-to-be-dosing-frequency-says-leerink-1034067414
3914.0,11/26/2024 2:20:51 PM,"Amgen weight loss data ‘underwhelms,’ says Deutsche Bank",TipRanks,/news/stocks/amgen-weight-loss-data-underwhelms-says-deutsche-bank-1034067412
3915.0,11/26/2024 2:55:12 PM,Early notable gainers among liquid option names on November 26th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-november-26th-1034067491
3916.0,11/26/2024 3:10:15 PM,"Trump Trade: Carmakers slip after 25% tariff threat on Mexico, Canada",TipRanks,/news/stocks/trump-trade-carmakers-slip-after-25-tariff-threat-on-mexico-canada-1034067545
3917.0,11/26/2024 3:13:10 PM,"Biggest stock movers Tuesday: PSTX, ARWR, KSS, ALEC, AMGN, EMBC, and more",Seeking Alpha,https://seekingalpha.com/news/4333610-biggest-stock-movers-tuesday-pstx-smtc-alec-lesl-wwd-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3918.0,11/26/2024 3:40:24 PM,Weight loss drugmakers in spotlight as White House proposes coverage,TipRanks,/news/stocks/weight-loss-drugmakers-in-spotlight-as-white-house-proposes-coverage-1034067621
3919.0,11/26/2024 5:05:29 PM,"Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/trump-threatens-tariffs-zoom-reports-q3-beat-morning-buzz-1034067844
3920.0,11/26/2024 6:05:25 PM,RBC sees little cause for concern over CMS’ proposed part D GLP-1 coverage rule,TipRanks,/news/stocks/rbc-sees-little-cause-for-concern-over-cms-proposed-part-d-glp-1-coverage-rule-1034067980
3921.0,11/27/2024 10:25:48 AM,Eli Lilly’s Stock Poised for Growth Amid Potential CMS Coverage for Zepbound,TipRanks,/news/stocks/eli-lilly-s-stock-poised-for-growth-amid-potential-cms-coverage-for-zepbound-1034071154
3922.0,11/27/2024 11:20:19 AM,Eli Lilly downgraded to Hold from Buy at Erste Group,TipRanks,/news/stocks/eli-lilly-downgraded-to-hold-from-buy-at-erste-group-1034071477
3923.0,11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3924.0,11/27/2024 5:16:04 PM,Short stock ideas from each sector with Earnings Quality in the bottom 20%,Seeking Alpha,https://seekingalpha.com/news/4340651-short-stock-ideas-from-each-sector-with-earnings-quality-in-the-bottom-20?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
3925.0,12/2/2024 12:47:11 PM,Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound,TipRanks,/news/stocks/eli-lilly-s-growth-driven-by-strong-prescription-trends-for-mounjaro-and-zepbound-1034087114
3926.0,12/2/2024 1:16:09 PM,Eli Lilly & Co (LLY) Gets a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-jefferies-1034087325
,12/3/2024 7:24:14 PM,BeiGene started at overweight at Morgan Stanley on Brukinsa market share growth,Seeking Alpha,https://seekingalpha.com/news/4360565-beigene-started-overweight-morgan-stanley-on-brukinsa-market-share-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/3/2024 7:40:10 PM,Truist biopharma analyst to hold an analyst/industry conference call,TipRanks,/news/stocks/truist-biopharma-analyst-to-hold-an-analyst-industry-conference-call-1034094073
,12/4/2024 11:50:40 AM,Lilly says Zepbound superior to Novo’s Wegovy weight loss in head-to-head trial,TipRanks,/news/stocks/lilly-says-zepbound-superior-to-novo-s-wegovy-weight-loss-in-head-to-head-trial-1034097098
,12/4/2024 12:00:13 PM,Eli Lilly announces topline results from SURMOUNT-5 trial,TipRanks,/news/stocks/eli-lilly-announces-topline-results-from-surmount-5-trial-1034097513
,12/4/2024 1:53:43 PM,Eli Lilly in deal with Rondo to develop bispecific antibodies for tumors,Seeking Alpha,https://seekingalpha.com/news/4362518-eli-lilly-deal-rondo-develop-bispecific-antibodies-tumors?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/4/2024 1:57:04 PM,Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial,Seeking Alpha,https://seekingalpha.com/news/4362474-eli-lillys-zepbound-outperforms-novo-wegovy-for-weight-loss-in-head-to-head-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/4/2024 2:04:21 PM,Lilly Says Zepbound Provided 47% Higher Relative Weight Loss Compared To Wegovy In SURMOUNT-5 Study ,RTTNews,/news/stocks/lilly-says-zepbound-provided-47-higher-relative-weight-loss-compared-to-wegovy-in-surmount-5-study-1034096430
,12/4/2024 2:05:51 PM,"Morning Movers: Salesforce jumps after Q3, Foot Locker sinks after guidance cut",TipRanks,/news/stocks/morning-movers-salesforce-jumps-after-q3-foot-locker-sinks-after-guidance-cut-1034098167
,12/4/2024 3:06:14 PM,"Lilly, Rondo to collaborate on CD28 bispecific antibody development",Seeking Alpha,https://seekingalpha.com/news/4362608-lilly-rondo-to-collaborate-on-cd28-bispecific-antibody-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/4/2024 5:15:25 PM,"Salesforce up after Q3, GM outlines $5B in China business charges: Morning Buzz",TipRanks,/news/stocks/salesforce-up-after-q3-gm-outlines-5b-in-china-business-charges-morning-buzz-1034098728
,12/4/2024 6:45:28 PM,"Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG",TipRanks,/news/stocks/viking-s-vk2735-likely-even-better-than-lilly-s-zepbound-says-btig-1034098997
,12/5/2024 11:20:48 AM,"Eli Lilly CEO says he will fight for FDA , challenge Kennedy’s stance, NYT says",TipRanks,/news/stocks/eli-lilly-ceo-says-he-will-fight-for-fda-challenge-kennedy-s-stance-nyt-says-1034101935
,12/5/2024 2:40:47 PM,"U.K. to limit Eli Lilly’s Mounjaro to patients with greatest need, STAT reports",TipRanks,/news/stocks/u-k-to-limit-eli-lilly-s-mounjaro-to-patients-with-greatest-need-stat-reports-1034103374
,12/5/2024 3:00:18 PM,Trump Trade: Fiserv shares slip as CEO set to join new administration,TipRanks,/news/stocks/trump-trade-fiserv-shares-slip-as-ceo-set-to-join-new-administration-1034103525
,12/5/2024 5:08:21 PM,"Dollar General reports mixed Q3, American Air raises Q4 outlook: Morning Buzz",TipRanks,/news/stocks/dollar-general-reports-mixed-q3-american-air-raises-q4-outlook-morning-buzz-1034104341
,12/5/2024 5:49:19 PM,"Pfizer, Lilly CEOs have dinner at Mar-a-Lago with Trump, RFK Jr. - report",Seeking Alpha,https://seekingalpha.com/news/4367278-pfizer-lilly-ceos-dinner-mar-a-lago-trump-rfk-jr?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/5/2024 8:35:17 PM,Eli Lilly announces $3B expansion to Wisconsin manufacturing facility,TipRanks,/news/stocks/eli-lilly-announces-3b-expansion-to-wisconsin-manufacturing-facility-1034105275
,12/5/2024 10:19:31 PM,Lilly planning $3B expansion of Wisconsin plant to boost production,Seeking Alpha,https://seekingalpha.com/news/4368316-lilly-planning-3b-expansion-of-wisconsin-plant-to-boost-production?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/6/2024 2:47:01 AM,Lilly Announces $3 Bln Expansion Of Manufacturing Facility In Wisconsin ,RTTNews,/news/stocks/lilly-announces-3-bln-expansion-of-manufacturing-facility-in-wisconsin-1034105621
,12/6/2024 5:59:14 AM,"Eli Lilly’s Zepbound Outperforms Competitor in Weight Loss Trial, Supporting Buy Rating",TipRanks,/news/stocks/eli-lilly-s-zepbound-outperforms-competitor-in-weight-loss-trial-supporting-buy-rating-1034106749
,12/6/2024 9:21:18 PM,Lilly tops Morgan Stanley's biopharma pick list for 2025,Seeking Alpha,https://seekingalpha.com/news/4372587-lilly-tops-morgan-stanleys-biopharma-pick-list-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/6/2024 10:44:19 PM,BioAge stock craters 70% on obesity drug study halt (update),Seeking Alpha,https://seekingalpha.com/news/4372757-bioage-stock-craters-on-obesity-drug-study-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/8/2024 8:45:14 AM,Eli Lilly & Co’s Promising Growth Driven by Mounjaro and Zepbound Performance,TipRanks,/news/stocks/eli-lilly-co-s-promising-growth-driven-by-mounjaro-and-zepbound-performance-1034110840
,12/9/2024 9:20:38 PM,"Eli Lilly announces $15B share repurchase program, 15% dividend increase",TipRanks,/news/stocks/eli-lilly-announces-15b-share-repurchase-program-15-dividend-increase-1034116292
,12/9/2024 10:50:07 PM,Eli Lilly to present Phase 3 results for Jaypirca at ASH meeting,TipRanks,/news/stocks/eli-lilly-to-present-phase-3-results-for-jaypirca-at-ash-meeting-1034116514
,12/9/2024 11:43:56 PM,Lilly reports positive Phase 3 data for Jaypirca in CLL/SLL,Seeking Alpha,https://seekingalpha.com/news/4380289-lilly-reports-positive-phase-3-data-for-jaypirca-in-cllsll?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/10/2024 1:25:00 AM,Lilly Board Approves New $15 Bln Share Repurchase Program; Hikes Dividend ,RTTNews,/news/stocks/lilly-board-approves-new-15-bln-share-repurchase-program-hikes-dividend-1034116266
,12/10/2024 5:23:49 AM,Eli Lilly hikes dividend by 15.4% to $1.50 a share; approves $15B share repurchase program,Seeking Alpha,https://seekingalpha.com/news/4380695-eli-lilly-hikes-dividend-by-154-to-150-a-share-approves-15b-share-repurchase-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/10/2024 11:55:27 AM,Eli Lilly reinstated with a Buy at BofA,TipRanks,/news/stocks/eli-lilly-reinstated-with-a-buy-at-bofa-1034119249
,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783
,12/10/2024 9:55:29 PM,Cantor Fitzgerald biotech analysts hold an analyst/industry conference call,TipRanks,/news/stocks/cantor-fitzgerald-biotech-analysts-hold-an-analyst-industry-conference-call-1034121668
,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/11/2024 1:20:18 PM,Eli Lilly announces results from the Phase 3 EMBER-3 study,TipRanks,/news/stocks/eli-lilly-announces-results-from-the-phase-3-ember-3-study-1034125730
,12/11/2024 1:31:17 PM,Eli Lilly announces results from EMBER-3 study of imlunestrant,TipRanks,/news/stocks/eli-lilly-announces-results-from-ember-3-study-of-imlunestrant-1034125835
,12/11/2024 2:15:11 PM,BofA views news of Lilly selling Zepbound through Ro as ‘mixed’ for Hims & Hers,TipRanks,/news/stocks/bofa-views-news-of-lilly-selling-zepbound-through-ro-as-mixed-for-hims-hers-1034126124
,12/11/2024 2:15:31 PM,"Ro, Eli Lilly to streamline patient access to Zepbound single-dose vials",TipRanks,/news/stocks/ro-eli-lilly-to-streamline-patient-access-to-zepbound-single-dose-vials-1034126121
,12/11/2024 2:55:17 PM,Lilly Reports Positive Phase 3 EMBER-3 Study Data In Advanced Breast Cancer ,RTTNews,/news/stocks/lilly-reports-positive-phase-3-ember-3-study-data-in-advanced-breast-cancer-1034124249
,12/11/2024 3:14:21 PM,Lilly to sell Zepbound through telehealth platform Ro,Seeking Alpha,https://seekingalpha.com/news/4385605-lilly-to-sell-zepbound-through-telehealth-platform-ro?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/11/2024 3:37:18 PM,Lilly reports positive Phase 3 breast cancer data for imlunestrant,Seeking Alpha,https://seekingalpha.com/news/4385611-lilly-reports-positive-phase-3-breast-cancer-data-for-imlunestrant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/11/2024 5:50:44 PM,"Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink",TipRanks,/news/stocks/ro-lilly-partnership-creates-volatility-for-hims-hers-shares-says-leerink-1034126630
,12/11/2024 7:45:11 PM,"Arvinas down on investors’ read of Lilly data, says BTIG",TipRanks,/news/stocks/arvinas-down-on-investors-read-of-lilly-data-says-btig-1034126879
,12/12/2024 6:05:08 PM,TD Cowen Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/td-cowen-keeps-their-buy-rating-on-eli-lilly-co-lly-1034132070
,12/13/2024 12:51:26 PM,"Lilly's Mounjaro does not need separate indication for sleep apnea, EMA panel determines",Seeking Alpha,https://seekingalpha.com/news/4386252-lillys-mounjaro-does-not-need-separate-approval-for-sleep-apnea-ema-panel-determines?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/13/2024 1:15:32 PM,Eli Lilly’s Omvoh recommended by CHMP for approval in EU,TipRanks,/news/stocks/eli-lilly-s-omvoh-recommended-by-chmp-for-approval-in-eu-1034136087
,12/13/2024 1:16:10 PM,Buy Rating for Eli Lilly & Co: Strategic Developments and Promising Oncology Pipeline Drive Optimism,TipRanks,/news/stocks/buy-rating-for-eli-lilly-co-strategic-developments-and-promising-oncology-pipeline-drive-optimism-1034136077
,12/13/2024 2:40:22 PM,Lilly Gets Positive CHMP Opinion For Omvoh In Crohn's Disease ,RTTNews,/news/stocks/lilly-gets-positive-chmp-opinion-for-omvoh-in-crohn-s-disease-1034134783
,12/13/2024 3:13:08 PM,Lilly gets positive EU regulatory opinion for Omvoh for Crohn's,Seeking Alpha,https://seekingalpha.com/news/4386294-lilly-gets-positive-eu-regulatory-opinion-for-omvoh-for-crohns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/13/2024 4:05:35 PM,"Study confirms semaglutide link to increased, but ‘low,’ risk of NAION",TipRanks,/news/stocks/study-confirms-semaglutide-link-to-increased-but-low-risk-of-naion-1034136623
,12/16/2024 12:16:34 PM,Foghorn to discontinue independent development of FHD-286 with decitabine in AML,TipRanks,/news/stocks/foghorn-to-discontinue-independent-development-of-fhd-286-with-decitabine-in-aml-1034141324
,12/16/2024 6:05:00 PM,Moderna remains the most shorted among S&P 500 healthcare stocks in November,Seeking Alpha,https://seekingalpha.com/news/4386556-moderna-remains-the-most-shorted-among-sp-500-healthcare-stocks-in-november?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/17/2024 11:10:44 AM,Eli Lilly announces regulatory approval for insulin manufactured in Egypt,TipRanks,/news/stocks/eli-lilly-announces-regulatory-approval-for-insulin-manufactured-in-egypt-1034145789
,12/17/2024 12:15:11 PM,Eli Lilly: Egyptian Drug Authority Approves Insulin Glargine Injection Manufactured By EVA Pharma ,RTTNews,/news/stocks/eli-lilly-egyptian-drug-authority-approves-insulin-glargine-injection-manufactured-by-eva-pharma-1034144962
,12/18/2024 1:05:07 AM,Eli Lilly’s Kisunla approved in China for Alzheimer’s Disease treatment,TipRanks,/news/stocks/eli-lilly-s-kisunla-approved-in-china-for-alzheimer-s-disease-treatment-1034148679
,12/18/2024 2:26:46 AM,China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment ,RTTNews,/news/stocks/china-approves-lilly-s-kisunla-for-early-symptomatic-alzheimer-s-disease-treatment-1034148446
,12/18/2024 12:00:22 PM,Eli Lilly Alzheimer's therapy approved in China,Seeking Alpha,https://seekingalpha.com/news/4387585-eli-lilly-alzheimers-therapy-approved-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 12:19:45 PM,Merck enters obesity drug race in pact with Chinese pharma Hansoh,Seeking Alpha,https://seekingalpha.com/news/4387598-merck-enters-obesity-drug-race-in-pact-with-hansoh?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 1:36:20 PM,Viking Therapeutics lower after Merck signs pact with Hansoh for GLP-1 drug,TipRanks,/news/stocks/viking-therapeutics-lower-after-merck-signs-pact-with-hansoh-for-glp-1-drug-1034152180
,12/18/2024 3:25:59 PM,Lilly rival gets FDA okay for Phase 2 study of obesity drug,Seeking Alpha,https://seekingalpha.com/news/4387649-lilly-rival-gets-fda-okay-for-phase-2-study-of-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 3:37:04 PM,Least shorted S&P 500 stocks in November,Seeking Alpha,https://seekingalpha.com/news/4387575-least-shorted-sp-500-stocks-in-november?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 3:49:06 PM,Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers,Seeking Alpha,https://seekingalpha.com/news/4387714-merck-hansoh-deal-hurts-obesity-drug-developers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 7:02:38 PM,"BioAge, Novartis team up to discover age-related disease targets",Seeking Alpha,https://seekingalpha.com/news/4387789-bioage-novartis-team-up-to-discover-age-related-disease-targets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/19/2024 2:46:52 PM,Hims & Hers Health falls as FDA issues unfavorable compounded GLP-1 decision,Seeking Alpha,https://seekingalpha.com/news/4388119-hims-hers-health-falls-fda-issues-unfavorable-compounded-glp-1-decision?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/19/2024 3:20:17 PM,Hims & Hers falls after FDA ends shortage of Lilly weight loss drug,TipRanks,/news/stocks/hims-hers-falls-after-fda-ends-shortage-of-lilly-weight-loss-drug-1034157985
,12/19/2024 3:40:18 PM,"End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink",TipRanks,/news/stocks/end-to-tirzepatide-shortage-has-read-on-hims-glp-1-trajectory-says-leerink-1034158026
,12/19/2024 8:43:24 PM,U.S. healthcare spending climbs 7.5% in 2023,Seeking Alpha,https://seekingalpha.com/news/4388656-us-healthcare-spending-accelerates-in-2023?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 11:31:34 AM,"Novo Nordisk crashes after data for next gen obesity drug, Eli Lilly spikes",Seeking Alpha,https://seekingalpha.com/news/4389022-novo-nordisk-stock-crashes-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 12:25:25 PM,"Weight loss seen with Novo’s CagriSema weaker than expected, says BofA",TipRanks,/news/stocks/weight-loss-seen-with-novo-s-cagrisema-weaker-than-expected-says-bofa-1034162421
,12/20/2024 12:30:43 PM,"Novo obesity data positive for Eli Lilly and Amgen, says UBS",TipRanks,/news/stocks/novo-obesity-data-positive-for-eli-lilly-and-amgen-says-ubs-1034162520
,12/20/2024 12:45:26 PM,BofA says Hims’ semaglutide compounding opportunity may be shorter than expected,TipRanks,/news/stocks/bofa-says-hims-semaglutide-compounding-opportunity-may-be-shorter-than-expected-1034162572
,12/20/2024 1:50:33 PM,"Novo obesity data ‘nearly a best-case’ for Eli Lilly, says Citi",TipRanks,/news/stocks/novo-obesity-data-nearly-a-best-case-for-eli-lilly-says-citi-1034162913
,12/20/2024 2:15:18 PM,"Morning Movers: Lilly rises, Novo Nordisk falls following CagriSema trial data",TipRanks,/news/stocks/morning-movers-lilly-rises-novo-nordisk-falls-following-cagrisema-trial-data-1034163121
,12/20/2024 2:55:14 PM,Early notable gainers among liquid option names on December 20th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-december-20th-1034163229
,12/20/2024 2:55:22 PM,Eli Lilly rises 6.3%,TipRanks,/news/stocks/eli-lilly-rises-6-3-1034163228
,12/20/2024 3:18:36 PM,Why is Novo Nordisk crashing after data for next-gen weight loss drug?,Seeking Alpha,https://seekingalpha.com/news/4389278-novo-nordisk-stock-down-lilly-up-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 4:30:27 PM,J.P. Morgan’s top Healthcare stocks for 2025,Seeking Alpha,https://seekingalpha.com/news/4389333-jp-morgans-top-healthcare-stocks-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 5:37:36 PM,Eli Lilly & Co: Strategic Expansion and Tactical DTC Advertising Bolster Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strategic-expansion-and-tactical-dtc-advertising-bolster-buy-rating-1034163710
,12/20/2024 6:20:47 PM,Bernstein Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bernstein-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1034163996
,12/20/2024 7:30:26 PM,"BMO lowers Novo Nordisk price target to $105, says reaction to data ‘overdone’",TipRanks,/news/stocks/bmo-lowers-novo-nordisk-price-target-to-105-says-reaction-to-data-overdone-1034164259
,12/20/2024 8:36:52 PM,Pfizer gets FDA accelerated approval for Braftovi,Seeking Alpha,https://seekingalpha.com/news/4389412-pfizer-gets-fda-accelerated-approval-for-braftovi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 8:38:54 PM,"Biggest stock movers Friday: RGTI, CCL, NVO, DXCM and more",Seeking Alpha,https://seekingalpha.com/news/4388947-biggest-stock-movers-friday-fdx-x-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 9:35:24 PM,Eli Lilly announces FDA approval for Zepbound,TipRanks,/news/stocks/eli-lilly-announces-fda-approval-for-zepbound-1034164381
,12/20/2024 9:50:31 PM,Eli Lilly announces FDA approval for Zepbound for obstructive sleep apnea,TipRanks,/news/stocks/eli-lilly-announces-fda-approval-for-zepbound-for-obstructive-sleep-apnea-1034164425
,12/20/2024 10:00:25 PM,Eli Lilly's Zepbound gains sleep apnea indication,Seeking Alpha,https://seekingalpha.com/news/4389472-eli-lilly-zepbound-gains-sleep-apnea-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/21/2024 2:08:17 AM,FDA Approves Lilly's Zepbound To Treat Obstructive Sleep Apnea In Adults With Obesity ,RTTNews,/news/stocks/fda-approves-lilly-s-zepbound-to-treat-obstructive-sleep-apnea-in-adults-with-obesity-1034164435
,12/21/2024 3:03:30 PM,Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup,Seeking Alpha,https://seekingalpha.com/news/4389541-novo-nordisk-raises-eli-lilly-post-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/21/2024 3:58:23 PM,Trending stocks in bearish pre-holiday week for U.S. stock market,Seeking Alpha,https://seekingalpha.com/news/4389543-trending-stocks-in-bearish-pre-holiday-week-for-us-stock-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/23/2024 2:32:49 PM,"Biggest stock movers Monday: HMC, XRX, RUM, and more",Seeking Alpha,https://seekingalpha.com/news/4389714-biggest-stock-movers-monday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/23/2024 5:35:08 PM,FDA revokes EUAs for some antibody treatments for COVID-19,TipRanks,/news/stocks/fda-revokes-euas-for-some-antibody-treatments-for-covid-19-1034169449
,12/23/2024 6:45:16 PM,Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports,TipRanks,/news/stocks/eli-lilly-commends-itc-ruling-cracking-down-on-unlawful-tirzepatide-imports-1034169599
,12/23/2024 7:28:23 PM,Anavex stock rallies 30% on business updates,Seeking Alpha,https://seekingalpha.com/news/4390016-anavex-stock-rallies-30-on-business-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/24/2024 4:35:44 PM,Eli Lilly's weight loss med tirzepatide gets endorsement from U.K.'s NICE,Seeking Alpha,https://seekingalpha.com/news/4390750-eli-lilly-weight-loss-med-tirzepatide-gets-endorsement-uk-nice?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/26/2024 1:03:42 PM,Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic,Seeking Alpha,https://seekingalpha.com/news/4390958-elon-musk-prefers-lilly-mounjaro-over-novo-ozempic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/28/2024 2:05:56 PM,Eli Lilly to end 2024 among best in Big Pharma; Novo among worst,Seeking Alpha,https://seekingalpha.com/news/4391294-eli-lilly-among-best-big-pharma-2024-novo-among-worst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/2/2025 3:20:56 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-kymera-therapeutics-kymr-and-sarepta-therapeutics-srpt-1034187927
,1/2/2025 4:27:35 PM,Weight loss drugs can cut grocery spending by up to 9%: study,Seeking Alpha,https://seekingalpha.com/news/4392036-weight-loss-drugs-can-cut-grocery-spending?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/2/2025 8:57:35 PM,Lilly seeking to join lawsuit over compounded GLP-1 drugs,Seeking Alpha,https://seekingalpha.com/news/4392105-lilly-seeking-to-join-lawsuit-over-compounded-glp-1-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/3/2025 4:21:15 PM,Viking Therapeutics among potential buyout candidates: Oppenheimer,Seeking Alpha,https://seekingalpha.com/news/4392377-viking-stock-among-buyout-targets-oppenheimer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/3/2025 11:54:07 PM,Novo Nordisk seeks to block compounded Victoza,Seeking Alpha,https://seekingalpha.com/news/4392489-novo-nordisk-seeks-to-block-compounded-victoza?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/6/2025 11:36:10 AM,Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point,TipRanks,/news/stocks/eli-lilly-co-strategic-growth-driven-by-mounjaro-and-zepbound-with-attractive-entry-point-1034194767
,1/6/2025 3:00:02 PM,"Healthcare sector's 2024 gainers and losers: Intuitive Surgical, Boston Scientific tops chart",Seeking Alpha,https://seekingalpha.com/news/4392667-healthcare-sectors-2024-gainers-and-losers-intuitive-surgical-boston-scientific-tops-chart?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/7/2025 11:37:44 AM,Eli Lilly & Co (LLY) Receives a Buy from Morgan Stanley,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-morgan-stanley-1034200150
,1/7/2025 4:25:17 PM,Eli Lilly call volume above normal and directionally bullish,TipRanks,/news/stocks/eli-lilly-call-volume-above-normal-and-directionally-bullish-1034201969
,1/7/2025 4:53:02 PM,FDA issues draft guidance on developing weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4393123-fda-issues-draft-guidance-developing-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/8/2025 6:30:03 AM,Truist Financial Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1034203919
,1/8/2025 8:35:29 PM,CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea,TipRanks,/news/stocks/cms-confirms-to-cnbc-medicare-plans-can-now-cover-zepbound-for-sleep-apnea-1034207692
,1/8/2025 9:02:40 PM,Lilly's Zepbound to be covered by Medicare for sleep apnea,Seeking Alpha,https://seekingalpha.com/news/4393567-lillys-zepbound-to-be-covered-by-medicare-for-sleep-apnea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/9/2025 4:35:33 PM,Drugs not selected for Medicare negotiations saw prices nearly double - report,Seeking Alpha,https://seekingalpha.com/news/4393809-drugs-not-selected-medicare-price-negotiation-nearly-doubled-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/10/2025 1:56:38 PM,"HIMS downgraded, agilon upgraded at Citi in 2025 Health Tech review",Seeking Alpha,https://seekingalpha.com/news/4394065-hims-stock-downgraded-agilon-stock-upgraded-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/10/2025 2:25:26 PM,Argus reveals top stock picks for 2025,TipRanks,/news/stocks/argus-reveals-top-stock-picks-for-2025-1034215881
,1/10/2025 6:35:25 PM,"Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says",TipRanks,/news/stocks/lilly-in-advanced-talks-to-buy-cancer-biotech-scorpion-for-up-to-2-5b-ft-says-1034216558
,1/10/2025 6:44:22 PM,"Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws",Seeking Alpha,https://seekingalpha.com/news/4394211-eli-lilly-in-talks-to-acquire-scorpion-therapeutics-ft-says-relay-therapeutics-surges?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/10/2025 7:01:52 PM,Lilly signs licensing deal with Mediar for IPF drug,Seeking Alpha,https://seekingalpha.com/news/4394217-lilly-signs-licensing-deal-with-mediar-for-ipf-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/11/2025 3:40:17 PM,Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bernstein-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034217251
,1/11/2025 7:25:15 PM,"Potential acquisition of Scorpion positive for Relay, says Barclays",TipRanks,/news/stocks/potential-acquisition-of-scorpion-positive-for-relay-says-barclays-1034217338
,1/11/2025 7:36:00 PM,"Key deals this week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and more",Seeking Alpha,https://seekingalpha.com/news/4393975-key-deals-this-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 7:51:35 AM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-sagimet-biosciences-inc-class-a-sgmt-1034219557
,1/13/2025 12:40:51 PM,Verve Therapeutics announces anticipated 2025 milestones,TipRanks,/news/stocks/verve-therapeutics-announces-anticipated-2025-milestones-1034221397
,1/13/2025 2:05:44 PM,Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B,TipRanks,/news/stocks/eli-lilly-to-acquire-scorpion-therapeutics-stx-478-program-for-up-to-2-5b-1034222120
,1/13/2025 2:45:15 PM,Eli Lilly to acquire Scorpion for up to $2.5B,Seeking Alpha,https://seekingalpha.com/news/4394548-eli-lilly-to-acquire-scorpion-for-up-to-2_5b?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 4:41:04 PM,Lilly oral obesity drug could get FDA okay in early 2026: report,Seeking Alpha,https://seekingalpha.com/news/4394612-lilly-oral-obesity-drug-could-get-fda-okay-in-early-2026-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 5:49:50 PM,Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash ,RTTNews,/news/stocks/eli-lilly-to-buy-scorpion-therapeutics-experimental-cancer-therapy-for-up-to-2-5-bln-in-cash-1034221909
,1/13/2025 6:20:20 PM,Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026,TipRanks,/news/stocks/eli-lilly-ceo-tells-bloomberg-tv-company-sees-weight-loss-pill-approval-in-2026-1034222788
,1/13/2025 6:49:49 PM,Lilly asked Feds to pause drug pricing negotiations: report,Seeking Alpha,https://seekingalpha.com/news/4394665-lilly-asked-feds-to-pause-drug-pricing-negotiations-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 10:54:17 PM,Obesity drug developer Metsera files for $100M IPO,Seeking Alpha,https://seekingalpha.com/news/4394524-obesity-drug-developer-metsera-files-for-100m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 2:05:21 PM,"Eli Lilly sees Q4 worldwide revenue ~$13.5B, consensus $13.95B",TipRanks,/news/stocks/eli-lilly-sees-q4-worldwide-revenue-~-13-5b-consensus-13-95b-1034226875
,1/14/2025 2:06:01 PM,"Eli Lilly sees FY25 revenue $58B-$61B, consensus $58.48B",TipRanks,/news/stocks/eli-lilly-sees-fy25-revenue-58b--61b-consensus-58-48b-1034226863
,1/14/2025 2:06:15 PM,"Eli Lilly cuts FY24 revenue view to ~$45B from $45.4B-$46B, consensus $45.55B",TipRanks,/news/stocks/eli-lilly-cuts-fy24-revenue-view-to-~-45b-from-45-4b--46b-consensus-45-55b-1034226859
,1/14/2025 2:11:09 PM,Eli Lilly sees growth in 2025 from new medicines,TipRanks,/news/stocks/eli-lilly-sees-growth-in-2025-from-new-medicines-1034226833
,1/14/2025 2:26:34 PM,Eli Lilly issues Q4 2024 revenue guidance below consensus,Seeking Alpha,https://seekingalpha.com/news/4394918-eli-lilly-issues-q4-2024-revenue-guidance-below-consensus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 2:36:59 PM,"Biggest stock movers Tuesday: LLY, HEES, KBH, CHGG, and more",Seeking Alpha,https://seekingalpha.com/news/4394789-biggest-stock-movers-tuesday-kbh-chgg-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 2:40:39 PM,"Drugmakers to push Trump to pause price negotiations, Bloomberg reports",TipRanks,/news/stocks/drugmakers-to-push-trump-to-pause-price-negotiations-bloomberg-reports-1034226968
,1/14/2025 3:06:07 PM,Eli Lilly falls -6.5%,TipRanks,/news/stocks/eli-lilly-falls--6-5-1034227045
,1/14/2025 3:29:45 PM,"Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25 ",RTTNews,/news/stocks/lilly-cuts-q4-revenue-view-below-market-lifts-fy24-outlook-sees-growth-in-fy25-1034225485
,1/14/2025 4:45:16 PM,Hims & Hers in focus as Eli Lilly obesity drug sales disappoint,Seeking Alpha,https://seekingalpha.com/news/4394979-hims-hers-stock-up-eli-lilly-glp-1-sales-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 4:50:26 PM,European markets ended mixed ahead of crucial economic data,Seeking Alpha,https://seekingalpha.com/news/4394774-european-markets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 5:00:54 PM,"Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz",TipRanks,/news/stocks/lilly-cuts-fy24-outlook-united-rentals-to-acquire-h-e-morning-buzz-1034227251
,1/14/2025 6:00:33 PM,Leerink remains bullish on Eli Lilly despite lower Q4 revenue guidance,TipRanks,/news/stocks/leerink-remains-bullish-on-eli-lilly-despite-lower-q4-revenue-guidance-1034227342
,1/14/2025 7:10:33 PM,ETF earnings: Biggest weeks for major funds as holdings report,Seeking Alpha,https://seekingalpha.com/news/4394999-etf-earnings-biggest-weeks-for-major-funds-as-holdings-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 11:35:23 PM,Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strong-growth-prospects-and-strategic-investments-justify-buy-rating-1034227794
,1/14/2025 11:35:47 PM,Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strong-long-term-growth-prospects-amid-q4-revenue-shortfall-justify-buy-rating-1034227791
,1/15/2025 9:35:14 AM,Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed,TipRanks,/news/stocks/eli-lilly-co-positive-long-term-outlook-despite-recent-setbacks-–-buy-rating-affirmed-1034230028
,1/15/2025 10:45:57 AM,Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strong-growth-prospects-and-strategic-positioning-justify-buy-rating-1034230334
,1/15/2025 12:01:55 PM,"European markets gain, UK inflation unexpectedly slows while yields dip",Seeking Alpha,https://seekingalpha.com/news/4395140-european-markets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/15/2025 12:05:14 PM,"Eli Lilly Q4 miss brings buying opportunity, says JPMorgan",TipRanks,/news/stocks/eli-lilly-q4-miss-brings-buying-opportunity-says-jpmorgan-1034231153
,1/15/2025 1:16:27 PM,Eli Lilly & Co (LLY) Gets a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-jefferies-1034231557
,1/15/2025 3:00:00 PM,Moderna remains the most shorted stock among S&P 500 healthcare stocks in the last month of 2024,Seeking Alpha,https://seekingalpha.com/news/4395003-moderna-remains-the-most-shorted-stock-among-sp-500-healthcare-stocks-in-the-last-month-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/15/2025 8:25:19 PM,Balanced Outlook with Long-Term Optimism: Steve Scala Maintains Buy Rating for Eli Lilly & Co,TipRanks,/news/stocks/balanced-outlook-with-long-term-optimism-steve-scala-maintains-buy-rating-for-eli-lilly-co-1034232627
,1/15/2025 8:25:50 PM,TD Cowen Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/td-cowen-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1034232622
,1/15/2025 9:16:24 PM,Eli Lilly’s Omvoh for Crohn’s disease approved by FDA,TipRanks,/news/stocks/eli-lilly-s-omvoh-for-crohn-s-disease-approved-by-fda-1034232692
,1/15/2025 9:31:33 PM,Lilly gets FDA approval for Omvoh for Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4395443-lilly-gets-fda-approval-for-omvoh-for-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/16/2025 4:35:50 AM,FDA Approves Lilly's Omvoh For Crohn's Disease Treatment ,RTTNews,/news/stocks/fda-approves-lilly-s-omvoh-for-crohn-s-disease-treatment-1034232823
,1/16/2025 9:50:52 AM,"Eli Lilly price target lowered to $970 from $1,050 at Berenberg",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-970-from-1-050-at-berenberg-1034234957
,1/16/2025 11:46:02 AM,"Insulin prices have dropped but some poor patients are paying more, NYT says",TipRanks,/news/stocks/insulin-prices-have-dropped-but-some-poor-patients-are-paying-more-nyt-says-1034235801
,1/16/2025 4:30:04 PM,Least shorted S&P 500 stocks in December,Seeking Alpha,https://seekingalpha.com/news/4395791-least-shorted-sp-500-stocks-in-december?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 12:21:15 PM,Eli Lilly price target lowered to $973 from $995 at Guggenheim,TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-973-from-995-at-guggenheim-1034240597
,1/17/2025 12:42:16 PM,Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4396073-novo-nordisk-stock-slips-data-higher-wegovy-dose?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 2:20:46 PM,Novo Nordisk price target lowered to $110 from $140 at Argus,TipRanks,/news/stocks/novo-nordisk-price-target-lowered-to-110-from-140-at-argus-1034241161
,1/17/2025 4:23:17 PM,Hims & Hers Health down 3% after BoA says Q4 revenue could be a miss,Seeking Alpha,https://seekingalpha.com/news/4396179-hims-hers-health-down-3-after-boa-says-q4-revenue-could-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772
,1/18/2025 4:31:23 PM,Trending stocks as Wall Street bounces back with strong week,Seeking Alpha,https://seekingalpha.com/news/4396381-trending-stocks-as-wall-street-bounces-back-with-strong-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/18/2025 8:56:17 PM,Chinese biotech dominance in R&D is on the rise,Seeking Alpha,https://seekingalpha.com/news/4396390-chinese-biotech-dominance-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/21/2025 12:47:53 PM,Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch,Seeking Alpha,https://seekingalpha.com/news/4396624-sanofi-trial-cialis-otc-no-longer-under-fda-hold?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/21/2025 2:15:58 PM,Eli Lilly & Co (LLY) Receives a Buy from Bank of America Securities,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-bank-of-america-securities-1034250898
,1/21/2025 4:06:24 PM,GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study,Seeking Alpha,https://seekingalpha.com/news/4396883-glp-1-weight-loss-drugs-linked-new-risks-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/21/2025 9:10:23 PM,Kyverna appoints Naji Gehchan as Chief Medical and Development Officer,TipRanks,/news/stocks/kyverna-appoints-naji-gehchan-as-chief-medical-and-development-officer-1034251781
,1/22/2025 4:44:48 PM,Top SA Quant-rated medical devices stocks as technicals look strong,Seeking Alpha,https://seekingalpha.com/news/4397413-top-sa-quant-rated-medical-devices-stocks-as-technicals-look-strong?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/23/2025 9:56:43 AM,Evercore ISI Sticks to Their Hold Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/evercore-isi-sticks-to-their-hold-rating-for-eli-lilly-co-lly-1034259293
,1/23/2025 10:36:05 AM,Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances,TipRanks,/news/stocks/eli-lilly-co-s-promising-growth-accelerated-revenue-and-drug-pipeline-advances-1034259549
,1/23/2025 10:55:09 AM,"Datadog, Booz Allen added to US 1 list at BofA, Lilly removed",TipRanks,/news/stocks/datadog-booz-allen-added-to-us-1-list-at-bofa-lilly-removed-1034259620
,1/23/2025 1:16:08 PM,Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline,TipRanks,/news/stocks/eli-lilly-co-buy-rating-backed-by-promising-orfoglipron-trials-and-strong-pharmaceutical-pipeline-1034261002
,1/23/2025 2:25:41 PM,Argus Research Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/argus-research-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034261371
,1/23/2025 11:07:44 PM,Allurion stock soars 70% on weight-loss therapy update,Seeking Alpha,https://seekingalpha.com/news/4398176-allurion-stock-soars-on-weight-loss-therapy-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/24/2025 11:42:31 AM,Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss,Seeking Alpha,https://seekingalpha.com/news/4398289-novo-nordisk-stock-spikes-new-weight-loss-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/24/2025 3:24:51 PM,"Biggest stock movers Friday: DAN, NVO, TXN, and more",Seeking Alpha,https://seekingalpha.com/news/4398236-biggest-stock-movers-friday-twlo-txn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/25/2025 8:36:19 PM,Pfizer succeeds in late-stage trial for colorectal cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4398681-pfizer-posts-trial-win-colorectal-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/27/2025 12:01:47 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1034272479
,1/27/2025 12:01:51 PM,Eli Lilly & Co (LLY) Gets a Buy from Citi,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-citi-1034272478
,1/27/2025 12:16:18 PM,Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034272593
,1/27/2025 5:58:21 PM,Novo Nordisk settles Minnesota insulin pricing case: report,Seeking Alpha,https://seekingalpha.com/news/4398943-novo-nordisk-settles-minnesota-insulin-pricing-case-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/27/2025 10:39:46 PM,Obesity drug developer Metsera sets terms for $275M IPO,Seeking Alpha,https://seekingalpha.com/news/4398987-obesity-drug-developer-metsera-sets-terms-for-275m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/28/2025 9:50:26 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (OtherNNCSF) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nanosonics-limited-othernncsf-and-eli-lilly-co-lly-1034276496
,1/28/2025 11:25:45 AM,"Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-970-from-1-000-at-wells-fargo-1034277033
,1/28/2025 11:36:26 AM,"Eli Lilly price target lowered to $1,190 from $1,250 at Citi",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-1-190-from-1-250-at-citi-1034277158
,1/28/2025 12:10:43 PM,BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly,TipRanks,/news/stocks/beyondspring-to-sell-portion-of-equity-interest-in-seed-for-35-4meli-lilly-1034277709
,1/28/2025 12:55:16 PM,Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability,TipRanks,/news/stocks/eli-lilly-co-receives-buy-rating-from-david-risinger-due-to-promising-tirzepatide-trial-results-and-competitive-tolerability-1034277953
,1/28/2025 7:50:14 PM,Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success,TipRanks,/news/stocks/leerink-says-eli-lilly-news-causes-concern-about-tectonic-s-tx45-success-1034279450
,1/28/2025 8:15:30 PM,Novo Nordisk's Ozempic gets FDA approval for kidney disease,Seeking Alpha,https://seekingalpha.com/news/4399631-novo-nordisk-ozempic-gets-fda-approval-for-kidney-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/28/2025 8:31:08 PM,Eli Lilly trial update on kidney drug hurts Tectonic,Seeking Alpha,https://seekingalpha.com/news/4399630-tectonic-stock-plunges-eli-lilly-trial-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/28/2025 9:20:22 PM,OnKure Therapeutics initiated with a Buy at JonesResearch,TipRanks,/news/stocks/onkure-therapeutics-initiated-with-a-buy-at-jonesresearch-1034279558
,1/29/2025 3:48:40 PM,Vaccine stocks in focus as RFK Jr. faces confirmation hearing,Seeking Alpha,https://seekingalpha.com/news/4400073-vaccine-stocks-in-focus-as-rfk-jr-faces-confirmation-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/29/2025 6:55:13 PM,"RFK Jr. comments contradict anti-vaccine legacy, says Truist",TipRanks,/news/stocks/rfk-jr-comments-contradict-anti-vaccine-legacy-says-truist-1034284331
,1/29/2025 8:54:46 PM,HHS Secretary nominee RFK Jr. faces contentious Senate hearing,Seeking Alpha,https://seekingalpha.com/news/4400271-hhs-secretary-nominee-rfk-jr_-faces-contentious-senate-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/30/2025 10:20:18 AM,Wells downgrades Vertex to Equal Weight on lack of catalysts,TipRanks,/news/stocks/wells-downgrades-vertex-to-equal-weight-on-lack-of-catalysts-1034287994
,1/30/2025 5:05:46 PM,Foghorn Therapeutics a new buy at B Riley on tumor fighting technology,Seeking Alpha,https://seekingalpha.com/news/4400869-foghorn-therapeutics-new-buy-b-riley-tumor-fighting-technology?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/30/2025 5:46:44 PM,RFK Jr. hails GLP-1 weight loss meds as 'miracle drugs',Seeking Alpha,https://seekingalpha.com/news/4400916-rfk-jr-hails-glp-1-weight-loss-meds-miracle-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/31/2025 6:08:16 PM,Metsera sees stock rally 54% following $275M IPO,Seeking Alpha,https://seekingalpha.com/news/4401417-metsera-sees-stock-rally-54-following-275m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/31/2025 8:00:55 PM,"Catalyst Watch: Tariff drama, OPEC+, Alphabet and Amazon earnings, Lennar spinoff",Seeking Alpha,https://seekingalpha.com/news/4401505-catalyst-watch-tariff-drama-opec-alphabet-and-amazon-earnings-lennar-spinoff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/1/2025 12:53:24 PM,Are healthcare stocks on the rebound?,Seeking Alpha,https://seekingalpha.com/news/4401695-are-healthcare-stocks-rebound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/1/2025 11:30:00 PM,Over 75% of companies beat EPS estimates this week - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4401476-over-75-of-companies-beat-eps-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/3/2025 12:15:43 PM,Truist Financial Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-eli-lilly-co-lly-1034303088
,2/3/2025 2:25:45 PM,"Eli Lilly price target raised to $1,038 from $1,029 at Truist",TipRanks,/news/stocks/eli-lilly-price-target-raised-to-1-038-from-1-029-at-truist-1034303923
,2/3/2025 5:30:39 PM,SA Asks: What's the most attractive weight-loss stock right now?,Seeking Alpha,https://seekingalpha.com/news/4401656-sa-asks-whats-the-most-attractive-weight-loss-stock-right-now?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/3/2025 5:44:37 PM,"Sens. Wyden, Warren press RFK Jr. on conflicts of interest ahead of vote",Seeking Alpha,https://seekingalpha.com/news/4402094-senators-wyden-warren-press-rfk-jr-conflicts-of-interest-ahead-vote?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 3:52:32 PM,RFK Jr. HHS nomination advances out of Senate Finance Committee,Seeking Alpha,https://seekingalpha.com/news/4402747-rfk-jr-hhs-nomination-advances-out-senate-finance-committee?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 9:17:26 AM,Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom,TipRanks,/news/stocks/eli-lilly-lly-stock-eyes-price-breakout-as-q4-results-loom-1034314164
,2/5/2025 11:19:20 AM,NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy,TipRanks,/news/stocks/nvo-earnings-novo-nordisk-jumps-on-healthy-sales-beat-driven-by-wegovy-1034314594
,2/5/2025 12:18:51 PM,Novo Nordisk beats in Q4 as Wegovy sales more than double,Seeking Alpha,https://seekingalpha.com/news/4403367-novo-nordisk-stock-higher-q4-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 12:36:27 PM,Are thinner people harming the environment? Novo emissions rise on Wegovy demand,Seeking Alpha,https://seekingalpha.com/news/4403390-are-thinner-people-harming-the-environment-novo-emissions-rise-on-wegovy-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 1:35:28 PM,Eli Lilly & Co (LLY) Gets a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-jefferies-1034315685
,2/5/2025 6:23:46 PM,Eli Lilly Q4 2024 Earnings Preview: All eyes on stronger 2025,Seeking Alpha,https://seekingalpha.com/news/4403802-eli-lilly-q4-2024-earnings-preview-all-eyes-on-stronger-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 6:40:19 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034317367
,2/5/2025 7:37:48 PM,Novo doubles down on next-gen weight loss therapy despite early setback,Seeking Alpha,https://seekingalpha.com/news/4403823-novo-nordisk-stock-new-plans-cagrisema?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 8:40:24 PM,Eli Lilly upgraded to Buy from Hold at Erste Group,TipRanks,/news/stocks/eli-lilly-upgraded-to-buy-from-hold-at-erste-group-1034317565
,2/6/2025 11:46:37 AM,"Eli Lilly Non-GAAP EPS of $5.32 beats by $0.24, revenue of $13.53B beats by $100M",Seeking Alpha,https://seekingalpha.com/news/4404290-eli-lilly-non-gaap-eps-of-5_51-beats-by-0_43-revenue-of-13_53b-beats-by-100m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 12:05:36 PM,"Options Volatility and Implied Earnings Moves Today, February 06, 2025",TipRanks,/news/stocks/options-volatility-and-implied-earnings-moves-today-february-06-2025-1034322024
,2/6/2025 12:11:16 PM,"Eli Lilly reports Q4 EPS $5.32, consensus $5.08",TipRanks,/news/stocks/eli-lilly-reports-q4-eps-5-32-consensus-5-08-1034321961
,2/6/2025 12:18:20 PM,"Eli Lilly sees FY25 EPS $22.50-$24.00, consensus $22.69",TipRanks,/news/stocks/eli-lilly-sees-fy25-eps-22-50--24-00-consensus-22-69-1034322169
,2/6/2025 12:24:20 PM,"Eli Lilly in charts: Mounjaro, Zepbound, and Jardiance drive sales growth in Q4",Seeking Alpha,https://seekingalpha.com/news/4404336-eli-lilly-in-charts-mounjaro-zepbound-and-jardiance-drive-sales-growth-in-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 12:36:04 PM,LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments,TipRanks,/news/stocks/lly-earnings-weight-loss-drug-demand-drives-eli-lilly-sales-as-investors-eye-next-gen-treatments-1034322370
,2/6/2025 12:39:18 PM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034322329
,2/6/2025 12:48:40 PM,"Eli Lilly And Co. Q4 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/eli-lilly-and-co-q4-profit-increases-beats-estimates-1034321794
,2/6/2025 1:00:13 PM,Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4,Seeking Alpha,https://seekingalpha.com/news/4404294-eli-lilly-stock-rises-q4-2024-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 1:08:03 PM,Eli Lilly Guides FY25 In Line With Estimates - Update ,RTTNews,/news/stocks/eli-lilly-guides-fy25-in-line-with-estimates-update-1034321922
,2/6/2025 1:57:03 PM,Morning Movers: Roblox sinks following fourth quarter results and guidance,TipRanks,/news/stocks/morning-movers-roblox-sinks-following-fourth-quarter-results-and-guidance-1034322920
,2/6/2025 2:03:42 PM,"4 stocks to watch on Thursday: HON, AMZN and more",Seeking Alpha,https://seekingalpha.com/news/4404375-4-stocks-to-watch-on-thursday-hon-amzn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 5:06:03 PM,"Qualcomm, Eli Lilly report quarterly earnings beats: Morning Buzz",TipRanks,/news/stocks/qualcomm-eli-lilly-report-quarterly-earnings-beats-morning-buzz-1034324189
,2/6/2025 5:36:07 PM,Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release,TipRanks,/news/stocks/eli-lilly-nyse-lly-speeds-up-weight-loss-drug-data-release-1034324309
,2/6/2025 6:35:50 PM,"White House readying order to fire thousands of federal health workers, WSJ says",TipRanks,/news/stocks/white-house-readying-order-to-fire-thousands-of-federal-health-workers-wsj-says-1034324421
,2/6/2025 6:40:55 PM,S&P 500 Gains Today Alongside Earnings Reports,TipRanks,/news/stocks/s-p-500-gains-today-alongside-earnings-reports-1034324418
,2/7/2025 11:38:52 AM,Citi Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/citi-keeps-their-buy-rating-on-eli-lilly-co-lly-1034326728
,2/7/2025 11:55:51 AM,Eli Lilly announces results from VIVID-2 study,TipRanks,/news/stocks/eli-lilly-announces-results-from-vivid-2-study-1034326794
,2/7/2025 1:30:44 PM,Viking Therapeutics price target lowered to $70 from $120 at Maxim,TipRanks,/news/stocks/viking-therapeutics-price-target-lowered-to-70-from-120-at-maxim-1034327597
,2/7/2025 1:32:58 PM,"Eli Lilly price target raised to $1,000 from $997 at BofA",TipRanks,/news/stocks/eli-lilly-price-target-raised-to-1-000-from-997-at-bofa-1034327580
,2/7/2025 2:58:59 PM,Lilly reports positive results for Omvoh in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4405158-lilly-reports-positive-results-for-omvoh-in-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/7/2025 3:21:13 PM,Trump Trade: President advocates to close carried interest tax loophole,TipRanks,/news/stocks/trump-trade-president-advocates-to-close-carried-interest-tax-loophole-1034328479
,2/7/2025 5:20:21 PM,Hims & Hers jumps ahead of controversial Super Bowl ad airing,TipRanks,/news/stocks/hims-hers-jumps-ahead-of-controversial-super-bowl-ad-airing-1034328929
,2/8/2025 9:04:00 PM,18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4405247-18-out-of-21-healthcare-companies-beat-profit-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
